0001628280-24-006158.txt : 20240222 0001628280-24-006158.hdr.sgml : 20240222 20240222074958 ACCESSION NUMBER: 0001628280-24-006158 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 135 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lantheus Holdings, Inc. CENTRAL INDEX KEY: 0001521036 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 352318913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36569 FILM NUMBER: 24662345 BUSINESS ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 BUSINESS PHONE: 978 671-8001 MAIL ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 FORMER COMPANY: FORMER CONFORMED NAME: Lantheus MI Holdings, Inc. DATE OF NAME CHANGE: 20110517 10-K 1 lnth-20231231.htm 10-K lnth-20231231
false2023FY0001521036http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold0.01252910.0178539http://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#LongTermDebtCurrenthttp://fasb.org/us-gaap/2023#LongTermDebtCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations15.33727200015210362023-01-012023-12-3100015210362023-06-30iso4217:USD00015210362024-02-15xbrli:shares00015210362023-12-3100015210362022-12-31iso4217:USDxbrli:shares00015210362022-01-012022-12-3100015210362021-01-012021-12-310001521036us-gaap:CommonStockMember2020-12-310001521036us-gaap:TreasuryStockCommonMember2020-12-310001521036us-gaap:AdditionalPaidInCapitalMember2020-12-310001521036us-gaap:RetainedEarningsMember2020-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100015210362020-12-310001521036us-gaap:RetainedEarningsMember2021-01-012021-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001521036us-gaap:CommonStockMember2021-01-012021-12-310001521036us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001521036us-gaap:CommonStockMember2021-12-310001521036us-gaap:TreasuryStockCommonMember2021-12-310001521036us-gaap:AdditionalPaidInCapitalMember2021-12-310001521036us-gaap:RetainedEarningsMember2021-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100015210362021-12-310001521036us-gaap:RetainedEarningsMember2022-01-012022-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001521036us-gaap:CommonStockMember2022-01-012022-12-310001521036us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001521036us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001521036us-gaap:CommonStockMember2022-12-310001521036us-gaap:TreasuryStockCommonMember2022-12-310001521036us-gaap:AdditionalPaidInCapitalMember2022-12-310001521036us-gaap:RetainedEarningsMember2022-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001521036us-gaap:RetainedEarningsMember2023-01-012023-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001521036us-gaap:CommonStockMember2023-01-012023-12-310001521036us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001521036us-gaap:CommonStockMember2023-12-310001521036us-gaap:TreasuryStockCommonMember2023-12-310001521036us-gaap:AdditionalPaidInCapitalMember2023-12-310001521036us-gaap:RetainedEarningsMember2023-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3100015210362020-02-202020-02-200001521036lnth:ProgenicsMember2020-02-202020-02-20xbrli:pure0001521036lnth:CashPayments2022Memberlnth:ProgenicsMember2020-02-200001521036lnth:ProgenicsMemberlnth:CashPayments2023Member2020-02-200001521036lnth:ConvertibleSeniorNotes2625PercentDue2027Memberus-gaap:SeniorNotesMember2023-12-310001521036lnth:PYLARIFYMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-12-310001521036lnth:PYLARIFYMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-01-012022-12-310001521036lnth:PYLARIFYMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-012021-12-310001521036lnth:DefinityMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-12-310001521036lnth:DefinityMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-01-012022-12-310001521036lnth:DefinityMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-012021-12-310001521036lnth:TechneLiteMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-12-310001521036lnth:TechneLiteMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-01-012022-12-310001521036lnth:TechneLiteMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-012021-12-310001521036srt:MinimumMemberus-gaap:BuildingMember2023-12-310001521036us-gaap:BuildingMembersrt:MaximumMember2023-12-310001521036us-gaap:LandImprovementsMembersrt:MinimumMember2023-12-310001521036us-gaap:LandImprovementsMembersrt:MaximumMember2023-12-310001521036us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2023-12-310001521036us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2023-12-310001521036us-gaap:FurnitureAndFixturesMember2023-12-310001521036us-gaap:LeaseholdImprovementsMember2023-12-310001521036us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MinimumMember2023-12-310001521036us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MaximumMember2023-12-3100015210362021-01-012021-03-310001521036us-gaap:ConvertibleDebtMember2023-12-310001521036us-gaap:ProductMember2023-01-012023-12-310001521036us-gaap:ProductMember2022-01-012022-12-310001521036us-gaap:ProductMember2021-01-012021-12-310001521036lnth:LicenseandRoyaltyRevenuesMember2023-01-012023-12-310001521036lnth:LicenseandRoyaltyRevenuesMember2022-01-012022-12-310001521036lnth:LicenseandRoyaltyRevenuesMember2021-01-012021-12-3100015210362022-01-012022-03-31lnth:productCategory0001521036lnth:LicenseAndRoyaltyRevenuesSalesBasedMilestonePaymentMember2023-10-012023-12-310001521036lnth:PYLARIFYMember2023-01-012023-12-310001521036lnth:PYLARIFYMember2022-01-012022-12-310001521036lnth:PYLARIFYMember2021-01-012021-12-310001521036lnth:OtherRadiopharmaceuticalOncologyMember2023-01-012023-12-310001521036lnth:OtherRadiopharmaceuticalOncologyMember2022-01-012022-12-310001521036lnth:OtherRadiopharmaceuticalOncologyMember2021-01-012021-12-310001521036lnth:RadiopharmaceuticalOncologyMember2023-01-012023-12-310001521036lnth:RadiopharmaceuticalOncologyMember2022-01-012022-12-310001521036lnth:RadiopharmaceuticalOncologyMember2021-01-012021-12-310001521036lnth:DefinityMember2023-01-012023-12-310001521036lnth:DefinityMember2022-01-012022-12-310001521036lnth:DefinityMember2021-01-012021-12-310001521036lnth:TechneLiteMember2023-01-012023-12-310001521036lnth:TechneLiteMember2022-01-012022-12-310001521036lnth:TechneLiteMember2021-01-012021-12-310001521036lnth:OtherPrecisionDiagnosticsMember2023-01-012023-12-310001521036lnth:OtherPrecisionDiagnosticsMember2022-01-012022-12-310001521036lnth:OtherPrecisionDiagnosticsMember2021-01-012021-12-310001521036lnth:TotalPrecisionDiagnosticsMember2023-01-012023-12-310001521036lnth:TotalPrecisionDiagnosticsMember2022-01-012022-12-310001521036lnth:TotalPrecisionDiagnosticsMember2021-01-012021-12-310001521036lnth:StrategicPartnershipsAndOtherMember2023-01-012023-12-310001521036lnth:StrategicPartnershipsAndOtherMember2022-01-012022-12-310001521036lnth:StrategicPartnershipsAndOtherMember2021-01-012021-12-310001521036us-gaap:MoneyMarketFundsMember2023-12-310001521036us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310001521036us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310001521036us-gaap:FairValueInputsLevel1Member2023-12-310001521036us-gaap:FairValueInputsLevel2Member2023-12-310001521036us-gaap:FairValueInputsLevel3Member2023-12-310001521036us-gaap:MoneyMarketFundsMember2022-12-310001521036us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-12-310001521036us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-12-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2022-12-310001521036us-gaap:FairValueInputsLevel1Member2022-12-310001521036us-gaap:FairValueInputsLevel2Member2022-12-310001521036us-gaap:FairValueInputsLevel3Member2022-12-310001521036us-gaap:RoyaltyMemberlnth:ProgenicsMember2022-01-012022-12-310001521036lnth:ProgenicsMember2022-01-012022-12-310001521036lnth:NetSalesTargetsForAzedraMemberlnth:ProgenicsMember2023-12-310001521036lnth:A1095CommercializationMemberlnth:ProgenicsMember2023-12-310001521036lnth:ProgenicsMemberlnth:A1404CommercializationMilestoneMember2023-12-310001521036lnth:ProgenicsMember2023-12-310001521036us-gaap:FairValueInputsLevel3Memberlnth:ContingentValueRightMember2022-12-310001521036lnth:MeasurementInputProbabilityOfSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Memberlnth:ContingentValueRightMember2022-12-310001521036lnth:A1095CommercializationMemberus-gaap:FairValueInputsLevel3Member2023-12-310001521036lnth:A1095CommercializationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036lnth:MeasurementInputProbabilityOfSuccessMemberlnth:A1095CommercializationMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036lnth:MeasurementInputProbabilityOfSuccessMemberlnth:A1095CommercializationMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Member2023-12-310001521036us-gaap:MeasurementInputDiscountRateMemberlnth:A1095CommercializationMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Member2023-12-310001521036us-gaap:MeasurementInputDiscountRateMemberlnth:A1095CommercializationMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Member2023-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036lnth:MeasurementInputProbabilityOfSuccessMemberlnth:ContingentConsiderationNetSalesTargetsMembersrt:MinimumMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Member2023-12-310001521036lnth:MeasurementInputProbabilityOfSuccessMemberlnth:ContingentConsiderationNetSalesTargetsMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMember2023-12-310001521036lnth:MeasurementInputProbabilityOfSuccessMemberlnth:ContingentConsiderationNetSalesTargetsMembersrt:MinimumMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036lnth:MeasurementInputProbabilityOfSuccessMemberlnth:ContingentConsiderationNetSalesTargetsMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMember2022-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:MeasurementInputDiscountRateMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Member2023-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:MeasurementInputDiscountRateMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMember2022-12-310001521036us-gaap:DomesticCountryMember2023-12-310001521036us-gaap:StateAndLocalJurisdictionMember2023-12-310001521036stpr:MAus-gaap:InvestmentCreditMember2023-12-310001521036lnth:LiabilitiesCurrentMember2023-12-310001521036us-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001521036lnth:DeferredIncomeTaxAssetsNetMember2023-12-310001521036us-gaap:LandMember2023-12-310001521036us-gaap:LandMember2022-12-310001521036us-gaap:BuildingMember2023-12-310001521036us-gaap:BuildingMember2022-12-310001521036lnth:MachineryEquipmentAndFixturesMember2023-12-310001521036lnth:MachineryEquipmentAndFixturesMember2022-12-310001521036us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310001521036us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-12-310001521036us-gaap:ConstructionInProgressMember2023-12-310001521036us-gaap:ConstructionInProgressMember2022-12-3100015210362023-01-012023-06-300001521036us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-03-310001521036us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberlnth:PuertoRicanRadiopharmacyServicingSubsidiaryMember2021-01-290001521036lnth:PuertoRicanRadiopharmacyServicingSubsidiaryMember2021-01-012021-12-310001521036us-gaap:TrademarksMembersrt:MinimumMember2023-12-310001521036us-gaap:TrademarksMembersrt:MaximumMember2023-12-310001521036us-gaap:TrademarksMember2023-12-310001521036us-gaap:CustomerRelationshipsMembersrt:MinimumMember2023-12-310001521036us-gaap:CustomerRelationshipsMembersrt:MaximumMember2023-12-310001521036us-gaap:CustomerRelationshipsMember2023-12-310001521036lnth:CurrentlyMarketedProductMembersrt:MinimumMember2023-12-310001521036lnth:CurrentlyMarketedProductMembersrt:MaximumMember2023-12-310001521036lnth:CurrentlyMarketedProductMember2023-12-310001521036srt:MinimumMemberus-gaap:LicensingAgreementsMember2023-12-310001521036us-gaap:LicensingAgreementsMembersrt:MaximumMember2023-12-310001521036us-gaap:LicensingAgreementsMember2023-12-310001521036us-gaap:DevelopedTechnologyRightsMember2023-12-310001521036us-gaap:TrademarksMembersrt:MinimumMember2022-12-310001521036us-gaap:TrademarksMembersrt:MaximumMember2022-12-310001521036us-gaap:TrademarksMember2022-12-310001521036us-gaap:CustomerRelationshipsMembersrt:MinimumMember2022-12-310001521036us-gaap:CustomerRelationshipsMembersrt:MaximumMember2022-12-310001521036us-gaap:CustomerRelationshipsMember2022-12-310001521036lnth:CurrentlyMarketedProductMembersrt:MinimumMember2022-12-310001521036lnth:CurrentlyMarketedProductMembersrt:MaximumMember2022-12-310001521036lnth:CurrentlyMarketedProductMember2022-12-310001521036srt:MinimumMemberus-gaap:LicensingAgreementsMember2022-12-310001521036us-gaap:LicensingAgreementsMembersrt:MaximumMember2022-12-310001521036us-gaap:LicensingAgreementsMember2022-12-310001521036us-gaap:DevelopedTechnologyRightsMember2022-12-310001521036lnth:CurrentlyMarketedProductMember2021-05-012021-05-310001521036lnth:IPRDMember2021-05-012021-05-3100015210362023-08-022023-08-020001521036us-gaap:LicensingAgreementsMember2023-08-020001521036us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001521036us-gaap:CostOfSalesMember2023-01-012023-12-310001521036lnth:CerveauTechnologiesIncMember2023-02-012023-02-280001521036lnth:CerveauTechnologiesIncMember2023-05-012023-05-310001521036lnth:A2019TermLoanFacilityMemberus-gaap:LineOfCreditMember2022-12-310001521036lnth:A2019TermLoanFacilityMemberus-gaap:LineOfCreditMember2022-12-012022-12-310001521036lnth:A2019RevolvingFacilityMemberus-gaap:LineOfCreditMember2022-12-310001521036lnth:A2019RevolvingFacilityMemberus-gaap:LineOfCreditMember2022-12-012022-12-310001521036lnth:A2022TermFacilityMemberus-gaap:LineOfCreditMember2022-12-310001521036us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001521036us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-012022-12-310001521036lnth:A2019TermLoanFacilityMemberus-gaap:LineOfCreditMember2022-01-012022-09-300001521036us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMember2023-12-310001521036us-gaap:LineOfCreditMemberus-gaap:LetterOfCreditMember2023-12-310001521036us-gaap:LineOfCreditMemberus-gaap:BridgeLoanMember2023-12-310001521036us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-01-012023-12-310001521036us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMember2023-01-012023-12-310001521036srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2023-01-012023-12-310001521036us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMembersrt:MaximumMember2023-01-012023-12-310001521036lnth:NetLeverageRatioMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-01-012023-12-310001521036lnth:NetLeverageRatioMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMember2023-01-012023-12-310001521036us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-31lnth:financial_covenant0001521036lnth:A2022FacilityCovenantsMemberlnth:Q12024Member2023-01-012023-12-310001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2022-12-080001521036us-gaap:ConvertibleDebtMember2022-12-082022-12-080001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2022-12-082022-12-080001521036us-gaap:ConvertibleDebtMembersrt:MinimumMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2023-12-310001521036us-gaap:ConvertibleDebtMembersrt:MaximumMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2023-12-310001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2023-12-310001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2023-01-012023-12-310001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2022-12-052022-12-050001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2022-12-082022-12-310001521036us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-03-310001521036us-gaap:InterestRateSwapMember2022-12-022022-12-020001521036us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310001521036us-gaap:CostOfSalesMember2022-01-012022-12-310001521036us-gaap:CostOfSalesMember2021-01-012021-12-310001521036us-gaap:SellingAndMarketingExpenseMember2023-01-012023-12-310001521036us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-310001521036us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001521036us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-310001521036us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001521036us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001521036us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001521036us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001521036us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001521036us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001521036us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001521036us-gaap:RestrictedStockMember2023-01-012023-12-310001521036us-gaap:RestrictedStockMember2023-12-310001521036us-gaap:RestrictedStockMember2022-01-012022-12-310001521036us-gaap:RestrictedStockMember2021-01-012021-12-310001521036lnth:TotalStockholderReturnRestrictedStockAwardsMember2023-01-012023-12-310001521036lnth:TotalStockholderReturnRestrictedStockAwardsMembersrt:MinimumMember2023-01-012023-12-310001521036lnth:TotalStockholderReturnRestrictedStockAwardsMembersrt:MaximumMember2023-01-012023-12-310001521036lnth:TotalStockholderReturnRestrictedStockAwardsMember2022-01-012022-12-310001521036lnth:TotalStockholderReturnRestrictedStockAwardsMember2021-01-012021-12-310001521036lnth:TotalStockholderReturnRestrictedStockAwardsMember2022-12-310001521036lnth:TotalStockholderReturnRestrictedStockAwardsMember2023-12-3100015210362022-12-012022-12-31lnth:lease0001521036lnth:NewYorkCityMember2020-06-190001521036lnth:SomersetNewJerseyMember2020-06-190001521036lnth:SomersetNewJerseyMember2021-10-310001521036lnth:BedfordMassachusettsMember2022-12-310001521036lnth:BedfordMassachusettsMember2022-02-280001521036lnth:BedfordMassachusettsMember2023-05-310001521036lnth:BedfordMassachusettsMember2023-09-0100015210362021-09-300001521036lnth:BedfordMassachusettsMember2023-12-310001521036lnth:CerveauTechnologiesIncMemberlnth:SalesMilestonesMember2023-02-012023-02-280001521036lnth:CerveauTechnologiesIncMemberlnth:ResearchRevenueMilestonesMember2023-02-012023-02-280001521036lnth:POINTBiopharmaMember2022-12-012022-12-310001521036lnth:PNT2002LicenseAgreementMember2022-12-012022-12-310001521036lnth:RegulatoryMilestonesMemberlnth:PNT2002LicenseAgreementMember2022-12-012022-12-310001521036lnth:SalesMilestonesMemberlnth:PNT2002LicenseAgreementMember2022-12-012022-12-310001521036lnth:PNT2003LicenseAgreementMember2022-12-012022-12-310001521036lnth:RegulatoryMilestonesMemberlnth:PNT2003LicenseAgreementMember2022-12-012022-12-310001521036lnth:SalesMilestonesMemberlnth:PNT2003LicenseAgreementMember2022-12-012022-12-310001521036lnth:POINTBiopharmaMember2022-01-012022-12-31lnth:Segment0001521036us-gaap:SubsequentEventMemberus-gaap:LicensingAgreementsMemberlnth:PerspectiveTherapeuticsIncMember2024-01-092024-01-090001521036us-gaap:SubsequentEventMemberlnth:PerspectiveTherapeuticsIncMember2024-01-090001521036us-gaap:SubsequentEventMemberlnth:PerspectiveTherapeuticsIncMember2024-01-092024-01-0900015210362023-10-012023-12-310001521036lnth:SamLenoMember2023-01-012023-12-310001521036lnth:SamLenoMember2023-10-012023-12-310001521036lnth:SamLenoMember2023-12-310001521036lnth:Amended10b51PlanMemberlnth:SamLenoMember2023-10-012023-12-310001521036lnth:Amended10b51PlanMemberlnth:SamLenoMember2023-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________________
FORM 10-K
_______________________________________________________________
(Mark One)
☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 001-36569
_______________________________________________________________
LANTHEUS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)
_______________________________________________________________
Delaware35-2318913
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
201 Burlington Road, South Building, Bedford, MA
01730
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (978) 671-8001
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per shareLNTHNASDAQ Global Market
Securities registered pursuant to Section 12(g) of the Act:
None
_______________________________________________________________
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  þ    No  ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  þ    No  ☐
Indicate by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  þ    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerþAccelerated filer☐
Non-accelerated filer☐ Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act)    Yes  ☐    No  þ
The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant on June 30, 2023 was approximately $5,672.5 million based on the last reported sale price of the registrant’s common stock on the NASDAQ Global Market on June 30, 2023 of $83.92 per share.
As of February 15, 2024 the registrant had 68,525,556 shares of common stock, $0.01 par value, outstanding.



DOCUMENTS INCORPORATED BY REFERENCE
Listed hereunder are the documents, portions of which are incorporated by reference, and the parts of this Form 10-K into which such portions are incorporated:
The Registrant’s Definitive Proxy Statement for use in connection with the Annual Meeting of Stockholders to be held on April 25, 2024, portions of which are incorporated by reference into Parts II and III of this Form 10-K. The 2024 Proxy Statement will be filed with the Securities and Exchange Commission no later than 120 days after the close of our year ended December 31, 2023.


LANTHEUS HOLDINGS, INC.
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
Page


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements contained in this Annual Report on Form 10-K are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements, including, in particular, statements about our plans, strategies, prospects and industry estimates, are subject to risks and uncertainties. These statements identify prospective information and can generally be identified by words such as “anticipates,” “believes,” “can,” “could,” “designed,” “estimates,” “expects,” “hopes,” “intends,” “launch,” “may,” “pipeline,” “plans,” “potential,” “predicts,” “seeks,” “should,” “target,” “will,” “would” and similar expressions, or by express or implied discussions regarding potential marketing approvals or new indications for the product candidates or approved products described in this Annual Report on Form 10-K, or regarding potential future revenues from such product candidates and products. Examples of forward-looking statements include statements we make relating to our outlook and expectations including, without limitation, in connection with:
•Continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment in which other imaging agents have been approved and are being commercialized, and our ability to clinically and commercially differentiate our products;
•Our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility;
•The global availability of Molybdenum-99 (“Mo-99”) and other raw materials and key components;
•Our strategies, future prospects, and projected growth, including revenue related to our collaboration agreements with POINT Biopharma Global Inc. (“POINT”), including our ability to obtain FDA approval for PNT2002 and PNT2003;
•Our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 as a research tool and under the license agreement through which we have rights to MK-6240, and to further develop and commercialize it as an approved product;
•Our ability to successfully execute on our agreements with Perspective Therapeutics, Inc. (“Perspective”), including finalizing the license agreements in the event we exercise our options to do so, and satisfying the closing conditions for the sale of the Somerset, NJ manufacturing facility and related assets, the value of our current and any future equity interest in Perspective, and Perspective’s ability to successfully develop its alpha-particle therapy and innovative platform technology;
•The efforts and timing for clinical development, regulatory approval and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; and
•Our ability to identify and acquire or in-license additional radiopharmaceutical therapeutic and diagnostic product opportunities in oncology and other strategic areas to grow our pipeline of products.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, such statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. These statements are neither statements of historical fact nor guarantees or assurances of future performance. The matters referred to in the forward-looking statements contained in this Annual Report on Form 10-K may not in fact occur. We caution you, therefore, against relying on any of these forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, "Risk Factors" in this Annual Report on Form 10-K.
Any forward-looking statement made by us in this Annual Report on Form 10-K speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
SUMMARY OF MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS
Our business is subject to a number of risks, including risks that may adversely affect our business, results of operations, cash flows, and prospects. These risks are discussed more fully below and include, but are not limited to, risks related to:
Risks Related to Our Portfolio of Commercial Products
•Our ability to continue to grow PYLARIFY including (A) the ability of positron emission tomography (“PET”) manufacturing facilities (“PMFs”) to manufacture PYLARIFY to meet product demand, (B) our ability to promote
1
PYLARIFY to customers, (C) our ability to obtain and maintain adequate coding, coverage, and payment for PYLARIFY, (D) our ability to maintain PYLARIFY as the leading prostate-specific membrane antigen (“PSMA”) PET imaging agent, including after the potential expiration of Transitional Pass-Through Payment Status (“TPT Status”) at the end of 2024, and (E) our ability to clinically and commercially differentiate PYLARIFY from other products.
•Our ability to continue to (A) grow the appropriate use of DEFINITY in suboptimal echocardiograms in a competitive environment and in the face of potential generic competition as a result of patent and regulatory exclusivity expirations, (B) maintain DEFINITY as the leading ultrasound enhancing agent, and (C) have third parties manufacture our products and our ability to manufacture the formulation of DEFINITY that requires refrigerated storage in our in-house manufacturing facility.
•Our dependence on a limited number of third party suppliers for Mo-99, which is a critical ingredient of TechneLite.
•Risks related to PYLCLARI, commercialized by Curium, including that the revenues generated for us thereby may not meet expectations.
Risks Related to Reimbursement and Regulation
•The dependence of many of our customers upon third party healthcare payors and the uncertainty of third party coverage and reimbursement rates.
•Uncertainties regarding the impact of U.S. and state healthcare reform measures and proposals on our business, including measures and proposals related to reimbursement for our current and potential future products, controls over drug pricing, drug pricing transparency, generic drug competition and the potential that efforts to extend or secure separate or otherwise adequate payment for radiopharmaceutical diagnostics are unsuccessful.
•Our being subject to extensive government regulation and oversight, our ability to comply with those regulations and the costs of compliance.
Risks Related to our Business Operations and Financial Results
•Our ability to hire or retain the number of qualified personnel, particularly scientific, medical and sales personnel, required for our business.
•Our ability to introduce new products and adapt to an evolving technology and medical practice landscape.
•Our ability to influence and manage the decision-making process with our collaboration partners, in particular where our partners are responsible for the performance of certain key tasks or functions, for example related to manufacturing or regulatory strategy, or where decisions may be controlled by, or subject to the approval of our collaboration partners, who may have views that differ from ours
Risks Related to Our and our Strategic Partners’ Portfolios of Clinical Development Candidates
•Risks associated with the development and commercialization of PNT2002, including (A) the outcome of the Phase 3 registrational clinical trial for PNT2002, which we refer to as SPLASH, after full data becomes available, (B) our ability to obtain regulatory approval for PNT2002; (C) the additional costs and risks associated with our ability to successfully launch PNT2002 as a commercial product; (D) the market and patient receptivity to PNT2002 as a radiopharmaceutical therapy; (E) the existence, availability and profile of competing products and therapies; (F) our ability to gain post-approval market acceptance and adequate coding, coverage and payment for PNT2002; and (G) POINT’s ability to successfully develop and scale the manufacturing capabilities to support the launch of PNT2002.
•Risks associated with the commercialization of PNT2003, including (A) the outcome of the patent infringement claim by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, in response to our filing of our Abbreviated New Drug Application (“ANDA”); (B) our ability to obtain regulatory approval for PNT2003, including the 180-day period of generic marketing exclusivity in the U.S. market as the “first applicant”, as provided under the Hatch-Waxman Act; (C) our ability to gain post-approval market acceptance and adequate coding, coverage and payment for PNT2003; and (D) POINT’s ability to successfully develop and scale the manufacturing capabilities to support the launch of PNT2003.
•Risks associated with MK-6240, including (A) our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 as a research tool and under the license agreement through which we have rights to MK-6240, and (B) our ability to further develop and commercialize it as an approved product, including obtaining regulatory approval and gaining post-approval market acceptance and adequate coding, coverage and payment.
2
•Risks associated with [18F] flurpiridaz (“flurpiridaz”), which we out-licensed to GE Healthcare Limited (“GE Healthcare”) in 2017, including GE Healthcare’s ability to (A) obtain regulatory approval, and (B) gain post-approval market acceptance and adequate coding, coverage and payment.
•Risks associated with our agreements with Perspective, including finalizing the license agreements in the event we exercise our options to do so, and satisfying the closing conditions for the sale of the Somerset, NJ manufacturing facility and related assets, the value of our current and any future equity interest in Perspective, and Perspective’s ability to successfully develop its alpha-particle therapy and innovative platform technology.
Risks Related to our Capital Structure
•Risks related to our outstanding indebtedness and our ability to satisfy those obligations, including the 2.625% Convertible Senior Notes due 2027 (the “Notes”).
•Risks related to the ownership of our common stock.
NOTE REGARDING COMPANY REFERENCES
Unless the context requires otherwise, references to “Lantheus,” “the Company,” “our company,” “we,” “us” and “our” refer to Lantheus Holdings, Inc. and, as the context requires, its direct and indirect subsidiaries; references to “Lantheus Holdings” refer to Lantheus Holdings, Inc.; references to “LMI” refer to Lantheus Medical Imaging, Inc., a wholly-owned subsidiary; references to “Cerveau,” “Lantheus Alpha,” “Lantheus Two,” “Lantheus Three” and “Progenics” refer to Cerveau Technologies, Inc.; Lantheus Alpha Therapy, LLC; Lantheus Two, LLC; Lantheus Three, LLC; and Progenics Pharmaceuticals, Inc., respectively, each a wholly-owned subsidiary of LMI, and references to “EXINI” refer to EXINI Diagnostics AB, a wholly-owned subsidiary of Progenics.
NOTE REGARDING TRADEMARKS
We own or have the rights to various trademarks, service marks and trade names, including, among others, the following: PYLARIFY®, DEFINITY®, and Find Fight and Follow® referred to in this Annual Report on Form 10-K. Solely for convenience, we refer to trademarks and service marks in this Annual Report on Form 10-K without the TM, SM and ® symbols. Those references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted under applicable law, our rights to our trademarks and service marks. Each trademark, trade name or service mark of any other company appearing in this Annual Report on Form 10-K is, to our knowledge, owned by that other company.
3
PART I
Item 1. Business
Overview
We are the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (“HCPs”) Find, Fight and Follow cancer, with a focus in prostate cancer. Our leading Precision Diagnostic products assist HCPs to Find and Follow diseases, with a focus in cardiology. Our Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms.
Our commercial products are used by cardiologists, internal medicine physicians, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings. We believe that our diagnostic products provide improved diagnostic information that enables HCPs to better detect and characterize, or rule out, disease, with the potential to achieve better patient outcomes, reduce patient risk and limit overall costs throughout the healthcare system.
We produce and market our products throughout the United States (the “United States” or the “U.S.”), selling primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies. We sell our products outside the U.S. through a combination of direct distribution in Canada and third party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Our executive offices are located in Bedford, Massachusetts, with additional offices in North Billerica, Massachusetts; Somerset, New Jersey (subject to the satisfaction of closing conditions for the sale of the Somerset facility and related assets to Perspective anticipated in the first half of 2024); Montreal, Canada and Lund, Sweden.
CEO Succession Plan
On January 23, 2024, we announced that, effective March 1, 2024, Brian Markison, our current Chair of the Board of Directors (“Board”), will become our Chief Executive Officer, and Mary Anne Heino, our current Chief Executive Officer, will retire and become the Chair of the Board. As part of this leadership transition, Mr. Markison assumed the role of Executive Chair of the Board as of January 23, 2024 until the effectiveness of his Chief Executive Officer appointment in March, and Board Member Julie McHugh became Lead Independent Director.
Strategic Agreements with Perspective Therapeutics
On January 9, 2024, we announced that we entered into multiple strategic agreements with Perspective, a radiopharmaceutical company that is pursuing advanced treatment applications for cancers throughout the body. Under the agreements, we obtained an option to exclusively license Perspective’s Pb212-VMT- ⍺-NET, a clinical stage alpha therapy in development for the treatment of neuroendocrine tumors, and an option to co-develop certain early-stage therapeutic candidates targeting prostate cancer using Perspective’s innovative platform technology for an aggregate upfront payment of $28 million in cash. We also agreed to purchase up to 19.9% of Perspective’s outstanding shares of common stock for up to approximately $33 million, subject to Perspective’s completion of a qualified third-party financing transaction and certain other closing conditions. In addition, Perspective agreed to acquire the assets and associated lease of our radiopharmaceutical manufacturing facility in Somerset, New Jersey. Following satisfaction of the closing conditions, on January 22, 2024, our subsidiary, Lantheus Alpha purchased 56,342,355 shares of Perspective’s common stock at a purchase price of $0.37 per share in a private placement transaction. The total consideration for the purchase was approximately $20.8 million in cash, which resulted in Lantheus Alpha holding approximately 10.74% of Perspective’s common stock as of the purchase date and retaining the right to purchase additional shares to bring its ownership up to an aggregate of 19.9%.
Exclusive License for PNT2002 & PNT2003
On December 20, 2022, we announced the closing of a set of strategic collaborations with POINT, in which we were granted a license to exclusive worldwide rights (excluding Japan, South Korea, China (including Hong Kong, Macau and Taiwan), Singapore and Indonesia) to co-develop and commercialize POINT’s PNT2002 and PNT2003 product candidates. PNT2002 is a PSMA-targeted radiopharmaceutical therapy in development for the treatment of metastatic castration-resistant prostate cancer (“mCRPC”). PNT2003 is a somatostatin receptor (“SSTR”) therapy with non-carrier added lutetium-177, which is in registration to treat patients with SSTR-positive neuroendocrine tumors.
On December 27, 2023, Eli Lilly and Company announced the completion of its acquisition of POINT. The acquisition is not expected to impact the status of the license agreements related to these product candidates or the work being performed in connection with those license agreements and our collaboration with POINT.

4

PNT2002
With respect to PNT2002, POINT is generally responsible for funding and development activities required for FDA approval, including generating all clinical and nonclinical data, analysis and other information, and we are responsible for preparing for and seeking regulatory approval, as well as performing and funding all future development and commercialization following such approval. POINT will be responsible for all manufacturing of PNT2002, subject to certain exceptions described in the license and collaboration agreement between Lantheus Two and POINT, dated November 11, 2022 (the “PNT2002 License Agreement”).
In April 2023, we announced with POINT that the FDA had granted Fast Track designation for PNT2002. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet needs.
On December 18, 2023, we announced positive topline results from SPLASH. SPLASH is designed to evaluate the efficacy and safety of PNT2002 in patients with mCRPC who have progressed following treatment with an androgen receptor pathway inhibitor (“ARPI”). The SPLASH trial met its primary endpoint, demonstrating a median radiographic progression-free survival (rPFS) per blinded independent central review of 9.5 months for patients treated with PNT2002, compared to 6.0 months for patients treated with ARPI in the control arm, a statistically significant 29% reduction in the risk of radiographic progression or death (hazard ratio (“HR”) 0.71; p=0.0088). At the time of the analysis, interim overall survival (“OS”) results were immature (46% of protocol-specified target OS events reached), and the HR was 1.11. We expect more mature overall survival data in 2024 prior to the potential submission of a New Drug Application (“NDA”).
PNT2002 demonstrated a favorable safety profile with grade ≥3 treatment-emergent adverse events (“TEAEs”) per Common Terminology Criteria for Adverse Events, serious TEAEs, and TEAEs leading to discontinuation occurring at lower rates in the PNT2002 arm than in the ARPI arm (30.1%, 17.1%, and 1.9% versus 36.9%, 23.1%, and 6.2%, respectively).
The open-label study randomized 412 patients with PSMA-expressing mCRPC who had progressed on ARPI therapy and either refused or were not eligible for chemotherapy, in a 2:1 randomization ratio. At the time of the analysis, 84.6% of patients who experienced progressive disease in the control arm subsequently crossed over to receive PNT2002. SPLASH was conducted across the United States, Canada, Europe, and the United Kingdom. Eighty percent of SPLASH patients resided in North America and approximately ten percent of all participants were Black or African American.
During 2023, we worked on establishing an Expanded Access Program, (“EAP”), for PNT2002. EAPs, which are also referred to as compassionate use programs, provide a potential pathway for patients with serious or life-threatening conditions to gain access to an investigational drug for treatment outside of a clinical trial. We expect to enroll the first patient in the EAP for PNT2002 during the first quarter of 2024.
PNT2003
With respect to PNT2003, POINT is responsible for curating all data, analysis and other information necessary for regulatory approval, and supporting us in the preparation of regulatory filings. We are responsible for preparing for and seeking regulatory approval of all such applications, as well as performing and funding all future development and commercialization of PNT2003 following such approval. POINT will be responsible for all manufacturing of PNT2003, subject to certain exceptions described in the license and collaboration agreement between Lantheus Three and POINT, dated November 11, 2022 (the “PNT2003 License Agreement”).
On January 11, 2024, we announced that our ANDA for Lutetium Lu 177 Dotatate (177Lu-PNT2003) had been accepted for filing by the FDA. On January 26, 2024, we were sued in the District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the Company’s ANDA filing. Based on the most recent update to the FDA’s online paragraph IV database listings, we believe we are the first applicant to have filed a substantially complete ANDA for Lutetium Lu 177 Dotatate containing a Paragraph IV certification under the provisions of the Hatch-Waxman Act. As the first applicant, we believe we will be eligible for 180 days of generic marketing exclusivity in the U.S.
Under the Hatch-Waxman Act, any company submitting an ANDA must make certain certifications with respect to the patent status of the drug for which it is seeking approval. In the event that such applicant plans to challenge the validity or enforceability of an existing listed patent or asserts that the proposed product does not infringe an existing listed patent, it files a “Paragraph IV” certification. We filed a Paragraph IV certification in connection with PNT2003. In the case of ANDAs, the Hatch-Waxman Act provides for a potential 180-day period of generic exclusivity for the first company to submit an ANDA with a Paragraph IV certification. This filing triggers a regulatory process in which the FDA is required to delay the final approval of subsequently filed ANDAs containing Paragraph IV certifications until 180 days after the first commercial marketing. When litigation is brought by the
5
patent holder in response to a Paragraph IV certification (like the Novartis entities did for our ANDA for PNT2003), the FDA generally may not approve the ANDA until the earlier of 30 months or a court decision finding the patent invalid, not infringed or unenforceable. The submission of our ANDA for PNT2003 could result in protracted and expensive patent litigation and the outcome of such litigation is uncertain.
Acquisition of Cerveau
On February 6, 2023, we announced that we acquired Cerveau. Cerveau holds the rights under a license agreement to develop and commercialize MK-6240, an investigational second-generation F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease. Under the terms of our purchase agreement, we paid the stockholders of Cerveau (the “Selling Stockholders”) an upfront payment of $35.0 million in February 2023 and an additional $10.0 million in May 2023 upon the successful completion of a technology transfer. The Selling Stockholders are also eligible to receive additional development and commercial milestone payments. Additionally, we will pay double-digit royalty payments for research revenue and commercial sales. Research revenue is derived from existing partnerships with pharmaceutical companies that use MK-6240 in clinical trials and includes milestone and dose-related payments. Pursuant to the terms of the stock purchase agreement for Cerveau, certain members of the Selling Stockholders will also provide transition and clinical development services for a prescribed time following the closing of the transaction.
Our Portfolio of Commercial Products
Radiopharmaceutical Oncology
Our commercial product in our Radiopharmaceutical Oncology category includes the following:
•PYLARIFY (also known as piflufolastat F 18, 18F-DCFPyL or PyL) is an F 18-labelled PSMA-targeted PET imaging agent used with PET/computed tomography (“CT”). PYLARIFY is indicated in the U.S. for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and in men with suspected recurrence based on elevated serum prostate-specific antigen (“PSA”) levels. Piflufolastat F 18 is approved under the name PYLCLARI in Europe and licensed by us to Curium.
Precision Diagnostics
Our commercial products in our Precision Diagnostics category include the following:
•DEFINITY is an injectable ultrasound enhancing agent with perflutren-containing lipid microspheres, or microbubbles, that is used in echocardiography exams. We offer two formulations of DEFINITY, one of which requires refrigerated storage (branded DEFINITY) and one which allows both storage and shipment at room temperature and provides clinicians an additional choice for greater utility of this formulation in broader clinical settings (branded DEFINITY RT). The indication for both formulations in the U.S. is for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. We believe we are currently the leading worldwide provider of ultrasound enhancing agents for use in echocardiography.
•TechneLite is a Technetium (“Tc-99m”) generator that provides the essential nuclear material used by radiopharmacies to radiolabel NEUROLITE, CARDIOLITE and other Tc-99m-based radiopharmaceuticals used in nuclear medicine procedures. TechneLite uses Mo-99 as its active ingredient.
•NEUROLITE is an injectable, Tc-99m-labeled imaging agent used with single-photon emission computed tomography (“SPECT”) technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.
•Xenon-133 (“Xenon”) is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also to image cerebral blood flow. Our Xenon is manufactured by a third party as a bi-product of Mo-99 production and is processed and finished by us.
•CARDIOLITE, also known by its generic name sestamibi, is an injectable, Tc-99m-labeled imaging agent used in myocardial perfusion imaging (“MPI”) procedures to assess blood flow to the muscle of the heart using SPECT. Included in CARDIOLITE revenues are branded CARDIOLITE and generic sestamibi revenues.
Strategic Partnerships and Other Revenue
Our commercial products in our Strategic Partnerships and Other Revenue product category include the following:
•RELISTOR (methylnaltrexone bromide) is a treatment for opioid-induced constipation (“OIC”) that decreases the constipating side effects induced by opioid pain medications such as morphine and codeine without diminishing their ability to relieve pain. RELISTOR is approved in two forms: a subcutaneous injection and an oral tablet. In 2011 Progenics licensed methylnaltrexone (MNTX) along with products containing MNTX, including both approved forms of RELISTOR, to Salix Pharmaceuticals, Inc., a Bausch Health company (“Bausch”) and on August 2, 2023, we sold the right to the RELISTOR net sales royalties under that license agreement and retained the rights to future sales-based milestone payments.
6
•Automated Bone Scan Index (“aBSI”) automatically calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network. aBSI is FDA cleared and CE marked. The software is currently used as one of the correlative objectives of the DORA trial, an open-labeled, randomized, Phase 3 study of docetaxel versus docetaxel in combination with radium-223 (Ra-223) in subjects with mCRPC. aBSI is also approved in Japan and part of the JSMO guidelines (Japanese Society of Medical Oncology) in support of clinicians with patient treatment selection. The Japanese non-exclusive rights to aBSI have been transferred and sold to FUJIFILM Toyama Chemical Co. Ltd. (“FUJIFILM”) under the name BONENAVI®.
•aPROMISE, which is currently commercialized as PYLARIFY AI in the U.S., is artificial intelligence medical device software that is designed to allow HCPs and researchers to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer, including those images obtained by using PYLARIFY.
Additional Information about our Product Categories
Radiopharmaceutical Oncology
Continued Growth of PYLARIFY
PYLARIFY is the leading radiopharmaceutical diagnostic agent indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and in men with suspected recurrence based on elevated PSA levels. PYLARIFY works by binding to PSMA, a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells. PYLARIFY works with PET/CT technology to produce a combined scan that enables the scan reader to detect and locate the disease.
According to the American Cancer Society, prostate cancer is the second most common cancer in American men - one in eight American men will be diagnosed with prostate cancer in their lifetimes and over 3.3 million American men are living with prostate cancer today. Based on estimates from third-party sources regarding the incidence of prostate cancer in men in the U.S., we believe the current market potential for PSMA PET imaging agents in the U.S. for 2024 could be about 445,000 scans, and the total addressable market by 2029 could be over 700,000 annual scans.
PYLARIFY is manufactured on a diverse, F 18 distributor supply network of PMFs, ensuring convenient and reliable supply. After being made on a cyclotron at a PMF, the F 18 is then combined with certain chemical ingredients in specially designed chemistry synthesis boxes to manufacture PYLARIFY. The finished PYLARIFY is then quality control tested and transferred to a radiopharmacist who prepares and dispenses patient-specific doses of the final product. Because each PMF manufacturing PYLARIFY is deemed by the FDA to be a separate manufacturing site, each is separately approved by the FDA. As of December 31, 2023, we had activated 54 PMF manufacturing sites in our PMF network, up from 37 activated sites as of December 31, 2022. These additional sites provide geographic breadth, out-the-door time flexibility and added optionality within our existing PMF network. Overall, we have achieved broad national distribution of PYLARIFY with customers in 47 of 50 states, the District of Columbia and Puerto Rico.
In addition to our network of commercial PMFs, we also work with academic medical centers in the U.S. that have radioisotope-producing cyclotrons and that have expressed an interest in manufacturing PYLARIFY. For this initiative, we enter into a fee-for-service arrangement under which the academic medical center manufactures F 18 on its cyclotron and completes the manufacturing process for PYLARIFY. PYLARIFY can then be used by the academic medical center itself, and in some cases distributed to other customers under separate purchase agreements.
Our Healthcare Procedure Coding System (“HCPCS”) code, which enables streamlined billing, went into effect as of January 1, 2022. In addition, effective January 1, 2022, the Centers for Medicare and Medicaid Services (“CMS”) granted TPT Status in the hospital outpatient setting for PYLARIFY, enabling traditional Medicare to provide an incremental payment for PET/CT scans performed with PYLARIFY in that setting. TPT Status for PYLARIFY is expected to expire on December 31, 2024.
In July 2023, CMS proposed possible changes to its regulations covering payment for diagnostic radiopharmaceuticals. This included, for the first time since 2008, options for separate payment for diagnostics instead of the current packaged payment following expiration of TPT Status. We, along with numerous industry organizations, submitted comments to CMS. In completing its 2023 rulemaking for the 2024 payment calendar year, CMS recognized the challenges of patient access to diagnostic radiopharmaceuticals and requested feedback on various payment alternatives that could provide separate reimbursement for these items, but the agency did not adopt any of these proposals in the final rule, while stating that it would continue to evaluate this issue in subsequent rulemaking. We plan to submit additional comments to CMS in connection with its 2024 rulemaking for the 2025 payment calendar year.
Our continued growth of PYLARIFY will depend on our ability to clinically and commercially differentiate PYLARIFY from other products on the market and to maintain PYLARIFY as the leading PSMA PET imaging agent in a competitive marketplace. PYLARIFY’s current competition is primarily two Gallium-68 (“Ga-68”)-based PSMA imaging agents, a fluorine-18-based PSMA
7
imaging agent, and other non-PSMA-based imaging agents commonly referred to as conventional imaging. Continued growth and revenue contribution from PYLARIFY will also depend on our ability to differentiate PYLARIFY in light of the potential loss of TPT Status, including through flexible and dependable access to PYLARIFY nationally, a best in class customer experience and through long-term strategic contracts.
We actively pursue patents in connection with PYLARIFY, both in the U.S. and internationally. In the U.S. for PYLARIFY, we have five Orange Book-listed patents, including composition of matter patents, the last of which expires in 2037. Outside of the U.S., we have, and are currently pursuing, additional PYLARIFY patents to obtain similar patent protection as in the U.S.
See Part I, Item 1A. “Risk Factors” for information regarding certain risks associated with PYLARIFY and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2023 and 2022 - Revenues” for further information on total revenue contributed by PYLARIFY since its approval.
Precision Diagnostics
Continued Growth of DEFINITY
DEFINITY is the leading ultrasound enhancing agent in the U.S. and is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. Numerous patient conditions can decrease the quality of images of the left ventricle, the primary pumping chamber of the heart. The term DEFINITY includes its activated and non-activated forms and the two formulations it is commercially available in; one that requires refrigerated storage and one that we have branded as DEFINITY RT that may be stored at room temperature.
DEFINITY is a clear, colorless, sterile liquid that, upon activation in a VIALMIX or VIALMIX RFID, medical devices specifically designed for DEFINITY, becomes a homogenous, opaque, milky white injectable suspension of perflutren-containing lipid microspheres. After activation and intravenous injection, DEFINITY opacifies the left ventricular chamber and improves the delineation of the left ventricular endocardial border, or innermost layer of tissue that lines the chamber of the left ventricle. Better visualization of the left ventricle allows clinicians to make more informed decisions about disease status.
Based on estimates from third party sources, we believe there were approximately 29 to 30 million echocardiograms performed in the U.S. in 2022 (the latest time period for which full year data is available). Assuming that between 20% and 30% of echocardiograms produce suboptimal images, as stated in the clinical literature, we estimate that approximately 6 to 9 million echocardiograms in 2022 produced suboptimal images.
Since its launch in 2001, DEFINITY has been used in imaging procedures in more than 25 million studies throughout the world. We estimate that, as of December 31, 2023, DEFINITY had over 80% share of the U.S. segment for ultrasound enhancing agents in echocardiography procedures. DEFINITY currently competes with two other FDA-approved ultrasound enhancing agents, as well as echocardiography without the use of ultrasound enhancing agents and non-echocardiography imaging modalities. DEFINITY and the other FDA-approved ultrasound enhancing agents all carry an FDA-required boxed warning, which has been modified over time, to notify physicians and patients about potentially serious safety concerns or risks posed by the products. See Part I, Item 1A. “Risk Factors-Ultrasound enhancing agents may cause side effects which could limit our ability to sell DEFINITY.”
We continue to actively pursue additional patents in connection with DEFINITY and DEFINITY RT, both in the U.S. and internationally. In the U.S. for DEFINITY, we have six Orange Book-listed method-of-use patents, one of which expires in 2035 and five of which expire in 2037, as well as additional manufacturing patents that are not Orange Book-listed expiring in 2037. In the U.S. for DEFINITY RT, we have eight Orange Book-listed patents, including two composition of matter patents which expire in 2035. The Orange Book-listed patents include a patent on the use of VIALMIX RFID (see below), which expires in 2037; we have submitted additional VIALMIX RFID patent applications in major markets throughout the world.
Even though our longest duration Orange Book-listed DEFINITY patent extends until March 2037, because our Orange Book-listed composition of matter patent expired in June 2019, we may face generic DEFINITY challenges in the near to intermediate term. See “Intellectual Property – Patents” below.
As noted above, DEFINITY is activated through the use of medical devices branded as VIALMIX and VIALMIX RFID. The activation rate and time are controlled by VIALMIX RFID through the use of radio-frequency identification technology (“RFID”) to ensure reproducible activation of DEFINITY. The RFID tag, which is affixed to the vial label, enables the DEFINITY vial to be appropriately activated with the VIALMIX RFID activation device.
To manufacture DEFINITY that requires refrigeration, historically, we have relied on Jubilant HollisterStier (“JHS”) as a significant supplier. We constructed a specialized in-house manufacturing facility at our North Billerica campus for purposes of
8
producing this formulation of DEFINITY and, potentially, other sterile vial products. On February 22, 2022, we received FDA approval of our supplemental new drug application (“sNDA”), authorizing commercial manufacturing of this formulation of DEFINITY at our new facility. We believe this investment provides supply chain redundancy, improved flexibility and reduced costs in a potentially more price competitive environment.
See Part I, Item 1A. “Risk Factors” for information regarding certain risks associated with DEFINITY and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2023 and 2022 - Revenues” for further information on revenue contributed by DEFINITY.
TechneLite
TechneLite is a self-contained system or generator of Tc-99m, a radioactive isotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents. Tc-99m results from the radioactive decay of Mo-99, itself a radioisotope with a 66-hour half-life sourced in our supply chain in nuclear research reactors located in Belgium, South Africa and Australia from enriched uranium. The TechneLite generator is a self-contained system that houses a vertical glass column at its core that contains Mo-99, which degrades to Tc-99m. During our manufacturing process, Mo-99 is added to the column within the generator where it is adsorbed onto alumina powder. The column is sterilized, enclosed in a lead shield and further sealed in a cylindrical plastic container, which is then immediately shipped to our radiopharmacy customers. Because of the short half-lives of Mo-99 and Tc-99m, radiopharmacies typically purchase TechneLite generators on a weekly basis pursuant to standing orders.
The Tc-99m produced by our TechneLite generator is the medical radioisotope that can be attached to a number of imaging agents, including our own NEUROLITE and CARDIOLITE products, during the radiolabeling process. To radiolabel a Tc-99m-based radiopharmaceutical, a vial of sterile saline and a vacuum vial are each affixed to the top of a TechneLite generator. The sterile saline is pulled through the generator where it attracts Tc-99m resulting from the radioactive decay of Mo-99 within the generator column. The Tc-99m-containing radioactive saline is then pulled into a vacuum vial and subsequently combined by a radiopharmacist with the applicable imaging agent, which allows the preparation of individual patient-specific radiolabeled imaging agent doses. When administered, the imaging agent binds to specific tissues or organs for a period of time, enabling the Tc-99m to illuminate the functional health of the imaged tissues or organs in a diagnostic image. Our ability to produce and market TechneLite is highly dependent on our supply of Mo-99. See “Raw Materials and Supply Relationships—Molybdenum-99” below.
TechneLite is currently marketed primarily in the U.S., Canada, Central America and South America, largely to radiopharmacies that prepare unit doses of radiopharmaceutical imaging agents and ship these preparations directly to hospitals for administration to patients. In the U.S., we have supply contracts with large radiopharmacy groups, including PharmaLogic Holdings Corp (“PharmaLogic”), Cardinal Health (“Cardinal”), RLS (USA) Inc. (previously GE Healthcare) (“RLS”) and United Pharmacy Partners (“UPPI”). We also supply generators on a purchase order basis to other customers. We estimate that TechneLite had approximately one third of the U.S. generator market as of December 31, 2023, competing primarily with Tc-99m-based generators produced by Curium.
We believe that our substantial capital investments in our TechneLite production line and our extensive experience in complying with the stringent regulatory requirements for the handling of nuclear materials, create significant and sustainable competitive advantages for us in generator manufacturing and distribution. Given our significant know-how and trade secrets associated with the methods of manufacturing and assembling the TechneLite generator, we believe we have a substantial amount of valuable and defensible proprietary intellectual property associated with the product. In addition, TechneLite has patent protection in the U.S. and various foreign countries on certain component technology currently until 2029, and we are pursuing additional patent protection in the U.S. and world-wide on other component technology that, if granted, would expire in 2040.
See Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2023 and 2022 - Revenues” for further information on revenue contributed by TechneLite.
Strategic Partnerships and Other Revenue
We continue to seek ways to further increase the overall value of our portfolio of products and product candidates. We are evaluating a number of different opportunities to collaborate, in-license or acquire additional products, product candidates, businesses and technologies to drive our future growth. In particular, we are focused on radiopharmaceutical therapeutic and diagnostic product opportunities in oncology and other strategic areas that complement our existing portfolio. Our Pharma Solutions business focuses on advancing innovative imaging biomarker solutions, such as MK-6240, through collaborations with pharmaceutical companies and academic centers. Our Digital Solutions business focuses on developing and commercializing 510(k) cleared and CE marked digital applications to enhance the performance of imaging agents; our Digital Solutions portfolio currently includes aBSI, aPROMISE and PYLARIFY AI.
Oncology
9
As we continue to pursue expanding strategic partnerships, our Pharma Solutions activities in oncology include:
•Prostate Cancer – We collaborate with pharmaceutical companies developing therapies and diagnostics in prostate cancer.
▪In July 2023, Curium (our licensee that is developing and commercializing piflufolastat F 18 in Europe) announced that it received marketing authorization for piflufolastat F 18, under the name PYLCLARI, from the European Commission. In addition, we previously entered into an agreement with Curium to add PYLARIFY to its U.S. ECLIPSE trial, a multi-center, open-label, randomized Phase 3 trial comparing the safety and efficacy of Curium’s PSMA-targeted therapeutic versus hormone therapy in patients mCRPC. PYLARIFY will be used to determine PSMA-avidity as part of patient selection.
•We have also entered into several other separate agreements, including with RefleXion Medical, Inc., POINT and Regeneron Pharmaceuticals, Inc., under which we supply PYLARIFY in connection with their clinical trials and with the Prostate Cancer Clinical Trial Consortium (“PCCTC”), a premier multicenter clinical research organization that specializes in prostate cancer research. The intent of the strategic collaboration with PCCTC is to integrate our artificial intelligence (“AI”) platform into PCCTC studies to advance the development and validation of novel AI-enabled biomarkers.
◦Immuno-Oncology - We entered into a strategic collaboration and license agreement with NanoMab Technology Limited (“NanoMab”), a privately-held biopharmaceutical company focused on the development of next generation radiopharmaceuticals for cancer precision medicine, to develop NM-01, a novel technetium-99m SPECT imaging agent under development to assess PD-L1 expression in cancer cells. In connection with the collaboration, NanoMab recently completed a Phase 2 clinical trial at King’s College London. The Phase 2 clinical trial was an open-label, single-arm trial in non-small cell lung cancer patients. The primary endpoint was the assessment of PD-L1 expression in primary tumor and metastatic lesions by NM-01 compared to immunohistochemistry. Other objectives were aimed at quantifying intra- and inter-tumoral heterogeneity of PD-L1 expression by NM-01, as well as establishing correlations with other diagnostic procedures. We expect results from the clinical trial to be presented at an upcoming medical congress.
◦Pan-Oncology - In collaboration with Ratio Therapeutics LLC (“Ratio”) (previously Noria Therapeutics, Inc.), we are developing LNTH-1363S, a novel copper-64 labeled PET imaging agent, targeting fibroblast activation protein alpha. We believe this diagnostic agent candidate could have broad potential applicability and use in oncology and also in inflammatory diseases. Recently, in collaboration with Ratio, we completed a Phase 1 study for LNTH-1363S to evaluate the pharmacokinetics, biodistribution and radiation dosimetry in adult healthy volunteers. We plan to initiate a Phase 1/2a study in patients in 2024.
Microbubble Franchise
In addition, we continue to seek to optimize our microbubble platform through new collaborations. Some of our microbubble collaborations are with the following parties: (i) Cerevast Medical, Inc. (“Cerevast”), in which our microbubbles will be used in connection with Cerevast’s ocular ultrasound device to improve blood flow in occluded retinal veins in the eye; (ii) CarThera SAS (“CarThera”), for the use of our microbubbles in combination with SonoCloud, a proprietary implantable device in development for the treatment of recurrent glioblastoma; (iii) Insightec Ltd. (“Insightec”), which will use our microbubbles in connection with the development of Insightec’s transcranial guided focused ultrasound device for the treatment of glioblastoma as well as other neurodegenerative conditions; (iv) Allegheny Health Network (“AHN”) which will use our microbubbles in combination with AHN’s ultrasound-assisted non-viral gene transfer technology for the development of a proposed treatment of xerostomia; and (v) SonoThera, Inc. (“SonoThera”), who will use our microbubbles in combination with their ultrasound-guided, non-viral, gene therapy platform and treatments.
In March 2012, we entered into a development and distribution arrangement with China Resources Double-Crane (“Double-Crane”) for DEFINITY in China, Hong Kong and Macau. Double-Crane has conducted on our behalf three confirmatory clinical trials in pursuit of cardiac, liver and kidney imaging indications, as well as one small pharmacokinetic study. In November 2022, we announced the approval of our Import Drug License application with the National Medical Products Administration (“NMPA”) for the use of DEFINITY in patients with suboptimal conventional echocardiography and to better identify the left ventricular endocardial border. Double-Crane is responsible for obtaining adequate coding, coverage and payment and commercializing DEFINITY in China under a local brand name. Double-Crane is also in the process of analyzing the clinical results relating to liver and kidney indications and will also work with us to prepare an Import Drug License application for those indications, as appropriate.

MK-6240
MK-6240 is an investigational clinical stage F 18-labeled PET imaging development candidate designed to detect Tau protein in the form of neurofibrillary tangles in the brains of patients with known or suspected Alzheimer’s disease. MK-6240 is being used as a
10
biomarker in more than 90 active clinical trials for Alzheimer’s disease therapeutic candidates. Research revenue related to MK-6240 is derived from the use of MK-6240 in those clinical trials and includes milestone and dose-related payments.
RELISTOR
•On August 2, 2023, we sold our right to our RELISTOR net sales royalties under our license agreement with Bausch; we retained the rights to future sales-based milestone payments. Pursuant to our license agreement with Bausch, we are eligible to receive one-time sales milestone payments upon achievement of specified U.S. net sales targets, including:

U.S. Net Sales Levels in any Single Calendar Year
Payment ($)
(In thousands)
In excess of $150 million
15,000
In excess of $200 million
20,000
In excess of $300 million
30,000
In excess of $750 million
50,000
In excess of $1 billion
75,000
Each sales milestone payment is payable one time only, regardless of the number of times the condition is satisfied, and all five remaining payments could be made within the same calendar year. During the fourth quarter of 2023, the Company earned the $15.0 million sales-based milestone payment listed above.
aBSI
•aBSI automatically calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network. The cloud based aBSI was made available for clinical use in the U.S. on August 5, 2019. In February 2020, Progenics received European Conformity Marking (“CE marking”) for the standalone workstation model of aBSI, meeting the quality standards set by the European Economic Area. In September 2020, the FDA granted 510(k) clearance for the use of aBSI as software-as-a-medical device on a GE Healthcare imaging system.
PYLARIFY AI
•PYLARIFY AI is artificial intelligence medical device software that is designed to allow healthcare professionals and researchers to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer, including those images obtained by using PYLARIFY. PYLARIFY AI has demonstrated improved consistency, accuracy and efficiency in quantitative assessment of PSMA PET/CT. The technology analyzes the PET/CT image to segment anatomical regions, including 51 bones and 12 soft tissue organs. This image segmentation enables automated localization, detection and quantification of potential PSMA-avid lesions in the PET/CT image, which is incorporated into a standardized report for physicians. PYLARIFY AI can be deployed either as a secure web cloud application or within the secure firewall of the institution on a local server. Once deployed, the adaptive application can be integrated into an institution’s existing clinical workflow, delivering a unique combination of clinical utility and technical flexibility. Our subsidiary, EXINI, was granted 510(k) clearance by the FDA in the U.S. and received a CE marking in Europe for aPROMISE. We commercially launched aPROMISE under the name PYLARIFY AI in the U.S. in November 2021 and the FDA granted us an additional 510(k) clearance during the second quarter of 2022.
[18F] flurpiridaz
•GE Healthcare Agreement – In 2017, we entered into a definitive, exclusive Collaboration and License Agreement with GE Healthcare for the continued Phase 3 development and worldwide commercialization of flurpiridaz, a fluorine 18-based PET MPI agent designed to assess blood flow to the heart in patients suspected of coronary artery disease (“CAD”). Under our agreement, GE Healthcare will complete the development of flurpiridaz, pursue worldwide regulatory approvals, and, if successful, lead a worldwide launch and commercialization of the agent, with us collaborating on both development and commercialization through a joint steering committee. We also have retained the right to co-promote the agent in the U.S. GE Healthcare’s development plan initially focuses on obtaining regulatory approval in the U.S., Japan, Europe and Canada. Under the agreement, we received an upfront cash payment of $5.0 million and are eligible to receive up to $60.0 million in regulatory and sales milestone payments, tiered double-digit royalties on U.S. sales, and mid-single digit royalties on sales outside of the U.S. In September 2022, we announced with GE Healthcare that the second Phase 3 clinical trial had met its co-primary endpoints of exceeding a 60% threshold for both sensitivity and specificity for detecting CAD. The findings,
11
shared at an American Society of Nuclear Cardiology conference, also indicated that cardiac PET imaging with flurpiridaz demonstrated higher diagnostic efficacy and image quality in patients with suspected CAD, compared with SPECT MPI, the predominant procedure currently used in nuclear cardiology. GE Healthcare recently announced that it had filed an NDA with the FDA for flurpiridaz. Assuming regulatory approval, we anticipate commercialization by GE Healthcare beginning in the second half of 2024.
See Part I, Item 1A. “Risk Factors” for information regarding certain risks associated with our strategic activities.
Our Clinical Development Candidates
In addition to our commercial products and strategic partnerships with third parties, we also have ongoing clinical development programs, including, among others, the following:
•PNT2002 is an investigational PSMA-targeted radiopharmaceutical therapy for the treatment of mCRPC. On December 18, 2023, we announced positive topline results from SPLASH, the Phase 3 registrational trial for PNT2002 designed to evaluate superiority to the standard of care in mCRPC pre-chemotherapy patients who have failed one androgen receptor pathway inhibitor.
•PNT2003 is an investigational SSTR therapy with non-carrier added lutetium-177, which is in registration to treat patients with SSTR-positive neuroendocrine tumors. On January 11, 2024, we announced that our ANDA for PNT2003 was accepted for filing by the FDA. On January 26, 2024, we were sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the filing of our ANDA and Paragraph IV certification, consistent with the process established by the Hatch-Waxman Act.
•MK-6240 is an investigational second-generation F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease. MK-6240 is currently being used in more than 90 active clinical trials for several Alzheimer’s disease therapeutic candidates being developed.
•LNTH-1363S is an investigational fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent candidate that we believe could have broad potential imaging applicability and use in oncology. Recently, we completed a Phase 1 study for LNTH-1363S to evaluate the pharmacokinetics, biodistribution and radiation dosimetry in adult healthy volunteers.
•1095 (also known as 131 I-MIP-1095) is an investigational PSMA-targeted iodine-131-labeled small molecule that is designed to deliver a dose of beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. We enrolled the last patient in our ARROW Phase 2 study during the second quarter of 2022. Patients in this study will be followed for one year after their first treatment for all efficacy endpoints and survival and safety data will be collected for an additional year.
For the years ended December 31, 2023, 2022 and 2021, we invested $77.7 million, $311.7 million and $45.0 million in research and development (“R&D”), respectively, primarily related to our clinical development candidates. In addition to our clinical development group, our R&D team also includes our Medical Affairs and Medical Information functions, which educate physicians on the scientific aspects of our commercial products and the approved indications.
See Part I, Item 1A. “Risk Factors” for information regarding certain risks associated with our strategic partnerships and clinical development programs.
12
Distribution, Marketing and Sales
The following table sets forth certain key market information for each of our commercial pharmaceutical products within each product category:
ProductApproved Markets
Radiopharmaceutical Oncology
PYLARIFY European Union*, United States
Precision Diagnostics
DEFINITY (or LUMINITY)Australia, Canada, China, European Union, European Economic Area, Israel, New Zealand, United Kingdom, United States
DEFINITY RTUnited States
TechneLiteAustralia, Canada, Colombia, Costa Rica, South Korea, Taiwan, United States
NEUROLITEAustralia, Belgium, Canada, Costa Rica, Denmark, France, Hong Kong, Italy, Japan, Luxembourg, South Korea, Spain, Taiwan, United States
XenonUnited States
CARDIOLITEAustralia, Canada, Israel, Japan, New Zealand, South Korea, Taiwan, United States
Strategic Partnerships and Other Revenue
RELISTOR (Solution for Injection 12 mg/0.6 mL vial)Austria, Belgium, Bulgaria, Canada, Switzerland, Cypress, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Croatia, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, United Kingdom, United States
RELISTOR (Solution for Injection in pre-filled syringe 8mg and pre-filled syringe 12 mg)Austria, Belgium, Bulgaria, Canada, Cypress, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Croatia, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, United Kingdom, United States
RELISTOR (methylnaltrexone bromide) Oral Tablet 140 mgUnited States
*Approved under the name PYLCLARI and licensed to Curium.
With respect to our medical devices:
•Progenics received CE marking for the standalone workstation model of aBSI, meeting the quality standards set by the European Economic Area. In September 2020, the FDA granted 510(k) clearance for the use of aBSI as software-as-a-medical device on a GE Healthcare imaging system.
•EXINI was granted 510(k) clearance by the FDA in the U.S. and received CE marking in Europe for aPROMISE. We launched aPROMISE under the name PYLARIFY AI in the U.S.
PYLARIFY sales are generated in the U.S. through an internal PYLARIFY sales team, as well as a sales team at some of our PMF partners. Sales of DEFINITY are generated in the U.S. through an internal DEFINITY sales team. While a small portion of our nuclear imaging product sales in the U.S. are generated through our internal sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical preparation capabilities, we primarily sell our nuclear imaging products, including TechneLite, NEUROLITE, Xenon, and CARDIOLITE, to large radiopharmacy chains. We have licensed RELISTOR to Bausch, and while we have sold the right to our RELISTOR net sales royalties under our license agreement, we have retained the rights to future sales-based milestone payments generated by Bausch.
Seasonality
We have some modest seasonality for our products as patients may seek to schedule diagnostic imaging and other procedures less frequently during the summer vacation months and over the year-end holidays.
Customers
No customer accounted for greater than 10% of revenues for the years ended December 31, 2023, 2022, and 2021.
13
Backlog
Our backlog consists of orders for which a delivery schedule within the next twelve months has been specified. Orders included in backlog may be canceled or rescheduled by customers at any time with the exception of TechneLite orders. For TechneLite, customers must provide us with four weeks advanced notice to cancel an order. We do not believe that our backlog at any particular time is meaningful because it has historically been immaterial relative to our consolidated revenues and is not necessarily indicative of future revenues for any given period.
Competition
We believe that our key product characteristics, such as proven efficacy, reliability and safety, coupled with our core competencies, such as our efficient manufacturing processes, our established distribution network, our experienced field sales organization and our customer service focus, are important factors that distinguish us from our competitors.
The markets for our products are highly competitive and continually evolving. Our principal competitors for our current commercial products and leading clinical development candidates include large, global companies that are more diversified than we are and that have substantial financial, manufacturing, sales and marketing, distribution and other resources.
•For PYLARIFY, our principal competitors are currently Telix Pharmaceuticals Limited, Novartis AG, and Blue Earth Diagonstics Ltd. (“Blue Earth”), a subsidiary of Bracco Diagnostics Inc. (“Bracco”).
•For DEFINITY, our competitors currently include GE Healthcare and Bracco.
•For a number of our SPECT radiopharmaceutical commercial products, our competitors currently include Curium, GE Healthcare, Bracco and Jubilant Life Sciences, an affiliate of JHS and Jubilant Radiopharma, and potentially BWXT Medical.
The markets into which any of our product candidates would be launched, if approved, are also highly competitive and continually evolving.
•For PNT2002 and 1095, our principal competitors may include Novartis AG; Telix Pharmaceuticals Limited; and Curium, each of which has commercialized products or product candidates in advanced clinical stage of development.
•For PNT2003, our principal competitor may include Novartis AG; ITM Radiopharma; and RayzeBio (under agreement to be acquired by Bristoll Meyers Squibb), each of which has commercialized products or product candidates in advanced clinical stage development.
•For MK-6240, our principal competitors may include Eli Lilly and Company and Life Molecular Imaging, each of which has commercialized products or product candidates in advanced clinical stage of development.
•For LNTH-1363S, our principal competitors may include Sofie Bioscience; GE Healthcare; and Novartis AG, each of which has product candidates in clinical stage of development.
We cannot anticipate the actions of our current or future competitors in the same or competing therapeutic and diagnostic modalities, such as significant price reductions on products that are comparable to our own, development of new products or other technologies that are more cost-effective or have superior performance than our current products or the introduction of generic versions after our proprietary products lose their patent protection. In addition, distributors of our products could attempt to shift end-users to competing modalities and products, or bundle the sale of a portfolio of products, to the detriment of our specific products. Our current or future products could be rendered obsolete or uneconomical as a result of these activities.
Further, the radiopharmaceutical and biopharmaceutical industry continues to evolve strategically, with several market participants recently sold. In addition, the supply-demand dynamics of the industry are complex because of large market positions of some participants, legacy businesses, government subsidies (in particular, relating to the manufacture of radioisotopes), government reimbursement policies, such as TPT Status, and group purchasing arrangements. We cannot predict what impact new owners and new operators may have on the strategic decision-making of our competitors, customers and suppliers.
Raw Materials and Supply Relationships
We rely on certain raw materials and supplies to produce our products. Due to the specialized nature of our products and the limited, and sometimes intermittent, supply of raw materials available in the market, we have established relationships with several key suppliers. For the year ended December 31, 2023, our largest suppliers of raw materials and supplies were Institute for Radioelements (“IRE”), the Australian Nuclear Science and Technology Organisation (“ANSTO”) and NTP Radioisotopes (“NTP”), which, in the aggregate, accounted for approximately 9.3% of our total purchases.
14
Molybdenum-99
Our TechneLite, CARDIOLITE and NEUROLITE products all rely on Mo-99, the radioisotope which is produced by bombarding uranium with neutrons in research reactors. With a 66-hour half-life, Mo-99 decays into, among other things, Tc-99m, another radioisotope with a half-life of six hours. Tc-99m is the isotope that is attached to radiopharmaceuticals, including our own NEUROLITE and CARDIOLITE, during the labeling process and is the most common radioisotope used for medical diagnostic imaging purposes.
We currently purchase finished Mo-99 from three of the four main processing sites in the world, namely IRE in Belgium, NTP in South Africa and ANSTO in Australia. These processing sites provide us Mo-99 from five of the six main Mo-99-producing reactors in the world, namely BR2 in Belgium, LVR-15 in the Czech Republic, HFR in The Netherlands, SAFARI in South Africa and OPAL in Australia.
Our agreement with IRE (the “IRE Agreement”) contains minimum percentage volume requirements and unit pricing. The IRE Agreement also requires IRE to provide certain favorable allocations of Mo-99 during periods of supply shortage or failure. The IRE Agreement allows for termination upon the occurrence of certain events, including failure by IRE to provide our required amount of Mo-99, material breach of any provision by either party, bankruptcy by either party or force majeure events. The IRE Agreement expires on December 31, 2024, and automatically renews on an annual basis thereafter, subject to prior notice of non-renewal by either party.
Our agreement with NTP (the “NTP Agreement”), with NTP acting for itself and on behalf of its subcontractor ANSTO, specifies our percentage purchase requirements and unit pricing, and provides for the supply of Mo-99. The NTP Agreement allows for termination upon the occurrence of certain events, including failure by NTP to provide our required amount of Mo-99, material breach of any provision by either party, bankruptcy by either party or force majeure events. The NTP Agreement expires on December 31, 2024.
Although we have a globally diverse Mo-99 supply with IRE in Belgium, NTP in South Africa, and ANSTO in Australia, we still face supplier and logistical challenges in our Mo-99 supply chain. When one supplier experiences outages, we generally rely on Mo-99 supply from the other suppliers to limit the impact of the outages. We believe we effectively manage these various supply chain challenges, but depending on reactor and processor schedules and operations, at times we have not been able to fill some or all of the demand for our TechneLite generators on certain manufacturing days. A prolonged disruption of service from one of our three Mo-99 processing sites or one of their main Mo-99-producing reactors could have a substantial negative effect on our business, results of operations, financial condition and cash flows.
Xenon
Xenon is a by-product of the Mo-99 production process. Under a strategic agreement entered into in 2021, we receive from IRE bulk unprocessed Xenon, which we process and finish for our customers at our North Billerica, Massachusetts manufacturing facility. That contract runs through December 31, 2025, with auto-renewal provisions and is terminable upon notice of non-renewal. Until we can qualify an additional source of bulk unprocessed Xenon, we will rely on IRE as a sole source provider.
Other Materials
We have additional supply arrangements for active pharmaceutical ingredients, excipients, packaging materials and other materials and components, none of which are exclusive, but a number of which are sole source, and all of which we currently believe are either in good standing or replaceable without any material disruption to our business.
See Part I, Item 1A. “Risk Factors” for information regarding certain risks associated with our raw materials and supply arrangements.
Manufacturing
The commercial manufacture of PYLARIFY required us to create a field-based network of specialized PMFs with radioisotope-producing cyclotrons. The radioisotope used in PYLARIFY is F 18, which has a 110 minute half-life, requiring that this agent be manufactured and distributed rapidly to end-users. After being made on a cyclotron at a PMF, the F 18 is then combined with certain chemical ingredients in specially designed chemistry synthesis boxes to manufacture PYLARIFY. The finished PYLARIFY is then quality control tested and transferred to a radiopharmacist who prepares and dispenses patient-specific doses from the final product. Because each of the PMFs manufacturing PYLARIFY is deemed by the FDA to be a separate manufacturing site, each requires separate FDA approval.
We have a specialized in-house manufacturing facility at our North Billerica campus for purposes of producing the formulation of DEFINITY that requires refrigerated storage and, potentially, other sterile vial products. On February 22, 2022, we received FDA
15
approval of our sNDA, authorizing commercial manufacturing of DEFINITY at our new facility. DEFINITY manufactured at this facility became commercially available on February 23, 2022. We believe this investment provides supply chain redundancy, improved flexibility and reduced costs in a potentially more price competitive environment.
We also manufacture TechneLite on an automated production line and we process and finish Xenon on a hot cell line at our North Billerica, Massachusetts facility.
We manufacture, finish and distribute our radiopharmaceutical products on a just-in-time basis, and supply our customers with these products either by next day delivery services or by either ground or air custom logistics. We believe that our substantial capital investments in our automated generator production line and our other manufacturing assets, which we have made over the years, and our extensive experience in complying with the stringent regulatory requirements for the handling of nuclear materials and operations in a highly regulated environment, create significant and sustainable competitive advantages for us.
In addition to our in-house manufacturing capabilities, a substantial portion of our products are manufactured by third party contract manufacturing organizations, and in certain instances, we rely on them for sole source manufacturing. To ensure the quality of the products that are manufactured by third parties, the key raw materials used in those products are first sent to our North Billerica, Massachusetts facility, where we test them prior to the third party manufacturing of the final product. For many of our products, after the final products are manufactured, they are sent back to us for final quality control testing, and then we ship them to our customers. We have expertise in the design, development and validation of complex manufacturing systems and processes, and our strong execution and quality control culture supports the just-in-time manufacturing model at our facilities.
Manufacturing and Supply Arrangements
We currently have the following technology transfer and manufacturing and supply agreements in place for some of our major products:
•PYLARIFY—We have entered into commercial supply agreements with different PMF networks. Our agreements with our PMF networks allow for the termination upon the occurrence of specified events, including material breach or bankruptcy by either party, and have various termination dates generally terminating between 2025 and 2030 and are subject to renewal provisions.
•DEFINITY, CARDIOLITE and NEUROLITE—In February 2022, we entered into a Manufacturing and Supply Agreement with JHS, for the manufacture of DEFINITY, CARDIOLITE, NEUROLITE and evacuation vials, the latter being an ancillary component for our TechneLite generators. The agreement expires on December 31, 2027, and can be renewed upon mutual consent. The agreement allows for termination upon the occurrence of certain events such as a material breach or default by either party, or bankruptcy by either party. The agreement also requires us to order from JHS a specified minimum percentage of our requirements for DEFINITY and fixed quantities of CARDIOLITE and NEUROLITE each year during the contract term.
See Part I, Item 1A. “Risk Factors” for information regarding certain risks associated with our manufacturing and supply relationships.
Intellectual Property
Patents, trademarks and other intellectual property rights, both in the U.S. and foreign countries, are very important to our business. We also rely on trade secrets, manufacturing know-how, technological innovations, licensing agreements and confidentiality agreements to maintain and improve our competitive position. We review third party proprietary rights, including patents and patent applications, as available, in an effort to develop an effective intellectual property strategy, avoid infringement of third party proprietary rights, identify licensing opportunities and monitor the intellectual property owned by others. Our ability to enforce, defend and protect our intellectual property rights may be limited in certain countries outside the U.S., which could make it easier for competitors to capture market position in those countries by utilizing technologies that are similar to those developed or licensed by us. Competitors also may harm our sales by designing products that mirror the capabilities of our products or technology without infringing our intellectual property rights. If we do not obtain sufficient protection for our intellectual property, or if we are unable to effectively enforce or defend our intellectual property rights or our freedom to operate, our competitiveness could be impaired, which would limit our growth and future revenue. If we elect to enforce our intellectual property rights, or are required to defend our rights, we could incur significant litigation expense.
Trademarks, Service Marks and Trade Names
We own various trademarks, service marks and trade names, including, among others, PYLARIFY, DEFINITY and Find Fight and Follow. We have generally registered these trademarks, as well as others, in the U.S. and/or numerous foreign jurisdictions.
16
Patents
We actively seek to protect the proprietary technology that we consider important to our business, including chemical species, compositions and formulations, their methods of use and processes for their manufacture, as new intellectual property is developed. In addition to seeking patent protection in the U.S., we file patent applications in numerous foreign countries in order to further protect the inventions that we consider important to the development of our international business. We also rely upon trade secrets and contracts to protect our proprietary information.
We have patent protection on certain of our commercial products and clinical development candidates. We typically seek patent protection in major markets around the world, including, among others, the U.S., Canada, Western Europe, Asia, Central America and South America. All patent terms described below are presented without giving effect to any applicable patent term adjustments or regulatory extensions.
PYLARIFY - We actively pursue patents in connection with PYLARIFY, both in the U.S. and internationally. In the U.S. for PYLARIFY, we have five Orange Book-listed patents, including composition of matter patents, the last of which expire in 2037. Outside of the U.S., we have, and are currently pursuing, additional PYLARIFY patents to obtain similar patent protection as in the U.S.
DEFINITY - We continue to actively pursue additional patents in connection with DEFINITY and DEFINITY RT, both in the U.S. and internationally. In the U.S. for DEFINITY, we have six Orange Book-listed method-of-use patents, one of which expires in 2035 and five of which expire in 2037, as well as additional manufacturing patents that are not Orange Book-listed expiring in 2037. In the U.S. for DEFINITY RT, we have eight Orange Book-listed patents, including two composition of matter patents which expire in 2035. Outside of the U.S., we are currently pursuing additional DEFINITY and DEFINITY RT patents to obtain similar patent protection as in the U.S. The Orange Book-listed patents include a patent on the use of VIALMIX RFID which expires in 2037; additional VIALMIX RFID patent applications have been submitted in major markets throughout the world.
Even though our longest duration Orange Book-listed DEFINITY patent extends until March 2037, because our Orange Book-listed composition of matter patent expired in June 2019, we may face generic DEFINITY challengers in the near to intermediate term. Under the Hatch-Waxman Act, the FDA can approve ANDAs for generic versions of drugs if the ANDA applicant demonstrates, among other things, that (i) its generic candidate is the same as the innovator product by establishing bioequivalence and providing relevant chemistry, manufacturing and product data, and (ii) either the marketing of that generic candidate does not infringe the Orange Book-listed patent(s) or the Orange Book-listed patent(s) is invalid. Similarly, the FDA can approve a Section 505(b)(2) NDA from an applicant that relies on some of the information required for marketing approval to come from studies which the applicant does not own or have a legal right of reference. With respect to the Orange Book-listed patent(s) covering an innovator product, the ANDA applicant or the Section 505(b)(2) applicant (if relying on studies related to the innovator product) (together, the “Applicant”) must give a notice (a “Notice”) to the innovator of its certification that its generic candidate will not infringe the innovator’s Orange Book-listed patent(s) or that the Orange Book-listed patent(s) is invalid. The innovator can then file suit against the Applicant within 45 days of receiving the Notice, and FDA approval to commercialize the generic candidate will be stayed (that is, delayed) for up to 30 months (measured from the date on which a Notice is received) while the patent dispute between the innovator and the Applicant is resolved in court. The 30-month stay could potentially expire sooner if the courts determine that no infringement had occurred or that the challenged Orange Book-listed patent is invalid or if the parties otherwise settle their dispute. Submission of an ANDA with a Paragraph IV certification can result in protracted and expensive patent litigation.
As of the date of filing of this Annual Report on Form 10-K, we have not received any Notice from an Applicant. If we were to (i) receive any such Notice in the future, (ii) bring a patent infringement suit against the Applicant within 45 days of receiving that Notice, and (iii) successfully obtain the full 30-month stay, then the Applicant would be precluded from commercializing a generic version of DEFINITY prior to the expiration of that 30-month stay period and, potentially, thereafter, depending on how the patent dispute is resolved. Solely by way of example and not based on any knowledge we currently have, if we received a Notice from an Applicant in March 2024 and the full 30-month stay were obtained, then the Applicant would be precluded from commercialization until at least September 2026. If we received a Notice some number of months in the future and the full 30-month stay were obtained, the commercialization date would roll forward in the future by the same number of months. In the event a 505(b)(2) applicant does not rely on studies related to the innovator product, the 30-month stay would not apply, but additional clinical trials may be required.
TechneLite - We currently own patents in the U.S. and various foreign countries on certain component technology expiring in 2029, and we are pursuing additional patent protection in the U.S. and world-wide on other component technology that, if granted, would expire in 2040. In addition, given the significant know-how and trade secrets associated with the methods of manufacturing and assembling the TechneLite generator, we believe we have a substantial amount of valuable and defensible proprietary intellectual property associated with the product.
17
PYLARIFY AI - U.S. Patents and pending patent applications worldwide relating to automated medical image analysis, have expiration ranging from 2037 to 2041.
Other Nuclear Products - Neither CARDIOLITE nor NEUROLITE is covered any longer by patent protection in either the U.S. or the rest of the world. We have patent protection in the U.S. that expires in October 2035 for an improved container for Xenon, and are pursuing similar patent protection outside the U.S.
aBSI - We own patents relating to automated detection of bone cancer metastases. The patents on this technology expire in the U.S. in 2032 and outside of the U.S. in 2028. Further, we own a U.S. patent and have patent applications that are pending in the U.S. and worldwide relating to aBSI improvements, which have expiration ranging from 2040 to 2041.
flurpiridaz - We own patents and patent applications in numerous jurisdictions covering composition, use, formulation and manufacturing, including in the U.S. a composition of matter patent expiring in 2026, a formulation patent expiring in 2032, a method-of-use patent expiring in 2028, and manufacturing-related patents expiring in 2031 and 2033, and various patent applications, some of which, if granted, will expire in 2033.
PNT2002 - We exclusively license granted U.S. patents and pending U.S. patent applications as well as pending patent applications in jurisdictions outside of the U.S. directed to formulations, use and manufacturing of PNT2002. The granted U.S. patents expire in 2041.
PNT2003 - We exclusively license pending U.S. patent applications as well as pending patent applications in jurisdictions outside of the U.S. directed to formulations, use and manufacturing of PNT2003 which, if granted, would expire in 2041.
MK-6240 - We exclusively license patents directed to composition of matter and methods of use of MK-6240 which expire in 2035.
1095 - We own patents relating to 1095, with the composition of matter patent as well as radiolabeled forms patent in the U.S. and Europe expiring in 2027. Additional U.S. patents that we own for stable compositions and radiolabeling processes expire, respectively, in 2030 and 2031.
LNTH-1363S - We exclusively license patent applications directed to compositions of matter and methods of use of LNTH-1363S. If granted, the last patent will expire in 2043.
NM-01- We exclusively license in the field of imaging, patents and applications directed to compositions of matter of NM-01. The granted U.S. patents expire in 2037.
1404 - We own patents relating to composition of matter, as well as technetium-99 labeled forms of 1404 expiring in the U.S. from 2029 to 2030, and expiring worldwide in 2029.
In addition to patents, we rely, where necessary, upon unpatented trade secrets and know-how, proprietary information and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees, consultants and other third parties and invention assignment agreements with our employees.
In addition, we license third-party technologies and other intellectual property rights that are incorporated into some elements of our drug discovery and development efforts. Some of these licenses are material to our business – for example, the licenses on the PYLARIFY patent family from Johns Hopkins University (“JHU”).
See Part I, Item 1A. “Risk Factors” for information regarding certain risks associated with our intellectual property.
Regulatory Matters
Food and Drug Laws
The development, manufacture and commercialization of our products are subject to comprehensive governmental regulation both within and outside the U.S. A number of factors substantially increase the time, difficulty and costs incurred in obtaining and maintaining the approval to market newly developed and existing products. These factors include governmental regulation, such as detailed inspection of and controls over research and laboratory procedures, clinical trials, manufacturing, marketing, advertising and promotion, sampling, distribution, import and export, record keeping and storage and disposal practices, together with various post-marketing requirements. Governmental regulatory actions can result in the seizure or recall of products, suspension or revocation of the authority necessary for their production and sale as well as other civil or criminal sanctions.
18
Our activities related to the development, manufacture, packaging or repackaging of our products subject us to a wide variety of laws and regulations. We are required to register for permits and/or licenses with, seek approvals from and comply with operating and security standards of, the FDA, the U.S. Nuclear Regulatory Commission (“NRC”), the U.S. Department of Health and Human Services (“HHS”), Health Canada, the European Medicines Agency (“EMA”), the U.K. Medicines and Healthcare Products Regulatory Agency (“MHRA”), the NMPA and various state and provincial boards of pharmacy, state and provincial controlled substance agencies, state and provincial health departments and/or comparable state and provincial agencies, as well as foreign agencies, and certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale.
The FDA and various state regulatory authorities regulate the research, testing, manufacture, safety, labeling, storage, recordkeeping, premarket approval, marketing, advertising and promotion, import and export, and sales and distribution of pharmaceutical products in the U.S. Prior to marketing a pharmaceutical product, we must first receive FDA approval. In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (“FDCA”) and implementing regulations. The process of obtaining regulatory approvals and compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Currently, the process required by the FDA before a drug product may be marketed in the U.S. generally involves the following:
•Completion of preclinical laboratory tests, animal studies and formulation studies according to current Good Laboratory Practices regulations;
•Submission to the FDA of an investigational new drug application (“IND”) which must become effective before human clinical trials may begin, including review and approval by any institutional review board (“IRB”), serving any of the institutions participating in the clinical trials;
•Performance of adequate and well-controlled human clinical trials according to current Good Clinical Practices and other requirements, to establish the safety and efficacy of the proposed drug product for its intended use;
•Submission to the FDA of an NDA for a new drug;
•Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug product is produced to assess compliance with current Good Manufacturing Practices (“cGMPs”) regulations; and
•FDA review and approval of the NDA.
The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approvals for our products in development will be granted on a timely basis, if at all. Once a pharmaceutical product is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity, formulation, and stability, as well as animal studies to assess its potential safety and efficacy. This testing culminates in the submission of the IND to the FDA.
Once the IND becomes effective, including review and approval by any IRB serving any of the institutions participating in the clinical trial, the clinical trial program may begin. Each new clinical trial protocol must be submitted to the FDA before the trial may begin. The person, entity or organization taking responsibility for the trial is referred to as the clinical trial sponsor. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:
•Phase 1. The product is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with those diseases.
•Phase 2. Involves trials in a limited patient population to identify possible adverse effects and safety risks, to evaluate preliminarily the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage and schedule.
•Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These trials are intended to collect sufficient safety and efficacy data to support the NDA for FDA approval.
Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. Submissions must also be made to inform the FDA of certain changes to the clinical trial protocol. Federal law also requires the sponsor to register the trials on public databases when they are initiated, and to disclose the results of the trials on public databases upon completion. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being
19
exposed to an unacceptable health risk. Similarly, any IRB serving any of the institutions participating in the clinical trial can suspend or terminate approval of a clinical trial at an institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the product has been associated with unexpected serious harm to patients. Failure to register a clinical trial or disclose study results within the required time periods could result in penalties, including civil monetary penalties.
Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf life.
The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the drug product, proposed labeling, and other relevant information, are submitted to the FDA as part of an NDA for a new drug, requesting approval to market the product. The submission of an NDA is subject to the payment of a substantial user fee. A waiver of that fee may be obtained under certain limited circumstances. The approval process is lengthy and difficult, and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied. The FDA has substantial discretion in the product approval process, and it is impossible to predict whether and when the FDA will grant marketing approval. The FDA may on occasion require the sponsor of an NDA to conduct additional clinical trials or to provide other scientific or technical information about the product, and these additional requirements may lead to unanticipated delay or expense. Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data.
If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require Phase 4 testing which involves clinical trials designed to further assess a drug product’s safety and effectiveness after NDA approval. The FDA also may impose one or more Risk Evaluation and Mitigation Strategies (“REMS”) to ensure that the benefits of a product outweigh its risks. A REMS could add training requirements for healthcare professionals, safety communications efforts and limits on channels of distribution, among other things. The sponsor would be required to evaluate and monitor the various REMS activities and adjust them if need be. Whether a REMS would be imposed on any of our products and any resulting financial impact is uncertain at this time.
Under the Orphan Drug Act, the FDA may designate a product as an Orphan Drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.
In the United States, Orphan Drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has Orphan Drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to Orphan Drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity.
Any drug products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on drug products that are placed on the market. Drugs may be promoted only for the approved indications and consistent with the provisions of the approved label and promotional claims must be appropriately balanced with important safety information and otherwise be adequately substantiated. Further, manufacturers of drugs must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented, and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.
20
Drug product manufacturers and other entities involved in the manufacturing and distribution of approved drugs products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain other agencies for compliance with cGMP and other laws. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the drug product. Manufacturers must establish validated systems to ensure that products meet specifications and regulatory standards, and test each product batch or lot prior to its release. In addition, manufacturers of commercial PET products such as PYLARIFY, including radiopharmacies, hospitals and academic medical centers, are required to submit either an NDA or ANDA in order to produce PET drugs for clinical use, or produce the drugs under an IND.
The FDA also regulates the preclinical and clinical testing, design, manufacture, safety, efficacy, labeling, storage, record keeping, sales and distribution, post-market adverse event reporting, import/export and advertising and promotion of any medical devices that we distribute pursuant to the FDCA and FDA’s implementing regulations. The Federal Trade Commission shares jurisdiction with the FDA over the promotion and advertising of certain medical devices. The FDA can also impose restrictions on the sale, distribution or use of medical devices at the time of their clearance or approval, or subsequent to marketing. Currently, medical devices comprise only a small portion of our revenues.
The FDA may withdraw marketing authorization for a product if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously-unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Further, the failure to maintain compliance with regulatory requirements may result in administrative or judicial actions, such as fines, civil monetary penalties, warning letters, holds on clinical trials, product recalls or seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions, or civil or criminal penalties.
Regulations are subject to change as a result of legislative, administrative or judicial action, which may also increase our costs or reduce sales or otherwise adversely impact our products. For example, on April 16, 2021 in the case Genus Medical Technologies LLC v. Food and Drug Administration, the U.S. Court of Appeals for the D.C. Circuit held that a product (other than a combination product) that meets the definitions of both “drug” and “device” under the FDCA must be regulated as a device. On August 9, 2021, the FDA announced that, as part of its implementation of this court decision, the FDA intended to regulate products that meet both the device and drug definition as devices, except where Congress intended a different classification. The FDA further indicated that it intended to bring previously classified products into line with the court decision and would reexamine whether individual imaging agents meet the device definition, which raised uncertainty as to how our some of our products would be regulated. Congress subsequently resolved this issue when it passed the Consolidated Appropriations Act of 2023, which amended the FDCA by adding a provision that deemed any contrast agent or radioactive drug to be a drug.
Because our operations include the manufacture and distribution of medical radioisotopes and other medical products, we are subject to regulation by the NRC and the departments of health of each state in which we operate and the applicable state boards of pharmacy. In addition, the FDA is also involved in the regulation of cyclotron facilities where PET products are produced in compliance with cGMP requirements and U.S. Pharmacopeia requirements for PET drug compounding.
Drug laws also are in effect in many of the non-U.S. markets in which we or our partners conduct business. These laws range from comprehensive drug approval requirements to requests for product data or certifications. In addition, inspection of and controls over manufacturing, as well as monitoring of adverse events, are components of most of these regulatory systems. Most of our business is subject to varying degrees of governmental regulation in the countries in which we or our partners operate, and the general trend is toward increasingly stringent regulation. The exercise of broad regulatory powers by the FDA continues to result in increases in the amount of testing and documentation required for approval or clearance of new drugs and devices, all of which add to the expense of product introduction. Similar trends also are evident in major non-U.S. markets, including Canada, the European Union, Australia and Japan.
To assess and facilitate compliance with applicable FDA, NRC and other state, federal and foreign regulatory requirements, we regularly review our quality systems to assess their effectiveness and identify areas for improvement. As part of our quality review, we perform assessments of our suppliers of the raw materials that are incorporated into products and conduct quality management reviews designed to inform management of key issues that may affect the quality of our products. From time to time, we may determine that products we manufactured or marketed do not meet our specifications, published standards, such as those issued by the International Standards Organization, or regulatory requirements. When a quality or regulatory issue is identified, we investigate the issue and take appropriate corrective action, such as withdrawal of the product from the market, correction of the product at the customer location, notice to the customer of revised labeling and other actions.
21
Hatch-Waxman Act
The Hatch-Waxman Act added two pathways for FDA drug approval. First, the Hatch-Waxman Act permits the FDA to approve ANDAs for generic versions of drugs if the ANDA applicant demonstrates, among other things, that its product is bioequivalent to the innovator product and provides relevant chemistry, manufacturing and product data. See “Item 1. Business - Patents.” Second, the Hatch-Waxman Act created what is known as a Section 505(b)(2) NDA, which requires the same information as a full NDA (known as a Section 505(b)(1) NDA), including full reports of clinical and preclinical studies but allows some of the information from the reports required for marketing approval to come from studies which the applicant does not own or have a legal right of reference. A Section 505(b)(2) NDA permits a manufacturer to obtain marketing approval for a drug without needing to conduct or obtain a right of reference for all of the required studies. The Hatch-Waxman Act also provides for: (1) restoration of a portion of a product’s patent term that was lost during clinical development and application review by the FDA; and (2) statutory protection, known as exclusivity, against the FDA’s acceptance or approval of certain competitor applications.
Under U.S. law, patent term extension can compensate for time lost during product development and the regulatory review process by returning up to five years of patent life for a patent that covers a new product or its use. This period is generally one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application. Patent term extensions, however, are subject to a maximum extension of five years, and the patent term extension cannot extend the remaining term of a patent beyond a total of 14 years. The application for patent term extension is subject to approval by the U.S. Patent and Trademark Office in conjunction with the FDA.
The Hatch-Waxman Act also provides for a period of statutory protection for new drugs that receive NDA approval from the FDA. If the FDA approves a Section 505(b)(1) NDA for a new drug that is a new chemical entity, meaning that the FDA has not previously approved any other new drug containing the same active moiety, then the Hatch-Waxman Act prohibits the submission or approval of an ANDA or a Section 505(b)(2) NDA for a period of five years from the date of approval of the NDA, except that the FDA may accept an application for review after four years under certain circumstances, specifically a patent challenge for one or more patents listed by the NDA holder in FDA’s publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), submitted in a “Paragraph IV” Certification. The Hatch-Waxman Act will not prevent the filing or approval of a full NDA, as opposed to an ANDA or Section 505(b)(2) NDA, for any drug, but the competitor would be required to conduct its own clinical trials, and any use of the drug for which marketing approval is sought could not violate another NDA holder’s patent claims. The Hatch-Waxman Act provides for a three-year period of exclusivity for an NDA for a new drug containing an active moiety that was previously approved by the FDA, but also includes new clinical data (other than bioavailability and bioequivalence studies) to support an innovation over the previously-approved drug and those studies were conducted or sponsored by the applicant and were essential to approval of the application. This three-year exclusivity period does not prohibit the FDA from accepting an application from a third party for a drug with that same innovation, but it does prohibit the FDA from approving that application for the three-year period. The three-year exclusivity does not prohibit the FDA, with limited exceptions, from approving generic drugs containing the same active ingredient but without the new innovation.
Reimbursement
The successful commercialization of our products is also subject to the availability of appropriate third-party coding, coverage and payment for our customers. Third-party payors in the U.S. include private payors, including managed care providers, and State and Federal healthcare programs, such as Medicare and Medicaid. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product. Coverage of a product does not ensure there will be an appropriate reimbursement amount for such product and the process to ensure appropriate reimbursement is outside our control. For private payors, coverage and reimbursement of our products vary from private payor to private payor. Many private payors, such as managed care providers, manage access to products, and may use medical policies (which may include specific coverage requirements such as prior authorization, re-authorization and achieving performance metrics under value-based contracts) to control utilization. Exclusion from or restriction in coverage can reduce product use. For government payors, we participate, as required, in the Medicaid drug rebate program, the Federal Supply Schedule (FSS) and the Public Health Service Act 340B program, which each require discounts for participation and may be subject to change. For Medicare, reimbursement to customers for our products is generally established through the rulemaking process or in discussion with Medicare Administrative Contractors (MACs). We have ongoing conversations with third-party payors to advocate for appropriate coding, coverage and payment for our portfolio of products.
Medicare Outpatient TPT Status
Part B of the Medicare program generally reimburses medical services and supplies, including drugs, provided to beneficiaries by physicians and other qualified healthcare professionals. Generally, drugs furnished “incident to” a physician’s service in the hospital outpatient setting of care are reimbursed at Average Sales Price (“ASP”) plus a certain additional percent, unless the product is treated as a “supply” in the performance of the procedure and “packaged” and paid as part of bundled payment for the procedure.
22
Novel drugs, however, may apply for TPT Status in which case they are provided a separate payment at ASP plus a certain additional percent for two to three years, regardless of whether they would ordinarily be packaged.
PYLARIFY has received TPT Status effective January 1, 2022 through December 31, 2024, thereby providing separate reimbursement to customers using PYLARIFY in the hospital outpatient setting during this specified period. The reimbursement rate for PYLARIFY was initially based on the wholesale acquisition cost (WAC) plus three percent until ASP could be established. In 2023, CMS established an ASP for PYLARIFY and reimbursed at a rate equal to ASP plus an add-on percentage that varied throughout the year.
PYLARIFY has been assigned Healthcare Common Procedure Coding System code A9595 (piflufolastat F 18, diagnostic, 1 millicurie) for identification in claims and can be used by both public and private payors. Under existing Medicare policy for the hospital outpatient setting of care, non-pass-through diagnostic radiopharmaceuticals are not separately paid and are instead packaged into payment for the underlying procedure. Therapeutic radiopharmaceuticals are paid separately by Medicare OPPS regardless of TPT Status. We plan to continue our advocacy efforts with CMS and private insurers so that PYLARIFY customers will have appropriate and adequate reimbursement following the expiration of TPT Status. We are also supporting trade associations in their efforts to have Congress pass the Facilitating Innovative Nuclear Diagnostics (FIND) Act, which would allow for separate payment for certain diagnostic radiopharmaceuticals, including PYLARIFY, similar to the way Medicare OPPS currently pays for other drugs, biologics, and therapeutic radiopharmaceuticals instead of under the current TPT structure of a separate payment that is limited to three years.
Healthcare Reform and Other Laws Affecting Payment
We operate in a highly regulated industry. The U.S. and state governments continue to propose and pass legislation that may affect the availability and cost of healthcare. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the “Healthcare Reform Act”), substantially changes the way in which healthcare is financed by both governmental and private insurers and has a significant impact on the pharmaceutical industry. The Healthcare Reform Act contains a number of provisions that affect coverage, reimbursement and/or delivery of drug products and the medical imaging procedures in which our drug products are used. Key provisions that currently affect our business include the following:
•increasing the presumed utilization rate for imaging equipment costing $1.0 million or more in the physician office and free-standing imaging facility setting which reduces the Medicare per procedure medical imaging reimbursement; which rate was further increased by subsequent legislation effective January 1, 2014;
•increasing drug rebates paid to state Medicaid programs under the Medicaid Drug Rebate Program for brand name prescription drugs and extending those rebates to Medicaid managed care organizations;
•expanding access to the 340B program by allowing additional covered entities to participate in the program; and
•imposing a non-deductible annual fee on pharmaceutical manufacturers or importers who sell brand name prescription drugs to specified federal government programs.
The Healthcare Reform Act also amended the federal self-referral laws, requiring referring physicians to inform patients under certain circumstances that the patients may obtain services, including PET, CT, MRI and certain other diagnostic imaging services, from a provider other than that physician, another physician in his or her group practice, or another individual under direct supervision of the physician or another physician in the group practice. The referring physician must provide each patient with a written list of other suppliers who furnish those services in the area in which the patient resides. These requirements could have the effect of shifting where certain diagnostic medical imaging procedures are performed.
The Healthcare Reform Act has been subject to political and judicial challenges, but it has generally withstood such challenges, and the main provisions of the Healthcare Reform Act remain in effect. More recently, Congress enacted the Inflation Reduction Act of 2022 (the “IRA”) which significantly impacts the pharmaceutical industry. Among other provisions, the IRA authorizes Medicare to negotiate pricing for the highest Medicare-spend drugs, as determined by their Medicare Part B and D spend, that have been on the market for an extended period of time without market competition. Although the IRA provides for a limited number of categorical exclusions from Medicare negotiation, radiopharmaceuticals are not among those categorical exclusions. CMS plans to begin implementing the first year of Medicare negotiation, which will be restricted to Part D drugs, starting in calendar years 2026 and 2027. We are currently focused on drugs that are covered under Part B, therefore we do not expect the Part D benefit redesign to have an impact on our portfolio. Part B drugs will be considered for Medicare negotiation beginning in calendar year 2028, and CMS will begin the process of identifying Part B drugs for negotiation as early as calendar year 2026. We are monitoring the implementation of the IRA to determine what impact, if any, this would have on our current products and product candidates in development.
The IRA also introduces rebate obligations for manufacturers of Part B and D drugs that take price increases which exceed the rate of inflation, similar to the longstanding Medicaid inflation rebates. Under these new Medicare inflation rebates, each Part B and D
23
single-source drug/biological and biosimilar will have an “inflation adjusted” payment amount calculated by CMS. If the manufacturer’s price increases for the relevant product exceeds the inflation adjusted payment amount, as trended forward by the rate of inflation, the manufacturer will be required to reimburse Medicare the difference between what Medicare paid for the product and what it would have paid based on the inflation adjusted payment amount.
Recent state legislative efforts seek to address drug costs and generally have focused on increasing transparency around drug costs or limiting drug prices. Some of those efforts have been subject to legal challenge.
General legislative cost control measures may also affect reimbursement for our products or services provided with our products. The Budget Control Act, as amended by the Bipartisan Budget Act of 2019, resulted in the imposition of 2% reductions in Medicare (but not Medicaid) payments to providers beginning in 2013 and will remain in effect through fiscal year 2030 unless additional Congressional action is taken. The imposition of the 2% payment adjustment had been suspended through March 31, 2022 and went into effect as of April 1, 2022. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our business results of operations, financial condition and cash flows.
Healthcare Fraud and Abuse Laws
We are subject to various federal, state and local laws targeting fraud and abuse in the healthcare industry, including anti-kickback and false claims laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and/or exclusion from federal health care programs (including Medicare and Medicaid). Federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry, and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the federal False Claims Act (“FCA”). Violations of international fraud and abuse laws could result in similar penalties, including exclusion from participation in health programs outside the U.S. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.
The federal Anti-Kickback Statute generally prohibits, among other things, a pharmaceutical manufacturer from directly or indirectly soliciting, offering, receiving, or paying any remuneration in cash or in kind where one purpose is either to induce the referral of an individual for, or the purchase or prescription of a particular drug that is payable by a federal health care program, including Medicare or Medicaid. The Healthcare Reform Act clarifies the intent requirements of the federal Anti-Kickback Statute, providing that a person or entity does not need to have actual knowledge of the statute or a specific intent to violate the statute. Violations of the federal Anti-Kickback Statute can result in exclusion from Medicare, Medicaid or other governmental programs as well as civil and criminal fines and penalties of up to $104,330 per violation and three times the amount of the unlawful remuneration. In addition, the Healthcare Reform Act revised the FCA to provide that a claim arising from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The majority of states also have anti-kickback, false claims, and similar fraud and abuse laws and although the specific provisions of these laws vary, their scope is generally broad, and there may not be regulations, guidance or court decisions that apply the laws to particular industry practices. There is, therefore, a possibility that our practices might be challenged under the anti-kickback statutes or similar laws.
Federal and state false claims laws generally prohibit anyone from knowingly and willfully, among other activities, presenting, or causing to be presented for payment to third party payors (including Medicare and Medicaid) claims for drugs or services that are false or fraudulent (which may include claims for services not provided as claimed or claims for medically unnecessary services). As discussed, a claim arising from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. False or fraudulent claims for purposes of the FCA carry fines and civil penalties for violations ranging from $11,665 to $23,331 for each false claim, plus up to three times the amount of damages sustained by the federal government and, most critically, may provide the basis for exclusion from federally funded healthcare programs. There is also a criminal FCA statute by which individuals or entities that submit false claims can face criminal penalties. In addition, under the federal Civil Monetary Penalty Law, the Department of Health and Human Services Office of Inspector General has the authority to exclude from participation in federal health care programs or to impose civil penalties against any person who, among other things, knowingly presents, or causes to be presented, certain false or otherwise improper claims. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws.
24
Laws and regulations have also been enacted by the U.S. federal government and various states, as well as by countries outside of the U.S., to regulate the sales and marketing practices of certain entities including pharmaceutical and device manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers; require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government; and/or require disclosure by pharmaceutical and device manufacturers to the government and/or public of financial interactions or other financial relationships with health care providers and other entities such as teaching hospitals (so-called “sunshine laws”). The Healthcare Reform Act requires manufacturers to submit information to the FDA on the identity and quantity of drug samples requested and distributed by a manufacturer during each year. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. The laws and regulations include requirements that can be unclear in their scope, nature, and required implementation by regulated entities. If we fail to comply with such laws and regulations, we could be subject to penalties and administrative actions under such laws and regulations.
Data Privacy, Security and Breach Notification
We are subject to data protection laws and regulations that set forth data privacy, security, and breach notification requirements. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on data protection and other data privacy and security issues. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws and federal and state consumer protection laws govern the collection, use, disclosure and protection of health-related and other personal information. In addition to establishing restrictions on how personal information may be collected, used, and disclosed, these laws and regulations provide various rights to data subjects with respect to their personal information and establish requirements for how personal information must be secured. In addition, every state in the United States now has a data breach notification law that requires regulated entities to report certain security breaches to affected data subjects, regulators, or other entities. Failure to comply with data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties and requirements to take corrective actions), private litigation (which may result in the award of damages against us), and/or adverse publicity, and could negatively affect our operating results, business, and reputation. In addition, we may obtain health information from third parties (e.g., healthcare providers who prescribe our products) that are themselves subject to privacy, security, and breach notification requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”). While we believe that we are neither a “covered entity” nor “business associate” subject directly to regulation under HIPAA, HIPAA’s criminal provisions can apply to entities other than “covered entities” or “business associates” in certain circumstances. Accordingly, we could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted.
In addition, a growing number of jurisdictions outside of the United States have enacted robust data protection laws. Certain of these laws have extraterritorial application. For example, the processing of personal data in the European Union is governed by the provisions of the General Data Protection Regulation, or GDPR, which came into effect on May 25, 2018. The GDPR applies to an entity established in the EU and extraterritorially to an entity outside of the EU that offers goods or services to, or monitors the behavior of, individuals located in the EU. Certain “special categories” of personal data, including data concerning health, are subject to enhanced protections under the GDPR. This regulation imposes several requirements on the controllers and processors of personal data, including the obligation to comply with various rights that individuals have with respect to their personal data and restrictions on the processing of personal data, and to provide notice of data processing obligations to the competent national data protection authorities. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States may result in significant fines and other administrative penalties.
In the United States, several state legislatures are considering enacting new data privacy legislation. One example of such legislation that has already been passed is the California Consumer Privacy Act (“CCPA”), which took effect on January 1, 2020 and imposes many requirements on certain for-profit businesses that process the personal information of California residents. Many of the CCPA’s requirements are similar to those found in the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects various rights, such as the right to request access to their personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of the “sale” of their personal information. In addition, the CCPA requires regulated businesses to implement reasonable security procedures and practices to protect personal information. The CCPA contains significant penalties for companies that violate its requirements. It also provides California residents a private right of action, including the ability to seek statutory damages, in the event of a breach involving their personal information resulting from a business’s failure to implement and maintain reasonable security procedures and practices. Compliance with the CCPA, and similar laws implemented in other states, is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.
25
On November 3, 2020, California passed the California Privacy Rights Act (“CPRA”) through a ballot initiative. The CPRA amends the CCPA and expands its protections for personal information, including by establishing a new California Privacy Protection Agency to enforce the CPRA and by providing California consumers various rights such as the right to restrict the processing of their “sensitive personal information.” The CPRA’s amendments to the CCPA took effect on January 1, 2023, and generally apply to personal information collected by regulated businesses on or after January 1, 2022.
Antitrust and Competition Laws
The federal government and most states have enacted antitrust laws that prohibit specific types of anti-competitive conduct, including price fixing, wage fixing, concerted refusals to deal, price discrimination and tying arrangements, as well as monopolization and acquisitions of competitors that have, or may have, a substantial adverse effect on competition. Violations of federal or state antitrust laws can result in various sanctions, including criminal and civil penalties. We believe we are in compliance with such federal and state laws, but courts or regulatory authorities may reach a determination in the future that could adversely affect our business, results of operations, financial condition and cash flows. In addition, we are subject to similar antitrust and anti-competition laws in foreign countries. We believe we are in compliance with such laws, however, any violation could create a substantial liability for us and also cause a loss of reputation in both foreign and domestic markets. 
Laws Relating to Foreign Trade
We are subject to various federal and foreign laws that govern our international business practices with respect to payments to government officials. Those laws include the Foreign Corrupt Practices Act (“FCPA”) which prohibits U.S. companies and their representatives from paying, offering to pay, promising, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the healthcare professionals we regularly interact with may meet the FCPA’s definition of a foreign government official. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls.
Those laws also include the U.K. Bribery Act (“Bribery Act”) which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official, and failing to have adequate procedures to prevent employees and other agents from giving bribes. U.S. companies that conduct business in the United Kingdom generally will be subject to the Bribery Act. Penalties under the Bribery Act include potentially unlimited fines for companies and criminal sanctions for corporate officers under certain circumstances.
Our policies mandate compliance with these anti-bribery laws. Our operations reach many parts of the world that have experienced governmental corruption to some degree, and in certain circumstances strict compliance with anti-bribery laws may conflict with local customs and practices. Despite our training and compliance programs, our internal control policies and procedures may not always protect us from reckless or criminal acts committed by our employees or agents.
We are also subject to trade control regulations and trade sanctions laws that restrict the movement of certain goods, currency, products, materials, services and technology to, and certain operations in, various countries or with certain persons. Our ability to transfer people and products among certain countries may be subjected to these laws and regulations.
Health and Safety Laws
We are also subject to various federal, state and local laws, regulations and recommendations, both in the U.S. and abroad, relating to safe working conditions, laboratory and manufacturing practices and the use, transportation and disposal of hazardous or potentially hazardous substances.
See Part I, Item 1A. “Risk Factors” for information regarding certain risks related to reimbursement and regulation.
Environmental Matters
We are subject to various federal, state and local laws and regulations relating to the protection of the environment, human health and safety in the U.S. and in other jurisdictions in which we operate. Our operations, like those of other medical product companies, involve the transport, use, handling, storage, exposure to and disposal of materials and wastes regulated under environmental laws, including hazardous and radioactive materials and wastes. If we violate these laws and regulations, we could be fined, criminally charged or otherwise sanctioned by regulators. We believe that our operations currently comply in all material respects with applicable environmental laws and regulations.
26
Certain environmental laws and regulations assess liability on current or previous owners or operators of real property for the cost of investigation, removal or remediation of hazardous materials or wastes at those formerly owned or operated properties or at third party properties at which they have disposed of hazardous materials or wastes. In addition to cleanup actions brought by governmental authorities, private parties could bring personal injury, property damage or other claims due to the presence of, or exposure to, hazardous materials or wastes. We currently are not party to any claims or any obligations to investigate or remediate any material contamination at any of our facilities, however, if we were found to be liable under one or more of these laws or regulations, it could create a substantial liability.
We are required to maintain a number of environmental permits and nuclear licenses for our North Billerica, Massachusetts campus, which includes our primary manufacturing, packaging and distribution facility. In particular, we must maintain a nuclear byproducts materials license issued by the Commonwealth of Massachusetts. This license requires that we provide financial assurance demonstrating our ability to cover the cost of decommissioning and decontaminating (“D&D”) the Billerica site at the end of its use as a nuclear facility. In addition, we have a radioactive production facility in Somerset, NJ where we must also maintain a number of environmental permits and nuclear licenses. We store low level radioactive waste at our facilities until the materials are below regulatory limits, as allowed by our licenses and permits. As of December 31, 2023, we currently estimate the D&D cost of all of our manufacturing sites to be approximately $25.1 million. As of December 31, 2023 and 2022, we have a liability of approximately $22.9 million and $22.5 million, respectively associated with our asset retirement obligations. We currently provide this financial assurance in the form of surety bonds.
We also actively monitor and seek to reduce our solid waste, energy and water usage, waste water discharge and greenhouse gas emissions. We generally contract with third parties for the disposal of wastes generated by our operations. In 2020, we developed a stormwater management operations and maintenance plan to minimize stormwater pollution from high impact activities. Improvements we made include (i) the regular inspection and cleaning of catch basins and piping to reduce sediment and debris wash out to adjacent wetlands; (ii) increasing street and parking lot cleaning to reduce pollutant run off; (iii) updating our snow removal plan at our North Billerica campus to reduce the impact to adjacent wetlands; and (iv) using salt brine as a pretreatment for winter storms to reduce the amount of salt use and run off.
With respect to sustainability, we track and monitor our energy use, water use, a limited scope of greenhouse gas emissions, and waste generation. We use an Energy Star Portfolio Manager to track energy and water use and have calculated scope 1 and 2 greenhouse gas emissions for our North Billerica Campus, with plans to expand these activities to other Lantheus properties. We will continue to compare our usage data against annual baselines, national medians, and similar buildings.
Environmental laws and regulations are complex, change frequently and have become more stringent over time. While we have budgeted for future capital and operating expenditures to maintain compliance with these laws and regulations, we cannot assure you that our costs of complying with current or future environmental protection, health and safety laws and regulations will not exceed our estimates or adversely affect our results of operations and financial condition. Further, we cannot assure you that we will not be subject to additional environmental claims for personal injury or cleanup in the future based on our past, present or future business activities. While it is not feasible to predict the future costs of ongoing environmental compliance, it is possible that there will be a need for future provisions for environmental costs that, in management’s opinion, are not likely to have a material effect on our financial condition, but could be material to the results of operations in any one accounting period.
See Part I, Item 1A. “Risk Factors” for information regarding certain risks associated with environmental matters.
Human Capital Management
As of December 31, 2023, we had 834 employees, of which 808 were located in the U.S. and 26 were located internationally. None of our employees are represented by a collective bargaining agreement, and we believe that our relationship with our employees is good.
Diversity, Inclusion, Ethics and Compliance
We believe that supporting our local community and instilling a diverse, inclusive, ethical and compliant culture makes us an employer of choice, allows us to maintain good standing with the regulatory authorities and our customers, and benefits our stockholders in the long run.
We have a female Chief Executive Officer who, effective March 1, 2024, will transition to Chair of the Board, over half of our Vice Presidents and above (including our senior management team, which we refer to as our “Expanded Executive Team”) are women, and approximately 50% of our employees are women. We continue to strive to improve our diversity and inclusion with a strategic emphasis beyond gender, and we require recruiters working with us to present diverse candidates. We also sponsor three Employee Resource Groups (“ERGs”), the Lantheus Diversity Connection ERG, the Women Leaders of Lantheus ERG, and the Professional Networking at Lantheus ERG.
27
We are committed to promoting a culture of ethics and compliance. Our Code of Conduct and Ethics reflects our commitment to corporate integrity and the underlying business practices and principles of behavior that support this commitment. Each year our employees complete mandatory training that includes anti-bribery/anti-corruption rules, insider trading prohibitions, confidentiality obligations, as well as specialized training in healthcare industry marketing practices. We have a formal Ethics and Compliance Committee that develops, implements and oversees our ethics and compliance programs. We also have a Supplier Code of Conduct, and we seek to do business with minority-owned, female-owned and other diverse businesses and organizations (including those owned or operated by veterans and disabled veterans) that appropriately reflect the communities in which we operate and the customer base we serve.
Compensation and Benefits
We seek to provide pay, benefits, and services that are competitive to market and create incentives to attract and retain employees. Our compensation package includes, among other things, market-competitive pay, cash bonuses, healthcare and defined contribution plan benefits, paid time off and family leave, and restricted stock and other equity grants to certain levels of employees. We are focused on pay equity and regularly assess pay among similar roles and responsibilities throughout our organization and in comparison to our peer group.
Communication and Engagement
We believe that our success depends on employees understanding how their work contributes to our overall strategy. To this end, we utilize a variety of channels to facilitate open and direct communication, including: (i) quarterly town hall meetings for our entire company; (ii) regular ongoing update communications, including through monthly newsletters and our recently launched intranet site; and (iii) an externally administered whistleblower hotline and website that is prominently advertised to our employees, and a whistleblower’s anonymity is protected, if so requested. We also established various employee recognition award programs to recognize and reward employees for specific outstanding accomplishments and to foster a positive employee relations climate.
Health, Wellness and Safety
We are committed to the health and safety of our employees, patients and other partners in the healthcare community. We work to promote an environment of awareness and shared responsibility for safety and regulatory compliance throughout the Company, in order to minimize risks of injury, exposure, or business impact.
Corporate History
Founded in 1956 as New England Nuclear Corporation, our medical imaging diagnostic business was purchased by E.I. du Pont de Nemours and Company (“DuPont”) in 1981. Bristol Myers Squibb (“BMS”) subsequently acquired our diagnostic medical imaging business as part of its acquisition of DuPont Pharmaceuticals in 2001. In January 2008, Avista Capital Partners, L.P., Avista Capital Partners (Offshore), L.P. and ACP-Lantern Co-Invest, LLC formed Lantheus Holdings and acquired our medical imaging business from BMS. On June 30, 2015, we completed an initial public offering of our common stock. We completed our acquisition of Progenics on June 19, 2020 (the “Progenics Acquisition”). We completed our acquisition of Cerveau Technologies, Inc. on February 6, 2023 (the “Cerveau Acquisition”). Our common stock is traded on the NASDAQ Global Market under the symbol “LNTH”.
Available Information
Our global Internet site is www.lantheus.com. We routinely make available important information, including copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after those reports are electronically filed with, or furnished to, the SEC, free of charge on our website at investor.lantheus.com. We recognize our website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with our disclosure obligations under SEC Regulation FD. Information contained on our website shall not be deemed incorporated into, or to be part of this Annual Report on Form 10-K, and any website references are not intended to be made through active hyperlinks.
Our reports filed with, or furnished to, the SEC are also available on the SEC’s website at www.sec.gov, and for Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, in an Inline Extensible Business Reporting Language (“iXBRL”) format. iXBRL is an electronic coding language used to create interactive financial statement data over the Internet.
28
Item 1A. Risk Factors
You should carefully consider the following risks. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. These risks could materially affect our business, results of operations or financial condition, cause the trading price of our outstanding common stock to decline materially or cause our actual results to differ materially from those expected or those expressed in any forward-looking statements made by us or on our behalf. See “Cautionary Note Regarding Forward-Looking Statements” and the risks of our businesses described elsewhere in this Annual Report on Form 10‑K.
Risks Related to Our Portfolio of Commercial Products
Our ability to continue to grow PYLARIFY as a commercial product is dependent on (A) the ability of PMFs to manufacture PYLARIFY to meet product demand, (B) our ability to promote PYLARIFY to customers, (C) our ability to obtain and maintain adequate coding, coverage and payment for PYLARIFY, (D) our ability to maintain PYLARIFY as the leading PSMA PET imaging agent, including after the potential expiration of TPT Status at the end of 2024 and (E) our ability to clinically and commercially differentiate PYLARIFY from other products.
To manufacture PYLARIFY, we assembled and qualified a nationwide network of PMFs with radioisotope-producing cyclotrons that make F 18, which has a 110-minute half-life, so PYLARIFY is manufactured and distributed rapidly to end-users. Because each of the PMFs manufacturing these products is deemed by the FDA to be a separate manufacturing site, each has to be separately approved by the FDA. Although PYLARIFY is broadly available across the U.S., we continue to seek qualification for additional PMFs in 2024 and can give no assurance that the FDA will continue to approve PMFs in accordance with our planned roll-out schedule. If FDA approval of manufacturing sites is delayed or withdrawn, our business, results of operations, financial condition and cash flows could be adversely affected.
PYLARIFY is sold in the U.S. to hospitals, independent imaging centers and government facilities and sales are generated through an internal PYLARIFY sales team, as well as a sales team at some of our PMF partners. We generally do not use group purchasing arrangements to sell PYLARIFY and require each customer to enter into a contract directly with us or our PMFs. Our ability to continue to successfully grow PYLARIFY depends, in part, on our ability to continue to enter into arrangements directly with the hospitals, independent imaging centers and government facilities that we serve. Any delay or inability to enter into these arrangements could have an adverse impact on our business, results of operations, financial condition and cash flows.
Obtaining adequate coding, coverage and payment for PYLARIFY is critical, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels to adequately cover our customers’ costs of using PYLARIFY in PET/CT imaging procedures. We received notification that our HCPCS code, which enables streamlined billing, went into effect as of January 1, 2022. In addition, effective January 1, 2022, CMS granted TPT Status for PYLARIFY, enabling traditional Medicare to provide an incremental payment for PET/CT scans performed with PYLARIFY in the hospital outpatient setting. TPT Status for PYLARIFY is expected to expire on December 31, 2024. After TPT Status expires, under current Medicare rules, PYLARIFY would not be separately reimbursed in the hospital outpatient setting but rather would be bundled into the facility payment a hospital receives for a PET/CT imaging procedure, and the facility payment may not always adequately cover the total cost of the procedure. We can give no assurance that any CMS reimbursement in the hospital outpatient setting that follows the expiration of TPT Status will be adequate to cover the cost of a PYLARIFY PET/CT imaging procedure. In addition, if other government payors or private payors do not provide adequate reimbursement for the use of PYLARIFY, our business, results of operations, financial condition and cash flows could be adversely affected. We plan to continue our advocacy efforts with CMS and private insurers so that PYLARIFY customers will have appropriate and adequate reimbursement following the expiration of TPT Status and we are also supporting trade associations in their efforts to have Congress pass the Facilitating Innovative Nuclear Diagnostics (FIND) Act, which would allow for separate payment for certain diagnostic radiopharmaceuticals, including PYLARIFY, similar to the way Medicare OPPS currently pays for other drugs, biologics, and therapeutic radiopharmaceuticals instead of under the current TPT structure of a separate payment that is limited to three years, however, we can give no assurances that we will be successful in those efforts or that the availability of TPT Status for other diagnostic radiopharmaceuticals will not impact clinical decision making regarding which product to use, which could have an adverse effect on our business, results of operations, financial condition and cash flows.
The successful growth of PYLARIFY is also dependent on our ability to clinically and commercially differentiate PYLARIFY from other products on the market and to maintain PYLARIFY as the leading PSMA PET imaging agent in a competitive environment in which other PSMA PET imaging agents have been approved. PYLARIFY currently competes with two commercially available Ga-68-based PSMA PET imaging agents from Telix Pharmaceuticals Limited and Novartis AG and an F 18 PSMA PET imaging agent from Blue Earth, as well as other non-PSMA PET imaging agents. To the extent we lose market share to existing or future competitors (including during any period of time in which our TPT Status has expired but TPT Status for a later-approved competitive products still exists), such loss of market share could have an adverse impact on our business, results of operations, financial condition and cash flows. Continued growth and revenue contribution from PYLARIFY will also depend on our ability to differentiate
29
PYLARIFY in light of the potential loss of TPT Status, including through flexible and dependable access to PYLARIFY nationally, a best in class customer experience and through long-term strategic contracts.
Our success in growing PYLARIFY also depends, in part, on our successfully establishing the use of PYLARIFY for approved indications and potentially for additional indications, including for patient selection for PSMA-targeted therapeutics. For example, we believe the approval of PLUVICTO for the treatment of adult patients with PSMA-positive mCRPC who have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy) created a new addressable market for the use of PSMA PET imaging in patient selection for PSMA-targeted therapy. However, the prescribing information for PLUVICTO specifies that a PSMA-11 based PSMA PET imaging agent be used for patient selection, and PYLARIFY is not a PSMA-11 based imaging agent. While we note that FDA-approved labels for F 18-based and PSMA-11 based PSMA PET imaging agents have generally been treated as a class of drugs, including by the National Comprehensive Cancer Center in its guidelines and the Society for Nuclear Medicine and Molecular Imaging in its appropriate use criteria, we can give no assurances that PLUVICTO prescribing information will be expanded to incorporate F 18-based PSMA PET imaging agents like PYLARIFY, or how clinical practice may evolve. To the extent we are unsuccessful in establishing the use of PYLARIFY for approved or new indications, such lack of success could have an adverse impact on our business, results of operations, financial condition and cash flows.
The near-term growth of our business is also dependent on our ability to continue to grow the appropriate use of DEFINITY in suboptimal echocardiograms in the face of competition from other existing echocardiography agents and potential generic competitors as a result of patent and regulatory exclusivity expirations.
The growth of our business is also dependent on our ability to continue to grow the appropriate use of DEFINITY in suboptimal echocardiograms. DEFINITY currently competes with ultrasound enhancing agents produced by GE Healthcare and Bracco, as well as echocardiography without ultrasound enhancing agents and other non-echocardiography agents.
We launched DEFINITY in 2001, and we continue to actively pursue additional patents in connection with DEFINITY and DEFINITY RT, both in the U.S. and internationally. In the U.S. for DEFINITY we have six Orange Book-listed method-of-use patents, one of which expires in 2035 and five of which expire in 2037, as well as additional manufacturing patents that are not Orange Book-listed expiring in 2037. In the U.S. for DEFINITY RT, we have eight Orange Book-listed patents, including two composition of matter patents that expire in 2035. Outside of the U.S., we are currently pursuing additional DEFINITY and DEFINITY RT patents to obtain similar patent protection as in the U.S. The Orange Book-listed patents include a patent on the use of VIALMIX RFID, which expires in 2037; additional VIALMIX RFID patent applications have been submitted in major markets throughout the world.
Because our Orange Book-listed composition of matter patent expired in June 2019, we may face generic DEFINITY challengers in the near to intermediate term. Under the Hatch-Waxman Act, the FDA can approve ANDAs for generic versions of drugs before the expiration of an Orange Book-listed patent covering the innovator product if the ANDA applicant demonstrates, among other things, that (i) its generic candidate is the same as the innovator product by establishing bioequivalence and providing relevant chemistry, manufacturing and product data, and (ii) either the marketing of that generic candidate does not infringe the Orange Book-listed patent(s) or the Orange Book-listed patent(s) is invalid. Similarly, the FDA can approve a Section 505(b)(2) NDA from an applicant that relies on some of the information required for marketing approval to come from studies which the applicant does not own or have a legal right of reference. The ANDA applicant or the Section 505(b)(2) applicant (if relying on studies related to the innovator product) (together, the “Applicant”) must also give Notice to the innovator, which would then enable the innovator to file suit against the Applicant within 45 days of receiving the Notice. If the innovator challenges the Applicant in court in a timely manner, then FDA approval to commercialize the generic candidate will be stayed (that is, delayed) for up to 30 months while the dispute between the innovator and the Applicant is resolved in court. The 30 month stay can be shortened if the patent infringement suit is resolved in the Applicant’s favor before the 30 month stay expires, and this may involve a successful challenge of the patent’s validity in U.S. Patent and Trademark Office (“USPTO”) proceedings and appeals process. In the event a 505(b)(2) applicant does not rely on studies related to the innovator product, the 30-month stay would not apply, but additional clinical trials may be required. We can give no assurance that we would have grounds to file a patent infringement suit, that we would obtain the full 30 month stay, that we would be successful on the merits asserting that an Applicant infringes our Orange Book-listed patent, or that we would be successful defending the validity of our Orange Book-listed patent in court or in a USPTO adversarial proceeding.
As of the date of filing of this Annual Report on Form 10-K, we have not received any such Notice from any Applicant, but we can give no assurance that we will not receive a Notice in the future. If we were to receive any such Notice in the future, we would review the Notice, evaluate the strength of any potential patent infringement claims, and be prepared to challenge the Applicant in a timely fashion, which would thereby trigger the stay of up to 30 months. We can give no assurance that we would have grounds to file a patent infringement suit, that we would obtain the full 30 month stay, that we would be successful on the merits asserting that an Applicant infringes our Orange Book-listed patent, or that we would be successful defending the validity of our Orange Book-listed patent in court or in a USPTO adversarial proceeding. If we were to receive such a Notice and to challenge the Applicant, patent litigation is complex and can be protracted and expensive, which could also have a negative effect on our business, results of operations and financial condition.
30
As part of our microbubble franchise strategy, (i) we have developed and received FDA approval for DEFINITY RT, a modified formulation of DEFINITY, (ii) we look for other opportunities to expand our microbubble franchise, including new applications beyond echocardiography and ultrasound enhancing agent imaging generally such as our strategic arrangements with Cerevast, CarThera, Insightec, AHN and SonoThera, and (iii) we have constructed a specialized in-house manufacturing facility at our North Billerica campus for purposes of producing the formulation of DEFINITY that requires refrigerated storage and, potentially, other sterile vial products. On February 22, 2022, we received FDA approval of our sNDA, authorizing commercial manufacturing of DEFINITY at our new facility. However, we can give no assurance that our microbubble franchise strategy will be successful or that the modified formulation, new applications or new manufacturing capabilities will grow our microbubble franchise.
If we are not able to continue to (i) grow DEFINITY and DEFINITY RT sales, which depend on one or more of the growth of echocardiograms, the growth in the appropriate use of ultrasound enhancing agents in suboptimal echocardiograms, and our ability to sustain and grow our leading position in the U.S. echocardiography ultrasound enhancing agent market, or (ii) be successful with our microbubble franchise strategy, we may not be able to continue to grow the revenue and cash flow of our business, which could have a negative effect on our business, results of operations and financial condition.
Our dependence upon third parties for the manufacture and supply of a substantial portion of our products and certain key components and raw materials and upon our in-house manufacturing for DEFINITY could prevent us from delivering our products to our customers in the required quantities, within the required timeframes, or at all, which could result in order cancellations and decreased revenues.
We obtain a substantial portion of our products from third party manufacturers and suppliers.
PYLARIFY is manufactured by a nationwide network of PMFs with radioisotope-producing cyclotrons. The radioisotope in PYLARIFY is fluorine-18, which has a 110-minute half-life, so PYLARIFY is manufactured and distributed rapidly to end-users. Because each of the PMFs manufacturing PLYARIFY is deemed by the FDA to be a separate manufacturing site, each has to be separately approved by the FDA. Although we have qualified and continue to qualify additional PMFs, we can give no assurance that the FDA will continue to approve PMFs in accordance with our planned roll-out schedule or that the PMFs will not experience issues with their ability to manufacture and deliver PYLARIFY to our customers. If FDA approval of manufacturing sites is delayed or withdrawn or our PMF sites experience manufacturing issues, our business, results of operations, financial condition and cash flows could be adversely affected.
We rely on JHS as a substantial supplier of DEFINITY, as well as our sole source manufacturer of NEUROLITE, CARDIOLITE and evacuation vials. We rely on Samsung Biologics Co., Ltd. (“SBL”) as our sole source manufacturer of DEFINITY RT. In addition, for reasons of quality assurance or cost-effectiveness, we purchase certain components and raw materials from sole suppliers (including, for example, the specially designed chemistry synthesis boxes and consumables used in the manufacturing of PYLARIFY, the lipid blend material and perflutren gas used in the manufacturing of DEFINITY and the lead casing for our TechneLite generators). Because we do not control the actual production of many of the products we sell and many of the raw materials and components that make up the products we sell, we may be subject to delays caused by interruption in production based on events and conditions outside of our control.
If we or one of our manufacturing partners or suppliers experiences an event, including a supply chain disruption, shortage or delay, logistics issue, labor dispute, natural disaster, fire, power outage, machinery breakdown, security problem, failure to meet regulatory requirements, product quality issue, technology transfer issue, cybersecurity breach or other issue, we or one of our manufacturing partners or suppliers may be unable to manufacture the relevant products at previous levels or on the forecasted schedule, if at all. Due to the stringent regulations and requirements of the governing regulatory authorities regarding the manufacture of our products, we may not be able to quickly restart manufacturing at a third party or our own facility or establish additional or replacement sources for certain products, components or materials.
In addition to our existing manufacturing relationships, we are also pursuing new manufacturing relationships to establish and secure additional or alternative suppliers for our commercial products. We also constructed a specialized in-house manufacturing facility at our North Billerica, Massachusetts campus for purposes of producing the formulation of DEFINITY that requires refrigerated storage and, potentially, other sterile vial products. On February 22, 2022, we received FDA approval of our sNDA, authorizing commercial manufacturing of DEFINITY at our new facility. This project provides a certain amount of supply chain redundancy for DEFINITY (other than DEFINITY RT, which is supplied solely by SBL). However, we cannot assure you that these activities or any of our additional supply activities will be successful or that we will be able to avoid or mitigate interim supply shortages before new sources of product are fully functional and qualified. In addition, we cannot assure you that our existing manufacturers or suppliers or any new manufacturers or suppliers can adequately maintain either their financial health, technical capabilities or regulatory compliance to allow continued production and supply. A reduction or interruption in manufacturing, or an inability to secure alternative sources of raw materials or components, could eventually have a material adverse effect on our business, results of operations, financial condition and cash flows.
31
The global supply of Mo-99 is fragile and not stable. Our dependence on a limited number of third party suppliers for Mo-99 could prevent us from delivering some of our products to our customers in the required quantities, within the required timeframe, or at all, which could result in order cancellations and decreased revenues.
A critical ingredient of TechneLite is Mo-99. We currently purchase finished Mo-99 from three of the four main processing sites in the world, namely IRE in Belgium, NTP in South Africa and ANSTO in Australia. These processing sites provide us Mo-99 from five of the six main Mo-99-producing reactors in the world, namely BR2 in Belgium, LVR-15 in the Czech Republic, HFR in The Netherlands, SAFARI in South Africa and OPAL in Australia.
Our agreement with NTP, acting for itself and on behalf of its subcontractor ANSTO, expires on December 31, 2024.
Although we have a globally diverse Mo-99 supply with IRE in Belgium, NTP in South Africa, and ANSTO in Australia, we still face supplier and logistical challenges in our Mo-99 supply chain. When one supplier experiences outages, we generally rely on Mo-99 supply from the other suppliers to limit the impact of the outages. We believe we effectively manage these various supply chain challenges, but depending on reactor and processor schedules and operations, at times we have not been able to fill some or all of the demand for our TechneLite generators on certain manufacturing days. A prolonged disruption of service from one of our three Mo-99 processing sites or one of their main Mo-99-producing reactors could have a substantial negative effect on our business, results of operations, financial condition and cash flows.
U.S., Canadian and international governments have encouraged the development of a number of alternative Mo-99 production projects with existing reactors and technologies as well as new technologies. However, we cannot say when, or if, the Mo-99 produced from these projects will become available. As a result, there is a limited amount of Mo-99 available which could limit the quantity of TechneLite that we could manufacture, sell and distribute, resulting in a substantial negative effect on our business, results of operations, financial condition and cash flows.
Most of the global suppliers of Mo-99 rely on Framatone-CERCA in France to fabricate uranium targets and in some cases fuel for research reactors from which Mo-99 is produced. Absent a new supplier, a supply disruption relating to uranium targets or fuel could have a substantial negative effect on our business, results of operations, financial condition and cash flows.
We can give no assurance that Curium will be successful with its commercialization of piflufolastat F 18 in Europe.
We have licensed exclusive rights to Curium to develop and commercialize piflufolastat F 18 in Europe. Under the terms of the collaboration, Curium is responsible for the development, regulatory approvals and commercialization of piflufolastat F 18 in Europe, and we are entitled to double-digit royalties on net sales of piflufolastat F 18. In July 2023, Curium announced that the EMA approved piflufolastat F 18 in Europe, under the name PYLCLARI. We cannot assure that Curium will be successful in commercializing it in Europe. Any failure or significant delay in Curium’s ability to successfully launch PYLCLARI in Europe may harm our business and delay or prevent us from being able to generate additional future royalty revenue from product sales.
We may not be able to successfully launch PYLARIFY AI as a commercial product.
We announced in November 2021 that PYLARIFY AI, our FDA-cleared medical device software, was commercially available in the United States. Our ability to successfully launch PYLARIFY AI as a commercial product depends in part on, among other things:
•the market receptivity to PYLARIFY AI as a new digital application for quantitative assessment of PSMA PET/CT images in prostate cancer;
•our ability, and our distributors’ abilities, to secure customers’ internal approvals and sell and deploy PYLARIFY AI at customer locations;
•interruptions or performance problems associated with our digital application, including a service outage; and
•a network or data security incident that allows unauthorized access to our network or data or our customers’ data.
Our just-in-time manufacturing of radiopharmaceutical products relies on the reliability of our equipment and processes, the timely receipt of radioactive raw materials and the timely shipment of finished goods, and any disruption of our supply or distribution networks could have a negative effect on our business.
At the facility on our North Billerica, Massachusetts campus, we manufacture TechneLite on an automated production line. As with all manufacturing facilities, equipment and infrastructure age and become subject to increasing maintenance and repair. If we experience an event, including a labor dispute, natural disaster, fire, power outage, machinery breakdown, security problem, failure to meet regulatory requirements, product quality issue, technology transfer issue or other issue, we may be unable to manufacture the relevant products at previous levels or on the forecasted schedule, if at all. Due to the stringent regulations and requirements of the
32
governing regulatory authorities regarding the manufacture of our products, we may not be able to quickly restart manufacturing at our facilities or establish additional or replacement sources for certain products, components or materials.
In addition, because a number of our radiopharmaceutical products, including PYLARIFY and our TechneLite generators rely on radioisotopes with limited half-lives, we or our partners must manufacture, finish and distribute these products on a just-in-time basis, because the underlying radioisotope is in a constant state of decay. For example, the radioisotope used in PYLARIFY is F 18, which has a 110 minute half-life, requiring that this product be manufactured and distributed within the same day to end-users. After being made on a cyclotron at a PMF, the F 18 is then combined with certain chemical ingredients in specially designed chemistry synthesis boxes to manufacture PYLARIFY. The finished PYLARIFY is then quality control tested and transferred to a radiopharmacist who prepares and dispenses patient-specific doses from the final product. Similarly, with respect to our TechneLite generators, if we receive Mo-99 in the morning of a manufacturing day for TechneLite generators, then we will generally ship finished generators to customers by the end of that same business day. Shipment of generators may be by next day delivery services or by either ground or air custom logistics. Any delay in us receiving radioisotopes from suppliers or being able to have finished products delivered to customers because of weather or other unforeseen transportation issues could have a negative effect on our business, results of operations, financial condition and cash flows.
In the U.S., we are heavily dependent on a few large customers to generate a majority of our revenues for our single-photon emission computerized tomography (SPECT) nuclear medical imaging products in our Precision Diagnostic product category. For PYLARIFY, we depend in part on some of our PMF partners to generate sales and collect revenue. Outside of the U.S., we rely primarily on distributors to generate a substantial portion of our revenue.
In the U.S., we have historically relied on a limited number of radiopharmacy customers, primarily Cardinal, RLS, UPPI, PharmaLogic and Jubilant Radiopharma, to purchase our nuclear imaging products in our Precision Diagnostic product category. Among the existing radiopharmacies in the U.S., continued consolidations, divestitures and reorganizations may have a negative effect on our business, results of operations, financial condition and cash flows. Our contractual arrangements with these radiopharmacy customers generally specify pricing levels and requirements to purchase minimum percentages of certain products during certain periods. The agreements generally may be terminated upon the occurrence of specified events, including a material breach by the other party and certain force majeure events. If these contracts are terminated prior to the expiration of their term, or are not renewed, or are renewed on terms that are less favorable to us, then such an event could have a material adverse effect on our business, results of operations, financial condition and cash flows.
For PYLARIFY, we depend in part on some of our PMF partners to generate sales and collect revenue. To the extent our PMF partners are unsuccessful in generating sales or in collecting revenue, such an event could have a material adverse effect on our business, results of operations, financial condition and cash flows.
We also continue to experience significant pricing pressures from our competitors, large customers and group purchasing organizations, and any significant, additional pricing pressures could lead to a reduction in revenue which could have a material adverse effect on our business, results of operations, financial condition and cash flows.
Outside of the U.S., we have no sales force and, consequently, rely on third party distributors, either on a country-by-country basis or on a multi-country, regional basis, to market, sell and distribute our products. In certain circumstances, distributors may also sell competing products to our own or products for competing diagnostic modalities and may have incentives to shift sales towards those competing products. As a result, we cannot assure you that our international distributors will increase or maintain current levels of unit sales or that we will be able to increase or maintain our current unit pricing, which, in turn, could have a material adverse effect on our business, results of operations, financial condition and cash flows.
We face significant competition in our business and may not be able to compete effectively.
The markets for our products are highly competitive and continually evolving. Our principal competitors for our current commercial products and leading clinical development candidates include large, global companies that are more diversified than we are and that have substantial financial, manufacturing, sales and marketing, distribution and other resources:
•For PYLARIFY, our competitors currently include approved imaging agents from Telix Pharmaceuticals Limited, Novartis AG, and Blue Earth, a subsidiary of Bracco.
•For DEFINITY, our competitors currently include GE Healthcare and Bracco.
•For a number of our radiopharmaceutical commercial products, our competitors currently include Curium, GE Healthcare, Bracco and Jubilant Life Sciences, an affiliate of JHS and Jubilant Radiopharma, and potentially BWXT Medical.
•For PNT2002 and 1095, our principal competitors may include Novartis AG; Telix Pharmaceuticals Limited; and Curium, each of which has commercialized products or product candidates in advanced clinical stage of development.
33
•For PNT2003, our principal competitor may include Novartis AG; ITM Radiopharma; and RayzeBio (under agreement to be acquired by Bristoll Meyers Squibb), each of which has commercialized products or product candidates in advanced clinical stage of development.
•For MK-6240, our principal competitors may include Eli Lilly and Company and Life Molecular Imaging, each of which has commercialized products or product candidates in advanced clinical stage of development. .
•For LNTH-1363S, our principal competitors may include Sofie Bioscience; GE Healthcare; and Novartis AG, each of which has product candidates in clinical stage of development.
We cannot anticipate the actions of our current or future competitors in the same or competing modalities, such as significant price reductions on products that are competitive with our own, development of new products that are more cost-effective or have superior performance than our current products or potential future products or the introduction of generic versions after our proprietary products lose their patent protection. In addition, distributors of our products could attempt to shift end-users to competing diagnostic modalities and products, or bundle the sale of a portfolio of products, in either case to the detriment of our specific products. Our current or future products could be rendered obsolete or uneconomical as a result of these activities.
Further, the radiopharmaceutical industry continues to evolve strategically, with several market participants recently sold. In addition, the supply-demand dynamics of the industry are complex because of large market positions of some participants, legacy businesses, government subsidies (in particular, relating to the manufacture of radioisotopes), and group purchasing arrangements. We cannot predict what impact new owners and new operators may have on the strategic decision-making of our competitors, customers and suppliers, and such decision-making could have a material adverse effect on our business, results of operations, financial condition and cash flows.
Ultrasound enhancing agents may cause side effects which could limit our ability to sell DEFINITY.
DEFINITY is an ultrasound enhancing agent based on perflutren lipid microspheres. In 2007, the FDA received reports of deaths and serious cardiopulmonary reactions following the administration of ultrasound enhancing agents used in echocardiography. Four of the 11 reported deaths were caused by cardiac arrest occurring either during or within 30 minutes following the administration of the ultrasound enhancing agent; most of the serious but non-fatal reactions also occurred in this time frame. As a result, in October 2007, the FDA requested that we and GE Healthcare, which distributes Optison, a competitor to DEFINITY, add a boxed warning to these products emphasizing the risk for serious cardiopulmonary reactions and that the use of these products was contraindicated in certain patients. In a strong reaction by the cardiology community to the FDA’s new position, a letter was sent to the FDA, signed by 161 doctors, stating that the benefit of these ultrasound enhancing agents outweighed the risks and urging that the boxed warning be removed. In May 2008, the FDA substantially modified the boxed warning. On May 2, 2011, the FDA held an advisory committee meeting to consider the status of ultrasound enhancing agents and the boxed warning. In October 2011, we received FDA approval of further modifications to the DEFINITY label, including: further relaxing the boxed warning; eliminating the sentence in the Indication and Use section “The safety and efficacy of DEFINITY with exercise stress or pharmacologic stress testing have not been established” (previously added in October 2007 in connection with the imposition of the box warning); and including summary data from the post-approval CaRES (Contrast echocardiography Registry for Safety Surveillance) safety registry and the post-approval pulmonary hypertension study. Further, in January 2017, the FDA approved an additional modification to the DEFINITY label, removing the contraindication statement related to use in patients with a known or suspected cardiac shunt. Bracco’s ultrasound enhancing agent, Lumason, has substantially similar safety labeling as DEFINITY and Optison. In April 2021, after reviewing certain adverse events that occurred in patients with a prior history of allergic reactions to polyethylene glycol (“PEG”), an inactive excipient in both DEFINITY and Lumason, the FDA and the marketing authorization holders of these products agreed to an additional contraindication for use of these products, including advising clinicians to assess patients for prior PEG hypersensitivity before administering these products. In June 2023, after reviewing adverse events that occurred in patients with history of sickle cell disease, we agreed with the FDA to amend the label to advise clinicians that if a patient with sickle cell disease experiences acute pain episodes following DEFINITY administration, use of DEFINITY in that patient should be discontinued. If additional safety issues arise (not only with DEFINITY but also potentially with Optison and Lumason), this may result in unfavorable changes in labeling or result in restrictions on the approval of our product, including removal of the product from the market. Lingering safety concerns about DEFINITY among some healthcare providers or future unanticipated side effects or safety concerns associated with DEFINITY could limit expanded use of DEFINITY and have a material adverse effect on the unit sales of this product and our financial condition and results of operations.
34
Risks Related to Reimbursement and Regulation
Many of our customers are highly dependent on payments from third-party payors, including government sponsored programs, particularly Medicare, in the U.S. and other countries in which we operate, and reductions in third party coverage and reimbursement rates for our products (or services provided with our products) could adversely affect our business and results of operations.
A substantial portion of our revenue depends on the extent to which the costs of our products purchased by our customers (or services provided with our products) are reimbursed by third party payors, including Medicare, Medicaid, other U.S. government sponsored programs, non-U.S. governmental payors and private payors. These third-party payors exercise significant control over patient access and increasingly use their enhanced bargaining power to secure discounted rates and impose other requirements that may reduce demand for our products. Our customers’ ability to obtain adequate reimbursement for products and services from these third-party payors affects the selection of products they purchase and the prices they are willing to pay. If Medicare and other third party payors do not provide adequate reimbursement for the costs of our products (or services provided using our products), deny the coverage of the products (or those services), or reduce current levels of reimbursement, healthcare professionals may not prescribe our products and providers and suppliers may not purchase our products.
In addition, demand for new products may be limited unless we obtain favorable reimbursement (including coding, coverage and payment) from governmental and private third party payors at the time of the product’s introduction, which will depend, in part, on our ability to demonstrate that a new agent has a positive impact on clinical outcomes. Third-party payors continually review their coverage policies for existing and new products and procedures and can deny coverage for products or procedures that include the use of our products or revise payment policies such that payments do not adequately cover the cost of our products. Even if third-party payors make coverage and reimbursement available, that reimbursement may not be adequate or these payors’ reimbursement policies may have an adverse effect on our business, results of operations, financial condition and cash flows.
For example, effective January 1, 2022, the CMS granted TPT Status in the hospital outpatient setting for PYLARIFY, enabling traditional Medicare to provide an incremental payment for PET/CT scans performed with PYLARIFY in that setting. TPT Status for PYLARIFY is expected to expire December 31, 2024. After TPT Status expires, under current Medicare rules, PYLARIFY would not be separately reimbursed in the hospital outpatient setting but rather would be bundled into the facility payment a hospital receives for a PET/CT imaging procedure, and the facility payment may not always cover the total cost of the procedure. In 2023 rulemaking for the 2024 payment calendar year, CMS recognized the challenges of patient access to diagnostic radiopharmaceuticals and requested feedback on various payment alternatives that could provide separate reimbursement for these items, but the agency did not adopt any of these proposals in the final rule, while stating that it would continue to evaluate this issue in subsequent rulemaking. We can give no assurance that any CMS reimbursement in the hospital outpatient setting that follows the expiration of TPT Status will be adequate to cover a PYLARIFY PET/CT imaging procedure or that the availability of TPT Status for other diagnostic radiopharmaceuticals will not impact clinical decision making regarding which product to use, which could have an adverse effect on our business, results of operations, financial condition and cash flows.
Over the past several years, Medicare has implemented numerous changes to payment policies for imaging procedures in both the hospital setting and non-hospital settings (which include physician offices and freestanding imaging facilities). Some of these changes have had a negative impact on utilization of imaging services. Examples of these changes include:
•Reducing payments for certain imaging procedures when performed together with other imaging procedures in the same family of procedures on the same patient on the same day in the physician office and free-standing imaging facility setting;
•Making significant revisions to the methodology for determining the practice expense component of the Medicare payment applicable to the physician office and free-standing imaging facility settings which results in a reduction in payment;
•Revising payment policies and reducing payment amounts for imaging procedures performed in the hospital outpatient settings; and
•Reducing prospective payment levels for applicable diagnosis-related groups in the hospital inpatient setting.
In the physician office and free-standing imaging facility setting, services provided using our products are reimbursed under the Medicare physician fee schedule. Payment rates under the Medicare physician fee schedule are regularly subject to updates to effectuate various policy goals of CMS and Congress. For example, in 2022, CMS reduced Medicare fee schedule payments rates in the agency’s final rulemaking, while a larger cut was put forth in the proposed rulemaking earlier that year. For 2023, CMS had finalized a reduction in the Medicare fee schedule payments rates, which was revised by Congress, pursuant to the Consolidated Appropriations Act, 2023, to a lesser reduction. Additionally, since 2019, fee schedule payments have been adjusted for certain physicians based on their performance under a consolidated measurement system (that measures performance with respect to quality, resource utilization, meaningful use of certified electronic health records technology, and clinical practice improvement activities).
35
From 2019 through payment year 2024, physicians may be eligible for a bonus based on the use of certain alternative payment models designated as “advanced” by CMS. The ongoing and future impact of these changes cannot be determined at this time.
We believe that Medicare changes to payment policies for imaging procedures applicable to non-hospital settings will continue to result in certain physician practices ceasing to provide these services and a further shifting of where certain medical imaging procedures are performed, from the physician office and free-standing imaging facility settings to the hospital outpatient setting. Changes applicable to Medicare payment in the hospital outpatient setting could also influence the decisions by hospital outpatient physicians to perform procedures that involve our products. Within the hospital outpatient setting, CMS payment policy is such that the use of many of our products are not separately payable by Medicare, although certain new drug products are eligible for separate (incremental) payment for the first three years after approval. Changes to the Medicare hospital outpatient prospective payment system payment rates, including reductions implemented for certain hospital outpatient sites, could influence the decisions by hospital outpatient physicians to perform procedures that involve our products.
We also believe that all of these changes and their resulting pressures may incrementally reduce the overall number of diagnostic medical imaging procedures performed. These changes overall could slow the acceptance and introduction of next-generation imaging equipment into the marketplace, which, in turn, could adversely impact the future market adoption of certain of our imaging agents already in the market or currently in development. We expect that there will continue to be proposals to reduce or limit Medicare and Medicaid payment for diagnostic services, which could impact our current or potential future diagnostic and other types of products and have a material adverse effect on our business, results of operations, financial condition and cash flows.
We also expect increased regulation and oversight of advanced diagnostic testing in which our products are used, although the timing of such regulation is uncertain after a recent pause by CMS. Under section 218(b) of the Protecting Access to Medicare Act, beginning January 1, 2020, a professional who is ordering advanced diagnostic imaging services (which include MRI, CT, nuclear medicine (including PET) and other advanced diagnostic imaging services that the Secretary of HHS may specify, but not currently including echocardiography) must consult a qualified clinical decision support mechanism, as identified by HHS, to determine whether the ordered service adheres to specified appropriate use criteria (“AUC”) developed or endorsed by CMS-qualified “provider led entities”. Medicare claims for such services must include information indicating whether services ordered would adhere to specified applicable AUC. Denial of claims for failure to include AUC consultation information on the claim form was set to begin on January 1, 2022, but was not implemented by CMS. In the CY 2024 Physician Fee Schedule Final Rule, CMS determined that it was not feasible to fully operationalize the AUC program consistent with the statute within the required time frame. Accordingly, the agency finalized an indefinite pause to the AUC program and the recission of the regulations promulgated thus far to implement the AUC program. While it is unclear when CMS will resume implementation of the AUC program, to the extent that these types of changes have the effect of reducing the aggregate number of diagnostic medical imaging procedures performed in the U.S., our business, results of operations, financial condition and cash flows would be adversely affected.
Medicare coverage of PET radiopharmaceuticals has been the subject of a large number of National Coverage Determinations (“NCDs”) by CMS since 2000. Specific indications for PET imaging were covered, some through Coverage with Evidence Development. CMS’s longtime policy, however, was that a particular use of PET scans is not covered unless an NCD specifically provided that such use was covered. Effective March 7, 2013, CMS revised its policy through an NCD to allow local Medicare Administrative Contractors (“MACs”) to determine coverage within their respective jurisdictions for PET using radiopharmaceuticals for their FDA-approved labeled indications for oncologic imaging. Effective January 1, 2022, non-coverage in the absence of an NCD has also been removed for non-oncologic indications of PET radiopharmaceuticals, allowing MACs to determine coverage for these indications within their respective jurisdictions. To the extent that CMS or the MACs impose more restrictive coverage, our business, results of operations, financial condition and cash flows would be adversely affected.
Reforms to the U.S. healthcare system may adversely affect our business.
A significant portion of our patient volume is derived from U.S. government healthcare programs, principally Medicare, which are highly regulated and subject to frequent and substantial changes. The Healthcare Reform Act substantially changed the way healthcare is financed by both governmental and private insurers. The law contains a number of provisions that affect coverage and reimbursement of drug products and medical imaging procedures in which our drug products are used and/or that could potentially reduce the aggregate number of diagnostic medical imaging procedures performed in the U.S. Subsequently, the Medicare Access and CHIP Reauthorization Act of 2015 significantly revised the methodology for updating the Medicare physician fee schedule. In 2017, Congress enacted legislation that effectively eliminated the Healthcare Reform Act’s “individual mandate” beginning in 2019. Congress continues to consider other healthcare reform legislation. There is no assurance that the Healthcare Reform Act, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative, judicial or administrative changes relating to healthcare reform will affect our business.
36
In addition, other legislative changes have been proposed and adopted since the Healthcare Reform Act was enacted. The Budget Control Act of 2011 and subsequent Congressional actions includes provisions to reduce the federal deficit. These provisions have resulted in the imposition of 2% reductions in Medicare payments to providers, which went into effect on April 1, 2013 and will remain in effect through fiscal year 2030. The imposition of the 2% payment adjustment had been suspended through March 31, 2022 and went into effect as of April 1, 2022. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our business, results of operations, financial condition and cash flows.
Further, changes in payor mix and reimbursement by private third-party payors may also affect our business. Rates paid by some private third-party payors are based, in part, on established physician, clinic and hospital charges and are generally higher than Medicare payment rates. Reductions in the amount of reimbursement paid for diagnostic medical imaging procedures, including the elimination of any additional payment such as TPT Status, and changes in the mix of our patients between non-governmental payors and government sponsored healthcare programs and among different types of non-government payor sources, could have a material adverse effect on our business, results of operations, financial condition and cash flows.
The full impact on our business of healthcare reforms and other new laws, or changes in existing laws, is uncertain. Nor is it clear whether additional legislative changes will be adopted or how those changes would affect our industry in general or our ability to successfully commercialize our products or develop or commercialize new products.
Our business and industry are subject to complex and costly regulations. If government regulations are interpreted or enforced in a manner adverse to us or our business, we may be subject to enforcement actions, penalties, exclusion and other material limitations on our operations.
Both before and after the approval of our products in development, we, our products, development products, operations, facilities, suppliers, distributors, contract manufacturers, contract research organizations and contract testing laboratories are subject to extensive and, in certain circumstances, expanding regulation by federal, state and local government agencies in the U.S. as well as non-U.S. and transnational laws and regulations, with regulations differing from country to country and even state to state, including, among other things, anti-trust and competition laws and regulations, and data privacy laws and regulations such as the General Data Protection Regulation in the European Union and the CCPA and the CPRA. In the U.S., the FDA regulates, among other things, the pre-clinical testing, clinical trials, manufacturing, safety, efficacy, potency, labeling, storage, record keeping, quality systems, advertising, promotion, sale, distribution, and import and export of drug products. We are required to register our business for permits and/or licenses with, and comply with the stringent requirements of the FDA, the NRC, the HHS, Health Canada, the EMA, the MHRA, the NMPA, state and provincial boards of pharmacy, state and provincial health departments and other federal, state and provincial agencies. Violation of any of these regulatory schemes, individually or collectively, could disrupt our business and have a material adverse effect on our business, results of operations, financial condition and cash flows.
Under U.S. law, for example, we are required to report certain adverse events and production problems, if any, to the FDA or other federal or state regulators. We also have similar adverse event and production reporting obligations outside of the U.S., including to the EMA and MHRA. Additionally, we must comply with requirements concerning advertising and promotion for our products, including the prohibition on the promotion of our products for indications for which they have not been approved by the FDA or a so-called “off-label use” or promotion that is inconsistent with the approved labeling. If the FDA determines that our promotional materials constitute unlawful promotion, it could request that we modify our promotional materials or subject us to regulatory or enforcement actions. Also, quality control and manufacturing procedures at our own facility and at third-party suppliers must conform to cGMP regulations and other applicable law after approval, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMPs and other applicable law, and, from time to time, makes those cGMPs more stringent. Accordingly, we and others with whom we work must expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control. If in the future issues arise at our own manufacturing facility or at a third-party manufacturer, the FDA could take regulatory action which could limit or suspend the ability to manufacture our products or have any additional products approved at the relevant facility for manufacture until the issues are resolved and remediated. Such a limitation or suspension could have a material adverse effect on our business, results of operations, financial condition and cash flows.
We are also subject to laws and regulations that govern financial and other arrangements between pharmaceutical manufacturers and healthcare providers, including federal and state anti-kickback statutes, federal and state false claims laws and regulations, federal and state “sunshine” laws and regulations and other fraud and abuse laws and regulations.
We must offer discounted pricing or rebates on purchases of pharmaceutical products under various federal and state healthcare programs, such as the Medicaid drug rebate program, the 340B drug pricing program and the Medicare Part D Program. We must also report specific prices to government agencies under healthcare programs, such as the Medicaid drug rebate program and Medicare Part B. Our Medicaid Drug Rebate agreements require us to report certain price information to the federal government. Determination of
37
the rebate amount that we pay to state Medicaid programs for our products, of prices charged to government and certain private payors for our products, or of amounts paid for our products under government healthcare programs, depends upon information reported by us to the government. If we provide customers or government officials with inaccurate information about the products’ pricing or eligibility for coverage, or the products fail to satisfy coverage requirements, we could be terminated from the rebate program, be excluded from participation in government healthcare programs, or be subject to potential liability under the False Claims Act or other laws and regulations.
Failure to comply with other requirements and restrictions placed upon us or our third-party manufacturers or suppliers by laws and regulations can result in fines, civil and criminal penalties, exclusion from federal healthcare programs and debarment. Possible consequences of those actions could include:
•Substantial modifications to our business practices and operations;
•Significantly reduced demand for our products (if products become ineligible for reimbursement under federal and state healthcare programs);
•A total or partial shutdown of production in one or more of the facilities where our products are produced while the alleged violation is being remediated;
•Delays in or the inability to obtain future pre-market clearances or approvals; and
•Withdrawals or suspensions of our current products from the market.
Our marketing and sales practices may contain risks that could result in significant liability, require us to change our business practices, and restrict our operations in the future.
We are subject to numerous domestic (federal, state and local) and foreign laws addressing fraud and abuse in the healthcare industry, including the FCA and federal Anti-Kickback Statute, self-referral laws, the FCPA, the Bribery Act, FDA promotional restrictions, the federal disclosure (sunshine) law and state marketing and disclosure (sunshine) laws. Violations of these laws are punishable by criminal or civil sanctions, including substantial fines, imprisonment and exclusion from participation in healthcare programs such as Medicare and Medicaid as well as health programs outside the U.S., and even settlement of alleged violations can result in the imposition of corporate integrity agreements that could subject us to additional compliance and reporting requirements and impact our business practices. These laws and regulations are complex and subject to changing interpretation and application, which could restrict our sales or marketing practices. Even minor and inadvertent irregularities could potentially give rise to a charge that the law has been violated. Although we believe we maintain an appropriate compliance program, we cannot be certain that the program will adequately detect or prevent violations and/or the relevant regulatory authorities may disagree with our interpretation. Additionally, if there is a change in law, regulation or administrative or judicial interpretations, we may have to change one or more of our business practices to be in compliance with these laws. Required changes could be costly and time consuming.
If our operations are found to be in violation of these laws or any other government regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, imprisonment, the curtailment or restructuring of our operations, or exclusion from state and federal healthcare programs including Medicare and Medicaid, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows.
Risks Related to Our Business Operations and Financial Results
We may not be able to hire or retain the number of qualified personnel, particularly scientific, medical and sales personnel, required for our business, which would harm the development and sales of our products and limit our ability to grow.
Competition in our industry for highly skilled scientific, healthcare and sales personnel is intense. In connection with the launch and continued growth of PYLARIFY, we hired additional employees to assist us with the commercialization of PYLARIFY, including in sales, marketing, reimbursement, quality and medical affairs. Although we were successful in hiring and onboarding those employees and we have not had any material difficulty in the past in hiring or retaining qualified personnel, if we are unable to retain our existing personnel, or attract and train additional qualified personnel, either because of competition in our industry for these personnel or insufficient financial resources, then our growth may be limited and it could have a material adverse effect on our business.
If we lose the services of our key personnel, our business could be adversely affected.
Our success is substantially dependent upon the performance, contributions and expertise of our chief executive officer, executive leadership and senior management team. Mary Anne Heino, our Chief Executive Officer, and other members of our executive leadership and senior management team play a significant role in formulating and executing on our long-term strategy, generating business and overseeing operations. We have employment agreements with Ms. Heino, Brian Markison, who will succeed Ms. Heino as Chief Executive Officer effective March 1, 2024, and a limited number of other individuals on our executive leadership
38
team, although we cannot prevent them from terminating their employment with us. We do not maintain key person life insurance policies on any of our executive officers. While we have experienced some turnover on our executive leadership team, we have generally been able to fill positions by either promoting existing employees or attracting new, qualified individuals to lead key functional areas. For example, on January 23, 2024, we announced that effective March 1, 2024, Brian Markison, our current Chair of the Board, will become our Chief Executive Officer, and Mary Anne Heino, our current Chief Executive Officer, will retire and become the Chair of the Board. Our inability to retain our existing executive leadership and senior management team, maintain an appropriate internal succession program or attract and retain additional qualified personnel could have a material adverse effect on our business.
Our business depends on our ability to successfully introduce new products and adapt to a changing technology and medical practice landscape.
The healthcare industry is characterized by continuous technological development resulting in changing customer preferences and requirements. The success of new product development depends on many factors, including our ability to fund development of new products or new indications for existing products, anticipate and satisfy customer needs, obtain timely regulatory approval based on performance of our products in development versus their clinical trial comparators, develop and manufacture products in a cost-effective and timely manner, maintain advantageous positions with respect to intellectual property and differentiate our products from our competitors. To compete successfully in the marketplace, we must make substantial investments in new product development, whether internally or externally through licensing or acquisitions. Our failure to introduce new and innovative products in a timely manner would have an adverse effect on our business, results of operations, financial condition and cash flows.
Even if we are able to develop, manufacture and obtain regulatory approvals for our new products, the success of these products would depend upon market acceptance and adequate coding, coverage and payment. Levels of market acceptance for our new products could be affected by a number of factors, including:
•The availability of alternative products from our competitors;
•The breadth of indications in which alternative products from our competitors can be marketed;
•The price of our products relative to those of our competitors;
•The timing of our market entry;
•Our ability to enter into commercial contracts to sell our products;
•Our ability to market and distribute our products effectively;
•Market acceptance of our products; and
•Our ability to obtain adequate coding, coverage and payment, including the availability of TPT Status.
The field of diagnostic medical imaging is dynamic, with new products, including equipment, software and products, continually being developed and existing products continually being refined. Our own diagnostic imaging agents compete not only with other similarly administered imaging agents but also with imaging agents employed in different and often competing diagnostic modalities, and in the case of DEFINITY, echocardiography procedures without ultrasound enhancing agents. New hardware, software or products in a given diagnostic modality may be developed that provide benefits superior to the then-dominant hardware, software and products in that modality, resulting in commercial displacement of the products. Similarly, changing perceptions about comparative efficacy and safety including, among other things, comparative radiation exposure, as well as changing availability of supply or the availability of additional payments for new devices such as TPT Status, may favor one product over another or one modality over another. In addition, new or revised appropriate use criteria developed by professional societies, to assist physicians and other health care providers in making appropriate imaging decisions for specific clinical conditions, can and have reduced the frequency of and demand for certain imaging modalities and imaging agents. To the extent there is technological obsolescence in any of our products that we manufacture, resulting in lower unit sales or decreased unit sales prices, we will have increased unit overhead allocable to the remaining market share, which could have a material adverse effect on our business, results of operations, financial condition and cash flows. Similar risks could apply to therapeutic products, including products we are developing.
Our future growth may depend on our ability to identify and acquire or in-license additional products, businesses or technologies, and if we do not successfully do so, or otherwise fail to integrate any new products, lines of business or technologies into our operations, we may have limited growth opportunities and it could result in significant impairment charges or other adverse financial consequences.
We seek to acquire or in-license products, businesses or technologies that we believe are a strategic fit with our business strategy. Future acquisitions or in-licenses, however, may entail numerous operational and financial risks, including:
•A reduction of our current financial resources;
39
•Incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;
•Difficulty or inability to secure financing to fund development activities for those acquired or in-licensed technologies;
•Higher than expected acquisition and integration costs;
•Disruption of our business, customer base and diversion of our management’s time and attention to develop acquired products or technologies; and
•Exposure to unknown liabilities.
We may not have sufficient resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. In particular, we may compete with larger pharmaceutical companies and other competitors in our efforts to establish new collaborations and in-licensing opportunities. These competitors likely will have access to greater financial resources than we do and may have greater expertise in identifying and evaluating new opportunities. Furthermore, there may be an overlap between our products or customers and the companies which we acquire that may create conflicts in relationships or other commitments detrimental to the integrated businesses. Additionally, the time between our expenditures to acquire or in-license new products, technologies or businesses and the subsequent generation of revenues from those acquired products, technologies or businesses (or the timing of revenue recognition related to licensing agreements and/or strategic collaborations) could cause fluctuations in our financial performance from period to period. Finally, if we devote resources to potential acquisitions or in-licensing opportunities that are never completed, or if we fail to realize the anticipated benefits of those efforts, we could incur significant impairment charges or other adverse financial consequences.
Challenges with product quality or product performance, including defects, caused by us or our manufacturers or suppliers could result in a decrease in customers and revenues, unexpected expenses and loss of market share.
The manufacture of our products is highly exacting and complex and must meet stringent quality requirements, due in part to strict regulatory requirements, including the FDA’s cGMPs. Problems may be identified or arise during manufacturing, quality review, packaging or shipment for a variety of reasons including equipment malfunction, failure to follow specific protocols and procedures, defective raw materials and environmental factors. Additionally, manufacturing flaws, component failures, design defects, off-label uses or inadequate disclosure of product-related information could result in an unsafe condition or the injury or death of a patient. Those events could lead to a recall of, or issuance of a safety alert relating to, our products or could harm our reputation and our ability to market our products in the future. We also may undertake voluntarily to recall products or temporarily shut down production lines based on internal safety and quality monitoring and testing data.
Quality, regulatory and recall challenges could cause us to incur significant costs, including costs to replace products, lost revenue, damage to customer relationships, time and expense spent investigating the cause and costs of any possible settlements or judgments related thereto and potentially cause similar losses with respect to other products. These challenges could also divert the attention of our management and employees from operational, commercial or other business efforts. If we deliver products with defects, or if there is a perception that our products or the processes related to our products contain errors or defects, we could incur additional recall and product liability costs, and our credibility and the market acceptance and sales of our products could be materially adversely affected. Due to the strong name recognition of our brands, an adverse event involving one of our products could result in reduced market acceptance and demand for all products within that brand, and could harm our reputation and our ability to market our products in the future. In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the suspension or delay of regulatory reviews of our applications for new product approvals. These challenges could have a material adverse effect on our business, results of operations, financial condition and cash flows.
In the ordinary course of business, we may be subject to product liability claims and lawsuits, including potential class actions, alleging that our products have resulted or could result in an unsafe condition or injury.
Any product liability claim brought against us, with or without merit, could be time consuming and costly to defend and could result in an increase of our insurance premiums. Although we have not had any such claims to date, claims that could be brought against us might not be covered by our insurance policies. Furthermore, although we currently have product liability insurance coverage with policy limits that we believe are customary for pharmaceutical companies in the diagnostic medical imaging industry and adequate to provide us with insurance coverage for foreseeable risks, even where the claim is covered by our insurance, our insurance coverage might be inadequate and we would have to pay the amount of any settlement or judgment that is in excess of our policy limits. We may not be able to obtain insurance on terms acceptable to us or at all, since insurance varies in cost and can be difficult to obtain. Our failure to maintain adequate insurance coverage or successfully defend against product liability claims could have a material adverse effect on our business, results of operations, financial condition and cash flows.
We use hazardous materials in our business and must comply with environmental laws and regulations, which can be expensive.
40
Our operations use hazardous materials and produce hazardous wastes, including radioactive, chemical and, in certain circumstances, biological materials and wastes. We are subject to a variety of federal, state and local laws and regulations as well as non-U.S. laws and regulations relating to the transport, use, handling, storage, exposure to and disposal of these materials and wastes. Environmental laws and regulations are complex, change frequently and have generally become more stringent over time. We are required to obtain, maintain and renew various environmental permits and nuclear licenses. Although we believe that our safety procedures for transporting, using, handling, storing and disposing of, and limiting exposure to, these materials and wastes comply in all material respects with the standards prescribed by applicable laws and regulations, the risk of accidental contamination or injury cannot be eliminated. We place a high priority on these safety procedures and seek to limit any inherent risks. We generally contract with third parties for the disposal of wastes generated by our operations. We store low level radioactive waste at our facility and dispose of the materials in accordance with applicable laws and regulations. A majority of our low level radioactive waste is held to decay until materials are no longer considered radioactive. Although we believe we have complied in all material respects with all applicable environmental, health and safety laws and regulations, we cannot assure you that we have been or will be in compliance with all such laws at all times. If we violate these laws, we could be fined, criminally charged or otherwise sanctioned by regulators. We may be required to incur further costs to comply with current or future environmental and safety laws and regulations. In addition, in the event of accidental contamination or injury from these materials, we could be held liable for any damages that result and any such liability could exceed our resources.
We previously leased a small portion of our North Billerica, Massachusetts campus to PerkinElmer for the manufacturing, finishing and packaging of certain radioisotopes, including Strontium-90, which has physical characteristics that make it more challenging to work with and dispose of than our own commercial radioisotopes, including a much longer half-life. PerkinElmer decommissioned its space and vacated the premises as of December 30, 2021. We are fully indemnified by PerkinElmer under our lease for any property damage or personal injury resulting from their activities in our facility. If any release or excursion of radioactive materials took place from their leased space that resulted in property damage or personal injury, the indemnification obligations were not honored, and we were forced to cover any related remediation, clean-up or other expenses, depending on the magnitude, the cost of such remediation, clean-up or other expenses could have a material adverse effect on our business, results of operations, financial condition and cash flows.
While we have budgeted for current and future capital and operating expenditures to maintain compliance with these laws and regulations, we cannot assure you that our costs of complying with current or future environmental, health and safety laws and regulations will not exceed our estimates or adversely affect our results of operations and financial condition. Further, we cannot assure you that we will not be subject to additional environmental claims for personal injury, investigation or cleanup in the future based on our past, present or future business activities.
If we are unable to protect our intellectual property, our competitors could develop and market products with features similar to our products, and demand for our products may decline.
Our commercial success will depend in part on obtaining and maintaining patent and trade secret protection of our commercial products and technologies and products in development as well as successfully enforcing and defending these patents and trade secrets against third parties and their challenges, both in the U.S. and in foreign countries. We will only be able to protect our intellectual property from unauthorized use by third parties to the extent that we maintain the secrecy of our trade secrets and can enforce our valid patents and trademarks.
The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. In addition, changes in either the patent laws or in interpretations of patent laws in the U.S. or other countries may diminish the value of our intellectual property and we may not receive the same degree of protection in every jurisdiction. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.
The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:
•We might not have been the first to make the inventions covered by each of our pending patent applications and issued patents, and we could lose our patent rights as a result;
•We might not have been the first to file patent applications for these inventions or our patent applications may not have been timely filed, and we could lose our patent rights as a result;
•Others may independently develop similar or alternative technologies or duplicate any of our technologies;
•It is possible that none of our pending patent applications will result in any further issued patents;
•Our issued patents may not provide a basis for commercially viable drugs, may not provide us with any protection from unauthorized use of our intellectual property by third parties, and may not provide us with any competitive advantages;
41
•The validity or enforceability of our patent applications or patents may be subject to challenge through interferences, oppositions, post-grant review, ex-parte re-examinations, inter partes review or similar administrative proceedings;
•While we generally apply for patents in those countries where we intend to make, have made, use or sell patented products, we may not be able to accurately predict all of the countries where patent protection will ultimately be desirable and may be precluded from doing so at a later date;
•We may choose not to seek patent protection in certain countries where the actual cost outweighs the perceived benefit at a certain time;
•Patents issued in foreign jurisdictions may have different scopes of coverage than our U.S. patents and so our products may not receive the same degree of protection in foreign countries as they would in the U.S.;
•We may not develop additional proprietary technologies that are patentable;
•The patents of others may have an adverse effect on our business; or
•The cost to defend our patents may be significant and may result in litigation which could be costly and time consuming.
Moreover, the issuance of a patent is not conclusive as to its validity or enforceability. A third party may challenge the validity or enforceability of a patent even after its issuance by the USPTO or the applicable foreign patent office. It is also uncertain how much protection, if any, will be afforded by our patents if we attempt to enforce them and they are challenged in court or in other proceedings, which may be brought in U.S. or non-U.S. jurisdictions to challenge the validity of a patent.
The initiation, defense and prosecution of intellectual property suits (including Hatch-Waxman related litigation), interferences, oppositions and related legal and administrative proceedings are costly, time consuming to pursue and result in a diversion of resources, including a significant amount of management time. The outcome of these proceedings is uncertain and could significantly harm our business. If we are not able to enforce and defend the patents of our technologies and products, then we will not be able to exclude competitors from marketing products that directly compete with our products, which could have a material and adverse effect on our business, results of operations, financial condition and cash flows.
We also rely on trade secrets and other know-how and proprietary information to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We use reasonable efforts to protect our trade secrets, but our employees, consultants, contractors, outside scientific partners and other advisors may unintentionally or willfully disclose our confidential information to competitors or other third parties. Enforcing a claim that a third party improperly obtained and is using our trade secrets is expensive, time consuming and resource intensive, and the outcome is unpredictable. In addition, courts outside the U.S. are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. We rely on confidentiality agreements with our collaborators, employees, consultants and other third parties and invention assignment agreements with our employees to protect our trade secrets and other know-how and proprietary information concerning our business. These confidentiality agreements may not prevent unauthorized disclosure of trade secrets and other know-how and proprietary information, and there can be no guarantee that an employee or an outside party will not make an unauthorized disclosure of our trade secrets, other technical know-how or proprietary information, or that we can detect such an unauthorized disclosure. We may not have adequate remedies for any unauthorized disclosure. This might happen intentionally or inadvertently. It is possible that a competitor will make use of that information, and that our competitive position will be compromised, in spite of any legal action we might take against persons making those unauthorized disclosures, which could have a material and adverse effect on our business, results of operations, financial condition and cash flows.
We rely on our trademarks, trade names and brand names to distinguish our products from the products of our competitors, and have registered or applied to register many of these trademarks. We cannot assure you that any pending trademark applications will be approved. Third parties may also oppose our trademark applications, or otherwise challenge our use of the trademarks. If our trademarks are successfully challenged, we could be forced to re-brand our products, which could result in loss of brand recognition, and could require us to devote resources to advertising and marketing new brands. Further, we cannot assure you that competitors will not infringe our trademarks, or that we will have adequate resources to enforce our trademarks.
Our patents are subject to generic challenge, and the validity, enforceability and commercial value of these patents are highly uncertain.
Our ability to obtain and defend our patents impacts the commercial value of our products and product candidates. Third parties have challenged and are likely to continue challenging the patents that have been issued or licensed to us. Patent protection involves complex legal and factual questions and, therefore, enforceability is uncertain. Our patents may be challenged, invalidated, held to be unenforceable, or circumvented, which could negatively impact their commercial value. Furthermore, patent applications filed outside the United States may be challenged by other parties, for example, by filing third-party observations that argue against patentability or an opposition. Such opposition proceedings are increasingly common in the EU and are costly to defend.
42
We may be subject to claims that we have infringed, misappropriated or otherwise violated the patent or other intellectual property rights of a third party. The outcome of any of these claims is uncertain and any unfavorable result could adversely affect our business, financial condition and results of operations.
We may be subject to claims by third parties that we have infringed, misappropriated or otherwise violated their intellectual property rights. We are aware of intellectual property rights held by third parties that relate to products or technologies we are developing. For example, we are aware of other groups investigating PSMA or related compounds and monoclonal antibodies directed at PSMA, PSMA-targeted imaging agents and therapeutics, and methylnaltrexone and other peripheral opioid antagonists, and of patents held, and patent applications filed, by these groups in those areas. While the validity of these issued patents, the patentability of pending patent applications and the applicability of any of them to our products and programs are uncertain, if asserted against us, any related patent or other intellectual property rights could adversely affect our ability to commercialize our products.
We may be subject to litigation over infringement claims regarding the products we manufacture or distribute or intend to manufacture or distribute. For example, on January 26, 2024, we were sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the filing of our ANDA for PNT2003 and Paragraph IV certification, consistent with the process established by the Hatch-Waxman Act. This type of litigation can be costly and time consuming and could divert management’s attention and resources, generate significant expenses, damage payments (potentially including treble damages) or restrictions or prohibitions on our use of our technology, which could adversely affect our business, results of operations, financial condition and cash flows. In addition, if we are found to be infringing on proprietary rights of others, we may be required to develop non-infringing technology, obtain a license (which may not be available on reasonable terms, or at all), make substantial one-time or ongoing royalty payments, or cease making, using and/or selling the infringing products, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows.
We may be adversely affected by prevailing economic conditions and financial, business and other factors beyond our control.
Our ability to attract and retain customers, invest in and grow our business, maintain our desired levels of costs of goods sold and operating expenses and meet our financial obligations depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the U.S. and inflationary pressures, including escalating energy prices. We cannot anticipate all the ways in which the current or future economic climate and financial market conditions could adversely impact our business. We are exposed to risks associated with reduced profitability and the potential financial instability of our customers, many of which may be adversely affected by volatile conditions in the financial markets. For example, unemployment and underemployment, and the resultant loss of insurance, may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, our customers may experience reductions in revenues, profitability and/or cash flow that could lead them to modify, delay or cancel orders for our products. If customers are not successful in generating sufficient revenue or are precluded from securing financing, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us. This, in turn, could adversely affect our financial condition and liquidity. To the extent prevailing economic conditions result in fewer procedures being performed, our business, results of operations, financial condition and cash flows could be adversely affected.
Similarly, we would expect our costs of goods sold and other operating expenses to change in the future in line with periodic inflationary changes in price levels. Because we intend to retain and continue to use our property and equipment, we believe that the incremental inflation related to the replacement costs of those items will not materially affect our operations. However, the rate of inflation affects our expenses, such as those for employee compensation, contract services, and transportation costs, which could increase our level of expenses and the rate at which we use our resources. While we generally believe that we will be able to offset the effect of price-level changes by adjusting our product prices and implementing operating efficiencies, any material unfavorable changes in price levels could have a material adverse effect on our financial condition, results of operations and cash flows.
Our business is subject to international economic, political and other risks that could negatively affect our results of operations or financial position.
For the year ended December 31, 2023, we derived approximately 2.6% of our revenues and sourced approximately 11.2% of our costs of goods sold outside of the United States. Accordingly, our business is subject to risks associated with doing business internationally, including:
•Less stable political and economic environment and changes in a specific country’s or region’s political or economic conditions;
43
•Changes in trade policies, regulatory requirements and other barriers, including, for example, U.S. trade sanctions against Iran and those countries and entities doing business with Iran, which could adversely impact international isotope production and, indirectly, our global supply chain;
•Potential global disruptions in air transport, which could adversely affect our international supply chains for radioisotopes and DEFINITY RT as well as international distribution channels for our commercial products;
•Entering into, renewing or enforcing commercial agreements with international governments or provincial authorities or entities directly or indirectly owned or controlled by such governments or authorities, such as our Belgian, Australian and South African isotope suppliers, IRE, ANSTO and NTP, and our Chinese development and commercialization partner, Double-Crane;
•International customers which are agencies or institutions owned or controlled by foreign governments;
•Local business practices which may be in conflict with the U.S. Foreign Corrupt Practices Act and U.K. Bribery Act;
•Currency fluctuations;
•Unfavorable labor regulations;
•Greater difficulties in relying on non-U.S. courts to enforce either local or U.S. laws, particularly with respect to intellectual property;
•Greater potential for intellectual property piracy;
•Greater difficulties in managing and staffing non-U.S. operations, including our EXINI operations in Sweden;
•The need to ensure compliance with the numerous in-country and international regulatory and legal requirements applicable to our business in each of these jurisdictions and to maintain an effective compliance program to ensure compliance with these requirements, including in connection with the GDPR in the EU;
•Changes in public attitudes about the perceived safety of nuclear facilities;
•Civil unrest or other catastrophic events; and
•Longer payment cycles of non-U.S. customers and difficulty collecting receivables in non-U.S. jurisdictions.
These factors are beyond our control. The realization of any of these or other risks associated with operating outside the United States could have a material adverse effect on our business, results of operations, financial condition and cash flows.
We face currency and other risks associated with international sales.
We generate revenue from export sales, as well as from operations conducted outside the United States. Operations outside the U.S. expose us to risks including fluctuations in currency values, trade restrictions, tariff and trade regulations, U.S. export controls, U.S. and non‑U.S. tax laws, shipping delays and economic and political instability. For example, violations of U.S. export controls, including those administered by the U.S. Treasury Department’s Office of Foreign Assets Control, could result in fines, other civil or criminal penalties and the suspension or loss of export privileges which could have a material adverse effect on our business, results of operations, financial conditions and cash flows.
Many of our customer relationships outside of the U.S. are, either directly or indirectly, with governmental entities, and we could be adversely affected by violations of the FCPA and similar worldwide anti-bribery laws outside the U.S.
The FCPA, the Bribery Act and similar worldwide anti-bribery laws in non-U.S. jurisdictions generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business.
The FCPA prohibits us from providing anything of value to foreign officials for the purposes of obtaining or retaining business or securing any improper business advantage. It also requires us to keep books and records that accurately and fairly reflect our transactions. Because of the predominance of government-sponsored healthcare systems around the world, many of our customer relationships outside of the U.S. are, either directly or indirectly, with governmental entities and are therefore subject to the FCPA and similar anti-bribery laws in non-U.S. jurisdictions. In addition, the provisions of the Bribery Act extend beyond bribery of foreign public officials and are more onerous than the FCPA in a number of other respects, including jurisdiction, non-exemption of facilitation payments and penalties.
44
Our policies mandate compliance with these anti-bribery laws. We operate in many parts of the world that have experienced governmental corruption to some degree, and in certain circumstances strict compliance with anti-bribery laws may conflict with local customs and practices. Despite our training and compliance programs, our internal control policies and procedures may not always protect us from reckless or criminal acts committed by our employees or agents. Violations of these laws, or allegations of those violations, could disrupt our business and result in a material adverse effect on our results of operations, financial condition and cash flows.
Our business depends on the continued effectiveness and availability of our information technology infrastructure, and failures of this infrastructure could harm our operations.
To remain competitive in our industry, we must employ information technologies to support manufacturing processes, quality processes, distribution, R&D and regulatory applications and that capture, manage and analyze large streams of data in compliance with applicable regulatory requirements. We rely extensively on technology, some of which is managed by third-party service providers, to allow the concurrent conduct of work sharing around the world. As with all information technology, our equipment and infrastructure age and become subject to increasing maintenance and repair and our systems generally are vulnerable to potential damage or interruptions from fires, natural disasters, power outages, blackouts, machinery breakdown, telecommunications failures and other unexpected events, as well as to break-ins, sabotage, increasingly sophisticated intentional acts of vandalism or cybersecurity threats which, due to the nature of such attacks, may remain undetected for a period of time. As these threats continue to evolve, we may be required to expend additional resources to enhance our information security measures or to investigate and remediate any information security vulnerabilities. Given the extensive reliance of our business on technology, any substantial disruption or resulting loss of data that is not avoided or corrected by our backup measures could harm our business, reputation, operations and financial condition.
A disruption in our computer networks, including those related to cybersecurity, could adversely affect our operations or financial position.
We believe that our cybersecurity program is designed to effectively mitigate the risks of material cybersecurity incidents. However, our management does not expect that our cybersecurity program will prevent or detect all occurrences of cybersecurity incidents, material or otherwise, and there is potential risk that certain cybersecurity breaches may go undetected for a period of time. The design of our cybersecurity program is based, in part, upon certain assumptions about the likelihood of future incidents, and there can be no assurance that any design will prevent or detect all cybersecurity breaches. Over time, certain aspects of cybersecurity programs may become inadequate because of changes in technology, sophistication of cybersecurity attacks, emerging threats or other conditions, or the degree of compliance with our policies and procedures may deteriorate.
We rely on our computer networks and systems, some of which are managed by third parties, to manage and store electronic information (including sensitive data such as confidential business information, personally identifiable data and personal health information), and to manage or support a variety of critical business processes and activities. We may face threats to our networks from unauthorized access, security breaches and other system disruptions. Despite our security measures, our infrastructure may be vulnerable to external or internal attacks. Any such security breach may compromise information stored on our networks and may result in significant data losses or theft of sensitive or proprietary information. A cybersecurity breach could hurt our reputation by adversely affecting the perception of customers and potential customers about the security of their orders and personal information, as well as the perception of our manufacturing partners of the security of their proprietary information. In addition, a cybersecurity attack could result in other negative consequences, including disruption of our internal operations, increased cybersecurity protection costs, lost revenue, regulatory actions or litigation. Any disruption of internal operations could also have a material adverse impact on our results of operations, financial condition and cash flows. To date, we have not experienced any known material cybersecurity attacks.
We may be limited in our ability to utilize, or may not be able to utilize, net operating loss carryforwards to reduce our future tax liability.
As of December 31, 2023, we had U.S. federal income tax loss carryforwards of $297.6 million, $157.9 million of which will expire between 2027 and 2037, $139.6 million of which can be carried forward indefinitely, and state income tax loss carryforwards of $12.5 million, tax-effected. We may be limited in our ability to use these tax loss carryforwards to reduce our future U.S. federal and state income tax liabilities if our future income is not sufficient to absorb the losses, or if we were to experience another “ownership change” as specified in Section 382 of the Internal Revenue Code including if we were to issue a certain amount of equity securities, certain of our stockholders were to sell shares of our common stock, or we were to enter into certain strategic transactions.
We are involved in various legal proceedings that are uncertain, costly and time-consuming and could have a material adverse impact on our business, financial condition and results of operations.
From time to time we are involved in legal proceedings and disputes and may be involved in litigation in the future. For example, on January 26, 2024, we were sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the
45
filing of our ANDA for PNT2003 and Paragraph IV certification, consistent with the process established by the Hatch-Waxman Act. These proceedings are complex and extended and occupy the resources of our management and employees.
Legal proceedings are also costly to prosecute and defend and may involve substantial awards or damages payable by us if not found in our favor. We may also be required to pay substantial amounts or grant certain rights on unfavorable terms in order to settle such proceedings.
Defending against or settling legal proceedings and any unfavorable legal decisions, settlements or orders could have a material adverse effect on our business, financial condition and results of operations and could cause the market value of our common stock to decline.
In particular, the pharmaceutical and medical device industries historically have generated substantial litigation concerning the manufacture, use and sale of products, and we expect this litigation activity to continue. As a result, we expect that patents related to our products will routinely be challenged, and our patents may not be upheld. In order to protect or enforce patent rights, we may initiate litigation against third parties. If we are not successful in defending an attack on our patents and maintaining exclusive rights to market one or more of our products still under patent protection, we could lose a significant portion of sales in a very short period. We may also become subject to infringement claims by third parties and may have to defend against charges that we violated patents or the proprietary rights of third parties. If we infringe the intellectual property rights of others, we could lose our right to develop, manufacture or sell products, or could be required to pay monetary damages or royalties to license proprietary rights from third parties.
In addition, in the U.S., it has become increasingly common for patent infringement actions to prompt claims that antitrust laws have been violated during the prosecution of the patent or during litigation involving the defense of that patent. Such claims by direct and indirect purchasers and other payors are typically filed as class actions. The relief sought may include treble damages and restitution claims. Similarly, antitrust claims may be brought by government entities or private parties following settlement of patent litigation, alleging that such settlements are anti-competitive and in violation of antitrust laws. In the U.S. and Europe, regulatory authorities have continued to challenge as anti-competitive so-called “reverse payment” settlements between branded and generic drug manufacturers. We may also be subject to other antitrust litigation involving competition claims unrelated to patent infringement and prosecution. A successful antitrust claim by a private party or government entity against us could have a material adverse effect on our business, financial condition and results of operations and could cause the market value of our common stock to decline.
Risks Related to our and our Strategic Partners’ Portfolios of Clinical Development Candidates
We may not, or may take longer to, realize the expected benefits and opportunities related to, the POINT License Agreements.
On December 20, 2022, we announced the closing of a set of strategic collaborations with an affiliate of POINT, in which we were granted a license to exclusive worldwide rights (excluding Japan, South Korea, China (including Hong Kong, Macau and Taiwan), Singapore and Indonesia) to co-develop and commercialize POINT’s PNT2002 and PNT2003 product candidates (the “POINT License Agreements”). The expected benefits and opportunities related to the POINT License Agreements may not be realized or may take longer to realize than expected due to, for example, challenges and uncertainties inherent in product research, development, manufacturing, regulatory approval, marketing and competition. In particular, activities under the POINT License Agreements may not result in viable products suitable for commercialization in a timely manner or at all, due to a variety of reasons, including any inability of the relevant parties to perform their commitments and obligations under the POINT License Agreements. The POINT License Agreements impose various development, regulatory filing, commercialization and other obligations on us, and require us to meet development timelines or to exercise commercially reasonable efforts to develop and commercialize licensed products. We, along with our counterparty in the POINT License Agreements, may not be able to meet expected or planned regulatory milestones and timelines due to a number of factors, including, with respect to PNT2003, potential litigation under the Hatch-Waxman Act that could impose a stay on FDA approval of up to 30 months. Even if the licensed products are suitable for commercialization in a timely manner, we may not achieve the expected revenues from the sale of such products, and our revenue, ability to achieve profitability and return on investment may be adversely affected.
With respect to PNT2002, on December 18, 2023, we announced positive topline results from SPLASH, the Phase 3 registrational trial for PNT2002. Although the topline results indicated that the SPLASH trial met its primary endpoint, at the time of our topline analysis, interim OS results were immature. We expect additional, follow-up data in 2024 prior to the potential submission of an NDA; however, we can give no assurance that, as additional data become available, such data will not be materially different from the topline data we previously published, or that such data will support an NDA filing, FDA approval, or successful commercialization of PNT2002.
In addition, we are dependent on POINT to develop commercial product capacity and manufacture clinical and commercial supply for both PNT2002 and PNT2003, as well as supply for our EAP for PNT2002.
46
Disagreements with the counterparty in the POINT License Agreements over proprietary rights, contract interpretation or the preferred course of product research, development or marketing, might cause delays in performance of the POINT License Agreements or termination of the POINT License Agreements, or might result in litigation or arbitration, which could be time-consuming and expensive.
In spite of our efforts, if we fail to comply with our obligations under the POINT License Agreements, the counterparty in the POINT License Agreements may conclude that we have materially breached and may terminate one or both of the POINT License Agreements, in which event we may lose our rights to develop and market PNT2002 and PNT2003 or incur liability for damages.
Any of the foregoing risks could materially and adversely affect our business, results of operations and prospects and the trading price of our common stock.
We may not, or may take longer to, realize the expected benefits and opportunities related to, the Cerveau Acquisition.
On February 6, 2023, we announced that we acquired Cerveau. Cerveau holds the rights under a license agreement to develop and commercialize MK-6240, an investigational second-generation F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease. MK-6240 is currently being used in more than 90 active clinical trials for several Alzheimer’s disease therapeutic candidates being developed. While we believe that MK-6240, as a Tau imaging agent, has the potential to play an important role in patient staging, selection, and monitoring for future treatments and could be a surrogate endpoint for treatment efficacy, we can give no assurance that we will be successful with continued development, regulatory approval and commercialization of the product candidate or that disagreements with the counterparty to our license agreement for MK-6240 or the Selling Stockholders will not arise over proprietary rights, contract interpretation or the preferred course of product research, development or marketing that might cause delays or termination of the license agreement, or might result in litigation or arbitration, which could be time-consuming and expensive.
The process of developing new drugs and obtaining regulatory approval is complex, time-consuming and costly, and the outcome is not certain.
We currently have clinical development programs in the U.S., including those related to PNT2002, PNT2003, MK-6240 and LNTH-1363S, and are exploring additional lifecycle management opportunities for some of our current products, including PYLARIFY. We also have a number of strategic partnerships relating to obtaining additional indications for existing commercial products or regulatory approval for clinical development candidates. To obtain regulatory approval for these products in the indications being pursued, we must conduct extensive human tests, which are referred to as clinical trials, as well as meet other rigorous regulatory requirements, as further described in Part I, Item 1. “Business—Regulatory Matters.” Satisfaction of all regulatory requirements typically takes many years and requires the expenditure of substantial resources. A number of other factors may cause significant delays in the completion of our clinical trials, including unexpected delays in the initiation of clinical sites, slower than projected enrollment, competition with ongoing clinical trials and scheduling conflicts with participating clinicians, regulatory requirements, limits on manufacturing capacity and failure of an investigational product to meet required standards for administration to humans. In addition, it may take longer than we project to achieve study endpoints and complete data analysis for a clinical trial or we may decide to slow down the enrollment in a trial in order to conserve financial resources or for other reasons.
Our products in development are also subject to the risks of failure inherent in drug development, drug testing and regulatory approval. The results of preliminary studies do not necessarily predict clinical success, and larger and later stage clinical trials may not produce the same results as earlier stage trials. Sometimes, products that have shown promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. Products in later stage clinical trials may fail to show desired safety and efficacy traits, despite having progressed through initial clinical testing. In addition, the data collected from clinical trials of our products in development may not be sufficient to support regulatory approval, or regulators could interpret the data differently and less favorably than we do. Further, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Clinical trials of potential products often reveal that it is not practical or feasible to continue development efforts. Regulatory authorities may require us or our partners to conduct additional clinical testing, in which case we would have to expend additional time and resources. Depending on the regulatory pathway selected for drug approval, such as by filing an ANDA or Section 505(b)(2) NDA that requires sending notice to the innovator of a drug, regulatory approval may also be delayed by litigation brought under the Hatch-Waxman Act. For example, on January 26, 2024, we were sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the filing of our ANDA for PNT2003 and Paragraph IV certification, consistent with the process established by the Hatch-Waxman Act. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in regulatory policy that occur prior to or during regulatory review. The failure to provide clinical and preclinical data that are adequate to demonstrate to the satisfaction of the regulatory authorities that our products in development are safe and effective for their proposed use will delay or preclude approval and will prevent us from marketing those products.
47
We are not permitted to market our products in development in the U.S. or other countries until we have received requisite regulatory approvals. For example, securing FDA approval for a new drug requires the submission of an NDA to the FDA for our products in development. The NDA must include extensive nonclinical and clinical data and supporting information to establish the product’s safety and effectiveness for each indication. The NDA must also include significant information regarding the chemistry, manufacturing and controls for the product. The FDA review process can take many years to complete, and approval is never guaranteed. If a product is approved, the FDA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling, impose restricted distribution programs, require expedited reporting of certain adverse events, or require costly ongoing requirements for post-marketing clinical trials and surveillance or other risk management measures to monitor the safety or efficacy of the product. In some instances, products in development may also be approved by filing an ANDA or Section 505(b)(2) NDA with the FDA (as further described in Part I, Item 1. “Business—Regulatory Matters—Hatch-Waxman Act.”); provided, however, that seeking regulatory approval under such pathways may subject the product candidate to delays caused by litigation brought by an innovator of similar drugs under the Hatch-Waxman Act, as is the case with our ANDA application and Paragraph IV certification for PNT2003. Markets outside of the U.S. also have requirements for approval of products with which we must comply prior to marketing. Obtaining regulatory approval for marketing of a product in one country does not ensure we will be able to obtain regulatory approval in other countries, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. Also, any regulatory approval of any of our products in development, once obtained, may be withdrawn. Approvals might not be granted on a timely basis, if at all.
We can give no assurance that GE Healthcare will be successful with the further clinical development of flurpiridaz.
In May 2015, we announced complete results from the first of two planned Phase 3 clinical trials for flurpiridaz. Although the development candidate appeared to be well-tolerated from a safety perspective and outperformed SPECT in a highly statistically significant manner in the co-primary endpoint of sensitivity and in the secondary endpoints of image quality and diagnostic certainty, flurpiridaz did not meet its other co-primary endpoint of non-inferiority for identifying subjects without disease. In April 2017, we entered into the License Agreement with GE Healthcare for the continued Phase 3 development and worldwide commercialization of flurpiridaz. Under the License Agreement, GE Healthcare agreed, among other things, to complete the worldwide development of flurpiridaz by conducting a second Phase 3 trial and pursue worldwide regulatory approvals. In September 2022, we announced with GE Healthcare that the second Phase 3 clinical trial had met its co-primary endpoints of exceeding a 60% threshold for both sensitivity and specificity for detecting CAD. The findings, shared at an American Society of Nuclear Cardiology conference, also demonstrated that cardiac PET imaging with flurpiridaz had higher diagnostic efficacy and image quality in patients with suspected CAD, compared with SPECT MPI, the predominant procedure currently used in nuclear cardiology. Notwithstanding these findings, we cannot assure that any of the data generated in either our or GE Healthcare’s sponsored Phase 3 study will be sufficient to support an NDA approval or that flurpiridaz will ever be approved as a PET MPI imaging agent by the FDA. While GE Healthcare recently announced that it had filed an NDA with the FDA for flurpiridaz, any failure or significant delay in receiving regulatory approval for the sale of flurpiridaz may harm our business and delay or prevent us from being able to generate additional future royalty revenue from product sales.
Even if clinical development candidates receive regulatory approval, we can give no assurance that they can be successfully commercialized.
Even if our clinical development candidates proceed through their clinical trials and ultimately receive regulatory approval, there is no guarantee that an approved product can be manufactured in commercial quantities at a reasonable cost or that such a product will be successfully marketed or distributed. For example, the manufacturing, marketing and distribution of a radiopharmaceutical like flurpiridaz and MK-6240 will require the creation of a field-based network of specialized PET manufacturing facilities, or PMFs, with radioisotope-producing cyclotrons, similar to what we created for PYLARIFY, and will need to be manufactured and distributed rapidly to end-users.
In addition, obtaining adequate coding, coverage and payment at appropriate payment levels for any clinical development candidate will be critical, including not only coverage from Medicare, Medicaid, and other government payors, but also from private payors. We can give no assurance, even if a clinical development candidate were to obtain regulatory approval, that adequate coding, coverage and payment could be secured to allow the approved products to become successfully commercialized.
We have been and expect to continue to be dependent on partners for the development of certain product candidates, which expose us to the risk of reliance on these partners.
In connection with our ongoing development activities, we currently depend, and expect to continue to depend, on numerous collaborators. For example, in addition to our collaboration with Curium on PYLCLARI in Europe, GE Healthcare on flurpiridaz and POINT on PNT2002 and PNT2003, we have other collaborations to develop and commercialize products. In addition, certain clinical trials for our product candidates may be conducted by government-sponsored agencies, and consequently will be dependent on governmental participation and funding. These arrangements expose us to the same considerations we face when contracting with third parties for our own trials.
48
If any of our collaborators breach or terminate its agreement with us or otherwise fail to conduct successfully and in a timely manner the collaborative activities for which they are responsible, the preclinical or clinical development or commercialization of the affected product candidate or research program could be delayed or terminated. We generally do not control the amount and timing of resources that our collaborators devote to our programs or product candidates. We also do not know whether current or future collaboration partners, if any, might pursue alternative technologies or develop alternative products either on their own or in collaboration with others, including our competitors, as a means for developing treatments for the diseases or conditions targeted by our collaborative arrangements. Our collaborators are also subject to similar development, regulatory, manufacturing, cyber-security and competitive risks as us, which may further impede their ability to successfully perform the collaborative activities for which they are responsible. Setbacks of these types to our collaborators could have a material adverse effect on our business, results of operations and financial condition.
We depend on licenses from third parties for our rights to develop and commercialize certain product candidates. If we fail to achieve milestone requirements or to satisfy other conditions, we may lose those rights under those license agreements, and our business, results of operations and financial condition could be adversely affected.
Many of our products or product candidates incorporate rights licensed by third parties -- for example, we license patent rights on PYLARIFY, PNT2002, PNT2003, MK-6240, LNTH-1363S and NM-01. We could lose the rights to develop or commercialize these products and product candidates if the related license agreement is terminated due to a breach by us or otherwise. In addition, we are required to make substantial cash payments, achieve milestones and satisfy other conditions, including filing for and obtaining marketing approvals and introducing products, sometimes in accordance with established timelines, to maintain rights under our license agreements. Due to the nature of these agreements and the uncertainties of development, we may not be able to achieve milestones or satisfy conditions to which we have contractually committed, and as a result may be unable to maintain our rights under these licenses. If we do not comply with our license agreements, the licensors may terminate them, which could result in our losing our rights to, and therefore being unable to commercialize, related products. This loss could have a material adverse effect on our business, results of operations and financial condition.
Risks Related to Our Capital Structure
The conditional conversion feature of the 2.625% Convertible Senior Notes due 2027, if triggered, may adversely affect our financial condition and operating results.
On December 8, 2022, we issued $575.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027 (the “Notes”), which included $75.0 million in aggregate principal amount of Notes sold pursuant to the full exercise of the initial purchasers’ option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among Holdings, LMI, and U.S. Bank Trust Company, National Association (“U.S. Bank”), as Trustee. Prior to the close of business on the business day immediately preceding September 15, 2027, the Notes may be converted at the option of the holders upon occurrence of specified events and during certain periods, and thereafter until the close of business on the business day immediately preceding the maturity date, the Notes may be converted at any time. If one or more holders elect to convert their Notes, we would be required to settle any converted principal amount of such Notes through the payment of cash and by paying or delivering, at our election, cash, shares of our common stock, or a combination of cash and shares, with respect to the remainder of our conversion obligation in excess of the aggregate principal amount of the Notes being converted, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.
The issuance or sale of shares of our common stock, or rights to acquire shares of our common stock, could depress the trading price of our common stock.
We may conduct future offerings of our common stock, preferred stock or other securities that are convertible into or exercisable for our common stock to finance our operations or fund acquisitions, or for other purposes. In addition, we expect to continue to grant equity awards to directors, officers and employees under our equity incentive plans. If we issue additional shares of our common stock or rights to acquire shares of our common stock, if any of our existing stockholders sells a substantial amount of our common stock, or if the market perceives that such issuances or sales may occur, then the trading price of our common stock may significantly decrease. In addition, our issuance of additional shares of common stock will dilute the ownership interests of our existing common stockholders.
Repurchases by us of our common stock may affect the value of our common stock.
In December 2022, our Board authorized the repurchase of up to $150.0 million in aggregate amount of our common stock under certain circumstances. We used approximately $75.0 million of the net proceeds from the Notes to repurchase shares of our common stock from purchasers of Notes in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate. The purchase price per share of the common stock repurchased in such transactions was equal to the closing sale price per share of our
49
common stock on December 5, 2022, which was $56.01 per share. Following this initial repurchase, we may from time to time repurchase additional shares of our common stock. Such repurchases could increase, or prevent a decrease in, the market price of our common stock.
We have indebtedness which may limit our financial and operating activities and may adversely affect our ability to incur additional debt to fund future needs.
As of December 31, 2023, we had approximately $575.0 million of total principal indebtedness remaining under the Notes and availability of $350.0 million under our five-year 2022 Revolving Facility. Our indebtedness and any future indebtedness we incur could:
•Require us to dedicate a substantial portion of cash flow from operations to the payment of interest on and principal of our indebtedness, thereby reducing the funds available for other purposes, including for working capital, capital expenditures and acquisitions;
•Make it more difficult for us to satisfy and comply with our obligations with respect to our outstanding indebtedness, namely the payment of interest and principal;
•Make it more difficult to refinance the outstanding indebtedness;
•Subject us to increased sensitivity to interest rate increases;
•Make us more vulnerable to economic downturns, adverse industry or company conditions or catastrophic external events;
•Limit our ability to withstand competitive pressures;
•Reduce our flexibility in planning for or responding to changing business, industry and economic conditions; and
•Place us at a competitive disadvantage to competitors that have relatively less debt than we have.
In addition, our level of indebtedness could limit our ability to obtain additional financing on acceptable terms, or at all, for working capital, capital expenditures and general corporate purposes. Our liquidity needs could vary significantly and may be affected by general economic conditions, industry trends, performance and many other factors outside our control.
We may not be able to generate sufficient cash flow to meet our debt service obligations.
Our ability to generate sufficient cash flow from operations to make scheduled payments on our debt obligations will depend on our future financial performance, which will be affected by a range of economic, competitive and business factors, many of which are outside of our control. If we do not generate sufficient cash flow from operations to satisfy our debt obligations, including interest and principal payments, our credit ratings could be downgraded, and we may have to undertake alternative financing plans, such as refinancing or restructuring our debt, selling assets, entering into additional corporate collaborations or licensing arrangements for one or more of our products in development, reducing or delaying capital investments or seeking to raise additional capital. We cannot assure you that any refinancing would be possible, that any assets could be sold, licensed or partnered, or, if sold, licensed or partnered, of the timing of the transactions and the amount of proceeds realized from those transactions, that additional financing could be obtained on acceptable terms, if at all, or that additional financing would be permitted under the terms of our various debt instruments then in effect. Furthermore, our ability to refinance would depend upon the condition of the financial and credit markets. Our inability to generate sufficient cash flow to satisfy our debt obligations, or to refinance our obligations on commercially reasonable terms or on a timely basis, would have an adverse effect on our business, results of operations and financial condition.
Despite our indebtedness, we may incur more debt, which could exacerbate the risks described above.
We and our subsidiaries may be able to incur substantial additional indebtedness in the future subject to the limitations contained in the agreements governing our debt, including the 2022 Revolving Facility. Although these agreements restrict us and our restricted subsidiaries from incurring additional indebtedness, these restrictions are subject to important exceptions and qualifications. For example, we are generally permitted to incur certain indebtedness, including indebtedness arising in the ordinary course of business, indebtedness among restricted subsidiaries and us and indebtedness relating to hedging obligations. If we or our subsidiaries incur additional debt, the risks that we and they now face as a result of our leverage could intensify. In addition, the 2022 Revolving Facility will not prevent us from incurring obligations that do not constitute indebtedness under that agreement.
Our 2022 Revolving Facility contains restrictions that will limit our flexibility in operating our business.
Our 2022 Revolving Facility contains various covenants that limit our ability to engage in specified types of transactions. These covenants limit our and our restricted subsidiaries’ ability to, among other things:
•Maintain net leverage above certain specified levels;
50
•Maintain interest coverage below certain specified levels;
•Incur additional debt;
•Pay dividends or make other distributions;
•Redeem stock;
•Issue stock of subsidiaries;
•Make certain investments;
•Create liens;
•Enter into transactions with affiliates; and
•Merge, consolidate or transfer all or substantially all of our assets.
A breach of any of these covenants could result in a default under the 2022 Revolving Facility. We may also be unable to take advantage of business opportunities that arise because of the limitations imposed on us by the restrictive covenants under our indebtedness.
U.S. credit markets may impact our ability to obtain financing or increase the cost of future financing, including interest rate fluctuations based on macroeconomic conditions that are beyond our control.
During periods of volatility and disruption in the U.S., European, or global credit markets, obtaining additional or replacement financing may be more difficult and the cost of issuing new debt or replacing or repaying our 2022 Facility could be higher than under our current 2022 Facility. Higher cost of new debt may limit our ability to have cash on hand for working capital, capital expenditures and acquisitions on terms that are acceptable to us. Additionally, our 2022 Facility has variable interest rates. By its nature, a variable interest rate will move up or down based on changes in the economy and other factors, all of which are beyond our control. If interest rates increase, our interest expense could increase, affecting earnings and reducing cash flows available for working capital, capital expenditures and acquisitions.
Our stock price could fluctuate significantly, which could cause the value of your investment to decline, and you may not be able to resell your shares at or above your purchase price.
Securities markets worldwide have experienced, and may continue to experience, significant price and volume fluctuations. This market volatility, as well as general economic, market or political conditions, could reduce the market price of our common stock regardless of our operating performance. The high and low closing sales prices of our common stock during the twelve months ended December 31, 2023 were $99.65 and $47.76, respectively. The trading price of our common stock is likely to be volatile and subject to wide price fluctuations in response to various factors, including:
•Market conditions in the broader stock market;
•Actual or anticipated fluctuations in our quarterly financial and operating results;
•Issuance of new or changed securities analysts’ reports or recommendations;
•Investor perceptions of us and the pharmaceutical and medical device industries;
•Sales, or anticipated sales, of large blocks of our stock;
•Acquisitions or introductions of new products or services by us or our competitors;
•Positive or negative results from our clinical development programs;
•Additions or departures of key personnel;
•Regulatory or political developments;
•Loss of intellectual property protections;
•Litigation and governmental investigations;
•Geopolitical events; and
•Changing economic conditions.
51
These and other factors may cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management from our business, which could significantly harm our profitability and reputation.
If securities or industry analysts do not publish research or reports about our business, if they adversely change their recommendations regarding our stock, or if our results of operations do not meet their expectations, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if one or more of the analysts who cover us downgrades our stock, or if our results of operations do not meet their expectations, our stock price could also decline.
We do not anticipate paying any cash dividends for the foreseeable future, and accordingly, stockholders must rely on stock appreciation for any return on their investment.
We have never declared or paid cash dividends on our capital stock. We currently intend to retain our future earnings, if any, for the foreseeable future, to repay indebtedness and to fund the development and growth of our business. We do not intend to pay any dividends to holders of our common stock and the agreements governing our senior secured credit facilities limit our ability to pay dividends. As a result, capital appreciation in the price of our common stock, if any, will be your only source of gain on an investment in our common stock.
Anti-takeover provisions in our charter documents and Delaware law and certain provisions in the Notes and Indenture may make an acquisition of us more difficult.
Our amended and restated certificate of incorporation and bylaws, as amended and restated, contain provisions that delay, defer or discourage transactions involving an actual or potential change in control of us or change in our management. These provisions may also discourage bids for our common stock at a premium over market price or adversely affect the market price of, and the voting and other rights of the holders of, our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors other than the candidates nominated by our Board. In addition, we are incorporated in Delaware and subject to the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit large stockholders from consummating a merger with, or acquisition of, us. These provisions may deter an acquisition of us that might otherwise be attractive to stockholders.
Certain provisions in the Notes and the Indenture could make it more difficult or more expensive for a third party to acquire us. For example, if a takeover would constitute a fundamental change, holders of the Notes will have the right to require us to repurchase their Notes in cash. In addition, if a takeover constitutes a make-whole fundamental change, we may be required to increase the conversion rate for holders who convert their Notes in connection with such takeover. In either case, and in other cases, our obligations under the Notes and the Indenture could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management, including in a transaction that holders of our common stock may view as favorable.
Item 1B. Unresolved Staff Comments
None.
Item 1C. Cybersecurity
Risk management and strategy
With respect to cybersecurity risks, we have invested and continually invest in new cybersecurity services, technologies, and capabilities. On an ongoing basis we provide our employees with comprehensive cybersecurity awareness training around phishing, malware and other cybersecurity risks, all in a manner reasonably intended to educate employees to safely avoid cyber attacks and mitigate the risk of employee related security breaches. In support of our cybersecurity program, our systems and services undergo regular reviews by management to determine if any insufficiencies in cybersecurity exist.
If an incident is detected, the Cybersecurity team follows the incident response policy to investigate, review and determine the potential impacts of such an incident. If the Cybersecurity team determines that an incident could reasonably be expected to have an impact on the financial condition or operations of the Company, it escalates the incident to the crisis management team, which includes executive management. The crisis management team further evaluates the potential impact and materiality of an event and the
52
appropriate response required. The crisis management team coordinates the appropriate response effort and communicates, as applicable, to the Audit Committee. To the extent that Cybersecurity incident is determined to be material, the appropriate public disclosures are made.
We monitor material risks from cybersecurity threats relating to potential compromises of sensitive information at our third-party business partners where relevant and reevaluate these risks periodically. We also perform third-party cybersecurity audits at least annually and conduct third-party security reviews and testing of our network, processes and systems periodically.
Impact of cybersecurity risks on business strategy, results of operations or financial condition
We rely on our computer networks and systems, some of which are managed by third-parties, to manage and store electronic information (including sensitive data such as confidential business information, personally identifiable data and personal health information), and to manage or support a variety of critical business processes and activities. We may face threats to our networks from unauthorized access, security breaches and other system disruptions. Despite our security measures, our infrastructure may be vulnerable to external or internal attacks. Any such security breach may compromise information stored on our networks and may result in significant data losses or theft of sensitive or proprietary information. A cybersecurity breach could hurt our reputation by adversely affecting the perception of customers and potential customers about the security of their orders and personal information, as well as the perception of our manufacturing partners of the security of their proprietary information. In addition, a cybersecurity attack could result in other negative consequences, including disruption of our internal operations, increased cybersecurity protection costs, lost revenue, regulatory actions or litigation. Any disruption of internal operations could also have a material adverse impact on our results of operations, financial condition and cash flows.
As of the date of this report, we have not experienced any known cybersecurity incidents, or a series of related incidents, that have materially affected or are reasonably likely to affect us, including our business strategy, results of operations or financial condition. For an additional description of these cybersecurity risks and potential related impacts on us, see “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K.
Governance
Our Board actively oversees our corporate strategy and enterprise risk management (“ERM”) programs, including those relating to cybersecurity and data privacy risks.
Our Audit Committee and Nominating and Corporate Governance Committee are primarily responsible for, among other things, overseeing our compliance and ERM programs, information technology systems, and our processes and data, including cybersecurity and data privacy. These responsibilities include reviewing and discussing with management our policies and processes relating to risk assessment and risk management. Cybersecurity and data privacy are regular topics on the Audit Committee’s agenda and management reviews at least quarterly the results of cybersecurity monitoring and discusses performance metrics, any incidents identified and potential recommended modifications to our technology, organization training, awareness and governance with our Audit Committee. A summary of these results are also reported by the Audit Committee to the Board at least annually.
Management, including our Chief Information Officer (“CIO”), who has over 25 years of experience serving primarily in the life science industry and is a recognized industry leader, is responsible for monitoring and assessing cybersecurity risks. Management reviews and determines the effectiveness of both internal and third-party leveraged expertise to ensure we have the appropriate knowledge base for risk coverage.
53
Item 2. Properties
The following table summarizes information regarding our significant leased and owned properties, as of December 31, 2023:
LocationPurposeSquare
Footage		OwnershipLease Term
End
U.S.
North Billerica,
Massachusetts
Manufacturing, Laboratory, Mixed Use and Other Office Space431,000 OwnedN/A
Bedford, MassachusettsExecutive Offices, Laboratory, Office Space88,200 LeasedDecember 2039
New York, New YorkOffice Space26,000 Leased*September 2030
Somerset, New JerseyManufacturing, Mixed Use and Office Space11,400 LeasedNovember 2028
Somerset, New JerseyOffice Space8,249 LeasedMarch 2027
Canada
QuebecMixed Use and Office Space1,106 LeasedMay 2024
QuebecDistribution Center and Office Space1,433 LeasedMay 2025
Sweden
LundOffice Space4,000 LeasedDecember 2024
* On October 11, 2021, we entered into an agreement to sublease our office space at the World Trade Center in New York City to an unrelated third party. Please refer to Note 16, “Leases” for further details.
** On January 9, 2024, we announced that Perspective agreed to acquire the assets and associated lease of our radiopharmaceutical manufacturing facility in Somerset, New Jersey, subject to customary closing conditions, including regulatory approval.
We believe all of these facilities are well-maintained and suitable for the office, manufacturing or warehouse operations conducted in them and provide adequate capacity for current and foreseeable future needs.
Item 3. Legal Proceedings
Information with respect to certain legal proceedings is included in Note 19, “Commitments and Contingencies”, to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, and is incorporated herein by reference.
Item 4. Mine Safety Disclosures
Not applicable
54
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Our common stock trades on the NASDAQ Global Market under the symbol “LNTH”.
Holders of Record
On February 15, 2024, there were approximately 30 stockholders of record of our common stock. This number does not include stockholders for whom shares are held in “nominee” or “street” name.
Performance Graph
The performance graph set forth below shall not be deemed “soliciting material” or to be “filed” with the SEC. This graph will not be deemed “incorporated by reference” into any filing under the Securities Act or the Exchange Act, whether such filing occurs before or after the date hereof, except to the extent that we explicitly incorporate it by reference into in such filing.
The following graph provides a comparison of the cumulative total shareholder return on our common shares with that of the cumulative total shareholder return on the (i) Russell 2000 Index, (ii) the NASDAQ US Small Cap Index and (iii) the NASDAQ US Mid Cap Index, commencing on December 31, 2018 and ending December 31, 2023. The graph assumes a hypothetical $100 investment in our common stock and in each of the comparative indices on December 31, 2018. Our historic share price performance is not necessarily indicative of future share price performance.
915
________________________________
* Assumes hypothetical investment of $100 in our common stock and each of the indices on December 31, 2018, including reinvestment of dividends.
55
Performance Graph Data
The following table sets forth the cumulative total shareholder return on the hypothetical $100 investment in our common stock and each of the comparative indices on December 31, 2018:
DateLantheus Holdings, Inc. (“LNTH”)Russell 2000 Index (“^RUT”)NASDAQ US Small Cap Index (“^NQUSS”)NASDAQ US Mid Cap Index (“^NQUSM”)
12/31/18$100.00 $100.00 $100.00 $100.00 
12/31/19$131.05 $123.72 $122.37 $126.72 
12/31/20$86.20 $146.44 $148.64 $145.38 
12/31/21$184.60 $166.50 $172.58 $171.68 
12/31/22$325.62 $130.60 $134.43 $139.97 
12/31/23$396.17 $150.31 $155.82 $163.12 

Dividend Policy
We did not declare or pay any dividends in 2023, and we do not currently intend to pay dividends in the foreseeable future. We currently expect to retain future earnings, if any, for the foreseeable future, to finance the growth and development of our business and to repay indebtedness. Our ability to pay dividends is restricted by our financing arrangements. See Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—External Sources of Liquidity” for further information.
Recent Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
The following table presents information with respect to purchases of common stock we made during the three months ended December 31, 2023. In December 2022, our Board authorized the repurchase of up to $150.0 million in aggregate amount of our common stock under certain circumstances. We used approximately $75.0 million of the net proceeds from the Notes to repurchase shares of our common stock from purchasers of the Notes in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate. The 2015 Equity Incentive Plan, adopted by us on June 24, 2015, as amended on April 26, 2016 and as further amended on April 27, 2017, April 24, 2019, April 28, 2021 and April 28, 2022 (the “2015 Plan”), provides for the withholding of shares to satisfy minimum statutory tax withholding obligations. It does not specify a maximum number of shares that can be withheld for this purpose. The shares of common stock withheld to satisfy minimum tax withholding obligations may be deemed to be “issuer purchases” of shares that are required to be disclosed pursuant to this Item 5.
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced ProgramsApproximate Dollar Value of Shares that May Yet Be Purchased Under the Program
October 2023 *4,984 $71.02 0$75.0 million
November 2023 *3,930 $68.38 0$75.0 million
December 2023 *4,061 $76.04 0$75.0 million
Total12,975 0$75.0 million
    ________________________________
*    Reflects shares withheld to satisfy minimum statutory tax withholding amounts due from employees related to the receipt of stock which resulted from the exercise for vesting of equity awards.
Securities Authorized for Issuance under Equity Compensations Plans
The information required with respect to this item is incorporated herein by reference to our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders to be filed with the SEC no later than 120 days after the close of our year ended December 31, 2023.
56
Item 6. [Reserved]
57
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read together with the consolidated financial statements and the related notes included in Item 8 of this Annual Report on Form 10-K. This discussion contains forward-looking statements related to future events and our future financial performance that are based on current expectations and subject to risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those set forth in Part I—Item 1A. “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements.” included in this Annual Report on Form 10-K.
This section discusses 2023 and 2022 items and year-to-year comparisons between 2023 and 2022. Discussions of 2021 items and year-to-year comparisons between 2022 and 2021 have been excluded from this Form 10-K and can be found in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023.
Overview
Our Business
We are the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (“HCPs”) Find, Fight and Follow cancer, with a focus on prostate cancer. Our leading Precision Diagnostic products assist HCPs to Find and Follow diseases, with a focus in cardiology. Our Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms.
Our commercial products are used by cardiologists, internal medicine physicians, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings. We believe that our diagnostic products provide improved information that enables HCPs to better detect and characterize, or rule out, disease, with the potential to achieve better patient outcomes, reduce patient risk and limit overall costs throughout the healthcare system.
We produce and market our products throughout the United States (the “U.S.”), selling primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies. We sell our products outside the U.S. through a combination of direct distribution in Canada and third party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Our executive offices are located in Bedford, Massachusetts, with additional offices in North Billerica, Massachusetts; Somerset, New Jersey; Montreal, Canada; and Lund, Sweden.
Recent Developments
CEO Succession Plan
On January 23, 2024, we announced that, effective March 1, 2024, Brian Markison, our current Chair of the Board, will become our Chief Executive Officer, and Mary Anne Heino, our current Chief Executive Officer, will retire and become the Chair of the Board. As part of this leadership transition, Mr. Markison assumed the role of Executive Chair of the Board as of January 23, 2024 until the effectiveness of his Chief Executive Officer appointment in March, and Board Member Julie McHugh became Lead Independent Director.
Strategic Agreements with Perspective Therapeutics
On January 9, 2024, we announced that we entered into multiple strategic agreements with Perspective, a radiopharmaceutical company that is pursuing advanced treatment applications for cancers throughout the body. Under the agreements, we obtained an option to exclusively license Perspective’s Pb212-VMT- ⍺-NET, a clinical stage alpha therapy in development for the treatment of neuroendocrine tumors, and an option to co-develop certain early-stage therapeutic candidates targeting prostate cancer using Perspective’s innovative platform technology, for an aggregate upfront payment of $28 million in cash. We also agreed to purchase up to 19.9% of Perspective’s outstanding shares of common stock for up to approximately $33 million, subject to Perspective’s completion of a qualified third-party financing transaction and certain other closing conditions. In addition, Perspective agreed to acquire the assets and associated lease of our radiopharmaceutical manufacturing facility in Somerset, New Jersey, subject to customary closing conditions, including regulatory approval.
On January 22, 2024, following the satisfaction of applicable closing conditions, our subsidiary, Lantheus Alpha, purchased 56,342,355 shares of Perspective’s common stock at a purchase price of $0.37 per share in a private placement transaction. The total consideration for the purchase was approximately $20.8 million in cash, which resulted in Lantheus Alpha holding approximately
58
10.74% of Perspective’s common stock as of the purchase date and retaining the right to purchase additional shares to bring its ownership up to an aggregate of 19.9%.
Exclusive License for PNT2002 and PNT2003
On December 20, 2022, we announced the closing of a set of strategic collaborations with POINT Biopharma Global Inc. (“POINT”), in which we were granted a license to exclusive worldwide rights (excluding Japan, South Korea, China (including Hong Kong, Macau, and Taiwan), Singapore, and Indonesia) to co-develop and commercialize POINT’s PNT2002 and PNT2003 product candidates.
On December 27, 2023, Eli Lilly announced the completion of its acquisition of POINT. The acquisition is no expected to impact the status of the PNT2002 License Agreement, the PNT2003 License Agreement, or the work being performed in connection with those agreements and our collaboration with POINT.
PNT2002
With respect to PNT2002, POINT is generally responsible for funding and development activities required for FDA approval, including generating all clinical and nonclinical data, analysis and other information, and we are responsible for preparing for and seeking regulatory approval for PNT2002, as well as performing and funding all future development and commercialization following such approval. POINT will be responsible for all manufacturing of PNT2002, subject to certain exceptions described in the license and collaboration agreement between Lantheus Two and POINT, dated November 11, 2022 (the “PNT2002 License Agreement”).
In April 2023, we announced with POINT that the FDA had granted Fast Track designation for PNT2002. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet needs.
On December 18, 2023, we announced positive topline results from SPLASH, the Phase 3 registrational trial for PNT2002. SPLASH was designed to evaluate the efficacy and safety of PNT2002 in patients with mCRPC who have progressed following treatment with an androgen receptor pathway inhibitor (“ARPI”). The SPLASH trial met its primary endpoint, demonstrating a median radiographic progression-free survival (rPFS) per blinded independent central review of 9.5 months for patients treated with PNT2002, compared to 6.0 months for patients treated with ARPI in the control arm, a statistically significant 29% reduction in the risk of radiographic progression or death (hazard ratio (“HR”) 0.71; p=0.0088). At the time of the analysis, interim overall survival (OS) results were immature (46% of protocol-specified target OS events reached), and the HR was 1.11. We expect more mature overall survival data in 2024 prior to the potential submission of a New Drug Application (“NDA”).
PNT2002 demonstrated a favorable safety profile with grade ≥3 treatment-emergent adverse events (TEAEs) per Common Terminology Criteria for Adverse Events, serious TEAEs, and TEAEs leading to discontinuation occurring at lower rates in the PNT2002 arm than in the control arm (30.1%, 17.1%, and 1.9% versus 36.9%, 23.1%, and 6.2%, respectively).
The open-label study randomized 412 patients with PSMA-expressing mCRPC who had progressed on ARPI therapy and either refused or were not eligible for chemotherapy, in a 2:1 randomization ratio. At the time of the analysis, 84.6% of patients who experienced progressive disease in the control arm subsequently crossed over to receive PNT2002. SPLASH was conducted across the U.S., Canada, Europe, and the United Kingdom. Eighty percent of SPLASH patients resided in North America and approximately ten percent of all participants were Black or African American.
During 2023, we worked on establishing an EAP, for PNT2002. EAPs, which are also referred to as compassionate use programs, provide a potential pathway for patients with serious or life-threatening conditions to gain access to an investigational drug for treatment outside of a clinical trial. We expect to enroll the first patient in the EAP for PNT2002 during the first quarter of 2024.
PNT2003
With respect to PNT2003, POINT is responsible for curating all data, analysis and other information necessary for regulatory approval, and supporting us in the preparation of regulatory filings. We are responsible for preparing for and seeking regulatory approval of all such applications, as well as performing and funding all future development and commercialization following such approval. POINT will be responsible for all manufacturing of PNT2003, subject to certain exceptions described in the license and collaboration agreement between Lantheus Three and POINT, dated November 11, 2022 (the “PNT2003 License Agreement”). On January 11, 2024, we announced that our ANDA for PNT2003 had been accepted for filing by the FDA. Based on the most recent update to the FDA’s online paragraph IV database listings, we believe we are the first applicant to have filed a substantially complete ANDA for Lutetium Lu 177 Dotatate containing a Paragraph IV certification under the provisions of the Hatch-Waxman Act. As the first applicant, we believe we will be eligible for 180 days of generic marketing exclusivity in the U.S. On January 26, 2024, we were sued in the District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the Company’s ANDA filing and Paragraph IV
59
certification, consistent with the process established by the Hatch-Waxman Act. Under the terms of the Hatch-Waxman Act, FDA approval of our ANDA filing could be subject to a stay of up to 30-months. If our filing is stayed for the full 30-month period and we are successful in obtaining FDA approval, we would expect to launch PNT2003 in 2026, although no assurance of that approval or timing can be assured.
For more information, see Note 21, “Acquisition of Assets” in our consolidated financial statements included herein.
Acquisition of Cerveau Technologies, Inc.
On February 6, 2023, we announced that we acquired Cerveau. Cerveau holds the rights under a license agreement to develop and commercialize MK-6240, an investigational second-generation F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease. Under the terms of the agreement, we paid the Selling Stockholders an upfront payment of $35.0 million in February 2023 and an additional $10.0 million in May 2023 upon the successful completion of a technology transfer. The Selling Stockholders are also eligible to receive additional development and commercial milestone payments. Additionally, we will pay double-digit royalty payments for research revenue and commercial sales. Research revenue is derived from existing partnerships with pharmaceutical companies that use MK-6240 in clinical trials and includes milestone and dose-related payments. Pursuant to the terms of the stock purchase agreement for Cerveau, certain members of the Selling Stockholders will also provide transition and clinical development services for a prescribed time following the closing of the transaction.
In September 2023, MK-6240 was granted Fast Track designation by the FDA.
For more information, see Note 21, “Acquisition of Assets” in our consolidated financial statements included herein.
Sale of RELISTOR Licensed Intangible Asset Associated with Net Sales Royalties
On August 2, 2023, we sold the right to our RELISTOR net sales royalties, which is classified as a licensed intangible asset (“RELISTOR royalty asset”), under our license agreement with Bausch; we retained the rights to future sales-based milestone payments. We received an initial payment of approximately $98.0 million in connection with the sale and we have the right to receive an additional payment from the buyer of $5.0 million if worldwide net sales of RELISTOR in 2025 exceed a specified threshold. The additional payment would be recognized upon achievement of the specified threshold. Decreases of $63.6 million of license assets and $17.5 million of associated accumulated amortization, as well as a gain of $51.8 million were recorded as a result of the sale. During the fourth quarter of 2023, the Company earned a $15 million sales-based milestone payment.
For more information, see Note 10, “Intangibles, Net and Goodwill” in our consolidated financial statements included herein.
Discontinuation of AZEDRA
On August 15, 2023, we announced our decision to discontinue the production and promotion of AZEDRA and that we would be winding down our Somerset, New Jersey manufacturing site. We will continue manufacturing AZEDRA into the first quarter of 2024, to the extent feasible, with the goal of providing doses of AZEDRA to current patients so they can complete their treatment regimen.
For more information, see Note 10, “Intangibles, Net and Goodwill” in our consolidated financial statements included herein.
Refinancing of 2019 Facility
In December 2022, we refinanced our existing credit facility, consisting of (i) a $200.0 million five-year term loan facility (the “2019 Term Facility”) and (ii) a $200.0 million five-year revolving credit facility (the “2019 Revolving Facility” and, together with the 2019 Term Facility, the “2019 Facility”), with a new $100.0 million delayed draw term loan facility (the “2022 Term Facility” and, the loans thereunder, the “Term Loans”) and a new $350.0 million five-year revolving credit facility (the “2022 Revolving Facility” and, together with the 2022 Term Facility, the “2022 Facility”).
We used approximately $7.8 million of cash on hand to primarily repay the principal amount of the loans outstanding related to the 2019 Facility through the nine months ended September 30, 2022. In addition, we used approximately $167.6 million of cash on hand to repay in full the aggregate remaining principal amount of the loans outstanding under the 2019 Facility and to pay related interest, transaction fees and expenses.
While the 2022 Term Facility allowed for a delayed draw term loan, the loan was not drawn upon. We recorded a loss on extinguishment of debt of $0.6 million related to the write-off of unamortized debt issuance costs and debt discounts associated with the 2019 Term Facility. In addition, we incurred and capitalized $2.7 million of new deferred financing costs related to the refinancing.
Issuance of Convertible Notes
60
On December 8, 2022, we issued $575.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027 (the “Notes”), which includes $75.0 million in aggregate principal amount of the Notes sold pursuant to the full exercise of the initial purchasers’ option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among the Company, LMI, as Guarantor, and U.S. Bank, as Trustee. The net proceeds from the issuance of the Notes were approximately $557.8 million, after deducting the initial purchasers’ discounts and offering expenses payable by us.
Key Factors Affecting Our Results
Our 2023 financial performance incorporates the results of the Cerveau Acquisition since the February 6, 2023 closing date.
Our business and financial performance have been, and continue to be, affected by the following:
Continued Growth of PYLARIFY
PYLARIFY, an F 18-labeled PET imaging agent targeting PSMA, was approved by the FDA in May 2021 and commercially launched in the U.S. in June 2021. PYLARIFY is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and in men with suspected recurrence based on elevated PSA levels. Both the National Comprehensive Cancer Center guidelines and the Society for Nuclear Medicine and Molecular Imaging appropriate use criteria note that PSMA PET imaging agents, including PYLARIFY, can be used for patient selection for PSMA-targeted radioligand therapy. PYLARIFY is available through a diverse, multi-partner network of PET manufacturing facilities (“PMFs”), including both commercial and academic partners.
The successful growth of PYLARIFY is dependent on our ability to sustain PYLARIFY as the leading PSMA PET imaging agent in an increasingly competitive marketplace. PYLARIFY’s competition includes two commercially available gallium-68-based PSMA imaging agents, an approved fluorine-18-based PSMA imaging agent, and other non-PSMA-based imaging agents commonly referred to as conventional imaging. We previously hired additional employees to assist us with the commercialization of PYLARIFY, including in Sales, Marketing, Reimbursement, Quality and Medical Affairs, and we will continue to make commercial investments necessary to drive PYLARIFY awareness and adoption. We believe that PYLARIFY currently has the largest dedicated field-based commercial team in the PSMA PET imaging agent space. Continued growth and revenue contribution from PYLARIFY will also depend on our ability to differentiate PYLARIFY in light of the potential loss of TPT Status, including through flexible and dependable access to PYLARIFY nationally, a best in class customer experience and through long-term strategic contracts.
Our HCPCS code, which enables streamlined billing, went into effect as of January 1, 2022. In addition, effective January 1, 2022, CMS granted TPT Status in the hospital outpatient setting for PYLARIFY, enabling traditional Medicare to provide an incremental payment for PET/CT scans performed with PYLARIFY in that setting. TPT Status for PYLARIFY could expire on December 31, 2024.
In 2023 rulemaking for the 2024 payment calendar year, CMS recognized the challenges of patient access to diagnostic radiopharmaceuticals and requested feedback on various payment alternatives that could provide separate reimbursement for these items, but the agency did not adopt any of these proposals in the final rule, while stating that it would continue to evaluate this issue in subsequent rulemaking. We intend to submit comments in connection with CMS’s 2024 rulemaking for 2025 payment calendar year to request that CMS establish separate payment for diagnostics instead of the current packaged payment following expiration of TPT Status.
Our plan to successfully grow PYLARIFY has also included highlighting its commercial and clinical value, as well as through strategic partnerships and collaborations, both for the commercialization of our product outside of the United States as well as for the use of our product potentially for additional indications or in connection with the development of PSMA-targeted therapeutics. With respect to commercializing PYLARIFY outside of the U.S., we previously licensed exclusive rights to Curium to develop and commercialize piflufolastat F 18 in Europe. In July 2023, Curium announced that it received marketing authorization for piflufolastat F 18 from the European Commission, which will be commercialized in the EU under the brand name PYLCLARI. With respect to the use of PYLARIFY in connection with the development of PSMA-targeted therapeutics, we have entered into multiple strategic collaborations with pharmaceutical companies. Additional information on collaborations using PYLARIFY are described further under Part I, Item 1. “Business - Strategic Partnerships and Other Revenue – Oncology.”
In connection with the acquisition of Progenics in June 2020, we issued CVRs tied to the financial performance of PYLARIFY. We paid $99.6 million to the CVR holders during May 2023 in full satisfaction of our obligations under the CVRs.
PYLARIFY AI Use
During 2021, we announced that EXINI was granted 510(k) clearance by the FDA in the U.S. and received CE marking in Europe for aPROMISE. We commercially launched aPROMISE under the name PYLARIFY AI in the U.S. in November 2021. During the second quarter of 2022, we received a new 510(k) clearance for an updated version of our PYLARIFY AI platform.
61
PYLARIFY AI is artificial intelligence medical device software designed to assist with the reading and quantification of PYLARIFY scans. The technology automatically analyzes a PSMA PET/CT image to segment anatomical regions – 51 bones and 12 soft tissue organs. This image segmentation enables automated localization, detection and quantification of potential PSMA-avid lesions in a PSMA PET/CT image, which data is then incorporated into the reporting system used by physicians.
During the third quarter of 2023, in collaboration with Curium, we customized and released our PYLARIFY AI platform for use in Europe. At the European Association of Nuclear Medicine meeting in Vienna, the PYLARIFY AI presentation was awarded the Top Rated Oral Presentation for response evaluation of metastatic prostate cancer patients.
Also in the third quarter of 2023, we announced a data agreement with the Prostate Cancer Clinical Trial Consortium (PCCTC) on its IRONMAN Registry for development and validation of PSMA biomarkers with PYLARIFY AI. The IRONMAN is the International Registry for Men with Advanced Prostate Cancer, the Registry is accumulating contextualized clinical and imaging data from more than 100 institutions across the globe.
During 2023, we also entered into an agreement with PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope), led by the European Association of Urology (project Coordinator) and Bayer AG (private leader) to use our AI technology to help validate the clinical utility of PYLARIFY AI enabled PSMA biomarker to diagnose, treat and monitor prostate cancer patients. PIONEER is a European Network of Excellence for Big Data in Prostate Cancer, consisting of 34 private and public stakeholders in prostate cancer research and clinical care from across 9 countries.
Continued Growth of DEFINITY
We believe we will be able to increase use of DEFINITY through continued education of physicians and healthcare providers about the benefits of ultrasound enhancing agents in suboptimal echocardiograms. The U.S. market currently has three echocardiography ultrasound enhancing agents approved by the FDA; we estimate that DEFINITY will continue to hold at least an 80% share of the U.S. segment for ultrasound enhancing agents in echocardiography procedures.
As we continue to grow our microbubble franchise, our activities include:
•Patents - We continue to actively pursue additional patents in connection with DEFINITY and DEFINITY RT, both in the U.S. and internationally. In the U.S. for DEFINITY, we have six Orange Book-listed method-of-use patents, one of which expires in 2035 and five of which expire in 2037, as well as additional manufacturing patents that are not Orange Book-listed expiring in 2037. For DEFINITY RT, we have eight Orange Book-listed patents, including two composition of matter patents which expire in 2035
•VIALMIX RFID – DEFINITY is activated through the use of medical devices branded as VIALMIX and VIALMIX RFID. The activation rate and time are controlled by VIALMIX RFID through the use of radio-frequency identification technology (“RFID”) to ensure reproducible activation of DEFINITY. The RFID tag, which is affixed to the vial label, enables the DEFINITY vial to be appropriately activated with the VIALMIX RFID activation device.
•DEFINITY RT - The formulation of DEFINITY that we have branded as DEFINITY RT allows both storage and shipment at room temperature and provides clinicians an additional choice and use in broader clinical settings. Given its physical characteristics, we believe DEFINITY RT is also well-suited for inclusion in kits requiring microbubbles for other indications and applications (including in kits developed by third parties of the type described further in the paragraph entitled “Microbubble Franchise” below).
Expansion of Strategic Partnerships and Other Revenue
We continue to seek ways to further increase the overall value of our portfolio of products and product candidates. We are evaluating a number of different opportunities to collaborate, in-license or acquire additional products, product candidates, businesses and technologies to drive our future growth. In particular, we are focused on late-stage radiopharmaceutical therapeutic and diagnostic product opportunities in oncology and other strategic areas that will complement our existing portfolio.
Our Strategic Partnerships and Other Revenue category includes our Strategic Partnerships, Pharma Solutions, and Digital Solutions businesses and is focused on enabling precision medicine with biomarkers and digital solutions.
•Strategic Partnerships – We seek to monetize our assets through our Strategic Partnerships business, by optimizing core assets geographically and by driving value through non-core assets. For example, we have licensed the development and commercialization rights of PYLARIFY in Europe to Curium. Similarly, we licensed the commercialization rights for flurpiridaz fluorine-18 to GE Healthcare Limited.
•Pharma Solutions – We use our Pharma Solutions business to offer our Biomarkers and Microbubble Platforms to pharmaceutical and start-up companies to support their research and development of therapeutic drugs and devices. The strategic goal of our Pharma Solutions business is to gain early access to innovation, de-risk the development, data generation
62
and co-funding of our pipeline through collaborations, embed our technologies in the clinical ecosystem and establish the clinical utility of product candidates and research tools in our pipeline. Our Biomarkers are intended to support patient selection and the monitoring of disease progression. For example, piflufolastat F 18 is currently being used by Curium and Regeneron in those companies’ prostate cancer therapeutic drug development programs, and was also used in the development of PNT2002. Our acquisition of Cerveau in February 2023 added MK-6240 to our biomarker portfolio. MK-6240 is currently being used in more than ninety active clinical trials for several Alzheimer’s disease therapeutic candidates. Most recently, in collaboration with Ratio, we completed a Phase 1 study for LNTH-1363S, our novel fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent candidate, to evaluate the pharmacokinetics, biodistribution and radiation dosimetry in adult healthy volunteers and plan to initiate a Phase 1/2a study in patients in 2024.
With respect to our Microbubble Platform, we generally enter into collaborations with partners that are designed to include our microbubble as part of a kit used with our partner’s medical device for therapeutic applications. In these collaborations, our microbubble is intended to be used as a vehicle to deliver a therapeutic drug.
•Digital Solutions – Our Digital Solutions are designed to enhance imaging value and the throughput, reproducibility and reliability of image analysis, as well as to inform treatment selection and response to therapy. Our Digital Solutions include aPROMISE and aBSI (as defined below), both of which are FDA cleared and CE marked. aPROMISE, which is currently sold as PYLARIFY AI in the U.S., is artificial intelligence medical device software that is designed to allow healthcare professionals and researchers to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer, including those images obtained by using PYLARIFY. Automated Bone Scan Index (“aBSI”) automatically calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network. The software is currently used as one of the correlative objectives of the DORA trial, an open-labeled, randomized, Phase 3 study of docetaxel versus docetaxel in combination with radium-223 (Ra-223) in subjects with mCRPC. We offer our Digital Solutions to HCPs for clinical use and to pharmaceutical companies for development purposes, and in some cases, we also obtain clinical imaging data that we may use to further develop artificial intelligence solutions.
Global Mo-99 Supply
We currently have Mo-99 supply agreements with Institute for Radioelements (“IRE”), running through December 31, 2024, with auto-renewal provisions that are terminable upon notice of non-renewal, and with NTP Radioisotopes (“NTP”), acting for itself and on behalf of its subcontractor, the Australian Nuclear Science and Technology Organisation (“ANSTO”), running through December 31, 2024.
Although we believe we have the most globally diverse Mo-99 supply with IRE in Belgium, NTP in South Africa, and ANSTO in Australia, we still face supplier and logistical challenges in our Mo-99 supply chain. When one supplier experiences outages, we generally rely on Mo-99 supply from the other suppliers to limit the impact of the outages. We believe we effectively manage these various supply chain challenges, but depending on reactor and processor schedules and operations, at times we have not been able to fill some or all of the demand for our TechneLite generators on certain manufacturing days. A prolonged disruption of service from one of our three Mo-99 processing sites or one of their main Mo-99-producing reactors could have a negative effect on our business, results of operations, financial condition and cash flows.
Inventory Supply & Third Party Suppliers
We obtain a substantial portion of our imaging agents from third-party suppliers. Jubilant HollisterStier (“JHS”) is currently a significant supplier of DEFINITY and our sole source manufacturer of NEUROLITE, CARDIOLITE and evacuation vials. Our manufacturing and supply agreement with JHS (the “JHS MSA”) runs through December 31, 2027 and can be further extended by mutual agreement of the parties. The JHS MSA requires us to purchase from JHS specified percentages of our total requirements for DEFINITY, as well as specified quantities of NEUROLITE, CARDIOLITE and evacuation vial products, each year during the contract term. Either party can terminate the JHS MSA upon the occurrence of certain events, including the material breach or bankruptcy of the other party. In addition to JHS, we rely on SBL as our sole source manufacturer of DEFINITY RT.
In 2021, we completed the construction of a specialized in-house manufacturing facility at our North Billerica campus to produce the formulation of DEFINITY that requires refrigerated storage. On February 22, 2022, we received FDA approval of our supplemental new drug application authorizing commercial manufacturing of DEFINITY at our new facility. We believe this investment provides supply chain redundancy, improved flexibility and reduced costs in a potentially more price competitive environment.
Radiopharmaceuticals are decaying radioisotopes with half-lives ranging from a few hours to several days. Radiopharmaceutical finished goods, such as doses of PYLARIFY, cannot be kept in inventory because of their limited shelf lives and are subject to just-in-time manufacturing, processing and distribution, which takes place at our 54 PMF manufacturing sites across the U.S., with respect to PYLARIFY, and at our facilities in North Billerica, Massachusetts, with respect to our TechneLite generators and Xenon
63
Research and Development Expenses
To ensure we remain the leading radiopharmaceutical-focused company in our industry, we have historically made and will continue to make substantial investments in new product development and lifecycle management for existing products, including:
•For PYLARIFY, we recently enrolled the first patient in a clinical trial to determine whether PYLARIFY can accurately detect the presence or absence of prostate cancer beyond the prostate gland in patients with favorable intermediate-risk prostate cancer, as well as how it may change the patient’s intended management. We are also exploring opportunities for the use of PYLARIFY beyond prostate cancer.
•For PNT2002 and PNT2003, we were granted a license to exclusive worldwide rights (excluding certain countries) for $260.0 million in upfront payments during the fourth quarter of 2022 and will potentially make additional payments as described below. We also filed an ANDA for PNT2003 as described further in the section entitled “Exclusive License for PNT2002 and PNT2003” above.
•For LNTH-1363S, in collaboration with Ratio, we recently completed a Phase 1 study for LNTH-1363S to evaluate the pharmacokinetics, biodistribution and radiation dosimetry in adult healthy volunteers. We plan to initiate a Phase 1/2a study in patients in 2024.
•For 1095, our PSMA-targeted iodine-131-labeled small molecule product candidate, we enrolled the last patient in our ARROW Phase 2 study during the second quarter of 2022. Patients in this study will be followed for one year after their first treatment for all efficacy endpoints and survival and safety data will be collected for an additional year.
PNT2002
Under the terms of the PNT2002 License Agreement, Lantheus Two paid POINT an upfront cash payment of $250.0 million, and could pay up to an additional $281.0 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2002. POINT is also eligible to receive up to $1.3 billion in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2002. In addition, after Lantheus Two achieves $500.0 million in cumulative gross profit, POINT is eligible to receive royalty payments of twenty percent of net sales of PNT2002. Prior to achieving that financial recoupment threshold, POINT is eligible to receive royalty payments of twenty percent on that portion of annual net sales of PNT2002 that generate annual gross profit in excess of specified levels.
PNT2003
Under the terms of the PNT2003 License Agreement, Lantheus Three, LLC paid POINT an upfront cash payment of $10.0 million, and could pay up to an additional $34.5 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2003. POINT is also eligible to receive up to $275.0 million in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2003. In addition, POINT is eligible to receive royalty payments of fifteen percent of net sales of PNT2003.
Our investments in these additional clinical activities and lifecycle management opportunities will increase our operating expenses and impact our results of operations and cash flow, and we can give no assurances as to whether any of these clinical development candidates or lifecycle management opportunities will be successful.
Strategic Partnerships and Other Revenue
We continue to seek ways to further increase the overall value of our portfolio of products and product candidates. We are evaluating a number of different opportunities to collaborate, in-license or acquire additional products, product candidates, businesses and technologies to drive our future growth. In particular, we are focused on therapeutic and diagnostic radiopharmaceutical product opportunities in oncology and other strategic areas that will complement our existing portfolio.
Oncology
As we continue to pursue expanding our strategic partnerships, our Pharma Solutions activities in oncology are designed to enable precision medicine using biomarkers and digital solutions that augment diagnostic productivity. For example, in prostate cancer, we collaborate with pharmaceutical companies by supplying them with piflufolastat F 18 for use in their therapeutic drug development programs. For immuno-oncology, we intend to offer NM-01, a novel technetium-99m SPECT imaging agent that we are developing to assess PD-L1 expression in cancer cells, for potential use as an efficacy and safety biomarker in immuno-oncology therapies. With respect to pan-oncology, we are further exploring the use of LNTH-1363S as an innovative imaging biomarker that targets fibroblast activation protein.
Microbubble Franchise
In addition, we continue to expand our microbubble franchise. Some of our microbubble collaborations are with the following parties: (i) Cerevast Medical, Inc. (“Cerevast”), in which our microbubbles will be used in connection with Cerevast’s ocular ultrasound device to improve blood flow in occluded retinal veins in the eye; (ii) CarThera SAS, for the use of our microbubbles in
64
combination with SonoCloud, a proprietary implantable device in development for the treatment of recurrent glioblastoma; (iii) Insightec Ltd. (“Insightec”), which will use our microbubbles in connection with the development of Insightec’s transcranial guided focused ultrasound device for the treatment of glioblastoma as well as other neurodegenerative conditions; (iv) Allegheny Health Network (“AHN”), which will use our microbubbles in combination with AHN’s ultrasound-assisted non-viral gene transfer technology for the development of a proposed treatment of xerostomia; and (v) SonoThera, which will use our microbubbles in combination with their ultrasound-guided, non-viral, gene therapy platform and treatments.
flurpiridaz
In September 2022, we announced with our strategic partner GE Healthcare Limited (“GE Healthcare”) that the recent Phase 3 clinical trial of our investigational radiotracer, flurpiridaz, had met its co-primary endpoints of exceeding a 60% threshold for both sensitivity and specificity for detecting coronary artery disease (“CAD”). The findings, shared at an American Society of Nuclear Cardiology conference, also demonstrated that cardiac PET imaging with flurpiridaz has higher diagnostic efficacy and image quality in patients with suspected CAD, compared with single photon emission computed tomography (“SPECT”) Myocardial Perfusion Imaging (“MPI”), the predominant procedure currently used in nuclear cardiology. We believe SPECT MPI represents approximately 6 million procedures per year in the U.S.
Under a Collaboration and License Agreement we entered into with GE Healthcare in 2017, GE Healthcare has led the funding and development of flurpiridaz, and, if the imaging agent is approved, will have the global commercialization rights for it. GE Healthcare recently announced that it had filed an NDA with the FDA for flurpiridaz. Assuming regulatory approval, we anticipate commercialization by GE Healthcare beginning in the second half of 2024. If flurpiridaz receives regulatory approval and is commercially successful, we will receive:
• up to $60 million in regulatory and sales milestone payments,
• tiered double-digit royalties on U.S. sales., and
• mid-single digit royalties on sales outside of the U.S.
Generally, our costs in connection with the strategic partnerships relate to intellectual property, the supply of drug and other ancillary expenses and the benefits can include possible supply, milestone and royalty payments, additional intellectual property rights and strategic relationships. For flurpiridaz, under the Collaboration and License Agreement, we retained ownership of all of the licensed intellectual property and bear the cost of patent prosecution and maintenance. We can give no assurance as to if or when or if any of these collaborations and other new initiatives, including our collaboration for flurpiridaz, will be successful or accretive to earnings.
65
Results of Operations
The following is a summary of our consolidated results of operations:

Year Ended
December 31,
2023 vs. 20222022 vs. 2021
(in thousands)202320222021Change
$		Change
%		Change
$		Change
%
Revenues$1,296,429 $935,061 $425,208 $361,368 38.6 %$509,853 119.9 %
Cost of goods sold586,886 353,358 237,513 233,528 66.1 %115,845 48.8 %
Gross profit709,543 581,703 187,695 127,840 22.0 %394,008 209.9 %
Operating expenses
Sales and marketing141,736 100,243 68,422 41,493 41.4 %31,821 46.5 %
General and administrative125,458 133,584 150,395 (8,126)(6.1)%(16,811)(11.2)%
Research and development77,707 311,681 44,966 (233,974)(75.1)%266,715 593.1 %
Total operating expenses344,901 545,508 263,783 (200,607)(36.8)%281,725 106.8 %
Gain on sales of assets— — 15,263 — N/A(15,263)N/A
      Operating income (loss)364,642 36,195 (60,825)328,447 907.4 %97,020 (159.5)%
Interest expense20,019 7,185 7,752 12,834 178.6 %(567)(7.3)%
Loss (gain) on extinguishment of debt— 588 (889)(588)(100.0)%1,477 (166.1)%
Other (income) loss, net(66,320)1,703 7,350 (68,023)(3,994.3)%(5,647)(76.8)%
Income (loss) before income taxes410,943 26,719 (75,038)384,224 1,438.0 %101,757 (135.6)%
Income tax expense (benefit)84,282 (1,348)(3,759)85,630 (6,352.4)%2,411 (64.1)%
Net income (loss)$326,661 $28,067 $(71,279)$298,594 1,063.9 %$99,346 (139.4)%

66
Comparison of the Periods Ended December 31, 2023 and 2022
Revenues
We classify our revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology consists of PYLARIFY and AZEDRA. In 2023, we announced our decision to discontinue the production and promotion of AZEDRA and we do not expect AZEDRA to contribute to the business after the first quarter of 2024. Precision Diagnostics includes DEFINITY, TechneLite and other diagnostic imaging products. Strategic Partnerships and Other Revenue primarily includes out-licensing arrangements and partnerships that focus on facilitating precision medicine through the use of biomarkers, digital solutions and radiotherapeutic platforms.
Revenues are summarized by product category on a net basis as follows:
Year Ended December 31,2023 vs. 2022
(in thousands)202320222021Change $Change %
PYLARIFY$851,303 $527,405 $43,414 $323,898 61.4 %
Other radiopharmaceutical oncology3,130 4,102 5,473 (972)(23.7)%
Total radiopharmaceutical oncology854,433 531,507 48,887 322,926 60.8 %
DEFINITY279,768 244,993 232,759 34,775 14.2 %
TechneLite87,370 88,864 91,293 (1,494)(1.7)%
Other precision diagnostics22,980 22,825 26,973 155 0.7 %
Total precision diagnostics390,118 356,682 351,025 33,436 9.4 %
Strategic Partnerships and other revenue51,878 46,872 25,296 5,006 10.7 %
Total revenues$1,296,429 $935,061 $425,208 $361,368 38.6 %
The increase in revenues for the year ended December 31, 2023, as compared to the prior year period, is primarily due to increased PYLARIFY and DEFINITY sales volume and RELISTOR milestone achievement of $15.0 million earned in the fourth quarter of 2023. The increase is offset, in part, by a decrease in Strategic Partnerships and Other Revenue due to the revenue recognized from the Novartis licensing agreement in the prior year described further under Note 3, “Disaggregation of Revenue” below and the sale of the RELISTOR royalty revenue asset.
Rebates and Allowances
Estimates for rebates and allowances represent our estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction to revenue and the establishment of a liability which is included in accrued expenses. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs for our products, administrative fees of group purchasing organizations and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third-party’s expected purchases and the resulting applicable contractual rebate to be earned over a contractual period.
An analysis of the amount of, and change in, reserves for rebates and allowances is summarized as follows:
(in thousands)Rebates and
Allowances
Balance, January 1, 2022$10,977 
Provision related to current period revenues26,683 
Adjustments relating to prior period revenues70 
Payments or credits made during the period(24,331)
Balance, December 31, 202213,399 
Provision related to current period revenues32,308 
Adjustments relating to prior period revenues(453)
Payments or credits made during the period(29,184)
Balance, December 31, 2023$16,070 

67
Gross Profit
The increase in gross profit for the year ended December 31, 2023, as compared to the prior year period, is primarily due to increased PYLARIFY and DEFINITY sales volume and a RELISTOR milestone achievement, partially offset by the impairment of the AZEDRA currently marketed intangible asset, the Novartis licensing payment in the prior year, amortization of Cerveau intangible assets, and the loss of RELISTOR royalty revenue due to the sale of the asset.
Sales and Marketing
Sales and marketing expenses consist primarily of salaries and other related costs for personnel in field sales, marketing and customer service functions. Other costs in sales and marketing expenses include the development and utilization of advertising and promotional material, professional services, market research and sales meetings.
Sales and marketing expenses increased $41.5 million for the year ended December 31, 2023, as compared to the prior year period. This was primarily driven by our investment in sales and marketing efforts in support of an expansion of our PYLARIFY sales force and supporting functions intended to support and expand adoption of PYLARIFY and pre-commercialization activities for certain product candidates.
General and Administrative
General and administrative expenses consist of salaries and other related costs for personnel in executive, finance, legal, information technology and human resource functions. Other costs included in general and administrative expenses are professional fees for information technology services, external legal fees, consulting and accounting services as well as bad debt expense, certain facility and insurance costs, including director and officer liability insurance.
General and administrative expenses decreased $8.1 million for the year ended December 31, 2023 compared to the prior year period. This was primarily driven by a $44.1 million net reduction for the fair value adjustments to the contingent asset and liabilities (refer to Note 4, “Fair Value of Financial Instruments”, for further details on contingent consideration liabilities, including CVRs) and an insurance settlement in 2023. These reductions were partially offset by increased employee-related costs, investments in technology, new lease expense, and increased professional fees.
Research and Development
Research and development expenses relate primarily to the development of new products to add to our portfolio and costs related to our medical affairs, medical information and regulatory functions.
Research and development expenses decreased $234.0 million for the year ended December 31, 2023 as compared to the prior year period. This was primarily driven by the $260.0 million upfront payment in 2022 for the two agreements with POINT, partially offset by in-process research and development (“IPR&D”) impairment loss of $15.6 million in connection with our discontinuation of the production and promotion of AZEDRA and higher employee related costs driven by increased headcount.
Interest Expense
Interest expense for the year ended December 31, 2023 increased $12.8 million as compared to the prior year period due to the issuance of the Notes on December 8, 2022.
Loss on Extinguishment of Debt
During the year ended December 31, 2022, we realized a $0.6 million loss on extinguishment of debt related to the refinancing of our existed indebtedness. There were no extinguishments on debt for the year ended December 31, 2023.
Other (Income) Loss
Other (income) loss increased by $68.0 million for the year ended December 31, 2023 as compared to the prior year period primarily due to the gain on sale of the RELISTOR licensed intangible asset associated with net sales royalties of $51.8 million and an increase in interest income.
Income Tax Expense (Benefit)
Our effective tax rate for each reporting period is presented as follows:
68
69
Year Ended
December 31,
20232022
Effective tax rate20.5%(5.0)%
Our effective tax rate in fiscal 2023 differs from the U.S. statutory rate of 21% primarily due to the income tax benefits associated with stock compensation deductions, additional net operating losses available for utilization under Internal Revenue Code Section 382 as a result of the sale of our RELISTOR royalty asset, and the release of uncertain tax positions, partially offset by state income taxes.
In accordance with our accounting policy, the change in the tax liabilities, penalties and interest associated with our uncertain tax positions (net of any offsetting federal or state benefit) is recognized within income tax expense (benefit). Our uncertain tax positions include indemnified liabilities, in accordance with the Stock and Asset Purchase Agreement entered into with BMS in 2008. Changes in the liability result in offsetting changes in the indemnification receivable. As these reserves change, adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the receivable from BMS continues to be considered recoverable by us, there will be no effect on net income and no net cash outflows related to these liabilities. During 2023, the Company released a significant portion of its indemnified liability due to the settlement of these positions in certain states at a cost significantly less than our accrual resulting in $5.2 million (net of federal or state benefit) income tax benefit. Refer to Note 5, Income Taxes.
Our effective tax rate in fiscal 2022 differs from the U.S. statutory rate of 21% primarily due to the income tax benefit for the release of a portion of our uncertain tax positions and the tax benefit associated with stock compensation deductions offset by tax expense from the change in fair value of contingent consideration and expense generated on the revaluation of the Company’s deferred state tax rate. During 2022, the Company released a significant portion of its indemnified liability due to the settlement of these positions in various states at a cost significantly less than our accrual resulting in $9.6 million (net of federal or state benefit) income tax benefit.
Liquidity and Capital Resources
Cash Flows
The following table provides information regarding our cash flows:
Year Ended
December 31,
(in thousands)202320222021
Net cash provided by operating activities$305,260 $281,781 $53,916 
Net cash provided by (used in) investing activities$5,939 $(276,547)$3,683 
Net cash (used in) provided by financing activities$(13,062)$311,691 $(39,332)
For a discussion of our liquidity and capital resources related to our cash flow activities for the fiscal year ended December 31, 2021, see “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our annual report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023.
Net Cash Provided by Operating Activities
Net cash provided by operating activities of $305.3 million during the year ended December 31, 2023 was primarily comprised of net income adjusted for the net effect of non-cash items such as impairment of long-lived assets, depreciation, amortization and accretion expense, gain on sale of our RELISTOR royalty asset, deferred income taxes, and stock-based compensation expense. The primary working capital sources of cash were the timing of payments to large vendors. The primary working capital uses of cash were a decrease to accruals related to the CVR payment, an increase in trade receivables associated primarily with the increase in PYLARIFY revenues, and an increase in inventory related to the timing of batch processes.
Net cash provided by operating activities of $281.8 million during the year ended December 31, 2022 was primarily comprised of net income adjusted for charges incurred in connection with acquired IPR&D and the net effect of non-cash items such as depreciation, amortization and accretion expense, the change in fair value of contingent assets and liabilities of $34.7 million (refer to Note 4, “Fair Value of Financial Instruments”, for further details on contingent consideration liabilities, including CVRs), and stock-based compensation expense. The primary working capital sources of cash were the increase in accruals associated with PYLARIFY sales. The primary working capital uses of cash were an increase in trade receivables associated primarily with the increase in PYLARIFY revenues.
70
Net Cash Provided by (Used in) Investing Activities
Net cash provided by investing activities during the year ended December 31, 2023 was primarily due to net cash proceeds of $97.8 million from the sale of our RELISTOR royalty asset offset by $45.3 million for our asset acquisition of Cerveau and $46.6 million of capital expenditures.
Net cash used in investing activities during the year ended December 31, 2022 was primarily due to the $260.0 million upfront payment to POINT and the $18.3 million of capital expenditures partially offset by $1.8 million received from the sale of our Puerto Rico subsidiary.
Net Cash (Used in) Provided by Financing Activities
Net cash used in financing activities during the year ended December 31, 2023 is primarily attributable to the payments for minimum statutory tax withholding related to net share settlement of equity awards of $14.4 million and the CVR initial valuation as of June 30, 2020 of $3.7 million, offset by proceeds of $3.8 million from stock option exercises.
Net cash provided by financing activities during the year ended December 31, 2022 is primarily attributable to the proceeds of $557.8 million received from the issuance of the Notes, proceeds of $7.5 million from stock option exercises and proceeds of $5.6 million from the voluntarily terminated interest rate swap contracts in connection with the refinancing of debt. These amounts were offset by payments on long-term debt and other borrowings of $175.0 million, repurchase of common stock of $75.0 million and payments for minimum statutory tax withholding related to net share settlement of equity awards of $7.8 million.
External Sources of Liquidity
In December 2022, we voluntarily repaid our 2019 $200.0 million five-year term loan facility. In addition, we replaced our $200.0 million revolving facility with the 2022 Revolving Facility. The terms of the 2022 Revolving Facility are set forth in the Credit Agreement, dated as of December 2, 2022, by and among us, the lenders from time to time party thereto and Citizens Bank, N.A., as administrative agent and collateral agent (the “2022 Credit Agreement”). We have the right to request an increase to the 2022 Revolver Facility or request the establishment of one or more new incremental term loan facilities, in an aggregate principal amount of up to $335.0 million or consolidated EBITDA for the four consecutive fiscal quarters most recently ended, plus additional amounts, in certain circumstances.
The Company used approximately $7.8 million of cash on hand to primarily repay the principal amount of the loans outstanding related to the 2019 Facility through the nine months ended September 30, 2022. In addition, in December 2022, the Company used approximately $167.6 million of cash on hand to repay in full the aggregate remaining principal amount of the loans outstanding under the 2019 Facility and to pay related interest, transaction fees and expenses.
Under the terms of the 2022 Revolving Facility, the lenders thereunder agreed to extend credit to us from time to time until December 2, 2027 consisting of revolving loans in an aggregate principal amount not to exceed $350.0 million at any time. The 2022 Revolving Facility includes a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”). The 2022 Revolving Facility includes a $10.0 million sub-facility for swingline loans (the “Swingline Loans”). The Letters of Credit, Swingline Loans and the borrowings under the 2022 Revolving Facility are expected to be used for working capital and other general corporate purposes.
Please refer to Note 12, “Long-Term Debt, Net, and Other Borrowings” for further details on the 2022 Facility.
As of December 31, 2023, we were in compliance with all financial and other covenants under the 2022 Credit Agreement.
On December 8, 2022, we issued $575.0 million in aggregate principal amount of the Notes, which includes $75.0 million in aggregate principal amount of Notes sold pursuant to the full exercise of the initial purchasers’ option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among the Company, LMI, as Guarantor, and U.S. Bank, as Trustee. The net proceeds from the issuance of the Notes were approximately $557.8 million, after deducting the initial purchasers’ discounts and offering expenses payable by us.
On March 31, 2021, we voluntarily repaid in full the entire outstanding principal on outstanding debt of Progenics that we assumed as a result of the Progenics Acquisition. The total amount we paid was $30.9 million, which included a prepayment amount of $0.5 million.
Our ability to fund our future capital needs will be affected by our ability to continue to generate cash from operations and may be affected by our ability to access the capital markets, money markets or other sources of funding, as well as the capacity and terms of our financing arrangements.
71
We may from time to time repurchase or otherwise retire our debt and take other steps to reduce our debt or otherwise improve our balance sheet. These actions may include prepayments of our term loans or other retirements or refinancing of outstanding debt, privately negotiated transactions or otherwise. The amount of debt that may be retired, if any, could be material and would be decided at the sole discretion of our Board and will depend on market conditions, our cash position and other considerations.
Funding Requirements
Our future capital requirements will depend on many factors, including:
•The level of product sales and the pricing environment of our currently marketed products, particularly PYLARIFY and DEFINITY, as well as any additional products that we may market in the future;
•Revenue mix shifts and associated volume and selling price changes that could result from contractual status changes with key customers and additional competition;
•The continued costs of the ongoing commercialization of our products;
•Our investment in the further clinical development and commercialization of products and development candidates, including PNT2002, PNT2003, 1095 and MK-6240;
•The costs of acquiring or in-licensing, developing, obtaining regulatory approval for, and commercializing, new products, businesses or technologies, including any potential related milestone or royalty payments, together with the costs of pursuing opportunities that are not eventually consummated;
•The costs of investing in our facilities, equipment and technology infrastructure;
•The costs and timing of establishing or amending manufacturing and supply arrangements for commercial supplies of our products and raw materials and components;
•Our ability to have products manufactured and released from manufacturing sites in a timely manner in the future, or to manufacture products at our in-house manufacturing facilities in amounts sufficient to meet our supply needs;
•The costs of further commercialization of our existing products, particularly in international markets, including product marketing, sales and distribution and whether we obtain local partners to help share such commercialization costs;
•The legal costs relating to maintaining, expanding and enforcing our intellectual property portfolio, pursuing insurance or other claims and defending against product liability, regulatory compliance, intellectual property or other claims, including the patent infringement claim related to the filing of our ANDA for PNT2003;
•The cost of interest on any additional borrowings which we may incur under our financing arrangements; and
•The impact of sustained inflation on our costs of goods sold and operating expenses.
Disruption in our financial performance could occur if we experience significant adverse changes in product or customer mix, broad economic downturns, sustained inflation, adverse industry or company conditions or catastrophic external events, including pandemics such as COVID-19, natural disasters and political or military conflict. If we experience one or more of these events in the future, we may be required to further implement expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.
If our capital resources become insufficient to meet our future capital requirements, we would need to finance our cash needs through public or private equity offerings, debt financings, assets securitizations, sale-leasebacks or other financing or strategic alternatives, to the extent such transactions are permissible under the covenants of our 2022 Credit Agreement. Additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all. If any of these transactions require an amendment or waiver under the covenants in our 2022 Credit Agreement, which could result in additional expenses associated with obtaining the amendment or waiver, we will seek to obtain such an amendment or waiver to remain in compliance with those covenants. However, we cannot provide assurance that such an amendment or waiver would be granted, or that additional capital will be available on acceptable terms, if at all.
At December 31, 2023, our only current committed external source of funds is our borrowing availability under our 2022 Revolving Facility. We had $713.7 million of cash and cash equivalents as of December 31, 2023. Our 2022 Revolving Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the 2022 Revolving Facility may affect our ability to comply with the covenants including the financial covenants restricting consolidated net leverage and interest coverage. Accordingly, we may be limited in utilizing the full amount of our 2022 Revolving Facility as a source of liquidity.
72
Based on our current operating plans, we believe our balance of cash and cash equivalents, which totaled $713.7 million as of December 31, 2023, along with cash generated by ongoing operations and continued access to our 2022 Revolving Facility, will be sufficient to satisfy our cash requirements over the next twelve months and beyond. Our material cash requirements include the following contractual and other obligations.
Debt
We completed a sale of $575.0 million in aggregate principal amount of the Notes due in 2027. As of December 31, 2023, we had no amounts of principal due within the next twelve months. Future interest payments associated with the Notes total $60.0 million, with $15.1 million payable within twelve months.
Leases
We have operating lease arrangements for certain facilities, including corporate and manufacturing space. As of December 31, 2023, we had fixed operating lease payment obligations of $99.5 million, with $4.6 million payable within twelve months.
We have lease arrangements for certain equipment. As of December 31, 2023, we had fixed finance lease payment obligations of $1.7 million, with $0.8 million payable within twelve months.
Purchase Obligations
We have purchase obligations that primarily consist of noncancelable obligations related to minimum quantities of goods or services that have been committed to be purchased on an annual basis. As of December 31, 2023, we had minimum purchase obligations of $10.9 million, with $2.7 million due within twelve months.
License Agreements
We have entered into license agreements in which fixed payments have been committed to be paid on an annual basis. As of December 31, 2023, we had no amount of fixed license payments due within twelve months. These amounts do not include potential milestone or contractual payment obligations contingent upon the achievement or occurrence of future milestones or events under our license agreements, because they are contingent and the amounts and timing of such potential obligations are unknown or uncertain. We may be required to pay additional amounts up to approximately $264.4 million in contingent payments under our license agreements.
Asset Acquisitions
During 2022, we entered into the POINT License Agreements, in which we made upfront payments of $260.0 million, and under which we may make additional milestone payments. The additional milestone payments are based on FDA approval and net sales and commercial milestones. Under the terms of the PNT2002 License Agreement, we have the potential to pay up to an additional $281.0 million in milestone payments and up to $1.3 billion in sales milestone payments upon the achievement of specified annual sales thresholds. Under the terms of the PNT2003 License Agreement, we have the potential to pay an additional $34.5 million in milestone payments and up to $275.0 million in sales milestone payments upon the achievement of specified annual sales thresholds. In total, we may be required to pay up to approximately $1.8 billion related to the asset acquisition. As of December 31, 2023, these contingent payments were not expected to be payable due to the uncertainty around the timing of the future cash flows.
On February 6, 2023, the Company acquired Cerveau and made an upfront payment of approximately $35.3 million to the Selling Stockholders. The Company paid the Selling Stockholders an additional $10.0 million in May 2023 upon the successful completion of a technology transfer. The Company could pay up to an additional $51.0 million in milestone payments upon achievement of specified U.S. regulatory milestones related to MK-6240. The Selling Stockholders are also eligible to receive up to $1.2 billion in sales milestone payments upon the achievement of specified annual commercial sales thresholds of MK-6240 in the event the Company pursues commercialization, as well as up to $13.5 million in research revenue milestones upon achievement of specified annual research revenue thresholds. Additionally, the Company will pay to the Selling Stockholders up to double-digit royalty payments for research revenue and commercial sales. As of December 31, 2023, these contingent payments were not expected to be payable due to the uncertainty around the timing of the future cash flows.
Other Long-Term Liabilities
Our other long-term liabilities in the consolidated balance sheet include the fair values of contingent consideration liabilities including contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013. We may be required to pay up to approximately $85.0 million related to the contingent consideration. As of December 31, 2023, these contingent payments were not expected to be payable within twelve months due to the uncertainty around the timing of the future cash flows.
73
Our other long-term liabilities in the consolidated balance sheet include unrecognized tax benefits and related interest and penalties. As of December 31, 2023, we had unrecognized tax benefits of $3.2 million, which included interest and penalties, classified as noncurrent liabilities. At this time, we are unable to make a reasonably reliable estimate of the timing of payments in individual years in connection with these tax liabilities.
Asset Retirement Obligation
We are required to provide the Massachusetts Department of Public Health and the New Jersey Department of Environmental Protection financial assurance demonstrating our ability to fund the decommissioning of our North Billerica, Massachusetts and Somerset, New Jersey production facilities, respectively, upon closure. We have provided this financial assurance in the form of a $30.3 million surety bond (the “Surety Bond”). As of December 31, 2023, the liability, which was approximately $22.9 million, was measured at the present value of the obligation expected to be incurred of approximately $25.1 million. These contingent payments are not expected to be payable within twelve months due to the uncertainty around the timing of the future cash flows related to the decommissioning of our radioactive operations.
Off-Balance Sheet Arrangements
As noted above, we have provided the Surety Bond to the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection.
Since inception, we have not engaged in any other off-balance sheet arrangements, including structured finance, special purpose entities or variable interest entities.
Effects of Inflation
We do not believe that inflation has had a significant impact on our revenues or results of operations. We expect our cost of product sales and other operating expenses will change in the future in line with periodic inflationary changes in price levels. Because we intend to retain and continue to use our property and equipment, we believe that the incremental inflation related to the replacement costs of those items will not materially affect our operations. However, the rate of inflation affects our expenses, such as those for employee compensation and contract services, which could increase our level of expenses and the rate at which we use our resources. While we generally believe that we will be able to offset some of the effect of price-level changes by adjusting our product prices and implementing operating efficiencies, any material unfavorable changes in price levels could have a material adverse effect on our financial condition, results of operations and cash flows.
Recent Accounting Standards
Refer to Note 2, “Summary of Significant Accounting Policies,” in the accompanying consolidated financial statements located under Item 8 of this Annual Report on Form 10-K for information regarding recently issued accounting standards that may have a significant impact on our business.
Critical Accounting Policies
The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements require us to make estimates and judgments that affect our reported assets and liabilities, revenues and expenses, and other financial information. Actual results may differ materially from these estimates under different assumptions and conditions. In addition, our reported financial condition and results of operations could vary due to a change in the application of a particular accounting standard.
We believe the following represent our critical accounting estimates used in the preparation of our financial statements.
Revenue from Contracts with Customers
Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. We recognize revenue when we satisfy our performance obligations by transferring control over products or services to our customers. The amount of revenue we recognize reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. To achieve this core principle, we apply the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy performance obligations.
We derive our revenues through arrangements with customers for product sales as well as licensing and royalty arrangements. We sell our products primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies, and we consider customer purchase orders, which in some cases are governed by master sales or group purchasing organization agreements, to be contracts with
74
our customers. In addition to these arrangements, we also enter into licensing agreements under which we license certain rights to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. We analyze various factors requiring management judgment when applying the five-step model to our contracts with customers.
Our product revenues are recorded at the net sales price (transaction price), which represents our sales price less estimates related to reserves which are established for items such as discounts, returns, rebates and allowances that may be provided for in certain contracts with our customers. Judgment is used in determining and updating our reserves on an ongoing basis, and where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ from our estimates.
For our licensing and royalty arrangements, we use judgment in determining the number of performance obligations in a license agreement by assessing whether the license is distinct or should be combined with another performance obligation as well as the nature of the license. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in a contract. These key assumptions may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.
Business Combinations
We account for business combinations using the acquisition method of accounting. We recognize the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. We assess the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired IPR&D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.
The fair values assigned to tangible and intangible assets acquired and liabilities assumed are based on our estimates and assumptions, as well as other information we have compiled, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and assumptions used in these estimates, it could result in a possible impairment of the intangible assets and goodwill, a required acceleration of the amortization expense of finite-lived intangible assets or the recognition of additional consideration, which would be expensed.
During the measurement period, which extends no later than one year from the acquisition date, we may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income.
Intangible and Long-Lived Assets
We test intangible and long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. We measure the recoverability of assets to be held and used by comparing the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If those assets are considered to be impaired, the impairment equals the amount by which the carrying amount of the assets exceeds the fair value of the assets. Any impairments are recorded as permanent reductions in the carrying amount of the assets. Long-lived assets, other than goodwill and other intangible assets, that are held for sale are recorded at the lower of the carrying value or the fair market value less the estimated cost to sell.
Intangible assets, consisting of trademarks, customer relationships, currently marketed products, licenses and developed technology are amortized in a method equivalent to the estimated utilization of the economic benefit of the asset.
Costs of IPR&D intangible assets acquired as part of an asset acquisition that have no alternative future use are expensed when incurred. Milestone payments made after regulatory approval are capitalized as an intangible asset and amortized over an estimated useful life of the product. Cash payments related to acquired IPR&D intangible assets are reflected as an investing cash flow in the Company's consolidated statement of cash flows.
75
Our IPR&D intangible assets include intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is whether we have obtained regulatory approval to market the underlying products in an applicable geographic region. Because obtaining regulatory approval can include significant risks and uncertainties, the eventual realized value of the acquired IPR&D projects may vary from their fair value at the date of acquisition. We classify IPR&D intangible assets acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset. We test our IPR&D intangible assets at least annually or when a triggering event occurs that could indicate a potential impairment and we recognize any impairment loss in our consolidated statements of operations.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk
We are exposed to market risk from changes in interest rates and foreign currency exchange rates. We may from time to time use derivative financial instruments or other financial instruments to hedge these economic exposures related to foreign currencies. We do not hold or issue financial instruments for trading purposes.
Interest Rate Risk
We are subject to interest rate risk in connection with our 2022 Revolving Facility, which is variable rate indebtedness. Interest rate changes could increase the amount of our interest payments and thus negatively impact our future earnings and cash flows. As of December 31, 2023, there was availability of $350.0 million on the 2022 Revolving Facility. Any increase in the interest rate under the 2022 Revolving Facility may have a negative impact on our future earnings to the extent we have outstanding borrowings under the 2022 Revolving Facility.
We had used interest rate swaps to reduce the variability in cash flows associated with a portion of our forecasted interest payments on its variable rate debt. We voluntarily terminated our interest rate swap contracts on December 2, 2022.
Foreign Currency Risk
We face exposure to movements in foreign currency exchange rates whenever we, or any of our subsidiaries, enter into transactions with third parties that are denominated in currencies other than our, or that subsidiary’s, functional currency. Intercompany transactions between entities that use different functional currencies also expose us to foreign currency risk.
During the years ended December 31, 2023, 2022 and 2021, the net impact of foreign currency changes on transactions was a loss of less than $0.1 million, $0.3 million and $0.3 million, respectively. From time to time, we enter into foreign currency forward contracts primarily to reduce the effects of fluctuating foreign currency exchange rates. We may enter into additional foreign currency forward contracts when deemed appropriate. We do not enter into foreign currency forward contracts for speculative or trading purposes.
The Canadian dollar presents the primary currency risk on our earnings. At December 31, 2023, a hypothetical 10% change in value of the U.S. dollar relative to the Canadian dollar would not have materially affected our financial instruments.
76
Item 8. Financial Statements and Supplementary Data

LANTHEUS HOLDINGS, INC.

77
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of Lantheus Holdings, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Lantheus Holdings, Inc. and subsidiaries (the "Company") as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), changes in stockholders’ equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 22, 2024, expressed an unqualified opinion on the Company's internal control over financial reporting.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Intangible Assets — Non-Cash Impairment Charge for AZEDRA Intangible Asset Group — Refer to Note 10 to the financial statements
Critical Audit Matter Description
In March 2023, the Company stopped all development activities in relation to a future indication associated with AZEDRA, which was classified as an in-process research and development (“IPR&D”) intangible asset. The asset group, which consisted of the IPR&D asset and a currently marketed product (the “AZEDRA intangible asset group”), was assessed for impairment. The Company considered several factors in estimating the future projections of revenues and cash flows of the AZEDRA intangible asset group as part of the impairment testing. The Company concluded that the carrying amount exceeded the fair value of the AZEDRA intangible asset group, which had no value. As a result of such assessment, the Company recorded a non-cash impairment charge in research and development expenses relating to the IPR&D asset and a non-cash impairment charge in cost of goods sold relating to the currently marketed indication of AZEDRA in the consolidated statement of operations for the year ended December 31, 2023.
We identified management’s estimates of future projections of revenue and cash flows used to determine the fair value of the AZEDRA intangible asset group used to record the non-cash impairment charge as a critical audit matter because of the significant estimates made by management. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the reasonableness of management’s estimates of future projections of revenues and cash flows.
78
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to management’s estimates of future revenues and cash flows used to record the non-cash impairment charge for the AZEDRA intangible asset group included the following, among others:
•We tested the effectiveness of controls over management’s review of the estimates of future projections of revenue and cash flows used to record the non-cash impairment charge for the AZEDRA intangible asset group.
•We assessed the reasonableness of management’s estimates of future projections of revenues and cash flows for the AZEDRA intangible asset group by:
◦Comparing historical results to the Company’s strategic plans.
◦Making inquiries of management and corroborating inquiries with the Company’s strategic planning group.
◦Reading internal communications to management and the Board of Directors.
•We evaluated whether the estimates of future projections of revenues and cash flows for AZEDRA were consistent with evidence obtained in other areas of the audit.

/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 22, 2024
We have served as the Company’s auditor since 2007.


79
Lantheus Holdings, Inc.
Consolidated Balance Sheets
(in thousands, except par value)
December 31,
20232022
Assets
Current assets
Cash and cash equivalents$713,656 $415,652 
Accounts receivable, net284,292 213,397 
Inventory64,029 35,475 
Other current assets16,683 13,092 
Assets held for sale7,159 — 
Total current assets1,085,819 677,616 
Property, plant and equipment, net146,697 122,166 
Intangibles, net151,985 315,285 
Goodwill61,189 61,189 
Deferred tax assets, net150,198 110,647 
Other long-term assets55,261 34,355 
Total assets$1,651,149 $1,321,258 
Liabilities and stockholders’ equity
Current liabilities
Current portion of long-term debt and other borrowings$823 $354 
Accounts payable41,189 20,563 
Short-term contingent liability— 99,700 
Accrued expenses and other liabilities145,338 127,084 
Total current liabilities187,350 247,701 
Asset retirement obligations22,916 22,543 
Long-term debt, net and other borrowings561,670 557,712 
Other long-term liabilities63,321 46,155 
Total liabilities835,257 874,111 
Commitments and contingencies (see Note 19)
Stockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)
— — 
Common stock ($0.01 par value, 250,000 shares authorized; 69,863 and 68,851 shares issued as of December 31, 2023 and 2022, respectively)
699 689 
Additional paid-in capital757,727 715,875 
Treasury Stock at cost - 1,339 shares as of December 31, 2023 and 2022
(75,000)(75,000)
Retained earnings (accumulated deficit)133,503 (193,158)
Accumulated other comprehensive loss(1,037)(1,259)
Total stockholders’ equity815,892 447,147 
Total liabilities and stockholders’ equity$1,651,149 $1,321,258 


The accompanying notes are an integral part of these consolidated financial statements.
80
Lantheus Holdings, Inc.
Consolidated Statements of Operations
(in thousands, except per share data)
 Year Ended
December 31,
 202320222021
Revenues$1,296,429 $935,061 $425,208 
Cost of goods sold586,886 353,358 237,513 
Gross profit709,543 581,703 187,695 
Operating expenses
Sales and marketing141,736 100,243 68,422 
General and administrative125,458 133,584 150,395 
Research and development77,707 311,681 44,966 
Total operating expenses344,901 545,508 263,783 
Gain on sales of assets— — 15,263 
      Operating income (loss)364,642 36,195 (60,825)
Interest expense20,019 7,185 7,752 
Loss (gain) on extinguishment of debt— 588 (889)
Other (income) loss, net(66,320)1,703 7,350 
Income (loss) before income taxes410,943 26,719 (75,038)
Income tax expense (benefit)84,282 (1,348)(3,759)
Net income (loss)$326,661 $28,067 $(71,279)
Net income (loss) per common share:
Basic$4.79 $0.41 $(1.06)
Diluted$4.65 $0.40 $(1.06)
Weighted-average common shares outstanding:
Basic68,266 68,487 67,486 
Diluted70,239 70,671 67,486 


The accompanying notes are an integral part of these consolidated financial statements.
81
Lantheus Holdings, Inc.
Consolidated Statements of Comprehensive Income (Loss)
(in thousands)
Year Ended
December 31,
202320222021
Net income (loss)$326,661 $28,067 $(71,279)
Other comprehensive income:
Foreign currency translation222 (505)(124)
Realized loss on cash flow hedges, net of tax— (269)— 
Unrealized gain on cash flow hedges, net of tax— — 1,687 
Total other comprehensive income (loss)222 (774)1,563 
Comprehensive income (loss)$326,883 $27,293 $(69,716)


The accompanying notes are an integral part of these consolidated financial statements.
82
Lantheus Holdings, Inc.
Consolidated Statements of Changes in Stockholders’ Equity
(in thousands)
Common StockTreasury StockAdditional
Paid-In
Capital		Retained EarningsAccumulated
Other
Comprehensive
Loss		Total
Stockholders’
Equity
SharesAmountSharesAmount
Balance, January 1, 202166,875 $669 — $— $665,530 $(149,946)$(2,048)$514,205 
Net loss— — — — — (71,279)— (71,279)
Other comprehensive loss— — — — — — 1,563 1,563 
Stock option exercises and employee stock plan purchases360 3 — — 6,059 — — 6,062 
Vesting of restricted stock awards611 6 — — (6)— — — 
Shares withheld to cover taxes(107)(1)— — (2,045)— — (2,046)
Stock-based compensation— — — — 15,934 — — 15,934 
Balance, December 31, 202167,739 677 — — 685,472 (221,225)(485)464,439 
Net income— — — — — 28,067 — 28,067 
Other comprehensive income— — — — — — (774)(774)
Stock option exercises and employee stock plan purchases411 4 — — 8,908 — — 8,912 
Vesting of restricted stock awards845 9 — — (9)— — — 
Shares withheld to cover taxes(144)(1)— — (7,758)— — (7,759)
Repurchase of common stock— — 1,339 (75,000)— — — (75,000)
Stock-based compensation— — — — 29,262 — — 29,262 
Balance, December 31, 202268,851 689 1,339 (75,000)715,875 (193,158)(1,259)447,147 
Net income— — — — — 326,661 — 326,661 
Other comprehensive loss— — — — — — 222 222 
Stock option exercises and employee stock plan purchases245 2 — — 5,747 — — 5,749 
Vesting of restricted stock awards and units962 10 — — (10)— — — 
Shares withheld to cover taxes(195)(2)— — (14,392)— — (14,394)
Stock-based compensation— — — — 50,507 — — 50,507 
Balance, December 31, 202369,863 $699 1,339 $(75,000)$757,727 $133,503 $(1,037)$815,892 


The accompanying notes are an integral part of these consolidated financial statements.
83
Lantheus Holdings, Inc.
Consolidated Statements of Cash Flows
(in thousands)
Year Ended December 31,
202320222021
Operating activities
Net income (loss)$326,661 $28,067 $(71,279)
Adjustments to reconcile net income (loss) to net cash flows from operating activities:
Depreciation, amortization and accretion60,043 47,929 42,288 
Impairment of long-lived assets138,050 — 9,729 
Asset retirement obligation acceleration— 280 5,259 
Gain on interest rate swap termination— (5,494)— 
Amortization of debt related costs4,300 1,249 676 
Changes in fair value of contingent assets and liabilities(9,275)34,700 72,400 
Charges incurred in connection with acquired IPR&D— 260,000 — 
Loss (gain) on extinguishment of debt— 588 (889)
Provision for excess and obsolete inventory7,914 7,145 4,057 
Stock-based compensation50,507 29,262 15,934 
Gain on disposal of assets(51,789)— (15,263)
Deferred taxes(55,632)(48,016)4,437 
Long-term indemnification receivable3,929 9,554 7,121 
Long-term income tax payable and other long-term liabilities(3,103)(12,477)(7,912)
Other4,855 4,059 2,512 
Changes in assets and liabilities which provided (used) cash:
Accounts receivable(68,637)(128,460)(33,102)
Inventory(36,220)(7,508)(3,549)
Other current assets(2,418)(2,440)(73)
Other long-term assets— (533)— 
Accounts payable17,189 301 5,425 
Accrued expenses and other liabilities(81,114)63,575 16,145 
Net cash provided by operating activities305,260 281,781 53,916 
Investing activities
Capital expenditures(46,555)(18,347)(12,140)
Proceeds from sale of assets, net97,839 1,800 15,823 
Acquisition of assets(45,345)(260,000)— 
Net cash provided by (used in) investing activities5,939 (276,547)3,683 
Financing activities
Proceeds from issuance of common stock1,933 1,375 767 
Debt issuance costs— (95)— 
Proceeds from issuance of long-term debt, net— 557,750 — 
Contingent value rights settlement(3,700)— — 
Payments on long-term debt and other borrowings(717)(175,385)(43,348)
Deferred financing costs— (2,315)— 
Proceeds from interest rate swap termination— 5,583 — 
Proceeds from stock option exercises3,816 7,537 5,295 
Payments for minimum statutory tax withholding related to net share settlement of equity awards(14,394)(7,759)(2,046)
Repurchase of common stock— (75,000)— 
Net cash (used in) provided by financing activities(13,062)311,691 (39,332)
Effect of foreign exchange rates on cash and cash equivalents(93)(335)(310)
Net increase in cash and cash equivalents and restricted cash298,044 316,590 17,957 
Cash and cash equivalents and restricted cash, beginning of year417,241 100,651 82,694 
Cash and cash equivalents and restricted cash, end of year$715,285 $417,241 $100,651 



84







Lantheus Holdings, Inc.
Consolidated Statements of Cash Flows (Continued)
(in thousands)
Year Ended December 31,
202320222021
Reconciliation to amounts within the consolidated balance sheets
Cash and cash equivalents$713,656 $415,652 $98,508 
Restricted cash included in other long-term assets1,629 1,589 2,143 
Cash, cash equivalents and restricted cash at end of period$715,285 $417,241 $100,651 
Year Ended December 31,
202320222021
Supplemental disclosure of cash flow information
Cash paid during the period for:
Interest$15,387 $5,064 $6,284 
Income taxes, net of refunds of $25, $50 and $315, respectively
$151,579 $54,049 $215 
Schedule of non-cash investing and financing activities
Additions of property, plant and equipment included in liabilities$6,978 $2,370 $1,262 
Right-of-use asset obtained in exchange for operating lease liabilities$29,396 $11,019 $683 


The accompanying notes are an integral part of these consolidated financial statements.
85
Lantheus Holdings, Inc.
Notes to Consolidated Financial Statements
1. Description of Business
Lantheus Holdings, Inc., a Delaware corporation, is the parent company of Lantheus Medical Imaging, Inc. (“LMI”) and LMI is the parent company of Progenics Pharmaceuticals, Inc., a Delaware corporation (“Progenics”), and Cerveau Technologies, Inc. (“Cerveau”). See “Progenics Acquisition” and “Acquisition of Assets”, respectively.
The Company develops, manufactures and commercializes innovative diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of cancer, heart disease and other diseases. The Company believes its diagnostic products result in improved diagnostic information that enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs throughout the healthcare system.
The Company’s commercial products are used by cardiologists, internal medicine physicians, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
The Company produces and markets its products throughout the U.S., selling primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies. The Company sells its products outside the U.S. through a combination of direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Sales of the Company’s prostate cancer diagnostic imaging agent, PYLARIFY (as defined below), are generated in the U.S. through an internal PYLARIFY sales team, as well as a sales team at some of the Company’s positron emission tomography (“PET”) manufacturing facilities (“PMF”) partners. Sales of the Company’s ultrasound enhancing agent, DEFINITY, are generated in the U.S. through an internal DEFINITY sales team. In the U.S., the Company’s other nuclear imaging products, including TechneLite, Xenon, NEUROLITE and CARDIOLITE, are primarily sold to commercial radiopharmacies, the majority of which are controlled by or associated with PharmaLogic, Cardinal, RLS, UPPI, and Jubilant Radiopharma. Research revenue is derived from existing partnerships with pharmaceutical companies that use our products and product candidates in clinical trials and includes milestone and dose-related payments. A small portion of the Company’s nuclear imaging product sales in the U.S. are generated through the Company’s internal sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical preparation capabilities.
In Europe, Australia, Asia-Pacific, Central America and South America, the Company generally relies on third-party distributors to market, sell and distribute its nuclear imaging and ultrasound enhancing agent products, either on a country-by-country basis or on a multi-country regional basis. The Company’s executive offices are located in Bedford, MA, with additional offices in North Billerica, MA, Somerset, NJ, Montreal, Canada and Lund, Sweden.
Progenics Acquisition
On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”).
In connection with the Progenics Acquisition, Lantheus Holdings issued 26,844,877 shares of Lantheus Holdings common stock and 86,630,633 contingent value rights (each a “CVR”) tied to the financial performance of PYLARIFY to former Progenics stockholders and option holders. Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of United States (“U.S.”) net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. The Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, was capped at 19.9% of the total consideration the Company paid in the Progenics Acquisition. Based on the Company’s 2022 PYLARIFY net sales, the Company determined that the aggregate payment obligation under the CVRs was $99.6 million, which was the maximum amount payable. The Company paid out this amount in May 2023 in full satisfaction of the CVRs.
2. Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
86
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, contingent assets and liabilities, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.
Revenue Recognition
The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services. See Note 3, “Revenue from Contracts with Customers” for further discussion on revenues.
Accounts Receivable, net
Accounts receivable consist of amounts billed and currently due from customers. The Company maintains an allowance for doubtful accounts for estimated losses. In determining the allowance, consideration includes the probability of recoverability based on past experience and general economic factors. Certain accounts receivable may be fully reserved when the Company becomes aware of any specific collection issues. The Company periodically reviews the aging of receivables, payment history and customer creditworthiness to determine if adjustments to the allowance for doubtful accounts is necessary. Allowance for doubtful accounts has been immaterial for all years presented.
Income Taxes
The Company accounts for income taxes using an asset and liability approach. Income tax (benefit) expense represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when such changes are enacted.
The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more-likely-than-not to be realized. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that the future tax benefit will not be realized. The assessment of whether or not a valuation allowance is required involves weighing both positive and negative evidence, including both historical and prospective information, with greater weight given to evidence that is objectively verifiable. A history of recent losses is negative evidence that is difficult to overcome with positive evidence. In evaluating prospective information there are four sources of taxable income: reversals of taxable temporary differences, items that can be carried back to prior tax years (such as net operating losses), pre-tax income, and prudent and feasible tax planning strategies. Adjustments to the deferred tax valuation allowances are made in the period when those assessments are made.
The Company accounts for uncertain tax positions using a two-step recognition threshold and measurement analysis method to determine the financial statement impact of uncertain tax positions taken or expected to be taken in a tax return. Differences between tax positions taken in a tax return and amounts recognized in the financial statements are recorded as adjustments to other long-term assets and liabilities, or adjustments to deferred taxes, or both. The Company records the related interest and penalties to income tax (benefit) expense.
Net Income (Loss) per Common Share
The Company computes earnings per share using the two-class method. Basic earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities as if those securities were converted or exercised. The Company’s potentially dilutive shares, which could include shares issuable upon conversion of the 2.625% Convertible Senior Notes due 2027 (the “Notes”), are considered to be common stock equivalents and are only included in the calculation of diluted net income per share when their effect is dilutive. The Company has the option to settle the Notes through cash settlement or a combination of cash and share settlement provided that the principal is settled in cash and the conversion spread is settled in cash or shares as elected by the Company. The Company applies the if-converted method for diluted earnings in order to reflect the conversion spread. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.
87
Cash and Cash Equivalents
Cash and cash equivalents include savings deposits, certificates of deposit and money market funds that have original maturities of three months or less when purchased.
Restricted Cash
Restricted cash as of December 31, 2023 and 2022, represents primarily collateral for a letter of credit securing a lease obligation and a security deposit. The Company believes the carrying value of these assets approximates fair value.
Concentration of Risks and Limited Suppliers
Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies.
As of December 31, 2023 and 2022, no customer accounted for greater than 10% of accounts receivable, net. No customer accounted for greater than 10% of revenues for the years ended December 31, 2023, 2022 and 2021.
The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.
The Company currently relies on JHS as its significant manufacturer of DEFINITY and its sole source manufacturer of NEUROLITE, CARDIOLITE and evacuation vials for TechneLite. The Company relies on Samsung Biologics Co., Ltd. (“SBL”) as its sole source manufacturer of DEFINITY RT. The Company has Mo-99 supply agreements with IRE of Belgium, running through December 31, 2024, with auto-renewal provisions and terminable upon notice of non-renewal, and with NTP and its subcontractor ANSTO, running through December 31, 2024.
The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:

Year Ended
December 31,
202320222021
PYLARIFY
65.7 %56.4 %10.2 %
DEFINITY21.6 %26.2 %54.7 %
TechneLite6.7 %9.5 %21.5 %
Inventory
Inventory includes material, direct labor and related manufacturing overhead and is stated at the lower of cost and net realizable value on a first-in, first-out basis. The Company records inventory when the Company takes title to the product.
The Company assesses the recoverability of inventory to determine whether adjustments for excess and obsolete inventory are required. Inventory that is in excess of future requirements is written down to its estimated net realizable value based on product shelf life, forecasted demand and other factors.
Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed as incurred. The Company had no inventory pending regulatory approval as of December 31, 2023.
Property, Plant and Equipment, net
Property, plant & equipment are stated at cost. Replacements of major units of property are capitalized, and replaced properties are retired. Replacements of minor components of property and repair and maintenance costs are charged to expense as incurred. Certain costs to obtain or develop computer software are capitalized and amortized over the estimated useful life of the software. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets and recorded
88
in costs of goods sold and operating expenses in the associated functional expense category which utilizes the associated asset. The estimated useful lives of the major classes of depreciable assets are as follows:

ClassRange of Estimated Useful Lives
Buildings
10 - 50 years
Land improvements
15 - 40 years
Machinery and equipment
3 - 15 years
Furniture and fixtures
15 years
Leasehold improvements
Lesser of lease term or 15 years
Computer software
3 - 5 years

Upon retirement or other disposal of property, plant & equipment, the cost and related amount of accumulated depreciation are removed from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds is included in operating income.
Included within machinery and equipment are spare parts. Spare parts include replacement parts relating to plant & equipment and are either recognized as an expense when consumed or reclassified and capitalized as part of the related asset and depreciated over the remaining useful life of the related asset.
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired IPR&D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.
During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition.
Goodwill
Goodwill is not amortized but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely-than-not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year.
In performing the Company’s annual assessment, the Company is permitted to first perform a qualitative test and if necessary, perform a quantitative test. If the Company is required to perform the quantitative impairment test of goodwill, the Company compares the fair value of a reporting unit to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting units using discounted cash flow or other valuation models, such as comparative transactions and market multiples. The Company performed a qualitative assessment and did not recognize any goodwill impairment charges during the years ended December 31, 2023, 2022 or 2021.
Intangible and Long-Lived Assets
89
The Company tests intangible and long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. The Company measures the recoverability of assets to be held and used by comparing the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If those assets are considered to be impaired, the impairment equals the amount by which the carrying amount of the assets exceeds the fair value of the assets. Any impairments are recorded as permanent reductions in the carrying amount of the assets. See Note 7, “Property, Plant and Equipment, Net” for further details on impairment. Long-lived assets, other than goodwill and other intangible assets that are held for sale are recorded at the lower of the carrying value or the fair market value less the estimated cost to sell.
Intangible assets, consisting of patents, trademarks, customer relationships, a currently marketed product, licenses and developed technology related to the Company’s products are amortized in a method equivalent to the estimated utilization of the economic benefit of the asset.
Costs of IPR&D intangible assets acquired as part of an asset acquisition that have no alternative future use are expensed when incurred. Milestone payments made after regulatory approval are capitalized as an intangible asset and amortized over an estimated useful life of the product. Cash payments related to acquired IPR&D intangible assets are reflected as an investing cash flow in the Company's consolidated statement of cash flows.
The Company’s IPR&D intangible assets includes intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. Because obtaining regulatory approval can include significant risks and uncertainties, the eventual realized value of the acquired IPR&D projects may vary from their fair value at the date of acquisition. The Company classifies IPR&D intangible assets acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, the Company will determine the useful life and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, the Company writes-off the remaining carrying amount of the associated IPR&D intangible asset. IPR&D intangible assets are tested at least annually as of October 31 or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in the Company’s consolidated statements of operations. See Note 10, “Intangibles, net and Goodwill” for further details on impairment.
Contingencies
In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, product and environmental liability. The Company records accruals for those loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized.
Convertible Notes
The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The change in fair value of any separately recognized derivative is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation.
Fair Values of Financial Instruments
The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The Company’s long-term debt has triggering events that would impact the fair value of the instruments. The Company determined that no triggering event has occurred during the years ended December 31, 2023 and December 31, 2022. As of December 31, 2023, the fair value of the Company’s convertible debt was estimated to be approximately $644.3 million based on external pricing data, including quoted market prices of these instruments and was classified as a Level 1 measurement within the fair value hierarchy. As of December 31, 2022, the carrying value of the Company’s convertible debt approximated fair value and was classified as a Level 1 measurement within the fair value hierarchy. The fair value See Note 4, “Fair Value of Financial Instruments”.
Contingent Consideration Liabilities
The estimated fair value of contingent consideration liabilities are initially measured and recorded on the acquisition date, are considered to be a Level 3 instrument and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations.
90
The estimated fair value is determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that include significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.
Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement.
The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based milestones, development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.
Derivative Instruments
The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged. Further, the Company must formally document the hedging relationship at inception and, on at least a quarterly basis, continually reevaluate the relationship to ensure it remains highly effective throughout the life of the hedge. The Company does not enter into derivative financial instruments for speculative or trading purposes.
Advertising and Promotion Costs
Advertising and promotion costs are expensed as incurred. During the years ended December 31, 2023, 2022 and 2021, the Company incurred $26.0 million, $26.0 million and $17.5 million, respectively in advertising and promotion costs, which are included in sales and marketing in the consolidated statements of operations.
Research and Development
Research and development costs are expensed as incurred and relate primarily to the development of new products to add to the Company’s portfolio and costs related to its medical affairs and medical information functions. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and recognized as an expense as the goods are delivered or the related services are performed.
Foreign Currency
The consolidated statements of operations of the Company’s foreign subsidiaries are translated into U.S. Dollars using weighted-average exchange rates. The net assets of the Company’s foreign subsidiaries are translated into U.S. Dollars using the end of period exchange rates. The impact from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive loss in the consolidated balance sheets.
Remeasurement of the Company’s foreign currency denominated transactions are included in net income. Transaction gains and losses are reported as a component of other loss (income) in the consolidated statements of operations.
Stock-Based Compensation
The Company’s stock-based compensation cost is measured at the grant date of the stock-based award based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period, and includes an estimate of the awards that will be forfeited. The Company estimates the fair value of each stock-based award on its measurement date using either the current market price of the stock, the Black-Scholes option valuation model or the Monte Carlo simulation valuation model, whichever is most appropriate. The Black-Scholes and Monte Carlo simulation valuation models incorporate assumptions such as stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield.
Expected volatility is based on the historical volatility of the Company’s stock price. The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the awards’ expected lives. Expected lives are principally based on the Company’s historical exercise experience with previously issued awards. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.
91
Expense for performance restricted stock awards is recognized based upon the fair value of the awards on the date of grant and the number of shares expected to vest based on the terms of the underlying award agreement and the requisite service period(s).
Other Loss (Income)
Other loss (income) consisted of the following:

 Year Ended
December 31,
(in thousands)202320222021
Foreign currency losses$21 $256 $274 
Tax indemnification expense, net4,943 9,554 7,121 
Interest income(19,638)(2,613)(45)
Interest rate swap termination— (5,494)— 
Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties(51,789)
Other143 — — 
Total other (income) loss $(66,320)$1,703 $7,350 

Comprehensive Income (Loss)
Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net income. For the Company, other comprehensive income (loss) consists of foreign currency translation gains and losses as well as realized and unrealized gains and losses on cash flow hedges related to the Company’s interest rate swaps. The accumulated other comprehensive income (loss) balance consists entirely of foreign currency translation gains and losses and realized and unrealized gains and losses on outstanding cash flow hedges related to the Company’s interest rate swaps.
Asset Retirement Obligations
The Company’s compliance with federal, state, local and foreign environmental laws and regulations may require it to remove or mitigate the effects of the disposal or release of chemical substances in jurisdictions where it does business or maintains properties. The Company establishes accruals when those costs are legally obligated and can be reasonably estimated. Accrual amounts are estimated, which may include the assistance of third-party environmental specialists, and are based on currently available information, regulatory requirements, remediation strategies, historical experience, the relative shares of the total remediation costs, a relevant discount rate, and the time periods of when estimated costs can be reasonably predicted. Changes in these assumptions could impact the Company’s future reported results.
The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts campus and its Somerset, New Jersey site. The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. The liability is measured at the present value of the obligation expected to be incurred and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the assets’ useful lives.
The Company has identified conditional asset retirement obligations related to the future removal and disposal of asbestos contained in certain of the buildings located on the Company’s North Billerica, Massachusetts campus. The Company believes the asbestos is appropriately contained and it is compliant with all applicable environmental regulations. If these properties undergo major renovations or are demolished, certain environmental regulations are in place, which specify the manner in which asbestos must be handled and disposed. The Company is required to record the fair value of these conditional liabilities if they can be reasonably estimated. As of December 31, 2023 and 2022, sufficient information was not available to estimate a liability for such conditional asset retirement obligations as the obligations to remove the asbestos from these properties have indeterminable settlement dates. As such, no liability for conditional asset retirement obligations has been recorded in the accompanying consolidated balance sheets as of December 31, 2023 and 2022.
92
Self-Insurance Reserves
The Company’s consolidated balance sheets at December 31, 2023 and 2022 include $1.0 million and $0.9 million of accrued liabilities associated with employee medical costs that are retained by the Company, respectively. The Company estimates the required liability of those claims on an undiscounted basis based upon various assumptions which include, but are not limited to, the Company’s historical loss experience and projected loss development factors. The required liability is also subject to adjustment in the future based upon changes in claims experience, including changes in the number of incidents (frequency) and change in the ultimate cost per incident (severity).
Recent Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company is currently in the process of evaluating the effects of this pronouncement on our related disclosures.
In December 2023, the FASB also issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on our related disclosures.
93
3. Revenue from Contracts with Customers
Revenue Recognition
Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services. To achieve this core principle, the Company applies the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the Company satisfies a performance obligation.
Disaggregation of Revenue
The following table summarizes revenue by revenue source as follows:
Year Ended December 31,
Major Products/Service Lines
(in thousands)		202320222021
    Product revenue, net(1)
$1,263,068 $887,038 $400,356 
    License and royalty revenues(2)
33,361 48,023 24,852 
Total revenues$1,296,429 $935,061 $425,208 
______________________________
(1)The Company’s product revenue includes PYLARIFY and DEFINITY, among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all of its principal products.
(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.
The Company classifies its revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology includes PYLARIFY and AZEDRA. In 2023, the Company announced its decision to discontinue the production and promotion of AZEDRA and it does not expect AZEDRA to contribute to the business after the first quarter of 2024. Precision Diagnostics includes DEFINITY, TechneLite and other diagnostic imaging products. Strategic Partnerships and Other Revenue includes strategic partnerships and other arrangements related to other products of the Company, including our royalty revenue from our license of RELISTOR. On August 2, 2023, the Company sold the RELISTOR royalty asset under its license agreement with Bausch; the Company retained the rights to future sales-based milestone payments. During the fourth quarter of 2023, the Company earned a $15.0 million sales-based milestone payment.
On January 31, 2022, the Company entered into a global settlement agreement with Novartis Pharma AG (“Novartis”), Advanced Accelerator Applications USA, Inc., Endocyte, Inc. and their affiliates (the “Novartis Agreement”) to settle certain disputes between the parties. Under the Novartis Agreement, Novartis agreed to make a lump sum payment to the Company, as well as to reimburse the Company for certain fees and expenses in connection with certain German litigation, and the Company agreed to license certain intellectual property to Novartis. In addition, the Company agreed to supply PYLARIFY for clinical purposes at an arms-length value which will be recorded revenue in the future as product is provided. In accordance with the Company's ASC 606, Revenue from Contracts with Customers, assessment, Novartis is considered to be a customer. The Company determined that the $24.0 million constituted a single element which was satisfied on the date of the execution of the Novartis Agreement. The Company determined that the license of intellectual property carried a fair value of $24.0 million. As such, the Company assigned the value to the fair value of the license, which constitutes the entire transaction price and does not require further allocation. The Company determined that the $24.0 million represented the point at which the licensee was able to use and benefit from the license and recognized revenue when the license was granted to Novartis upon execution of the Novartis Agreement. The Company recognized the $24.0 million fee as revenue on its consolidated statement of operations for the quarter ended March 31, 2022. The Company received the $24.0 million payment in April 2022.
Revenue by product category on a net basis is as follows:
94
Year Ended December 31,
(in thousands)202320222021
PYLARIFY$851,303 $527,405 $43,414 
Other radiopharmaceutical oncology3,130 4,102 5,473 
Total radiopharmaceutical oncology854,433 531,507 48,887 
DEFINITY279,768 244,993 232,759 
TechneLite87,370 88,864 91,293 
Other precision diagnostics22,980 22,825 26,973 
Total precision diagnostics390,118 356,682 351,025 
Strategic Partnerships and other revenue51,878 46,872 25,296 
Total revenues$1,296,429 $935,061 $425,208 
Product Revenue, Net
The Company sells its products principally to hospitals, independent diagnostic testing facilities, and radiopharmacies. The Company considers customer purchase orders, which in some cases are governed by master sales or group purchasing organization agreements, to be the contracts with a customer.
For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 60 days from invoicing, the Company has elected to use the significant financing component practical expedient.
The Company allocates the transaction price to each distinct product based on their relative standalone selling price. The product price as specified on the purchase order is considered the standalone selling price as it is an observable input which depicts the price as if sold to a similar customer in similar circumstances.
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which typically occurs upon delivery to the customer. Further, in determining whether control has transferred, the Company considers if there is a present right to payment and legal title, along with risks and rewards of ownership having transferred to the customer.
Frequently, the Company receives orders for products to be delivered over multiple dates that may extend across several reporting periods. The Company invoices for each delivery upon shipment and recognizes revenues for each distinct product delivered, assuming transfer of control has occurred.
The Company generally does not separately charge customers for shipping and handling costs, but any shipping and handling costs charged to customers are included in product revenue, net. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.
Variable Consideration
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the
95
Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect product revenue and earnings in the period such variances become known.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying consolidated balance sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. The Company estimates the amount of rebates and allowances that are explicitly stated in the Company’s contracts based on a combination of actual purchases and an estimate of the customer’s buying patterns.
Product Returns: The Company generally offers customers a limited right of return due to non-conforming product. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. Reserves for product returns are not significant to the Company due to the nature of its products including radiopharmaceutical products with limited half-lives.
An analysis of the amount of, and change in, reserves is summarized as follows:
(in thousands)Rebates and
Allowances
Balance, January 1, 2022$10,977 
Provision related to current period revenues26,683 
Adjustments relating to prior period revenues70 
Payments or credits made during the period(24,331)
Balance, December 31, 202213,399 
Provision related to current period revenues32,308 
Adjustments relating to prior period revenues(453)
Payments or credits made during the period(29,184)
Balance, December 31, 2023$16,070 
License and Royalty Revenues
The Company has entered into licensing agreements, under which it licenses certain rights to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. The Company also has distribution licenses which are treated as combined performance obligations with the delivery of its products and are classified as product revenue, net.
In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step approach stated earlier. The Company uses judgment in determining the number of performance obligations in a license agreement by assessing whether the license is distinct or should be combined with another performance obligation, as well as the nature of the license. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
96
Milestone Payments: At the inception of each arrangement that includes development or sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are outside the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and royalty revenues and earnings in the period of adjustment. At December 31, 2023, the variable consideration for the milestone payments is constrained and is excluded from contract price until the milestone is achieved by the customer.
Royalty Revenues: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
Contract Costs
The Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient to expense the costs as they are incurred, within sales and marketing expenses, since the amortization period is less than one year.
The Company recognized certain revenues as follows:
Year Ended December 31,
(in thousands)20232022
Amounts included in the contract liability at the beginning of the period$682 $244 
The Company did not record any revenue related to performance obligations satisfied (or partially satisfied) in previous periods during the years ended December 31, 2023 and 2022.
The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.
97
4. Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
•Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
•Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
•Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.
The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market.
The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:

 December 31, 2023
(in thousands)Total Fair
Value		Level 1Level 2Level 3
Assets:
Money market funds$574,131 $574,131 $— $— 
Total assets$574,131 $574,131 $— $— 
Liabilities:
Contingent consideration liabilities$2,700 $— $— $2,700 
Total liabilities$2,700 $— $— $2,700 
 December 31, 2022
(in thousands)Total Fair
Value		Level 1Level 2Level 3
Assets:
Money market funds$342,646 $342,646 $— $— 
Total assets$342,646 $342,646 $— $— 
Liabilities:
Contingent consideration liabilities$111,600 $— $— $111,600 
Total liabilities$111,600 $— $— $111,600 
During the years ended December 31, 2023 and 2022, there were no transfers into or out of Level 3. On December 2, 2022, the Company voluntarily terminated the interest rate swap contracts in connection with the refinancing of debt.
As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. (“CytoDyn”) related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions
98
pertaining to regulatory events and sales targets. During the fourth quarter of 2022, the Company reduced the probability to zero as CytoDyn withdrew their regulatory application. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.
As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum cap. Refer to Note 1, “Basis of Presentation” for further details on the CVRs. The Company paid out the maximum amount payable under the CVRs from available cash in May 2023 in full satisfaction of the CVR obligation.
The Company also assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 (also known as 131 I-MIP-1095) and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the 2013 Acquisition each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success.
Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities will be consistent with any recurring fair value estimate of such contingent consideration liabilities.
The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of liabilities using Level 3 inputs as of December 31, 2023.



99
Fair Value as ofAssumptions
(in thousands)December 31, 2023December 31, 2022Valuation TechniqueUnobservable InputDecember 31, 2023December 31, 2022
Contingent consideration liability:
Net sales targets – PYLARIFY (CVRs)N/A$99,700 Probability adjusted discounted cash flow modelPeriod of expected milestone achievement and sales targetsN/A2022 – 2023
Probability of successN/A100 %
1095 commercialization milestone1,800 1,700 Probability adjusted discounted cash flow model
Period of expected milestone achievement20262026
Probability of success40 %40 %
Discount rate4.1 %3.8 %
Net sales targets – AZEDRA and 1095900 10,200 Monte Carlo simulation
Probability of success and sales targets
0% - 40%
20% - 100%
Discount rate
15%
16% - 17%
Total$2,700 $111,600 
For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:

Financial AssetsFinancial Liabilities
(in thousands)Years Ended December 31,Years Ended December 31,
2023202220232022
Fair value, beginning of period$— $9,300 $111,600 $86,200 
Changes in fair value included in net income (loss)— (9,300)(9,275)25,400 
Cash Payments— — (99,625)— 
Fair value, end of period$— $— $2,700 $111,600 
The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in a general and administrative expense of $9.3 million for the year ended December 31, 2023 and was primarily due to changes in revenue forecasts, changes in market conditions, an increase in discount rates (excluding the CVRs) and the passage of time. The Company made the applicable cash payment related to the CVRs in May 2023.
100
5. Income Taxes
The components of income (loss) before provision (benefit) for income taxes consists of the following:
Year Ended
December 31,
(in thousands)202320222021
U.S.$410,326 $29,012 $(76,389)
International617 (2,293)1,351 
Income (loss) before income taxes$410,943 $26,719 $(75,038)
The Company’s provision (benefit) for income taxes consists of the following:
Year Ended
December 31,
(in thousands)202320222021
Current
Federal$110,108 $42,532 $— 
State29,806 4,302 (8,166)
International— (166)(30)
139,914 46,668 (8,196)
Deferred
Federal(45,252)(39,920)1,048 
State(10,739)(8,315)3,058 
International359 219 331 
(55,632)(48,016)4,437 
Income tax expense (benefit)$84,282 $(1,348)$(3,759)
The reconciliation of income taxes at the U.S. federal statutory rate to the income tax expense (benefit) is as follows:
Year Ended
December 31,
(in thousands)202320222021
U.S. statutory rate$86,298 $5,611 $(15,758)
Permanent items1,042 2,309 1,764 
Sale of RELISTOR licensed intangible asset associated with net sales royalties(10,817)— — 
Section 162(m)307 247 1,028 
Uncertain tax positions(5,045)(12,629)(8,952)
Tax credits(2,118)(4,085)(990)
State and local taxes18,726 67 656 
Impact on deferred taxes of change in tax rate(330)4,169 3,049 
Changes in fair value of contingent assets and liabilities(1,948)5,422 15,015 
Foreign tax rate differential128 68 23 
Valuation allowance(4)(30)(400)
Stock compensation(3,941)(4,612)(1,164)
Change in indemnification deferred tax asset1,240 2,343 1,786 
Other744 (228)184 
Income tax expense (benefit)$84,282 $(1,348)$(3,759)
The components of deferred income tax assets (liabilities) are as follows:
101
December 31,
(in thousands)20232022
Deferred Tax Assets
Federal benefit of state taxes payable$263 $1,739 
Reserves, accruals and other18,923 31,532 
Inventory obsolescence— 919 
Capitalized research and development17,142 79,946 
Stock compensation9,266 — 
Intangible assets25,214 — 
Net operating loss carryforwards80,184 88,014 
Lease liability14,365 — 
Deferred tax assets165,357 202,150 
Deferred Tax Liabilities
Reserves, accruals and other— (5,354)
Right-of-use asset(11,543)— 
Intangible assets— (80,770)
Amortization of intangibles other than goodwill— (385)
Depreciation— (1,469)
Deferred tax liability(11,543)(87,978)
Less: valuation allowance(3,616)(3,525)
$150,198 $110,647 
Recorded in the accompanying consolidated balance sheets as:
Noncurrent deferred tax assets, net$150,198 $110,647 
The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. Under the Act, research and experimental expenditures incurred for tax years beginning after December 31, 2021, must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on where the research activities are conducted. If the requirement to capitalize Section 174 expenditures is not modified, it may impact our cash tax liability in future years. The increase in worldwide net deferred tax assets is primarily due to the tax capitalization of the Company’s current year research and development expenses that are not currently deductible in 2023 and the decrease in deferred tax liabilities related to the AZEDRA and RELISTOR royalty intangible assets, partially offset by utilization of net operating losses.
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence. As of December 31, 2023 and 2022, the Company maintains a valuation allowance of $3.6 million and $3.5 million, respectively, primarily related to net deferred tax assets of certain of its foreign subsidiaries.
Utilization of net operating loss carryforwards and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 (“IRC Section 382”) and with Section 383 of the Internal Revenue Code of 1986, as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards and research and development credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change, as defined by IRC Section 382, results from transactions which impact the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.
At December 31, 2023, the Company had U.S. federal net operating loss carryforwards of approximately $297.6 million, $157.9 million of which will expire between 2027 and 2037, and $139.6 million of which can be carried forward indefinitely. The Company’s state net operating losses are $12.5 million on a tax-effected basis, which will expire between 2024 and 2040. The Company has state research credit carryforwards of $2.1 million, which will expire between 2026 and 2038. The Company has state investment tax credit carryforwards of $0.8 million which have no expiration date.
102
The Company’s U.S. federal income tax returns are subject to examination for three years after the filing date of the return. The state and foreign income tax returns are subject to examination for periods varying from three to four years after filing, depending on the specific jurisdiction’s statutes of limitation, and in the case of Sweden, up to six years after the end of the financial year.
A reconciliation of the Company’s changes in uncertain tax positions for 2023 and 2022 is as follows:
(in thousands)Amount
Balance of uncertain tax positions as of January 1, 2021$5,292 
  Additions related to current year tax positions— 
  Reductions related to prior year tax positions(188)
  Settlements(1,446)
  Lapse of statute of limitations— 
Balance of uncertain tax positions as of December 31, 20213,658 
   Additions related to current year tax positions— 
   Reductions related to prior year tax positions(1,180)
   Settlements(306)
   Lapse of statute of limitations(692)
Balance of uncertain tax positions as of December 31, 20221,480 
   Additions related to current year tax positions3,749 
   Reductions related to prior year tax positions(688)
   Settlements(442)
   Lapse of statute of limitations— 
Balance of uncertain tax positions as of December 31, 2023$4,099 
In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into an indemnification agreement with BMS for any payments made to settle those uncertain tax positions with the taxing authorities.
In accordance with the Company’s accounting policy, the change in the tax liability, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change, adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities. Included in other (income) loss for the years ended December 31, 2023, 2022 and 2021, is tax indemnification expense (income), net of $4.9 million, $9.6 million and $7.1 million, respectively.
As of December 31, 2023 and 2022, total liabilities for uncertain tax positions including interest and penalties were $5.4 million and $8.3 million, respectively, consisting of uncertain tax positions of $4.1 million and $1.5 million, respectively, interest accruals of $1.3 million and $6.4 million, respectively, and no penalty accruals as of December 31, 2023 and $0.4 million of penalty accruals as of December 31, 2022. The increase in uncertain tax positions during the year ended December 31, 2023 was primarily related to certain acquired tax attributes. As of December 31, 2023, $1.3 million, $3.2 million, and $0.9 million of these liabilities were recorded in current liabilities, other long-term liabilities, and as a reduction of deferred tax assets, respectively. As of December 31, 2022 these liabilities were included in other long-term liabilities. Included in the 2023, 2022 and 2021 tax provisions are benefits of $5.0 million, $12.6 million and $9.0 million, respectively, relating to reversals of uncertain tax positions recognized upon settlements, effective settlements, or lapses of relevant statutes of limitation, partially offset by interest accruals.

103
6. Inventory
Inventory consisted of the following:

December 31,
(in thousands)20232022
Raw materials$31,259 $19,987 
Work in process13,807 8,234 
Finished goods18,963 7,254 
Total inventory$64,029 $35,475 
Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. The Company has no inventory pending regulatory approval as of December 31, 2023.
7. Property, Plant and Equipment, Net
Property, plant and equipment, net, consisted of the following:
 December 31,
(in thousands)20232022
Land$9,480 $13,450 
Buildings73,441 76,329 
Machinery, equipment and fixtures102,576 92,604 
Computer software27,259 25,864 
Construction in progress40,964 14,047 
253,720 222,294 
Less: accumulated depreciation and amortization(107,023)(100,128)
Total property, plant and equipment, net$146,697 $122,166 
Depreciation and amortization expense related to property, plant & equipment, net, was $13.2 million, $13.7 million and $13.2 million for the years ended December 31, 2023, 2022 and 2021, respectively.
The Company tests long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. During the year ended December 31, 2021, the Company reviewed certain facts relating to an asset group that included the right-of-use (“ROU”) asset associated with the lease of office space in the World Trade Center (the “WTC lease”) in New York City and resulted in a change to the asset group due to the negotiation of a sublease. Please refer to Note 16, “Leases” for further details.
During the three months ended June 30, 2023, as a result of a decline in expected future cash flows related to a certain asset group, the Company determined certain impairment triggers had occurred. The Company reviewed revised undiscounted cash flows that were estimated to be generated by the asset group as of June 30, 2023. Based on the undiscounted cash flow analysis, the Company determined that the asset group had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on their discounted cash flows. The carrying value exceeded the fair value and as a result, the Company recorded a noncash impairment of $6.0 million for the six months ended June 30, 2023 in cost of goods sold in the consolidated statements of operations.
Long-Lived Assets Held for Sale
During the first quarter of 2023, the Company committed to a plan to sell a portion of its land and buildings associated with its Billerica, Massachusetts campus. Effective March 16, 2023, the Company entered into a purchase and sale agreement (the “P&S”) with a prospective buyer. The assets were classified as held for sale and comprised entirely of property, plant and equipment, net. The Company determined that the fair value of the net assets being sold exceeded the carrying value as of September 30, 2023. The purchase price for the campus sale is $10.0 million in cash. The transaction is expected to close in the second or third quarter of 2024.

104
8. Sale of Puerto Rico Subsidiary
During the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021.
The purchase price for the stock sale was $18.0 million in cash, which included a holdback amount of $1.8 million that was remitted to the Company as of December 31, 2021, and paid in the first quarter of 2022; the purchase price also included a working capital adjustment. The SPA contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA.
The Company determined that this sale of certain net assets did not constitute a strategic shift that had a major effect on the Company’s operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s accompanying consolidated financial statements.
The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income (loss) in the consolidated statements of operations for the year ended December 31, 2021.
9. Asset Retirement Obligations
The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and Somerset, New Jersey sites. As of December 31, 2023, the liability is measured at the present value of the obligation expected to be incurred, of approximately $25.1 million.
The following table provides a summary of the changes in the Company’s asset retirement obligations:

(in thousands)Amount
Balance, January 1, 2022$20,833 
Change in useful life estimate280 
Accretion expense1,430 
Balance, December 31, 202222,543 
Accretion expense373 
Balance, December 31, 2023$22,916 
The Company is required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts and Somerset, New Jersey production facilities, respectively, upon closure. The Company has provided this financial assurance in the form of a $30.3 million surety bond.
105
10. Intangibles, Net and Goodwill
Intangibles, net, consisted of the following:
 December 31, 2023
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 – 25
Straight-Line$13,540 $(12,216)$1,324 
Customer relationships
15 – 25
Accelerated157,995 (117,574)40,421 
Currently marketed product
9 – 15
Straight-Line132,800 (38,277)94,523 
Licenses
11 – 16
Straight-Line22,233 (7,972)14,261 
Developed technology9Straight-Line2,400 (944)1,456 
Total$328,968 $(176,983)$151,985 

December 31, 2022
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 – 25
Straight-Line$13,540 $(12,061)$1,479 
Customer relationships
15 – 25
Accelerated96,681 (95,009)1,672 
Currently marketed product
9 – 15
Straight-Line275,700 (47,628)228,072 
Licenses
11 – 16
Straight-Line85,800 (19,101)66,699 
Developed technology9Straight-Line2,400 (677)1,723 
IPR&DN/AN/A15,640 — 15,640 
Total$489,761 $(174,476)$315,285 
The Company recorded amortization expense for its intangible assets of $46.4 million, $33.2 million and $27.5 million for the years ended December 31, 2023, 2022 and 2021, respectively.
In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset.
On August 2, 2023, the Company sold the right to its RELISTOR royalty asset under its license agreement with Bausch; the Company retained the rights to future sales-based milestone payments. The Company received an initial payment of approximately $98.0 million in connection with the sale and has the right to receive an additional payment from the buyer of $5.0 million if worldwide net sales of RELISTOR in 2025 exceed a specified threshold. The additional payment would be recognized upon achievement of the specified threshold. Decreases of $63.6 million of license assets and $17.5 million of associated accumulated amortization, as well as a gain of $51.8 million were recorded as a result of the sale. During the fourth quarter of 2023, the Company earned a $15.0 million sales-based milestone payment.
In March 2023, the Company stopped all development activities in relation to a future indication associated with AZEDRA, which was classified as an IPR&D intangible asset. The asset group, which consisted of the IPR&D asset and a currently marketed product (the “AZEDRA intangible asset group”), was assessed for impairment. The Company considered several factors in estimating the future projections of revenues and cash flows of the AZEDRA intangible asset group as part of the impairment testing. The Company concluded that the carrying amount exceeded the fair value of the AZEDRA intangible asset group, which had no value. The Company recorded a non-cash impairment charge of $15.6 million in research and development expenses relating to the IPR&D asset and $116.4 million in cost of goods sold relating to the currently marketed indication of AZEDRA in the consolidated statement of operations for the year ended December 31, 2023.
On August 15, 2023, the Company announced that it had made the decision to discontinue the production and promotion of AZEDRA and would be winding down its Somerset, New Jersey manufacturing site. The Company will continue manufacturing AZEDRA into the first quarter of 2024, to the extent feasible, with the goal of providing doses of AZEDRA to current patients so they can complete their treatment regimen. See Note 7, “Property, Plant and Equipment, Net” for impairment analysis.
In February 2023, the Company entered into an agreement with the stockholders of Cerveau to purchase all of the outstanding capital stock of Cerveau for approximately $35.3 million. In May 2023, upon successful completion of a technology transfer, the Company paid $10.0 million to the selling stockholders of Cerveau. This additional contingent payment was capitalized as part of the
106
asset cost and increased the Company’s customer relationship intangible assets. See Note 21, “Acquisition of Assets” for further discussion of the Cerveau acquisition.
The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:
(in thousands)Amount
2024$39,726 
202524,409 
202625,206 
202719,680 
202816,195 
2029 and thereafter 26,769 
Total$151,985 
11. Accrued Expenses and Other Liabilities and Other Long-Term Liabilities
Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:
 December 31,
(in thousands)20232022
Compensation and benefits$36,331 $30,425 
Freight, distribution and operations67,529 49,067 
Accrued rebates, discounts and chargebacks16,070 13,399 
Accrued professional fees10,244 8,668 
Other15,164 25,525 
Total accrued expenses and other liabilities$145,338 $127,084 
Operating lease liabilities (Note 16)$54,453 $25,442 
Long-term contingent liability (Note 4)2,700 11,900 
Other long-term liabilities6,168 8,813 
Total other long-term liabilities$63,321 $46,155 

12. Long-Term Debt, Net, and Other Borrowings
As of December 31, 2023, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:
(in thousands)Amount
2024$— 
2025— 
2026— 
2027575,000 
2028— 
Total principal outstanding575,000 
Unamortized debt issuance costs(13,955)
Finance lease liabilities1,448 
Total562,493 
Less: current portion(823)
Total long-term debt, net, and other borrowings$561,670 
In December 2022, the Company refinanced its existing credit facility, consisting of (i) a $200.0 million five-year term loan facility (the “2019 Term Facility”) and (ii) a $200.0 million five-year revolving credit facility (the “2019 Revolving Facility” and, together with the 2019 Term Facility, the “2019 Facility”), with a new $100.0 million delayed draw term loan facility (the “2022 Term
107
Facility” and, the loans thereunder, the “Term Loans”) and a new $350.0 million five-year revolving credit facility (the “2022 Revolving Facility” and, together with the 2022 Term Facility, the “2022 Facility”).
The Company used approximately $7.8 million of cash on hand to primarily repay the principal amount of the loans outstanding related to the 2019 Facility through the nine months ended September 30, 2022. In addition, in December 2022, the Company used approximately $167.6 million of cash on hand to repay in full the aggregate remaining principal amount of the loans outstanding under the 2019 Facility and to pay related interest, transaction fees and expenses.
The Company paid off the 2019 Term Facility using available cash and did not utilize another term loan to fund the payoff. While the 2022 Term Facility allowed for a delayed draw term loan, the loan was not drawn upon. The Company recorded a loss on extinguishment of debt of $0.6 million related to the write-off of unamortized debt issuance costs and debt discounts associated with the 2019 Term Facility. In addition, the Company incurred and capitalized $2.7 million of new deferred financing costs related to the refinancing.
2022 Revolving Facility
Under the terms of the 2022 Revolving Facility, the lenders are committed to extending credit to the Company from time to time until December 2, 2027 consisting of revolving loans (the “Revolving Loans”) in an aggregate principal amount not to exceed $350.0 million (the “Revolving Commitment”) at any time, including a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”) and a $10.0 million sub-facility for swingline loans (the “Swingline Loans”). The Letters of Credit, Swingline Loans and the Revolving Loans, if used, are expected to be used for working capital and for other general corporate purposes.
The Revolving Loans bear interest, with pricing based from time to time at the Company’s election, at (i) the secured overnight financing rate as published by the Federal Reserve Bank of New York on its website plus an applicable margin that ranges from 1.50% to 2.50% based on the Company’s total net leverage ratio or (ii) the alternative base rate plus an applicable margin that ranges from 0.50% to 1.50% based on the Company’s total net leverage ratio. The 2022 Revolving Facility also includes an unused commitment fee at a rate ranging from 0.15% to 0.35% per annum based on the Company’s total net leverage ratio.
The Company is permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans, Letters of Credit and Swingline Loans exceeds the total Revolving Commitment, the Company must prepay the Revolving Loans in an amount equal to such excess. The Company is not required to make mandatory prepayments under the 2022 Revolving Facility. As of December 31, 2023, there were no outstanding borrowings under the 2022 Revolving Facility.
The Company has the right to request an increase to the Revolving Commitment in an aggregate principal amount of up to the sum of $335.0 million or consolidated EBITDA for the four consecutive fiscal quarters most recently ended, plus additional amounts in certain circumstances (collectively, the “Incremental Cap”), minus certain incremental term loans made pursuant to specified incremental term loan commitments (“Incremental Term Loans”). The Company has the right to request Incremental Term Loans in an aggregate principal amount of up to the Incremental Cap less any incremental increases to the Revolving Commitment. Proceeds of Incremental Term Loans may be used for working capital and for other general corporate purposes and will bear interest at rates agreed between the Company and the lenders providing the Incremental Term Loans.
2022 Facility Covenants
The 2022 Facility contains a number of affirmative, negative and reporting covenants, as well as financial maintenance covenants pursuant to which the Company is required to be in quarterly compliance, measured on a trailing four quarter basis, with two financial covenants. The minimum interest coverage ratio, commencing with the fiscal quarter ended December 31, 2022, must be at least 3.00 to 1.00. The maximum total net leverage ratio permitted by the financial covenant, commencing with the fiscal quarter ending March 31, 2024, is 3.50 to 1.00.
The 2022 Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.
Upon an event of default, the Administrative Agent will have the right to declare the loans and other obligations outstanding under the 2022 Facility immediately due and payable and all commitments immediately terminated.
The 2022 Facility is guaranteed by Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus MI Real Estate, LLC, and obligations under the 2022 Facility are generally secured by first priority liens over substantially all of the assets of each of
108
LMI, Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus MI Real Estate, LLC (subject to customary exclusions set forth in the transaction documents) owned as of December 2, 2022 or thereafter acquired.
Convertible Notes
On December 8, 2022, the Company issued $575.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027 (the “Notes”), which includes $75.0 million in aggregate principal amount of Notes sold pursuant to the full exercise of the initial purchasers’ option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among the Company, LMI (the “Guarantor”), a wholly owned subsidiary of the Company, as Guarantor, and U.S. Bank Trust Company, National Association, as Trustee. The net proceeds from the issuance of the Notes were approximately $557.8 million after deducting the initial purchasers’ discounts and offering expenses payable by the Company.
The Notes are senior unsecured obligations of the Company. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Guarantor. The Notes bear interest at a rate of 2.625% per year, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023, and will mature on December 15, 2027 unless earlier redeemed, repurchased or converted in accordance with their terms. The initial conversion rate for the Notes is 12.5291 shares of the Company’s common stock per $1,000 in principal amount of Notes (which is equivalent to an initial conversion price of approximately $79.81 per share of the Company’s common stock, representing an initial conversion premium of approximately 42.5% above the closing price of $56.01 per share of the Company’s common stock on December 5, 2022). In no event shall the conversation rate per $1,000 in principal amount of notes exceed 17.8539 shares of the Company’s common stock. Prior to the close of business on the business day immediately preceding September 15, 2027, the Notes may be converted at the option of the holders only upon occurrence of specified events and during certain periods, and thereafter until the close of business on the business day immediately preceding the maturity date, the Notes may be converted at any time. The Company will satisfy any conversion by paying cash up to the aggregate principal amount of the Notes to be converted and by paying or delivering, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Company may redeem for cash all or any portion of the Notes, at its option, on or after December 22, 2025 if the closing sale price per share of the Company’s common stock exceeds 130% of the conversion price of the Notes for a specified period of time. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
The Company evaluated the Notes upon completion of the sale and concluded on the following features:
•Conversion Feature: The Company determined that the conversion feature qualifies for the classification of equity. As a result, the conversion feature should not be bifurcated as a derivative instrument and the Notes were accounted for as a single liability.
•Redemption Features: The redemption features were reviewed within the Notes and the Company determined that the redemption features are closely related to the Notes and as such should not be separately accounted for as a bifurcated derivative instrument.
•Additional Interest Features: The Notes may result in additional interest if the Company fails to timely file any document or report that the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The Company will pay additional interest on the notes at a rate equal to 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day the Company failure to file has occurred or the notes are not otherwise freely tradable. Further, if the notes are assigned a restricted CUSIP number or the notes are not otherwise freely tradable pursuant to Rule 144 under the Securities Act by holders other than our affiliates or holders that were our affiliates at any time during the three months immediately preceding as of the 385th day after the last date of original issuance of the notes offered hereby, the Company will pay additional interest on the notes at a rate equal to (i) 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day until the restrictive legend has been removed from the notes, the notes are assigned an unrestricted CUSIP and the notes are freely tradable. The Company concluded that the interest feature is unrelated to the credit risk and should be bifurcated from the Notes, however, the Company assessed the probabilities of triggering events occurring under these features and does not expect to trigger the aforementioned events. These events will continue to be monitored to determine whether the interest feature will be bifurcated if it has value.
As of December 31, 2023, the carrying value of the Notes was $575.0 million, had an unamortized discount of zero, and the fair value of the liability was $575.0 million. The Company recorded interest expense of approximately $15.1 million related to the Notes for the year ended December 31, 2023.
13. Derivative Instruments
109
The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps was approximately 0.82%. This agreement involved the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s consolidated balance sheets at fair value, and changes in the fair value of the swap agreements were recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur.
On December 2, 2022, the Company voluntarily terminated the interest rate swap contracts in connection with the refinancing of debt. Upon termination, the Company received approximately $5.6 million in cash and the remaining balance of approximately $5.5 million in accumulated other comprehensive income (loss) related to the interest rate swap contracts were reclassified into earnings.
14. Accumulated Other Comprehensive Loss
The components of Accumulated Other Comprehensive Loss, net of tax of zero and zero for the year ended December 31, 2023 and 2022, respectively, consisted of the following:

(in thousands)Foreign currency translationUnrealized loss on cash flow hedgesAccumulated other comprehensive loss
Balance at January 1, 2023$(1,259)$— $(1,259)
Other comprehensive income (loss) before reclassifications222 — 222 
Balance at December 31, 2023$(1,037)$— $(1,037)
Balance at January 1, 2022$(754)$269 $(485)
Other comprehensive income (loss) before reclassifications(505)5,838 5,333 
Amounts reclassified to earnings— (6,107)(6,107)
Balance at December 31, 2022$(1,259)$— $(1,259)

15. Stock-Based Compensation
Equity Incentive Plans
As of December 31, 2023, the Company’s approved equity incentive plans included the 2015 Equity Incentive Plan (“2015 Plan”), the 2013 Equity Incentive Plan (“2013 Plan”), and the 2008 Equity Incentive Plan (“2008 Plan”). These plans are administered by the Board of Directors and permit the granting of stock options, stock appreciation rights, restricted stock, restricted stock units and dividend equivalent rights to employees, officers, directors and consultants of the Company.
The Company has certain stock option and restricted stock awards outstanding under each of its equity incentive plans but, upon adoption of the 2015 Plan, no longer grants new equity awards under its 2008 and 2013 Plans. The Company adopted its 2015 Plan in June 2015 and subsequently amended the plan in April 2016, 2017, 2019, 2021 and 2022 which increased the common stock reserved for issuance under the plan to an aggregate 10,930,277 shares. The Company assumed Progenics equity plans due to the acquisition as discussed in Note 1, “Description of Business”. The Company no longer grants new equity awards under the Progenics equity plans.
110
Stock-based compensation expense recognized in the consolidated statements of operations is summarized below:
Year Ended
December 31,
(in thousands)202320222021
Cost of goods sold$9,126 $4,422 $2,370 
Sales and marketing9,500 6,185 2,472 
General and administrative24,807 14,876 9,092 
Research and development7,074 3,779 2,000 
Total stock-based compensation expense$50,507 $29,262 $15,934 
Stock Options
Stock option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. All option awards have a ten-year contractual term.
A summary of option activity for 2023 is presented below:
Total
Stock
Options		Weighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term
(Years)		Aggregate
Intrinsic
Value
Balance at January 1, 2023874,749 $30.37 5.819,058,224 
Options granted332,368 $76.41 
Options exercised(214,619)$19.02 
Options cancelled and forfeited(35,326)$51.30 
Outstanding at December 31, 2023957,172 $48.13 6.718,283,464 
Vested and expected to vest at December 31, 2023957,172 $48.13 6.718,283,464 
Exercisable at December 31, 2023466,039 $26.99 4.416,462,767 
The table below summarizes the key weighted-average assumptions used in valuing stock options granted:
Year Ended December 31,
202320222021
Expected volatility56.1 %62.1 %— %
Risk-free interest rate4.0 %2.0 %— %
Expected life (in years)6.06.0—
Expected dividend yield———
During the years ended December 31, 2023, 2022 and 2021, 214,619, 397,822 and 318,662 options were exercised having aggregate intrinsic values of $12.9 million, $13.1 million and $1.6 million, respectively.
As of December 31, 2023, there was $13.2 million of unrecognized compensation expense related to outstanding stock options, which is expected to be recognized over a weighted-average period of 2.0 years.
111
Restricted Stock
A summary of restricted stock awards and restricted stock units activity for 2023 is presented below:
SharesWeighted-
Average Grant
Date Fair Value Per Share
Nonvested balance at January 1, 20231,249,992 $34.65 
Granted710,985 $74.38 
Vested(612,912)$29.78 
Forfeited(137,806)$50.36 
Nonvested balance at December 31, 20231,210,259 $58.71 
Restricted stock generally vest over 3 years. As of December 31, 2023, there was $48.4 million of unrecognized compensation expense related to outstanding restricted stock, which is expected to be recognized over a weighted-average period of 2.0 years.
The weighted average grant-date fair value for restricted stock granted during the fiscal years ended December 31, 2023, 2022 and 2021 was $74.38, $51.51 and $20.14 per share, respectively. The total fair value of restricted stock vested in fiscal years 2023, 2022 and 2021 was $18.3 million, $11.9 million and $8.8 million, respectively.
Total Stockholder Return Restricted Stock Awards (“TSR Awards”)
During the years ended December 31, 2023, 2022 and 2021, the Company granted total stockholder return (“TSR”) Awards that include a three-year market condition where the performance measurement period is three years. Vesting of the TSR Awards is based on the Company’s level of attainment of specified TSR targets relative to the percentage appreciation of a specified index of companies for the respective three-year period and is also subject to the continued employment of the grantees. The number of shares that are earned over the performance period ranges from 0% to 200% of the initial award. The fair value of these awards are based on a Monte Carlo simulation valuation model with the following assumptions:
Year Ended December 31,
202320222021
Expected volatility52.8 %56.6 %54.0 %
Risk-free interest rate4.6 %1.7 %30.0 %
Expected life (in years)2.82.82.8
Expected dividend yield———
A summary of TSR Award activity for 2023 is presented below:
SharesWeighted-
Average Grant
Date Fair Value Per Share
Nonvested balance at January 1, 2023658,875 $48.58 
Granted365,478 $127.75 
Vested(348,302)$23.43 
Forfeited(45,997)$57.77 
Nonvested balance at December 31, 2023630,054 $78.91 
As of December 31, 2023, there was $26.2 million of unrecognized compensation expense related to outstanding performance restricted stock which is expected to be recognized over a weighted-average period of 2.0 years.
The weighted average grant-date fair value for TSR Awards granted during the fiscal years ended December 31, 2023, 2022 and 2021 was $127.75, $95.31 and $31.25 per share, respectively. The total fair value of TSR Awards vested in fiscal years 2023, 2022 and 2021 was $8.2 million, $8.8 million and $2.0 million, respectively.
Common Stock Repurchases
112
In December 2022, the Company’s Board of Directors authorized the repurchase of up to $150.0 million in aggregate amount of the Company’s common stock under certain circumstances. The Company used approximately $75.0 million of the net proceeds from the Notes to repurchase shares of their common stock from purchasers of the Notes in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate. The purchase price per share of the common stock repurchased in such transactions was equal to the closing sale price per share of the Company’s common stock on the date of the offering memorandum used for the Notes, which was $56.01 per share. Following this initial repurchase, the Company may from time to time repurchase additional shares of their common stock. In the year ended December 31, 2022, the Company purchased approximately 1.3 million shares of their outstanding common stock for $75.0 million as part of the program. The Company did not purchase any shares of its outstanding common stock in the year ended December 31, 2023.
16. Leases
The Company determines if an arrangement is a lease at inception. The Company has operating and finance leases for vehicles, corporate offices and certain equipment.
Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease agreements with lease and non-lease components are accounted for separately. As the Company’s leases do not provide an implicit rate, the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
The Company assumed two operating leases as a result of the Progenics acquisition related to office space at the World Trade Center in New York City, pursuant to a lease agreement expiring in September 2030 (the “WTC Lease”), and a radiopharmaceutical manufacturing facility in Somerset, New Jersey, under a sublease agreement expiring in November 2028, which were recorded as of June 19, 2020, for $18.6 million and $0.6 million, respectively. The Company entered into an operating lease related to office space in Somerset, New Jersey, under a lease agreement expiring in August 2026, which was recorded in October 2021 for $0.7 million. The Company entered into an operating lease agreement in February 2022 to lease office space in Bedford, Massachusetts, under a lease agreement expiring in June 2031, which commenced and was recorded in December 2022 for $11.0 million.
On May 4, 2023, the Company entered into a modification to the operating lease for office space in Bedford, Massachusetts, (the “Existing Premises”) that was executed in February 2022. The lease commenced and was recorded in December 2022 for $11.0 million and the initial term was set to expire in June 2031. The lease modification includes a lease of additional office and laboratory space at the Bedford location (the “Additional Premises”) for a term of 15 years and 4 months and extends the term of the lease for the Existing Premises to be coterminous with the term of the lease for the Additional Premises. As a result of the extended term for the Existing Premises, the Company recorded an additional right-of-use asset and liability of $6.0 million in May 2023. The modification also contains a provision to convert the rent schedule of the Existing Premises from gross to triple net in 2024, which may result in an additional adjustment to the right-of-use asset and liability. In September 2023, the landlord provided notice to the Company that its renovations of the Additional Premises were completed. As a result of the notice, the Company recorded an additional right-of-use asset and liability of $23.5 million as of September 1, 2023. To determine the value of the additional right-of-use asset and liability, the Company was required to calculate the discount rate of the lease modification. The discount rate was determined based on the expected lease term and by comparing interest rates in the market for similar borrowings with comparable credit quality of the Company. The lease for the Additional Premises allows for the extension of five years to begin immediately upon the expiration of the original term.
Leases with an initial term of 12 months or less are not recorded on the balance sheet as the Company has elected to apply the short-term lease exemption. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.
Operating and finance lease assets and liabilities are as follows:
113
(in thousands)ClassificationDecember 31, 2023December 31, 2022
Assets
OperatingOther long-term assets$45,325 $19,033 
FinanceProperty, plant and equipment, net1,438 582 
Total leased assets$46,763 $19,615 
Liabilities
Current
     OperatingAccrued expenses and other liabilities$1,904 $2,177 
     FinanceCurrent portion of long-term debt and other borrowings823 354 
Noncurrent
     OperatingOther long-term liabilities54,453 25,442 
     FinanceLong-term debt, net and other borrowings625 231 
Total leased liabilities$57,805 $28,204 
In the third quarter of 2021, with respect to the office space in the World Trade Center, the Company negotiated a sublease agreement with an unrelated third party that was signed on October 11, 2021 (the “Sublease”) and has a term of nine years, which represents the remaining term of the WTC Lease. Both the WTC Lease and the Sublease are classified by the Company as operating leases. As a result of the negotiations of the Sublease, the Company determined that an impairment triggering event had occurred. Accordingly, the Company performed an undiscounted cash flow analysis related to the asset group as of September 30, 2021. Based on the undiscounted cash flow analysis, the Company determined that the asset group, including the ROU asset, had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on its discounted cash flows. The carrying value exceeded the fair value and, as a result, the Company recorded a non-cash impairment of $9.5 million for the year ended December 31, 2021 in general and administrative expenses in the consolidated statements of operations.
The components of lease expense were as follows:
 
(in thousands)Year Ended
December 31, 2023		Year Ended
December 31, 2022
Operating lease expense$4,627 $1,797 
Finance lease expense
      Amortization of ROU assets795 426 
      Interest on lease liabilities81 28 
Total lease expense$5,503 $2,251 
114
Other information related to leases were as follows:
December 31, 2023December 31, 2022
Weighted-average remaining lease term (Years):
      Operating leases13.57.9
      Finance leases2.31.9
Weighted-average discount rate:
      Operating leases7.3%4.8%
      Finance leases6.2%4.4%
(in thousands)Year Ended
December 31, 2023		Year Ended
December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:                   
      Operating cash flows from operating leases$3,462$2,440
      Operating cash flows from finance leases8128
      Financing cash flows from finance leases504384
ROU assets obtained in exchange for lease obligations:
      Operating leases29,39611,019
      Finance leases1,437582
Future minimum lease payments under non-cancellable leases as of December 31, 2023 were as follows:
(in thousands)
Operating Leases
Finance Leases
2024$4,624 $846 
20255,413 664 
20267,090 151 
20277,312 — 
20287,453 — 
Thereafter67,642 — 
  Total future minimum lease payments99,534 1,661 
Less: interest43,177 213 
  Total$56,357 $1,448 

17. Other Assets
Other assets are comprised of the following:
 December 31,
(in thousands)20232022
Prepaid Expenses$16,437 $12,887 
Other Current Assets246 205 
Total other current assets$16,683 $13,092 
ROU Asset (Note 16)$45,325 $19,033 
Other Long-Term Assets9,936 15,322 
Total other long-term assets$55,261 $34,355 

115
18. Net Income (Loss) Per Common Share
A summary of net income (loss) per common share is presented below:
 Year Ended
December 31,
(in thousands, except per share amounts)202320222021
Net income (loss)$326,661 $28,067 $(71,279)
Basic weighted-average common shares outstanding68,266 68,487 67,486 
Effect of dilutive stock options346 439 — 
Effect of dilutive restricted stock1,428 1,745 — 
Effect of convertible debt instrument199 — — 
Diluted weighted-average common shares outstanding70,239 70,671 67,486 
Basic income (loss) per common share$4.79 $0.41 $(1.06)
Diluted income (loss) per common share$4.65 $0.40 $(1.06)
Antidilutive securities excluded from diluted net income (loss) per common share421 358 2,893 
Impact of the Convertible Notes
The Company considered whether the notes are participating securities through the two-class method. The Company determined that if a cash dividend is paid that is greater than the then stock price, the holder of Notes will receive cash on an if-converted basis. While this feature is considered to be a participating right; basic earnings per share is only impacted if the Company’s earning exceeds the current share price, regardless of whether such dividend is declared. During the year ended December 31, 2023, no such dividend was declared. In addition, the Company is required to settle the principal amount of the Notes in cash upon conversion, and therefore, the Company uses the if-converted method for calculating any potential dilutive effect of the conversion option on diluted net income per share, if applicable, unless the application of the two-class method is dilutive. The conversion option will have a dilutive impact on net income per share of Common Stock when the average price per share of the Company’s Common Stock for a given period exceeds the conversion price of the Notes of $79.81 per share.    
19. Commitments and Contingencies
Purchase Commitments
The Company has entered into purchasing arrangements in which minimum quantities of goods or services have been committed to be purchased on an annual basis.
As of December 31, 2023, future payments required under purchase commitments are as follows:
(in thousands)Amount
20242,716 
20252,716 
20262,716 
20272,716 
2028 and thereafter— 
Total$10,864 
The Company has entered into agreements which contain certain percentage volume purchase requirements. The Company has excluded these future purchase commitments from the table above since there are no minimum purchase commitments or payments under these agreements.
License Agreements
The Company has entered into license agreements in which fixed payments have been committed to be paid on an annual basis.
As of December 31, 2023, no future fixed payments are required under license agreements. The Company may be required to pay additional amounts up to approximately $264.4 million in contingent payments under the Company’s license agreements. These
116
contingent payments include potential milestone or contractual payment obligations contingent upon the achievement or occurrence of future milestones or events and the amounts and timing of such potential obligations are unknown or uncertain.
Legal Proceedings
From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.
As of December 31, 2023, the Company did not have any material ongoing litigation to which the Company was a party. On January 26, 2024, the Company was sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the filing of our ANDA and Paragraph IV certification, consistent with the process established by the Hatch-Waxman Act. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved.
20. 401(k) Plan
The Company maintains a qualified 401(k) plan (the “401(k) Plan”) for its U.S. employees. The 401(k) Plan covers U.S. employees who meet certain eligibility requirements. Under the terms of the 401(k) Plan, the employees may elect to make tax-deferred contributions through payroll deductions within statutory and plan limits, and the Company may elect to make non-elective discretionary contributions. The Company may also make optional contributions to the 401(k) Plan for any plan year at its discretion.
Expense recognized by the Company for matching contributions made to the 401(k) Plan was $4.1 million, $3.1 million and $2.6 million for the years ended December 31, 2023, 2022 and 2021, respectively.
117
21. Acquisition of Assets
On February 6, 2023, the Company acquired Cerveau. Cerveau holds the rights under a license agreement to develop and commercialize MK-6240, an investigational second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease. The Company determined that upon review of the Cerveau acquisition, the transaction did not meet the definition of a business combination and is therefore treated as an asset acquisition.
In February 2023, the Company made an upfront payment of approximately $35.3 million to the stockholders of Cerveau (the “Selling Stockholders”) and paid the Selling Stockholders an additional $10.0 million in May 2023 upon the successful completion of a technology transfer. The Company could pay up to an additional $51.0 million in milestone payments upon achievement of specified U.S. regulatory milestones related to MK-6240. The Selling Stockholders are also eligible to receive up to $1.2 billion in sales milestone payments upon the achievement of specified annual commercial sales thresholds of MK-6240 in the event the Company pursues commercialization, as well as up to $13.5 million in research revenue milestones upon achievement of specified annual research revenue thresholds. Additionally, the Company will pay to the Selling Stockholders up to double-digit royalty payments for research revenue and commercial sales. Research revenue is derived from existing partnerships with pharmaceutical companies that use MK-6240 in clinical trials and includes milestone and dose-related payments. The purchase agreement pursuant to which the Company purchased Cerveau specifies, among other things, that certain members of the Selling Stockholders will also provide transition and clinical development services for a prescribed time following the closing of the transaction.
In December 2022, the Company made upfront payments of $260.0 million to POINT as a part of an asset acquisition with the potential for additional milestone payments of approximately $1.8 billion between the two licensed assets based on U.S. Food and Drug Administration (“FDA”) approval and net sales and commercial milestones.
Under the terms of the PNT2002 License Agreement, Lantheus Two paid POINT an upfront cash payment of $250.0 million, and could pay up to an additional $281.0 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2002. POINT is also eligible to receive up to $1.3 billion in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2002.
Under the terms of the PNT2003 License Agreement, Lantheus Three paid POINT an upfront cash payment of $10.0 million, and could pay up to an additional $34.5 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2003. POINT is also eligible to receive up to $275.0 million in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2003.
Additionally, the Company will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003. Costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use are expensed when incurred, and therefore, a charge of $260.0 million was recognized in research and development expenses during the year ended December 31, 2022.
22. Segment Information
The Company operates as one business segment. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

23. Subsequent Event
On January 9, 2024, the Company entered into multiple strategic agreements with Perspective Therapeutics, Inc. (“Perspective”), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. Under the agreements:
•The Company obtained an option to exclusively license Perspective’s Pb212-VMT-⍺-NET, a clinical stage alpha therapy in development for the treatment of neuroendocrine tumors, and an option to co-develop certain early stage therapeutic candidates targeting prostate cancer using Perspective’s innovative platform technology, for an aggregate upfront payment of $28 million in cash;
•Lantheus agreed to purchase up to 19.9% of Perspective’s outstanding shares of common stock for up to approximately $33 million, subject to completion of a qualified third party financing transaction and certain other closing conditions; and
•Perspective agreed to acquire the assets and associated lease of Lantheus’ radiopharmaceutical manufacturing facility in Somerset, New Jersey for an undisclosed price, subject to customary closing conditions including regulatory approval.

118
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A. Controls and Procedures
Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), its principal executive officer and principal financial officer, respectively, has evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were effective as of the period covered by this report.
Management’s Annual Report on Internal Control Over Financial Reporting
Our management, with the participation of our CEO and CFO, is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control system is designed to provide reasonable assurance to our management and Board of Directors regarding the preparation and fair presentation of published financial statements.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making its assessment of internal control over financial reporting, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013). Based on this assessment, management concluded that, as of December 31, 2023, our internal control over financial reporting was effective.
Deloitte & Touche LLP, an independent registered public accounting firm that audited our financial statements for the fiscal year ended December 31, 2023, included in this report, has issued an attestation report on the effectiveness of our internal control over financial reporting. This report is set forth below:
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of Lantheus Holdings, Inc.
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of Lantheus Holdings, Inc. and subsidiaries (the “Company”) as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2023, of the Company and our report dated February 22, 2024, expressed an unqualified opinion on those financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
119
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 22, 2024
Changes in Internal Controls Over Financial Reporting
There were no changes in our internal control over financial reporting for the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
We are continually monitoring and assessing the pandemic status and geopolitical environment to determine any potential impact on the design and operating effectiveness of our internal controls over financial reporting.
Item 9B. Other Information
On November 7, 2023, Sam Leno, a member of our Board, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”), providing for the potential sale of up to 2,045 shares of our common stock obtained from the exercise of vested stock options covered by the 10b5-1 Plan, between March 4, 2024 and May 15, 2024. On November 29, 2023, Mr. Leno amended his 10b5-1 Plan to add the potential sale of up to 20,344 additional shares of our common stock obtained from the exercise of vested stock options covered by the 10b5-1 Plan, between March 4, 2024 and May 15, 2024.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not Applicable.
120
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Pursuant to Section 406 of the Sarbanes-Oxley Act of 2002, we have adopted a code of conduct and ethics (our “Code of Conduct”) for all of our employees, including our CEO, CFO and other senior financial officers, or persons performing similar functions, and each of the non-employee directors on our Board. Our Code of Conduct is currently available on our website, www.lantheus.com. The information on our web site is not part of, and is not incorporated into, this Annual Report on Form 10-K. We intend to provide any required disclosure of any amendment to or waiver from such code that applies to our CEO, CFO and other senior financial officers, or persons performing similar functions, in a Current Report on Form 8-K filed with the SEC.
The additional information required with respect to this item will be incorporated herein by reference to our Definitive Proxy Statement for our 2023 Annual Meeting of Stockholders or an amendment of this report to be filed with the SEC no later than 120 days after the close of our year ended December 31, 2023.
Item 11. Executive Compensation
The information required with respect to this item will be incorporated herein by reference to our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders or an amendment of this report to be filed with the SEC no later than 120 days after the close of our year ended December 31, 2023.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required with respect to this item will be incorporated herein by reference to our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders or an amendment of this report to be filed with the SEC no later than 120 days after the close of our year ended December 31, 2023.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required with respect to this item will be incorporated herein by reference to our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders or an amendment of this report to be filed with the SEC no later than 120 days after the close of our year ended December 31, 2023.
Item 14. Principal Accountant Fees and Services
The information required with respect to this item will be incorporated herein by reference to our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders or an amendment of this report to be filed with the SEC no later than 120 days after the close of our year ended December 31, 2023.
121
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a)(1)     Financial Statements
(a)(2) Schedules
All schedules are omitted because they are not applicable, not required, or because the required information is included in the consolidated financial statements or notes thereto.
(a)(3) Exhibits
EXHIBIT INDEX
Incorporated by Reference
Exhibit
Number		Description of ExhibitsFormFile NumberExhibitFiling Date
3.18-K001-365693.1April 27, 2018
3.28-K001-365693.2December 28, 2022
4.18-K001-365694.1June 30, 2015
4.2*
4.38-K001-365694.1December 8, 2022
10.1+S-4333-16978510.18October 6, 2010
10.2+S-4333-16978510.19October 6, 2010
10.3+S-4333-16978510.20October 6, 2010
10.4+S-4333-16978510.21October 6, 2010
10.5+8-K333-16978510.1May 6, 2013
10.6+8-K333-16978510.2May 6, 2013
10.7+8-K333-16978510.3May 6, 2013
10.8+S-1333-19699810.37June 24, 2015
10.9+S-1333-19699810.38June 24, 2015
10.10+S-1333-19699810.39June 24, 2015
10.11+S-1333-19699810.40June 24, 2015
10.12+S-1333-19699810.41June 24, 2015
10.13+8-K001-3656910.1April 28, 2016
10.14+8-K001-3656910.1April 28, 2017
10.15+8-K001-3656910.2April 28, 2017
10.16†10-Q001-3656910.1August 1, 2017
10.17+10-K001-3656910.68February 20, 2019
10.18+10-K001-3656910.70February 20, 2019
10.19+10-K001-3656910.71February 20, 2019
10.20+10-Q001-3656910.1April 30, 2019
10.21+10-Q001-3656910.2July 25, 2019
122
Incorporated by Reference
Exhibit
Number		Description of ExhibitsFormFile NumberExhibitFiling Date
10.22+S-8333-2394914.4June 26, 2020
10.23+S-8333-2394914.5June 26, 2020
10.248-K000-2314310.46 (21)January 5, 2016
10.25+8-K001-3656910April 29, 2021
10.26††10-Q001-3656910.1April 29, 2022
10.2710-Q001-3656910.2April 29, 2022
10.2810-Q001-3656910.3April 29, 2022
10.2910-Q001-3656910.4April 29, 2022
10.308-K001-3656910.1May 2, 2022
10.31††8-K000-3656910.1November 14, 2022
10.328-K001-3656910.1December 5, 2022
10.33+8-K001-3656910.1May 1, 2023
10.34††10-Q001-3656910.1August 3, 2023
19.1*


21.1*
23.1*
24.1*
31.1*
31.2*
32.1**
97.1*
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Data File (embedded within the Inline XBRL document)
________________________________
*    Filed herewith.
**    Furnished herewith.
††    Portions of this exhibit have been omitted for confidential treatment pursuant to Item 601(b)(10)(iv) of Regulation S-K.
+    Indicates management contract or compensatory plan or arrangement.
†    Confidential treatment requested as to certain portions, which portions have been filed separately with the Securities and Exchange Commission

Item 16. Form 10-K Summary
None.
123
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LANTHEUS HOLDINGS, INC.
By:/S/ MARY ANNE HEINO
Name:Mary Anne Heino
Title:Chief Executive Officer
Date:February 22, 2024
We, the undersigned directors and officers of Lantheus Holdings, Inc., hereby severally constitute and appoint Mary Anne Heino, Robert J. Marshall, Jr. and Daniel Niedzwiecki, and each of them individually, with full powers of substitution and resubstitution, our true and lawful attorneys, with full powers to them and each of them to sign for us, in our names and in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the SEC, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
SignatureTitleDate
/S/ MARY ANNE HEINOChief Executive Officer and Director
(Principal Executive Officer)		February 22, 2024
Mary Anne Heino
/S/ ROBERT J. MARSHALL, JR.Chief Financial Officer and Treasurer
(Principal Financial Officer)		February 22, 2024
Robert J. Marshall, Jr.
/S/ ANDREA SABENSChief Accounting Officer
(Principal Accounting Officer)		February 22, 2024
Andrea Sabens
/S/ BRIAN MARKISONExecutive Chair of the Board of DirectorsFebruary 22, 2024
Brian Markison
/S/ MINNIE BAYLOR-HENRYDirectorFebruary 22, 2024
Minnie Baylor-Henry
/S/ GÉRARD BER
DirectorFebruary 22, 2024
Gérard Ber
/S/ SAMUEL R. LENODirectorFebruary 22, 2024
Samuel R. Leno
/S/ HEINZ MÄUSLI
DirectorFebruary 22, 2024
Heinz Mäusli
/S/ JULIE H. MCHUGHDirectorFebruary 22, 2024
Julie H. McHugh
/S/ GARY J. PRUDENDirectorFebruary 22, 2024
Gary J. Pruden
/S/ DR. JAMES H. THRALLDirectorFebruary 22, 2024
Dr. James H. Thrall

 EX-4.2 2 ex42descriptionofregistran.htm EX-4.2 Document

Exhibit 4.2

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
The following description sets forth certain material terms and provisions of Lantheus Holdings, Inc.’s (the “Company”, “us”, “we”, or “our”) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended.
DESCRIPTION OF CAPITAL STOCK
 
The following summary description sets forth some of the general terms and provisions of the capital stock. Because this is a summary description, it does not contain all of the information that may be important to you. For a more detailed description of the preferred and common stock, you should refer to the provisions of our amended and restated certificate of incorporation and our bylaws, as amended and restated, each of which is an exhibit to the Annual Report on Form 10-K to which this description is an exhibit.
General
Our authorized capital stock consists of 250,000,000 shares of common stock, par value $0.01 per share, and 25,000,000 shares of preferred stock, par value $0.01 per share. The shares of common stock currently outstanding are fully paid and nonassessable. No shares of preferred stock are currently outstanding.
Common Stock
Holders of our common stock are entitled to the following rights:
Voting Rights
Each share of common stock entitles the holder to one vote with respect to each matter presented to our stockholders on which the holders of common stock are entitled to vote; provided, however, that the Board of Directors may issue or grant shares of common stock that are subject to vesting or forfeiture and that restrict or eliminate voting rights with respect to such shares until any such vesting criteria is satisfied or such forfeiture provisions lapse. Our common stock votes as a single class on all matters relating to the election and removal of directors on our Board of Directors and as provided by law. Holders of our common stock do not have cumulative voting rights. Except as otherwise provided in our amended and restated certificate of incorporation or our bylaws or required by law, all matters to be voted on by our stockholders must be approved by a majority of the shares present in person or by proxy at the meeting and entitled to vote on the subject matter.
Dividend Rights
Holders of common stock share equally on a per share basis in any dividend declared by our Board of Directors, subject to any preferential rights of the holders of any outstanding preferred stock.
Liquidation Rights
In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of our common stock would be entitled to share ratably in our assets that are legally available for distribution to stockholders after payment of liabilities. If we have any preferred stock outstanding at that time, holders of the preferred stock may be entitled to distribution and/or liquidation preferences. In either case, we must pay the applicable distribution to the holders of our preferred stock before we may pay distributions to the holders of our common stock.
Other Rights
Our stockholders have no subscription privileges. Our common stock does not entitle its holders to preemptive rights for additional shares. All of the outstanding shares of our common stock are fully paid and nonassessable. The rights, preferences and privileges of the holders of our common stock are subject to the rights of the holders of shares of any series of preferred stock which we may issue.


Preferred Stock
Our Board of Directors is authorized to provide for the issuance of preferred stock in one or more series and to fix the preferences, powers and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including the dividend rate, conversion rights, voting rights, redemption rights and liquidation preference and to fix the number of shares to be included in any such series without any further vote or action by our stockholders. Any preferred stock so issued may rank senior to our common stock with respect to the payment of dividends or amounts upon liquidation, dissolution or winding up, or both. In addition, any such shares of preferred stock may have class or series voting rights. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of our Company without further action by the stockholders and may adversely affect the voting and other rights of the holders of our common stock.
Anti-takeover Provisions
Our amended and restated certificate of incorporation and bylaws contain provisions that delay, defer or discourage transactions involving an actual or potential change in control of us or change in our management. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our board the power to discourage transactions that some stockholders may favor, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Accordingly, these provisions could adversely affect the price of our common stock.
Classified Board
Our amended and restated certificate of incorporation provides that our board is comprised of such number of directors as may be fixed from time to time by resolution of at least a majority of our Board of Directors then in office and that our board is divided into three classes, with one class being elected at each annual meeting of stockholders. Each director serves a three-year term, with expiration staggered according to class.
The classification of our board could make it more difficult for a third-party to acquire, or discourage a third party from seeking to acquire, control of our Company.
Requirements for Advance Notification of Stockholder Meetings, Nominations and Proposals
Our bylaws provide that special meetings of the stockholders may be called only upon the request of a majority of our board or upon the request of the chairman of our Board of Directors or our Chief Executive Officer.
Our bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board or a committee of our board. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply with the advance notice requirements of directors. Our bylaws allow our Board of Directors to adopt such rules and regulations for the conduct of the meetings as they may deem proper, which may be delegated to a chairperson of the meeting and which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our Company.
No Stockholder Action by Written Consent
Our amended and restated certificate of incorporation provides that, subject to the rights of any holders of preferred stock to act by written consent instead of a meeting, stockholder action may be taken only at an annual meeting or special meeting of stockholders and may not be taken by written consent instead of a meeting, unless the action to be taken by written consent of stockholders and the taking of this action by written consent has been unanimously approved in advance by our board. Failure to satisfy any of the requirements for a stockholder meeting could delay, prevent or invalidate stockholder action.
Section 203 of the Delaware General Corporation Law, as amended (“DGCL”)
We are subject to Section 203 of the DGCL, which regulates acquisitions of some Delaware corporations. In general, Section 203 prohibits, with some exceptions, a publicly held Delaware corporation from engaging in a “business combination” with an


“interested stockholder” for a period of three years following the date of the transaction in which the person became an interested stockholder, unless:
•the board of directors of the corporation approved the business combination or the other transaction in which the person became an interested stockholder prior to the date of the business combination or other transaction;
•upon consummation of the transaction that resulted in the person becoming an interested stockholder, the person owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers of the corporation and shares issued under employee stock plans under which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
•on or subsequent to the date the person became an interested stockholder, the board of directors of the corporation approved the business combination and the stockholders of the corporation authorized the business combination at an annual or special meeting of stockholders by the affirmative vote of at least 66⅔% of the outstanding stock of the corporation not owned by the interested stockholder.
Section 203 of the DGCL generally defines a “business combination” to include any of the following:
•any merger or consolidation involving the corporation and the interested stockholder;
•any sale, transfer, pledge or other disposition of 10% or more of the corporation’s assets or outstanding stock involving the interested stockholder;
•in general, any transaction that results in the issuance or transfer by the corporation of any of its stock to the interested stockholder;
•any transaction involving the corporation that has the effect of increasing the proportionate share of its stock owned by the interested stockholder; or
•the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.
In general, Section 203 defines an “interested stockholder” as any person who, together with the person’s affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock.
Section 203 of the DGCL could depress our stock price and delay, discourage or prohibit transactions not approved in advance by our board of directors, such as takeover attempts that might otherwise involve the payment to our stockholders of a premium over the market price of our common stock.
Exclusive Forum
Our amended and restated certificate of incorporation provides that, unless we consent in writing in advance to the selection of an alternative forum, the Delaware Court of Chancery shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by, or any wrongdoing by, any of our directors, officers or employees to our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation (including as it may be amended from time to time) or our bylaws, (iv) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our bylaws, or (v) any action asserting a claim governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits with respect to such claims. However, it is possible that a court could rule that this provision is unenforceable or inapplicable.
Listing
Our common stock is listed on the NASDAQ Global Market under the symbol “LNTH.”
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

 EX-19.1 3 ex191insidertradingpolicy0.htm EX-19.1 Document

Exhibit 19.1
LANTHEUS HOLDINGS, INC.
Policy on Insider Trading and Communications with the Public

This Policy on Insider Trading and Communications with the Public (this “Policy”) applies to:
•the purchase or sale of securities in Lantheus Holdings, Inc. (referred to herein as “Lantheus” and the “Company”);
•the communication of material nonpublic information about the Company to persons or entities outside of the Company; and
•(i) the purchase or sale of securities of any other public company (including the Company’s past, current or potential customers, vendors, suppliers, collaborators or business development partners), when material nonpublic information about that other public company is obtained in the course of employment with, or other services performed on behalf of, the Company, and (ii) the communication of any material nonpublic information about any of these other public companies with anyone outside the Company.
Who is Subject to this Policy?
All of the following persons and entities are subject to this Policy:
(a)“Company Personnel,” which is defined to mean: (i) all members of the Board of Directors, officers and employees of the Company and its subsidiaries; and (ii) all agents, contractors and consultants of the Company who have access to or receive material nonpublic information about the Company or any other company or entity with which the Company has done, does or intends to do, business in the course of their employment with, engagement by, or association with, the Company;
(b)“Family Members,” which is defined to mean: (i) all family members (including any spouse, child, stepchild, grandchild, parent, stepparent, grandparent, sibling, mother or father-in-law, son or daughter-in-law, or brother-in-law or sister-in-law, as well as any similar adoptive relationships) who live in the household of Company Personnel, (ii) all other persons who live in the household of Company Personnel and (ii) all family members who do not live in the household of Company Personnel, but whose transactions in Company securities are directed by, or subject to the influence or control of, Company Personnel (such as parents or children who consult with persons identified in clauses (i) and (ii) above before they trade in Company securities);
(c)“Controlled Entities,” which is defined to mean all entities, including corporations, partnerships or trusts, whose transactions in Company securities are directed by, or subject to the influence or control of, Company Personnel or their Family Members; and
(d)“Other Covered Persons,” which is defined to mean all persons and entities (other than Family Members and Controlled Entities) whose transactions in Company securities are directed by, or subject to the influence or control of, Company Personnel.
All Company Personnel are obligated to inform their Family Members, Controlled Entities and Other Covered Persons (collectively, that Company Personnel’s “Related Persons”) of the requirements of this Policy and to direct their compliance with this Policy.
In addition, as specified in Section 4 of this Policy, all Designated Persons (as defined below) are (a) subject to additional restrictions relating to the prohibition of purchases and sales of Company securities during Blackout Periods (as defined below) and (b) required to pre-clear purchases and sales of Company securities (even outside of Blackout Periods). Other Company Personnel who are not Designated Persons should also read those sections of this Policy to help guide their own actions on a prophylactic basis.
The following are “Designated Persons” under this Policy:
•all members of the Board of Directors and all members of the Executive Team, Expanded Executive Team and the Lantheus Leadership Group;
•all Company Personnel in the Finance, Internal Audit, Tax, Business Development, Human Resources, Investor Relations, Corporate Communications and attorneys in the Legal departments;
•all other Company Personnel significantly involved in working on significant business development matters;
•all Company Personnel otherwise designated as such by the General Counsel or Chief Financial Officer; and
•all of their respective Related Persons.
1

This Policy has been adopted to ensure compliance with the federal securities laws, and also to prevent even the appearance of improper conduct on the part of anyone employed by or associated with the Company (not just so-called “insiders”), and should be viewed in addition to any restrictions on trading in Company securities imposed by employment or other agreements between Company Personnel and the Company. We have all worked hard over the years to establish a reputation for integrity and ethical conduct, and we cannot afford to have that reputation damaged.
What Is Insider Trading?
Insider trading occurs when a person who is aware of material nonpublic information about the Company buys or sells the Company’s securities.
A director, officer or other employee, agent, consultant, or any other advisor owing a duty of trust and confidence to the Company (such as accountants or outside attorneys), may also violate the insider trading laws if he or she communicates – or “tips” – material nonpublic information to another person or entity without authorization by the Company, and that other person or entity trades on the basis of that information.
Information is (i) “material” if a reasonable investor would consider it important in deciding whether to buy, hold or sell securities and (ii) “nonpublic” if it has not been disseminated in a manner making it available to investors generally. These concepts are discussed and illustrated in more detail in Section 2 below.
What Securities Are Subject to This Policy?
The insider trading (including tipping) prohibitions are not limited to trading in the common stock of the Company. Under the law, insider trading in any security (including stock options, debt instruments or preferred stock) is illegal. Also, this Policy applies to trading in the securities of any other public company (including the Company’s past, current or potential customers, vendors, suppliers, collaborators or business development partners), when material nonpublic information about that other public company is obtained in the course of employment with, or other services performed on behalf of, the Company.
Questions
Questions about this Policy or any proposed transaction should be directed to the General Counsel (or his or her designee).

1.POLICY STATEMENTS
Statement of Insider Trading Policy
It is the policy of the Company that Company Personnel who are aware of material nonpublic information relating to the Company or its affiliated entities may not, directly or indirectly through Related Persons or other persons or entities, (a) buy or sell securities (including buying or selling puts, calls and options) of the Company or any of its affiliated entities, or engage in any other action to take personal advantage of that information, until the information becomes public or is no longer material, or (b) pass that information on to others outside the Company, including family and friends. In addition, it is the policy of the Company that Company Personnel who, in the course of working for the Company, learn of material nonpublic information about a company with which the Company has done, does, or will do, business (including business development targets, collaborators, customers or suppliers of the Company) may not trade in that company’s securities until the information becomes public or is no longer material.
Transactions that may be necessary or justifiable for independent personal reasons (such as the need to raise money for an emergency expenditure) are not exempt from this Policy. The securities laws do not recognize those kinds of mitigating circumstances, and, in any event, even the appearance of an improper transaction must be avoided to preserve the Company’s reputation for adhering to the highest standards of conduct and ethics.
Please note that the trading prohibitions and restrictions set forth in this Policy will be superseded by any greater prohibitions or restrictions prescribed by federal or state securities laws and regulations (e.g., short-swing trading by executive officers or directors subject to Section 16 or restrictions on the sale of securities subject to Rule 144 of the Securities Act of 1933). Any Company Personnel who is uncertain whether other prohibitions or restrictions apply should ask the General Counsel (or his or her designee).
Statement of Communications Policy
The Company engages in communications with investors, securities analysts and the financial press. It is against the law – specifically, Regulation FD adopted by the Securities and Exchange Commission (the “SEC”) – as well as this Policy, for any person acting on behalf of the Company to disclose material nonpublic information selectively to securities professionals (including, for example, buy and sell-side analysts, institutional investment managers and investment companies) or investors in any security of the Company under circumstances where it is reasonably foreseeable that the recipient may trade on the basis of that information, unless the information has first or simultaneously has been disclosed to the public.
Only the Chairperson of the Board, the Lead Independent Director, the Chief Executive Officer, the President, the Chief Financial Officer and any other person or investor relations firm expressly designated by the Chief Executive Officer or the
2

Board of Directors are authorized to speak on behalf of the Company. Anyone who communicates without proper authorization will not only violate this Policy, but may also violate the anti-tipping provisions of the insider trading laws. Accordingly, information may not be disclosed to anyone outside the Company (including analysts, stockholders, potential investors, journalists or any media outlet, family members and friends) other than in accordance with the procedures set forth in this Policy under the heading “Procedures for Communications with the Public” in Section 8 below. Moreover, neither the Company nor its business may be discussed in any social media platform (such as LinkedIn, Facebook or Twitter), internet “chat room” or any other internet- or social media-based forum (other than reposting or distributing previously-approved Company communications).

2.MATERIALITY AND PUBLIC DISSEMINATION
Both the insider trading laws and Regulation FD use the same concepts of “materiality” and a similar concept of when information becomes “public.”
Material Information
Information is “material” if a reasonable investor would consider it important in making a decision to buy, hold or sell securities. Any information that could be expected to affect the Company’s stock price, whether it is positive or negative, should be considered material. Some examples of information that ordinarily would be regarded as material include, but are not limited to:
•Projected future or unreported actual revenues, earnings, losses or cash flows and asset or liability levels;
•Any changes to revenue or earnings guidance;
•Revenue or earnings that are inconsistent with the consensus expectations of the investment community;
•A proposed acquisition (whether of a material asset or a business or entity), license or collaboration, or a proposed sale or disposition;
•A significant expansion or cutback of operations;
•A significant product change or important information about a product or the development of a product;
•A development in the regulatory approval process regarding one of the Company’s products in development;
•Extraordinary management or business developments;
•Changes in executive management;
•Significant lawsuits or legal settlements;
•A proposed strategic partnership, joint venture or distribution agreement;
•The potential or actual gain or loss of a significant business development partner, customer, supplier, contract or purchase order;
•Company restructuring;
•Potential equity issuances;
•Borrowing activities, including contemplated financings and refinancings (other than in the ordinary course);
•A change in dividend policy, the declaration of a stock split or an offering of additional securities;
•Significant related party transactions;
•The establishment of a repurchase program for Company securities;
•A change in pricing or cost structure;
•Major marketing changes;
•A change in auditors or notification that the auditor’s reports may no longer be relied upon;
•The imposition of a ban on trading in Company securities or the securities of another company; or
•Impending bankruptcy or the existence of severe liquidity problems.
3

When Information Is “Nonpublic”
Information that has not been disclosed to the public is generally considered to be “nonpublic” information. If you are aware of material nonpublic information, you may not trade until that information has been disclosed broadly to the marketplace (such as by a widely disseminated press release or an SEC filing) and the investing public has had time to absorb the information fully. To avoid the appearance of impropriety, as a general rule, information should not be considered fully absorbed by the marketplace until after the first full business day after the information is publicly released by the Company. If, for example, the Company were to make an announcement on a Monday prior to 9:30 a.m. New York time, you should not trade in the Company’s securities until after 9:30 a.m. New York time on Tuesday. If an announcement were made on a Monday after 4:00 p.m. New York time, you should not trade in the Company’s securities until after 9:30 a.m. New York time on Wednesday.
If you have any question as to whether information is publicly available, please err on the side of caution and direct an inquiry to the General Counsel (or his or her designee).

3.PROHIBITED TRANSACTIONS
The Company considers it improper and inappropriate for Company Personnel to engage in short-term or speculative transactions in the Company’s securities. It therefore is the Company’s policy that Company Personnel may not engage in any of the following transactions:
•Short-Term Trading. A Company Personnel’s short-term trading of the Company’s securities may be distracting and may unduly focus on the Company’s short-term stock market performance instead of the Company’s long-term business objectives. For these reasons, Company Personnel who purchase Company securities in the open market may not sell any Company securities of the same class during the six months following that purchase. Please note that shares purchased through either an employee stock purchase plan or employee stock option plan are not subject to this restriction.
•Short Sales. Short sales of the Company’s securities evidence an expectation on the part of the seller that the securities will decline in value and, therefore, signal to the market that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce the seller’s incentive to improve the Company’s performance. For these reasons, short sales of the Company’s securities are prohibited by this Policy. In addition, Section 16(c) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), also prohibits directors and officers from engaging in short sales.
•Publicly Traded Options. A transaction in options is, in effect, a bet on the short-term movement of the Company’s stock and, therefore, creates the appearance that trading is based on inside information. Transactions in options also may focus attention on short-term performance at the expense of the Company’s long-term objectives. Accordingly, transactions in puts, calls or other derivative securities on an exchange or in any other organized market, are prohibited by this Policy. (Please note that option positions arising from certain types of hedging transactions are governed by the section captioned “Hedging Transactions” below.)
•Hedging Transactions. Certain forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts, allow Company Personnel to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock. These transactions allow Company Personnel to continue to own the covered securities, but without the full risks and rewards of ownership. When that occurs, Company Personnel may no longer have the same objectives as the Company’s other stockholders. Therefore, Company Personnel are prohibited from engaging in hedging transactions.
•Margin Loans and Pledges. Company Personnel may not subject any Company stock or other securities subject to this Policy to margin loans and may not pledge Company stock or other securities as collateral for loans or other obligations.

4.ADDITIONAL RESTRICTIONS ON SECURITIES TRANSACTIONS
Blackout Periods    
To ensure compliance with this Policy and applicable federal and state securities laws, the Company requires that all Designated Persons and any persons acting on behalf of any Designated Persons, refrain from conducting transactions (for their own or related accounts) involving the purchase or sale of the Company’s securities during the following periods (the “Blackout Periods”):
•The period commencing on 16th day of the last month of each fiscal quarter (i.e., March 16th, June 16th, September 16th and December 16th) and ending after the first full Trading Day (as defined below) after the date on which the Company discloses its financial results for that fiscal period.
•Any other period designated by the General Counsel or Chief Financial Officer.
4

“Trading Day” means any day on which the Nasdaq Stock Market is open.
The purpose behind the Blackout Period is to avoid any improper transactions. All Designated Persons and any persons acting on behalf of Designated Persons must comply with the Blackout Period requirements. Specific exceptions may be made (other than for regular quarterly Blackout Periods), with approval from the General Counsel (or his or her designee), when Company Personnel does not possess material nonpublic information and the exception would not otherwise contravene the law or the purposes of this Policy. Any request for an exception from this Policy must be directed to the Company’s General Counsel (or his or her designee).
The safest period for trading in the Company’s securities, assuming the absence of material nonpublic information, generally is the first ten Trading Days following the end of the Blackout Period. The regular quarterly Blackout Periods are particularly sensitive periods and particular attention must be made to ensure that transactions in the Company’s securities are made in accordance with the applicable laws. This is because Company Personnel will, as any quarter progresses, be increasingly likely to possess material, nonpublic information about the expected financial results for that quarter.
From time to time, the Company may impose other Blackout Periods (i.e., outside of the regular quarterly Blackout Periods) during which Designated Persons and any persons acting on behalf of Designated Persons must suspend trading because of developments known to the Company and not yet disclosed to the public. In such an event, a Designated Person may not engage in any transaction involving the purchase or sale of the Company’s securities during that period and should not disclose to others the fact of such a suspension in trading.
Even at times that do not fall within a Blackout Period, any person possessing material nonpublic information concerning the Company should not engage in any transactions in the Company’s securities until that information has been known publicly for at least one full Trading Day. Each Designated Person is individually responsible at all times for compliance with the prohibitions on insider trading. Trading in the Company’s securities outside the Blackout Period should not be considered a “safe harbor,” and all Company Personnel should use good judgment at all times.
Mandatory Pre-Clearance
All Designated Persons must pre-clear his, her or its trade in Company securities with the General Counsel (or his or her designee) before the trade may occur.
Any Designated Person seeking to pre-clear a trade in Company securities must notify the General Counsel (or his or her designee) of the desire to conduct a trade on the date of the proposed transaction. If, after receiving pre-clearance, the transaction does not occur on the date proposed, the requestor must reinstitute the pre-clearance process. The General Counsel (or his or her designee) is obligated to inform the requesting individual of a decision with respect to the request as soon as reasonably practical after considering all the circumstances relevant to a determination.
Pre-clearance requests by Designated Persons will not be granted during any regular quarterly Blackout Periods. The General Counsel (or his or her designee) may exercise discretion in determining whether to alert the requestor of the reason(s) for denial of pre-clearance, whether based on the pendency of a Blackout Period or any other reason.
Even if approval to trade pursuant to the pre-clearance process is obtained, or pre-clearance is not required for a particular transaction under this section of this Policy (see below), the requesting Designated Person (and/or any Related Person) may NOT trade in the Company’s securities if he, she or it is aware of material nonpublic information about the Company or any of the companies covered by this Policy. This Policy does not require pre-clearance of transactions in any other company’s securities unless otherwise indicated in writing by the General Counsel or the Chief Financial Officer.
Within one (1) business day of completing any purchase or sale of Company securities that has been pre-cleared, any Designated Person who is subject to Section 16 of the Exchange Act must provide to the General Counsel (or his or her designee) a copy of documentation confirming those transactions. This Policy does not require submission of trade confirmations in Company or other companies’ securities unless otherwise indicated in writing by the General Counsel or the Chief Financial Officer.
Rule 10b5-1 Trading Plans
Overview
Rule 10b5-1 promulgated under the Exchange Act provides an affirmative defense to employees, officers and directors of public companies (so called “insiders”) against insider trading violations for transactions executed under a previously established contract, plan or instruction to trade in the Company’s securities (a “Trading Plan”) entered into in good faith and in accordance with the terms of Rule 10b5-1 and all applicable state laws . The rule presents an opportunity for insiders to establish arrangements to sell (or purchase) Company securities without the restrictions imposed by trading windows and blackout periods imposed by this Policy— even when the insider possess material nonpublic information. A well-conceived program might also reduce negative publicity that can result when key insiders sell.
Company Personnel may enter into a Trading Plan only when he or she is not in possession of material, non-public information, and only during an open trading window period outside of a blackout period. Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made
5

pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company’s legal team to assist in the preparation and filing of a required Form 4.
The Company reserves the right from time to time to suspend, discontinue or otherwise prohibit any transaction in the Company’s securities, even pursuant to a previously approved Trading Plan, if the Company’s General Counsel, or such other person as the Board of Directors may designate from time to time (the “Authorizing Officer”), or the Board of Directors, in its discretion, determines that such suspension, discontinuation or other prohibition is in the best interests of the Company. Any trading plan submitted for approval hereunder should explicitly acknowledge the Company’s right to prohibit transactions in the Company’s securities. Failure to discontinue purchases and sales as directed shall constitute a violation of the terms of this Policy and result in a loss of the exemption set forth herein.
Company Personnel may adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company’s stock, including the exercise of options. Trades pursuant to a Trading Plan generally may occur at any time. However, Rule 10b5-1 and the Company require a cooling-off period between the establishment of a Trading Plan and commencement of any transactions under such plan. For directors and the Company’s executive officers and principal accounting officer, trading under a Trading Plan may not begin until the later of: (1) 90 days following the adoption or modification of a Trading Plan; or (2) two business days following the disclosure in certain periodic reports (Forms 10-Q or 10-K) of the Company’s financial results for the fiscal quarter in which a Trading Plan was adopted or modified (but not to exceed 120 days following plan adoption or modification). For all other persons (other than the Company), trading under a Trading Plan may not begin until 30 days after the adoption or modification of the Trading Plan. In addition, and except as otherwise permitted by Rule 10b5-1, an individual may not (1) have multiple outstanding overlapping Trading Plans or (2) during any 12-month period, enter into more than one single-trade Trading Plan. Please review the following description of how a Trading Plan works.
Pursuant to Rule 10b5-1, an individual’s purchase or sale of securities will not be “on the basis of” material, non-public information if:
•First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written plan for trading the securities (i.e., the Trading Plan).
•Second, the Trading Plan must either:
•specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold and the date on which the securities are to be purchased or sold;
•include a written formula or algorithm or computer program for determining the amount, price and date of the transactions; or
•prohibit the individual from exercising any subsequent influence over how, when or whether to effect purchases or sales of the Company’s stock under the Trading Plan in question.
•Third, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan.
The initiation of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company’s securities, and such initiation or modification is subject to all limitations and prohibitions relating to transactions in the Company’s securities covered by this Policy.
Rule 10b5-1 also has a general “good faith” requirement and persons entering into Trading Plans must act in good faith with respect to the Trading Plan throughout the duration of the Trading Plan. Trading Plans adopted by Company Personnel are required to include representations by Company Personnel certifying that the he or she: (i) is not aware of material non-public information about the Company or its securities and (ii) is adopting the Trading Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5.
Company Personnel must submit the draft of each Trading Plan and each trading plan that does not satisfy the requirements of Rule 10b5-1, and any modification thereof, to the General Counsel or Authorized Officer for approval, who may impose such conditions on the implementation and operation of such plans as the Authorizing Officer deems necessary or advisable. However, compliance of a Trading Plan with the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not the Company or the Authorizing Officer. Such a plan may not be established during a Blackout Period or any other time during which he or she is aware of any material nonpublic information regarding the Company. Company Personnel also must request pre-clearance for any modification or termination of any such plan once established.
It is the policy of the Company that the following people are required to execute any proposed trades in the Company’s securities through a Trading Plan:
•all members of the Board of Directors and all members of the Executive Team and the Expanded Executive Team;
6

•all attorneys in the Legal department;
•all Company Personnel in the Finance, Internal Audit, Tax, Investor Relations or Corporate Communications departments who is required to sign the Supplemental Code of Ethics; and
•all Company Personnel otherwise designated as such by the General Counsel or Chief Financial Officer.

Termination of and Amendments to Trading Plans
Termination of or amendments to Trading Plans should occur only in unusual circumstances. Effectiveness of any termination or amendment of a Trading Plan will be subject to the prior review and approval of the Authorizing Officer. Once a Trading Plan has been terminated, for those participants eligible to trade outside of a Trading Plan, such participants should wait at least 30 days before trading outside of a Trading Plan (and, in any event, the participant must comply with the cooling-off period requirements described above in connection with the adoption or modification of a Trading Plan, including any modification of a Trading Plan deemed to be the termination of such plan and the adoption of a new plan as described below). Please note that termination of a Trading Plan can result in the loss of an affirmative defense for past or future transactions under a Trading Plan. A participant should consult with their own legal counsel before deciding to terminate a Trading Plan and should not assume that compliance with the 30-day bar will protect them from possible adverse legal consequences of a Trading Plan termination.
If approved by an Authorizing Officer, a person may amend an existing Trading Plan so long as such person acts in good faith and such amendments are made outside of a blackout period and at a time when the Trading Plan participant does not possess material, non-public information. A modification or change to a Trading Plan that impacts the amount, price, or timing of the purchase or sale of the securities (or a modification or change to a written formula or algorithm, or computer program that affects the amount, price, or timing of the purchase or sale of the securities) thereunder is deemed a termination of the original plan and the adoption of a new plan, subject to a new cooling-off period.
Under certain circumstances, a Trading Plan must be terminated. This may include circumstances such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company. The Authorizing Officer or administrator of the Company’s stock plans is authorized to notify the broker in such circumstances, thereby insulating the participant in the event of termination.
Discretionary Plans
Although non-discretionary Trading Plans are preferred, discretionary Trading Plans, where the discretion or control over trading is transferred to a broker which does not have access to the Company’s material, non-public information, are permitted if pre-approved by the Authorizing Officer.
Any Trading Plan, arrangement or trading instructions, etc., involving potential sales or purchases of the Company securities or option exercises, including but not limited to, blind trusts, discretionary accounts with banks or brokers, or limit orders, must be pre-approved by an Authorizing Officer. The actual transactions effected pursuant to a pre-approved Trading Plan will not be subject to further pre-clearance for transactions in the Company’s securities once the Trading Plan or other arrangement has been pre-approved.
Public Disclosure
The Company may make a public announcement that Trading Plans are being implemented in accordance with Rule 10b5-1. It will consider in each case whether a public announcement of a particular Trading Plan should be made. It may also make public announcements or respond to inquiries from analysts, stockholders or the media as transactions are made under a Trading Plan. In addition, the Company will provide the disclosures required pursuant to Item 408(a) of Regulation S-K regarding the adoption or termination of trading plans (whether or not they satisfy the requirements of Rule 10b5-1 and including any modification of a trading plan deemed to be the termination of such plan and the adoption of a new trading plan) by directors and executive officers and the material terms of these plans including, without limitation: (i) the name and title of the director or executive officer (including the principal accounting officer) adopting the plan; (ii) the date of adoption or termination of the plan; (iii) the duration of the plan; and (iv) the aggregate number of securities to be sold or purchased under the plan. The Company will also provide the disclosures required pursuant to Item 408(b) of Regulation S-K regarding this Policy and, when required, will file a copy of this Policy as an exhibit to its Annual Report on Form 10-K.
Prohibited Transactions
The transactions prohibited under Section 3 of this Policy, including among others short sales and hedging transactions, may not be carried out through a Trading Plan or other arrangement or trading instruction involving potential sales or purchases of the Company’s securities.
No Section 16 Protection
The use of Trading Plans does not exempt participants from complying with the Section 16 reporting rules or liability for short-swing trades.
7

Limitation on Liability
None of the Company, the Authorizing Officer or the Company’s other employees will have any liability for any delay in reviewing, or refusal of, a Trading Plan submitted pursuant to this Policy. Notwithstanding any review of a Trading Plan pursuant to this Policy, none of the Company, the Authorizing Officer or the Company’s other employees assumes any liability for the legality or consequences relating to such Trading Plan to the person adopting such Trading Plan.
Exceptions to Blackout Period Prohibitions and Pre-Clearance Requirements
The following transactions in Company securities are not prohibited during Blackout Periods, and pre-clearance is not required for the following transactions in Company securities:
•purchases or sales of securities pursuant to pre-arranged allocation elections made under any tax-qualified employee benefit plan of the Company;
•purchases or sales of Company securities by a Designated Person in a registered public offering or in an offering under Rule 144A of the Securities Act of 1933 that is available to the Designated Person on the same terms and conditions as to all other participants in the offering; provided, however, that the General Counsel (or his or her designee) must be notified of all such purchases or sales by the Designated Person on or prior to the day such purchase or sale occurs; or
•transactions effected in accordance with a properly established Rule 10b5-1 trading plan.

5.POST-TERMINATION TRANSACTIONS    
If your employment or engagement with the Company ends during a Blackout Period, this Policy (including its pre-clearance requirements and trading prohibitions during a Blackout Period) will continue to apply to your transactions in Company securities until that Blackout Period ends.
As a reminder, if you are in possession of material nonpublic information when your employment or engagement terminates, you may not trade in Company securities until that information has become public or is no longer material.

6.TRANSACTIONS UNDER COMPANY EQUITY INCENTIVE PLANS
General
Any (i) purchase of Company securities from the Company, or (ii) sales of Company securities to the Company, are not subject to this Policy.
Options
This Policy’s trading restrictions do not apply to (i) the exercise of employee stock options issued under any of the Company’s equity incentive plans or, (ii) if the Company requires, any market sale of shares issued upon the exercise of employee stock options to generate proceeds to cover the exercise price of those employee stock options and/or any withholding tax obligations at the time of exercise.
The Policy’s trading restrictions do apply, however, to any other market sale of the shares issued upon that exercise of employee stock options, including to the extent that the holder of those underlying shares (as opposed to the Company) makes an investment decision to sell those shares into the market to generate proceeds to cover the exercise price of those employee stock options and/or any withholding tax obligations at the time of exercise (or for any other reason).
Restricted Stock / Restricted Stock Units
This Policy’s trading restrictions do not apply to (i) the vesting of restricted stock or restricted stock units or (ii) the Company’s withholding of shares (or, if the Company requires, any market sale of shares) to satisfy tax withholding requirements upon the vesting of any restricted stock or restricted stock units.
The Policy’s trading restrictions do apply, however, to any market sale of vested restricted stock or restricted stock units directed by the holder, including if the holder (as opposed to the Company) makes an investment decision to sell the shares into the market to cover any withholding tax obligations at the time of vesting (or for any other reason).

8

7.GIFTS AND OTHER TRANSFERS NOT INVOLVING A PURCHASE OR SALE
Gifts of Company securities to charities or other persons (including Family Members or Controlled Entities), as well as transfers to or from trusts or partnerships, by any person subject to this Policy are permitted, subject to any Blackout Periods and pre-clearance in accordance with the pre-clearance procedures in Section 4 of this Policy.

8.PROCEDURES FOR COMMUNICATIONS WITH THE PUBLIC
General Considerations
The Company is required under Regulation FD of the federal securities laws to avoid the selective disclosure of material nonpublic information. Company Personnel may not, therefore, disclose information to anyone outside the Company, including analysts, stockholders, journalists or any media outlet, family members and friends, other than in accordance with all Company policies and procedures. Company Personnel also may not discuss the Company or its business on social media (like LinkedIn, Facebook or Twitter), in an internet “chat room” or any other internet- or social media-based forum (other than reposting or distributing previously-approved Company communications).
The Company has established procedures for releasing material information in a manner that is designed to achieve broad public dissemination of that information immediately upon its release.
Authorized Spokespersons    
Senior officials of the Company, or any other director, officer, employee or agent of the Company who regularly communicates with investors and/or securities professionals, may be deemed to be persons “acting on behalf of” the Company for purposes of Regulation FD. Accordingly, Company Personnel may subject the Company to possible SEC enforcement action for a violation of Regulation FD if Company Personnel orally, or in writing, communicate material nonpublic information to securities professionals or investors in situations where the Company has not either previously, or simultaneously, released that information to the public pursuant to one or more of the following methods:
•Form 8-K or other document filed with, or submitted to, the SEC;
•A widely disseminated press release;
•A conference call or webcast of such call that is open to the public at large (albeit solely on a “listen-only” basis where an authorized spokesperson deems it appropriate), and has been the subject of adequate advance notice within the meaning of Regulation FD; or
•Posted on a portion of the Company’s website that is open to the public at large and has been the subject of adequate advance notice within the meaning of Regulation FD.
The Company limits the number of spokespersons authorized to communicate on behalf of the Company with any person or entity outside the Company – both to ensure compliance with Regulation FD and otherwise to protect the confidentiality of sensitive business or financial information regarding the Company. Accordingly, the Company has designated the Chairperson of the Board of Directors, the Lead Independent Director, the Chief Executive Officer, the President, the Chief Financial Officer, the Investor Relations / Corporate Communications departments and any other person or investor relations firm expressly designated by the Chief Executive Officer or the Board of Directors as the sole authorized spokespersons for the Company. These people typically lead or participate in the presentations at the Company’s quarterly earnings or other conference calls. From time to time, other employees or members of the Board of Directors may be expressly designated as authorized spokespersons to respond to specific inquiries or to make specific presentations to the investment community as necessary or appropriate, in which case they too will be deemed to be “authorized spokespersons” for purposes of this Policy.
All inquiries regarding the Company or its securities made by any person or entity outside the Company, including but not limited to securities analysts, members of the media, existing stockholders and/or debtholders and potential investors (except in the context of planned and authorized presentations) with regard to the Company’s business operations or prospects as well as the Company’s financial condition, results of operations or any development or plan affecting the Company, should be referred immediately and exclusively to the Chairperson of the Board of Directors, the Lead Independent Director, the Chief Executive Officer, the President or the Chief Financial Officer (or their respective designees) or the Investor Relations / Corporate Communications departments.
Inadvertent Disclosure    
Should Company Personnel become aware of facts suggesting that material nonpublic information may have been communicated in violation of this Policy to a securities professional, an actual or potential investor or the press – regardless of whether the source or means (oral, written or electronic (e.g., e-mail, Internet chat room, social media, etc.)), then that Company Personnel must notify the General Counsel (or his or her designee) immediately. In certain circumstances, steps can be taken immediately upon discovery of the selective disclosure to protect both the Company and the person responsible for that communication. Regulation FD, for example, gives a brief period, generally 24 hours, after discovery of a careless or inadvertent selective disclosure to avoid potential SEC enforcement action by fully disclosing the information to the public.
9

Advance Review of Speeches and Presentations    
Company Personnel need to be mindful of the information they share in speeches, presentations and meetings.
•Corporate, Investor and Analyst Presentations. Whenever practicable, the Company will encourage corporate, investor and analyst conferences, presentations and meetings in which Company Personnel participate to be open to the public and simultaneously webcast. Special care should be taken in the case of statements made in the context of informal or one-on-one meetings with analysts or investors to avoid the inadvertent disclosure of material nonpublic information.

Only the Chairperson of the Board of Directors, the Lead Independent Director, the Chief Executive Officer, the President and the Chief Financial Officer (and their respective designees) are authorized to speak or present in these situations. Other Company Personnel must obtain authorization to participate in any corporate, investor or analyst conferences, presentations and meetings from the Chairperson of the Board of Directors, the Chief Executive Officer, the President or the Chief Financial Officer (or his or her respective designee). Presentations and speeches should be provided by email to, and reviewed and authorized by, (i) the General Counsel (or his or her respective designee) and (ii) at least one of the Chief Executive Officer, the President or the Chief Financial Officer.
•Other Presentations. Any other, planned or pre-scripted portions of any other conferences or presentations to be given regarding the Company should be provided by email to, and reviewed and authorized by, the General Counsel (or his or her respective designee) in advance. If the presentation is not open to the public, consideration should be given to appropriate public dissemination of the material to be presented.
Responding to Rumors
Rumors and media reports concerning the business and affairs of the Company may circulate from time to time. It is the Company’s general policy not to comment upon such rumors and/or to publish corrections about inaccurate or incomplete media statements. Company Personnel should not comment upon or respond to such rumors and/or media reports. Requests for comments or responses should be referred to the Chairperson of the Board of Directors, the Lead Independent Director, the Chief Executive Officer, the President or the Chief Financial Officer.
Broad, Public Dissemination
It is the Company’s policy to disseminate material information broadly throughout the marketplace. In disclosing material information, the Company follows a regimen intended to disseminate the news broadly. Specifically, the Company has a policy of disclosing information to the public pursuant to any or all of the means described above in the section captioned “Authorized Spokespersons” above.
Material information should not be disclosed initially in investor forums to which access may be limited (such as investor conferences and “one-on-one” meetings with investors or analysts). That kind of limited disclosure can create an unfair advantage for such persons. For purposes of these discussions, the key litmus test is that material information must be disseminated broadly before or as it is discussed with any investor or analyst.

9.    POLICY ADMINISTRATION, ETC.    
The General Counsel (or his or her designee) will administer this Policy (provided that, in the event of any situation involving the General Counsel as a Company Personnel, the Chief Financial Officer will administer this Policy and all references in this Policy to General Counsel will be deemed to refer to the Chief Financial Officer for those purposes). Accordingly, any person who has a question about this Policy or its application to any proposed transaction may obtain additional guidance from the General Counsel (or his or her designee). Ultimately, however, the responsibility for adhering to this Policy and avoiding unlawful transactions rests with the individual Company Personnel.

10.TRAINING UNDER THE POLICY
Each of the Company Personnel subject to this Policy must train on this Policy (through the Company’s electronic training platform or otherwise) to ensure he or she has received, read, fully understands and complies with this Policy.

11.THE CONSEQUENCES OF VIOLATION
Insider trading is a serious crime. Not only does it damage those directly involved, but it also adversely affects the company whose directors, officers and other employees, agents, consultants or securities, were the subject of the offense. A company’s reputation for integrity and honesty is an important corporate asset that can be harmed significantly through an insider trading investigation conducted either by the SEC or the U.S. Department of Justice, even if no charges ultimately are brought. The consequences of violations of the federal securities laws governing insider trading (including tipping) are serious:
10

•For individuals who trade on inside information (or tip inside information to others):
ocivil penalty of up to three times the profit gained or loss avoided;
ocriminal fine (no matter how small the profit) of up to $5 million;
ojail term of up to 25 years;
odisgorgement of profits;
ocease-and-desist order to stop the violation, and penalties for violations of those orders or the federal securities laws; and
othe SEC may seek to bar an individual found to have engaged in insider trading from serving as an officer or director of the Company or any other public company that files reports with the SEC.
•For a company (as well as possibly any supervisory person) that fails to take appropriate steps to prevent illegal trading or tipping by an employee, director or other person or entity covered by that company’s policy:
ocivil penalty not to exceed the greater of $1 million or three times the profit gained or loss avoided as a result of that person’s violation; and
ocriminal penalty of up to $25 million.
•For Illegal Tipping (including as a result of unauthorized selective disclosure). Penalties may apply regardless of whether the tipper derives any benefits from the tippee’s trading activities. In addition, the person making the communication might be sued by the SEC as a “cause” of the Company’s Regulation FD violation.
The Company, its directors, officers and the supervisory personnel as designated from time to time by the General Counsel of the Company (or his or her designee), could be deemed “controlling persons” under the federal securities laws, subject to potential liability for insider trading (including tipping) based on another person’s violations. Accordingly, it is important for these people to maintain an awareness of possible insider trading violations by persons under their control and to take measures where appropriate to prevent those violations. Directors, officers and other supervisory personnel who become aware of a potential violation of the insider trading prohibitions and/or a potential violation of this Policy must immediately advise the General Counsel of the Company (or his or her designee) and must take steps where appropriate to prevent persons under their supervision from misusing material nonpublic information regarding the Company or any other company or entity covered by this Policy.
Company-Imposed Sanctions
The failure to comply with this Policy may subject Company Personnel to Company-imposed sanctions, including termination for cause, whether or not the failure to comply results in a violation of law. Needless to say, a violation of law, or even an SEC investigation that does not result in prosecution, can tarnish one’s reputation and irreparably damage a career.



Rev. 01/2024
*     *     *
11
 EX-21.1 4 ex211subsidiariesq42023.htm EX-21.1 Document

Exhibit 21.1
LANTHEUS HOLDINGS, INC.
SUBSIDIARIES
 
SubsidiaryState or Other Jurisdiction of Organization
Lantheus Medical Imaging, Inc.Delaware
Lantheus MI Canada, Inc.Canada
Lantheus MI Real Estate, LLCDelaware
Lantheus MI UK LimitedEngland and Wales
Lantheus EU LimitedIreland
Lantheus Two, LLCDelaware
Lantheus Three, LLCDelaware
Progenics Pharmaceuticals, Inc.Delaware
Molecular Insight Pharmaceuticals, Inc.Delaware
MNTX Royalties Sub LLCDelaware
EXINI Diagnostics ABSweden
Excelsior Life Sciences Ireland LimitedIreland
Progenics Pharmaceuticals Nevada, Inc.Nevada
PSMA Development Company LLCDelaware
Cerveau Technologies,Inc.Delaware


 EX-23.1 5 ex231consentq42023.htm EX-23.1 Document

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement Nos. 333-271973, 333-264890, 333-258454, 333-239491, 333-214343, 333-205211, 333-220049, 333-220050 and 333-232919 on Form S-8 of our reports dated February 22, 2024, relating to the financial statements of Lantheus Holdings, Inc. and the effectiveness of Lantheus Holdings, Inc.'s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.


/s/ Deloitte & Touche LLP

Boston, Massachusetts
February 22, 2024


 EX-31.1 6 ex311ceocertificationq42023.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
EXCHANGE ACT RULE 13a-14(a)
I, Mary Anne Heino, certify that:
1.I have reviewed this Annual Report on Form 10-K of Lantheus Holdings, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:February 22, 2024
/s/ MARY ANNE HEINO
Name:Mary Anne Heino
Title:Chief Executive Officer


 EX-31.2 7 lnth10k-123123ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
EXCHANGE ACT RULE 13a-14(a)
I, Robert J. Marshall, certify that:
1.I have reviewed this Annual Report on Form 10-K of Lantheus Holdings, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 Date: February 22, 2024
 
/s/ ROBERT J. MARSHALL, JR.
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer
(Principal Financial Officer)


 EX-32.1 8 lnth10k-123123ex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Mary Anne Heino, the Chief Executive Officer, and Robert J. Marshall, Jr., the Chief Financial Officer, of Lantheus Holdings, Inc. (the “Company”), hereby certify, that, to their knowledge:
 
1.The Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: February 22, 2024

/s/ MARY ANNE HEINO
Name: Mary Anne Heino
Title: Chief Executive Officer
 (Principal Executive Officer)
Date: February 22, 2024
 
/s/ ROBERT J. MARSHALL, JR.
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer
(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-97.1 9 ex971lantheus-executivecom.htm EX-97.1 Document

Exhibit 97.1
Lantheus Holdings, Inc.
Amended and Restated
Executive Compensation Clawback Policy
Lantheus Holdings, Inc. (the “Company”) hereby adopts this Amended and Restated Executive Compensation Clawback Policy (this “Policy”), effective as of October 2, 2023 (the “Effective Date”). Certain capitalized terms are defined in Section 4 below.
1.Introduction. This Policy is intended to provide for the recovery of erroneously awarded incentive-based compensation in the event that the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws. This Policy imposes legally binding obligations on each Executive Officer.
2.Intent and Administration. This Policy is intended to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D-1 under the Exchange Act and Nasdaq Stock Market Rule 5608. This Policy shall be interpreted to facilitate compliance with applicable laws, rules and regulations, including interpretations thereof promulgated or issued by the Securities and Exchange Commission (the “Commission”) or Nasdaq, as applicable. This Policy shall be administered by the Board or, if so designated by the Board, the Committee, in which case references herein to the Board shall be deemed references to the Committee. The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. Any determination of the Board or the Committee under this Policy will be conclusive and binding on the Company and the applicable Executive Officer(s). Subject to compliance with the Policy, the determination of the Board or the Committee need not be uniform with respect to all Officers.
3.Dissemination and Acknowledgement of this Policy. A copy of this Policy shall be provided to, and acknowledged by, each Executive Officer.
4.Definitions. For purposes of this Policy, the following terms have the meanings set forth below.
(a)“Accounting Restatement” means any accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
(b)“Board” means the Board of Directors of the Company.
(c)“Committee” means the Talent and Compensation Committee of the Board.
(d)“Erroneously Awarded Incentive-Based Compensation” means the amount of Recoverable Incentive-Based Compensation Received that exceeds the amount of Recoverable Incentive-Based Compensation that otherwise would have been Received had it been determined based on the restated amounts. The amount of Erroneously Awarded Incentive-Based Compensation must be computed without regard to any taxes paid.
(e)“Executive Officer” means the Company’s chief executive officer, president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company’s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy making functions for the Company. All executive officers identified by the Company pursuant to Item 401(b) of Regulation S-K shall be deemed to be Executive Officers.
(f)“Financial Reporting Measure” means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures that are
1

derived wholly or in part from such measures. Stock price and total shareholder return (whether absolute or relative) are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the Commission.
(g)“Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure (including any time-based equity).
(h)Incentive-Based Compensation is deemed “Received” in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.
(i)“Recoverable Incentive-Based Compensation” means all Incentive-Based Compensation Received by a person:
(i)after the later of (1) beginning service as an Executive Officer and (2) the Effective Date;
(ii)who served as an Executive Officer at any time during the performance period for that Incentive-Based Compensation;
(iii)while the Company has a class of securities listed on a national securities exchange or a national securities association; and
(iv)during the Recovery Period.
(j)“Recovery Period” means the three completed fiscal years immediately preceding the Restatement Date. The Recovery Period also includes any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years. A transition period between the last day of the Company’s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to twelve months shall be deemed a completed fiscal year.
(k)“Restatement Date” means the date that the Company is required to prepare an Accounting Restatement, which is the earlier to occur of:
(i)the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; or
(ii)the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.
5.Financial Restatement.
(a)In the event that the Company is required to prepare an Accounting Restatement, the Company shall recover reasonably promptly from each Executive Officer the amount of Erroneously Awarded Incentive-Based Compensation, regardless of fault or responsibility and regardless of if or when the Accounting Restatement is filed with the Commission.
(b)Under this Policy, each Executive Officer is legally obligated, both during and after employment, to reimburse the Company reasonably promptly for any Erroneously Awarded Incentive-Based Compensation.
(c)Any employment agreement, equity award agreement, compensation plan or other compensatory agreement or arrangement with any Executive Officer entered into on or after the Effective Date shall be deemed to include, as a condition to the receipt of any Incentive-Based Compensation from the Company, an agreement by the Executive Officer to be bound by this Policy.
6.Recovery Procedure.
2

(a)If the Company is required to prepare an Accounting Restatement, the Board shall reasonably promptly determine the amount of any Erroneously Awarded Incentive-Based Compensation. The Board shall have discretion to determine the appropriate means of recovering Erroneously Awarded Incentive-Based Compensation based on the particular facts and circumstances of each recovery. Notwithstanding the foregoing, except as provided in Section 8, the Company shall not accept an amount less than the amount of the Erroneously Awarded Incentive-Based Compensation in satisfaction of an Executive Officer’s obligations under this Policy.
(b)For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Incentive-Based Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement:
(i)the Board shall make a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received; and
(ii)the Board shall maintain documentation of its determination of that reasonable estimate and provide such documentation to Nasdaq.
(c)If an Executive Officer fails to repay all Erroneously Awarded Incentive-Based Compensation to the Company when due, (i) the Company shall seek, subject only to the exceptions in provided in Section 8, to recover such Erroneously Awarded Incentive-Based Compensation from the Executive Officer and (ii) the Executive Officer shall reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously Awarded Incentive-Based Compensation.
7.Recovery of Other Equity-Based Compensation. At the sole discretion of the Board, in the event that the Company is required to prepare an Accounting Restatement, the Company may recover from each Executive Officer all or a portion of equity-based compensation that was granted, earned, or vested based on criteria other than the attainment of a Financial Reporting Measure, and Received by such person, subject to the criteria set forth in Sections 4(i)(i)-(iv) (and all references therein to “Incentive-Based Compensation” will be deemed to include all equity-based compensation), up to an amount that the Board determines that such equity-based compensation exceeds the amount of equity-based compensation that otherwise would have been Received had it been determined based on the restated amounts. The Board shall have discretion to determine the appropriate (i) method of calculating the amount to be recovered pursuant to this Section 7, and (ii) means of recovering such amount, based on the particular facts and circumstances of each Accounting Restatement.
8.Exceptions. The Company need not recover Erroneously Awarded Incentive-Based Compensation in the following circumstances if the Committee (or in the absence of such a committee, a majority of the independent directors serving on the Board), has made a determination that recovery would be impracticable:
(a)the direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered; provided, however, that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Incentive-Based Compensation based on expense of enforcement, the Company must make a reasonable attempt to recover such Erroneously Awarded Incentive-Based Compensation, document such reasonable attempt(s) to recover, and provide that documentation to Nasdaq;
(b)recovery would violate home country law where that law was adopted prior to November 28, 2022; provided, however, that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Incentive-Based Compensation based on violation of home country law, the Company must obtain an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation, and must provide such opinion to Nasdaq; or
(c)recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. § 401(a)(13) or 26 U.S.C. § 411(a) and regulations thereunder.
9.Disclosure. The Company shall file all disclosures with respect to this Policy in accordance with the requirements of federal securities laws, including the disclosure required by applicable Commission filings.
3

10.Prohibition of Indemnification. The Company shall not insure or indemnify any Executive Officer against (a) the loss of any Erroneously Awarded Incentive-Based Compensation that is repaid, returned or recovered pursuant to this Policy, or (b) any claims relating to the Company’s enforcement of its rights under this Policy. Although Executive Officers may purchase insurance to cover their potential recovery obligations, the Company shall not pay or reimburse the Executive Officer for premiums for any such policy. Further, the Company shall not agree to exempt any Incentive-Based Compensation from the application of this Policy or to waive the Company’s right to recover any Erroneously Awarded Incentive-Based Compensation. This Policy shall supersede any such agreement or waiver (whether entered into before, on, or after the Effective Date), including any indemnification agreement.
11.Other Recovery Rights; Credit for Recovery. The Company’s right to recoupment set forth in this Policy is in addition to any other rights that the Company or any of its affiliates may have against any Executive Officer, including any remedies at law or in equity; provided that, effective as of the Effective Date, this Policy amends and restates in its entirety the Executive Compensation Clawback Policy previously made effective as of January 1, 2022. Application of this Policy does not preclude the Company or any of its affiliates from taking any other action to enforce an Executive Officer’s obligations to the Company, including termination of employment. If the Company shall recover from any Executive Officer any Erroneously Awarded Incentive-Based Compensation through any means outside this Policy, the amount recovered shall be credited against the amount owed by the Executive Officer under this Policy with respect to such Erroneously Awarded Incentive-Based Compensation. Subject to compliance with Section 409A of the Internal Revenue Code of 1986, as amended, any amount that is required to be forfeited to the Company pursuant to this Policy may, in the sole discretion of the Board, be offset against any amounts otherwise owed to the applicable Executive Officer by the Company or any subsidiary thereof (whether as wages or vacation pay or pursuant to any benefit plan or other compensatory arrangement).
12.Binding Effect. This Policy shall be binding on and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators and other legal representatives.
13.Survival; No Release or Waiver of Claims. Neither the termination of employment of an Executive Officer nor ceasing to serve as an Executive Officer shall affect the Executive Officer’s obligations under this Policy, which shall survive such termination or change in service. Each Executive Officer agrees that no general or limited release or waiver by the Company of any claims or rights shall release or waive, or be deemed to release or waive, any of the Company’s rights under this Policy (or any obligations of the Executive Officer under this Policy) unless, and only to the extent that, such release or waiver expressly refers to this Policy by name and expressly states that the Company intends to release its rights under this Policy.
14.Severability. If any provision of this Policy or the application of such provision is adjudicated to be invalid, illegal or unenforceable in any respect, that invalidity, illegality or unenforceability shall not affect any other provision of this Policy, and the invalid, illegal or unenforceable provision shall be deemed to be amended to the minimum extent necessary to render that provision or the application thereof enforceable.
15.Governing Law. This Policy shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to its conflicts of laws.
16.Amendment; Termination; Waiver. This Policy may be amended, modified or terminated at any time by the Board of Directors of the Company. The Committee shall have the discretion to waive any provision of this Policy, but only to the extent that such waiver would not result in a violation by the Company of any applicable law, rule or regulation, including Rule 10D-1 under the Exchange Act and Nasdaq Rule 5608.

* * *
4
 EX-101.SCH 10 lnth-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Changes in Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Revenue from Contracts with Customers link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Property, Plant & Equipment, Net link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Sale of Puerto Rico Subsidiary link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Asset Retirement Obligations link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Intangibles, Net and Goodwill link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Long-Term Debt, Net, and Other Borrowings link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Derivative Instruments link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Other Assets link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Net Income (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - 401(k) Plan link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Acquisition of Assets link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Revenue from Contracts with Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Property, Plant & Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Asset Retirement Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Intangibles, Net and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Net Income (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Summary of Significant Accounting Policies - Schedule of Product Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Summary of Significant Accounting Policies - Advertising and Promotion Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Other Loss (Income) (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Revenue from Contracts with Customers - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Revenue from Contracts with Customers - Schedule Of Rebates and Allowances (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Revenue from Contracts with Customers - Schedule Of Contract Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Fair Value of Financial Instruments - Schedule of Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Instruments With Significant Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Income Taxes - Schedule of Components of Income Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Income Taxes - Schedule of (Benefit) Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Income Taxes - Schedule of Differences in Statutory Rate and Effective Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Income Taxes - Schedule of Components of Deferred Income Tax Assets (Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Income Taxes - Reconciliation of Uncertain Tax Positions (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Property, Plant & Equipment, Net - Schedule of Property, Plant & Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Property, Plant & Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Sale of Puerto Rico Subsidiary (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Asset Retirement Obligations - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Intangibles, Net and Goodwill - Schedule of Intangibles, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Intangibles, Net and Goodwill - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Intangibles, Net and Goodwill - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Long-Term Debt, Net, and Other Borrowings - Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Long-Term Debt, Net, and Other Borrowings - Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Long-Term Debt, Net, and Other Borrowings - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Stock-Based Compensation - Equity Incentive Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Stock-Based Compensation - Schedule of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Stock-Based Compensation - Valuation Model Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Stock-Based Compensation - Stock Options Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - Stock-Based Compensation - Restricted Stock and TSR (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - Stock-Based Compensation - Schedule of Total Stockholder Return Restricted Awards (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - Stock-Based Compensation - Schedule of TSR Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - Stock-Based Compensation - Schedule Common Stock Repurchases (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - Leases - Schedule of Operating and Financing Lease Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - Leases - Schedule of Components of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954540 - Disclosure - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954541 - Disclosure - Net Income (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954542 - Disclosure - Commitments and Contingencies - Schedule of Purchase Commitments Under Noncancelable Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954543 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954544 - Disclosure - 401(k) Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954545 - Disclosure - Acquisition of Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954546 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954547 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 lnth-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 lnth-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 lnth-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Royalty percentage Asset Acquisition, Royalty Percentage Asset Acquisition, Royalty Percentage Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Accumulated other comprehensive loss, tax AOCI Tax, Attributable to Parent Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Loss (gain) on extinguishment of debt Gain (Loss) on Extinguishment of Debt, before Debt Issuance Cost Writeoff Research and development Research and Development Expense Changes in assets and liabilities which provided (used) cash: Increase (Decrease) in Operating Capital [Abstract] Contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Freight, distribution and operations Accrued Freight Costs Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for freight and distribution costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value TechneLite Techne Lite [Member] Techne Lite [Member] Progenics Progenics [Member] Progenics IPR & D IPR & D [Member] IPR & D Payment terms Revenue, Performance Obligation, Description of Payment Terms Deferred taxes Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities, Deferred Income Tax Expense (Benefit) Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities, Deferred Income Tax Expense (Benefit) Fair value, beginning of period Fair value, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Insider Trading Policies and Procedures [Line Items] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Other long-term assets Increase (Decrease) in Other Noncurrent Assets Provision for excess and obsolete inventory Inventory Write-down Ownership [Axis] Ownership [Axis] Minimum interest coverage ratio Debt Instrument, Covenant Compliance, Minimum Interest Coverage Ratio Debt Instrument, Covenant Compliance, Minimum Interest Coverage Ratio Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Vesting of restricted stock awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Current liabilities Liabilities, Current [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding) Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Impact on deferred taxes of change in tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Options cancelled and forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Diluted (in dollars per share) Diluted income (loss) per common share (in dollars per share) Earnings Per Share, Diluted Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Unrealized gain on cash flow hedges, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Impairment, lessor asset under operating lease Impairment, Lessor Asset under Operating Lease Extinguishment of debt, amount Extinguishment of Debt, Amount Line of Credit Line of Credit [Member] Trading Symbol Trading Symbol Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 2029 and thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Intangible and Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Long-term indemnification receivable Increase (Decrease) in Income Taxes Receivable SOFR Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Machinery and equipment Machinery and Equipment [Member] Total, cost Intangible Assets, Gross (Excluding Goodwill) Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stockholders’ equity Equity, Attributable to Parent [Abstract] Other Long-Term Assets Other Assets, Miscellaneous, Noncurrent Total Stockholder Return Restricted Stock Awards Total Stockholder Return Restricted Stock Awards [Member] Total Stockholder Return Restricted Stock Awards [Member] Schedule of Net Income (loss) Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Executive Category: Executive Category [Axis] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Estimated Useful Lives of Major Classes of Depreciable Assets Schedule of Property, Plant, and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Hedging Relationship [Domain] Hedging Relationship [Domain] 2025 Long-Term Debt, Maturity, Year Two Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Small Business Entity Small Business 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] 2028 Finance Lease, Liability, to be Paid, Year Five Letter of Credit Letter of Credit [Member] Total radiopharmaceutical oncology Radiopharmaceutical Oncology [Member] Radiopharmaceutical Oncology Notional amount Derivative, Notional Amount License and Royalty Revenues, Sales-Based Milestone Payment License and Royalty Revenues, Sales-Based Milestone Payment [Member] License and Royalty Revenues, Sales-Based Milestone Payment Schedule of Restricted Stock Awards Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Sales Milestones Sales Milestones [Member] Sales Milestones Percentage of total consideration Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Total Consideration Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Total Consideration Trademarks Trademarks [Member] Stock compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Retirement Benefits [Abstract] Retirement Benefits [Abstract] Schedule of Future Payments Required Contractual Obligation, Fiscal Year Maturity [Table Text Block] Other long-term liabilities Other Sundry Liabilities, Noncurrent Shares withheld to cover taxes Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation PYLARIFY PYLARIFY [Member] PYLARIFY 2028 and thereafter Purchase Obligation, to be Paid, Year Five and Thereafter Purchase Obligation, to be Paid, Year Five and Thereafter Interest expense, debt Interest Expense, Debt Decrease in indefinite lived assets Indefinite-Lived Intangible Assets, Period Increase (Decrease) Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract] 2019 Revolving Facility 2019 Revolving Facility [Member] 2019 Revolving Facility [Member] Antidilutive securities excluded from diluted net income (loss) per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule of non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Reconciliation of Uncertain Tax Positions [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag General and administrative General and Administrative Expense [Member] Property, plant and equipment, gross Property, Plant and Equipment, Gross Right-of-use asset obtained in exchange for operating lease liabilities Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Leases Lessee, Finance Leases [Text Block] Machinery, equipment and fixtures Machinery Equipment And Fixtures [Member] Machinery Equipment And Fixtures [Member] Schedule of Provision (benefit) for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Strategic Partnerships and other revenue Strategic Partnerships And Other [Member] Strategic Partnerships And Other Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Prepaid Expenses Prepaid Expense, Current Operating Operating Lease, Liability, Current Interest on lease liabilities Finance Lease, Interest Expense Schedule of Other Assets Schedule of Other Assets [Table Text Block] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Total Finite-Lived Intangible Assets, Net Property, Plant & Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Currently marketed product Currently Marketed Product [Member] Currently Marketed Product Accumulated Amortization Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Debt instrument, fair value Debt Instrument, Fair Value Disclosure Schedule of Components of Income (loss) Before Provision (benefit) for Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] International Income (Loss) from Continuing Operations before Income Taxes, Foreign Gross profit Gross Profit Permanent items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Schedule of Valuation Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Proceeds from interest rate swap termination Proceeds From Termination Of Derivatives Proceeds From Termination Of Derivatives Security Exchange Name Security Exchange Name Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Vesting percentages attainable during period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Options Employee Stock Option [Member] Derivative Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Performance awards, measurement period Share Based Compensation Arrangement By Share Based Payment Award, Performance Measurement Period Share Based Compensation Arrangement By Share Based Payment Award, Performance Measurement Period Asset Acquisition [Table] Asset Acquisition [Table] Maximum Maximum [Member] Depreciation, amortization and accretion Depreciation, Amortization and Accretion, Net Document Type Document Type Other Other Nonoperating Expense Tabular List, Table Tabular List [Table Text Block] Amended 10b5-1 Plan [Member] Amended 10b5-1 Plan Inventory Inventory, Policy [Policy Text Block] 2026 Finance Lease, Liability, to be Paid, Year Three Operating loss carryforwards expire Operating Loss Carryforwards, Subject to Expiration Operating Loss Carryforwards, Subject to Expiration Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Federal Current Federal Tax Expense (Benefit) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other Other Noncash Income (Expense) Business Acquisition [Axis] Business Acquisition [Axis] Derivative [Table] Derivative [Table] Self-Insurance Reserves Self Insurance Reserve [Policy Text Block] Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] State Deferred State and Local Income Tax Expense (Benefit) Variable Rate [Axis] Variable Rate [Axis] Raw materials Inventory, Raw Materials, Net of Reserves Title of 12(b) Security Title of 12(b) Security Total amount awarded Litigation Settlement, Amount Awarded from Other Party Asset Acquisition [Line Items] Asset Acquisition [Line Items] Indefinite lived, cost Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Ownership percentage Subsidiary, Ownership Percentage, Noncontrolling Owner Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Nonvested beginning balance (in dollars per share) Nonvested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Puerto Rican Radiopharmacy Servicing Subsidiary Puerto Rican Radiopharmacy Servicing Subsidiary [Member] Puerto Rican Radiopharmacy Servicing Subsidiary Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Current Lease, Liability, Current [Abstract] Lease, Liability, Current [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Total lease expense Lease, Cost Reserves, accruals and other Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals Inventory obsolescence Deferred Tax Assets, Inventory Business combination common stock under contingent value right (in shares) Business Combination, Consideration Transferred, Contingent Value Right Business Combination, Consideration Transferred, Contingent Value Right Statistical Measurement [Axis] Statistical Measurement [Axis] Other current assets Increase (Decrease) in Other Current Assets Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Obligation expected to be incurred Asset Retirement Obligation Lessor term of contract Lessor, Operating Lease, Term of Contract Product revenue, net Product [Member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Measure: Measure [Axis] Interest rate swap termination Gain (Loss) Related to Litigation Settlement Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Advertising and promotion costs Advertising Expense Accrued expenses and other liabilities Total accrued expenses and other liabilities Accounts Payable and Other Accrued Liabilities, Current Schedule of Components of Deferred Incomes Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Derivative Instruments Derivatives, Policy [Policy Text Block] 2027 Purchase Obligation, to be Paid, Year Four Federal benefit of state taxes payable Deferred Tax Assets, State Taxes 2024 Purchase Obligation, to be Paid, Year One 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating cash flows from operating leases Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Cash Payments, 2023 Cash Payments, 2023 [Member] Cash Payments, 2023 [Member] Concentration of Risks and Limited Suppliers Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location 401(k) Plan Retirement Benefits [Text Block] Debt instrument, stock price percentage Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger State and local taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Deferred Income Tax Assets, Net Deferred Income Tax Assets, Net [Member] Deferred Income Tax Assets, Net Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Total leased assets Lease, Right-Of-Use Asset Lease, Right-Of-Use Asset Interest rate swaps Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Deferred Tax Liabilities Deferred Tax Liabilities, Gross [Abstract] Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] Aggregate cash payments percentage Business Combination, Contingent Liability, Contingent Value Right Percentage Of Net Sales Business Combination, Contingent Liability, Contingent Value Right Percentage Of Net Sales Schedule of Maturities of Principal Obligations Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Current income tax expense (benefit), total Current Income Tax Expense (Benefit) Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Cash Payments, 2022 Cash Payments, 2022 [Member] Cash Payments, 2022 [Member] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Property, Plant & Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Capitalized research and development Deferred Tax Assets, in Process Research and Development Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Sales and marketing Selling and Marketing Expense General and administrative General and Administrative Expense Audit Information [Abstract] Audit Information Accrued professional fees Accrued Professional Fees, Current Capital expenditures Payments for Capital Improvements Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Total current assets Assets, Current Impairment of long-lived assets Asset Impairment Charges Contingent consideration liabilities Business Combination, Contingent Consideration, Liability Schedule of Product Concentration Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Section 162(m) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Section 162 Effective Income Tax Rate Reconciliation, Nondeductible Expense, Section 162 Total Purchase Obligation Net Income (Loss) per Common Share Earnings Per Share, Policy [Policy Text Block] Total Long-Term Debt and Lease Obligation, Including Current Maturities Intangibles, Net and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Repurchase of common stock (in shares) Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Concentration risk percentage Concentration Risk, Percentage Fair value, beginning of period Fair value, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Current Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Schedule of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five Change in indemnification deferred tax asset Effective Income Tax Rate Reconciliation, Increase In Indemnification Deferred Tax Asset Effective Income Tax Rate Reconciliation, Increase In Indemnification Deferred Tax Asset 2027 Finance Lease, Liability, to be Paid, Year Four Accounts Receivable, net Accounts Receivable [Policy Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Expected Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Short-term contingent liability Business Combination, Contingent Consideration, Liability, Current Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Effect of convertible notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Deferred Tax Assets Deferred Tax Assets, Gross [Abstract] Gain on sales of assets Gain (Loss) on Disposition of Other Assets Furniture and fixtures Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Business Combination and Asset Acquisition [Abstract] Cash Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Goodwill, impairment loss Goodwill, Impairment Loss Less: valuation allowance Deferred tax asset, valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Amounts included in the contract liability at the beginning of the period Contract with Customer, Liability, Revenue Recognized Restricted cash included in other long-term assets Restricted Cash and Cash Equivalents Unrealized loss on cash flow hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Monte Carlo simulation Monte Carlo Simulation [Member] Monte Carlo Simulation Total long-term debt, net, and other borrowings Long-Term Debt and Lease Obligation Asset acquisition, additional milestone payments Asset Acquisition, Consideration Transferred, Contingent Consideration Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Other Assets Other Assets Disclosure [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Line of credit facility, accordion feature, higher borrowing capacity option Line of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option Line of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option Sale of RELISTOR licensed intangible asset associated with net sales royalties Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount Intangibles, net Total, net Intangible Assets, Net (Excluding Goodwill) Deferred tax assets Deferred Tax Assets, Gross 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Common Stock Common Stock [Member] Proceeds from income tax refunds Proceeds from Income Tax Refunds Individual: Individual [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Income Statement Location [Domain] Income Statement Location [Domain] Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Royalty Royalty [Member] Probability adjusted discounted cash flow model Valuation Technique, Discounted Cash Flow [Member] Minimum Minimum [Member] Property, plant and equipment, net Property, Plant and Equipment, Net Potential payments, high Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Proceeds from issuance of long-term debt, net Proceeds from Issuance of Long-Term Debt Foreign currency losses Gain (Loss), Foreign Currency Transaction, before Tax Assets Lease, Right-Of-Use Asset [Abstract] Lease, Right-Of-Use Asset [Abstract] Total net leverage ratio Debt Instrument, Covenant Leverage Ratio Debt Instrument, Covenant Leverage Ratio Payments for minimum statutory tax withholding related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Total leased liabilities Lease, Liability Lease, Liability Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets, net Noncurrent deferred tax assets, net Deferred Income Tax Assets, Net Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Payments to acquire interest Payments to Acquire Interest in Subsidiaries and Affiliates Retained Earnings Retained Earnings [Member] Current portion of long-term debt and other borrowings Long-Term Debt, Current Maturities Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties Proceeds From Sale Of Royalty Rights, Additional Payment Proceeds From Sale Of Royalty Rights, Additional Payment Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Basic (in dollars per share) Basic income (loss) per common share (in dollars per share) Earnings Per Share, Basic Accounting Policies [Abstract] Accounting Policies [Abstract] Gain on disposal of assets Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties Gain on sales of assets Gain (Loss) on Disposition of Assets Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Net deferred tax assets Deferred Tax Assets, Net Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Changes in fair value of contingent assets and liabilities Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Principles of Consolidation Consolidation, Policy [Policy Text Block] Operating lease, liability, current, statement of financial position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Business combination, consideration transferred, equity interests issued (in shares) Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Shares Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Shares Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Accounts payable Increase (Decrease) in Accounts Payable Repayments of debt Repayments of Lines of Credit Schedule of Reconciliation of the Company's Changes in Uncertain Tax Positions Summary of Income Tax Contingencies [Table Text Block] Entity Public Float Entity Public Float Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount Probability of success and sales targets Measurement Input, Probability Of Success [Member] Measurement Input, Probability Of Success DEFINITY DEFINITY [Member] DEFINITY [Member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Total principal outstanding Long-Term Debt, Gross All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Compensation Amount Outstanding Recovery Compensation Amount Schedule of Operating and Finance Lease Assets and Liabilities Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Amendment 2022 Credit Facility 2022 Facility Covenants [Member] 2022 Facility Covenants Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income tax expense (benefit), total Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from stock option exercises Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Finance lease liabilities Finance Lease, Liability Convertible Debt Convertible Debt [Member] Document Financial Statement Error Correction Document Financial Statement Error Correction [Flag] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period 2.625% Convertible Senior Notes due 2027 2.625% Convertible Senior Notes due 2027 [Member] 2.625% Convertible Senior Notes due 2027 Investment Tax Credit Carryforward Investment Tax Credit Carryforward [Member] 2024 Long-Term Debt, Maturity, Year One Share price (in dollars per share) Share Price Total operating expenses Operating Expenses Before Gain Loss On Sale Of Assets Operating Expenses Before Gain Loss On Sale Of Assets Schedule of Asset Retirement Obligations Schedule of Change in Asset Retirement Obligation [Table Text Block] Effect of dilutive share based compensation (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Net sales targets – PYLARIFY (CVRs) Contingent Value Right [Member] Contingent Value Right Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Finance leases Finance Lease, Weighted Average Discount Rate, Percent Finance Finance Lease, Liability, Noncurrent Schedule of Valuation and Qualifying Accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Treasury Stock Treasury Stock, Common [Member] Income tax expense (benefit) Income tax expense (benefit) Income Tax Expense (Benefit) Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Finance Finance Lease, Right-of-Use Asset, after Accumulated Amortization Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Equity [Abstract] Inventory Inventory Disclosure [Text Block] Operating leases Operating Lease, Weighted Average Remaining Lease Term Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Money market funds Money Market Funds [Member] Debt instrument, covenant percentage of additional interest Debt Instrument, Covenant Compliance, Percentage Of Additional Interest Upon Noncompliance Debt Instrument, Covenant Compliance, Percentage Of Additional Interest Upon Noncompliance Tax credits Tax Credit Carryforward, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Shares withheld to cover taxes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Credit Facility [Domain] Credit Facility [Domain] Fair Value Option, Disclosures [Table] Fair Value Option, Disclosures [Table] Debt instrument, basis rate Debt Instrument, Basis Spread on Variable Rate Estimated useful lives Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] 2019 Term Loan Facility 2019 Term Loan Facility [Member] 2019 Term Loan Facility Schedule of contracts with customer Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Asset Retirement Obligations Asset Retirement Obligation Disclosure [Text Block] Less: interest Finance Lease, Liability, Undiscounted Excess Amount Revenue from Contract with Customers Revenue from Contract with Customer [Text Block] Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-In Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Balance Sheet Location [Axis] Balance Sheet Location [Axis] Cover [Abstract] 1404 Commercialization Milestone 1404 Commercialization Milestone [Member] 1404 Commercialization Milestone Subsequent Event Subsequent Events [Text Block] Amortization of debt related costs Amortization of Debt Issuance Costs Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Accrued liabilities associated with employee medical costs Self Insurance Reserve, Noncurrent Other long-term liabilities Total other long-term liabilities Other Liabilities, Noncurrent Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Options cancelled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Cash Flow Hedge Cash Flow Hedging [Member] Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Amortization of ROU assets Finance Lease, Right-of-Use Asset, Amortization Segment Information Segment Reporting Disclosure [Text Block] Net increase in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Renewal term Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Finance Finance Lease, Liability, Current Work in process Inventory, Work in Process, Net of Reserves State Research Credit State and Local Jurisdiction [Member] Realized loss on cash flow hedges, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Unrealized Gain (Loss), after Reclassification and Tax, Parent Other Comprehensive Income (Loss), Cash Flow Hedge, Realized Gain (Loss), after Reclassification and Tax, Parent Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Operating income (loss) Operating Income (Loss) Measurement period adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Deferred tax liability Deferred Tax Liabilities, Gross Purchase price as a percentage of principal amount Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Property, Plant and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Weighted- Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Outstanding borrowings Long-Term Line of Credit Customer relationships Customer Relationships [Member] Variable Rate [Domain] Variable Rate [Domain] Changes in fair value included in net income (loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Statistical Measurement [Domain] Statistical Measurement [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Nonvested beginning balance (in shares) Nonvested ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Long-Term Debt, Net, and Other Borrowings Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Depreciation and amortization expense Cost, Depreciation, Amortization and Depletion Effect of foreign exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Exercisable, weighted average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Discontinued Operations and Disposal Groups [Abstract] Restatement Determination Date: Restatement Determination Date [Axis] Long-term income tax payable and other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Commitments and contingencies (see Note 19) Commitments and Contingencies Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Impairment Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) PNT2003 License Agreement PNT2003 License Agreement [Member] PNT2003 License Agreement Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Financial assurance in form of surety bond Financial Assurance In Form Of Surety Bond Represents the amount of financial assurance given in the form of surety bond. Reconciliation to amounts within the consolidated balance sheets Reconciliation to Amounts Within the Consolidated Balance Sheets [Abstract] Reconciliation to Amounts Within the Consolidated Balance Sheets Concentration Risk [Line Items] Concentration Risk [Line Items] Other Current Assets Other Assets, Miscellaneous, Current Weighted-average discount rate: Lease, Weighted Average Discount Rate, Percent [Abstract] Lease, Weighted Average Discount Rate, Percent [Abstract] Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted- Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Contingent value rights settlement Payment for Contingent Consideration Liability, Financing Activities PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Cerveau Technologies, Inc Cerveau Technologies, Inc [Member] Cerveau Technologies, Inc Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Treasury stock, shares (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Options outstanding, beginning balance (in shares) Options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Fair value of debt Long-Term Debt, Fair Value Net income (loss) Net income (loss) Net (loss) income Net income (loss) Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] 2025 Finance Lease, Liability, to be Paid, Year Two Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Other precision diagnostics Other Precision Diagnostics [Member] Other Precision Diagnostics Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Leverage Ratio Range Net Leverage Ratio [Member] Net Leverage Ratio [Member] Repurchase of common stock Repurchase of common stock Stock Repurchased During Period, Value Change in useful life estimate Asset Retirement Obligation, Revision of Estimate Amounts reclassified to earnings Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Options exercised (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic Cost of goods sold Cost of Goods and Services Sold Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Proceeds from sale of assets, net Proceeds from Sale of Productive Assets Schedule of RSU Valuation Model Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Name Measure Name Name Forgone Recovery, Individual Name Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Goodwill Goodwill Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Asset Acquisition [Domain] Asset Acquisition [Domain] Underlying Securities Award Underlying Securities Amount Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Cash Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Operating lease liabilities (Note 16) Operating Operating Lease, Liability, Noncurrent Weighted-average remaining lease term (Years): Lease, Weighted Average Remaining Lease Term [Abstract] Lease, Weighted Average Remaining Lease Term [Abstract] Debt instrument, term (in years) Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Accrued rebates, discounts and chargebacks Accrued Rebates Discounts And Chargebacks Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates, discounts and chargebacks. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Schedule of Financial Instruments with Significant Level 3 Inputs Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Proceeds from selling rights to the royalties Proceeds From Sale Of Royalty Rights Proceeds From Sale Of Royalty Rights Royalty percentage Royalty Percentage Royalty Percentage Debt issuance costs Payments of Debt Issuance Costs Net proceeds from the notes Proceeds from Repayment of Loans to Purchase Common Stock Financial Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Somerset, New Jersey Somerset, New Jersey [Member] Somerset, New Jersey Income Statement Location [Axis] Income Statement Location [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Deferred financing costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Asset Retirement Obligation Disclosure [Abstract] Asset Retirement Obligation Disclosure [Abstract] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Schedule of Future Minimum Lease Payments Under Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Reserves, accruals and other Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Schedule of Components of Lease Expense and Other Information Lease, Cost [Table Text Block] Inventory Increase (Decrease) in Inventories Asset retirement obligation acceleration Asset Retirement Obligation, Acceleration Expense Asset Retirement Obligation, Acceleration Expense Derivative Instruments and Hedging Activities Disclosure [Abstract] Other radiopharmaceutical oncology Other Radiopharmaceutical Oncology [Member] Other Radiopharmaceutical Oncology Interest expense Interest Expense Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Additions of property, plant and equipment included in liabilities Capital Expenditures Incurred but Not yet Paid Loss (gain) on extinguishment of debt Gain (loss) on extinguishment of debt Gain (Loss) on Extinguishment of Debt Share based compensation, shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Options outstanding, weighted average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Operating loss carried forward Operating Loss Carryforwards, Not Subject to Expiration Operating Loss Carryforwards, Not Subject to Expiration Trading Arrangement: Trading Arrangement [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Liability measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Stock option exercises and employee stock plan purchases Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Ownership Plan Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Ownership Plan Debt instrument, unamortized discount Debt Instrument, Unamortized Discount Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Discount rate Measurement Input, Discount Rate [Member] 2026 Long-Term Debt, Maturity, Year Three Stock option exercises and employee stock plan purchases (in shares) Stock Issued During Period, Shares, Options Exercises During Period and Employee Stock Ownership Plan Stock Issued During Period, Shares, Options Exercises During Period and Employee Stock Ownership Plan Reductions related to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Q1 2024 Q1 2024 [Member] Q1 2024 Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Contingent payments Contingent Payments Under Company's License Agreements Contingent Payments Under Company's License Agreements Additions related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents and restricted cash, beginning of year Cash and cash equivalents and restricted cash, end of year Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Operating lease expense Operating Lease, Cost Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Less: current portion Long-Term Debt and Lease Obligation, Current Treasury Stock at cost - 1,339 shares as of December 31, 2023 and 2022 Treasury Stock, Common, Value Debt Instrument, convertible, carrying amount Long-Term Debt Total assets Assets, Fair Value Disclosure 1095 commercialization milestone 1095 Commercialization [Member] 1095 Commercialization 2027 Long-Term Debt, Maturity, Year Four Average fixed interest rate Derivative, Average Fixed Interest Rate Foreign currency translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Weighted-average remaining period for recognition of unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Right-of-use asset Deferred Tax Liabilities, Right Of Use Assets Deferred Tax Liabilities, Right Of Use Assets Uncertain tax positions Tax provision benefit/expense Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Federal Domestic Tax Authority [Member] Entity Address, Address Line One Entity Address, Address Line One PNT2002 License Agreement PNT2002 License Agreement [Member] PNT2002 License Agreement Finite-lived intangible assets, period increase (decrease) Finite-Lived Intangible Assets, Period Increase (Decrease) Acquisition of Assets Asset Acquisition [Text Block] Subsequent Event [Table] Subsequent Event [Table] Initial conversion premium Debt Instrument, Convertible, Conversion Premium Represents the initial conversion premium of as a percentage of last reported sale price of the Common Stock. Recorded in the accompanying consolidated balance sheets as: Components of Deferred Tax Assets and Liabilities [Abstract] 2024 Finance Lease, Liability, to be Paid, Year One Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair Value, Option, Quantitative Disclosures [Line Items] Fair Value, Option, Quantitative Disclosures [Line Items] Sam Leno [Member] Sam Leno Subsequent Event Subsequent Event [Member] Net operating loss carryovers Operating Loss Carryforwards Schedule of Finite-Lived Intangibles Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Total precision diagnostics Total Precision Diagnostics [Member] Total Precision Diagnostics Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Other current assets Total other current assets Other Assets, Current U.S. statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Inventory Total inventory Inventory, Net Bedford, Massachusetts Bedford, Massachusetts [Member] Bedford, Massachusetts Land Land [Member] Sale of Puerto Rico Subsidiary Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Advertising and Promotion Costs Advertising Cost [Policy Text Block] Total Shareholder Return Amount Total Shareholder Return Amount Repurchase of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Number of covenants Debt Instrument, Covenant Compliance, Number Of Financial Covenants Debt Instrument, Covenant Compliance, Number Of Financial Covenants International Deferred Foreign Income Tax Expense (Benefit) Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of other loss (income) Schedule of Other Nonoperating Income (Expense) [Table Text Block] Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Debt instrument, face amount Debt Instrument, Face Amount Current assets Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Total future minimum lease payments Finance Lease, Liability, to be Paid Initial conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Convertible, conversion ratio Debt Instrument, Convertible, Conversion Ratio Disposal Group Name [Domain] Disposal Group Name [Domain] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Total Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Research Revenue Milestones Research Revenue Milestones [Member] Research Revenue Milestones Number of product categories Revenue from Contract with Customer, Number Of Product Categories Revenue from Contract with Customer, Number Of Product Categories Operating lease liability Total Operating Lease, Liability ROU assets obtained in exchange for lease obligations: Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Asset Acquisition [Axis] Asset Acquisition [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Disposal group consideration Purchase price for stock Disposal Group, Including Discontinued Operation, Consideration Accumulated Other Comprehensive Loss Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Provision related to current period revenues SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Expense recognized by the company for matching contributions Defined Contribution Plan, Cost All Executive Categories All Executive Categories [Member] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] POINT Biopharma POINT Biopharma [Member] POINT Biopharma Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net income (loss) per common share: Earnings Per Share [Abstract] Common stock ($0.01 par value, 250,000 shares authorized; 69,863 and 68,851 shares issued as of December 31, 2023 and 2022, respectively) Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Operating lease, liability, noncurrent, statement of financial position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Senior Notes Senior Notes [Member] Deferred Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Financing cash flows from finance leases Finance Lease, Principal Payments Schedule of Future Minimum Lease Payments Under Finance Leases Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Net sales targets – AZEDRA and 1095 Contingent Consideration, Net Sales Targets [Member] Contingent Consideration, Net Sales Targets Penalty accruals Unrecognized Tax Benefits, Income Tax Penalties Accrued Finance lease, right-of-use asset, statement of financial position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other (income) loss, net Total other (income) loss Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Long-term contingent liability (Note 4) Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Change in fair value of the contingent financial asset and contingent financial liabilities Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) Schedule of Reconciliation of Income Taxes at the U.S. Federal Statutory Rate to the Actual Income Taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Uncertain tax positions Beginning balance of uncertain tax positions Ending balance of uncertain tax positions Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Convertible Notes Debt, Policy [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Base Rate Base Rate [Member] Buildings Buildings Building [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Stock compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Payments or credits made during the period SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Other Other Accrued Liabilities, Current Product Concentration Risk Product Concentration Risk [Member] Description of Business Nature of Operations [Text Block] Interest rate Debt Instrument, Interest Rate, Stated Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Pre-tax book gain on disposal Gain (Loss) on Disposition of Business Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Restricted stock Restricted Stock [Member] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Subsequent Events [Abstract] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Noncash impairment Tangible Asset Impairment Charges Level 2 Fair Value, Inputs, Level 2 [Member] Acquisition of assets Payments to Acquire Productive Assets Liabilities, Current Liabilities, Current [Member] Liabilities, Current Disposal Group Classification [Domain] Disposal Group Classification [Domain] Deferred financing costs Payments Of Deferred Financing Costs Payments Of Deferred Financing Costs Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Useful Lives (in years) Finite-Lived Intangible Asset, Useful Life 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Options outstanding, beginning balance (in dollars per share) Options outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Charges incurred in connection with acquired IPR&D Business Combination, Increase (Decrease) In Acquired Intangible Assets Business Combination, Increase (Decrease) In Acquired Intangible Assets City Area Code City Area Code Product and Service [Axis] Product and Service [Axis] Net Income (Loss) Per Common Share Earnings Per Share [Text Block] Total liabilities for uncertain tax positions including interest and penalties Unrecognized Tax Benefits, Including Interest And Penalties Unrecognized Tax Benefits, Including Interest And Penalties Asset Retirement Obligations Asset Retirement Obligation [Policy Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Net Sales Targets For Azedra Net Sales Targets For Azedra [Member] Net Sales Targets For Azedra Term of contract Lessee, Operating Lease, Term of Contract Noncurrent Lease, Liability, Noncurrent [Abstract] Lease, Liability, Noncurrent [Abstract] Computer software Software and Software Development Costs [Member] Land improvements Land Improvements [Member] Schedule of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total liabilities Liabilities, Fair Value Disclosure Financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Operating lease, right-of-use asset, statement of financial position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Income taxes, net of refunds of $25, $50 and $315, respectively Income Taxes Paid, Net Developed technology Developed Technology Rights [Member] Schedule of Stock-Based Compensation Expense Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other long-term assets Total other long-term assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Operating lease, right-of-use asset ROU Asset Operating Lease, Right-of-Use Asset Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] International Current Foreign Tax Expense (Benefit) Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Finance lease expense Finance Lease, Expense [Abstract] Finance Lease, Expense [Abstract] Finance lease, liability, current, statement of financial position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Arrangement Duration Trading Arrangement Duration Contingent Consideration Liabilities Contingent Liability Reserve Estimate, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Lease liability Deferred Tax Assets, Lease Liability Deferred Tax Assets, Lease Liability 2025 Purchase Obligation, to be Paid, Year Two 2026 Purchase Obligation, to be Paid, Year Three Fair Values of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] License and royalty revenues License and Royalty Revenues [Member] License and Royalty Revenues [Member] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Accrued Expenses and Other Liabilities and Other Long-Term Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Adjustments to reconcile net income (loss) to net cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Bridge Loan Bridge Loan [Member] Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Fair value of vested shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Disposal group holdback amount Disposal Group, Including Discontinued Operation, Consideration, Holdback Amount Disposal Group, Including Discontinued Operation, Consideration, Holdback Amount Income Taxes Income Tax, Policy [Policy Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Asset Retirement Obligation, Roll Forward Analysis [Roll Forward] Asset Retirement Obligation, Roll Forward Analysis [Roll Forward] Insider Trading Arrangements [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Options outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Amortization of intangibles other than goodwill Deferred Tax Liabilities, Intangible Assets Other Than Goodwill Deferred Tax Liabilities, Intangible Assets Other Than Goodwill 2022 Term Facility 2022 Term Facility [Member] 2022 Term Facility Adjustments relating to prior period revenues SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Regulatory Milestones Regulatory Milestones [Member] Regulatory Milestones 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two New York City New York City [Member] New York City Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of goods sold Cost of Sales [Member] Changes in fair value of contingent assets and liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Massachusetts MASSACHUSETTS Auditor Name Auditor Name Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of leases Number Of Operating Leases Number Of Operating Leases Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Vesting of restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Disposal Group Name [Axis] Disposal Group Name [Axis] Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Payments on long-term debt and other borrowings Repayments of Long-Term Debt Entity Central Index Key Entity Central Index Key Gain on interest rate swap termination Derivative, Gain (Loss) on Derivative, Net Changes in fair value included in net income (loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Total stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Cost Finite-Lived Intangible Assets, Gross Finished goods Inventory, Finished Goods, Net of Reserves Income Tax Authority [Domain] Income Tax Authority [Domain] Compensation and benefits Employee-related Liabilities, Current Revenue Benchmark Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Total other comprehensive income (loss) Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Accretion expense Asset Retirement Obligation, Accretion Expense Foreign tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Revenues Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Asset retirement obligations Balance at the beginning of the period Balance at the ending of the period Asset Retirement Obligations, Noncurrent Operating leases Operating Lease, Weighted Average Discount Rate, Percent Licenses Licensing Agreements [Member] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Business Combinations Business Combinations Policy [Policy Text Block] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Finance leases Finance Lease, Weighted Average Remaining Lease Term Finance lease, liability, noncurrent, statement of financial position [Extensible List] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Leasehold improvements Leasehold Improvements [Member] Sales and marketing Selling and Marketing Expense [Member] Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Perspective Therapeutics, Inc Perspective Therapeutics, Inc [Member] Perspective Therapeutics, Inc Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Operating expenses Operating Expenses [Abstract] Payments to acquire license agreement Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Thereafter Finance Lease, Liability, to be Paid, after Year Five Business combination contingent value right of total consideration Business Combination, Contingent Liability, Contingent Value Right, Consideration Business Combination, Contingent Liability, Contingent Value Right, Consideration Tax indemnification expense, net Indemnification expense Tax Indemnification Agreement, Income (Expense) Represents the tax indemnification income (loss) earned during the period. Proceeds from convertible debt Proceeds from Convertible Debt Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 2028 Long-Term Debt, Maturity, Year Five Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Construction in progress Construction in Progress [Member] Financial Assets Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Non-PEO NEO Non-PEO NEO [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Basic weighted-average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Unamortized debt issuance costs Unamortized Debt Issuance Expense Depreciation Deferred Tax Liabilities, Property, Plant and Equipment Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] 2.625% Convertible Senior Notes due 2027 Convertible Senior Notes 2.625 Percent Due 2027 [Member] Convertible Senior Notes 2.625 Percent Due 2027 Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Line of credit facility, unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Payment for acquisitions Payments For Asset Acquisitions Payments For Asset Acquisitions Interest accruals Unrecognized Tax Benefits, Interest on Income Taxes Accrued Intangible assets Deferred Tax Liabilities, Intangible Assets Liabilities Lease, Liability [Abstract] Lease, Liability [Abstract] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] EX-101.PRE 14 lnth-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 lnth-20231231_g1.jpg begin 644 lnth-20231231_g1.jpg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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Feb. 15, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-36569    
Entity Registrant Name LANTHEUS HOLDINGS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 35-2318913    
Entity Address, Address Line One 201 Burlington Road, South Building    
Entity Address, City or Town Bedford    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 01730    
City Area Code 978    
Local Phone Number 671-8001    
Title of 12(b) Security Common Stock, $0.01 par value per share    
Trading Symbol LNTH    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction false    
Entity Shell Company false    
Entity Public Float     $ 5,672.5
Entity Common Stock, Shares Outstanding   68,525,556  
Documents Incorporated by Reference
DOCUMENTS INCORPORATED BY REFERENCE
Listed hereunder are the documents, portions of which are incorporated by reference, and the parts of this Form 10-K into which such portions are incorporated:
The Registrant’s Definitive Proxy Statement for use in connection with the Annual Meeting of Stockholders to be held on April 25, 2024, portions of which are incorporated by reference into Parts II and III of this Form 10-K. The 2024 Proxy Statement will be filed with the Securities and Exchange Commission no later than 120 days after the close of our year ended December 31, 2023. 		   
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001521036    

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Firm ID 34
Auditor Location Boston, Massachusetts
Auditor Name Deloitte & Touche LLP
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 713,656 $ 415,652
Accounts receivable, net 284,292 213,397
Inventory 64,029 35,475
Other current assets 16,683 13,092
Assets held for sale 7,159 0
Total current assets 1,085,819 677,616
Property, plant and equipment, net 146,697 122,166
Intangibles, net 151,985 315,285
Goodwill 61,189 61,189
Deferred tax assets, net 150,198 110,647
Other long-term assets 55,261 34,355
Total assets 1,651,149 1,321,258
Current liabilities    
Current portion of long-term debt and other borrowings 823 354
Accounts payable 41,189 20,563
Short-term contingent liability 0 99,700
Accrued expenses and other liabilities 145,338 127,084
Total current liabilities 187,350 247,701
Asset retirement obligations 22,916 22,543
Total long-term debt, net, and other borrowings 561,670 557,712
Other long-term liabilities 63,321 46,155
Total liabilities 835,257 874,111
Commitments and contingencies (see Note 19)
Stockholders’ equity    
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding) 0 0
Common stock ($0.01 par value, 250,000 shares authorized; 69,863 and 68,851 shares issued as of December 31, 2023 and 2022, respectively) 699 689
Additional paid-in capital 757,727 715,875
Treasury Stock at cost - 1,339 shares as of December 31, 2023 and 2022 (75,000) (75,000)
Retained earnings (accumulated deficit) 133,503 (193,158)
Accumulated other comprehensive loss (1,037) (1,259)
Total stockholders’ equity 815,892 447,147
Total liabilities and stockholders’ equity $ 1,651,149 $ 1,321,258
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 25,000,000 25,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 69,863,000 68,851,000
Common stock, shares outstanding (in shares) 69,863,000 68,851,000
Treasury stock, shares (in shares) 1,339,000 1,339,000
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Revenues $ 1,296,429 $ 935,061 $ 425,208
Cost of goods sold 586,886 353,358 237,513
Gross profit 709,543 581,703 187,695
Operating expenses      
Sales and marketing 141,736 100,243 68,422
General and administrative 125,458 133,584 150,395
Research and development 77,707 311,681 44,966
Total operating expenses 344,901 545,508 263,783
Gain on sales of assets 0 0 15,263
Operating income (loss) 364,642 36,195 (60,825)
Interest expense 20,019 7,185 7,752
Loss (gain) on extinguishment of debt 0 588 (889)
Other (income) loss, net (66,320) 1,703 7,350
Income (loss) before income taxes 410,943 26,719 (75,038)
Income tax expense (benefit) 84,282 (1,348) (3,759)
Net income (loss) $ 326,661 $ 28,067 $ (71,279)
Net income (loss) per common share:      
Basic (in dollars per share) $ 4.79 $ 0.41 $ (1.06)
Diluted (in dollars per share) $ 4.65 $ 0.40 $ (1.06)
Weighted-average common shares outstanding:      
Basic (in shares) 68,266 68,487 67,486
Diluted (in shares) 70,239 70,671 67,486
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ 326,661 $ 28,067 $ (71,279)
Other comprehensive income:      
Foreign currency translation 222 (505) (124)
Realized loss on cash flow hedges, net of tax 0 (269) 0
Unrealized gain on cash flow hedges, net of tax 0 0 1,687
Total other comprehensive income (loss) 222 (774) 1,563
Comprehensive income (loss) $ 326,883 $ 27,293 $ (69,716)
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Treasury Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2020   66,875,000        
Beginning balance (in shares) at Dec. 31, 2020     0      
Beginning balance at Dec. 31, 2020 $ 514,205 $ 669 $ 0 $ 665,530 $ (149,946) $ (2,048)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (loss) income (71,279)       (71,279)  
Other comprehensive (loss) income 1,563         1,563
Stock option exercises and employee stock plan purchases (in shares)   360,000        
Stock option exercises and employee stock plan purchases 6,062 $ 3   6,059    
Vesting of restricted stock awards (in shares)   611,000        
Vesting of restricted stock awards 0 $ 6   (6)    
Shares withheld to cover taxes (in shares)   (107,000)        
Shares withheld to cover taxes (2,046) $ (1)   (2,045)    
Stock-based compensation 15,934     15,934    
Ending balance (in shares) at Dec. 31, 2021   67,739,000        
Ending balance (in shares) at Dec. 31, 2021     0      
Ending balance at Dec. 31, 2021 464,439 $ 677 $ 0 685,472 (221,225) (485)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (loss) income 28,067       28,067  
Other comprehensive (loss) income (774)         (774)
Stock option exercises and employee stock plan purchases (in shares)   411,000        
Stock option exercises and employee stock plan purchases 8,912 $ 4   8,908    
Vesting of restricted stock awards (in shares)   845,000        
Vesting of restricted stock awards 0 $ 9   (9)    
Shares withheld to cover taxes (in shares)   (144,000)        
Shares withheld to cover taxes $ (7,759) $ (1)   (7,758)    
Repurchase of common stock (in shares) (1,300,000)   1,339,000      
Repurchase of common stock $ (75,000)   $ (75,000)      
Stock-based compensation $ 29,262     29,262    
Ending balance (in shares) at Dec. 31, 2022 68,851,000 68,851,000        
Ending balance (in shares) at Dec. 31, 2022 1,339,000   1,339,000      
Ending balance at Dec. 31, 2022 $ 447,147 $ 689 $ (75,000) 715,875 (193,158) (1,259)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (loss) income 326,661       326,661  
Other comprehensive (loss) income 222         222
Stock option exercises and employee stock plan purchases (in shares)   245,000        
Stock option exercises and employee stock plan purchases 5,749 $ 2   5,747    
Vesting of restricted stock awards (in shares)   962,000        
Vesting of restricted stock awards 0 $ 10   (10)    
Shares withheld to cover taxes (in shares)   (195,000)        
Shares withheld to cover taxes $ (14,394) $ (2)   (14,392)    
Repurchase of common stock (in shares) 0          
Stock-based compensation $ 50,507     50,507    
Ending balance (in shares) at Dec. 31, 2023 69,863,000 69,863,000        
Ending balance (in shares) at Dec. 31, 2023 1,339,000   1,339,000      
Ending balance at Dec. 31, 2023 $ 815,892 $ 699 $ (75,000) $ 757,727 $ 133,503 $ (1,037)
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating activities      
Net income (loss) $ 326,661 $ 28,067 $ (71,279)
Adjustments to reconcile net income (loss) to net cash flows from operating activities:      
Depreciation, amortization and accretion 60,043 47,929 42,288
Impairment of long-lived assets 138,050 0 9,729
Asset retirement obligation acceleration 0 280 5,259
Gain on interest rate swap termination 0 (5,494) 0
Amortization of debt related costs 4,300 1,249 676
Changes in fair value of contingent assets and liabilities (9,275) 34,700 72,400
Charges incurred in connection with acquired IPR&D 0 260,000 0
Loss (gain) on extinguishment of debt 0 588 (889)
Provision for excess and obsolete inventory 7,914 7,145 4,057
Stock-based compensation 50,507 29,262 15,934
Gain on disposal of assets (51,789) 0 (15,263)
Deferred taxes (55,632) (48,016) 4,437
Long-term indemnification receivable 3,929 9,554 7,121
Long-term income tax payable and other long-term liabilities (3,103) (12,477) (7,912)
Other 4,855 4,059 2,512
Changes in assets and liabilities which provided (used) cash:      
Accounts receivable (68,637) (128,460) (33,102)
Inventory (36,220) (7,508) (3,549)
Other current assets (2,418) (2,440) (73)
Other long-term assets 0 (533) 0
Accounts payable 17,189 301 5,425
Accrued expenses and other liabilities (81,114) 63,575 16,145
Net cash provided by operating activities 305,260 281,781 53,916
Investing activities      
Capital expenditures (46,555) (18,347) (12,140)
Proceeds from sale of assets, net 97,839 1,800 15,823
Acquisition of assets (45,345) (260,000) 0
Net cash provided by (used in) investing activities 5,939 (276,547) 3,683
Financing activities      
Proceeds from issuance of common stock 1,933 1,375 767
Debt issuance costs 0 (95) 0
Proceeds from issuance of long-term debt, net 0 557,750 0
Contingent value rights settlement (3,700) 0 0
Payments on long-term debt and other borrowings (717) (175,385) (43,348)
Deferred financing costs 0 (2,315) 0
Proceeds from interest rate swap termination 0 5,583 0
Proceeds from stock option exercises 3,816 7,537 5,295
Payments for minimum statutory tax withholding related to net share settlement of equity awards (14,394) (7,759) (2,046)
Repurchase of common stock 0 (75,000) 0
Net cash (used in) provided by financing activities (13,062) 311,691 (39,332)
Effect of foreign exchange rates on cash and cash equivalents (93) (335) (310)
Net increase in cash and cash equivalents and restricted cash 298,044 316,590 17,957
Cash and cash equivalents and restricted cash, beginning of year 417,241 100,651 82,694
Cash and cash equivalents and restricted cash, end of year 715,285 417,241 100,651
Reconciliation to amounts within the consolidated balance sheets      
Cash and cash equivalents 713,656 415,652 98,508
Restricted cash included in other long-term assets 1,629 1,589 2,143
Cash, cash equivalents and restricted cash at end of period 715,285 417,241 100,651
Supplemental disclosure of cash flow information      
Interest 15,387 5,064 6,284
Income taxes, net of refunds of $25, $50 and $315, respectively 151,579 54,049 215
Schedule of non-cash investing and financing activities      
Additions of property, plant and equipment included in liabilities 6,978 2,370 1,262
Right-of-use asset obtained in exchange for operating lease liabilities $ 29,396 $ 11,019 $ 683
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Cash Flows [Abstract]      
Proceeds from income tax refunds $ 25 $ 50 $ 315
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Description of Business
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business Description of Business
Lantheus Holdings, Inc., a Delaware corporation, is the parent company of Lantheus Medical Imaging, Inc. (“LMI”) and LMI is the parent company of Progenics Pharmaceuticals, Inc., a Delaware corporation (“Progenics”), and Cerveau Technologies, Inc. (“Cerveau”). See “Progenics Acquisition” and “Acquisition of Assets”, respectively.
The Company develops, manufactures and commercializes innovative diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of cancer, heart disease and other diseases. The Company believes its diagnostic products result in improved diagnostic information that enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs throughout the healthcare system.
The Company’s commercial products are used by cardiologists, internal medicine physicians, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
The Company produces and markets its products throughout the U.S., selling primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies. The Company sells its products outside the U.S. through a combination of direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Sales of the Company’s prostate cancer diagnostic imaging agent, PYLARIFY (as defined below), are generated in the U.S. through an internal PYLARIFY sales team, as well as a sales team at some of the Company’s positron emission tomography (“PET”) manufacturing facilities (“PMF”) partners. Sales of the Company’s ultrasound enhancing agent, DEFINITY, are generated in the U.S. through an internal DEFINITY sales team. In the U.S., the Company’s other nuclear imaging products, including TechneLite, Xenon, NEUROLITE and CARDIOLITE, are primarily sold to commercial radiopharmacies, the majority of which are controlled by or associated with PharmaLogic, Cardinal, RLS, UPPI, and Jubilant Radiopharma. Research revenue is derived from existing partnerships with pharmaceutical companies that use our products and product candidates in clinical trials and includes milestone and dose-related payments. A small portion of the Company’s nuclear imaging product sales in the U.S. are generated through the Company’s internal sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical preparation capabilities.
In Europe, Australia, Asia-Pacific, Central America and South America, the Company generally relies on third-party distributors to market, sell and distribute its nuclear imaging and ultrasound enhancing agent products, either on a country-by-country basis or on a multi-country regional basis. The Company’s executive offices are located in Bedford, MA, with additional offices in North Billerica, MA, Somerset, NJ, Montreal, Canada and Lund, Sweden.
Progenics Acquisition
On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”).
In connection with the Progenics Acquisition, Lantheus Holdings issued 26,844,877 shares of Lantheus Holdings common stock and 86,630,633 contingent value rights (each a “CVR”) tied to the financial performance of PYLARIFY to former Progenics stockholders and option holders. Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of United States (“U.S.”) net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. The Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, was capped at 19.9% of the total consideration the Company paid in the Progenics Acquisition. Based on the Company’s 2022 PYLARIFY net sales, the Company determined that the aggregate payment obligation under the CVRs was $99.6 million, which was the maximum amount payable. The Company paid out this amount in May 2023 in full satisfaction of the CVRs.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, contingent assets and liabilities, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.
Revenue Recognition
The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services. See Note 3, “Revenue from Contracts with Customers” for further discussion on revenues.
Accounts Receivable, net
Accounts receivable consist of amounts billed and currently due from customers. The Company maintains an allowance for doubtful accounts for estimated losses. In determining the allowance, consideration includes the probability of recoverability based on past experience and general economic factors. Certain accounts receivable may be fully reserved when the Company becomes aware of any specific collection issues. The Company periodically reviews the aging of receivables, payment history and customer creditworthiness to determine if adjustments to the allowance for doubtful accounts is necessary. Allowance for doubtful accounts has been immaterial for all years presented.
Income Taxes
The Company accounts for income taxes using an asset and liability approach. Income tax (benefit) expense represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when such changes are enacted.
The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more-likely-than-not to be realized. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that the future tax benefit will not be realized. The assessment of whether or not a valuation allowance is required involves weighing both positive and negative evidence, including both historical and prospective information, with greater weight given to evidence that is objectively verifiable. A history of recent losses is negative evidence that is difficult to overcome with positive evidence. In evaluating prospective information there are four sources of taxable income: reversals of taxable temporary differences, items that can be carried back to prior tax years (such as net operating losses), pre-tax income, and prudent and feasible tax planning strategies. Adjustments to the deferred tax valuation allowances are made in the period when those assessments are made.
The Company accounts for uncertain tax positions using a two-step recognition threshold and measurement analysis method to determine the financial statement impact of uncertain tax positions taken or expected to be taken in a tax return. Differences between tax positions taken in a tax return and amounts recognized in the financial statements are recorded as adjustments to other long-term assets and liabilities, or adjustments to deferred taxes, or both. The Company records the related interest and penalties to income tax (benefit) expense.
Net Income (Loss) per Common Share
The Company computes earnings per share using the two-class method. Basic earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities as if those securities were converted or exercised. The Company’s potentially dilutive shares, which could include shares issuable upon conversion of the 2.625% Convertible Senior Notes due 2027 (the “Notes”), are considered to be common stock equivalents and are only included in the calculation of diluted net income per share when their effect is dilutive. The Company has the option to settle the Notes through cash settlement or a combination of cash and share settlement provided that the principal is settled in cash and the conversion spread is settled in cash or shares as elected by the Company. The Company applies the if-converted method for diluted earnings in order to reflect the conversion spread. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.
Cash and Cash Equivalents
Cash and cash equivalents include savings deposits, certificates of deposit and money market funds that have original maturities of three months or less when purchased.
Restricted Cash
Restricted cash as of December 31, 2023 and 2022, represents primarily collateral for a letter of credit securing a lease obligation and a security deposit. The Company believes the carrying value of these assets approximates fair value.
Concentration of Risks and Limited Suppliers
Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies.
As of December 31, 2023 and 2022, no customer accounted for greater than 10% of accounts receivable, net. No customer accounted for greater than 10% of revenues for the years ended December 31, 2023, 2022 and 2021.
The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.
The Company currently relies on JHS as its significant manufacturer of DEFINITY and its sole source manufacturer of NEUROLITE, CARDIOLITE and evacuation vials for TechneLite. The Company relies on Samsung Biologics Co., Ltd. (“SBL”) as its sole source manufacturer of DEFINITY RT. The Company has Mo-99 supply agreements with IRE of Belgium, running through December 31, 2024, with auto-renewal provisions and terminable upon notice of non-renewal, and with NTP and its subcontractor ANSTO, running through December 31, 2024.
The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:

Year Ended
December 31,
202320222021
PYLARIFY
65.7 %56.4 %10.2 %
DEFINITY21.6 %26.2 %54.7 %
TechneLite6.7 %9.5 %21.5 %
Inventory
Inventory includes material, direct labor and related manufacturing overhead and is stated at the lower of cost and net realizable value on a first-in, first-out basis. The Company records inventory when the Company takes title to the product.
The Company assesses the recoverability of inventory to determine whether adjustments for excess and obsolete inventory are required. Inventory that is in excess of future requirements is written down to its estimated net realizable value based on product shelf life, forecasted demand and other factors.
Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed as incurred. The Company had no inventory pending regulatory approval as of December 31, 2023.
Property, Plant and Equipment, net
Property, plant & equipment are stated at cost. Replacements of major units of property are capitalized, and replaced properties are retired. Replacements of minor components of property and repair and maintenance costs are charged to expense as incurred. Certain costs to obtain or develop computer software are capitalized and amortized over the estimated useful life of the software. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets and recorded
in costs of goods sold and operating expenses in the associated functional expense category which utilizes the associated asset. The estimated useful lives of the major classes of depreciable assets are as follows:

ClassRange of Estimated Useful Lives
Buildings
10 - 50 years
Land improvements
15 - 40 years
Machinery and equipment
3 - 15 years
Furniture and fixtures
15 years
Leasehold improvements
Lesser of lease term or 15 years
Computer software
3 - 5 years

Upon retirement or other disposal of property, plant & equipment, the cost and related amount of accumulated depreciation are removed from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds is included in operating income.
Included within machinery and equipment are spare parts. Spare parts include replacement parts relating to plant & equipment and are either recognized as an expense when consumed or reclassified and capitalized as part of the related asset and depreciated over the remaining useful life of the related asset.
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired IPR&D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.
During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition.
Goodwill
Goodwill is not amortized but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely-than-not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year.
In performing the Company’s annual assessment, the Company is permitted to first perform a qualitative test and if necessary, perform a quantitative test. If the Company is required to perform the quantitative impairment test of goodwill, the Company compares the fair value of a reporting unit to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting units using discounted cash flow or other valuation models, such as comparative transactions and market multiples. The Company performed a qualitative assessment and did not recognize any goodwill impairment charges during the years ended December 31, 2023, 2022 or 2021.
Intangible and Long-Lived Assets
The Company tests intangible and long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. The Company measures the recoverability of assets to be held and used by comparing the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If those assets are considered to be impaired, the impairment equals the amount by which the carrying amount of the assets exceeds the fair value of the assets. Any impairments are recorded as permanent reductions in the carrying amount of the assets. See Note 7, “Property, Plant and Equipment, Net” for further details on impairment. Long-lived assets, other than goodwill and other intangible assets that are held for sale are recorded at the lower of the carrying value or the fair market value less the estimated cost to sell.
Intangible assets, consisting of patents, trademarks, customer relationships, a currently marketed product, licenses and developed technology related to the Company’s products are amortized in a method equivalent to the estimated utilization of the economic benefit of the asset.
Costs of IPR&D intangible assets acquired as part of an asset acquisition that have no alternative future use are expensed when incurred. Milestone payments made after regulatory approval are capitalized as an intangible asset and amortized over an estimated useful life of the product. Cash payments related to acquired IPR&D intangible assets are reflected as an investing cash flow in the Company's consolidated statement of cash flows.
The Company’s IPR&D intangible assets includes intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. Because obtaining regulatory approval can include significant risks and uncertainties, the eventual realized value of the acquired IPR&D projects may vary from their fair value at the date of acquisition. The Company classifies IPR&D intangible assets acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, the Company will determine the useful life and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, the Company writes-off the remaining carrying amount of the associated IPR&D intangible asset. IPR&D intangible assets are tested at least annually as of October 31 or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in the Company’s consolidated statements of operations. See Note 10, “Intangibles, net and Goodwill” for further details on impairment.
Contingencies
In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, product and environmental liability. The Company records accruals for those loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized.
Convertible Notes
The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The change in fair value of any separately recognized derivative is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation.
Fair Values of Financial Instruments
The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The Company’s long-term debt has triggering events that would impact the fair value of the instruments. The Company determined that no triggering event has occurred during the years ended December 31, 2023 and December 31, 2022. As of December 31, 2023, the fair value of the Company’s convertible debt was estimated to be approximately $644.3 million based on external pricing data, including quoted market prices of these instruments and was classified as a Level 1 measurement within the fair value hierarchy. As of December 31, 2022, the carrying value of the Company’s convertible debt approximated fair value and was classified as a Level 1 measurement within the fair value hierarchy. The fair value See Note 4, “Fair Value of Financial Instruments”.
Contingent Consideration Liabilities
The estimated fair value of contingent consideration liabilities are initially measured and recorded on the acquisition date, are considered to be a Level 3 instrument and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations.
The estimated fair value is determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that include significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.
Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement.
The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based milestones, development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.
Derivative Instruments
The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged. Further, the Company must formally document the hedging relationship at inception and, on at least a quarterly basis, continually reevaluate the relationship to ensure it remains highly effective throughout the life of the hedge. The Company does not enter into derivative financial instruments for speculative or trading purposes.
Advertising and Promotion Costs
Advertising and promotion costs are expensed as incurred. During the years ended December 31, 2023, 2022 and 2021, the Company incurred $26.0 million, $26.0 million and $17.5 million, respectively in advertising and promotion costs, which are included in sales and marketing in the consolidated statements of operations.
Research and Development
Research and development costs are expensed as incurred and relate primarily to the development of new products to add to the Company’s portfolio and costs related to its medical affairs and medical information functions. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and recognized as an expense as the goods are delivered or the related services are performed.
Foreign Currency
The consolidated statements of operations of the Company’s foreign subsidiaries are translated into U.S. Dollars using weighted-average exchange rates. The net assets of the Company’s foreign subsidiaries are translated into U.S. Dollars using the end of period exchange rates. The impact from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive loss in the consolidated balance sheets.
Remeasurement of the Company’s foreign currency denominated transactions are included in net income. Transaction gains and losses are reported as a component of other loss (income) in the consolidated statements of operations.
Stock-Based Compensation
The Company’s stock-based compensation cost is measured at the grant date of the stock-based award based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period, and includes an estimate of the awards that will be forfeited. The Company estimates the fair value of each stock-based award on its measurement date using either the current market price of the stock, the Black-Scholes option valuation model or the Monte Carlo simulation valuation model, whichever is most appropriate. The Black-Scholes and Monte Carlo simulation valuation models incorporate assumptions such as stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield.
Expected volatility is based on the historical volatility of the Company’s stock price. The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the awards’ expected lives. Expected lives are principally based on the Company’s historical exercise experience with previously issued awards. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.
Expense for performance restricted stock awards is recognized based upon the fair value of the awards on the date of grant and the number of shares expected to vest based on the terms of the underlying award agreement and the requisite service period(s).
Other Loss (Income)
Other loss (income) consisted of the following:

 Year Ended
December 31,
(in thousands)202320222021
Foreign currency losses$21 $256 $274 
Tax indemnification expense, net4,943 9,554 7,121 
Interest income(19,638)(2,613)(45)
Interest rate swap termination— (5,494)— 
Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties(51,789)
Other143 — — 
Total other (income) loss $(66,320)$1,703 $7,350 

Comprehensive Income (Loss)
Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net income. For the Company, other comprehensive income (loss) consists of foreign currency translation gains and losses as well as realized and unrealized gains and losses on cash flow hedges related to the Company’s interest rate swaps. The accumulated other comprehensive income (loss) balance consists entirely of foreign currency translation gains and losses and realized and unrealized gains and losses on outstanding cash flow hedges related to the Company’s interest rate swaps.
Asset Retirement Obligations
The Company’s compliance with federal, state, local and foreign environmental laws and regulations may require it to remove or mitigate the effects of the disposal or release of chemical substances in jurisdictions where it does business or maintains properties. The Company establishes accruals when those costs are legally obligated and can be reasonably estimated. Accrual amounts are estimated, which may include the assistance of third-party environmental specialists, and are based on currently available information, regulatory requirements, remediation strategies, historical experience, the relative shares of the total remediation costs, a relevant discount rate, and the time periods of when estimated costs can be reasonably predicted. Changes in these assumptions could impact the Company’s future reported results.
The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts campus and its Somerset, New Jersey site. The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. The liability is measured at the present value of the obligation expected to be incurred and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the assets’ useful lives.
The Company has identified conditional asset retirement obligations related to the future removal and disposal of asbestos contained in certain of the buildings located on the Company’s North Billerica, Massachusetts campus. The Company believes the asbestos is appropriately contained and it is compliant with all applicable environmental regulations. If these properties undergo major renovations or are demolished, certain environmental regulations are in place, which specify the manner in which asbestos must be handled and disposed. The Company is required to record the fair value of these conditional liabilities if they can be reasonably estimated. As of December 31, 2023 and 2022, sufficient information was not available to estimate a liability for such conditional asset retirement obligations as the obligations to remove the asbestos from these properties have indeterminable settlement dates. As such, no liability for conditional asset retirement obligations has been recorded in the accompanying consolidated balance sheets as of December 31, 2023 and 2022.
Self-Insurance Reserves
The Company’s consolidated balance sheets at December 31, 2023 and 2022 include $1.0 million and $0.9 million of accrued liabilities associated with employee medical costs that are retained by the Company, respectively. The Company estimates the required liability of those claims on an undiscounted basis based upon various assumptions which include, but are not limited to, the Company’s historical loss experience and projected loss development factors. The required liability is also subject to adjustment in the future based upon changes in claims experience, including changes in the number of incidents (frequency) and change in the ultimate cost per incident (severity).
Recent Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company is currently in the process of evaluating the effects of this pronouncement on our related disclosures.
In December 2023, the FASB also issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on our related disclosures.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue from Contracts with Customers
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customers Revenue from Contracts with Customers
Revenue Recognition
Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services. To achieve this core principle, the Company applies the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the Company satisfies a performance obligation.
Disaggregation of Revenue
The following table summarizes revenue by revenue source as follows:
Year Ended December 31,
Major Products/Service Lines
(in thousands)		202320222021
    Product revenue, net(1)
$1,263,068 $887,038 $400,356 
    License and royalty revenues(2)
33,361 48,023 24,852 
Total revenues$1,296,429 $935,061 $425,208 
______________________________
(1)The Company’s product revenue includes PYLARIFY and DEFINITY, among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all of its principal products.
(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.
The Company classifies its revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology includes PYLARIFY and AZEDRA. In 2023, the Company announced its decision to discontinue the production and promotion of AZEDRA and it does not expect AZEDRA to contribute to the business after the first quarter of 2024. Precision Diagnostics includes DEFINITY, TechneLite and other diagnostic imaging products. Strategic Partnerships and Other Revenue includes strategic partnerships and other arrangements related to other products of the Company, including our royalty revenue from our license of RELISTOR. On August 2, 2023, the Company sold the RELISTOR royalty asset under its license agreement with Bausch; the Company retained the rights to future sales-based milestone payments. During the fourth quarter of 2023, the Company earned a $15.0 million sales-based milestone payment.
On January 31, 2022, the Company entered into a global settlement agreement with Novartis Pharma AG (“Novartis”), Advanced Accelerator Applications USA, Inc., Endocyte, Inc. and their affiliates (the “Novartis Agreement”) to settle certain disputes between the parties. Under the Novartis Agreement, Novartis agreed to make a lump sum payment to the Company, as well as to reimburse the Company for certain fees and expenses in connection with certain German litigation, and the Company agreed to license certain intellectual property to Novartis. In addition, the Company agreed to supply PYLARIFY for clinical purposes at an arms-length value which will be recorded revenue in the future as product is provided. In accordance with the Company's ASC 606, Revenue from Contracts with Customers, assessment, Novartis is considered to be a customer. The Company determined that the $24.0 million constituted a single element which was satisfied on the date of the execution of the Novartis Agreement. The Company determined that the license of intellectual property carried a fair value of $24.0 million. As such, the Company assigned the value to the fair value of the license, which constitutes the entire transaction price and does not require further allocation. The Company determined that the $24.0 million represented the point at which the licensee was able to use and benefit from the license and recognized revenue when the license was granted to Novartis upon execution of the Novartis Agreement. The Company recognized the $24.0 million fee as revenue on its consolidated statement of operations for the quarter ended March 31, 2022. The Company received the $24.0 million payment in April 2022.
Revenue by product category on a net basis is as follows:
Year Ended December 31,
(in thousands)202320222021
PYLARIFY$851,303 $527,405 $43,414 
Other radiopharmaceutical oncology3,130 4,102 5,473 
Total radiopharmaceutical oncology854,433 531,507 48,887 
DEFINITY279,768 244,993 232,759 
TechneLite87,370 88,864 91,293 
Other precision diagnostics22,980 22,825 26,973 
Total precision diagnostics390,118 356,682 351,025 
Strategic Partnerships and other revenue51,878 46,872 25,296 
Total revenues$1,296,429 $935,061 $425,208 
Product Revenue, Net
The Company sells its products principally to hospitals, independent diagnostic testing facilities, and radiopharmacies. The Company considers customer purchase orders, which in some cases are governed by master sales or group purchasing organization agreements, to be the contracts with a customer.
For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 60 days from invoicing, the Company has elected to use the significant financing component practical expedient.
The Company allocates the transaction price to each distinct product based on their relative standalone selling price. The product price as specified on the purchase order is considered the standalone selling price as it is an observable input which depicts the price as if sold to a similar customer in similar circumstances.
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which typically occurs upon delivery to the customer. Further, in determining whether control has transferred, the Company considers if there is a present right to payment and legal title, along with risks and rewards of ownership having transferred to the customer.
Frequently, the Company receives orders for products to be delivered over multiple dates that may extend across several reporting periods. The Company invoices for each delivery upon shipment and recognizes revenues for each distinct product delivered, assuming transfer of control has occurred.
The Company generally does not separately charge customers for shipping and handling costs, but any shipping and handling costs charged to customers are included in product revenue, net. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.
Variable Consideration
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the
Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect product revenue and earnings in the period such variances become known.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying consolidated balance sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. The Company estimates the amount of rebates and allowances that are explicitly stated in the Company’s contracts based on a combination of actual purchases and an estimate of the customer’s buying patterns.
Product Returns: The Company generally offers customers a limited right of return due to non-conforming product. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. Reserves for product returns are not significant to the Company due to the nature of its products including radiopharmaceutical products with limited half-lives.
An analysis of the amount of, and change in, reserves is summarized as follows:
(in thousands)Rebates and
Allowances
Balance, January 1, 2022$10,977 
Provision related to current period revenues26,683 
Adjustments relating to prior period revenues70 
Payments or credits made during the period(24,331)
Balance, December 31, 202213,399 
Provision related to current period revenues32,308 
Adjustments relating to prior period revenues(453)
Payments or credits made during the period(29,184)
Balance, December 31, 2023$16,070 
License and Royalty Revenues
The Company has entered into licensing agreements, under which it licenses certain rights to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. The Company also has distribution licenses which are treated as combined performance obligations with the delivery of its products and are classified as product revenue, net.
In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step approach stated earlier. The Company uses judgment in determining the number of performance obligations in a license agreement by assessing whether the license is distinct or should be combined with another performance obligation, as well as the nature of the license. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Milestone Payments: At the inception of each arrangement that includes development or sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are outside the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and royalty revenues and earnings in the period of adjustment. At December 31, 2023, the variable consideration for the milestone payments is constrained and is excluded from contract price until the milestone is achieved by the customer.
Royalty Revenues: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
Contract Costs
The Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient to expense the costs as they are incurred, within sales and marketing expenses, since the amortization period is less than one year.
The Company recognized certain revenues as follows:
Year Ended December 31,
(in thousands)20232022
Amounts included in the contract liability at the beginning of the period$682 $244 
The Company did not record any revenue related to performance obligations satisfied (or partially satisfied) in previous periods during the years ended December 31, 2023 and 2022.
The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
•Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
•Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
•Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.
The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market.
The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:

 December 31, 2023
(in thousands)Total Fair
Value		Level 1Level 2Level 3
Assets:
Money market funds$574,131 $574,131 $— $— 
Total assets$574,131 $574,131 $— $— 
Liabilities:
Contingent consideration liabilities$2,700 $— $— $2,700 
Total liabilities$2,700 $— $— $2,700 
 December 31, 2022
(in thousands)Total Fair
Value		Level 1Level 2Level 3
Assets:
Money market funds$342,646 $342,646 $— $— 
Total assets$342,646 $342,646 $— $— 
Liabilities:
Contingent consideration liabilities$111,600 $— $— $111,600 
Total liabilities$111,600 $— $— $111,600 
During the years ended December 31, 2023 and 2022, there were no transfers into or out of Level 3. On December 2, 2022, the Company voluntarily terminated the interest rate swap contracts in connection with the refinancing of debt.
As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. (“CytoDyn”) related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions
pertaining to regulatory events and sales targets. During the fourth quarter of 2022, the Company reduced the probability to zero as CytoDyn withdrew their regulatory application. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.
As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum cap. Refer to Note 1, “Basis of Presentation” for further details on the CVRs. The Company paid out the maximum amount payable under the CVRs from available cash in May 2023 in full satisfaction of the CVR obligation.
The Company also assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 (also known as 131 I-MIP-1095) and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the 2013 Acquisition each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success.
Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities will be consistent with any recurring fair value estimate of such contingent consideration liabilities.
The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of liabilities using Level 3 inputs as of December 31, 2023.
Fair Value as ofAssumptions
(in thousands)December 31, 2023December 31, 2022Valuation TechniqueUnobservable InputDecember 31, 2023December 31, 2022
Contingent consideration liability:
Net sales targets – PYLARIFY (CVRs)N/A$99,700 Probability adjusted discounted cash flow modelPeriod of expected milestone achievement and sales targetsN/A2022 – 2023
Probability of successN/A100 %
1095 commercialization milestone1,800 1,700 Probability adjusted discounted cash flow model
Period of expected milestone achievement20262026
Probability of success40 %40 %
Discount rate4.1 %3.8 %
Net sales targets – AZEDRA and 1095900 10,200 Monte Carlo simulation
Probability of success and sales targets
0% - 40%
20% - 100%
Discount rate
15%
16% - 17%
Total$2,700 $111,600 
For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:

Financial AssetsFinancial Liabilities
(in thousands)Years Ended December 31,Years Ended December 31,
2023202220232022
Fair value, beginning of period$— $9,300 $111,600 $86,200 
Changes in fair value included in net income (loss)— (9,300)(9,275)25,400 
Cash Payments— — (99,625)— 
Fair value, end of period$— $— $2,700 $111,600 
The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in a general and administrative expense of $9.3 million for the year ended December 31, 2023 and was primarily due to changes in revenue forecasts, changes in market conditions, an increase in discount rates (excluding the CVRs) and the passage of time. The Company made the applicable cash payment related to the CVRs in May 2023.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of income (loss) before provision (benefit) for income taxes consists of the following:
Year Ended
December 31,
(in thousands)202320222021
U.S.$410,326 $29,012 $(76,389)
International617 (2,293)1,351 
Income (loss) before income taxes$410,943 $26,719 $(75,038)
The Company’s provision (benefit) for income taxes consists of the following:
Year Ended
December 31,
(in thousands)202320222021
Current
Federal$110,108 $42,532 $— 
State29,806 4,302 (8,166)
International— (166)(30)
139,914 46,668 (8,196)
Deferred
Federal(45,252)(39,920)1,048 
State(10,739)(8,315)3,058 
International359 219 331 
(55,632)(48,016)4,437 
Income tax expense (benefit)$84,282 $(1,348)$(3,759)
The reconciliation of income taxes at the U.S. federal statutory rate to the income tax expense (benefit) is as follows:
Year Ended
December 31,
(in thousands)202320222021
U.S. statutory rate$86,298 $5,611 $(15,758)
Permanent items1,042 2,309 1,764 
Sale of RELISTOR licensed intangible asset associated with net sales royalties(10,817)— — 
Section 162(m)307 247 1,028 
Uncertain tax positions(5,045)(12,629)(8,952)
Tax credits(2,118)(4,085)(990)
State and local taxes18,726 67 656 
Impact on deferred taxes of change in tax rate(330)4,169 3,049 
Changes in fair value of contingent assets and liabilities(1,948)5,422 15,015 
Foreign tax rate differential128 68 23 
Valuation allowance(4)(30)(400)
Stock compensation(3,941)(4,612)(1,164)
Change in indemnification deferred tax asset1,240 2,343 1,786 
Other744 (228)184 
Income tax expense (benefit)$84,282 $(1,348)$(3,759)
The components of deferred income tax assets (liabilities) are as follows:
December 31,
(in thousands)20232022
Deferred Tax Assets
Federal benefit of state taxes payable$263 $1,739 
Reserves, accruals and other18,923 31,532 
Inventory obsolescence— 919 
Capitalized research and development17,142 79,946 
Stock compensation9,266 — 
Intangible assets25,214 — 
Net operating loss carryforwards80,184 88,014 
Lease liability14,365 — 
Deferred tax assets165,357 202,150 
Deferred Tax Liabilities
Reserves, accruals and other— (5,354)
Right-of-use asset(11,543)— 
Intangible assets— (80,770)
Amortization of intangibles other than goodwill— (385)
Depreciation— (1,469)
Deferred tax liability(11,543)(87,978)
Less: valuation allowance(3,616)(3,525)
$150,198 $110,647 
Recorded in the accompanying consolidated balance sheets as:
Noncurrent deferred tax assets, net$150,198 $110,647 
The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. Under the Act, research and experimental expenditures incurred for tax years beginning after December 31, 2021, must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on where the research activities are conducted. If the requirement to capitalize Section 174 expenditures is not modified, it may impact our cash tax liability in future years. The increase in worldwide net deferred tax assets is primarily due to the tax capitalization of the Company’s current year research and development expenses that are not currently deductible in 2023 and the decrease in deferred tax liabilities related to the AZEDRA and RELISTOR royalty intangible assets, partially offset by utilization of net operating losses.
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence. As of December 31, 2023 and 2022, the Company maintains a valuation allowance of $3.6 million and $3.5 million, respectively, primarily related to net deferred tax assets of certain of its foreign subsidiaries.
Utilization of net operating loss carryforwards and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 (“IRC Section 382”) and with Section 383 of the Internal Revenue Code of 1986, as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards and research and development credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change, as defined by IRC Section 382, results from transactions which impact the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.
At December 31, 2023, the Company had U.S. federal net operating loss carryforwards of approximately $297.6 million, $157.9 million of which will expire between 2027 and 2037, and $139.6 million of which can be carried forward indefinitely. The Company’s state net operating losses are $12.5 million on a tax-effected basis, which will expire between 2024 and 2040. The Company has state research credit carryforwards of $2.1 million, which will expire between 2026 and 2038. The Company has state investment tax credit carryforwards of $0.8 million which have no expiration date.
The Company’s U.S. federal income tax returns are subject to examination for three years after the filing date of the return. The state and foreign income tax returns are subject to examination for periods varying from three to four years after filing, depending on the specific jurisdiction’s statutes of limitation, and in the case of Sweden, up to six years after the end of the financial year.
A reconciliation of the Company’s changes in uncertain tax positions for 2023 and 2022 is as follows:
(in thousands)Amount
Balance of uncertain tax positions as of January 1, 2021$5,292 
  Additions related to current year tax positions— 
  Reductions related to prior year tax positions(188)
  Settlements(1,446)
  Lapse of statute of limitations— 
Balance of uncertain tax positions as of December 31, 20213,658 
   Additions related to current year tax positions— 
   Reductions related to prior year tax positions(1,180)
   Settlements(306)
   Lapse of statute of limitations(692)
Balance of uncertain tax positions as of December 31, 20221,480 
   Additions related to current year tax positions3,749 
   Reductions related to prior year tax positions(688)
   Settlements(442)
   Lapse of statute of limitations— 
Balance of uncertain tax positions as of December 31, 2023$4,099 
In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into an indemnification agreement with BMS for any payments made to settle those uncertain tax positions with the taxing authorities.
In accordance with the Company’s accounting policy, the change in the tax liability, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change, adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities. Included in other (income) loss for the years ended December 31, 2023, 2022 and 2021, is tax indemnification expense (income), net of $4.9 million, $9.6 million and $7.1 million, respectively.
As of December 31, 2023 and 2022, total liabilities for uncertain tax positions including interest and penalties were $5.4 million and $8.3 million, respectively, consisting of uncertain tax positions of $4.1 million and $1.5 million, respectively, interest accruals of $1.3 million and $6.4 million, respectively, and no penalty accruals as of December 31, 2023 and $0.4 million of penalty accruals as of December 31, 2022. The increase in uncertain tax positions during the year ended December 31, 2023 was primarily related to certain acquired tax attributes. As of December 31, 2023, $1.3 million, $3.2 million, and $0.9 million of these liabilities were recorded in current liabilities, other long-term liabilities, and as a reduction of deferred tax assets, respectively. As of December 31, 2022 these liabilities were included in other long-term liabilities. Included in the 2023, 2022 and 2021 tax provisions are benefits of $5.0 million, $12.6 million and $9.0 million, respectively, relating to reversals of uncertain tax positions recognized upon settlements, effective settlements, or lapses of relevant statutes of limitation, partially offset by interest accruals.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Inventory
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consisted of the following:

December 31,
(in thousands)20232022
Raw materials$31,259 $19,987 
Work in process13,807 8,234 
Finished goods18,963 7,254 
Total inventory$64,029 $35,475 
Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. The Company has no inventory pending regulatory approval as of December 31, 2023.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property, Plant & Equipment, Net
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant & Equipment, Net Property, Plant and Equipment, Net
Property, plant and equipment, net, consisted of the following:
 December 31,
(in thousands)20232022
Land$9,480 $13,450 
Buildings73,441 76,329 
Machinery, equipment and fixtures102,576 92,604 
Computer software27,259 25,864 
Construction in progress40,964 14,047 
253,720 222,294 
Less: accumulated depreciation and amortization(107,023)(100,128)
Total property, plant and equipment, net$146,697 $122,166 
Depreciation and amortization expense related to property, plant & equipment, net, was $13.2 million, $13.7 million and $13.2 million for the years ended December 31, 2023, 2022 and 2021, respectively.
The Company tests long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. During the year ended December 31, 2021, the Company reviewed certain facts relating to an asset group that included the right-of-use (“ROU”) asset associated with the lease of office space in the World Trade Center (the “WTC lease”) in New York City and resulted in a change to the asset group due to the negotiation of a sublease. Please refer to Note 16, “Leases” for further details.
During the three months ended June 30, 2023, as a result of a decline in expected future cash flows related to a certain asset group, the Company determined certain impairment triggers had occurred. The Company reviewed revised undiscounted cash flows that were estimated to be generated by the asset group as of June 30, 2023. Based on the undiscounted cash flow analysis, the Company determined that the asset group had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on their discounted cash flows. The carrying value exceeded the fair value and as a result, the Company recorded a noncash impairment of $6.0 million for the six months ended June 30, 2023 in cost of goods sold in the consolidated statements of operations.
Long-Lived Assets Held for Sale
During the first quarter of 2023, the Company committed to a plan to sell a portion of its land and buildings associated with its Billerica, Massachusetts campus. Effective March 16, 2023, the Company entered into a purchase and sale agreement (the “P&S”) with a prospective buyer. The assets were classified as held for sale and comprised entirely of property, plant and equipment, net. The Company determined that the fair value of the net assets being sold exceeded the carrying value as of September 30, 2023. The purchase price for the campus sale is $10.0 million in cash. The transaction is expected to close in the second or third quarter of 2024.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Sale of Puerto Rico Subsidiary
 12 Months Ended
Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Sale of Puerto Rico Subsidiary Sale of Puerto Rico Subsidiary
During the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021.
The purchase price for the stock sale was $18.0 million in cash, which included a holdback amount of $1.8 million that was remitted to the Company as of December 31, 2021, and paid in the first quarter of 2022; the purchase price also included a working capital adjustment. The SPA contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA.
The Company determined that this sale of certain net assets did not constitute a strategic shift that had a major effect on the Company’s operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s accompanying consolidated financial statements.
The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income (loss) in the consolidated statements of operations for the year ended December 31, 2021.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Asset Retirement Obligations
 12 Months Ended
Dec. 31, 2023
Asset Retirement Obligation Disclosure [Abstract]  
Asset Retirement Obligations Asset Retirement Obligations
The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and Somerset, New Jersey sites. As of December 31, 2023, the liability is measured at the present value of the obligation expected to be incurred, of approximately $25.1 million.
The following table provides a summary of the changes in the Company’s asset retirement obligations:

(in thousands)Amount
Balance, January 1, 2022$20,833 
Change in useful life estimate280 
Accretion expense1,430 
Balance, December 31, 202222,543 
Accretion expense373 
Balance, December 31, 2023$22,916 
The Company is required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts and Somerset, New Jersey production facilities, respectively, upon closure. The Company has provided this financial assurance in the form of a $30.3 million surety bond.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Intangibles, Net and Goodwill
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangibles, Net and Goodwill Intangibles, Net and Goodwill
Intangibles, net, consisted of the following:
 December 31, 2023
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 – 25
Straight-Line$13,540 $(12,216)$1,324 
Customer relationships
15 – 25
Accelerated157,995 (117,574)40,421 
Currently marketed product
9 – 15
Straight-Line132,800 (38,277)94,523 
Licenses
11 – 16
Straight-Line22,233 (7,972)14,261 
Developed technology9Straight-Line2,400 (944)1,456 
Total$328,968 $(176,983)$151,985 

December 31, 2022
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 – 25
Straight-Line$13,540 $(12,061)$1,479 
Customer relationships
15 – 25
Accelerated96,681 (95,009)1,672 
Currently marketed product
9 – 15
Straight-Line275,700 (47,628)228,072 
Licenses
11 – 16
Straight-Line85,800 (19,101)66,699 
Developed technology9Straight-Line2,400 (677)1,723 
IPR&DN/AN/A15,640 — 15,640 
Total$489,761 $(174,476)$315,285 
The Company recorded amortization expense for its intangible assets of $46.4 million, $33.2 million and $27.5 million for the years ended December 31, 2023, 2022 and 2021, respectively.
In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset.
On August 2, 2023, the Company sold the right to its RELISTOR royalty asset under its license agreement with Bausch; the Company retained the rights to future sales-based milestone payments. The Company received an initial payment of approximately $98.0 million in connection with the sale and has the right to receive an additional payment from the buyer of $5.0 million if worldwide net sales of RELISTOR in 2025 exceed a specified threshold. The additional payment would be recognized upon achievement of the specified threshold. Decreases of $63.6 million of license assets and $17.5 million of associated accumulated amortization, as well as a gain of $51.8 million were recorded as a result of the sale. During the fourth quarter of 2023, the Company earned a $15.0 million sales-based milestone payment.
In March 2023, the Company stopped all development activities in relation to a future indication associated with AZEDRA, which was classified as an IPR&D intangible asset. The asset group, which consisted of the IPR&D asset and a currently marketed product (the “AZEDRA intangible asset group”), was assessed for impairment. The Company considered several factors in estimating the future projections of revenues and cash flows of the AZEDRA intangible asset group as part of the impairment testing. The Company concluded that the carrying amount exceeded the fair value of the AZEDRA intangible asset group, which had no value. The Company recorded a non-cash impairment charge of $15.6 million in research and development expenses relating to the IPR&D asset and $116.4 million in cost of goods sold relating to the currently marketed indication of AZEDRA in the consolidated statement of operations for the year ended December 31, 2023.
On August 15, 2023, the Company announced that it had made the decision to discontinue the production and promotion of AZEDRA and would be winding down its Somerset, New Jersey manufacturing site. The Company will continue manufacturing AZEDRA into the first quarter of 2024, to the extent feasible, with the goal of providing doses of AZEDRA to current patients so they can complete their treatment regimen. See Note 7, “Property, Plant and Equipment, Net” for impairment analysis.
In February 2023, the Company entered into an agreement with the stockholders of Cerveau to purchase all of the outstanding capital stock of Cerveau for approximately $35.3 million. In May 2023, upon successful completion of a technology transfer, the Company paid $10.0 million to the selling stockholders of Cerveau. This additional contingent payment was capitalized as part of the
asset cost and increased the Company’s customer relationship intangible assets. See Note 21, “Acquisition of Assets” for further discussion of the Cerveau acquisition.
The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:
(in thousands)Amount
2024$39,726 
202524,409 
202625,206 
202719,680 
202816,195 
2029 and thereafter 26,769 
Total$151,985 
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accrued Expenses and Other Liabilities and Other Long-Term Liabilities
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities and Other Long-Term Liabilities Accrued Expenses and Other Liabilities and Other Long-Term Liabilities
Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:
 December 31,
(in thousands)20232022
Compensation and benefits$36,331 $30,425 
Freight, distribution and operations67,529 49,067 
Accrued rebates, discounts and chargebacks16,070 13,399 
Accrued professional fees10,244 8,668 
Other15,164 25,525 
Total accrued expenses and other liabilities$145,338 $127,084 
Operating lease liabilities (Note 16)$54,453 $25,442 
Long-term contingent liability (Note 4)2,700 11,900 
Other long-term liabilities6,168 8,813 
Total other long-term liabilities$63,321 $46,155 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Long-Term Debt, Net, and Other Borrowings
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Long-Term Debt, Net, and Other Borrowings Long-Term Debt, Net, and Other Borrowings
As of December 31, 2023, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:
(in thousands)Amount
2024$— 
2025— 
2026— 
2027575,000 
2028— 
Total principal outstanding575,000 
Unamortized debt issuance costs(13,955)
Finance lease liabilities1,448 
Total562,493 
Less: current portion(823)
Total long-term debt, net, and other borrowings$561,670 
In December 2022, the Company refinanced its existing credit facility, consisting of (i) a $200.0 million five-year term loan facility (the “2019 Term Facility”) and (ii) a $200.0 million five-year revolving credit facility (the “2019 Revolving Facility” and, together with the 2019 Term Facility, the “2019 Facility”), with a new $100.0 million delayed draw term loan facility (the “2022 Term
Facility” and, the loans thereunder, the “Term Loans”) and a new $350.0 million five-year revolving credit facility (the “2022 Revolving Facility” and, together with the 2022 Term Facility, the “2022 Facility”).
The Company used approximately $7.8 million of cash on hand to primarily repay the principal amount of the loans outstanding related to the 2019 Facility through the nine months ended September 30, 2022. In addition, in December 2022, the Company used approximately $167.6 million of cash on hand to repay in full the aggregate remaining principal amount of the loans outstanding under the 2019 Facility and to pay related interest, transaction fees and expenses.
The Company paid off the 2019 Term Facility using available cash and did not utilize another term loan to fund the payoff. While the 2022 Term Facility allowed for a delayed draw term loan, the loan was not drawn upon. The Company recorded a loss on extinguishment of debt of $0.6 million related to the write-off of unamortized debt issuance costs and debt discounts associated with the 2019 Term Facility. In addition, the Company incurred and capitalized $2.7 million of new deferred financing costs related to the refinancing.
2022 Revolving Facility
Under the terms of the 2022 Revolving Facility, the lenders are committed to extending credit to the Company from time to time until December 2, 2027 consisting of revolving loans (the “Revolving Loans”) in an aggregate principal amount not to exceed $350.0 million (the “Revolving Commitment”) at any time, including a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”) and a $10.0 million sub-facility for swingline loans (the “Swingline Loans”). The Letters of Credit, Swingline Loans and the Revolving Loans, if used, are expected to be used for working capital and for other general corporate purposes.
The Revolving Loans bear interest, with pricing based from time to time at the Company’s election, at (i) the secured overnight financing rate as published by the Federal Reserve Bank of New York on its website plus an applicable margin that ranges from 1.50% to 2.50% based on the Company’s total net leverage ratio or (ii) the alternative base rate plus an applicable margin that ranges from 0.50% to 1.50% based on the Company’s total net leverage ratio. The 2022 Revolving Facility also includes an unused commitment fee at a rate ranging from 0.15% to 0.35% per annum based on the Company’s total net leverage ratio.
The Company is permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans, Letters of Credit and Swingline Loans exceeds the total Revolving Commitment, the Company must prepay the Revolving Loans in an amount equal to such excess. The Company is not required to make mandatory prepayments under the 2022 Revolving Facility. As of December 31, 2023, there were no outstanding borrowings under the 2022 Revolving Facility.
The Company has the right to request an increase to the Revolving Commitment in an aggregate principal amount of up to the sum of $335.0 million or consolidated EBITDA for the four consecutive fiscal quarters most recently ended, plus additional amounts in certain circumstances (collectively, the “Incremental Cap”), minus certain incremental term loans made pursuant to specified incremental term loan commitments (“Incremental Term Loans”). The Company has the right to request Incremental Term Loans in an aggregate principal amount of up to the Incremental Cap less any incremental increases to the Revolving Commitment. Proceeds of Incremental Term Loans may be used for working capital and for other general corporate purposes and will bear interest at rates agreed between the Company and the lenders providing the Incremental Term Loans.
2022 Facility Covenants
The 2022 Facility contains a number of affirmative, negative and reporting covenants, as well as financial maintenance covenants pursuant to which the Company is required to be in quarterly compliance, measured on a trailing four quarter basis, with two financial covenants. The minimum interest coverage ratio, commencing with the fiscal quarter ended December 31, 2022, must be at least 3.00 to 1.00. The maximum total net leverage ratio permitted by the financial covenant, commencing with the fiscal quarter ending March 31, 2024, is 3.50 to 1.00.
The 2022 Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.
Upon an event of default, the Administrative Agent will have the right to declare the loans and other obligations outstanding under the 2022 Facility immediately due and payable and all commitments immediately terminated.
The 2022 Facility is guaranteed by Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus MI Real Estate, LLC, and obligations under the 2022 Facility are generally secured by first priority liens over substantially all of the assets of each of
LMI, Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus MI Real Estate, LLC (subject to customary exclusions set forth in the transaction documents) owned as of December 2, 2022 or thereafter acquired.
Convertible Notes
On December 8, 2022, the Company issued $575.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027 (the “Notes”), which includes $75.0 million in aggregate principal amount of Notes sold pursuant to the full exercise of the initial purchasers’ option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among the Company, LMI (the “Guarantor”), a wholly owned subsidiary of the Company, as Guarantor, and U.S. Bank Trust Company, National Association, as Trustee. The net proceeds from the issuance of the Notes were approximately $557.8 million after deducting the initial purchasers’ discounts and offering expenses payable by the Company.
The Notes are senior unsecured obligations of the Company. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Guarantor. The Notes bear interest at a rate of 2.625% per year, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023, and will mature on December 15, 2027 unless earlier redeemed, repurchased or converted in accordance with their terms. The initial conversion rate for the Notes is 12.5291 shares of the Company’s common stock per $1,000 in principal amount of Notes (which is equivalent to an initial conversion price of approximately $79.81 per share of the Company’s common stock, representing an initial conversion premium of approximately 42.5% above the closing price of $56.01 per share of the Company’s common stock on December 5, 2022). In no event shall the conversation rate per $1,000 in principal amount of notes exceed 17.8539 shares of the Company’s common stock. Prior to the close of business on the business day immediately preceding September 15, 2027, the Notes may be converted at the option of the holders only upon occurrence of specified events and during certain periods, and thereafter until the close of business on the business day immediately preceding the maturity date, the Notes may be converted at any time. The Company will satisfy any conversion by paying cash up to the aggregate principal amount of the Notes to be converted and by paying or delivering, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Company may redeem for cash all or any portion of the Notes, at its option, on or after December 22, 2025 if the closing sale price per share of the Company’s common stock exceeds 130% of the conversion price of the Notes for a specified period of time. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
The Company evaluated the Notes upon completion of the sale and concluded on the following features:
•Conversion Feature: The Company determined that the conversion feature qualifies for the classification of equity. As a result, the conversion feature should not be bifurcated as a derivative instrument and the Notes were accounted for as a single liability.
•Redemption Features: The redemption features were reviewed within the Notes and the Company determined that the redemption features are closely related to the Notes and as such should not be separately accounted for as a bifurcated derivative instrument.
•Additional Interest Features: The Notes may result in additional interest if the Company fails to timely file any document or report that the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The Company will pay additional interest on the notes at a rate equal to 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day the Company failure to file has occurred or the notes are not otherwise freely tradable. Further, if the notes are assigned a restricted CUSIP number or the notes are not otherwise freely tradable pursuant to Rule 144 under the Securities Act by holders other than our affiliates or holders that were our affiliates at any time during the three months immediately preceding as of the 385th day after the last date of original issuance of the notes offered hereby, the Company will pay additional interest on the notes at a rate equal to (i) 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day until the restrictive legend has been removed from the notes, the notes are assigned an unrestricted CUSIP and the notes are freely tradable. The Company concluded that the interest feature is unrelated to the credit risk and should be bifurcated from the Notes, however, the Company assessed the probabilities of triggering events occurring under these features and does not expect to trigger the aforementioned events. These events will continue to be monitored to determine whether the interest feature will be bifurcated if it has value.
As of December 31, 2023, the carrying value of the Notes was $575.0 million, had an unamortized discount of zero, and the fair value of the liability was $575.0 million. The Company recorded interest expense of approximately $15.1 million related to the Notes for the year ended December 31, 2023.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Derivative Instruments
 12 Months Ended
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments Derivative Instruments
The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps was approximately 0.82%. This agreement involved the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s consolidated balance sheets at fair value, and changes in the fair value of the swap agreements were recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur.
On December 2, 2022, the Company voluntarily terminated the interest rate swap contracts in connection with the refinancing of debt. Upon termination, the Company received approximately $5.6 million in cash and the remaining balance of approximately $5.5 million in accumulated other comprehensive income (loss) related to the interest rate swap contracts were reclassified into earnings.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accumulated Other Comprehensive Loss
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss
The components of Accumulated Other Comprehensive Loss, net of tax of zero and zero for the year ended December 31, 2023 and 2022, respectively, consisted of the following:

(in thousands)Foreign currency translationUnrealized loss on cash flow hedgesAccumulated other comprehensive loss
Balance at January 1, 2023$(1,259)$— $(1,259)
Other comprehensive income (loss) before reclassifications222 — 222 
Balance at December 31, 2023$(1,037)$— $(1,037)
Balance at January 1, 2022$(754)$269 $(485)
Other comprehensive income (loss) before reclassifications(505)5,838 5,333 
Amounts reclassified to earnings— (6,107)(6,107)
Balance at December 31, 2022$(1,259)$— $(1,259)
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
Equity Incentive Plans
As of December 31, 2023, the Company’s approved equity incentive plans included the 2015 Equity Incentive Plan (“2015 Plan”), the 2013 Equity Incentive Plan (“2013 Plan”), and the 2008 Equity Incentive Plan (“2008 Plan”). These plans are administered by the Board of Directors and permit the granting of stock options, stock appreciation rights, restricted stock, restricted stock units and dividend equivalent rights to employees, officers, directors and consultants of the Company.
The Company has certain stock option and restricted stock awards outstanding under each of its equity incentive plans but, upon adoption of the 2015 Plan, no longer grants new equity awards under its 2008 and 2013 Plans. The Company adopted its 2015 Plan in June 2015 and subsequently amended the plan in April 2016, 2017, 2019, 2021 and 2022 which increased the common stock reserved for issuance under the plan to an aggregate 10,930,277 shares. The Company assumed Progenics equity plans due to the acquisition as discussed in Note 1, “Description of Business”. The Company no longer grants new equity awards under the Progenics equity plans.
Stock-based compensation expense recognized in the consolidated statements of operations is summarized below:
Year Ended
December 31,
(in thousands)202320222021
Cost of goods sold$9,126 $4,422 $2,370 
Sales and marketing9,500 6,185 2,472 
General and administrative24,807 14,876 9,092 
Research and development7,074 3,779 2,000 
Total stock-based compensation expense$50,507 $29,262 $15,934 
Stock Options
Stock option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. All option awards have a ten-year contractual term.
A summary of option activity for 2023 is presented below:
Total
Stock
Options		Weighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term
(Years)		Aggregate
Intrinsic
Value
Balance at January 1, 2023874,749 $30.37 5.819,058,224 
Options granted332,368 $76.41 
Options exercised(214,619)$19.02 
Options cancelled and forfeited(35,326)$51.30 
Outstanding at December 31, 2023957,172 $48.13 6.718,283,464 
Vested and expected to vest at December 31, 2023957,172 $48.13 6.718,283,464 
Exercisable at December 31, 2023466,039 $26.99 4.416,462,767 
The table below summarizes the key weighted-average assumptions used in valuing stock options granted:
Year Ended December 31,
202320222021
Expected volatility56.1 %62.1 %— %
Risk-free interest rate4.0 %2.0 %— %
Expected life (in years)6.06.0—
Expected dividend yield———
During the years ended December 31, 2023, 2022 and 2021, 214,619, 397,822 and 318,662 options were exercised having aggregate intrinsic values of $12.9 million, $13.1 million and $1.6 million, respectively.
As of December 31, 2023, there was $13.2 million of unrecognized compensation expense related to outstanding stock options, which is expected to be recognized over a weighted-average period of 2.0 years.
Restricted Stock
A summary of restricted stock awards and restricted stock units activity for 2023 is presented below:
SharesWeighted-
Average Grant
Date Fair Value Per Share
Nonvested balance at January 1, 20231,249,992 $34.65 
Granted710,985 $74.38 
Vested(612,912)$29.78 
Forfeited(137,806)$50.36 
Nonvested balance at December 31, 20231,210,259 $58.71 
Restricted stock generally vest over 3 years. As of December 31, 2023, there was $48.4 million of unrecognized compensation expense related to outstanding restricted stock, which is expected to be recognized over a weighted-average period of 2.0 years.
The weighted average grant-date fair value for restricted stock granted during the fiscal years ended December 31, 2023, 2022 and 2021 was $74.38, $51.51 and $20.14 per share, respectively. The total fair value of restricted stock vested in fiscal years 2023, 2022 and 2021 was $18.3 million, $11.9 million and $8.8 million, respectively.
Total Stockholder Return Restricted Stock Awards (“TSR Awards”)
During the years ended December 31, 2023, 2022 and 2021, the Company granted total stockholder return (“TSR”) Awards that include a three-year market condition where the performance measurement period is three years. Vesting of the TSR Awards is based on the Company’s level of attainment of specified TSR targets relative to the percentage appreciation of a specified index of companies for the respective three-year period and is also subject to the continued employment of the grantees. The number of shares that are earned over the performance period ranges from 0% to 200% of the initial award. The fair value of these awards are based on a Monte Carlo simulation valuation model with the following assumptions:
Year Ended December 31,
202320222021
Expected volatility52.8 %56.6 %54.0 %
Risk-free interest rate4.6 %1.7 %30.0 %
Expected life (in years)2.82.82.8
Expected dividend yield———
A summary of TSR Award activity for 2023 is presented below:
SharesWeighted-
Average Grant
Date Fair Value Per Share
Nonvested balance at January 1, 2023658,875 $48.58 
Granted365,478 $127.75 
Vested(348,302)$23.43 
Forfeited(45,997)$57.77 
Nonvested balance at December 31, 2023630,054 $78.91 
As of December 31, 2023, there was $26.2 million of unrecognized compensation expense related to outstanding performance restricted stock which is expected to be recognized over a weighted-average period of 2.0 years.
The weighted average grant-date fair value for TSR Awards granted during the fiscal years ended December 31, 2023, 2022 and 2021 was $127.75, $95.31 and $31.25 per share, respectively. The total fair value of TSR Awards vested in fiscal years 2023, 2022 and 2021 was $8.2 million, $8.8 million and $2.0 million, respectively.
Common Stock Repurchases
In December 2022, the Company’s Board of Directors authorized the repurchase of up to $150.0 million in aggregate amount of the Company’s common stock under certain circumstances. The Company used approximately $75.0 million of the net proceeds from the Notes to repurchase shares of their common stock from purchasers of the Notes in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate. The purchase price per share of the common stock repurchased in such transactions was equal to the closing sale price per share of the Company’s common stock on the date of the offering memorandum used for the Notes, which was $56.01 per share. Following this initial repurchase, the Company may from time to time repurchase additional shares of their common stock. In the year ended December 31, 2022, the Company purchased approximately 1.3 million shares of their outstanding common stock for $75.0 million as part of the program. The Company did not purchase any shares of its outstanding common stock in the year ended December 31, 2023.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Leases Leases
The Company determines if an arrangement is a lease at inception. The Company has operating and finance leases for vehicles, corporate offices and certain equipment.
Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease agreements with lease and non-lease components are accounted for separately. As the Company’s leases do not provide an implicit rate, the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
The Company assumed two operating leases as a result of the Progenics acquisition related to office space at the World Trade Center in New York City, pursuant to a lease agreement expiring in September 2030 (the “WTC Lease”), and a radiopharmaceutical manufacturing facility in Somerset, New Jersey, under a sublease agreement expiring in November 2028, which were recorded as of June 19, 2020, for $18.6 million and $0.6 million, respectively. The Company entered into an operating lease related to office space in Somerset, New Jersey, under a lease agreement expiring in August 2026, which was recorded in October 2021 for $0.7 million. The Company entered into an operating lease agreement in February 2022 to lease office space in Bedford, Massachusetts, under a lease agreement expiring in June 2031, which commenced and was recorded in December 2022 for $11.0 million.
On May 4, 2023, the Company entered into a modification to the operating lease for office space in Bedford, Massachusetts, (the “Existing Premises”) that was executed in February 2022. The lease commenced and was recorded in December 2022 for $11.0 million and the initial term was set to expire in June 2031. The lease modification includes a lease of additional office and laboratory space at the Bedford location (the “Additional Premises”) for a term of 15 years and 4 months and extends the term of the lease for the Existing Premises to be coterminous with the term of the lease for the Additional Premises. As a result of the extended term for the Existing Premises, the Company recorded an additional right-of-use asset and liability of $6.0 million in May 2023. The modification also contains a provision to convert the rent schedule of the Existing Premises from gross to triple net in 2024, which may result in an additional adjustment to the right-of-use asset and liability. In September 2023, the landlord provided notice to the Company that its renovations of the Additional Premises were completed. As a result of the notice, the Company recorded an additional right-of-use asset and liability of $23.5 million as of September 1, 2023. To determine the value of the additional right-of-use asset and liability, the Company was required to calculate the discount rate of the lease modification. The discount rate was determined based on the expected lease term and by comparing interest rates in the market for similar borrowings with comparable credit quality of the Company. The lease for the Additional Premises allows for the extension of five years to begin immediately upon the expiration of the original term.
Leases with an initial term of 12 months or less are not recorded on the balance sheet as the Company has elected to apply the short-term lease exemption. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.
Operating and finance lease assets and liabilities are as follows:
(in thousands)ClassificationDecember 31, 2023December 31, 2022
Assets
OperatingOther long-term assets$45,325 $19,033 
FinanceProperty, plant and equipment, net1,438 582 
Total leased assets$46,763 $19,615 
Liabilities
Current
     OperatingAccrued expenses and other liabilities$1,904 $2,177 
     FinanceCurrent portion of long-term debt and other borrowings823 354 
Noncurrent
     OperatingOther long-term liabilities54,453 25,442 
     FinanceLong-term debt, net and other borrowings625 231 
Total leased liabilities$57,805 $28,204 
In the third quarter of 2021, with respect to the office space in the World Trade Center, the Company negotiated a sublease agreement with an unrelated third party that was signed on October 11, 2021 (the “Sublease”) and has a term of nine years, which represents the remaining term of the WTC Lease. Both the WTC Lease and the Sublease are classified by the Company as operating leases. As a result of the negotiations of the Sublease, the Company determined that an impairment triggering event had occurred. Accordingly, the Company performed an undiscounted cash flow analysis related to the asset group as of September 30, 2021. Based on the undiscounted cash flow analysis, the Company determined that the asset group, including the ROU asset, had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on its discounted cash flows. The carrying value exceeded the fair value and, as a result, the Company recorded a non-cash impairment of $9.5 million for the year ended December 31, 2021 in general and administrative expenses in the consolidated statements of operations.
The components of lease expense were as follows:
 
(in thousands)Year Ended
December 31, 2023		Year Ended
December 31, 2022
Operating lease expense$4,627 $1,797 
Finance lease expense
      Amortization of ROU assets795 426 
      Interest on lease liabilities81 28 
Total lease expense$5,503 $2,251 
Other information related to leases were as follows:
December 31, 2023December 31, 2022
Weighted-average remaining lease term (Years):
      Operating leases13.57.9
      Finance leases2.31.9
Weighted-average discount rate:
      Operating leases7.3%4.8%
      Finance leases6.2%4.4%
(in thousands)Year Ended
December 31, 2023		Year Ended
December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:                   
      Operating cash flows from operating leases$3,462$2,440
      Operating cash flows from finance leases8128
      Financing cash flows from finance leases504384
ROU assets obtained in exchange for lease obligations:
      Operating leases29,39611,019
      Finance leases1,437582
Future minimum lease payments under non-cancellable leases as of December 31, 2023 were as follows:
(in thousands)
Operating Leases
Finance Leases
2024$4,624 $846 
20255,413 664 
20267,090 151 
20277,312 — 
20287,453 — 
Thereafter67,642 — 
  Total future minimum lease payments99,534 1,661 
Less: interest43,177 213 
  Total$56,357 $1,448 
Leases Leases
The Company determines if an arrangement is a lease at inception. The Company has operating and finance leases for vehicles, corporate offices and certain equipment.
Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease agreements with lease and non-lease components are accounted for separately. As the Company’s leases do not provide an implicit rate, the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
The Company assumed two operating leases as a result of the Progenics acquisition related to office space at the World Trade Center in New York City, pursuant to a lease agreement expiring in September 2030 (the “WTC Lease”), and a radiopharmaceutical manufacturing facility in Somerset, New Jersey, under a sublease agreement expiring in November 2028, which were recorded as of June 19, 2020, for $18.6 million and $0.6 million, respectively. The Company entered into an operating lease related to office space in Somerset, New Jersey, under a lease agreement expiring in August 2026, which was recorded in October 2021 for $0.7 million. The Company entered into an operating lease agreement in February 2022 to lease office space in Bedford, Massachusetts, under a lease agreement expiring in June 2031, which commenced and was recorded in December 2022 for $11.0 million.
On May 4, 2023, the Company entered into a modification to the operating lease for office space in Bedford, Massachusetts, (the “Existing Premises”) that was executed in February 2022. The lease commenced and was recorded in December 2022 for $11.0 million and the initial term was set to expire in June 2031. The lease modification includes a lease of additional office and laboratory space at the Bedford location (the “Additional Premises”) for a term of 15 years and 4 months and extends the term of the lease for the Existing Premises to be coterminous with the term of the lease for the Additional Premises. As a result of the extended term for the Existing Premises, the Company recorded an additional right-of-use asset and liability of $6.0 million in May 2023. The modification also contains a provision to convert the rent schedule of the Existing Premises from gross to triple net in 2024, which may result in an additional adjustment to the right-of-use asset and liability. In September 2023, the landlord provided notice to the Company that its renovations of the Additional Premises were completed. As a result of the notice, the Company recorded an additional right-of-use asset and liability of $23.5 million as of September 1, 2023. To determine the value of the additional right-of-use asset and liability, the Company was required to calculate the discount rate of the lease modification. The discount rate was determined based on the expected lease term and by comparing interest rates in the market for similar borrowings with comparable credit quality of the Company. The lease for the Additional Premises allows for the extension of five years to begin immediately upon the expiration of the original term.
Leases with an initial term of 12 months or less are not recorded on the balance sheet as the Company has elected to apply the short-term lease exemption. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.
Operating and finance lease assets and liabilities are as follows:
(in thousands)ClassificationDecember 31, 2023December 31, 2022
Assets
OperatingOther long-term assets$45,325 $19,033 
FinanceProperty, plant and equipment, net1,438 582 
Total leased assets$46,763 $19,615 
Liabilities
Current
     OperatingAccrued expenses and other liabilities$1,904 $2,177 
     FinanceCurrent portion of long-term debt and other borrowings823 354 
Noncurrent
     OperatingOther long-term liabilities54,453 25,442 
     FinanceLong-term debt, net and other borrowings625 231 
Total leased liabilities$57,805 $28,204 
In the third quarter of 2021, with respect to the office space in the World Trade Center, the Company negotiated a sublease agreement with an unrelated third party that was signed on October 11, 2021 (the “Sublease”) and has a term of nine years, which represents the remaining term of the WTC Lease. Both the WTC Lease and the Sublease are classified by the Company as operating leases. As a result of the negotiations of the Sublease, the Company determined that an impairment triggering event had occurred. Accordingly, the Company performed an undiscounted cash flow analysis related to the asset group as of September 30, 2021. Based on the undiscounted cash flow analysis, the Company determined that the asset group, including the ROU asset, had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on its discounted cash flows. The carrying value exceeded the fair value and, as a result, the Company recorded a non-cash impairment of $9.5 million for the year ended December 31, 2021 in general and administrative expenses in the consolidated statements of operations.
The components of lease expense were as follows:
 
(in thousands)Year Ended
December 31, 2023		Year Ended
December 31, 2022
Operating lease expense$4,627 $1,797 
Finance lease expense
      Amortization of ROU assets795 426 
      Interest on lease liabilities81 28 
Total lease expense$5,503 $2,251 
Other information related to leases were as follows:
December 31, 2023December 31, 2022
Weighted-average remaining lease term (Years):
      Operating leases13.57.9
      Finance leases2.31.9
Weighted-average discount rate:
      Operating leases7.3%4.8%
      Finance leases6.2%4.4%
(in thousands)Year Ended
December 31, 2023		Year Ended
December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:                   
      Operating cash flows from operating leases$3,462$2,440
      Operating cash flows from finance leases8128
      Financing cash flows from finance leases504384
ROU assets obtained in exchange for lease obligations:
      Operating leases29,39611,019
      Finance leases1,437582
Future minimum lease payments under non-cancellable leases as of December 31, 2023 were as follows:
(in thousands)
Operating Leases
Finance Leases
2024$4,624 $846 
20255,413 664 
20267,090 151 
20277,312 — 
20287,453 — 
Thereafter67,642 — 
  Total future minimum lease payments99,534 1,661 
Less: interest43,177 213 
  Total$56,357 $1,448 
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Assets
 12 Months Ended
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other Assets Other Assets
Other assets are comprised of the following:
 December 31,
(in thousands)20232022
Prepaid Expenses$16,437 $12,887 
Other Current Assets246 205 
Total other current assets$16,683 $13,092 
ROU Asset (Note 16)$45,325 $19,033 
Other Long-Term Assets9,936 15,322 
Total other long-term assets$55,261 $34,355 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income (Loss) Per Common Share
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Net Income (Loss) Per Common Share Net Income (Loss) Per Common Share
A summary of net income (loss) per common share is presented below:
 Year Ended
December 31,
(in thousands, except per share amounts)202320222021
Net income (loss)$326,661 $28,067 $(71,279)
Basic weighted-average common shares outstanding68,266 68,487 67,486 
Effect of dilutive stock options346 439 — 
Effect of dilutive restricted stock1,428 1,745 — 
Effect of convertible debt instrument199 — — 
Diluted weighted-average common shares outstanding70,239 70,671 67,486 
Basic income (loss) per common share$4.79 $0.41 $(1.06)
Diluted income (loss) per common share$4.65 $0.40 $(1.06)
Antidilutive securities excluded from diluted net income (loss) per common share421 358 2,893 
Impact of the Convertible Notes
The Company considered whether the notes are participating securities through the two-class method. The Company determined that if a cash dividend is paid that is greater than the then stock price, the holder of Notes will receive cash on an if-converted basis. While this feature is considered to be a participating right; basic earnings per share is only impacted if the Company’s earning exceeds the current share price, regardless of whether such dividend is declared. During the year ended December 31, 2023, no such dividend was declared. In addition, the Company is required to settle the principal amount of the Notes in cash upon conversion, and therefore, the Company uses the if-converted method for calculating any potential dilutive effect of the conversion option on diluted net income per share, if applicable, unless the application of the two-class method is dilutive. The conversion option will have a dilutive impact on net income per share of Common Stock when the average price per share of the Company’s Common Stock for a given period exceeds the conversion price of the Notes of $79.81 per share.
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Purchase Commitments
The Company has entered into purchasing arrangements in which minimum quantities of goods or services have been committed to be purchased on an annual basis.
As of December 31, 2023, future payments required under purchase commitments are as follows:
(in thousands)Amount
20242,716 
20252,716 
20262,716 
20272,716 
2028 and thereafter— 
Total$10,864 
The Company has entered into agreements which contain certain percentage volume purchase requirements. The Company has excluded these future purchase commitments from the table above since there are no minimum purchase commitments or payments under these agreements.
License Agreements
The Company has entered into license agreements in which fixed payments have been committed to be paid on an annual basis.
As of December 31, 2023, no future fixed payments are required under license agreements. The Company may be required to pay additional amounts up to approximately $264.4 million in contingent payments under the Company’s license agreements. These
contingent payments include potential milestone or contractual payment obligations contingent upon the achievement or occurrence of future milestones or events and the amounts and timing of such potential obligations are unknown or uncertain.
Legal Proceedings
From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.
As of December 31, 2023, the Company did not have any material ongoing litigation to which the Company was a party. On January 26, 2024, the Company was sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the filing of our ANDA and Paragraph IV certification, consistent with the process established by the Hatch-Waxman Act. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved.
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
401(k) Plan
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
401(k) Plan 401(k) Plan
The Company maintains a qualified 401(k) plan (the “401(k) Plan”) for its U.S. employees. The 401(k) Plan covers U.S. employees who meet certain eligibility requirements. Under the terms of the 401(k) Plan, the employees may elect to make tax-deferred contributions through payroll deductions within statutory and plan limits, and the Company may elect to make non-elective discretionary contributions. The Company may also make optional contributions to the 401(k) Plan for any plan year at its discretion.
Expense recognized by the Company for matching contributions made to the 401(k) Plan was $4.1 million, $3.1 million and $2.6 million for the years ended December 31, 2023, 2022 and 2021, respectively.
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisition of Assets
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisition of Assets Acquisition of Assets
On February 6, 2023, the Company acquired Cerveau. Cerveau holds the rights under a license agreement to develop and commercialize MK-6240, an investigational second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease. The Company determined that upon review of the Cerveau acquisition, the transaction did not meet the definition of a business combination and is therefore treated as an asset acquisition.
In February 2023, the Company made an upfront payment of approximately $35.3 million to the stockholders of Cerveau (the “Selling Stockholders”) and paid the Selling Stockholders an additional $10.0 million in May 2023 upon the successful completion of a technology transfer. The Company could pay up to an additional $51.0 million in milestone payments upon achievement of specified U.S. regulatory milestones related to MK-6240. The Selling Stockholders are also eligible to receive up to $1.2 billion in sales milestone payments upon the achievement of specified annual commercial sales thresholds of MK-6240 in the event the Company pursues commercialization, as well as up to $13.5 million in research revenue milestones upon achievement of specified annual research revenue thresholds. Additionally, the Company will pay to the Selling Stockholders up to double-digit royalty payments for research revenue and commercial sales. Research revenue is derived from existing partnerships with pharmaceutical companies that use MK-6240 in clinical trials and includes milestone and dose-related payments. The purchase agreement pursuant to which the Company purchased Cerveau specifies, among other things, that certain members of the Selling Stockholders will also provide transition and clinical development services for a prescribed time following the closing of the transaction.
In December 2022, the Company made upfront payments of $260.0 million to POINT as a part of an asset acquisition with the potential for additional milestone payments of approximately $1.8 billion between the two licensed assets based on U.S. Food and Drug Administration (“FDA”) approval and net sales and commercial milestones.
Under the terms of the PNT2002 License Agreement, Lantheus Two paid POINT an upfront cash payment of $250.0 million, and could pay up to an additional $281.0 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2002. POINT is also eligible to receive up to $1.3 billion in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2002.
Under the terms of the PNT2003 License Agreement, Lantheus Three paid POINT an upfront cash payment of $10.0 million, and could pay up to an additional $34.5 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2003. POINT is also eligible to receive up to $275.0 million in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2003.
Additionally, the Company will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003. Costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use are expensed when incurred, and therefore, a charge of $260.0 million was recognized in research and development expenses during the year ended December 31, 2022.
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one business segment. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Event
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Event Subsequent Event
On January 9, 2024, the Company entered into multiple strategic agreements with Perspective Therapeutics, Inc. (“Perspective”), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. Under the agreements:
•The Company obtained an option to exclusively license Perspective’s Pb212-VMT-⍺-NET, a clinical stage alpha therapy in development for the treatment of neuroendocrine tumors, and an option to co-develop certain early stage therapeutic candidates targeting prostate cancer using Perspective’s innovative platform technology, for an aggregate upfront payment of $28 million in cash;
•Lantheus agreed to purchase up to 19.9% of Perspective’s outstanding shares of common stock for up to approximately $33 million, subject to completion of a qualified third party financing transaction and certain other closing conditions; and
•Perspective agreed to acquire the assets and associated lease of Lantheus’ radiopharmaceutical manufacturing facility in Somerset, New Jersey for an undisclosed price, subject to customary closing conditions including regulatory approval.
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure      
Net income (loss) $ 326,661 $ 28,067 $ (71,279)
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended 12 Months Ended
Dec. 31, 2023
shares
Dec. 31, 2023
shares
Trading Arrangements, by Individual    
Rule 10b5-1 Arrangement Adopted true  
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Sam Leno [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   On November 7, 2023, Sam Leno, a member of our Board, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”), providing for the potential sale of up to 2,045 shares of our common stock obtained from the exercise of vested stock options covered by the 10b5-1 Plan, between March 4, 2024 and May 15, 2024. On November 29, 2023, Mr. Leno amended his 10b5-1 Plan to add the potential sale of up to 20,344 additional shares of our common stock obtained from the exercise of vested stock options covered by the 10b5-1 Plan, between March 4, 2024 and May 15, 2024.
Name Sam Leno  
Title member of our Board  
Adoption Date November 7, 2023  
Arrangement Duration 72 days  
Aggregate Available 2,045 2,045
Amended 10b5-1 Plan [Member] | Sam Leno [Member]    
Trading Arrangements, by Individual    
Rule 10b5-1 Arrangement Adopted true  
Adoption Date November 29, 2023  
Arrangement Duration 72 days  
Aggregate Available 20,344 20,344
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation and Principles of Consolidation
The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP.
Principles of Consolidation The consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, contingent assets and liabilities, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.
Revenue Recognition
Revenue Recognition
The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services. See Note 3, “Revenue from Contracts with Customers” for further discussion on revenues.
Accounts Receivable, net
Accounts Receivable, net
Accounts receivable consist of amounts billed and currently due from customers. The Company maintains an allowance for doubtful accounts for estimated losses. In determining the allowance, consideration includes the probability of recoverability based on past experience and general economic factors. Certain accounts receivable may be fully reserved when the Company becomes aware of any specific collection issues. The Company periodically reviews the aging of receivables, payment history and customer creditworthiness to determine if adjustments to the allowance for doubtful accounts is necessary. Allowance for doubtful accounts has been immaterial for all years presented.
Income Taxes
Income Taxes
The Company accounts for income taxes using an asset and liability approach. Income tax (benefit) expense represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when such changes are enacted.
The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more-likely-than-not to be realized. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that the future tax benefit will not be realized. The assessment of whether or not a valuation allowance is required involves weighing both positive and negative evidence, including both historical and prospective information, with greater weight given to evidence that is objectively verifiable. A history of recent losses is negative evidence that is difficult to overcome with positive evidence. In evaluating prospective information there are four sources of taxable income: reversals of taxable temporary differences, items that can be carried back to prior tax years (such as net operating losses), pre-tax income, and prudent and feasible tax planning strategies. Adjustments to the deferred tax valuation allowances are made in the period when those assessments are made.
The Company accounts for uncertain tax positions using a two-step recognition threshold and measurement analysis method to determine the financial statement impact of uncertain tax positions taken or expected to be taken in a tax return. Differences between tax positions taken in a tax return and amounts recognized in the financial statements are recorded as adjustments to other long-term assets and liabilities, or adjustments to deferred taxes, or both. The Company records the related interest and penalties to income tax (benefit) expense.
Net Income (Loss) per Common Share
Net Income (Loss) per Common Share
The Company computes earnings per share using the two-class method. Basic earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities as if those securities were converted or exercised. The Company’s potentially dilutive shares, which could include shares issuable upon conversion of the 2.625% Convertible Senior Notes due 2027 (the “Notes”), are considered to be common stock equivalents and are only included in the calculation of diluted net income per share when their effect is dilutive. The Company has the option to settle the Notes through cash settlement or a combination of cash and share settlement provided that the principal is settled in cash and the conversion spread is settled in cash or shares as elected by the Company. The Company applies the if-converted method for diluted earnings in order to reflect the conversion spread. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents include savings deposits, certificates of deposit and money market funds that have original maturities of three months or less when purchased.
Restricted Cash
Restricted Cash
Restricted cash as of December 31, 2023 and 2022, represents primarily collateral for a letter of credit securing a lease obligation and a security deposit. The Company believes the carrying value of these assets approximates fair value.
Concentration of Risks and Limited Suppliers
Concentration of Risks and Limited Suppliers
Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies.
As of December 31, 2023 and 2022, no customer accounted for greater than 10% of accounts receivable, net. No customer accounted for greater than 10% of revenues for the years ended December 31, 2023, 2022 and 2021.
The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.
The Company currently relies on JHS as its significant manufacturer of DEFINITY and its sole source manufacturer of NEUROLITE, CARDIOLITE and evacuation vials for TechneLite. The Company relies on Samsung Biologics Co., Ltd. (“SBL”) as its sole source manufacturer of DEFINITY RT. The Company has Mo-99 supply agreements with IRE of Belgium, running through December 31, 2024, with auto-renewal provisions and terminable upon notice of non-renewal, and with NTP and its subcontractor ANSTO, running through December 31, 2024.
Inventory
Inventory
Inventory includes material, direct labor and related manufacturing overhead and is stated at the lower of cost and net realizable value on a first-in, first-out basis. The Company records inventory when the Company takes title to the product.
The Company assesses the recoverability of inventory to determine whether adjustments for excess and obsolete inventory are required. Inventory that is in excess of future requirements is written down to its estimated net realizable value based on product shelf life, forecasted demand and other factors.
Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed as incurred.
Property, Plant and Equipment, net
Property, Plant and Equipment, net
Property, plant & equipment are stated at cost. Replacements of major units of property are capitalized, and replaced properties are retired. Replacements of minor components of property and repair and maintenance costs are charged to expense as incurred. Certain costs to obtain or develop computer software are capitalized and amortized over the estimated useful life of the software. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets and recorded
in costs of goods sold and operating expenses in the associated functional expense category which utilizes the associated asset. The estimated useful lives of the major classes of depreciable assets are as follows:

ClassRange of Estimated Useful Lives
Buildings
10 - 50 years
Land improvements
15 - 40 years
Machinery and equipment
3 - 15 years
Furniture and fixtures
15 years
Leasehold improvements
Lesser of lease term or 15 years
Computer software
3 - 5 years

Upon retirement or other disposal of property, plant & equipment, the cost and related amount of accumulated depreciation are removed from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds is included in operating income.
Included within machinery and equipment are spare parts. Spare parts include replacement parts relating to plant & equipment and are either recognized as an expense when consumed or reclassified and capitalized as part of the related asset and depreciated over the remaining useful life of the related asset.
Business Combinations
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired IPR&D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.
During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition.
Goodwill
Goodwill
Goodwill is not amortized but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely-than-not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year.
In performing the Company’s annual assessment, the Company is permitted to first perform a qualitative test and if necessary, perform a quantitative test. If the Company is required to perform the quantitative impairment test of goodwill, the Company compares the fair value of a reporting unit to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting units using discounted cash flow or other valuation models, such as comparative transactions and market multiples. The Company performed a qualitative assessment and did not recognize any goodwill impairment charges during the years ended December 31, 2023, 2022 or 2021.
Intangible and Long-Lived Assets
Intangible and Long-Lived Assets
The Company tests intangible and long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. The Company measures the recoverability of assets to be held and used by comparing the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If those assets are considered to be impaired, the impairment equals the amount by which the carrying amount of the assets exceeds the fair value of the assets. Any impairments are recorded as permanent reductions in the carrying amount of the assets. See Note 7, “Property, Plant and Equipment, Net” for further details on impairment. Long-lived assets, other than goodwill and other intangible assets that are held for sale are recorded at the lower of the carrying value or the fair market value less the estimated cost to sell.
Intangible assets, consisting of patents, trademarks, customer relationships, a currently marketed product, licenses and developed technology related to the Company’s products are amortized in a method equivalent to the estimated utilization of the economic benefit of the asset.
Costs of IPR&D intangible assets acquired as part of an asset acquisition that have no alternative future use are expensed when incurred. Milestone payments made after regulatory approval are capitalized as an intangible asset and amortized over an estimated useful life of the product. Cash payments related to acquired IPR&D intangible assets are reflected as an investing cash flow in the Company's consolidated statement of cash flows.
The Company’s IPR&D intangible assets includes intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. Because obtaining regulatory approval can include significant risks and uncertainties, the eventual realized value of the acquired IPR&D projects may vary from their fair value at the date of acquisition. The Company classifies IPR&D intangible assets acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, the Company will determine the useful life and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, the Company writes-off the remaining carrying amount of the associated IPR&D intangible asset. IPR&D intangible assets are tested at least annually as of October 31 or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in the Company’s consolidated statements of operations. See Note 10, “Intangibles, net and Goodwill” for further details on impairment.
Contingencies
Contingencies
In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, product and environmental liability. The Company records accruals for those loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized.
Convertible Notes
Convertible Notes
The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The change in fair value of any separately recognized derivative is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation.
Fair Values of Financial Instruments
Fair Values of Financial Instruments
The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The Company’s long-term debt has triggering events that would impact the fair value of the instruments. The Company determined that no triggering event has occurred during the years ended December 31, 2023 and December 31, 2022. As of December 31, 2023, the fair value of the Company’s convertible debt was estimated to be approximately $644.3 million based on external pricing data, including quoted market prices of these instruments and was classified as a Level 1 measurement within the fair value hierarchy. As of December 31, 2022, the carrying value of the Company’s convertible debt approximated fair value and was classified as a Level 1 measurement within the fair value hierarchy. The fair value See Note 4, “Fair Value of Financial Instruments”.
Contingent Consideration Liabilities
Contingent Consideration Liabilities
The estimated fair value of contingent consideration liabilities are initially measured and recorded on the acquisition date, are considered to be a Level 3 instrument and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations.
The estimated fair value is determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that include significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.
Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement.
The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based milestones, development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.
Derivative Instruments
Derivative Instruments
The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged. Further, the Company must formally document the hedging relationship at inception and, on at least a quarterly basis, continually reevaluate the relationship to ensure it remains highly effective throughout the life of the hedge. The Company does not enter into derivative financial instruments for speculative or trading purposes.
Advertising and Promotion Costs
Advertising and Promotion Costs
Advertising and promotion costs are expensed as incurred.
Research and Development
Research and Development
Research and development costs are expensed as incurred and relate primarily to the development of new products to add to the Company’s portfolio and costs related to its medical affairs and medical information functions. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and recognized as an expense as the goods are delivered or the related services are performed.
Foreign Currency
Foreign Currency
The consolidated statements of operations of the Company’s foreign subsidiaries are translated into U.S. Dollars using weighted-average exchange rates. The net assets of the Company’s foreign subsidiaries are translated into U.S. Dollars using the end of period exchange rates. The impact from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive loss in the consolidated balance sheets.
Remeasurement of the Company’s foreign currency denominated transactions are included in net income. Transaction gains and losses are reported as a component of other loss (income) in the consolidated statements of operations.
Stock-Based Compensation
Stock-Based Compensation
The Company’s stock-based compensation cost is measured at the grant date of the stock-based award based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period, and includes an estimate of the awards that will be forfeited. The Company estimates the fair value of each stock-based award on its measurement date using either the current market price of the stock, the Black-Scholes option valuation model or the Monte Carlo simulation valuation model, whichever is most appropriate. The Black-Scholes and Monte Carlo simulation valuation models incorporate assumptions such as stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield.
Expected volatility is based on the historical volatility of the Company’s stock price. The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the awards’ expected lives. Expected lives are principally based on the Company’s historical exercise experience with previously issued awards. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.
Expense for performance restricted stock awards is recognized based upon the fair value of the awards on the date of grant and the number of shares expected to vest based on the terms of the underlying award agreement and the requisite service period(s).
Comprehensive Income (Loss)
Comprehensive Income (Loss)
Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net income. For the Company, other comprehensive income (loss) consists of foreign currency translation gains and losses as well as realized and unrealized gains and losses on cash flow hedges related to the Company’s interest rate swaps. The accumulated other comprehensive income (loss) balance consists entirely of foreign currency translation gains and losses and realized and unrealized gains and losses on outstanding cash flow hedges related to the Company’s interest rate swaps.
Asset Retirement Obligations
Asset Retirement Obligations
The Company’s compliance with federal, state, local and foreign environmental laws and regulations may require it to remove or mitigate the effects of the disposal or release of chemical substances in jurisdictions where it does business or maintains properties. The Company establishes accruals when those costs are legally obligated and can be reasonably estimated. Accrual amounts are estimated, which may include the assistance of third-party environmental specialists, and are based on currently available information, regulatory requirements, remediation strategies, historical experience, the relative shares of the total remediation costs, a relevant discount rate, and the time periods of when estimated costs can be reasonably predicted. Changes in these assumptions could impact the Company’s future reported results.
The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts campus and its Somerset, New Jersey site. The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. The liability is measured at the present value of the obligation expected to be incurred and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the assets’ useful lives.
The Company has identified conditional asset retirement obligations related to the future removal and disposal of asbestos contained in certain of the buildings located on the Company’s North Billerica, Massachusetts campus. The Company believes the asbestos is appropriately contained and it is compliant with all applicable environmental regulations. If these properties undergo major renovations or are demolished, certain environmental regulations are in place, which specify the manner in which asbestos must be handled and disposed. The Company is required to record the fair value of these conditional liabilities if they can be reasonably estimated. As of December 31, 2023 and 2022, sufficient information was not available to estimate a liability for such conditional asset retirement obligations as the obligations to remove the asbestos from these properties have indeterminable settlement dates. As such, no liability for conditional asset retirement obligations has been recorded in the accompanying consolidated balance sheets as of December 31, 2023 and 2022.
Self-Insurance Reserves
Self-Insurance Reserves
The Company’s consolidated balance sheets at December 31, 2023 and 2022 include $1.0 million and $0.9 million of accrued liabilities associated with employee medical costs that are retained by the Company, respectively. The Company estimates the required liability of those claims on an undiscounted basis based upon various assumptions which include, but are not limited to, the Company’s historical loss experience and projected loss development factors. The required liability is also subject to adjustment in the future based upon changes in claims experience, including changes in the number of incidents (frequency) and change in the ultimate cost per incident (severity).
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company is currently in the process of evaluating the effects of this pronouncement on our related disclosures.
In December 2023, the FASB also issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on our related disclosures.
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of Product Concentration Risk
The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:

Year Ended
December 31,
202320222021
PYLARIFY
65.7 %56.4 %10.2 %
DEFINITY21.6 %26.2 %54.7 %
TechneLite6.7 %9.5 %21.5 %
Schedule of Estimated Useful Lives of Major Classes of Depreciable Assets The estimated useful lives of the major classes of depreciable assets are as follows:
ClassRange of Estimated Useful Lives
Buildings
10 - 50 years
Land improvements
15 - 40 years
Machinery and equipment
3 - 15 years
Furniture and fixtures
15 years
Leasehold improvements
Lesser of lease term or 15 years
Computer software
3 - 5 years
Property, plant and equipment, net, consisted of the following:
 December 31,
(in thousands)20232022
Land$9,480 $13,450 
Buildings73,441 76,329 
Machinery, equipment and fixtures102,576 92,604 
Computer software27,259 25,864 
Construction in progress40,964 14,047 
253,720 222,294 
Less: accumulated depreciation and amortization(107,023)(100,128)
Total property, plant and equipment, net$146,697 $122,166 
Schedule of other loss (income)
Other loss (income) consisted of the following:

 Year Ended
December 31,
(in thousands)202320222021
Foreign currency losses$21 $256 $274 
Tax indemnification expense, net4,943 9,554 7,121 
Interest income(19,638)(2,613)(45)
Interest rate swap termination— (5,494)— 
Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties(51,789)
Other143 — — 
Total other (income) loss $(66,320)$1,703 $7,350 
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue from Contracts with Customers (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes revenue by revenue source as follows:
Year Ended December 31,
Major Products/Service Lines
(in thousands)		202320222021
    Product revenue, net(1)
$1,263,068 $887,038 $400,356 
    License and royalty revenues(2)
33,361 48,023 24,852 
Total revenues$1,296,429 $935,061 $425,208 
______________________________
(1)The Company’s product revenue includes PYLARIFY and DEFINITY, among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all of its principal products.
(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.
Revenue by product category on a net basis is as follows:
Year Ended December 31,
(in thousands)202320222021
PYLARIFY$851,303 $527,405 $43,414 
Other radiopharmaceutical oncology3,130 4,102 5,473 
Total radiopharmaceutical oncology854,433 531,507 48,887 
DEFINITY279,768 244,993 232,759 
TechneLite87,370 88,864 91,293 
Other precision diagnostics22,980 22,825 26,973 
Total precision diagnostics390,118 356,682 351,025 
Strategic Partnerships and other revenue51,878 46,872 25,296 
Total revenues$1,296,429 $935,061 $425,208 
Schedule of Valuation and Qualifying Accounts
An analysis of the amount of, and change in, reserves is summarized as follows:
(in thousands)Rebates and
Allowances
Balance, January 1, 2022$10,977 
Provision related to current period revenues26,683 
Adjustments relating to prior period revenues70 
Payments or credits made during the period(24,331)
Balance, December 31, 202213,399 
Provision related to current period revenues32,308 
Adjustments relating to prior period revenues(453)
Payments or credits made during the period(29,184)
Balance, December 31, 2023$16,070 
Schedule of contracts with customer
The Company recognized certain revenues as follows:
Year Ended December 31,
(in thousands)20232022
Amounts included in the contract liability at the beginning of the period$682 $244 
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments (Tables)
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis
The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:

 December 31, 2023
(in thousands)Total Fair
Value		Level 1Level 2Level 3
Assets:
Money market funds$574,131 $574,131 $— $— 
Total assets$574,131 $574,131 $— $— 
Liabilities:
Contingent consideration liabilities$2,700 $— $— $2,700 
Total liabilities$2,700 $— $— $2,700 
 December 31, 2022
(in thousands)Total Fair
Value		Level 1Level 2Level 3
Assets:
Money market funds$342,646 $342,646 $— $— 
Total assets$342,646 $342,646 $— $— 
Liabilities:
Contingent consideration liabilities$111,600 $— $— $111,600 
Total liabilities$111,600 $— $— $111,600 
Fair Value Measurement Inputs and Valuation Techniques
The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of liabilities using Level 3 inputs as of December 31, 2023.
Fair Value as ofAssumptions
(in thousands)December 31, 2023December 31, 2022Valuation TechniqueUnobservable InputDecember 31, 2023December 31, 2022
Contingent consideration liability:
Net sales targets – PYLARIFY (CVRs)N/A$99,700 Probability adjusted discounted cash flow modelPeriod of expected milestone achievement and sales targetsN/A2022 – 2023
Probability of successN/A100 %
1095 commercialization milestone1,800 1,700 Probability adjusted discounted cash flow model
Period of expected milestone achievement20262026
Probability of success40 %40 %
Discount rate4.1 %3.8 %
Net sales targets – AZEDRA and 1095900 10,200 Monte Carlo simulation
Probability of success and sales targets
0% - 40%
20% - 100%
Discount rate
15%
16% - 17%
Total$2,700 $111,600 
Schedule of Financial Instruments with Significant Level 3 Inputs
For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:

Financial AssetsFinancial Liabilities
(in thousands)Years Ended December 31,Years Ended December 31,
2023202220232022
Fair value, beginning of period$— $9,300 $111,600 $86,200 
Changes in fair value included in net income (loss)— (9,300)(9,275)25,400 
Cash Payments— — (99,625)— 
Fair value, end of period$— $— $2,700 $111,600 
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Components of Income (loss) Before Provision (benefit) for Income Taxes
The components of income (loss) before provision (benefit) for income taxes consists of the following:
Year Ended
December 31,
(in thousands)202320222021
U.S.$410,326 $29,012 $(76,389)
International617 (2,293)1,351 
Income (loss) before income taxes$410,943 $26,719 $(75,038)
Schedule of Provision (benefit) for Income Taxes
The Company’s provision (benefit) for income taxes consists of the following:
Year Ended
December 31,
(in thousands)202320222021
Current
Federal$110,108 $42,532 $— 
State29,806 4,302 (8,166)
International— (166)(30)
139,914 46,668 (8,196)
Deferred
Federal(45,252)(39,920)1,048 
State(10,739)(8,315)3,058 
International359 219 331 
(55,632)(48,016)4,437 
Income tax expense (benefit)$84,282 $(1,348)$(3,759)
Schedule of Reconciliation of Income Taxes at the U.S. Federal Statutory Rate to the Actual Income Taxes
The reconciliation of income taxes at the U.S. federal statutory rate to the income tax expense (benefit) is as follows:
Year Ended
December 31,
(in thousands)202320222021
U.S. statutory rate$86,298 $5,611 $(15,758)
Permanent items1,042 2,309 1,764 
Sale of RELISTOR licensed intangible asset associated with net sales royalties(10,817)— — 
Section 162(m)307 247 1,028 
Uncertain tax positions(5,045)(12,629)(8,952)
Tax credits(2,118)(4,085)(990)
State and local taxes18,726 67 656 
Impact on deferred taxes of change in tax rate(330)4,169 3,049 
Changes in fair value of contingent assets and liabilities(1,948)5,422 15,015 
Foreign tax rate differential128 68 23 
Valuation allowance(4)(30)(400)
Stock compensation(3,941)(4,612)(1,164)
Change in indemnification deferred tax asset1,240 2,343 1,786 
Other744 (228)184 
Income tax expense (benefit)$84,282 $(1,348)$(3,759)
Schedule of Components of Deferred Incomes Tax Assets (Liabilities)
The components of deferred income tax assets (liabilities) are as follows:
December 31,
(in thousands)20232022
Deferred Tax Assets
Federal benefit of state taxes payable$263 $1,739 
Reserves, accruals and other18,923 31,532 
Inventory obsolescence— 919 
Capitalized research and development17,142 79,946 
Stock compensation9,266 — 
Intangible assets25,214 — 
Net operating loss carryforwards80,184 88,014 
Lease liability14,365 — 
Deferred tax assets165,357 202,150 
Deferred Tax Liabilities
Reserves, accruals and other— (5,354)
Right-of-use asset(11,543)— 
Intangible assets— (80,770)
Amortization of intangibles other than goodwill— (385)
Depreciation— (1,469)
Deferred tax liability(11,543)(87,978)
Less: valuation allowance(3,616)(3,525)
$150,198 $110,647 
Recorded in the accompanying consolidated balance sheets as:
Noncurrent deferred tax assets, net$150,198 $110,647 
Schedule of Reconciliation of the Company's Changes in Uncertain Tax Positions
A reconciliation of the Company’s changes in uncertain tax positions for 2023 and 2022 is as follows:
(in thousands)Amount
Balance of uncertain tax positions as of January 1, 2021$5,292 
  Additions related to current year tax positions— 
  Reductions related to prior year tax positions(188)
  Settlements(1,446)
  Lapse of statute of limitations— 
Balance of uncertain tax positions as of December 31, 20213,658 
   Additions related to current year tax positions— 
   Reductions related to prior year tax positions(1,180)
   Settlements(306)
   Lapse of statute of limitations(692)
Balance of uncertain tax positions as of December 31, 20221,480 
   Additions related to current year tax positions3,749 
   Reductions related to prior year tax positions(688)
   Settlements(442)
   Lapse of statute of limitations— 
Balance of uncertain tax positions as of December 31, 2023$4,099 
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Inventory (Tables)
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory
Inventory consisted of the following:

December 31,
(in thousands)20232022
Raw materials$31,259 $19,987 
Work in process13,807 8,234 
Finished goods18,963 7,254 
Total inventory$64,029 $35,475 
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property, Plant & Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant, and Equipment, Net The estimated useful lives of the major classes of depreciable assets are as follows:
ClassRange of Estimated Useful Lives
Buildings
10 - 50 years
Land improvements
15 - 40 years
Machinery and equipment
3 - 15 years
Furniture and fixtures
15 years
Leasehold improvements
Lesser of lease term or 15 years
Computer software
3 - 5 years
Property, plant and equipment, net, consisted of the following:
 December 31,
(in thousands)20232022
Land$9,480 $13,450 
Buildings73,441 76,329 
Machinery, equipment and fixtures102,576 92,604 
Computer software27,259 25,864 
Construction in progress40,964 14,047 
253,720 222,294 
Less: accumulated depreciation and amortization(107,023)(100,128)
Total property, plant and equipment, net$146,697 $122,166 
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Asset Retirement Obligations (Tables)
 12 Months Ended
Dec. 31, 2023
Asset Retirement Obligation Disclosure [Abstract]  
Schedule of Asset Retirement Obligations
The following table provides a summary of the changes in the Company’s asset retirement obligations:

(in thousands)Amount
Balance, January 1, 2022$20,833 
Change in useful life estimate280 
Accretion expense1,430 
Balance, December 31, 202222,543 
Accretion expense373 
Balance, December 31, 2023$22,916 
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Intangibles, Net and Goodwill (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangibles
Intangibles, net, consisted of the following:
 December 31, 2023
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 – 25
Straight-Line$13,540 $(12,216)$1,324 
Customer relationships
15 – 25
Accelerated157,995 (117,574)40,421 
Currently marketed product
9 – 15
Straight-Line132,800 (38,277)94,523 
Licenses
11 – 16
Straight-Line22,233 (7,972)14,261 
Developed technology9Straight-Line2,400 (944)1,456 
Total$328,968 $(176,983)$151,985 

December 31, 2022
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 – 25
Straight-Line$13,540 $(12,061)$1,479 
Customer relationships
15 – 25
Accelerated96,681 (95,009)1,672 
Currently marketed product
9 – 15
Straight-Line275,700 (47,628)228,072 
Licenses
11 – 16
Straight-Line85,800 (19,101)66,699 
Developed technology9Straight-Line2,400 (677)1,723 
IPR&DN/AN/A15,640 — 15,640 
Total$489,761 $(174,476)$315,285 
Schedule of Indefinite-Lived Intangible Assets
Intangibles, net, consisted of the following:
 December 31, 2023
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 – 25
Straight-Line$13,540 $(12,216)$1,324 
Customer relationships
15 – 25
Accelerated157,995 (117,574)40,421 
Currently marketed product
9 – 15
Straight-Line132,800 (38,277)94,523 
Licenses
11 – 16
Straight-Line22,233 (7,972)14,261 
Developed technology9Straight-Line2,400 (944)1,456 
Total$328,968 $(176,983)$151,985 

December 31, 2022
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 – 25
Straight-Line$13,540 $(12,061)$1,479 
Customer relationships
15 – 25
Accelerated96,681 (95,009)1,672 
Currently marketed product
9 – 15
Straight-Line275,700 (47,628)228,072 
Licenses
11 – 16
Straight-Line85,800 (19,101)66,699 
Developed technology9Straight-Line2,400 (677)1,723 
IPR&DN/AN/A15,640 — 15,640 
Total$489,761 $(174,476)$315,285 
Schedule of Expected Future Amortization Expense
The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:
(in thousands)Amount
2024$39,726 
202524,409 
202625,206 
202719,680 
202816,195 
2029 and thereafter 26,769 
Total$151,985 
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables)
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:
 December 31,
(in thousands)20232022
Compensation and benefits$36,331 $30,425 
Freight, distribution and operations67,529 49,067 
Accrued rebates, discounts and chargebacks16,070 13,399 
Accrued professional fees10,244 8,668 
Other15,164 25,525 
Total accrued expenses and other liabilities$145,338 $127,084 
Operating lease liabilities (Note 16)$54,453 $25,442 
Long-term contingent liability (Note 4)2,700 11,900 
Other long-term liabilities6,168 8,813 
Total other long-term liabilities$63,321 $46,155 
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Long-Term Debt, Net, and Other Borrowings (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Maturities of Principal Obligations
As of December 31, 2023, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:
(in thousands)Amount
2024$— 
2025— 
2026— 
2027575,000 
2028— 
Total principal outstanding575,000 
Unamortized debt issuance costs(13,955)
Finance lease liabilities1,448 
Total562,493 
Less: current portion(823)
Total long-term debt, net, and other borrowings$561,670 
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accumulated Other Comprehensive Loss (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Loss
The components of Accumulated Other Comprehensive Loss, net of tax of zero and zero for the year ended December 31, 2023 and 2022, respectively, consisted of the following:

(in thousands)Foreign currency translationUnrealized loss on cash flow hedgesAccumulated other comprehensive loss
Balance at January 1, 2023$(1,259)$— $(1,259)
Other comprehensive income (loss) before reclassifications222 — 222 
Balance at December 31, 2023$(1,037)$— $(1,037)
Balance at January 1, 2022$(754)$269 $(485)
Other comprehensive income (loss) before reclassifications(505)5,838 5,333 
Amounts reclassified to earnings— (6,107)(6,107)
Balance at December 31, 2022$(1,259)$— $(1,259)
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense Recognized
Stock-based compensation expense recognized in the consolidated statements of operations is summarized below:
Year Ended
December 31,
(in thousands)202320222021
Cost of goods sold$9,126 $4,422 $2,370 
Sales and marketing9,500 6,185 2,472 
General and administrative24,807 14,876 9,092 
Research and development7,074 3,779 2,000 
Total stock-based compensation expense$50,507 $29,262 $15,934 
Schedule of Option Activity
A summary of option activity for 2023 is presented below:
Total
Stock
Options		Weighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term
(Years)		Aggregate
Intrinsic
Value
Balance at January 1, 2023874,749 $30.37 5.819,058,224 
Options granted332,368 $76.41 
Options exercised(214,619)$19.02 
Options cancelled and forfeited(35,326)$51.30 
Outstanding at December 31, 2023957,172 $48.13 6.718,283,464 
Vested and expected to vest at December 31, 2023957,172 $48.13 6.718,283,464 
Exercisable at December 31, 2023466,039 $26.99 4.416,462,767 
Schedule of Valuation Model
The table below summarizes the key weighted-average assumptions used in valuing stock options granted:
Year Ended December 31,
202320222021
Expected volatility56.1 %62.1 %— %
Risk-free interest rate4.0 %2.0 %— %
Expected life (in years)6.06.0—
Expected dividend yield———
Schedule of Restricted Stock Awards Activity
A summary of restricted stock awards and restricted stock units activity for 2023 is presented below:
SharesWeighted-
Average Grant
Date Fair Value Per Share
Nonvested balance at January 1, 20231,249,992 $34.65 
Granted710,985 $74.38 
Vested(612,912)$29.78 
Forfeited(137,806)$50.36 
Nonvested balance at December 31, 20231,210,259 $58.71 
A summary of TSR Award activity for 2023 is presented below:
SharesWeighted-
Average Grant
Date Fair Value Per Share
Nonvested balance at January 1, 2023658,875 $48.58 
Granted365,478 $127.75 
Vested(348,302)$23.43 
Forfeited(45,997)$57.77 
Nonvested balance at December 31, 2023630,054 $78.91 
Schedule of RSU Valuation Model The fair value of these awards are based on a Monte Carlo simulation valuation model with the following assumptions:
Year Ended December 31,
202320222021
Expected volatility52.8 %56.6 %54.0 %
Risk-free interest rate4.6 %1.7 %30.0 %
Expected life (in years)2.82.82.8
Expected dividend yield———
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Schedule of Operating and Finance Lease Assets and Liabilities
Operating and finance lease assets and liabilities are as follows:
(in thousands)ClassificationDecember 31, 2023December 31, 2022
Assets
OperatingOther long-term assets$45,325 $19,033 
FinanceProperty, plant and equipment, net1,438 582 
Total leased assets$46,763 $19,615 
Liabilities
Current
     OperatingAccrued expenses and other liabilities$1,904 $2,177 
     FinanceCurrent portion of long-term debt and other borrowings823 354 
Noncurrent
     OperatingOther long-term liabilities54,453 25,442 
     FinanceLong-term debt, net and other borrowings625 231 
Total leased liabilities$57,805 $28,204 
Schedule of Components of Lease Expense and Other Information
The components of lease expense were as follows:
 
(in thousands)Year Ended
December 31, 2023		Year Ended
December 31, 2022
Operating lease expense$4,627 $1,797 
Finance lease expense
      Amortization of ROU assets795 426 
      Interest on lease liabilities81 28 
Total lease expense$5,503 $2,251 
Other information related to leases were as follows:
December 31, 2023December 31, 2022
Weighted-average remaining lease term (Years):
      Operating leases13.57.9
      Finance leases2.31.9
Weighted-average discount rate:
      Operating leases7.3%4.8%
      Finance leases6.2%4.4%
(in thousands)Year Ended
December 31, 2023		Year Ended
December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:                   
      Operating cash flows from operating leases$3,462$2,440
      Operating cash flows from finance leases8128
      Financing cash flows from finance leases504384
ROU assets obtained in exchange for lease obligations:
      Operating leases29,39611,019
      Finance leases1,437582
Schedule of Future Minimum Lease Payments Under Operating Leases
Future minimum lease payments under non-cancellable leases as of December 31, 2023 were as follows:
(in thousands)
Operating Leases
Finance Leases
2024$4,624 $846 
20255,413 664 
20267,090 151 
20277,312 — 
20287,453 — 
Thereafter67,642 — 
  Total future minimum lease payments99,534 1,661 
Less: interest43,177 213 
  Total$56,357 $1,448 
Schedule of Future Minimum Lease Payments Under Finance Leases
Future minimum lease payments under non-cancellable leases as of December 31, 2023 were as follows:
(in thousands)
Operating Leases
Finance Leases
2024$4,624 $846 
20255,413 664 
20267,090 151 
20277,312 — 
20287,453 — 
Thereafter67,642 — 
  Total future minimum lease payments99,534 1,661 
Less: interest43,177 213 
  Total$56,357 $1,448 
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Assets
Other assets are comprised of the following:
 December 31,
(in thousands)20232022
Prepaid Expenses$16,437 $12,887 
Other Current Assets246 205 
Total other current assets$16,683 $13,092 
ROU Asset (Note 16)$45,325 $19,033 
Other Long-Term Assets9,936 15,322 
Total other long-term assets$55,261 $34,355 
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income (Loss) Per Common Share (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Net Income (loss) Per Common Share
A summary of net income (loss) per common share is presented below:
 Year Ended
December 31,
(in thousands, except per share amounts)202320222021
Net income (loss)$326,661 $28,067 $(71,279)
Basic weighted-average common shares outstanding68,266 68,487 67,486 
Effect of dilutive stock options346 439 — 
Effect of dilutive restricted stock1,428 1,745 — 
Effect of convertible debt instrument199 — — 
Diluted weighted-average common shares outstanding70,239 70,671 67,486 
Basic income (loss) per common share$4.79 $0.41 $(1.06)
Diluted income (loss) per common share$4.65 $0.40 $(1.06)
Antidilutive securities excluded from diluted net income (loss) per common share421 358 2,893 
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Payments Required
As of December 31, 2023, future payments required under purchase commitments are as follows:
(in thousands)Amount
20242,716 
20252,716 
20262,716 
20272,716 
2028 and thereafter— 
Total$10,864 
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Description of Business (Details) - USD ($)
$ in Thousands
Feb. 20, 2020
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Business combination, consideration transferred, equity interests issued (in shares) 26,844,877    
Business combination common stock under contingent value right (in shares) 86,630,633    
Contingent consideration liabilities   $ 2,700 $ 111,600
Progenics      
Business Acquisition [Line Items]      
Aggregate cash payments percentage 40.00%    
Percentage of total consideration 19.90%    
Business combination contingent value right of total consideration $ 99,600    
Progenics | Cash Payments, 2022      
Business Acquisition [Line Items]      
Contingent consideration liabilities 100,000    
Progenics | Cash Payments, 2023      
Business Acquisition [Line Items]      
Contingent consideration liabilities $ 150,000    
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Dec. 31, 2023
Debt Instrument [Line Items]    
Measurement period adjustment $ 2.6  
Convertible Debt    
Debt Instrument [Line Items]    
Fair value of debt   $ 644.3
2.625% Convertible Senior Notes due 2027 | Senior Notes    
Debt Instrument [Line Items]    
Interest rate   2.625%
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Schedule of Product Concentration Risk (Details) - Revenue Benchmark - Product Concentration Risk
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
PYLARIFY      
Concentration Risk [Line Items]      
Concentration risk percentage 65.70% 56.40% 10.20%
DEFINITY      
Concentration Risk [Line Items]      
Concentration risk percentage 21.60% 26.20% 54.70%
TechneLite      
Concentration Risk [Line Items]      
Concentration risk percentage 6.70% 9.50% 21.50%
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)
Dec. 31, 2023
Buildings | Minimum  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 10 years
Buildings | Maximum  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 50 years
Land improvements | Minimum  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 15 years
Land improvements | Maximum  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 40 years
Machinery and equipment | Minimum  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 3 years
Machinery and equipment | Maximum  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 15 years
Furniture and fixtures  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 15 years
Leasehold improvements  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 15 years
Computer software | Minimum  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 3 years
Computer software | Maximum  
Property, Plant & Equipment [Line Items]  
Estimated useful lives 5 years
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Goodwill, impairment loss $ 0 $ 0 $ 0
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Advertising and Promotion Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Advertising and promotion costs $ 26.0 $ 26.0 $ 17.5
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Stock Based Compensation (Details)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Expected dividend yield 0.00%
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Schedule Of Other Loss (Income) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Foreign currency losses $ 21 $ 256 $ 274
Tax indemnification expense, net 4,943 9,554 7,121
Interest income (19,638) (2,613) (45)
Interest rate swap termination 0 (5,494) 0
Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties (51,789) 0 (15,263)
Other 143 0 0
Total other (income) loss $ (66,320) $ 1,703 $ 7,350
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Self-Insurance Reserves (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Accrued liabilities associated with employee medical costs $ 1.0 $ 0.9
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]        
Total revenues   $ 1,296,429 $ 935,061 $ 425,208
Product revenue, net        
Disaggregation of Revenue [Line Items]        
Total revenues   1,263,068 887,038 400,356
License and royalty revenues        
Disaggregation of Revenue [Line Items]        
Total revenues   33,361 48,023 24,852
Total radiopharmaceutical oncology        
Disaggregation of Revenue [Line Items]        
Total revenues   854,433 531,507 48,887
PYLARIFY        
Disaggregation of Revenue [Line Items]        
Total revenues   851,303 527,405 43,414
Other radiopharmaceutical oncology        
Disaggregation of Revenue [Line Items]        
Total revenues   3,130 4,102 5,473
Total precision diagnostics        
Disaggregation of Revenue [Line Items]        
Total revenues   390,118 356,682 351,025
DEFINITY        
Disaggregation of Revenue [Line Items]        
Total revenues   279,768 244,993 232,759
TechneLite        
Disaggregation of Revenue [Line Items]        
Total revenues   87,370 88,864 91,293
Other precision diagnostics        
Disaggregation of Revenue [Line Items]        
Total revenues   22,980 22,825 26,973
Strategic Partnerships and other revenue        
Disaggregation of Revenue [Line Items]        
Total revenues   $ 51,878 $ 46,872 $ 25,296
License and Royalty Revenues, Sales-Based Milestone Payment        
Disaggregation of Revenue [Line Items]        
Total revenues $ 15,000      
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue from Contracts with Customers - Narrative (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
productCategory
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Disaggregation of Revenue [Line Items]          
Number of product categories | productCategory     3    
Revenues     $ 1,296,429 $ 935,061 $ 425,208
Total amount awarded   $ 24,000      
Payment terms     standard payment terms are 30 to 60 days    
License and Royalty Revenues, Sales-Based Milestone Payment          
Disaggregation of Revenue [Line Items]          
Revenues $ 15,000        
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue from Contracts with Customers - Schedule Of Rebates and Allowances (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Beginning balance $ 13,399 $ 10,977
Provision related to current period revenues 32,308 26,683
Adjustments relating to prior period revenues (453) 70
Payments or credits made during the period (29,184) (24,331)
Ending balance $ 16,070 $ 13,399
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue from Contracts with Customers - Schedule Of Contract Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]    
Amounts included in the contract liability at the beginning of the period $ 682 $ 244
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets $ 574,131 $ 342,646
Contingent consideration liabilities 2,700 111,600
Total liabilities 2,700 111,600
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 574,131 342,646
Contingent consideration liabilities 0 0
Total liabilities 0 0
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 0 0
Contingent consideration liabilities 0 0
Total liabilities 0 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 0 0
Contingent consideration liabilities 2,700 111,600
Total liabilities 2,700 111,600
Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market funds 574,131 342,646
Money market funds | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market funds 574,131 342,646
Money market funds | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market funds 0 0
Money market funds | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market funds $ 0 $ 0
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Feb. 20, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Fair Value, Option, Quantitative Disclosures [Line Items]        
Revenues   $ 1,296,429 $ 935,061 $ 425,208
Contingent consideration liabilities   2,700 $ 111,600  
Change in fair value of the contingent financial asset and contingent financial liabilities   $ 9,300    
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]   General and administrative    
Progenics        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Royalty percentage     5.00%  
Aggregate cash payments percentage 40.00%      
Potential payments, high   $ 85,000    
Progenics | Cash Payments, 2022        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities $ 100,000      
Progenics | Cash Payments, 2023        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities $ 150,000      
Progenics | Net Sales Targets For Azedra        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   70,000    
Progenics | 1095 commercialization milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   5,000    
Progenics | 1404 Commercialization Milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   $ 10,000    
Royalty | Progenics        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Revenues     $ 5,000  
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments - Schedule of Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent consideration liabilities $ 2,700 $ 111,600
Level 3    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent consideration liabilities 2,700 111,600
Net sales targets – PYLARIFY (CVRs) | Level 3    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent consideration liabilities   $ 99,700
Net sales targets – PYLARIFY (CVRs) | Level 3 | Probability of success and sales targets | Probability adjusted discounted cash flow model    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input   1
1095 commercialization milestone | Level 3    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent consideration liabilities $ 1,800 $ 1,700
1095 commercialization milestone | Level 3 | Probability of success and sales targets | Probability adjusted discounted cash flow model    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.40 0.40
1095 commercialization milestone | Level 3 | Discount rate | Probability adjusted discounted cash flow model    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.041 0.038
Net sales targets – AZEDRA and 1095 | Level 3    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent consideration liabilities $ 900 $ 10,200
Net sales targets – AZEDRA and 1095 | Level 3 | Probability of success and sales targets | Monte Carlo simulation | Minimum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0 0.20
Net sales targets – AZEDRA and 1095 | Level 3 | Probability of success and sales targets | Monte Carlo simulation | Maximum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.40 1
Net sales targets – AZEDRA and 1095 | Level 3 | Discount rate | Monte Carlo simulation    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.15  
Net sales targets – AZEDRA and 1095 | Level 3 | Discount rate | Monte Carlo simulation | Minimum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input   0.16
Net sales targets – AZEDRA and 1095 | Level 3 | Discount rate | Monte Carlo simulation | Maximum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input   0.17
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value of Financial Instruments - Schedule of Financial Instruments With Significant Level 3 Inputs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Financial Assets    
Fair value, beginning of period $ 0 $ 9,300
Changes in fair value included in net income (loss) 0 (9,300)
Cash Payments 0 0
Fair value, end of period 0 0
Financial Liabilities    
Fair value, beginning of period 111,600 86,200
Changes in fair value included in net income (loss) (9,275) 25,400
Cash Payments (99,625) 0
Fair value, end of period $ 2,700 $ 111,600
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] General and administrative  
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] General and administrative  
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Schedule of Components of Income Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
U.S. $ 410,326 $ 29,012 $ (76,389)
International 617 (2,293) 1,351
Income (loss) before income taxes $ 410,943 $ 26,719 $ (75,038)
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Schedule of (Benefit) Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Current      
Federal $ 110,108 $ 42,532 $ 0
State 29,806 4,302 (8,166)
International 0 (166) (30)
Current income tax expense (benefit), total 139,914 46,668 (8,196)
Deferred      
Federal (45,252) (39,920) 1,048
State (10,739) (8,315) 3,058
International 359 219 331
Deferred income tax expense (benefit), total (55,632) (48,016) 4,437
Income tax expense (benefit) $ 84,282 $ (1,348) $ (3,759)
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Schedule of Differences in Statutory Rate and Effective Rate (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
U.S. statutory rate $ 86,298 $ 5,611 $ (15,758)
Permanent items 1,042 2,309 1,764
Sale of RELISTOR licensed intangible asset associated with net sales royalties (10,817) 0 0
Section 162(m) 307 247 1,028
Uncertain tax positions (5,045) (12,629) (8,952)
Tax credits (2,118) (4,085) (990)
State and local taxes 18,726 67 656
Impact on deferred taxes of change in tax rate (330) 4,169 3,049
Changes in fair value of contingent assets and liabilities (1,948) 5,422 15,015
Foreign tax rate differential 128 68 23
Valuation allowance (4) (30) (400)
Stock compensation (3,941) (4,612) (1,164)
Change in indemnification deferred tax asset 1,240 2,343 1,786
Other 744 (228) 184
Income tax expense (benefit) $ 84,282 $ (1,348) $ (3,759)
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Schedule of Components of Deferred Income Tax Assets (Liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred Tax Assets    
Federal benefit of state taxes payable $ 263 $ 1,739
Reserves, accruals and other 18,923 31,532
Inventory obsolescence 0 919
Capitalized research and development 17,142 79,946
Stock compensation 9,266 0
Intangible assets 25,214 0
Net operating loss carryforwards 80,184 88,014
Lease liability 14,365 0
Deferred tax assets 165,357 202,150
Deferred Tax Liabilities    
Reserves, accruals and other 0 (5,354)
Right-of-use asset (11,543) 0
Intangible assets 0 (80,770)
Amortization of intangibles other than goodwill 0 (385)
Depreciation 0 (1,469)
Deferred tax liability (11,543) (87,978)
Less: valuation allowance (3,616) (3,525)
Net deferred tax assets 150,198 110,647
Recorded in the accompanying consolidated balance sheets as:    
Noncurrent deferred tax assets, net $ 150,198 $ 110,647
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating Loss Carryforwards [Line Items]        
Deferred tax asset, valuation allowance $ 3,616,000 $ 3,525,000    
Indemnification expense 4,943,000 9,554,000 $ 7,121,000  
Total liabilities for uncertain tax positions including interest and penalties 5,400,000 8,300,000    
Uncertain tax positions 4,099,000 1,480,000 3,658,000 $ 5,292,000
Interest accruals 1,300,000 6,400,000    
Penalty accruals 0 400,000    
Tax provision benefit/expense 5,045,000 $ 12,629,000 $ 8,952,000  
Liabilities, Current        
Operating Loss Carryforwards [Line Items]        
Total liabilities for uncertain tax positions including interest and penalties 1,300,000      
Other Noncurrent Liabilities        
Operating Loss Carryforwards [Line Items]        
Total liabilities for uncertain tax positions including interest and penalties 3,200,000      
Deferred Income Tax Assets, Net        
Operating Loss Carryforwards [Line Items]        
Total liabilities for uncertain tax positions including interest and penalties 900,000      
Federal        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryovers 297,600,000      
Operating loss carryforwards expire 157,900,000      
Operating loss carried forward 139,600,000      
State Research Credit        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryovers 12,500,000      
Tax credits 2,100,000      
Massachusetts | Investment Tax Credit Carryforward        
Operating Loss Carryforwards [Line Items]        
Tax credits $ 800,000      
XML 89 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Reconciliation of Uncertain Tax Positions (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Reconciliation of Uncertain Tax Positions [Roll Forward]      
Beginning balance of uncertain tax positions $ 1,480 $ 3,658 $ 5,292
Additions related to current year tax positions 3,749 0 0
Reductions related to prior year tax positions (688) (1,180) (188)
Settlements (442) (306) (1,446)
Lapse of statute of limitations 0 (692) 0
Ending balance of uncertain tax positions $ 4,099 $ 1,480 $ 3,658
XML 90 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
Inventory (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 31,259 $ 19,987
Work in process 13,807 8,234
Finished goods 18,963 7,254
Total inventory $ 64,029 $ 35,475
XML 91 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property, Plant & Equipment, Net - Schedule of Property, Plant & Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant & Equipment [Line Items]    
Property, plant and equipment, gross $ 253,720 $ 222,294
Less: accumulated depreciation and amortization (107,023) (100,128)
Property, plant and equipment, net 146,697 122,166
Land    
Property, Plant & Equipment [Line Items]    
Property, plant and equipment, gross 9,480 13,450
Buildings    
Property, Plant & Equipment [Line Items]    
Property, plant and equipment, gross 73,441 76,329
Machinery, equipment and fixtures    
Property, Plant & Equipment [Line Items]    
Property, plant and equipment, gross 102,576 92,604
Computer software    
Property, Plant & Equipment [Line Items]    
Property, plant and equipment, gross 27,259 25,864
Construction in progress    
Property, Plant & Equipment [Line Items]    
Property, plant and equipment, gross $ 40,964 $ 14,047
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property, Plant & Equipment, Net - Additional Information (Details) - USD ($)
$ in Millions
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Mar. 31, 2023
Property, Plant & Equipment [Line Items]          
Depreciation and amortization expense   $ 13.2 $ 13.7 $ 13.2  
Noncash impairment $ 6.0        
Disposal Group, Disposed of by Sale, Not Discontinued Operations          
Property, Plant & Equipment [Line Items]          
Disposal group consideration         $ 10.0
XML 93 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
Sale of Puerto Rico Subsidiary (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Mar. 31, 2023
Jan. 29, 2021
Puerto Rican Radiopharmacy Servicing Subsidiary      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Pre-tax book gain on disposal $ 15.3    
Disposal Group, Disposed of by Sale, Not Discontinued Operations      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Purchase price for stock   $ 10.0  
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Puerto Rican Radiopharmacy Servicing Subsidiary      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Purchase price for stock     $ 18.0
Disposal group holdback amount     $ 1.8
XML 94 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
Asset Retirement Obligations - Additional Information (Details)
$ in Millions
Dec. 31, 2023
USD ($)
Asset Retirement Obligation Disclosure [Abstract]  
Obligation expected to be incurred $ 25.1
Financial assurance in form of surety bond $ 30.3
XML 95 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]    
Balance at the beginning of the period $ 22,543 $ 20,833
Change in useful life estimate   280
Accretion expense 373 1,430
Balance at the ending of the period $ 22,916 $ 22,543
XML 96 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
Intangibles, Net and Goodwill - Schedule of Intangibles, Net (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Aug. 02, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]      
Indefinite lived, cost     $ 15,640
Total, cost $ 328,968   489,761
Accumulated Amortization (176,983)   (174,476)
Total 151,985    
Total, net 151,985   315,285
Trademarks      
Finite-Lived Intangible Assets [Line Items]      
Cost 13,540   13,540
Accumulated Amortization (12,216)   (12,061)
Total $ 1,324   $ 1,479
Trademarks | Minimum      
Finite-Lived Intangible Assets [Line Items]      
Useful Lives (in years) 15 years   15 years
Trademarks | Maximum      
Finite-Lived Intangible Assets [Line Items]      
Useful Lives (in years) 25 years   25 years
Customer relationships      
Finite-Lived Intangible Assets [Line Items]      
Cost $ 157,995   $ 96,681
Accumulated Amortization (117,574)   (95,009)
Total $ 40,421   $ 1,672
Customer relationships | Minimum      
Finite-Lived Intangible Assets [Line Items]      
Useful Lives (in years) 15 years   15 years
Customer relationships | Maximum      
Finite-Lived Intangible Assets [Line Items]      
Useful Lives (in years) 25 years   25 years
Currently marketed product      
Finite-Lived Intangible Assets [Line Items]      
Cost $ 132,800   $ 275,700
Accumulated Amortization (38,277)   (47,628)
Total $ 94,523   $ 228,072
Currently marketed product | Minimum      
Finite-Lived Intangible Assets [Line Items]      
Useful Lives (in years) 9 years   9 years
Currently marketed product | Maximum      
Finite-Lived Intangible Assets [Line Items]      
Useful Lives (in years) 15 years   15 years
Licenses      
Finite-Lived Intangible Assets [Line Items]      
Cost $ 22,233 $ 63,600 $ 85,800
Accumulated Amortization (7,972) $ (17,500) (19,101)
Total $ 14,261   $ 66,699
Licenses | Minimum      
Finite-Lived Intangible Assets [Line Items]      
Useful Lives (in years) 11 years   11 years
Licenses | Maximum      
Finite-Lived Intangible Assets [Line Items]      
Useful Lives (in years) 16 years   16 years
Developed technology      
Finite-Lived Intangible Assets [Line Items]      
Useful Lives (in years) 9 years   9 years
Cost $ 2,400   $ 2,400
Accumulated Amortization (944)   (677)
Total $ 1,456   $ 1,723
XML 97 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
Intangibles, Net and Goodwill - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 02, 2023
May 31, 2023
Feb. 28, 2023
May 31, 2021
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Indefinite-lived Intangible Assets [Line Items]                
Amortization expense           $ 46,400 $ 33,200 $ 27,500
Proceeds from selling rights to the royalties $ 98,000              
Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties 5,000              
Accumulated amortization         $ 176,983 176,983 174,476  
Gain on sales of assets           51,789 0 15,263
Revenues           1,296,429 935,061 $ 425,208
License and Royalty Revenues, Sales-Based Milestone Payment                
Indefinite-lived Intangible Assets [Line Items]                
Revenues         15,000      
Cerveau Technologies, Inc                
Indefinite-lived Intangible Assets [Line Items]                
Payment for acquisitions   $ 10,000 $ 35,300          
Asset acquisition, consideration transferred   $ 10,000            
Research and development                
Indefinite-lived Intangible Assets [Line Items]                
Impairment           $ 15,600    
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]           Research and development    
Cost of goods sold                
Indefinite-lived Intangible Assets [Line Items]                
Impairment           $ 116,400    
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]           Cost of goods sold    
IPR & D                
Indefinite-lived Intangible Assets [Line Items]                
Decrease in indefinite lived assets       $ 132,800        
Currently marketed product                
Indefinite-lived Intangible Assets [Line Items]                
Finite-lived intangible assets, period increase (decrease)       $ 132,800        
Cost         132,800 $ 132,800 275,700  
Accumulated amortization         38,277 38,277 47,628  
Licenses                
Indefinite-lived Intangible Assets [Line Items]                
Cost 63,600       22,233 22,233 85,800  
Accumulated amortization $ 17,500       $ 7,972 $ 7,972 $ 19,101  
XML 98 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
Intangibles, Net and Goodwill - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2024 $ 39,726
2025 24,409
2026 25,206
2027 19,680
2028 16,195
2029 and thereafter 26,769
Total $ 151,985
XML 99 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Compensation and benefits $ 36,331 $ 30,425
Freight, distribution and operations 67,529 49,067
Accrued rebates, discounts and chargebacks 16,070 13,399
Accrued professional fees 10,244 8,668
Other 15,164 25,525
Total accrued expenses and other liabilities 145,338 127,084
Operating lease liabilities (Note 16) 54,453 25,442
Long-term contingent liability (Note 4) 2,700 11,900
Other long-term liabilities 6,168 8,813
Total other long-term liabilities $ 63,321 $ 46,155
XML 100 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
Long-Term Debt, Net, and Other Borrowings - Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
2024 $ 0  
2025 0  
2026 0  
2027 575,000  
2028 0  
Total principal outstanding 575,000  
Unamortized debt issuance costs (13,955)  
Finance lease liabilities 1,448  
Total 562,493  
Less: current portion (823)  
Total long-term debt, net, and other borrowings $ 561,670 $ 557,712
XML 101 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
Long-Term Debt, Net, and Other Borrowings - Additional Information (Details)
 1 Months Ended 9 Months Ended 12 Months Ended
Dec. 08, 2022
USD ($)
$ / shares
Dec. 05, 2022
Dec. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
financial_covenant
$ / shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Debt Instrument [Line Items]                
Gain (loss) on extinguishment of debt           $ 0 $ (588,000) $ 889,000
Number of covenants | financial_covenant           2    
Minimum interest coverage ratio     3.00 3.00     3.00  
Convertible Debt                
Debt Instrument [Line Items]                
Extinguishment of debt, amount $ 75,000,000              
2.625% Convertible Senior Notes due 2027 | Convertible Debt                
Debt Instrument [Line Items]                
Debt instrument, face amount $ 575,000,000              
Interest rate 2.625%              
Proceeds from convertible debt $ 557,800,000              
Initial conversion price (in dollars per share) | $ / shares $ 79.81         $ 79.81    
Initial conversion premium 42.50%              
Share price (in dollars per share) | $ / shares $ 56.01              
Convertible, conversion ratio   0.0125291   0.0178539        
Debt instrument, stock price percentage 130.00%              
Purchase price as a percentage of principal amount 100.00%              
Debt Instrument, convertible, carrying amount           $ 575,000,000    
Debt instrument, unamortized discount           0    
Debt instrument, fair value           575,000,000    
Interest expense, debt           $ 15,100,000    
Amendment 2022 Credit Facility | Q1 2024                
Debt Instrument [Line Items]                
Total net leverage ratio           3.50    
Minimum | 2.625% Convertible Senior Notes due 2027 | Convertible Debt                
Debt Instrument [Line Items]                
Debt instrument, covenant percentage of additional interest           0.25%    
Maximum | 2.625% Convertible Senior Notes due 2027 | Convertible Debt                
Debt Instrument [Line Items]                
Debt instrument, covenant percentage of additional interest           0.50%    
2019 Term Loan Facility | Line of Credit                
Debt Instrument [Line Items]                
Line of credit facility, maximum borrowing capacity     $ 200,000,000 $ 200,000,000     $ 200,000,000  
Debt instrument, term (in years)     5 years          
Repayments of debt     $ 167,600,000   $ 7,800,000      
Gain (loss) on extinguishment of debt     (600,000)          
Deferred financing costs     2,700,000 2,700,000     2,700,000  
2019 Revolving Facility | Line of Credit                
Debt Instrument [Line Items]                
Line of credit facility, maximum borrowing capacity     $ 200,000,000 200,000,000     200,000,000  
Debt instrument, term (in years)     5 years          
2022 Term Facility | Line of Credit                
Debt Instrument [Line Items]                
Line of credit facility, maximum borrowing capacity     $ 100,000,000 100,000,000     100,000,000  
Revolving Credit Facility | Line of Credit                
Debt Instrument [Line Items]                
Line of credit facility, maximum borrowing capacity     $ 350,000,000 $ 350,000,000     $ 350,000,000  
Debt instrument, term (in years)     5 years          
Outstanding borrowings           $ 0    
Revolving Credit Facility | Minimum | SOFR | Line of Credit                
Debt Instrument [Line Items]                
Debt instrument, basis rate           1.50%    
Revolving Credit Facility | Minimum | Base Rate | Line of Credit                
Debt Instrument [Line Items]                
Debt instrument, basis rate           0.50%    
Revolving Credit Facility | Minimum | Leverage Ratio Range | Line of Credit                
Debt Instrument [Line Items]                
Line of credit facility, unused capacity, commitment fee percentage           0.15%    
Revolving Credit Facility | Maximum | Line of Credit                
Debt Instrument [Line Items]                
Line of credit facility, maximum borrowing capacity           $ 350,000,000    
Line of credit facility, accordion feature, higher borrowing capacity option           $ 335,000,000    
Revolving Credit Facility | Maximum | SOFR | Line of Credit                
Debt Instrument [Line Items]                
Debt instrument, basis rate           2.50%    
Revolving Credit Facility | Maximum | Base Rate | Line of Credit                
Debt Instrument [Line Items]                
Debt instrument, basis rate           1.50%    
Revolving Credit Facility | Maximum | Leverage Ratio Range | Line of Credit                
Debt Instrument [Line Items]                
Line of credit facility, unused capacity, commitment fee percentage           0.35%    
Letter of Credit | Line of Credit                
Debt Instrument [Line Items]                
Line of credit facility, maximum borrowing capacity           $ 20,000,000    
Bridge Loan | Line of Credit                
Debt Instrument [Line Items]                
Line of credit facility, maximum borrowing capacity           $ 10,000,000    
XML 102 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
Derivative Instruments (Details) - USD ($)
 12 Months Ended
Dec. 02, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Mar. 31, 2020
Derivative [Line Items]          
Proceeds from interest rate swap termination   $ 0 $ 5,583,000 $ 0  
Interest rate swaps          
Derivative [Line Items]          
Proceeds from interest rate swap termination $ 5,600,000        
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax $ 5,500,000        
Cash Flow Hedge | Interest rate swaps          
Derivative [Line Items]          
Notional amount         $ 100,000,000
Average fixed interest rate         0.82%
XML 103 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accumulated Other Comprehensive Loss (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive loss, tax $ 0 $ 0
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 447,147,000 464,439,000
Other comprehensive income (loss) before reclassifications 222,000 5,333,000
Amounts reclassified to earnings   (6,107,000)
Ending balance 815,892,000 447,147,000
Accumulated other comprehensive loss    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (1,259,000) (485,000)
Ending balance (1,037,000) (1,259,000)
Foreign currency translation    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (1,259,000) (754,000)
Other comprehensive income (loss) before reclassifications 222,000 (505,000)
Amounts reclassified to earnings   0
Ending balance (1,037,000) (1,259,000)
Unrealized loss on cash flow hedges    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 0 269,000
Other comprehensive income (loss) before reclassifications 0 5,838,000
Amounts reclassified to earnings   (6,107,000)
Ending balance $ 0 $ 0
XML 104 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Equity Incentive Plans (Details)
Dec. 31, 2023
shares
Share-Based Payment Arrangement [Abstract]  
Share based compensation, shares authorized (in shares) 10,930,277
XML 105 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 50,507 $ 29,262 $ 15,934
Cost of goods sold      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 9,126 4,422 2,370
Sales and marketing      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 9,500 6,185 2,472
General and administrative      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 24,807 14,876 9,092
Research and development      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 7,074 $ 3,779 $ 2,000
XML 106 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Schedule of Stock Options (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]      
Contractual term 10 years    
Total Stock Options      
Options outstanding, beginning balance (in shares) 874,749    
Options granted (in shares) 332,368    
Options exercised (in shares) (214,619) (397,822) (318,662)
Options cancelled and forfeited (in shares) (35,326)    
Options outstanding, ending balance (in shares) 957,172 874,749  
Exercisable (in shares) 466,039    
Weighted- Average Exercise Price      
Options outstanding, beginning balance (in dollars per share) $ 30.37    
Options granted (in dollars per share) 76.41    
Options exercised (in dollars per share) 19.02    
Options cancelled and forfeited (in dollars per share) 51.30    
Options outstanding, ending balance (in dollars per share) 48.13 $ 30.37  
Exercisable (in dollars per share) $ 26.99    
Weighted- Average Remaining Contractual Term (Years)      
Options outstanding, weighted average remaining contractual term (in years) 6 years 8 months 12 days 5 years 9 months 18 days  
Exercisable, weighted average remaining contractual term (in years) 4 years 4 months 24 days    
Options outstanding, aggregate intrinsic value $ 18,283,464 $ 19,058,224  
Exercisable, aggregate intrinsic value $ 16,462,767    
XML 107 R92.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Valuation Model Assumptions (Details) - Options - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected volatility 56.10% 62.10% 0.00%
Risk-free interest rate 4.00% 2.00% 0.00%
Expected life (in years) 6 years 6 years  
Expected dividend yield $ 0 $ 0 $ 0
XML 108 R93.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Stock Options Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]      
Options exercised (in shares) 214,619 397,822 318,662
Aggregate intrinsic value $ 12.9 $ 13.1 $ 1.6
Unrecognized compensation expense $ 13.2    
Weighted-average remaining period for recognition of unrecognized compensation costs 2 years    
XML 109 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Shares  
Nonvested beginning balance (in shares) | shares 1,249,992
Granted (in shares) | shares 710,985
Vested (in shares) | shares (612,912)
Forfeited (in shares) | shares (137,806)
Nonvested ending balance (in shares) | shares 1,210,259
Weighted- Average Grant Date Fair Value Per Share  
Nonvested beginning balance (in dollars per share) | $ / shares $ 34.65
Granted (in dollars per share) | $ / shares 74.38
Vested (in dollars per share) | $ / shares 29.78
Forfeited (in dollars per share) | $ / shares 50.36
Nonvested, ending balance (in dollars per share) | $ / shares $ 58.71
XML 110 R95.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Restricted Stock and TSR (Narrative) (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation expense $ 13,200,000    
Weighted-average remaining period for recognition of unrecognized compensation costs 2 years    
Granted (in dollars per share) $ 74.38    
Restricted stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
Unrecognized compensation expense $ 48,400,000    
Weighted-average remaining period for recognition of unrecognized compensation costs 2 years    
Granted (in dollars per share) $ 74.38 $ 51.51 $ 20.14
Fair value of vested shares $ 18,300,000 $ 11,900,000 $ 8,800,000
Total Stockholder Return Restricted Stock Awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation expense $ 26,200,000    
Weighted-average remaining period for recognition of unrecognized compensation costs 2 years    
Granted (in dollars per share) $ 127.75 $ 95.31 $ 31.25
Fair value of vested shares $ 8,200,000 $ 8,800,000 $ 2,000,000
Performance awards, measurement period 3 years    
Total Stockholder Return Restricted Stock Awards | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentages attainable during period 0.00%    
Total Stockholder Return Restricted Stock Awards | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentages attainable during period 200.00%    
XML 111 R96.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Schedule of Total Stockholder Return Restricted Awards (Details) - Total Stockholder Return Restricted Stock Awards - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected volatility 52.80% 56.60% 54.00%
Risk-free interest rate 4.60% 1.70% 30.00%
Expected life (in years) 2 years 9 months 18 days 2 years 9 months 18 days 2 years 9 months 18 days
Expected dividend yield $ 0 $ 0 $ 0
XML 112 R97.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Schedule of TSR Award Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Shares      
Nonvested beginning balance (in shares) 1,249,992    
Granted (in shares) 710,985    
Vested (in shares) (612,912)    
Forfeited (in shares) (137,806)    
Nonvested ending balance (in shares) 1,210,259 1,249,992  
Weighted- Average Grant Date Fair Value Per Share      
Nonvested beginning balance (in dollars per share) $ 34.65    
Granted (in dollars per share) 74.38    
Vested (in dollars per share) 29.78    
Forfeited (in dollars per share) 50.36    
Nonvested, ending balance (in dollars per share) $ 58.71 $ 34.65  
Total Stockholder Return Restricted Stock Awards      
Shares      
Nonvested beginning balance (in shares) 658,875    
Granted (in shares) 365,478    
Vested (in shares) (348,302)    
Forfeited (in shares) (45,997)    
Nonvested ending balance (in shares) 630,054 658,875  
Weighted- Average Grant Date Fair Value Per Share      
Nonvested beginning balance (in dollars per share) $ 48.58    
Granted (in dollars per share) 127.75 $ 95.31 $ 31.25
Vested (in dollars per share) 23.43    
Forfeited (in dollars per share) 57.77    
Nonvested, ending balance (in dollars per share) $ 78.91 $ 48.58  
XML 113 R98.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation - Schedule Common Stock Repurchases (Details) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]      
Stock repurchase program, authorized amount $ 150,000,000   $ 150,000,000
Net proceeds from the notes $ 75,000,000    
Sale of stock, price per share (in dollars per share) $ 56.01   $ 56.01
Repurchase of common stock (in shares)   0 1,300,000
Repurchase of common stock     $ 75,000,000
XML 114 R99.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Additional Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
lease
Sep. 01, 2023
USD ($)
May 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Feb. 28, 2022
USD ($)
Oct. 31, 2021
USD ($)
Sep. 30, 2021
Jun. 19, 2020
USD ($)
Lessee, Lease, Description [Line Items]                  
Number of leases | lease   2              
Operating lease liability   $ 56,357              
Operating lease, right-of-use asset   $ 45,325     $ 19,033        
Lessor term of contract               9 years  
Impairment, lessor asset under operating lease $ 9,500                
New York City                  
Lessee, Lease, Description [Line Items]                  
Operating lease liability                 $ 18,600
Somerset, New Jersey                  
Lessee, Lease, Description [Line Items]                  
Operating lease liability             $ 700   $ 600
Bedford, Massachusetts                  
Lessee, Lease, Description [Line Items]                  
Term of contract   15 years 3 months 29 days              
Operating lease liability     $ 23,500 $ 6,000 $ 11,000 $ 11,000      
Operating lease, right-of-use asset     $ 23,500 $ 6,000          
Renewal term     5 years            
XML 115 R100.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Schedule of Operating and Financing Lease Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Assets    
Operating lease, right-of-use asset $ 45,325 $ 19,033
Finance 1,438 582
Total leased assets $ 46,763 $ 19,615
Operating lease, right-of-use asset, statement of financial position [Extensible List] Other long-term assets Other long-term assets
Finance lease, right-of-use asset, statement of financial position [Extensible List] Property, plant and equipment, net Property, plant and equipment, net
Current    
Operating $ 1,904 $ 2,177
Finance 823 354
Noncurrent    
Operating 54,453 25,442
Finance 625 231
Total leased liabilities $ 57,805 $ 28,204
Operating lease, liability, current, statement of financial position [Extensible List] Accrued expenses and other liabilities Accrued expenses and other liabilities
Finance lease, liability, current, statement of financial position [Extensible List] Current portion of long-term debt and other borrowings Current portion of long-term debt and other borrowings
Operating lease, liability, noncurrent, statement of financial position [Extensible List] Other long-term liabilities Other long-term liabilities
Finance lease, liability, noncurrent, statement of financial position [Extensible List] Total long-term debt, net, and other borrowings Total long-term debt, net, and other borrowings
XML 116 R101.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Schedule of Components of Lease Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
Operating lease expense $ 4,627 $ 1,797
Finance lease expense    
Amortization of ROU assets 795 426
Interest on lease liabilities 81 28
Total lease expense $ 5,503 $ 2,251
XML 117 R102.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Schedule of Other Information Related to Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Weighted-average remaining lease term (Years):      
Operating leases 13 years 6 months 7 years 10 months 24 days  
Finance leases 2 years 3 months 18 days 1 year 10 months 24 days  
Weighted-average discount rate:      
Operating leases 7.30% 4.80%  
Finance leases 6.20% 4.40%  
Cash paid for amounts included in the measurement of lease liabilities:      
Operating cash flows from operating leases $ 3,462 $ 2,440  
Operating cash flows from finance leases 81 28  
Financing cash flows from finance leases 504 384  
ROU assets obtained in exchange for lease obligations:      
Operating leases 29,396 11,019 $ 683
Finance leases $ 1,437 $ 582  
XML 118 R103.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Schedule of Future Minimum Lease Payments (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Operating Leases  
2024 $ 4,624
2025 5,413
2026 7,090
2027 7,312
2028 7,453
Thereafter 67,642
Total future minimum lease payments 99,534
Less: interest 43,177
Total 56,357
Finance Leases  
2024 846
2025 664
2026 151
2027 0
2028 0
Thereafter 0
Total future minimum lease payments 1,661
Less: interest 213
Finance lease liabilities $ 1,448
XML 119 R104.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid Expenses $ 16,437 $ 12,887
Other Current Assets 246 205
Total other current assets 16,683 13,092
ROU Asset 45,325 19,033
Other Long-Term Assets 9,936 15,322
Total other long-term assets $ 55,261 $ 34,355
XML 120 R105.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]      
Net income (loss) $ 326,661 $ 28,067 $ (71,279)
Basic weighted-average common shares outstanding 68,266 68,487 67,486
Effect of convertible notes (in shares) 199 0 0
Diluted weighted-average common shares outstanding (in shares) 70,239 70,671 67,486
Basic income (loss) per common share (in dollars per share) $ 4.79 $ 0.41 $ (1.06)
Diluted income (loss) per common share (in dollars per share) $ 4.65 $ 0.40 $ (1.06)
Antidilutive securities excluded from diluted net income (loss) per common share (in shares) 421 358 2,893
Options      
Debt Instrument [Line Items]      
Effect of dilutive share based compensation (in shares) 346 439 0
Restricted stock      
Debt Instrument [Line Items]      
Effect of dilutive share based compensation (in shares) 1,428 1,745 0
XML 121 R106.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Schedule of Purchase Commitments Under Noncancelable Arrangements (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2024 $ 2,716
2025 2,716
2026 2,716
2027 2,716
2028 and thereafter 0
Total $ 10,864
XML 122 R107.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Additional Information (Details)
$ in Millions
Dec. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Contingent payments $ 264.4
XML 123 R108.htm IDEA: XBRL DOCUMENT v3.24.0.1
401(k) Plan (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Retirement Benefits [Abstract]      
Expense recognized by the company for matching contributions $ 4.1 $ 3.1 $ 2.6
XML 124 R109.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisition of Assets (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
May 31, 2023
Feb. 28, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Asset Acquisition [Line Items]            
Research and development       $ 77,707 $ 311,681 $ 44,966
Cerveau Technologies, Inc            
Asset Acquisition [Line Items]            
Payment for acquisitions $ 10,000 $ 35,300        
Asset acquisition, additional milestone payments   51,000        
Cerveau Technologies, Inc | Sales Milestones            
Asset Acquisition [Line Items]            
Asset acquisition, additional milestone payments   1,200,000        
Cerveau Technologies, Inc | Research Revenue Milestones            
Asset Acquisition [Line Items]            
Asset acquisition, additional milestone payments   $ 13,500        
POINT Biopharma            
Asset Acquisition [Line Items]            
Payment for acquisitions     $ 260,000      
Asset acquisition, additional milestone payments     1,800,000      
Research and development         $ 260,000  
PNT2002 License Agreement            
Asset Acquisition [Line Items]            
Payment for acquisitions     $ 250,000      
Royalty percentage     20.00%      
PNT2002 License Agreement | Sales Milestones            
Asset Acquisition [Line Items]            
Asset acquisition, additional milestone payments     $ 1,300,000      
PNT2002 License Agreement | Regulatory Milestones            
Asset Acquisition [Line Items]            
Asset acquisition, additional milestone payments     281,000      
PNT2003 License Agreement            
Asset Acquisition [Line Items]            
Payment for acquisitions     $ 10,000      
Royalty percentage     15.00%      
PNT2003 License Agreement | Sales Milestones            
Asset Acquisition [Line Items]            
Asset acquisition, additional milestone payments     $ 275,000      
PNT2003 License Agreement | Regulatory Milestones            
Asset Acquisition [Line Items]            
Asset acquisition, additional milestone payments     $ 34,500      
XML 125 R110.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information (Details)
 12 Months Ended
Dec. 31, 2023
Segment
Segment Reporting [Abstract]  
Number of operating segments 1
XML 126 R111.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Event (Details) - Subsequent Event
$ in Millions
Jan. 09, 2024
USD ($)
Licenses | Perspective Therapeutics, Inc  
Subsequent Event [Line Items]  
Payments to acquire license agreement $ 28
Perspective Therapeutics, Inc  
Subsequent Event [Line Items]  
Ownership percentage 19.90%
Payments to acquire interest $ 33
EXCEL 128 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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�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�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end XML 129 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 130 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 132 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 284 541 1 false 104 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.lantheus.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.lantheus.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets Sheet http://www.lantheus.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Operations Sheet http://www.lantheus.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Changes in Stockholders??? Equity Sheet http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity Consolidated Statements of Changes in Stockholders??? Equity Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows Sheet http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Statement - Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.lantheus.com/role/ConsolidatedStatementsofCashFlowsParenthetical Consolidated Statements of Cash Flows (Parenthetical) Statements 9 false false R10.htm 0000010 - Disclosure - Description of Business Sheet http://www.lantheus.com/role/DescriptionofBusiness Description of Business Notes 10 false false R11.htm 0000011 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 0000012 - Disclosure - Revenue from Contracts with Customers Sheet http://www.lantheus.com/role/RevenuefromContractswithCustomers Revenue from Contracts with Customers Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value of Financial Instruments Sheet http://www.lantheus.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 13 false false R14.htm 0000014 - Disclosure - Income Taxes Sheet http://www.lantheus.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 0000015 - Disclosure - Inventory Sheet http://www.lantheus.com/role/Inventory Inventory Notes 15 false false R16.htm 0000016 - Disclosure - Property, Plant & Equipment, Net Sheet http://www.lantheus.com/role/PropertyPlantEquipmentNet Property, Plant & Equipment, Net Notes 16 false false R17.htm 0000017 - Disclosure - Sale of Puerto Rico Subsidiary Sheet http://www.lantheus.com/role/SaleofPuertoRicoSubsidiary Sale of Puerto Rico Subsidiary Notes 17 false false R18.htm 0000018 - Disclosure - Asset Retirement Obligations Sheet http://www.lantheus.com/role/AssetRetirementObligations Asset Retirement Obligations Notes 18 false false R19.htm 0000019 - Disclosure - Intangibles, Net and Goodwill Sheet http://www.lantheus.com/role/IntangiblesNetandGoodwill Intangibles, Net and Goodwill Notes 19 false false R20.htm 0000020 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities Sheet http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilities Accrued Expenses and Other Liabilities and Other Long-Term Liabilities Notes 20 false false R21.htm 0000021 - Disclosure - Long-Term Debt, Net, and Other Borrowings Sheet http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowings Long-Term Debt, Net, and Other Borrowings Notes 21 false false R22.htm 0000022 - Disclosure - Derivative Instruments Sheet http://www.lantheus.com/role/DerivativeInstruments Derivative Instruments Notes 22 false false R23.htm 0000023 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.lantheus.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 23 false false R24.htm 0000024 - Disclosure - Stock-Based Compensation Sheet http://www.lantheus.com/role/StockBasedCompensation Stock-Based Compensation Notes 24 false false R25.htm 0000025 - Disclosure - Leases Sheet http://www.lantheus.com/role/Leases Leases Notes 25 false false R26.htm 0000026 - Disclosure - Other Assets Sheet http://www.lantheus.com/role/OtherAssets Other Assets Notes 26 false false R27.htm 0000027 - Disclosure - Net Income (Loss) Per Common Share Sheet http://www.lantheus.com/role/NetIncomeLossPerCommonShare Net Income (Loss) Per Common Share Notes 27 false false R28.htm 0000028 - Disclosure - Commitments and Contingencies Sheet http://www.lantheus.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 28 false false R29.htm 0000029 - Disclosure - 401(k) Plan Sheet http://www.lantheus.com/role/A401kPlan 401(k) Plan Notes 29 false false R30.htm 0000030 - Disclosure - Acquisition of Assets Sheet http://www.lantheus.com/role/AcquisitionofAssets Acquisition of Assets Notes 30 false false R31.htm 0000031 - Disclosure - Segment Information Sheet http://www.lantheus.com/role/SegmentInformation Segment Information Notes 31 false false R32.htm 0000032 - Disclosure - Subsequent Event Sheet http://www.lantheus.com/role/SubsequentEvent Subsequent Event Notes 32 false false R33.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 33 false false R34.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 34 false false R35.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.lantheus.com/role/SummaryofSignificantAccountingPolicies 35 false false R36.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.lantheus.com/role/SummaryofSignificantAccountingPolicies 36 false false R37.htm 9954473 - Disclosure - Revenue from Contracts with Customers (Tables) Sheet http://www.lantheus.com/role/RevenuefromContractswithCustomersTables Revenue from Contracts with Customers (Tables) Tables http://www.lantheus.com/role/RevenuefromContractswithCustomers 37 false false R38.htm 9954474 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.lantheus.com/role/FairValueofFinancialInstruments 38 false false R39.htm 9954475 - Disclosure - Income Taxes (Tables) Sheet http://www.lantheus.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.lantheus.com/role/IncomeTaxes 39 false false R40.htm 9954476 - Disclosure - Inventory (Tables) Sheet http://www.lantheus.com/role/InventoryTables Inventory (Tables) Tables http://www.lantheus.com/role/Inventory 40 false false R41.htm 9954477 - Disclosure - Property, Plant & Equipment, Net (Tables) Sheet http://www.lantheus.com/role/PropertyPlantEquipmentNetTables Property, Plant & Equipment, Net (Tables) Tables http://www.lantheus.com/role/PropertyPlantEquipmentNet 41 false false R42.htm 9954478 - Disclosure - Asset Retirement Obligations (Tables) Sheet http://www.lantheus.com/role/AssetRetirementObligationsTables Asset Retirement Obligations (Tables) Tables http://www.lantheus.com/role/AssetRetirementObligations 42 false false R43.htm 9954479 - Disclosure - Intangibles, Net and Goodwill (Tables) Sheet http://www.lantheus.com/role/IntangiblesNetandGoodwillTables Intangibles, Net and Goodwill (Tables) Tables http://www.lantheus.com/role/IntangiblesNetandGoodwill 43 false false R44.htm 9954480 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables) Sheet http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesTables Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables) Tables http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilities 44 false false R45.htm 9954481 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Tables) Sheet http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsTables Long-Term Debt, Net, and Other Borrowings (Tables) Tables http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowings 45 false false R46.htm 9954482 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.lantheus.com/role/AccumulatedOtherComprehensiveLoss 46 false false R47.htm 9954483 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.lantheus.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.lantheus.com/role/StockBasedCompensation 47 false false R48.htm 9954484 - Disclosure - Leases (Tables) Sheet http://www.lantheus.com/role/LeasesTables Leases (Tables) Tables http://www.lantheus.com/role/Leases 48 false false R49.htm 9954485 - Disclosure - Other Assets (Tables) Sheet http://www.lantheus.com/role/OtherAssetsTables Other Assets (Tables) Tables http://www.lantheus.com/role/OtherAssets 49 false false R50.htm 9954486 - Disclosure - Net Income (Loss) Per Common Share (Tables) Sheet http://www.lantheus.com/role/NetIncomeLossPerCommonShareTables Net Income (Loss) Per Common Share (Tables) Tables http://www.lantheus.com/role/NetIncomeLossPerCommonShare 50 false false R51.htm 9954487 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.lantheus.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.lantheus.com/role/CommitmentsandContingencies 51 false false R52.htm 9954488 - Disclosure - Description of Business (Details) Sheet http://www.lantheus.com/role/DescriptionofBusinessDetails Description of Business (Details) Details http://www.lantheus.com/role/DescriptionofBusiness 52 false false R53.htm 9954489 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 53 false false R54.htm 9954490 - Disclosure - Summary of Significant Accounting Policies - Schedule of Product Concentration Risk (Details) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails Summary of Significant Accounting Policies - Schedule of Product Concentration Risk (Details) Details 54 false false R55.htm 9954491 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details) Details 55 false false R56.htm 9954492 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails Summary of Significant Accounting Policies - Goodwill (Details) Details 56 false false R57.htm 9954493 - Disclosure - Summary of Significant Accounting Policies - Advertising and Promotion Costs (Details) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingandPromotionCostsDetails Summary of Significant Accounting Policies - Advertising and Promotion Costs (Details) Details 57 false false R58.htm 9954494 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails Summary of Significant Accounting Policies - Stock Based Compensation (Details) Details 58 false false R59.htm 9954495 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Other Loss (Income) (Details) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails Summary of Significant Accounting Policies - Schedule Of Other Loss (Income) (Details) Details 59 false false R60.htm 9954496 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance Reserves (Details) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesSelfInsuranceReservesDetails Summary of Significant Accounting Policies - Self-Insurance Reserves (Details) Details 60 false false R61.htm 9954497 - Disclosure - Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue (Details) Sheet http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue (Details) Details 61 false false R62.htm 9954498 - Disclosure - Revenue from Contracts with Customers - Narrative (Details) Sheet http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails Revenue from Contracts with Customers - Narrative (Details) Details 62 false false R63.htm 9954499 - Disclosure - Revenue from Contracts with Customers - Schedule Of Rebates and Allowances (Details) Sheet http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfRebatesandAllowancesDetails Revenue from Contracts with Customers - Schedule Of Rebates and Allowances (Details) Details 63 false false R64.htm 9954500 - Disclosure - Revenue from Contracts with Customers - Schedule Of Contract Costs (Details) Sheet http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfContractCostsDetails Revenue from Contracts with Customers - Schedule Of Contract Costs (Details) Details 64 false false R65.htm 9954501 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) Details 65 false false R66.htm 9954502 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 66 false false R67.htm 9954503 - Disclosure - Fair Value of Financial Instruments - Schedule of Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails Fair Value of Financial Instruments - Schedule of Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) Details 67 false false R68.htm 9954504 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Instruments With Significant Level 3 Inputs (Details) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails Fair Value of Financial Instruments - Schedule of Financial Instruments With Significant Level 3 Inputs (Details) Details 68 false false R69.htm 9954505 - Disclosure - Income Taxes - Schedule of Components of Income Before Income Taxes (Details) Sheet http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofIncomeBeforeIncomeTaxesDetails Income Taxes - Schedule of Components of Income Before Income Taxes (Details) Details 69 false false R70.htm 9954506 - Disclosure - Income Taxes - Schedule of (Benefit) Provision for Income Taxes (Details) Sheet http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails Income Taxes - Schedule of (Benefit) Provision for Income Taxes (Details) Details 70 false false R71.htm 9954507 - Disclosure - Income Taxes - Schedule of Differences in Statutory Rate and Effective Rate (Details) Sheet http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails Income Taxes - Schedule of Differences in Statutory Rate and Effective Rate (Details) Details 71 false false R72.htm 9954508 - Disclosure - Income Taxes - Schedule of Components of Deferred Income Tax Assets (Liabilities) (Details) Sheet http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails Income Taxes - Schedule of Components of Deferred Income Tax Assets (Liabilities) (Details) Details 72 false false R73.htm 9954509 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 73 false false R74.htm 9954510 - Disclosure - Income Taxes - Reconciliation of Uncertain Tax Positions (Details) Sheet http://www.lantheus.com/role/IncomeTaxesReconciliationofUncertainTaxPositionsDetails Income Taxes - Reconciliation of Uncertain Tax Positions (Details) Details 74 false false R75.htm 9954511 - Disclosure - Inventory (Details) Sheet http://www.lantheus.com/role/InventoryDetails Inventory (Details) Details http://www.lantheus.com/role/InventoryTables 75 false false R76.htm 9954512 - Disclosure - Property, Plant & Equipment, Net - Schedule of Property, Plant & Equipment (Details) Sheet http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails Property, Plant & Equipment, Net - Schedule of Property, Plant & Equipment (Details) Details 76 false false R77.htm 9954513 - Disclosure - Property, Plant & Equipment, Net - Additional Information (Details) Sheet http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails Property, Plant & Equipment, Net - Additional Information (Details) Details 77 false false R78.htm 9954514 - Disclosure - Sale of Puerto Rico Subsidiary (Details) Sheet http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails Sale of Puerto Rico Subsidiary (Details) Details http://www.lantheus.com/role/SaleofPuertoRicoSubsidiary 78 false false R79.htm 9954515 - Disclosure - Asset Retirement Obligations - Additional Information (Details) Sheet http://www.lantheus.com/role/AssetRetirementObligationsAdditionalInformationDetails Asset Retirement Obligations - Additional Information (Details) Details 79 false false R80.htm 9954516 - Disclosure - Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Details) Sheet http://www.lantheus.com/role/AssetRetirementObligationsScheduleofReconciliationofCompanysAssetRetirementObligationsDetails Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Details) Details 80 false false R81.htm 9954517 - Disclosure - Intangibles, Net and Goodwill - Schedule of Intangibles, Net (Details) Sheet http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails Intangibles, Net and Goodwill - Schedule of Intangibles, Net (Details) Details 81 false false R82.htm 9954518 - Disclosure - Intangibles, Net and Goodwill - Additional Information (Details) Sheet http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails Intangibles, Net and Goodwill - Additional Information (Details) Details 82 false false R83.htm 9954519 - Disclosure - Intangibles, Net and Goodwill - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) Sheet http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails Intangibles, Net and Goodwill - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) Details 83 false false R84.htm 9954520 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) Sheet http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) Details http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesTables 84 false false R85.htm 9954521 - Disclosure - Long-Term Debt, Net, and Other Borrowings - Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility (Details) Sheet http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails Long-Term Debt, Net, and Other Borrowings - Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility (Details) Details 85 false false R86.htm 9954522 - Disclosure - Long-Term Debt, Net, and Other Borrowings - Additional Information (Details) Sheet http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails Long-Term Debt, Net, and Other Borrowings - Additional Information (Details) Details 86 false false R87.htm 9954523 - Disclosure - Derivative Instruments (Details) Sheet http://www.lantheus.com/role/DerivativeInstrumentsDetails Derivative Instruments (Details) Details http://www.lantheus.com/role/DerivativeInstruments 87 false false R88.htm 9954524 - Disclosure - Accumulated Other Comprehensive Loss (Details) Sheet http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails Accumulated Other Comprehensive Loss (Details) Details http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossTables 88 false false R89.htm 9954525 - Disclosure - Stock-Based Compensation - Equity Incentive Plans (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationEquityIncentivePlansDetails Stock-Based Compensation - Equity Incentive Plans (Details) Details 89 false false R90.htm 9954526 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details) Details 90 false false R91.htm 9954527 - Disclosure - Stock-Based Compensation - Schedule of Stock Options (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails Stock-Based Compensation - Schedule of Stock Options (Details) Details 91 false false R92.htm 9954528 - Disclosure - Stock-Based Compensation - Valuation Model Assumptions (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails Stock-Based Compensation - Valuation Model Assumptions (Details) Details 92 false false R93.htm 9954529 - Disclosure - Stock-Based Compensation - Stock Options Narrative (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationStockOptionsNarrativeDetails Stock-Based Compensation - Stock Options Narrative (Details) Details 93 false false R94.htm 9954530 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) Details 94 false false R95.htm 9954531 - Disclosure - Stock-Based Compensation - Restricted Stock and TSR (Narrative) (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails Stock-Based Compensation - Restricted Stock and TSR (Narrative) (Details) Details 95 false false R96.htm 9954532 - Disclosure - Stock-Based Compensation - Schedule of Total Stockholder Return Restricted Awards (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails Stock-Based Compensation - Schedule of Total Stockholder Return Restricted Awards (Details) Details 96 false false R97.htm 9954533 - Disclosure - Stock-Based Compensation - Schedule of TSR Award Activity (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails Stock-Based Compensation - Schedule of TSR Award Activity (Details) Details 97 false false R98.htm 9954534 - Disclosure - Stock-Based Compensation - Schedule Common Stock Repurchases (Details) Sheet http://www.lantheus.com/role/StockBasedCompensationScheduleCommonStockRepurchasesDetails Stock-Based Compensation - Schedule Common Stock Repurchases (Details) Details 98 false false R99.htm 9954535 - Disclosure - Leases - Additional Information (Details) Sheet http://www.lantheus.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 99 false false R100.htm 9954536 - Disclosure - Leases - Schedule of Operating and Financing Lease Assets and Liabilities (Details) Sheet http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails Leases - Schedule of Operating and Financing Lease Assets and Liabilities (Details) Details 100 false false R101.htm 9954537 - Disclosure - Leases - Schedule of Components of Lease Expense (Details) Sheet http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails Leases - Schedule of Components of Lease Expense (Details) Details 101 false false R102.htm 9954538 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details) Sheet http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails Leases - Schedule of Other Information Related to Leases (Details) Details 102 false false R103.htm 9954539 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details) Sheet http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails Leases - Schedule of Future Minimum Lease Payments (Details) Details 103 false false R104.htm 9954540 - Disclosure - Other Assets (Details) Sheet http://www.lantheus.com/role/OtherAssetsDetails Other Assets (Details) Details http://www.lantheus.com/role/OtherAssetsTables 104 false false R105.htm 9954541 - Disclosure - Net Income (Loss) Per Common Share (Details) Sheet http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails Net Income (Loss) Per Common Share (Details) Details http://www.lantheus.com/role/NetIncomeLossPerCommonShareTables 105 false false R106.htm 9954542 - Disclosure - Commitments and Contingencies - Schedule of Purchase Commitments Under Noncancelable Arrangements (Details) Sheet http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails Commitments and Contingencies - Schedule of Purchase Commitments Under Noncancelable Arrangements (Details) Details 106 false false R107.htm 9954543 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.lantheus.com/role/CommitmentsandContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 107 false false R108.htm 9954544 - Disclosure - 401(k) Plan (Details) Sheet http://www.lantheus.com/role/A401kPlanDetails 401(k) Plan (Details) Details http://www.lantheus.com/role/A401kPlan 108 false false R109.htm 9954545 - Disclosure - Acquisition of Assets (Details) Sheet http://www.lantheus.com/role/AcquisitionofAssetsDetails Acquisition of Assets (Details) Details http://www.lantheus.com/role/AcquisitionofAssets 109 false false R110.htm 9954546 - Disclosure - Segment Information (Details) Sheet http://www.lantheus.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.lantheus.com/role/SegmentInformation 110 false false R111.htm 9954547 - Disclosure - Subsequent Event (Details) Sheet http://www.lantheus.com/role/SubsequentEventDetails Subsequent Event (Details) Details http://www.lantheus.com/role/SubsequentEvent 111 false false All Reports Book All Reports lnth-20231231.htm lnth-20231231.xsd lnth-20231231_cal.xml lnth-20231231_def.xml lnth-20231231_lab.xml lnth-20231231_pre.xml lnth-20231231_g1.jpg http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 135 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lnth-20231231.htm": { "nsprefix": "lnth", "nsuri": "http://www.lantheus.com/20231231", "dts": { "inline": { "local": [ "lnth-20231231.htm" ] }, "schema": { "local": [ "lnth-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "lnth-20231231_cal.xml" ] }, "definitionLink": { "local": [ "lnth-20231231_def.xml" ] }, "labelLink": { "local": [ "lnth-20231231_lab.xml" ] }, "presentationLink": { "local": [ "lnth-20231231_pre.xml" ] } }, "keyStandard": 495, "keyCustom": 46, "axisStandard": 34, "axisCustom": 1, "memberStandard": 54, "memberCustom": 48, "hidden": { "total": 26, "http://fasb.org/us-gaap/2023": 20, "http://xbrl.sec.gov/ecd/2023": 2, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 284, "entityCount": 1, "segmentCount": 104, "elementCount": 901, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1228, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 14, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://www.lantheus.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.lantheus.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.lantheus.com/role/ConsolidatedBalanceSheets", "longName": "0000003 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R4": { "role": "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "longName": "0000005 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R6": { "role": "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R7": { "role": "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity", "longName": "0000007 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity", "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R9": { "role": "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "longName": "0000009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIncomeTaxRefunds", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIncomeTaxRefunds", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.lantheus.com/role/DescriptionofBusiness", "longName": "0000010 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.lantheus.com/role/RevenuefromContractswithCustomers", "longName": "0000012 - Disclosure - Revenue from Contracts with Customers", "shortName": "Revenue from Contracts with Customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.lantheus.com/role/FairValueofFinancialInstruments", "longName": "0000013 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.lantheus.com/role/IncomeTaxes", "longName": "0000014 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.lantheus.com/role/Inventory", "longName": "0000015 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.lantheus.com/role/PropertyPlantEquipmentNet", "longName": "0000016 - Disclosure - Property, Plant & Equipment, Net", "shortName": "Property, Plant & Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiary", "longName": "0000017 - Disclosure - Sale of Puerto Rico Subsidiary", "shortName": "Sale of Puerto Rico Subsidiary", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.lantheus.com/role/AssetRetirementObligations", "longName": "0000018 - Disclosure - Asset Retirement Obligations", "shortName": "Asset Retirement Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.lantheus.com/role/IntangiblesNetandGoodwill", "longName": "0000019 - Disclosure - Intangibles, Net and Goodwill", "shortName": "Intangibles, Net and Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilities", "longName": "0000020 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities", "shortName": "Accrued Expenses and Other Liabilities and Other Long-Term Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowings", "longName": "0000021 - Disclosure - Long-Term Debt, Net, and Other Borrowings", "shortName": "Long-Term Debt, Net, and Other Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.lantheus.com/role/DerivativeInstruments", "longName": "0000022 - Disclosure - Derivative Instruments", "shortName": "Derivative Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLoss", "longName": "0000023 - Disclosure - Accumulated Other Comprehensive Loss", "shortName": "Accumulated Other Comprehensive Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.lantheus.com/role/StockBasedCompensation", "longName": "0000024 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.lantheus.com/role/Leases", "longName": "0000025 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.lantheus.com/role/OtherAssets", "longName": "0000026 - Disclosure - Other Assets", "shortName": "Other Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.lantheus.com/role/NetIncomeLossPerCommonShare", "longName": "0000027 - Disclosure - Net Income (Loss) Per Common Share", "shortName": "Net Income (Loss) Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.lantheus.com/role/CommitmentsandContingencies", "longName": "0000028 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.lantheus.com/role/A401kPlan", "longName": "0000029 - Disclosure - 401(k) Plan", "shortName": "401(k) Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.lantheus.com/role/AcquisitionofAssets", "longName": "0000030 - Disclosure - Acquisition of Assets", "shortName": "Acquisition of Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.lantheus.com/role/SegmentInformation", "longName": "0000031 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.lantheus.com/role/SubsequentEvent", "longName": "0000032 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-279", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:MtrlTermsOfTrdArrTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-279", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:MtrlTermsOfTrdArrTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.lantheus.com/role/RevenuefromContractswithCustomersTables", "longName": "9954473 - Disclosure - Revenue from Contracts with Customers (Tables)", "shortName": "Revenue from Contracts with Customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables", "longName": "9954474 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.lantheus.com/role/IncomeTaxesTables", "longName": "9954475 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.lantheus.com/role/InventoryTables", "longName": "9954476 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.lantheus.com/role/PropertyPlantEquipmentNetTables", "longName": "9954477 - Disclosure - Property, Plant & Equipment, Net (Tables)", "shortName": "Property, Plant & Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.lantheus.com/role/AssetRetirementObligationsTables", "longName": "9954478 - Disclosure - Asset Retirement Obligations (Tables)", "shortName": "Asset Retirement Obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.lantheus.com/role/IntangiblesNetandGoodwillTables", "longName": "9954479 - Disclosure - Intangibles, Net and Goodwill (Tables)", "shortName": "Intangibles, Net and Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesTables", "longName": "9954480 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables)", "shortName": "Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsTables", "longName": "9954481 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Tables)", "shortName": "Long-Term Debt, Net, and Other Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossTables", "longName": "9954482 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.lantheus.com/role/StockBasedCompensationTables", "longName": "9954483 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.lantheus.com/role/LeasesTables", "longName": "9954484 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "lnth:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lnth:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.lantheus.com/role/OtherAssetsTables", "longName": "9954485 - Disclosure - Other Assets (Tables)", "shortName": "Other Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.lantheus.com/role/NetIncomeLossPerCommonShareTables", "longName": "9954486 - Disclosure - Net Income (Loss) Per Common Share (Tables)", "shortName": "Net Income (Loss) Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.lantheus.com/role/CommitmentsandContingenciesTables", "longName": "9954487 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.lantheus.com/role/DescriptionofBusinessDetails", "longName": "9954488 - Disclosure - Description of Business (Details)", "shortName": "Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-43", "name": "lnth:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-43", "name": "lnth:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954489 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-67", "name": "us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails", "longName": "9954490 - Disclosure - Summary of Significant Accounting Policies - Schedule of Product Concentration Risk (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Product Concentration Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-48", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-48", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails", "longName": "9954491 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-57", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-57", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails", "longName": "9954492 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details)", "shortName": "Summary of Significant Accounting Policies - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "us-gaap:GoodwillImpairmentLoss", "span", "div", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "us-gaap:GoodwillImpairmentLoss", "span", "div", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingandPromotionCostsDetails", "longName": "9954493 - Disclosure - Summary of Significant Accounting Policies - Advertising and Promotion Costs (Details)", "shortName": "Summary of Significant Accounting Policies - Advertising and Promotion Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdvertisingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdvertisingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails", "longName": "9954494 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details)", "shortName": "Summary of Significant Accounting Policies - Stock Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails", "longName": "9954495 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Other Loss (Income) (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule Of Other Loss (Income) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesSelfInsuranceReservesDetails", "longName": "9954496 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance Reserves (Details)", "shortName": "Summary of Significant Accounting Policies - Self-Insurance Reserves (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:SelfInsuranceReserveNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:SelfInsuranceReservePolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:SelfInsuranceReserveNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:SelfInsuranceReservePolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails", "longName": "9954497 - Disclosure - Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue (Details)", "shortName": "Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-69", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R62": { "role": "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails", "longName": "9954498 - Disclosure - Revenue from Contracts with Customers - Narrative (Details)", "shortName": "Revenue from Contracts with Customers - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "lnth:RevenueFromContractWithCustomerNumberOfProductCategories", "unitRef": "productcategory", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lnth:RevenueFromContractWithCustomerNumberOfProductCategories", "unitRef": "productcategory", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfRebatesandAllowancesDetails", "longName": "9954499 - Disclosure - Revenue from Contracts with Customers - Schedule Of Rebates and Allowances (Details)", "shortName": "Revenue from Contracts with Customers - Schedule Of Rebates and Allowances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R64": { "role": "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfContractCostsDetails", "longName": "9954500 - Disclosure - Revenue from Contracts with Customers - Schedule Of Contract Costs (Details)", "shortName": "Revenue from Contracts with Customers - Schedule Of Contract Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "longName": "9954501 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "longName": "9954502 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R67": { "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "longName": "9954503 - Disclosure - Fair Value of Financial Instruments - Schedule of Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-121", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R68": { "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails", "longName": "9954504 - Disclosure - Fair Value of Financial Instruments - Schedule of Financial Instruments With Significant Level 3 Inputs (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Financial Instruments With Significant Level 3 Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R69": { "role": "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofIncomeBeforeIncomeTaxesDetails", "longName": "9954505 - Disclosure - Income Taxes - Schedule of Components of Income Before Income Taxes (Details)", "shortName": "Income Taxes - Schedule of Components of Income Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails", "longName": "9954506 - Disclosure - Income Taxes - Schedule of (Benefit) Provision for Income Taxes (Details)", "shortName": "Income Taxes - Schedule of (Benefit) Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails", "longName": "9954507 - Disclosure - Income Taxes - Schedule of Differences in Statutory Rate and Effective Rate (Details)", "shortName": "Income Taxes - Schedule of Differences in Statutory Rate and Effective Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails", "longName": "9954508 - Disclosure - Income Taxes - Schedule of Components of Deferred Income Tax Assets (Liabilities) (Details)", "shortName": "Income Taxes - Schedule of Components of Deferred Income Tax Assets (Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsStateTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsStateTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails", "longName": "9954509 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "lnth:UnrecognizedTaxBenefitsIncludingInterestAndPenalties", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R74": { "role": "http://www.lantheus.com/role/IncomeTaxesReconciliationofUncertainTaxPositionsDetails", "longName": "9954510 - Disclosure - Income Taxes - Reconciliation of Uncertain Tax Positions (Details)", "shortName": "Income Taxes - Reconciliation of Uncertain Tax Positions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R75": { "role": "http://www.lantheus.com/role/InventoryDetails", "longName": "9954511 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails", "longName": "9954512 - Disclosure - Property, Plant & Equipment, Net - Schedule of Property, Plant & Equipment (Details)", "shortName": "Property, Plant & Equipment, Net - Schedule of Property, Plant & Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails", "longName": "9954513 - Disclosure - Property, Plant & Equipment, Net - Additional Information (Details)", "shortName": "Property, Plant & Equipment, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CostDepreciationAmortizationAndDepletion", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostDepreciationAmortizationAndDepletion", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails", "longName": "9954514 - Disclosure - Sale of Puerto Rico Subsidiary (Details)", "shortName": "Sale of Puerto Rico Subsidiary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-157", "name": "us-gaap:GainLossOnSaleOfBusiness", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "us-gaap:GainLossOnSaleOfBusiness", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.lantheus.com/role/AssetRetirementObligationsAdditionalInformationDetails", "longName": "9954515 - Disclosure - Asset Retirement Obligations - Additional Information (Details)", "shortName": "Asset Retirement Obligations - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AssetRetirementObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AssetRetirementObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.lantheus.com/role/AssetRetirementObligationsScheduleofReconciliationofCompanysAssetRetirementObligationsDetails", "longName": "9954516 - Disclosure - Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Details)", "shortName": "Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AssetRetirementObligationsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:AssetRetirementObligationsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R81": { "role": "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails", "longName": "9954517 - Disclosure - Intangibles, Net and Goodwill - Schedule of Intangibles, Net (Details)", "shortName": "Intangibles, Net and Goodwill - Schedule of Intangibles, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "longName": "9954518 - Disclosure - Intangibles, Net and Goodwill - Additional Information (Details)", "shortName": "Intangibles, Net and Goodwill - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails", "longName": "9954519 - Disclosure - Intangibles, Net and Goodwill - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details)", "shortName": "Intangibles, Net and Goodwill - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails", "longName": "9954520 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details)", "shortName": "Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails", "longName": "9954521 - Disclosure - Long-Term Debt, Net, and Other Borrowings - Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility (Details)", "shortName": "Long-Term Debt, Net, and Other Borrowings - Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "longName": "9954522 - Disclosure - Long-Term Debt, Net, and Other Borrowings - Additional Information (Details)", "shortName": "Long-Term Debt, Net, and Other Borrowings - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lnth:DebtInstrumentCovenantComplianceNumberOfFinancialCovenants", "unitRef": "financial_covenant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R87": { "role": "http://www.lantheus.com/role/DerivativeInstrumentsDetails", "longName": "9954523 - Disclosure - Derivative Instruments (Details)", "shortName": "Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-1", "name": "lnth:ProceedsFromTerminationOfDerivatives", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-221", "name": "lnth:ProceedsFromTerminationOfDerivatives", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R88": { "role": "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails", "longName": "9954524 - Disclosure - Accumulated Other Comprehensive Loss (Details)", "shortName": "Accumulated Other Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AociTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AociTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.lantheus.com/role/StockBasedCompensationEquityIncentivePlansDetails", "longName": "9954525 - Disclosure - Stock-Based Compensation - Equity Incentive Plans (Details)", "shortName": "Stock-Based Compensation - Equity Incentive Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails", "longName": "9954526 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details)", "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails", "longName": "9954527 - Disclosure - Stock-Based Compensation - Schedule of Stock Options (Details)", "shortName": "Stock-Based Compensation - Schedule of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails", "longName": "9954528 - Disclosure - Stock-Based Compensation - Valuation Model Assumptions (Details)", "shortName": "Stock-Based Compensation - Valuation Model Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-242", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-242", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.lantheus.com/role/StockBasedCompensationStockOptionsNarrativeDetails", "longName": "9954529 - Disclosure - Stock-Based Compensation - Stock Options Narrative (Details)", "shortName": "Stock-Based Compensation - Stock Options Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R94": { "role": "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "longName": "9954530 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)", "shortName": "Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": null }, "R95": { "role": "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "longName": "9954531 - Disclosure - Stock-Based Compensation - Restricted Stock and TSR (Narrative) (Details)", "shortName": "Stock-Based Compensation - Restricted Stock and TSR (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-245", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R96": { "role": "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "longName": "9954532 - Disclosure - Stock-Based Compensation - Schedule of Total Stockholder Return Restricted Awards (Details)", "shortName": "Stock-Based Compensation - Schedule of Total Stockholder Return Restricted Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-249", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-249", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails", "longName": "9954533 - Disclosure - Stock-Based Compensation - Schedule of TSR Award Activity (Details)", "shortName": "Stock-Based Compensation - Schedule of TSR Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-249", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R98": { "role": "http://www.lantheus.com/role/StockBasedCompensationScheduleCommonStockRepurchasesDetails", "longName": "9954534 - Disclosure - Stock-Based Compensation - Schedule Common Stock Repurchases (Details)", "shortName": "Stock-Based Compensation - Schedule Common Stock Repurchases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-256", "name": "us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R99": { "role": "http://www.lantheus.com/role/LeasesAdditionalInformationDetails", "longName": "9954535 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-4", "name": "lnth:NumberOfOperatingLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "lnth:NumberOfOperatingLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails", "longName": "9954536 - Disclosure - Leases - Schedule of Operating and Financing Lease Assets and Liabilities (Details)", "shortName": "Leases - Schedule of Operating and Financing Lease Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R101": { "role": "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails", "longName": "9954537 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)", "shortName": "Leases - Schedule of Components of Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails", "longName": "9954538 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details)", "shortName": "Leases - Schedule of Other Information Related to Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R103": { "role": "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails", "longName": "9954539 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details)", "shortName": "Leases - Schedule of Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.lantheus.com/role/OtherAssetsDetails", "longName": "9954540 - Disclosure - Other Assets (Details)", "shortName": "Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R105": { "role": "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "longName": "9954541 - Disclosure - Net Income (Loss) Per Common Share (Details)", "shortName": "Net Income (Loss) Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R106": { "role": "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails", "longName": "9954542 - Disclosure - Commitments and Contingencies - Schedule of Purchase Commitments Under Noncancelable Arrangements (Details)", "shortName": "Commitments and Contingencies - Schedule of Purchase Commitments Under Noncancelable Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R107": { "role": "http://www.lantheus.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "longName": "9954543 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-4", "name": "lnth:ContingentPaymentsUnderCompanysLicenseAgreements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "lnth:ContingentPaymentsUnderCompanysLicenseAgreements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.lantheus.com/role/A401kPlanDetails", "longName": "9954544 - Disclosure - 401(k) Plan (Details)", "shortName": "401(k) Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R109": { "role": "http://www.lantheus.com/role/AcquisitionofAssetsDetails", "longName": "9954545 - Disclosure - Acquisition of Assets (Details)", "shortName": "Acquisition of Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-190", "name": "us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "unique": true } }, "R110": { "role": "http://www.lantheus.com/role/SegmentInformationDetails", "longName": "9954546 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } }, "R111": { "role": "http://www.lantheus.com/role/SubsequentEventDetails", "longName": "9954547 - Disclosure - Subsequent Event (Details)", "shortName": "Subsequent Event (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-276", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-276", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20231231.htm", "first": true, "unique": true } } }, "tag": { "lnth_A1095CommercializationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "A1095CommercializationMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1095 commercialization milestone", "label": "1095 Commercialization [Member]", "documentation": "1095 Commercialization" } } }, "auth_ref": [] }, "lnth_A1404CommercializationMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "A1404CommercializationMilestoneMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1404 Commercialization Milestone", "label": "1404 Commercialization Milestone [Member]", "documentation": "1404 Commercialization Milestone" } } }, "auth_ref": [] }, "lnth_A2019RevolvingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "A2019RevolvingFacilityMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Revolving Facility", "label": "2019 Revolving Facility [Member]", "documentation": "2019 Revolving Facility [Member]" } } }, "auth_ref": [] }, "lnth_A2019TermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "A2019TermLoanFacilityMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Term Loan Facility", "label": "2019 Term Loan Facility [Member]", "documentation": "2019 Term Loan Facility" } } }, "auth_ref": [] }, "lnth_A2022FacilityCovenantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "A2022FacilityCovenantsMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment 2022 Credit Facility", "label": "2022 Facility Covenants [Member]", "documentation": "2022 Facility Covenants" } } }, "auth_ref": [] }, "lnth_A2022TermFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "A2022TermFacilityMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Term Facility", "label": "2022 Term Facility [Member]", "documentation": "2022 Term Facility" } } }, "auth_ref": [] }, "lnth_A2625ConvertibleSeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "A2625ConvertibleSeniorNotesDue2027Member", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.625% Convertible Senior Notes due 2027", "label": "2.625% Convertible Senior Notes due 2027 [Member]", "documentation": "2.625% Convertible Senior Notes due 2027" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses and Other Liabilities and Other Long-Term Liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails", "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "totalLabel": "Total accrued expenses and other liabilities", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r37", "r842" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Valuation and Qualifying Accounts", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r961" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r373", "r374" ] }, "lnth_AccruedFreightCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "AccruedFreightCostsCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Freight, distribution and operations", "label": "Accrued Freight Costs Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for freight and distribution costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40" ] }, "lnth_AccruedRebatesDiscountsAndChargebacksCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "AccruedRebatesDiscountsAndChargebacksCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued rebates, discounts and chargebacks", "label": "Accrued Rebates Discounts And Chargebacks Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates, discounts and chargebacks. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r82", "r265", "r681" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss on cash flow hedges", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r278", "r287", "r288", "r589", "r810", "r944" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r286", "r287", "r623", "r624", "r625", "r626", "r627", "r628" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r49", "r50", "r164", "r271", "r677", "r700", "r701" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r286", "r287", "r623", "r624", "r625", "r626", "r627", "r628" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails", "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "Accumulated other comprehensive loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r21", "r50", "r595", "r598", "r651", "r696", "r697", "r944", "r945", "r946", "r955", "r956", "r957" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r6", "r21", "r50", "r287", "r288", "r624", "r625", "r626", "r627", "r628", "r944" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r898" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r155" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r537", "r538", "r539", "r709", "r955", "r956", "r957", "r998", "r1020" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r904" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r904" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r904" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r904" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld to cover taxes", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r94", "r95", "r499" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash flows from operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising and Promotion Costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r232" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingandPromotionCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising and promotion costs", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r545" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r868", "r880", "r890", "r916" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r871", "r883", "r893", "r919" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r904" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r911" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r875", "r884", "r894", "r911", "r920", "r924", "r932" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r930" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r532", "r544" ] }, "lnth_Amended10b51PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "Amended10b51PlanMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Amended 10b5-1 Plan [Member]", "documentation": "Amended 10b5-1 Plan" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt related costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r168", "r446", "r631", "r949" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r75", "r80" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from diluted net income (loss) per common share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r341" ] }, "us-gaap_AociTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociTaxAttributableToParent", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss, tax", "label": "AOCI Tax, Attributable to Parent", "documentation": "Amount of tax expense (benefit) allocated to accumulated other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r990" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, consideration transferred", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r840", "r991", "r992", "r993" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, additional milestone payments", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r991", "r992", "r993" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r990" ] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Line Items]", "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r990" ] }, "lnth_AssetAcquisitionRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "AssetAcquisitionRoyaltyPercentage", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty percentage", "label": "Asset Acquisition, Royalty Percentage", "documentation": "Asset Acquisition, Royalty Percentage" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTable", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Table]", "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r990" ] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTextBlock", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of Assets", "label": "Asset Acquisition [Text Block]", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": [ "r990" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r11", "r81" ] }, "us-gaap_AssetRetirementObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligation", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Obligation expected to be incurred", "label": "Asset Retirement Obligation", "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r402", "r405" ] }, "lnth_AssetRetirementObligationAccelerationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "AssetRetirementObligationAccelerationExpense", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Asset retirement obligation acceleration", "label": "Asset Retirement Obligation, Acceleration Expense", "documentation": "Asset Retirement Obligation, Acceleration Expense" } } }, "auth_ref": [] }, "us-gaap_AssetRetirementObligationAccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationAccretionExpense", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsScheduleofReconciliationofCompanysAssetRetirementObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion expense", "label": "Asset Retirement Obligation, Accretion Expense", "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability." } } }, "auth_ref": [ "r403", "r406" ] }, "us-gaap_AssetRetirementObligationDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Asset Retirement Obligation Disclosure [Abstract]", "label": "Asset Retirement Obligation Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetRetirementObligationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligations" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Retirement Obligations", "label": "Asset Retirement Obligation Disclosure [Text Block]", "documentation": "The entire disclosure for an asset retirement obligation and the associated long-lived asset. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r239", "r401", "r404" ] }, "us-gaap_AssetRetirementObligationRevisionOfEstimate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationRevisionOfEstimate", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsScheduleofReconciliationofCompanysAssetRetirementObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in useful life estimate", "label": "Asset Retirement Obligation, Revision of Estimate", "documentation": "Amount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation." } } }, "auth_ref": [ "r407" ] }, "us-gaap_AssetRetirementObligationRollForwardAnalysisRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationRollForwardAnalysisRollForward", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsScheduleofReconciliationofCompanysAssetRetirementObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]", "label": "Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AssetRetirementObligationsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationsNoncurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsScheduleofReconciliationofCompanysAssetRetirementObligationsDetails", "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Asset retirement obligations", "periodStartLabel": "Balance at the beginning of the period", "periodEndLabel": "Balance at the ending of the period", "label": "Asset Retirement Obligations, Noncurrent", "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r966" ] }, "us-gaap_AssetRetirementObligationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationsPolicy", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Retirement Obligations", "label": "Asset Retirement Obligation [Policy Text Block]", "documentation": "Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset." } } }, "auth_ref": [ "r401" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r216", "r269", "r302", "r350", "r359", "r364", "r378", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r587", "r591", "r613", "r671", "r737", "r842", "r857", "r972", "r973", "r1007" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "lnth_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.lantheus.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating and Finance Lease Assets and Liabilities", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r260", "r276", "r302", "r378", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r587", "r591", "r613", "r842", "r972", "r973", "r1007" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r124" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r137", "r144", "r188", "r191", "r258", "r259" ] }, "lnth_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.lantheus.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r862", "r863", "r876" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.lantheus.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r862", "r863", "r876" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.lantheus.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r862", "r863", "r876" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r927" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r928" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r923" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r923" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r923" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r923" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r923" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r923" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r528", "r529", "r530", "r531" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r926" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r925" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r924" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r924" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r113", "r117" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "lnth_BedfordMassachusettsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "BedfordMassachusettsMember", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bedford, Massachusetts", "label": "Bedford, Massachusetts [Member]", "documentation": "Bedford, Massachusetts" } } }, "auth_ref": [] }, "us-gaap_BridgeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BridgeLoanMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bridge Loan", "label": "Bridge Loan [Member]", "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place." } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Buildings", "terseLabel": "Buildings", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r189" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r584", "r834", "r835" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r100", "r101", "r584", "r834", "r835" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r584" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "lnth_BusinessCombinationConsiderationTransferredContingentValueRight": { "xbrltype": "sharesItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "BusinessCombinationConsiderationTransferredContingentValueRight", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination common stock under contingent value right (in shares)", "label": "Business Combination, Consideration Transferred, Contingent Value Right", "documentation": "Business Combination, Consideration Transferred, Contingent Value Right" } } }, "auth_ref": [] }, "lnth_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, consideration transferred, equity interests issued (in shares)", "label": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Shares", "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Shares" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of contingent assets and liabilities", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r586", "r948" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential payments, high", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r106" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration liabilities", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r105", "r585" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term contingent liability", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r105" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability measurement input", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r608" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term contingent liability (Note 4)", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r105" ] }, "lnth_BusinessCombinationContingentLiabilityContingentValueRightConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "BusinessCombinationContingentLiabilityContingentValueRightConsideration", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination contingent value right of total consideration", "label": "Business Combination, Contingent Liability, Contingent Value Right, Consideration", "documentation": "Business Combination, Contingent Liability, Contingent Value Right, Consideration" } } }, "auth_ref": [] }, "lnth_BusinessCombinationContingentLiabilityContingentValueRightPercentageOfNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "BusinessCombinationContingentLiabilityContingentValueRightPercentageOfNetSales", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate cash payments percentage", "label": "Business Combination, Contingent Liability, Contingent Value Right Percentage Of Net Sales", "documentation": "Business Combination, Contingent Liability, Contingent Value Right Percentage Of Net Sales" } } }, "auth_ref": [] }, "lnth_BusinessCombinationContingentLiabilityContingentValueRightPercentageOfTotalConsideration": { "xbrltype": "percentItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "BusinessCombinationContingentLiabilityContingentValueRightPercentageOfTotalConsideration", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of total consideration", "label": "Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Total Consideration", "documentation": "Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Total Consideration" } } }, "auth_ref": [] }, "lnth_BusinessCombinationIncreaseDecreaseInAcquiredIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "BusinessCombinationIncreaseDecreaseInAcquiredIntangibleAssets", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Charges incurred in connection with acquired IPR&D", "label": "Business Combination, Increase (Decrease) In Acquired Intangible Assets", "documentation": "Business Combination, Increase (Decrease) In Acquired Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement period adjustment", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period", "documentation": "Amount of increase (decrease) in income that would have been recognized in previous periods if the adjustments to provisional amounts were recognized as of the acquisition date." } } }, "auth_ref": [ "r583" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r99" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Additions of property, plant\u00a0and equipment included in liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r61", "r62", "r63" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets", "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r58", "r263", "r801" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r263" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r59", "r215" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of year", "periodEndLabel": "Cash and cash equivalents and restricted cash, end of year", "totalLabel": "Cash, cash equivalents and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r58", "r177", "r299" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r177" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedge", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r111" ] }, "lnth_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee [Abstract]" } } }, "auth_ref": [] }, "lnth_CashPayments2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "CashPayments2022Member", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Payments, 2022", "label": "Cash Payments, 2022 [Member]", "documentation": "Cash Payments, 2022 [Member]" } } }, "auth_ref": [] }, "lnth_CashPayments2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "CashPayments2023Member", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Payments, 2023", "label": "Cash Payments, 2023 [Member]", "documentation": "Cash Payments, 2023 [Member]" } } }, "auth_ref": [] }, "lnth_CerveauTechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "CerveauTechnologiesIncMember", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cerveau Technologies, Inc", "label": "Cerveau Technologies, Inc [Member]", "documentation": "Cerveau Technologies, Inc" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r902" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r903" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r903" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (see Note 19)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r46", "r132", "r673", "r724" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r193", "r409", "r410", "r784", "r968" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r83", "r785" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r845", "r846", "r847", "r849", "r850", "r851", "r854", "r955", "r956", "r998", "r1018", "r1020" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r154" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r154", "r725" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r154" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r22", "r154", "r725", "r743", "r1020", "r1021" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock ($0.01 par value, 250,000 shares authorized; 69,863 and 68,851 shares issued as of December 31, 2023 and 2022, respectively)", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r154", "r676", "r842" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r908" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r907" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r909" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r906" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recorded in the accompanying consolidated balance sheets as:", "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r51", "r282", "r284", "r291", "r667", "r686" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r163", "r290", "r666", "r685" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss)", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r67", "r69", "r126", "r127", "r372", "r783" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r67", "r69", "r126", "r127", "r372", "r702", "r783" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r67", "r69", "r126", "r127", "r372", "r783", "r940" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Risks and Limited Suppliers", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r134", "r235" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r783" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r67", "r69", "r126", "r127", "r372" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r66", "r67", "r69", "r70", "r126", "r212", "r783" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r67", "r69", "r126", "r127", "r372", "r783" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r107", "r811" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails", "http://www.lantheus.com/role/DescriptionofBusinessDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "lnth_ContingentConsiderationNetSalesTargetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ContingentConsiderationNetSalesTargetsMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales targets \u2013 AZEDRA and 1095", "label": "Contingent Consideration, Net Sales Targets [Member]", "documentation": "Contingent Consideration, Net Sales Targets" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails", "http://www.lantheus.com/role/DescriptionofBusinessDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ContingentLiabilityReserveEstimatePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentLiabilityReserveEstimatePolicy", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Liabilities", "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates." } } }, "auth_ref": [ "r213", "r214" ] }, "lnth_ContingentPaymentsUnderCompanysLicenseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ContingentPaymentsUnderCompanysLicenseAgreements", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent payments", "label": "Contingent Payments Under Company's License Agreements", "documentation": "Contingent Payments Under Company's License Agreements" } } }, "auth_ref": [] }, "lnth_ContingentValueRightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ContingentValueRightMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales targets \u2013 PYLARIFY (CVRs)", "label": "Contingent Value Right [Member]", "documentation": "Contingent Value Right" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of contracts with customer", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r976" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfContractCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts included in the contract liability at the beginning of the period", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r476" ] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Payments Required", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r953" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r195", "r425", "r426", "r436", "r437", "r438", "r442", "r443", "r444", "r445", "r446", "r818", "r819", "r820", "r821", "r822" ] }, "lnth_ConvertibleSeniorNotes2625PercentDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ConvertibleSeniorNotes2625PercentDue2027Member", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.625% Convertible Senior Notes due 2027", "label": "Convertible Senior Notes 2.625 Percent Due 2027 [Member]", "documentation": "Convertible Senior Notes 2.625 Percent Due 2027" } } }, "auth_ref": [] }, "us-gaap_CostDepreciationAmortizationAndDepletion": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostDepreciationAmortizationAndDepletion", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization expense", "label": "Cost, Depreciation, Amortization and Depletion", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service." } } }, "auth_ref": [ "r947" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r170", "r662" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r256", "r305", "r306", "r428", "r456", "r652", "r807", "r809" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r943", "r952", "r989" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r943", "r952" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Current income tax expense (benefit), total", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r208", "r572", "r578", "r952" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r943", "r952", "r989" ] }, "lnth_CurrentlyMarketedProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "CurrentlyMarketedProductMember", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currently marketed product", "label": "Currently Marketed Product [Member]", "documentation": "Currently Marketed Product" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r103" ] }, "lnth_DebtCovenantPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DebtCovenantPeriodAxis", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "documentation": "Debt Covenant Period [Axis]" } } }, "auth_ref": [] }, "lnth_DebtCovenantPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DebtCovenantPeriodDomain", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Covenant Period [Domain]", "label": "Debt Covenant Period [Domain]", "documentation": "[Domain] for Debt Covenant Period [Axis]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Net, and Other Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r194", "r301", "r424", "r430", "r431", "r432", "r433", "r434", "r435", "r440", "r447", "r448", "r450" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r34", "r148", "r149", "r217", "r220", "r308", "r425", "r426", "r427", "r428", "r429", "r431", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r632", "r818", "r819", "r820", "r821", "r822", "r950" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, basis rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails_1": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 3.0 }, "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total principal outstanding", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r34", "r220", "r451" ] }, "lnth_DebtInstrumentConvertibleConversionPremium": { "xbrltype": "percentItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DebtInstrumentConvertibleConversionPremium", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion premium", "label": "Debt Instrument, Convertible, Conversion Premium", "documentation": "Represents the initial conversion premium of as a percentage of last reported sale price of the Common Stock." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r196", "r427" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible, conversion ratio", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r43", "r87", "r198", "r199", "r427" ] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, stock price percentage", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "lnth_DebtInstrumentCovenantComplianceMinimumInterestCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DebtInstrumentCovenantComplianceMinimumInterestCoverageRatio", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum interest coverage ratio", "label": "Debt Instrument, Covenant Compliance, Minimum Interest Coverage Ratio", "documentation": "Debt Instrument, Covenant Compliance, Minimum Interest Coverage Ratio" } } }, "auth_ref": [] }, "lnth_DebtInstrumentCovenantComplianceNumberOfFinancialCovenants": { "xbrltype": "integerItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DebtInstrumentCovenantComplianceNumberOfFinancialCovenants", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of covenants", "label": "Debt Instrument, Covenant Compliance, Number Of Financial Covenants", "documentation": "Debt Instrument, Covenant Compliance, Number Of Financial Covenants" } } }, "auth_ref": [] }, "lnth_DebtInstrumentCovenantCompliancePercentageOfAdditionalInterestUponNoncompliance": { "xbrltype": "percentItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DebtInstrumentCovenantCompliancePercentageOfAdditionalInterestUponNoncompliance", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant percentage of additional interest", "label": "Debt Instrument, Covenant Compliance, Percentage Of Additional Interest Upon Noncompliance", "documentation": "Debt Instrument, Covenant Compliance, Percentage Of Additional Interest Upon Noncompliance" } } }, "auth_ref": [] }, "lnth_DebtInstrumentCovenantLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DebtInstrumentCovenantLeverageRatio", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total net leverage ratio", "label": "Debt Instrument, Covenant Leverage Ratio", "documentation": "Debt Instrument, Covenant Leverage Ratio" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r129", "r131", "r425", "r632", "r819", "r820" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, fair value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r438", "r612", "r819", "r820" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r42", "r426" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r308", "r425", "r426", "r427", "r428", "r429", "r431", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r632", "r818", "r819", "r820", "r821", "r822", "r950" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r44", "r308", "r425", "r426", "r427", "r428", "r429", "r431", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r632", "r818", "r819", "r820", "r821", "r822", "r950" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price as a percentage of principal amount", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "documentation": "Percentage of principal amount of debt redeemed." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r44", "r87", "r88", "r128", "r129", "r131", "r133", "r197", "r199", "r308", "r425", "r426", "r427", "r428", "r429", "r431", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r632", "r818", "r819", "r820", "r821", "r822", "r950" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term (in years)", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, unamortized discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r128", "r131", "r975" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r130", "r436", "r452", "r819", "r820" ] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes", "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r14" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r952", "r988", "r989" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r208", "r952", "r988" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets", "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, net", "verboseLabel": "Noncurrent deferred tax assets, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r554", "r555" ] }, "lnth_DeferredIncomeTaxAssetsNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DeferredIncomeTaxAssetsNetMember", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Income Tax Assets, Net", "label": "Deferred Income Tax Assets, Net [Member]", "documentation": "Deferred Income Tax Assets, Net" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income tax expense (benefit), total", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r11", "r208", "r242", "r577", "r578", "r952" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Deferred tax liability", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r151", "r152", "r218", "r566" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r952", "r988", "r989" ] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r567" ] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets", "label": "Deferred Tax Assets, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research and development", "label": "Deferred Tax Assets, in Process Research and Development", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r98", "r987" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory obsolescence", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r98", "r987" ] }, "lnth_DeferredTaxAssetsLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DeferredTaxAssetsLeaseLiability", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Deferred Tax Assets, Lease Liability", "documentation": "Deferred Tax Assets, Lease Liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r986" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r98", "r987" ] }, "us-gaap_DeferredTaxAssetsStateTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsStateTaxes", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal benefit of state taxes payable", "label": "Deferred Tax Assets, State Taxes", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r98", "r987" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves, accruals and other", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r98", "r987" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: valuation allowance", "terseLabel": "Deferred tax asset, valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r568" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liabilities", "label": "Deferred Tax Liabilities, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reserves, accruals and other", "label": "Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from reserves and accruals." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Intangible assets", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r98", "r987" ] }, "lnth_DeferredTaxLiabilitiesIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DeferredTaxLiabilitiesIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of intangibles other than goodwill", "label": "Deferred Tax Liabilities, Intangible Assets Other Than Goodwill", "documentation": "Deferred Tax Liabilities, Intangible Assets Other Than Goodwill" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r98", "r987" ] }, "lnth_DeferredTaxLiabilitiesRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofDeferredIncomeTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Right-of-use asset", "label": "Deferred Tax Liabilities, Right Of Use Assets", "documentation": "Deferred Tax Liabilities, Right Of Use Assets" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/A401kPlanDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expense recognized by the company for matching contributions", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r495" ] }, "lnth_DefinityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DefinityMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DEFINITY", "label": "DEFINITY [Member]", "documentation": "DEFINITY [Member]" } } }, "auth_ref": [] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation, amortization and accretion", "label": "Depreciation, Amortization and Accretion, Net", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11" ] }, "us-gaap_DerivativeAverageFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAverageFixedInterestRate", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average fixed interest rate", "label": "Derivative, Average Fixed Interest Rate", "documentation": "Average fixed interest rate related to the group of interest rate derivatives." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r714", "r716", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r752", "r753", "r754", "r755", "r758", "r759", "r760", "r761", "r775", "r776", "r777", "r778", "r845", "r847" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on interest rate swap termination", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r996" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r114", "r116", "r118", "r119", "r714", "r716", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r752", "r753", "r754", "r755", "r758", "r759", "r760", "r761", "r775", "r776", "r777", "r778", "r809", "r845", "r847" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/DerivativeInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r211", "r593", "r600" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r23", "r114", "r118" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r600" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r994", "r995" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r23", "r108", "r109", "r110", "r112", "r115", "r118", "r120", "r122", "r123", "r600" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r23", "r108", "r109", "r112", "r121", "r307" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r209" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r475", "r824", "r825", "r826", "r827", "r828", "r829", "r830" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r475", "r824", "r825", "r826", "r827", "r828", "r829", "r830" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r977" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r497", "r502", "r533", "r534", "r536", "r837" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of RSU Valuation Model", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r15", "r91" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails", "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r258" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails", "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails", "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r12", "r29" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails", "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Disposal group consideration", "terseLabel": "Purchase price for stock", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "lnth_DisposalGroupIncludingDiscontinuedOperationConsiderationHoldbackAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationHoldbackAmount", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group holdback amount", "label": "Disposal Group, Including Discontinued Operation, Consideration, Holdback Amount", "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Holdback Amount" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiary" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Puerto Rico Subsidiary", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r136", "r187" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r834", "r835" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r862", "r863", "r876" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r862", "r863", "r876", "r912" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r897" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r860" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per common share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic income (loss) per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r292", "r318", "r319", "r320", "r321", "r322", "r327", "r330", "r338", "r339", "r340", "r344", "r602", "r603", "r668", "r687", "r813" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted income (loss) per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r292", "r318", "r319", "r320", "r321", "r322", "r330", "r338", "r339", "r340", "r344", "r602", "r603", "r668", "r687", "r813" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) per Common Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r326", "r341", "r342", "r343" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r622" ] }, "lnth_EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in indemnification deferred tax asset", "label": "Effective Income Tax Rate Reconciliation, Increase In Indemnification Deferred Tax Asset", "documentation": "Effective Income Tax Rate Reconciliation, Increase In Indemnification Deferred Tax Asset" } } }, "auth_ref": [] }, "lnth_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Section 162(m)", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Section 162", "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Section 162" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/StockBasedCompensationStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining period for recognition of unrecognized compensation costs", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r535" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/StockBasedCompensationStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r982" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r859" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r859" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r859" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r937" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r859" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r859" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r859" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r859" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r938" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails", "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r22", "r257", "r286", "r287", "r288", "r313", "r314", "r315", "r317", "r323", "r325", "r345", "r379", "r380", "r457", "r537", "r538", "r539", "r573", "r574", "r594", "r595", "r596", "r597", "r598", "r599", "r601", "r623", "r624", "r625", "r626", "r627", "r628", "r651", "r696", "r697", "r698", "r709", "r765" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r905" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r868", "r880", "r890", "r916" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r865", "r877", "r887", "r913" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r911" ] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extinguishment of debt, amount", "label": "Extinguishment of Debt, Amount", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r605", "r606", "r611" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r605", "r606", "r611" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r24" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r438", "r481", "r482", "r483", "r484", "r485", "r486", "r606", "r656", "r657", "r658", "r819", "r820", "r831", "r832", "r833" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r604" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r438", "r481", "r486", "r606", "r656", "r831", "r832", "r833" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r438", "r481", "r486", "r606", "r657", "r819", "r820", "r831", "r832", "r833" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r438", "r481", "r482", "r483", "r484", "r485", "r486", "r606", "r658", "r819", "r820", "r831", "r832", "r833" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in fair value included in net income (loss)", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r609" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r125" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value, beginning of period", "periodEndLabel": "Fair value, end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r25" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in fair value included in net income (loss)", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r609" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r125" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value, beginning of period", "periodEndLabel": "Fair value, end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r25" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r438", "r481", "r482", "r483", "r484", "r485", "r486", "r656", "r657", "r658", "r819", "r820", "r831", "r832", "r833" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in fair value of the contingent financial asset and contingent financial liabilities", "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Instruments with Significant Level 3 Inputs", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r25", "r30" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement in which net income is reported that includes unrealized gain (loss) from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r16", "r33" ] }, "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOptionQuantitativeDisclosuresLineItems", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Option, Quantitative Disclosures [Line Items]", "label": "Fair Value, Option, Quantitative Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r614", "r615", "r616" ] }, "us-gaap_FairValueOptionQuantitativeDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOptionQuantitativeDisclosuresTable", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Option, Disclosures [Table]", "label": "Fair Value Option, Disclosures [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option." } } }, "auth_ref": [ "r614", "r615", "r616" ] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3)." } } }, "auth_ref": [ "r609" ] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth_ref": [ "r609" ] }, "lnth_FinanceLeaseExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "FinanceLeaseExpenseAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease expense", "label": "Finance Lease, Expense [Abstract]", "documentation": "Finance Lease, Expense [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r637", "r643", "r841" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r639", "r645" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails_1": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 1.0 }, "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails", "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r635", "r649" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails": { "parentTag": "lnth_LeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r635" ] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, liability, current, statement of financial position [Extensible List]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r636" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.lantheus.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments Under Finance Leases", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1005" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails": { "parentTag": "lnth_LeaseLiability", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r635" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, liability, noncurrent, statement of financial position [Extensible List]", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": [ "r636" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r649" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r649" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r638", "r645" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails": { "parentTag": "lnth_LeaseRightOfUseAsset", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r634" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of ROU assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r637", "r643", "r841" ] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, right-of-use asset, statement of financial position [Extensible List]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": [ "r636" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r648", "r841" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r647", "r841" ] }, "lnth_FinancialAssuranceInFormOfSuretyBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "FinancialAssuranceInFormOfSuretyBond", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assurance in form of surety bond", "label": "Financial Assurance In Form Of Surety Bond", "documentation": "Represents the amount of financial assurance given in the form of surety bond." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Useful Lives (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "terseLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r267", "r395" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r185" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r185" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r185" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r185" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r185" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r392", "r394", "r395", "r397", "r663", "r664" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r184", "r664" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r663" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r76", "r79" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r184", "r663" ] }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets, period increase (decrease)", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency losses", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r618", "r619", "r620", "r621", "r762" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r617" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r872", "r884", "r894", "r920" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r872", "r884", "r894", "r920" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r872", "r884", "r894", "r920" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r872", "r884", "r894", "r920" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r872", "r884", "r894", "r920" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 }, "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows", "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on disposal of assets", "negatedLabel": "Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties", "terseLabel": "Gain on sales of assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r949" ] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax book gain on disposal", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r590", "r949" ] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sales of assets", "label": "Gain (Loss) on Disposition of Other Assets", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": [ "r949" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest rate swap termination", "label": "Gain (Loss) Related to Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r969" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows", "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (gain) on extinguishment of debt", "verboseLabel": "Gain (loss) on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r11", "r85", "r86" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (gain) on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt, before Debt Issuance Cost Writeoff", "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs." } } }, "auth_ref": [ "r85", "r86" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "lnth_OperatingExpensesBeforeGainLossOnSaleOfAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r171", "r747" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r167" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r266", "r388", "r665", "r817", "r842", "r962", "r963" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwill" ], "lang": { "en-us": { "role": { "terseLabel": "Intangibles, Net and Goodwill", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r183" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r387", "r391", "r817" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, impairment loss", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r11", "r389", "r390", "r391", "r817" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r169", "r302", "r350", "r358", "r363", "r366", "r378", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r613", "r815", "r972" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r23" ] }, "lnth_IPRDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "IPRDMember", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPR & D", "label": "IPR & D [Member]", "documentation": "IPR & D" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r862", "r863", "r876" ] }, "us-gaap_ImpairmentLessorAssetUnderOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentLessorAssetUnderOperatingLease", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, lessor asset under operating lease", "label": "Impairment, Lessor Asset under Operating Lease", "documentation": "Amount of impairment for lessor's underlying asset for which right to use has been conveyed to lessee under operating lease." } } }, "auth_ref": [ "r399", "r650" ] }, "us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill." } } }, "auth_ref": [ "r398" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r949", "r964" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible and Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofIncomeBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r303", "r579" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofIncomeBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r165", "r222", "r350", "r358", "r363", "r366", "r669", "r683", "r815" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofIncomeBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofComponentsofIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r303", "r579" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r834", "r835" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r17", "r29", "r35", "r137", "r139", "r140", "r141", "r142", "r143", "r145", "r146", "r147", "r192" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r400", "r408", "r748" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r408", "r748" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r18" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r304", "r549", "r558", "r564", "r570", "r575", "r580", "r581", "r582", "r708" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "http://www.lantheus.com/role/IncomeTaxesScheduleofBenefitProvisionforIncomeTaxesDetails", "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "totalLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r229", "r243", "r324", "r325", "r355", "r556", "r576", "r688" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r285", "r552", "r553", "r564", "r565", "r569", "r571", "r704" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact on deferred taxes of change in tax rate", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r551", "r557" ] }, "us-gaap_IncomeTaxReconciliationDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationDispositionOfAssets", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of RELISTOR licensed intangible asset associated with net sales royalties", "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign tax rate differential", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r557" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Permanent items", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of contingent assets and liabilities", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State and local taxes", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxContingencies", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncertain tax positions", "negatedTerseLabel": "Tax provision benefit/expense", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsOther", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesScheduleofDifferencesinStatutoryRateandEffectiveRateDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits." } } }, "auth_ref": [ "r984" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes, net of refunds of $25, $50 and $315, respectively", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r60" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Long-term indemnification receivable", "label": "Increase (Decrease) in Income Taxes Receivable", "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities which provided (used) cash:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r948" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other long-term assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r948" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term income tax payable and other long-term liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of convertible notes (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": [ "r334", "r335", "r340" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive share based compensation (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r331", "r332", "r333", "r340", "r501" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r393", "r396" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite lived, cost", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r186" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r77", "r186" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in indefinite lived assets", "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r186" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r875", "r884", "r894", "r911", "r920", "r924", "r932" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r930" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r864", "r936" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r864", "r936" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r864", "r936" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total, cost", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r266" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangibles, net", "totalLabel": "Total, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r74", "r78" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r130", "r224", "r289", "r354", "r630", "r749", "r855", "r1019" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, debt", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r173", "r444", "r454", "r821", "r822" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r295", "r297", "r298" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swaps", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r798", "r852", "r853" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/Inventory" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r381" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r182", "r804" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.lantheus.com/role/InventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets", "http://www.lantheus.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Total inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r273", "r802", "r842" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r230", "r262", "r272", "r381", "r382", "r384", "r661", "r812" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r182", "r806" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r182", "r805" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for excess and obsolete inventory", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r383" ] }, "us-gaap_InvestmentCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCreditMember", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Tax Credit Carryforward", "label": "Investment Tax Credit Carryforward [Member]", "documentation": "Investment tax credit carryforwards arising from certain qualifying capital expenditures including, but not limited to, rehabilitation, energy, advanced coal project and gasification project." } } }, "auth_ref": [ "r96" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r172", "r353" ] }, "us-gaap_LandImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandImprovementsMember", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land improvements", "label": "Land Improvements [Member]", "documentation": "Additions or improvements to real estate held." } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r978" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease expense", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r642", "r841" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.lantheus.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Lease Expense and Other Information", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1004" ] }, "lnth_LeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LeaseLiability", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total leased liabilities", "label": "Lease, Liability", "documentation": "Lease, Liability" } } }, "auth_ref": [] }, "lnth_LeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LeaseLiabilityAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Lease, Liability [Abstract]", "documentation": "Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "lnth_LeaseLiabilityCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LeaseLiabilityCurrentAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Lease, Liability, Current [Abstract]", "documentation": "Lease, Liability, Current [Abstract]" } } }, "auth_ref": [] }, "lnth_LeaseLiabilityNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LeaseLiabilityNoncurrentAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent", "label": "Lease, Liability, Noncurrent [Abstract]", "documentation": "Lease, Liability, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "lnth_LeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total leased assets", "label": "Lease, Right-Of-Use Asset", "documentation": "Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "lnth_LeaseRightOfUseAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LeaseRightOfUseAssetAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Lease, Right-Of-Use Asset [Abstract]", "documentation": "Lease, Right-Of-Use Asset [Abstract]" } } }, "auth_ref": [] }, "lnth_LeaseWeightedAverageDiscountRatePercentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LeaseWeightedAverageDiscountRatePercentAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate:", "label": "Lease, Weighted Average Discount Rate, Percent [Abstract]", "documentation": "Lease, Weighted Average Discount Rate, Percent [Abstract]" } } }, "auth_ref": [] }, "lnth_LeaseWeightedAverageRemainingLeaseTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term (Years):", "label": "Lease, Weighted Average Remaining Lease Term [Abstract]", "documentation": "Lease, Weighted Average Remaining Lease Term [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r189" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.lantheus.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r633" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r641" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r641" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.lantheus.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments Under Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1005" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1003" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1003" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.lantheus.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r633" ] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor term of contract", "label": "Lessor, Operating Lease, Term of Contract", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1006" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r39", "r302", "r378", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r588", "r591", "r592", "r613", "r723", "r814", "r857", "r972", "r1007", "r1008" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r159", "r221", "r679", "r842", "r951", "r960", "r1000" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r41", "r261", "r302", "r378", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r588", "r591", "r592", "r613", "r842", "r972", "r1007", "r1008" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "lnth_LiabilitiesCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LiabilitiesCurrentMember", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Current", "label": "Liabilities, Current [Member]", "documentation": "Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r124" ] }, "lnth_LicenseAndRoyaltyRevenuesSalesBasedMilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LicenseAndRoyaltyRevenuesSalesBasedMilestonePaymentMember", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License and Royalty Revenues, Sales-Based Milestone Payment", "label": "License and Royalty Revenues, Sales-Based Milestone Payment [Member]", "documentation": "License and Royalty Revenues, Sales-Based Milestone Payment" } } }, "auth_ref": [] }, "lnth_LicenseandRoyaltyRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LicenseandRoyaltyRevenuesMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "License and royalty revenues", "label": "License and Royalty Revenues [Member]", "documentation": "License and Royalty Revenues [Member]" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails", "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r104", "r548", "r983" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding borrowings", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r34", "r220", "r1016" ] }, "lnth_LineOfCreditFacilityAccordionFeatureHigherBorrowingCapacityOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "LineOfCreditFacilityAccordionFeatureHigherBorrowingCapacityOption", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, accordion feature, higher borrowing capacity option", "label": "Line of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option", "documentation": "Line of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r38" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedFromOtherParty", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total amount awarded", "label": "Litigation Settlement, Amount Awarded from Other Party", "documentation": "Amount awarded from other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, convertible, carrying amount", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r34", "r220", "r437", "r453", "r819", "r820", "r1016" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 1.0 }, "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets", "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total long-term debt, net, and other borrowings", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r34", "r672" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: current portion", "label": "Long-Term Debt and Lease Obligation, Current", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": [ "r40" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt and Lease Obligation, Including Current Maturities", "documentation": "Amount of long-term debt and lease obligation, including portion classified as current." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt and other borrowings", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r270" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of debt", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r308", "r442" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r308", "r442" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r308", "r442" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r308", "r442" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r308", "r442" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r44" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r44", "r84" ] }, "stpr_MA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "MA", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Massachusetts", "label": "MASSACHUSETTS" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "lnth_MachineryEquipmentAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "MachineryEquipmentAndFixturesMember", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery, equipment and fixtures", "label": "Machinery Equipment And Fixtures [Member]", "documentation": "Machinery Equipment And Fixtures [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails", "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r411", "r412", "r413", "r414", "r496", "r660", "r695", "r715", "r716", "r768", "r770", "r772", "r773", "r779", "r795", "r796", "r816", "r823", "r836", "r844", "r974", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r903" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r903" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r999" ] }, "lnth_MeasurementInputProbabilityOfSuccessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "MeasurementInputProbabilityOfSuccessMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability of success and sales targets", "label": "Measurement Input, Probability Of Success [Member]", "documentation": "Measurement Input, Probability Of Success" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r607" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails", "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r411", "r412", "r413", "r414", "r496", "r660", "r695", "r715", "r716", "r768", "r770", "r772", "r773", "r779", "r795", "r796", "r816", "r823", "r836", "r844", "r974", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r923" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r979" ] }, "lnth_MonteCarloSimulationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "MonteCarloSimulationMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monte Carlo simulation", "label": "Monte Carlo Simulation [Member]", "documentation": "Monte Carlo Simulation" } } }, "auth_ref": [] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfRebatesandAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r931" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r904" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r231", "r244" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r296" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r296" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r177", "r178", "r179" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 }, "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows", "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity", "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "netLabel": "Net income (loss)", "verboseLabel": "Net (loss) income", "terseLabel": "Net income (loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r166", "r179", "r223", "r259", "r280", "r283", "r288", "r302", "r316", "r318", "r319", "r320", "r321", "r324", "r325", "r336", "r350", "r358", "r363", "r366", "r378", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r603", "r613", "r684", "r745", "r763", "r764", "r815", "r855", "r972" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r293", "r318", "r319", "r320", "r321", "r327", "r328", "r337", "r340", "r350", "r358", "r363", "r366", "r815" ] }, "lnth_NetLeverageRatioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "NetLeverageRatioMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leverage Ratio Range", "label": "Net Leverage Ratio [Member]", "documentation": "Net Leverage Ratio [Member]" } } }, "auth_ref": [] }, "lnth_NetSalesTargetsForAzedraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "NetSalesTargetsForAzedraMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Sales Targets For Azedra", "label": "Net Sales Targets For Azedra [Member]", "documentation": "Net Sales Targets For Azedra" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "lnth_NewYorkCityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "NewYorkCityMember", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New York City", "label": "New York City [Member]", "documentation": "New York City" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r903" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r872", "r884", "r894", "r911", "r920" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r901" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r900" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r911" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r931" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r931" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of non-cash investing and financing activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "lnth_NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities, Deferred Income Tax Expense (Benefit)", "documentation": "Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities, Deferred Income Tax Expense (Benefit)" } } }, "auth_ref": [] }, "lnth_NumberOfOperatingLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "NumberOfOperatingLeases", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of leases", "label": "Number Of Operating Leases", "documentation": "Number Of Operating Leases" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.lantheus.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r959" ] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": [ "r32", "r50" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "lnth_OperatingExpensesBeforeGainLossOnSaleOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "OperatingExpensesBeforeGainLossOnSaleOfAssets", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses Before Gain Loss On Sale Of Assets", "documentation": "Operating Expenses Before Gain Loss On Sale Of Assets" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r350", "r358", "r363", "r366", "r815" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r644", "r841" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails", "http://www.lantheus.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liability", "terseLabel": "Total", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r635" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails": { "parentTag": "lnth_LeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r635" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, liability, current, statement of financial position [Extensible List]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r636" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails": { "parentTag": "lnth_LeaseLiability", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails", "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities (Note 16)", "verboseLabel": "Operating", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r635" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, liability, noncurrent, statement of financial position [Extensible List]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r636" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r640", "r645" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails": { "parentTag": "lnth_LeaseRightOfUseAsset", "weight": 1.0, "order": 1.0 }, "http://www.lantheus.com/role/OtherAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails", "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails", "http://www.lantheus.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, right-of-use asset", "verboseLabel": "ROU Asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r634" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOperatingandFinancingLeaseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, right-of-use asset, statement of financial position [Extensible List]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r636" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r648", "r841" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r647", "r841" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryovers", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r97" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "lnth_OperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carried forward", "label": "Operating Loss Carryforwards, Not Subject to Expiration", "documentation": "Operating Loss Carryforwards, Not Subject to Expiration" } } }, "auth_ref": [] }, "lnth_OperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "OperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards expire", "label": "Operating Loss Carryforwards, Subject to Expiration", "documentation": "Operating Loss Carryforwards, Subject to Expiration" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r96" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r40" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.lantheus.com/role/OtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets", "http://www.lantheus.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "totalLabel": "Total other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r275", "r842" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/OtherAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/OtherAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets", "label": "Other Assets, Miscellaneous, Current", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/OtherAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Long-Term Assets", "label": "Other Assets, Miscellaneous, Noncurrent", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.lantheus.com/role/OtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets", "http://www.lantheus.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "totalLabel": "Total other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r268" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r9", "r20", "r210" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on cash flow hedges, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r277" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r277", "r279" ] }, "lnth_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Realized loss on cash flow hedges, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Unrealized Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge, Realized Gain (Loss), after Reclassification and Tax, Parent" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity", "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "terseLabel": "Other comprehensive (loss) income", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r9", "r20", "r210", "r281", "r284" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 }, "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails", "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "totalLabel": "Total other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r45" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r179" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r174" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 }, "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income) loss, net", "negatedTotalLabel": "Total other (income) loss", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r174" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r903" ] }, "lnth_OtherPrecisionDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "OtherPrecisionDiagnosticsMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other precision diagnostics", "label": "Other Precision Diagnostics [Member]", "documentation": "Other Precision Diagnostics" } } }, "auth_ref": [] }, "lnth_OtherRadiopharmaceuticalOncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "OtherRadiopharmaceuticalOncologyMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other radiopharmaceutical oncology", "label": "Other Radiopharmaceutical Oncology [Member]", "documentation": "Other Radiopharmaceutical Oncology" } } }, "auth_ref": [] }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSundryLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Sundry Liabilities, Noncurrent", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date." } } }, "auth_ref": [ "r150", "r219" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r870", "r882", "r892", "r918" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r873", "r885", "r895", "r921" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r873", "r885", "r895", "r921" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "lnth_PNT2002LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "PNT2002LicenseAgreementMember", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PNT2002 License Agreement", "label": "PNT2002 License Agreement [Member]", "documentation": "PNT2002 License Agreement" } } }, "auth_ref": [] }, "lnth_PNT2003LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "PNT2003LicenseAgreementMember", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PNT2003 License Agreement", "label": "PNT2003 License Agreement [Member]", "documentation": "PNT2003 License Agreement" } } }, "auth_ref": [] }, "lnth_POINTBiopharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "POINTBiopharmaMember", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "POINT Biopharma", "label": "POINT Biopharma [Member]", "documentation": "POINT Biopharma" } } }, "auth_ref": [] }, "lnth_PYLARIFYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "PYLARIFYMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PYLARIFY", "label": "PYLARIFY [Member]", "documentation": "PYLARIFY" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r899" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Contingent value rights settlement", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r8" ] }, "lnth_PaymentsForAssetAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "PaymentsForAssetAcquisitions", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for acquisitions", "label": "Payments For Asset Acquisitions", "documentation": "Payments For Asset Acquisitions" } } }, "auth_ref": [] }, "us-gaap_PaymentsForCapitalImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForCapitalImprovements", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments for Capital Improvements", "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use." } } }, "auth_ref": [ "r176" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r55" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r57" ] }, "lnth_PaymentsOfDeferredFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "PaymentsOfDeferredFinancingCosts", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred financing costs", "label": "Payments Of Deferred Financing Costs", "documentation": "Payments Of Deferred Financing Costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for minimum statutory tax withholding related to net share settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r294" ] }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire interest", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)." } } }, "auth_ref": [ "r52" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of assets", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r228", "r991", "r992", "r993" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire license agreement", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r176" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r902" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r902" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/A401kPlan" ], "lang": { "en-us": { "role": { "terseLabel": "401(k) Plan", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r478", "r479", "r480", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r833" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r901" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r911" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r904" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r900" ] }, "lnth_PerspectiveTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "PerspectiveTherapeuticsIncMember", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Perspective Therapeutics, Inc", "label": "Perspective Therapeutics, Inc [Member]", "documentation": "Perspective Therapeutics, Inc" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r153", "r455" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r153", "r725" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r153", "r455" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r153", "r725", "r743", "r1020", "r1021" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r153", "r675", "r842" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/OtherAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/OtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r274", "r385", "r386", "r803" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from convertible debt", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r54" ] }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIncomeTaxRefunds", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from income tax refunds", "label": "Proceeds from Income Tax Refunds", "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r60", "r178" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of long-term debt, net", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r54", "r705" ] }, "us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentOfLoansToPurchaseCommonStock", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleCommonStockRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from the notes", "label": "Proceeds from Repayment of Loans to Purchase Common Stock", "documentation": "Cash inflow from repayment of loans for purchasing common stock." } } }, "auth_ref": [ "r53" ] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of assets, net", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r175" ] }, "lnth_ProceedsFromSaleOfRoyaltyRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ProceedsFromSaleOfRoyaltyRights", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from selling rights to the royalties", "label": "Proceeds From Sale Of Royalty Rights", "documentation": "Proceeds From Sale Of Royalty Rights" } } }, "auth_ref": [] }, "lnth_ProceedsFromSaleOfRoyaltyRightsAdditionalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ProceedsFromSaleOfRoyaltyRightsAdditionalPayment", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties", "label": "Proceeds From Sale Of Royalty Rights, Additional Payment", "documentation": "Proceeds From Sale Of Royalty Rights, Additional Payment" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock option exercises", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r7", "r28" ] }, "lnth_ProceedsFromTerminationOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ProceedsFromTerminationOfDerivatives", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows", "http://www.lantheus.com/role/DerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from interest rate swap termination", "label": "Proceeds From Termination Of Derivatives", "documentation": "Proceeds From Termination Of Derivatives" } } }, "auth_ref": [] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue, net", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r824" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r368", "r662", "r689", "r690", "r691", "r692", "r693", "r694", "r799", "r824", "r843", "r942", "r970", "r971", "r977", "r1017" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r368", "r662", "r689", "r690", "r691", "r692", "r693", "r694", "r799", "r824", "r843", "r942", "r970", "r971", "r977", "r1017" ] }, "lnth_ProgenicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ProgenicsMember", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Progenics", "label": "Progenics [Member]", "documentation": "Progenics" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant\u00a0and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r941", "r965" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails", "http://www.lantheus.com/role/SubsequentEventDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r13" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant & Equipment, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r187", "r236", "r240", "r241" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant\u00a0and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r189", "r264", "r682" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails", "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant & Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property, plant\u00a0and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r13", "r670", "r682", "r842" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant\u00a0and Equipment, net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r13", "r236", "r240", "r680" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetTables", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Useful Lives of Major Classes of Depreciable Assets", "verboseLabel": "Schedule of Property, Plant, and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r13" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails", "http://www.lantheus.com/role/SubsequentEventDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r189" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "lnth_PuertoRicanRadiopharmacyServicingSubsidiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "PuertoRicanRadiopharmacyServicingSubsidiaryMember", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Puerto Rican Radiopharmacy Servicing Subsidiary", "label": "Puerto Rican Radiopharmacy Servicing Subsidiary [Member]", "documentation": "Puerto Rican Radiopharmacy Servicing Subsidiary" } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligation", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInFourthYear", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Purchase Obligation, to be Paid, Year Four", "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInSecondYear", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Purchase Obligation, to be Paid, Year Two", "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInThirdYear", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Purchase Obligation, to be Paid, Year Three", "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "lnth_PurchaseObligationToBePaidYearFiveAndThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "PurchaseObligationToBePaidYearFiveAndThereafter", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesScheduleofPurchaseCommitmentsUnderNoncancelableArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028 and thereafter", "label": "Purchase Obligation, to be Paid, Year Five and Thereafter", "documentation": "Purchase Obligation, to be Paid, Year Five and Thereafter" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r899" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r899" ] }, "lnth_Q12024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "Q12024Member", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Q1 2024", "label": "Q1 2024 [Member]", "documentation": "Q1 2024" } } }, "auth_ref": [] }, "lnth_RadiopharmaceuticalOncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "RadiopharmaceuticalOncologyMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total radiopharmaceutical oncology", "label": "Radiopharmaceutical Oncology [Member]", "documentation": "Radiopharmaceutical Oncology" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails", "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r411", "r412", "r413", "r414", "r479", "r496", "r528", "r529", "r530", "r659", "r660", "r695", "r715", "r716", "r768", "r770", "r772", "r773", "r779", "r795", "r796", "r816", "r823", "r836", "r844", "r847", "r967", "r974", "r1010", "r1011", "r1012", "r1013", "r1014" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails", "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails", "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r411", "r412", "r413", "r414", "r479", "r496", "r528", "r529", "r530", "r659", "r660", "r695", "r715", "r716", "r768", "r770", "r772", "r773", "r779", "r795", "r796", "r816", "r823", "r836", "r844", "r847", "r967", "r974", "r1010", "r1011", "r1012", "r1013", "r1014" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified to earnings", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r32", "r50" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesReconciliationofUncertainTaxPositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Uncertain Tax Positions [Roll Forward]", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "lnth_ReconciliationToAmountsWithinTheConsolidatedBalanceSheetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ReconciliationToAmountsWithinTheConsolidatedBalanceSheetsAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation to amounts within the consolidated balance sheets", "label": "Reconciliation to Amounts Within the Consolidated Balance Sheets [Abstract]", "documentation": "Reconciliation to Amounts Within the Consolidated Balance Sheets" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r865", "r877", "r887", "r913" ] }, "lnth_RegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "RegulatoryMilestonesMember", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory Milestones", "label": "Regulatory Milestones [Member]", "documentation": "Regulatory Milestones" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of debt", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r56", "r950" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on long-term debt and other borrowings", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r56", "r706" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r305", "r306", "r428", "r456", "r652", "r808", "r809" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "lnth_OperatingExpensesBeforeGainLossOnSaleOfAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails", "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r135", "r547", "r1015" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r546" ] }, "lnth_ResearchRevenueMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ResearchRevenueMilestonesMember", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Revenue Milestones", "label": "Research Revenue Milestones [Member]", "documentation": "Research Revenue Milestones" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r866", "r878", "r888", "r914" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r867", "r879", "r889", "r915" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r874", "r886", "r896", "r922" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other long-term assets", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r58", "r215", "r263", "r299", "r674" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r263" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r64" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings (accumulated deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r156", "r200", "r678", "r699", "r701", "r707", "r726", "r842" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r257", "r313", "r314", "r315", "r317", "r323", "r325", "r379", "r380", "r537", "r538", "r539", "r573", "r574", "r594", "r596", "r597", "r599", "r601", "r696", "r698", "r709", "r1020" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Total revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r351", "r352", "r357", "r361", "r362", "r368", "r370", "r372", "r474", "r475", "r662" ] }, "lnth_RevenueFromContractWithCustomerNumberOfProductCategories": { "xbrltype": "integerItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "RevenueFromContractWithCustomerNumberOfProductCategories", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of product categories", "label": "Revenue from Contract with Customer, Number Of Product Categories", "documentation": "Revenue from Contract with Customer, Number Of Product Categories" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r245", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r797" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomers" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customers", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r245", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r477" ] }, "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment terms", "label": "Revenue, Performance Obligation, Description of Payment Terms", "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration." } } }, "auth_ref": [ "r460" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r646", "r841" ] }, "lnth_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": [ "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for lease obligations:", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows", "http://www.lantheus.com/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Right-of-use asset obtained in exchange for operating lease liabilities", "terseLabel": "Operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r646", "r841" ] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r978" ] }, "lnth_RoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "RoyaltyPercentage", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty percentage", "label": "Royalty Percentage", "documentation": "Royalty Percentage" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r931" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r931" ] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleCommonStockRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, price per share (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "lnth_SalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "SalesMilestonesMember", "presentation": [ "http://www.lantheus.com/role/AcquisitionofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Milestones", "label": "Sales Milestones [Member]", "documentation": "Sales Milestones" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r372", "r939" ] }, "lnth_SamLenoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "SamLenoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Sam Leno [Member]", "documentation": "Sam Leno" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Loss", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r50", "r1001", "r1002" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.lantheus.com/role/DescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r100", "r101", "r584" ] }, "us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Asset Retirement Obligations", "label": "Schedule of Change in Asset Retirement Obligation [Table Text Block]", "documentation": "Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation." } } }, "auth_ref": [ "r966" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision (benefit) for Income Taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r205" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Deferred Incomes Tax Assets (Liabilities)", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r204" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Income (loss) Per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r958" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Income Taxes at the U.S. Federal Statutory Rate to the Actual Income Taxes", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r203" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense Recognized", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r93" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r605", "r606" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r76", "r79", "r663" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangibles", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r76", "r79" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income (loss) Before Provision (benefit) for Income Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r952" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r31", "r186" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r31", "r186" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.lantheus.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r36", "r160", "r161", "r162" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Principal Obligations", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://www.lantheus.com/role/OtherAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of other loss (income)", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails", "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r498", "r500", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r528", "r529", "r530", "r531" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r26", "r27", "r92" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Valuation Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r202" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Awards Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Future Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r79" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Product Concentration Risk", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r66", "r67", "r69", "r70", "r126", "r212" ] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r997" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r858" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r861" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r370", "r371", "r711", "r712", "r713", "r769", "r771", "r774", "r780", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r800", "r825", "r847", "r977", "r1017" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.lantheus.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r356", "r360", "r364", "r365", "r366", "r367", "r368", "r369", "r372" ] }, "us-gaap_SelfInsuranceReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReserveNoncurrent", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesSelfInsuranceReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities associated with employee medical costs", "label": "Self Insurance Reserve, Noncurrent", "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReservePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReservePolicyTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Self-Insurance Reserves", "label": "Self Insurance Reserve [Policy Text Block]", "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR)." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofOperations": { "parentTag": "lnth_OperatingExpensesBeforeGainLossOnSaleOfAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r167" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r837" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r520" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r520" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r518" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r518" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested beginning balance (in shares)", "periodEndLabel": "Nonvested ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r515", "r516" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested beginning balance (in dollars per share)", "periodEndLabel": "Nonvested, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r515", "r516" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Grant Date\u00a0Fair\u00a0Value\u00a0Per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r519" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of vested shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r522" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r519" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r529" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r528" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r530" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term." } } }, "auth_ref": [ "r529" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r498", "r500", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r528", "r529", "r530", "r531" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationEquityIncentivePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation, shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r839" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (Years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r509" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r509" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r522" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options cancelled and forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r981" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options cancelled and forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r981" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r511" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning balance (in shares)", "periodEndLabel": "Options outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r507", "r508" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Stock Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Options outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r507", "r508" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "lnth_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceMeasurementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceMeasurementPeriod", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance awards, measurement period", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Performance Measurement Period", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Performance Measurement Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails", "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r528", "r529", "r530", "r531" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r512" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r511" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r497", "r506", "r525", "r526", "r527", "r528", "r531", "r540", "r541", "r542", "r543" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentages attainable during period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r980" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r838" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "http://www.lantheus.com/role/StockBasedCompensationValuationModelAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r527" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r91" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, weighted average remaining contractual term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r91" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, weighted average remaining contractual term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r201" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld to cover taxes (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r180", "r300" ] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetScheduleofPropertyPlantEquipmentDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer software", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "lnth_SomersetNewJerseyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "SomersetNewJerseyMember", "presentation": [ "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Somerset, New Jersey", "label": "Somerset, New Jersey [Member]", "documentation": "Somerset, New Jersey" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State Research Credit", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails", "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r22", "r47", "r257", "r286", "r287", "r288", "r313", "r314", "r315", "r317", "r323", "r325", "r345", "r379", "r380", "r457", "r537", "r538", "r539", "r573", "r574", "r594", "r595", "r596", "r597", "r598", "r599", "r601", "r623", "r624", "r625", "r626", "r627", "r628", "r651", "r696", "r697", "r698", "r709", "r765" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.lantheus.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r246", "r255", "r370", "r371", "r711", "r712", "r713", "r769", "r771", "r774", "r780", "r782", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r800", "r825", "r847", "r977", "r1017" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r313", "r314", "r315", "r345", "r662", "r703", "r710", "r717", "r718", "r719", "r720", "r721", "r722", "r725", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r742", "r744", "r746", "r747", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r765", "r848" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r313", "r314", "r315", "r345", "r662", "r703", "r710", "r717", "r718", "r719", "r720", "r721", "r722", "r725", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r742", "r744", "r746", "r747", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r765", "r848" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r869", "r881", "r891", "r917" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "lnth_StockIssuedDuringPeriodSharesOptionsExercisesDuringPeriodandEmployeeStockOwnershipPlan": { "xbrltype": "sharesItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "StockIssuedDuringPeriodSharesOptionsExercisesDuringPeriodandEmployeeStockOwnershipPlan", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option exercises and employee stock plan purchases (in shares)", "label": "Stock Issued During Period, Shares, Options Exercises During Period and Employee Stock Ownership Plan", "documentation": "Stock Issued During Period, Shares, Options Exercises During Period and Employee Stock Ownership Plan" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock awards (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r22", "r153", "r154", "r200" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleofStockOptionsDetails", "http://www.lantheus.com/role/StockBasedCompensationStockOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options exercised (in shares)", "verboseLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r22", "r153", "r154", "r200", "r512" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock awards", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r22", "r200" ] }, "lnth_StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option exercises and employee stock plan purchases", "label": "Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Ownership Plan", "documentation": "Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Ownership Plan" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationScheduleCommonStockRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity", "http://www.lantheus.com/role/StockBasedCompensationScheduleCommonStockRepurchasesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r22", "r153", "r154", "r200", "r706", "r765", "r781" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity", "http://www.lantheus.com/role/StockBasedCompensationScheduleCommonStockRepurchasesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "terseLabel": "Repurchase of common stock", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r22", "r153", "r154", "r200", "r709", "r765", "r781", "r856" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveLossDetails", "http://www.lantheus.com/role/ConsolidatedBalanceSheets", "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r154", "r157", "r158", "r181", "r727", "r743", "r766", "r767", "r842", "r857", "r951", "r960", "r1000", "r1020" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "lnth_StrategicPartnershipsAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "StrategicPartnershipsAndOtherMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic Partnerships and other revenue", "label": "Strategic Partnerships And Other [Member]", "documentation": "Strategic Partnerships And Other" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r629", "r654" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r629", "r654" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r629", "r654" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r629", "r654" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.lantheus.com/role/SubsequentEventDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r629", "r654" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.lantheus.com/role/SubsequentEvent" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r653", "r655" ] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Company's Changes in Uncertain Tax Positions", "label": "Summary of Income Tax Contingencies [Table Text Block]", "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r19", "r206", "r207" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r910" ] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/PropertyPlantEquipmentNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash impairment", "label": "Tangible Asset Impairment Charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r138", "r190" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credits", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r97" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r96" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r96" ] }, "lnth_TaxIndemnificationAgreementIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "TaxIndemnificationAgreementIncomeExpense", "crdr": "credit", "calculation": { "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleOfOtherLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax indemnification expense, net", "negatedLabel": "Indemnification expense", "label": "Tax Indemnification Agreement, Income (Expense)", "documentation": "Represents the tax indemnification income (loss) earned during the period." } } }, "auth_ref": [] }, "lnth_TechneLiteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "TechneLiteMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails", "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesScheduleofProductConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TechneLite", "label": "Techne Lite [Member]", "documentation": "Techne Lite [Member]" } } }, "auth_ref": [] }, "lnth_TotalPrecisionDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "TotalPrecisionDiagnosticsMember", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total precision diagnostics", "label": "Total Precision Diagnostics [Member]", "documentation": "Total Precision Diagnostics" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r902" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r909" ] }, "lnth_TotalStockholderReturnRestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "TotalStockholderReturnRestrictedStockAwardsMember", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationRestrictedStockandTSRNarrativeDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTSRAwardActivityDetails", "http://www.lantheus.com/role/StockBasedCompensationScheduleofTotalStockholderReturnRestrictedAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Stockholder Return Restricted Stock Awards", "label": "Total Stockholder Return Restricted Stock Awards [Member]", "documentation": "Total Stockholder Return Restricted Stock Awards [Member]" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, net", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r225", "r226", "r227", "r375", "r376", "r377" ] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksMember", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetandGoodwillScheduleofIntangiblesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r102" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r930" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r932" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r933" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r934" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r932" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r932" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r935" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r933" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r89" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.lantheus.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r89" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.lantheus.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury Stock at cost - 1,339 shares as of December 31, 2023 and 2022", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r48", "r89", "r90" ] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails_1": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsScheduleofMinimumPaymentsMaturitiesofPrincipalObligationsUnderTermFacilityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r929" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.lantheus.com/role/IncomeTaxesReconciliationofUncertainTaxPositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncertain tax positions", "periodStartLabel": "Beginning balance of uncertain tax positions", "periodEndLabel": "Ending balance of uncertain tax positions", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r550", "r559" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesReconciliationofUncertainTaxPositionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reductions related to prior year tax positions", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r560" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesReconciliationofUncertainTaxPositionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlements", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r562" ] }, "lnth_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.lantheus.com/20231231", "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total liabilities for uncertain tax positions including interest and penalties", "label": "Unrecognized Tax Benefits, Including Interest And Penalties", "documentation": "Unrecognized Tax Benefits, Including Interest And Penalties" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Penalty accruals", "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued", "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return." } } }, "auth_ref": [ "r985" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesReconciliationofUncertainTaxPositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions related to current year tax positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r561" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest accruals", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "documentation": "Amount of interest expense accrued for an underpayment of income taxes." } } }, "auth_ref": [ "r985" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesReconciliationofUncertainTaxPositionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Lapse of statute of limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r563" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r71", "r72", "r73", "r233", "r234", "r237", "r238" ] }, "us-gaap_ValuationAllowancesAndReservesAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesAdjustments", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfRebatesandAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments relating to prior period revenues", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment", "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment." } } }, "auth_ref": [ "r954" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfRebatesandAllowancesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r309", "r312" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfRebatesandAllowancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision related to current period revenues", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": [ "r310" ] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersScheduleOfRebatesandAllowancesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments or credits made during the period", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability adjusted discounted cash flow model", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r999" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsScheduleofQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r24" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "verboseLabel": "Diluted weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r329", "r340" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations", "http://www.lantheus.com/role/NetIncomeLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Basic weighted-average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r327", "r340" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.lantheus.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average common shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(13)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r227": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "20", "Topic": "410", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "(m)", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//410-20/tableOfContent" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481999/410-20-25-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481879/410-20-45-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-4A" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-31" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-32" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-13" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 136 0001628280-24-006158-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-006158-xbrl.zip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�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�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end XML 137 lnth-20231231_htm.xml IDEA: XBRL DOCUMENT 0001521036 2023-01-01 2023-12-31 0001521036 2023-06-30 0001521036 2024-02-15 0001521036 2023-12-31 0001521036 2022-12-31 0001521036 2022-01-01 2022-12-31 0001521036 2021-01-01 2021-12-31 0001521036 us-gaap:CommonStockMember 2020-12-31 0001521036 us-gaap:TreasuryStockCommonMember 2020-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001521036 us-gaap:RetainedEarningsMember 2020-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001521036 2020-12-31 0001521036 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001521036 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001521036 us-gaap:CommonStockMember 2021-12-31 0001521036 us-gaap:TreasuryStockCommonMember 2021-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001521036 us-gaap:RetainedEarningsMember 2021-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001521036 2021-12-31 0001521036 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001521036 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001521036 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001521036 us-gaap:CommonStockMember 2022-12-31 0001521036 us-gaap:TreasuryStockCommonMember 2022-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001521036 us-gaap:RetainedEarningsMember 2022-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001521036 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001521036 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001521036 us-gaap:CommonStockMember 2023-12-31 0001521036 us-gaap:TreasuryStockCommonMember 2023-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001521036 us-gaap:RetainedEarningsMember 2023-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001521036 2020-02-20 2020-02-20 0001521036 lnth:ProgenicsMember 2020-02-20 2020-02-20 0001521036 lnth:ProgenicsMember lnth:CashPayments2022Member 2020-02-20 0001521036 lnth:ProgenicsMember lnth:CashPayments2023Member 2020-02-20 0001521036 lnth:ConvertibleSeniorNotes2625PercentDue2027Member us-gaap:SeniorNotesMember 2023-12-31 0001521036 lnth:PYLARIFYMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001521036 lnth:PYLARIFYMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0001521036 lnth:PYLARIFYMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0001521036 lnth:DefinityMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001521036 lnth:DefinityMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0001521036 lnth:DefinityMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0001521036 lnth:TechneLiteMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001521036 lnth:TechneLiteMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0001521036 lnth:TechneLiteMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0001521036 srt:MinimumMember us-gaap:BuildingMember 2023-12-31 0001521036 srt:MaximumMember us-gaap:BuildingMember 2023-12-31 0001521036 srt:MinimumMember us-gaap:LandImprovementsMember 2023-12-31 0001521036 srt:MaximumMember us-gaap:LandImprovementsMember 2023-12-31 0001521036 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0001521036 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0001521036 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001521036 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001521036 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001521036 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001521036 2021-01-01 2021-03-31 0001521036 us-gaap:ConvertibleDebtMember 2023-12-31 0001521036 us-gaap:ProductMember 2023-01-01 2023-12-31 0001521036 us-gaap:ProductMember 2022-01-01 2022-12-31 0001521036 us-gaap:ProductMember 2021-01-01 2021-12-31 0001521036 lnth:LicenseandRoyaltyRevenuesMember 2023-01-01 2023-12-31 0001521036 lnth:LicenseandRoyaltyRevenuesMember 2022-01-01 2022-12-31 0001521036 lnth:LicenseandRoyaltyRevenuesMember 2021-01-01 2021-12-31 0001521036 2022-01-01 2022-03-31 0001521036 lnth:LicenseAndRoyaltyRevenuesSalesBasedMilestonePaymentMember 2023-10-01 2023-12-31 0001521036 lnth:PYLARIFYMember 2023-01-01 2023-12-31 0001521036 lnth:PYLARIFYMember 2022-01-01 2022-12-31 0001521036 lnth:PYLARIFYMember 2021-01-01 2021-12-31 0001521036 lnth:OtherRadiopharmaceuticalOncologyMember 2023-01-01 2023-12-31 0001521036 lnth:OtherRadiopharmaceuticalOncologyMember 2022-01-01 2022-12-31 0001521036 lnth:OtherRadiopharmaceuticalOncologyMember 2021-01-01 2021-12-31 0001521036 lnth:RadiopharmaceuticalOncologyMember 2023-01-01 2023-12-31 0001521036 lnth:RadiopharmaceuticalOncologyMember 2022-01-01 2022-12-31 0001521036 lnth:RadiopharmaceuticalOncologyMember 2021-01-01 2021-12-31 0001521036 lnth:DefinityMember 2023-01-01 2023-12-31 0001521036 lnth:DefinityMember 2022-01-01 2022-12-31 0001521036 lnth:DefinityMember 2021-01-01 2021-12-31 0001521036 lnth:TechneLiteMember 2023-01-01 2023-12-31 0001521036 lnth:TechneLiteMember 2022-01-01 2022-12-31 0001521036 lnth:TechneLiteMember 2021-01-01 2021-12-31 0001521036 lnth:OtherPrecisionDiagnosticsMember 2023-01-01 2023-12-31 0001521036 lnth:OtherPrecisionDiagnosticsMember 2022-01-01 2022-12-31 0001521036 lnth:OtherPrecisionDiagnosticsMember 2021-01-01 2021-12-31 0001521036 lnth:TotalPrecisionDiagnosticsMember 2023-01-01 2023-12-31 0001521036 lnth:TotalPrecisionDiagnosticsMember 2022-01-01 2022-12-31 0001521036 lnth:TotalPrecisionDiagnosticsMember 2021-01-01 2021-12-31 0001521036 lnth:StrategicPartnershipsAndOtherMember 2023-01-01 2023-12-31 0001521036 lnth:StrategicPartnershipsAndOtherMember 2022-01-01 2022-12-31 0001521036 lnth:StrategicPartnershipsAndOtherMember 2021-01-01 2021-12-31 0001521036 us-gaap:MoneyMarketFundsMember 2023-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001521036 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001521036 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001521036 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001521036 us-gaap:MoneyMarketFundsMember 2022-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001521036 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001521036 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001521036 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001521036 us-gaap:RoyaltyMember lnth:ProgenicsMember 2022-01-01 2022-12-31 0001521036 lnth:ProgenicsMember 2022-01-01 2022-12-31 0001521036 lnth:ProgenicsMember lnth:NetSalesTargetsForAzedraMember 2023-12-31 0001521036 lnth:ProgenicsMember lnth:A1095CommercializationMember 2023-12-31 0001521036 lnth:ProgenicsMember lnth:A1404CommercializationMilestoneMember 2023-12-31 0001521036 lnth:ProgenicsMember 2023-12-31 0001521036 lnth:ContingentValueRightMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001521036 lnth:ContingentValueRightMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-12-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-12-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0001521036 lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001521036 lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001521036 srt:MinimumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember lnth:MonteCarloSimulationMember 2023-12-31 0001521036 srt:MaximumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember lnth:MonteCarloSimulationMember 2023-12-31 0001521036 srt:MinimumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember lnth:MonteCarloSimulationMember 2022-12-31 0001521036 srt:MaximumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember lnth:MonteCarloSimulationMember 2022-12-31 0001521036 lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:MonteCarloSimulationMember 2023-12-31 0001521036 srt:MinimumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:MonteCarloSimulationMember 2022-12-31 0001521036 srt:MaximumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:MonteCarloSimulationMember 2022-12-31 0001521036 us-gaap:DomesticCountryMember 2023-12-31 0001521036 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001521036 stpr:MA us-gaap:InvestmentCreditMember 2023-12-31 0001521036 lnth:LiabilitiesCurrentMember 2023-12-31 0001521036 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0001521036 lnth:DeferredIncomeTaxAssetsNetMember 2023-12-31 0001521036 us-gaap:LandMember 2023-12-31 0001521036 us-gaap:LandMember 2022-12-31 0001521036 us-gaap:BuildingMember 2023-12-31 0001521036 us-gaap:BuildingMember 2022-12-31 0001521036 lnth:MachineryEquipmentAndFixturesMember 2023-12-31 0001521036 lnth:MachineryEquipmentAndFixturesMember 2022-12-31 0001521036 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001521036 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-12-31 0001521036 us-gaap:ConstructionInProgressMember 2023-12-31 0001521036 us-gaap:ConstructionInProgressMember 2022-12-31 0001521036 2023-01-01 2023-06-30 0001521036 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2023-03-31 0001521036 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember lnth:PuertoRicanRadiopharmacyServicingSubsidiaryMember 2021-01-29 0001521036 lnth:PuertoRicanRadiopharmacyServicingSubsidiaryMember 2021-01-01 2021-12-31 0001521036 srt:MinimumMember us-gaap:TrademarksMember 2023-12-31 0001521036 srt:MaximumMember us-gaap:TrademarksMember 2023-12-31 0001521036 us-gaap:TrademarksMember 2023-12-31 0001521036 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0001521036 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0001521036 us-gaap:CustomerRelationshipsMember 2023-12-31 0001521036 srt:MinimumMember lnth:CurrentlyMarketedProductMember 2023-12-31 0001521036 srt:MaximumMember lnth:CurrentlyMarketedProductMember 2023-12-31 0001521036 lnth:CurrentlyMarketedProductMember 2023-12-31 0001521036 srt:MinimumMember us-gaap:LicensingAgreementsMember 2023-12-31 0001521036 srt:MaximumMember us-gaap:LicensingAgreementsMember 2023-12-31 0001521036 us-gaap:LicensingAgreementsMember 2023-12-31 0001521036 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001521036 srt:MinimumMember us-gaap:TrademarksMember 2022-12-31 0001521036 srt:MaximumMember us-gaap:TrademarksMember 2022-12-31 0001521036 us-gaap:TrademarksMember 2022-12-31 0001521036 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2022-12-31 0001521036 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2022-12-31 0001521036 us-gaap:CustomerRelationshipsMember 2022-12-31 0001521036 srt:MinimumMember lnth:CurrentlyMarketedProductMember 2022-12-31 0001521036 srt:MaximumMember lnth:CurrentlyMarketedProductMember 2022-12-31 0001521036 lnth:CurrentlyMarketedProductMember 2022-12-31 0001521036 srt:MinimumMember us-gaap:LicensingAgreementsMember 2022-12-31 0001521036 srt:MaximumMember us-gaap:LicensingAgreementsMember 2022-12-31 0001521036 us-gaap:LicensingAgreementsMember 2022-12-31 0001521036 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0001521036 lnth:CurrentlyMarketedProductMember 2021-05-01 2021-05-31 0001521036 lnth:IPRDMember 2021-05-01 2021-05-31 0001521036 2023-08-02 2023-08-02 0001521036 us-gaap:LicensingAgreementsMember 2023-08-02 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001521036 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001521036 lnth:CerveauTechnologiesIncMember 2023-02-01 2023-02-28 0001521036 lnth:CerveauTechnologiesIncMember 2023-05-01 2023-05-31 0001521036 lnth:A2019TermLoanFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001521036 lnth:A2019TermLoanFacilityMember us-gaap:LineOfCreditMember 2022-12-01 2022-12-31 0001521036 lnth:A2019RevolvingFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001521036 lnth:A2019RevolvingFacilityMember us-gaap:LineOfCreditMember 2022-12-01 2022-12-31 0001521036 lnth:A2022TermFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001521036 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001521036 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-01 2022-12-31 0001521036 lnth:A2019TermLoanFacilityMember us-gaap:LineOfCreditMember 2022-01-01 2022-09-30 0001521036 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-12-31 0001521036 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2023-12-31 0001521036 us-gaap:BridgeLoanMember us-gaap:LineOfCreditMember 2023-12-31 0001521036 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001521036 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001521036 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2023-01-01 2023-12-31 0001521036 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2023-01-01 2023-12-31 0001521036 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember lnth:NetLeverageRatioMember 2023-01-01 2023-12-31 0001521036 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember lnth:NetLeverageRatioMember 2023-01-01 2023-12-31 0001521036 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-12-31 0001521036 lnth:A2022FacilityCovenantsMember lnth:Q12024Member 2023-01-01 2023-12-31 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2022-12-08 0001521036 us-gaap:ConvertibleDebtMember 2022-12-08 2022-12-08 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2022-12-08 2022-12-08 0001521036 srt:MinimumMember lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2023-12-31 0001521036 srt:MaximumMember lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2023-12-31 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2023-12-31 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2022-12-05 2022-12-05 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2022-12-08 2022-12-31 0001521036 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-31 0001521036 us-gaap:InterestRateSwapMember 2022-12-02 2022-12-02 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-12-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-12-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0001521036 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001521036 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001521036 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001521036 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001521036 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001521036 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001521036 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001521036 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001521036 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001521036 us-gaap:RestrictedStockMember 2023-12-31 0001521036 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001521036 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001521036 lnth:TotalStockholderReturnRestrictedStockAwardsMember 2023-01-01 2023-12-31 0001521036 srt:MinimumMember lnth:TotalStockholderReturnRestrictedStockAwardsMember 2023-01-01 2023-12-31 0001521036 srt:MaximumMember lnth:TotalStockholderReturnRestrictedStockAwardsMember 2023-01-01 2023-12-31 0001521036 lnth:TotalStockholderReturnRestrictedStockAwardsMember 2022-01-01 2022-12-31 0001521036 lnth:TotalStockholderReturnRestrictedStockAwardsMember 2021-01-01 2021-12-31 0001521036 lnth:TotalStockholderReturnRestrictedStockAwardsMember 2022-12-31 0001521036 lnth:TotalStockholderReturnRestrictedStockAwardsMember 2023-12-31 0001521036 2022-12-01 2022-12-31 0001521036 lnth:NewYorkCityMember 2020-06-19 0001521036 lnth:SomersetNewJerseyMember 2020-06-19 0001521036 lnth:SomersetNewJerseyMember 2021-10-31 0001521036 lnth:BedfordMassachusettsMember 2022-12-31 0001521036 lnth:BedfordMassachusettsMember 2022-02-28 0001521036 lnth:BedfordMassachusettsMember 2023-05-31 0001521036 lnth:BedfordMassachusettsMember 2023-09-01 0001521036 2021-09-30 0001521036 lnth:BedfordMassachusettsMember 2023-12-31 0001521036 lnth:CerveauTechnologiesIncMember lnth:SalesMilestonesMember 2023-02-01 2023-02-28 0001521036 lnth:CerveauTechnologiesIncMember lnth:ResearchRevenueMilestonesMember 2023-02-01 2023-02-28 0001521036 lnth:POINTBiopharmaMember 2022-12-01 2022-12-31 0001521036 lnth:PNT2002LicenseAgreementMember 2022-12-01 2022-12-31 0001521036 lnth:PNT2002LicenseAgreementMember lnth:RegulatoryMilestonesMember 2022-12-01 2022-12-31 0001521036 lnth:PNT2002LicenseAgreementMember lnth:SalesMilestonesMember 2022-12-01 2022-12-31 0001521036 lnth:PNT2003LicenseAgreementMember 2022-12-01 2022-12-31 0001521036 lnth:PNT2003LicenseAgreementMember lnth:RegulatoryMilestonesMember 2022-12-01 2022-12-31 0001521036 lnth:PNT2003LicenseAgreementMember lnth:SalesMilestonesMember 2022-12-01 2022-12-31 0001521036 lnth:POINTBiopharmaMember 2022-01-01 2022-12-31 0001521036 lnth:PerspectiveTherapeuticsIncMember us-gaap:LicensingAgreementsMember us-gaap:SubsequentEventMember 2024-01-09 2024-01-09 0001521036 lnth:PerspectiveTherapeuticsIncMember us-gaap:SubsequentEventMember 2024-01-09 0001521036 lnth:PerspectiveTherapeuticsIncMember us-gaap:SubsequentEventMember 2024-01-09 2024-01-09 0001521036 2023-10-01 2023-12-31 0001521036 lnth:SamLenoMember 2023-01-01 2023-12-31 0001521036 lnth:SamLenoMember 2023-10-01 2023-12-31 0001521036 lnth:SamLenoMember 2023-12-31 0001521036 lnth:SamLenoMember lnth:Amended10b51PlanMember 2023-10-01 2023-12-31 0001521036 lnth:SamLenoMember lnth:Amended10b51PlanMember 2023-12-31 iso4217:USD shares iso4217:USD shares pure lnth:productCategory lnth:financial_covenant lnth:lease lnth:Segment false 2023 FY 0001521036 http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold 0.0125291 0.0178539 http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#LongTermDebtCurrent http://fasb.org/us-gaap/2023#LongTermDebtCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations P15Y3M29D P72D P72D 10-K true 2023-12-31 --12-31 false 001-36569 LANTHEUS HOLDINGS, INC. DE 35-2318913 201 Burlington Road, South Building Bedford MA 01730 978 671-8001 Common Stock, $0.01 par value per share LNTH NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 5672500000 68525556 <div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Listed hereunder are the documents, portions of which are incorporated by reference, and the parts of this Form 10-K into which such portions are incorporated:</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Registrant’s Definitive Proxy Statement for use in connection with the Annual Meeting of Stockholders to be held on April 25, 2024, portions of which are incorporated by reference into Parts II and III of this Form 10-K. The 2024 Proxy Statement will be filed with the Securities and Exchange Commission no later than 120 days after the close of our year ended December 31, 2023.</span> 34 Deloitte & Touche LLP Boston, Massachusetts 713656000 415652000 284292000 213397000 64029000 35475000 16683000 13092000 7159000 0 1085819000 677616000 146697000 122166000 151985000 315285000 61189000 61189000 150198000 110647000 55261000 34355000 1651149000 1321258000 823000 354000 41189000 20563000 0 99700000 145338000 127084000 187350000 247701000 22916000 22543000 561670000 557712000 63321000 46155000 835257000 874111000 0.01 0.01 25000000 25000000 0 0 0 0 0 0 0.01 0.01 250000000 250000000 69863000 69863000 68851000 68851000 699000 689000 757727000 715875000 1339000 1339000 75000000 75000000 133503000 -193158000 -1037000 -1259000 815892000 447147000 1651149000 1321258000 1296429000 935061000 425208000 586886000 353358000 237513000 709543000 581703000 187695000 141736000 100243000 68422000 125458000 133584000 150395000 77707000 311681000 44966000 344901000 545508000 263783000 0 0 15263000 364642000 36195000 -60825000 20019000 7185000 7752000 0 -588000 889000 66320000 -1703000 -7350000 410943000 26719000 -75038000 84282000 -1348000 -3759000 326661000 28067000 -71279000 4.79 0.41 -1.06 4.65 0.40 -1.06 68266000 68487000 67486000 70239000 70671000 67486000 326661000 28067000 -71279000 222000 -505000 -124000 0 -269000 0 0 0 1687000 222000 -774000 1563000 326883000 27293000 -69716000 66875000 669000 0 0 665530000 -149946000 -2048000 514205000 -71279000 -71279000 1563000 1563000 360000 3000 6059000 6062000 611000 6000 -6000 0 107000 1000 2045000 2046000 15934000 15934000 67739000 677000 0 0 685472000 -221225000 -485000 464439000 28067000 28067000 -774000 -774000 411000 4000 8908000 8912000 845000 9000 -9000 0 144000 1000 7758000 7759000 -1339000 75000000 75000000 29262000 29262000 68851000 689000 1339000 -75000000 715875000 -193158000 -1259000 447147000 326661000 326661000 222000 222000 245000 2000 5747000 5749000 962000 10000 -10000 0 195000 2000 14392000 14394000 50507000 50507000 69863000 699000 1339000 -75000000 757727000 133503000 -1037000 815892000 326661000 28067000 -71279000 60043000 47929000 42288000 138050000 0 9729000 0 280000 5259000 0 5494000 0 4300000 1249000 676000 -9275000 34700000 72400000 0 -260000000 0 0 -588000 889000 7914000 7145000 4057000 50507000 29262000 15934000 51789000 0 15263000 -55632000 -48016000 4437000 -3929000 -9554000 -7121000 -3103000 -12477000 -7912000 -4855000 -4059000 -2512000 68637000 128460000 33102000 36220000 7508000 3549000 2418000 2440000 73000 0 533000 0 17189000 301000 5425000 -81114000 63575000 16145000 305260000 281781000 53916000 46555000 18347000 12140000 97839000 1800000 15823000 45345000 260000000 0 5939000 -276547000 3683000 1933000 1375000 767000 0 95000 0 0 557750000 0 3700000 0 0 717000 175385000 43348000 0 2315000 0 0 5583000 0 3816000 7537000 5295000 14394000 7759000 2046000 0 75000000 0 -13062000 311691000 -39332000 -93000 -335000 -310000 298044000 316590000 17957000 417241000 100651000 82694000 715285000 417241000 100651000 713656000 415652000 98508000 1629000 1589000 2143000 715285000 417241000 100651000 15387000 5064000 6284000 25000 50000 315000 151579000 54049000 215000 6978000 2370000 1262000 29396000 29396000 11019000 11019000 683000 Description of Business<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lantheus Holdings, Inc., a Delaware corporation, is the parent company of Lantheus Medical Imaging, Inc. (“LMI”) and LMI is the parent company of Progenics Pharmaceuticals, Inc., a Delaware corporation (“Progenics”), and Cerveau Technologies, Inc. (“Cerveau”). See “Progenics Acquisition” and “Acquisition of Assets”, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops, manufactures and commercializes innovative diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of cancer, heart disease and other diseases. The Company believes its diagnostic products result in improved diagnostic information that enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs throughout the healthcare system.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s commercial products are used by cardiologists, internal medicine physicians, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company produces and markets its products throughout the U.S., selling primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies. The Company sells its products outside the U.S. through a combination of direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company’s prostate cancer diagnostic imaging agent, PYLARIFY (as defined below), are generated in the U.S. through an internal PYLARIFY sales team, as well as a sales team at some of the Company’s positron emission tomography (“PET”) manufacturing facilities (“PMF”) partners. Sales of the Company’s ultrasound enhancing agent, DEFINITY, are generated in the U.S. through an internal DEFINITY sales team. In the U.S., the Company’s other nuclear imaging products, including TechneLite, Xenon, NEUROLITE and CARDIOLITE, are primarily sold to commercial radiopharmacies, the majority of which are controlled by or associated with PharmaLogic, Cardinal, RLS, UPPI, and Jubilant Radiopharma. Research revenue is derived from existing partnerships with pharmaceutical companies that use our products and product candidates in clinical trials and includes milestone and dose-related payments. A small portion of the Company’s nuclear imaging product sales in the U.S. are generated through the Company’s internal sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical preparation capabilities. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Australia, Asia-Pacific, Central America and South America, the Company generally relies on third-party distributors to market, sell and distribute its nuclear imaging and ultrasound enhancing agent products, either on a country-by-country basis or on a multi-country regional basis. The Company’s executive offices are located in Bedford, MA, with additional offices in North Billerica, MA, Somerset, NJ, Montreal, Canada and Lund, Sweden.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Progenics Acquisition</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”).</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Progenics Acquisition, Lantheus Holdings issued 26,844,877 shares of Lantheus Holdings common stock and 86,630,633 contingent value rights (each a “CVR”) tied to the financial performance of PYLARIFY to former Progenics stockholders and option holders. Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of United States (“U.S.”) net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. The Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, was capped at 19.9% of the total consideration the Company paid in the Progenics Acquisition. Based on the Company’s 2022 PYLARIFY net sales, the Company determined that the aggregate payment obligation under the CVRs was $99.6 million, which was the maximum amount payable. The Company paid out this amount in May 2023 in full satisfaction of the CVRs.</span></div> 26844877 86630633 0.40 100000000 150000000 0.199 99600000 Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, contingent assets and liabilities, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services. See Note 3, “Revenue from Contracts with Customers” for further discussion on revenues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of amounts billed and currently due from customers. The Company maintains an allowance for doubtful accounts for estimated losses. In determining the allowance, consideration includes the probability of recoverability based on past experience and general economic factors. Certain accounts receivable may be fully reserved when the Company becomes aware of any specific collection issues. The Company periodically reviews the aging of receivables, payment history and customer creditworthiness to determine if adjustments to the allowance for doubtful accounts is necessary. Allowance for doubtful accounts has been immaterial for all years presented. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using an asset and liability approach. Income tax (benefit) expense represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when such changes are enacted.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more-likely-than-not to be realized. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that the future tax benefit will not be realized. The assessment of whether or not a valuation allowance is required involves weighing both positive and negative evidence, including both historical and prospective information, with greater weight given to evidence that is objectively verifiable. A history of recent losses is negative evidence that is difficult to overcome with positive evidence. In evaluating prospective information there are four sources of taxable income: reversals of taxable temporary differences, items that can be carried back to prior tax years (such as net operating losses), pre-tax income, and prudent and feasible tax planning strategies. Adjustments to the deferred tax valuation allowances are made in the period when those assessments are made.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a two-step recognition threshold and measurement analysis method to determine the financial statement impact of uncertain tax positions taken or expected to be taken in a tax return. Differences between tax positions taken in a tax return and amounts recognized in the financial statements are recorded as adjustments to other long-term assets and liabilities, or adjustments to deferred taxes, or both. The Company records the related interest and penalties to income tax (benefit) expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) per Common Share</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes earnings per share using the two-class method. Basic earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities as if those securities were converted or exercised. The Company’s potentially dilutive shares, which could include shares issuable upon conversion of the 2.625% Convertible Senior Notes due 2027 (the “Notes”), are considered to be common stock equivalents and are only included in the calculation of diluted net income per share when their effect is dilutive. The Company has the option to settle the Notes through cash settlement or a combination of cash and share settlement provided that the principal is settled in cash and the conversion spread is settled in cash or shares as elected by the Company. The Company applies the if-converted method for diluted earnings in order to reflect the conversion spread. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include savings deposits, certificates of deposit and money market funds that have original maturities of three months or less when purchased.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash as of December 31, 2023 and 2022, represents primarily collateral for a letter of credit securing a lease obligation and a security deposit. The Company believes the carrying value of these assets approximates fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks and Limited Suppliers</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, no customer accounted for greater than 10% of accounts receivable, net. No customer accounted for greater than 10% of revenues for the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently relies on JHS as its significant manufacturer of DEFINITY and its sole source manufacturer of NEUROLITE, CARDIOLITE and evacuation vials for TechneLite. The Company relies on Samsung Biologics Co., Ltd. (“SBL”) as its sole source manufacturer of DEFINITY RT. The Company has Mo-99 supply agreements with IRE of Belgium, running through December 31, 2024, with auto-renewal provisions and terminable upon notice of non-renewal, and with NTP and its subcontractor ANSTO, running through December 31, 2024.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.555%"><tr><td style="width:1.0%"></td><td style="width:36.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PYLARIFY</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEFINITY</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TechneLite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory includes material, direct labor and related manufacturing overhead and is stated at the lower of cost and net realizable value on a first-in, first-out basis. The Company records inventory when the Company takes title to the product.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of inventory to determine whether adjustments for excess and obsolete inventory are required. Inventory that is in excess of future requirements is written down to its estimated net realizable value based on product shelf life, forecasted demand and other factors.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed as incurred. The Company had no inventory pending regulatory approval as of December 31, 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, net</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant &amp; equipment are stated at cost. Replacements of major units of property are capitalized, and replaced properties are retired. Replacements of minor components of property and repair and maintenance costs are charged to expense as incurred. Certain costs to obtain or develop computer software are capitalized and amortized over the estimated useful life of the software. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets and recorded </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in costs of goods sold and operating expenses in the associated functional expense category which utilizes the associated asset. The estimated useful lives of the major classes of depreciable assets are as follows:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.500%"><tr><td style="width:1.0%"></td><td style="width:46.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of lease term or 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or other disposal of property, plant &amp; equipment, the cost and related amount of accumulated depreciation are removed from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds is included in operating income.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within machinery and equipment are spare parts. Spare parts include replacement parts relating to plant &amp; equipment and are either recognized as an expense when consumed or reclassified and capitalized as part of the related asset and depreciated over the remaining useful life of the related asset. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired IPR&amp;D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely-than-not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the Company’s annual assessment, the Company is permitted to first perform a qualitative test and if necessary, perform a quantitative test. If the Company is required to perform the quantitative impairment test of goodwill, the Company compares the fair value of a reporting unit to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting units using discounted cash flow or other valuation models, such as comparative transactions and market multiples. The Company performed a qualitative assessment and did not recognize any goodwill impairment charges during the years ended December 31, 2023, 2022 or 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible and Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests intangible and long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. The Company measures the recoverability of assets to be held and used by comparing the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If those assets are considered to be impaired, the impairment equals the amount by which the carrying amount of the assets exceeds the fair value of the assets. Any impairments are recorded as permanent reductions in the carrying amount of the assets. See Note 7, “Property, Plant and Equipment, Net” for further details on impairment. Long-lived assets, other than goodwill and other intangible assets that are held for sale are recorded at the lower of the carrying value or the fair market value less the estimated cost to sell.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, consisting of patents, trademarks, customer relationships, a currently marketed product, licenses and developed technology related to the Company’s products are amortized in a method equivalent to the estimated utilization of the economic benefit of the asset.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of IPR&amp;D intangible assets acquired as part of an asset acquisition that have no alternative future use are expensed when incurred. Milestone payments made after regulatory approval are capitalized as an intangible asset and amortized over an estimated useful life of the product. Cash payments related to acquired IPR&amp;D intangible assets are reflected as an investing cash flow in the Company's consolidated statement of cash flows.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s IPR&amp;D intangible assets includes intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. Because obtaining regulatory approval can include significant risks and uncertainties, the eventual realized value of the acquired IPR&amp;D projects may vary from their fair value at the date of acquisition. The Company classifies IPR&amp;D intangible assets acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, the Company will determine the useful life and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, the Company writes-off the remaining carrying amount of the associated IPR&amp;D intangible asset. IPR&amp;D intangible assets are tested at least annually as of October 31 or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in the Company’s consolidated statements of operations. See Note 10, “Intangibles, net and Goodwill” for further details on impairment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, product and environmental liability. The Company records accruals for those loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The change in fair value of any separately recognized derivative is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Values of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The Company’s long-term debt has triggering events that would impact the fair value of the instruments. The Company determined that no triggering event has occurred during the years ended December 31, 2023 and December 31, 2022. As of December 31, 2023, the fair value of the Company’s convertible debt was estimated to be approximately $644.3 million based on external pricing data, including quoted market prices of these instruments and was classified as a Level 1 measurement within the fair value hierarchy. As of December 31, 2022, the carrying value of the Company’s convertible debt approximated fair value and was classified as a Level 1 measurement within the fair value hierarchy. The fair value See Note 4, “Fair Value of Financial Instruments”.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of contingent consideration liabilities are initially measured and recorded on the acquisition date, are considered to be a Level 3 instrument and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value is determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that include significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based milestones, development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged. Further, the Company must formally document the hedging relationship at inception and, on at least a quarterly basis, continually reevaluate the relationship to ensure it remains highly effective throughout the life of the hedge. The Company does not enter into derivative financial instruments for speculative or trading purposes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Promotion Costs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising and promotion costs are expensed as incurred. During the years ended December 31, 2023, 2022 and 2021, the Company incurred $26.0 million, $26.0 million and $17.5 million, respectively in advertising and promotion costs, which are included in sales and marketing in the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and relate primarily to the development of new products to add to the Company’s portfolio and costs related to its medical affairs and medical information functions. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and recognized as an expense as the goods are delivered or the related services are performed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of operations of the Company’s foreign subsidiaries are translated into U.S. Dollars using weighted-average exchange rates. The net assets of the Company’s foreign subsidiaries are translated into U.S. Dollars using the end of period exchange rates. The impact from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive loss in the consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of the Company’s foreign currency denominated transactions are included in net income. Transaction gains and losses are reported as a component of other loss (income) in the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s stock-based compensation cost is measured at the grant date of the stock-based award based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period, and includes an estimate of the awards that will be forfeited. The Company estimates the fair value of each stock-based award on its measurement date using either the current market price of the stock, the Black-Scholes option valuation model or the Monte Carlo simulation valuation model, whichever is most appropriate. The Black-Scholes and Monte Carlo simulation valuation models incorporate assumptions such as stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on the historical volatility of the Company’s stock price. The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the awards’ expected lives. Expected lives are principally based on the Company’s historical exercise experience with previously issued awards. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense for performance restricted stock awards is recognized based upon the fair value of the awards on the date of grant and the number of shares expected to vest based on the terms of the underlying award agreement and the requisite service period(s).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Loss (Income)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other loss (income) consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.500%"><tr><td style="width:1.0%"></td><td style="width:50.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.493%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax indemnification expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap termination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (income) loss </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,320)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net income. For the Company, other comprehensive income (loss) consists of foreign currency translation gains and losses as well as realized and unrealized gains and losses on cash flow hedges related to the Company’s interest rate swaps. The accumulated other comprehensive income (loss) balance consists entirely of foreign currency translation gains and losses and realized and unrealized gains and losses on outstanding cash flow hedges related to the Company’s interest rate swaps.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Retirement Obligations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s compliance with federal, state, local and foreign environmental laws and regulations may require it to remove or mitigate the effects of the disposal or release of chemical substances in jurisdictions where it does business or maintains properties. The Company establishes accruals when those costs are legally obligated and can be reasonably estimated. Accrual amounts are estimated, which may include the assistance of third-party environmental specialists, and are based on currently available information, regulatory requirements, remediation strategies, historical experience, the relative shares of the total remediation costs, a relevant discount rate, and the time periods of when estimated costs can be reasonably predicted. Changes in these assumptions could impact the Company’s future reported results.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts campus and its Somerset, New Jersey site. The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. The liability is measured at the present value of the obligation expected to be incurred and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the assets’ useful lives.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified conditional asset retirement obligations related to the future removal and disposal of asbestos contained in certain of the buildings located on the Company’s North Billerica, Massachusetts campus. The Company believes the asbestos is appropriately contained and it is compliant with all applicable environmental regulations. If these properties undergo major renovations or are demolished, certain environmental regulations are in place, which specify the manner in which asbestos must be handled and disposed. The Company is required to record the fair value of these conditional liabilities if they can be reasonably estimated. As of December 31, 2023 and 2022, sufficient information was not available to estimate a liability for such conditional asset retirement obligations as the obligations to remove the asbestos from these properties have indeterminable settlement dates. As such, no liability for conditional asset retirement obligations has been recorded in the accompanying consolidated balance sheets as of December 31, 2023 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance Reserves</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated balance sheets at December 31, 2023 and 2022 include $1.0 million and $0.9 million of accrued liabilities associated with employee medical costs that are retained by the Company, respectively. The Company estimates the required liability of those claims on an undiscounted basis based upon various assumptions which include, but are not limited to, the Company’s historical loss experience and projected loss development factors. The required liability is also subject to adjustment in the future based upon changes in claims experience, including changes in the number of incidents (frequency) and change in the ultimate cost per incident (severity).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company is currently in the process of evaluating the effects of this pronouncement on our related disclosures.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB also issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on our related disclosures.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div>The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, contingent assets and liabilities, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services. See Note 3, “Revenue from Contracts with Customers” for further discussion on revenues.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div>Accounts receivable consist of amounts billed and currently due from customers. The Company maintains an allowance for doubtful accounts for estimated losses. In determining the allowance, consideration includes the probability of recoverability based on past experience and general economic factors. Certain accounts receivable may be fully reserved when the Company becomes aware of any specific collection issues. The Company periodically reviews the aging of receivables, payment history and customer creditworthiness to determine if adjustments to the allowance for doubtful accounts is necessary. Allowance for doubtful accounts has been immaterial for all years presented. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using an asset and liability approach. Income tax (benefit) expense represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when such changes are enacted.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more-likely-than-not to be realized. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that the future tax benefit will not be realized. The assessment of whether or not a valuation allowance is required involves weighing both positive and negative evidence, including both historical and prospective information, with greater weight given to evidence that is objectively verifiable. A history of recent losses is negative evidence that is difficult to overcome with positive evidence. In evaluating prospective information there are four sources of taxable income: reversals of taxable temporary differences, items that can be carried back to prior tax years (such as net operating losses), pre-tax income, and prudent and feasible tax planning strategies. Adjustments to the deferred tax valuation allowances are made in the period when those assessments are made.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a two-step recognition threshold and measurement analysis method to determine the financial statement impact of uncertain tax positions taken or expected to be taken in a tax return. Differences between tax positions taken in a tax return and amounts recognized in the financial statements are recorded as adjustments to other long-term assets and liabilities, or adjustments to deferred taxes, or both. The Company records the related interest and penalties to income tax (benefit) expense.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) per Common Share</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes earnings per share using the two-class method. Basic earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities as if those securities were converted or exercised. The Company’s potentially dilutive shares, which could include shares issuable upon conversion of the 2.625% Convertible Senior Notes due 2027 (the “Notes”), are considered to be common stock equivalents and are only included in the calculation of diluted net income per share when their effect is dilutive. The Company has the option to settle the Notes through cash settlement or a combination of cash and share settlement provided that the principal is settled in cash and the conversion spread is settled in cash or shares as elected by the Company. The Company applies the if-converted method for diluted earnings in order to reflect the conversion spread. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.</span></div> 0.02625 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include savings deposits, certificates of deposit and money market funds that have original maturities of three months or less when purchased.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash as of December 31, 2023 and 2022, represents primarily collateral for a letter of credit securing a lease obligation and a security deposit. The Company believes the carrying value of these assets approximates fair value.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks and Limited Suppliers</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, no customer accounted for greater than 10% of accounts receivable, net. No customer accounted for greater than 10% of revenues for the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently relies on JHS as its significant manufacturer of DEFINITY and its sole source manufacturer of NEUROLITE, CARDIOLITE and evacuation vials for TechneLite. The Company relies on Samsung Biologics Co., Ltd. (“SBL”) as its sole source manufacturer of DEFINITY RT. The Company has Mo-99 supply agreements with IRE of Belgium, running through December 31, 2024, with auto-renewal provisions and terminable upon notice of non-renewal, and with NTP and its subcontractor ANSTO, running through December 31, 2024.</span></div> <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.555%"><tr><td style="width:1.0%"></td><td style="width:36.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PYLARIFY</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEFINITY</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TechneLite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.657 0.564 0.102 0.216 0.262 0.547 0.067 0.095 0.215 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory includes material, direct labor and related manufacturing overhead and is stated at the lower of cost and net realizable value on a first-in, first-out basis. The Company records inventory when the Company takes title to the product.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of inventory to determine whether adjustments for excess and obsolete inventory are required. Inventory that is in excess of future requirements is written down to its estimated net realizable value based on product shelf life, forecasted demand and other factors.</span></div>Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed as incurred. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, net</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant &amp; equipment are stated at cost. Replacements of major units of property are capitalized, and replaced properties are retired. Replacements of minor components of property and repair and maintenance costs are charged to expense as incurred. Certain costs to obtain or develop computer software are capitalized and amortized over the estimated useful life of the software. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets and recorded </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in costs of goods sold and operating expenses in the associated functional expense category which utilizes the associated asset. The estimated useful lives of the major classes of depreciable assets are as follows:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.500%"><tr><td style="width:1.0%"></td><td style="width:46.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of lease term or 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or other disposal of property, plant &amp; equipment, the cost and related amount of accumulated depreciation are removed from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds is included in operating income.</span></div>Included within machinery and equipment are spare parts. Spare parts include replacement parts relating to plant &amp; equipment and are either recognized as an expense when consumed or reclassified and capitalized as part of the related asset and depreciated over the remaining useful life of the related asset. The estimated useful lives of the major classes of depreciable assets are as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.500%"><tr><td style="width:1.0%"></td><td style="width:46.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of lease term or 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.638%"><tr><td style="width:1.0%"></td><td style="width:64.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,441 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,329 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,864 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,720 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,294 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,697 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,166 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P10Y P50Y P15Y P40Y P3Y P15Y P15Y P15Y P3Y P5Y <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired IPR&amp;D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition.</span></div> 2600000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely-than-not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the Company’s annual assessment, the Company is permitted to first perform a qualitative test and if necessary, perform a quantitative test. If the Company is required to perform the quantitative impairment test of goodwill, the Company compares the fair value of a reporting unit to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting units using discounted cash flow or other valuation models, such as comparative transactions and market multiples. The Company performed a qualitative assessment and did not recognize any goodwill impairment charges during the years ended December 31, 2023, 2022 or 2021.</span></div> 0 0 0 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible and Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests intangible and long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. The Company measures the recoverability of assets to be held and used by comparing the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If those assets are considered to be impaired, the impairment equals the amount by which the carrying amount of the assets exceeds the fair value of the assets. Any impairments are recorded as permanent reductions in the carrying amount of the assets. See Note 7, “Property, Plant and Equipment, Net” for further details on impairment. Long-lived assets, other than goodwill and other intangible assets that are held for sale are recorded at the lower of the carrying value or the fair market value less the estimated cost to sell.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, consisting of patents, trademarks, customer relationships, a currently marketed product, licenses and developed technology related to the Company’s products are amortized in a method equivalent to the estimated utilization of the economic benefit of the asset.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of IPR&amp;D intangible assets acquired as part of an asset acquisition that have no alternative future use are expensed when incurred. Milestone payments made after regulatory approval are capitalized as an intangible asset and amortized over an estimated useful life of the product. Cash payments related to acquired IPR&amp;D intangible assets are reflected as an investing cash flow in the Company's consolidated statement of cash flows.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s IPR&amp;D intangible assets includes intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. Because obtaining regulatory approval can include significant risks and uncertainties, the eventual realized value of the acquired IPR&amp;D projects may vary from their fair value at the date of acquisition. The Company classifies IPR&amp;D intangible assets acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, the Company will determine the useful life and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, the Company writes-off the remaining carrying amount of the associated IPR&amp;D intangible asset. IPR&amp;D intangible assets are tested at least annually as of October 31 or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in the Company’s consolidated statements of operations. See Note 10, “Intangibles, net and Goodwill” for further details on impairment.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, product and environmental liability. The Company records accruals for those loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The change in fair value of any separately recognized derivative is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Values of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The Company’s long-term debt has triggering events that would impact the fair value of the instruments. The Company determined that no triggering event has occurred during the years ended December 31, 2023 and December 31, 2022. As of December 31, 2023, the fair value of the Company’s convertible debt was estimated to be approximately $644.3 million based on external pricing data, including quoted market prices of these instruments and was classified as a Level 1 measurement within the fair value hierarchy. As of December 31, 2022, the carrying value of the Company’s convertible debt approximated fair value and was classified as a Level 1 measurement within the fair value hierarchy. The fair value See Note 4, “Fair Value of Financial Instruments”.</span></div> 644300000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of contingent consideration liabilities are initially measured and recorded on the acquisition date, are considered to be a Level 3 instrument and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value is determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that include significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's acquisitions accounted for as asset acquisitions may also include contingent consideration payments to be made for sales-based milestones, development and regulatory milestones. The Company assesses whether such contingent consideration meets the definition of a derivative. Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration payments required to be accounted for as derivatives are recorded at fair value on the date of the acquisition and are subsequently remeasured to fair value at each reporting date. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged. Further, the Company must formally document the hedging relationship at inception and, on at least a quarterly basis, continually reevaluate the relationship to ensure it remains highly effective throughout the life of the hedge. The Company does not enter into derivative financial instruments for speculative or trading purposes.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Promotion Costs</span></div>Advertising and promotion costs are expensed as incurred. 26000000 26000000 17500000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and relate primarily to the development of new products to add to the Company’s portfolio and costs related to its medical affairs and medical information functions. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and recognized as an expense as the goods are delivered or the related services are performed.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of operations of the Company’s foreign subsidiaries are translated into U.S. Dollars using weighted-average exchange rates. The net assets of the Company’s foreign subsidiaries are translated into U.S. Dollars using the end of period exchange rates. The impact from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive loss in the consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of the Company’s foreign currency denominated transactions are included in net income. Transaction gains and losses are reported as a component of other loss (income) in the consolidated statements of operations.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s stock-based compensation cost is measured at the grant date of the stock-based award based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period, and includes an estimate of the awards that will be forfeited. The Company estimates the fair value of each stock-based award on its measurement date using either the current market price of the stock, the Black-Scholes option valuation model or the Monte Carlo simulation valuation model, whichever is most appropriate. The Black-Scholes and Monte Carlo simulation valuation models incorporate assumptions such as stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on the historical volatility of the Company’s stock price. The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the awards’ expected lives. Expected lives are principally based on the Company’s historical exercise experience with previously issued awards. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense for performance restricted stock awards is recognized based upon the fair value of the awards on the date of grant and the number of shares expected to vest based on the terms of the underlying award agreement and the requisite service period(s).</span></div> 0 <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other loss (income) consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.500%"><tr><td style="width:1.0%"></td><td style="width:50.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.493%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax indemnification expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap termination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of RELISTOR licensed intangible asset associated with net sales royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (income) loss </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,320)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -21000 -256000 -274000 -4943000 -9554000 -7121000 19638000 2613000 45000 0 5494000 0 51789000 143000 0 0 66320000 -1703000 -7350000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net income. For the Company, other comprehensive income (loss) consists of foreign currency translation gains and losses as well as realized and unrealized gains and losses on cash flow hedges related to the Company’s interest rate swaps. The accumulated other comprehensive income (loss) balance consists entirely of foreign currency translation gains and losses and realized and unrealized gains and losses on outstanding cash flow hedges related to the Company’s interest rate swaps.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Retirement Obligations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s compliance with federal, state, local and foreign environmental laws and regulations may require it to remove or mitigate the effects of the disposal or release of chemical substances in jurisdictions where it does business or maintains properties. The Company establishes accruals when those costs are legally obligated and can be reasonably estimated. Accrual amounts are estimated, which may include the assistance of third-party environmental specialists, and are based on currently available information, regulatory requirements, remediation strategies, historical experience, the relative shares of the total remediation costs, a relevant discount rate, and the time periods of when estimated costs can be reasonably predicted. Changes in these assumptions could impact the Company’s future reported results.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts campus and its Somerset, New Jersey site. The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. The liability is measured at the present value of the obligation expected to be incurred and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the assets’ useful lives.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified conditional asset retirement obligations related to the future removal and disposal of asbestos contained in certain of the buildings located on the Company’s North Billerica, Massachusetts campus. The Company believes the asbestos is appropriately contained and it is compliant with all applicable environmental regulations. If these properties undergo major renovations or are demolished, certain environmental regulations are in place, which specify the manner in which asbestos must be handled and disposed. The Company is required to record the fair value of these conditional liabilities if they can be reasonably estimated. As of December 31, 2023 and 2022, sufficient information was not available to estimate a liability for such conditional asset retirement obligations as the obligations to remove the asbestos from these properties have indeterminable settlement dates. As such, no liability for conditional asset retirement obligations has been recorded in the accompanying consolidated balance sheets as of December 31, 2023 and 2022.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance Reserves</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated balance sheets at December 31, 2023 and 2022 include $1.0 million and $0.9 million of accrued liabilities associated with employee medical costs that are retained by the Company, respectively. The Company estimates the required liability of those claims on an undiscounted basis based upon various assumptions which include, but are not limited to, the Company’s historical loss experience and projected loss development factors. The required liability is also subject to adjustment in the future based upon changes in claims experience, including changes in the number of incidents (frequency) and change in the ultimate cost per incident (severity).</span></div> 1000000 900000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company is currently in the process of evaluating the effects of this pronouncement on our related disclosures.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB also issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on our related disclosures.</span></div> Revenue from Contracts with Customers<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services. To achieve this core principle, the Company applies the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the Company satisfies a performance obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by revenue source as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.598%"><tr><td style="width:1.0%"></td><td style="width:32.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Products/Service Lines<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Product revenue, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    License and royalty revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296,429 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935,061 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ______________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The Company’s product revenue includes PYLARIFY and DEFINITY, among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all of its principal products.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology includes PYLARIFY and AZEDRA. In 2023, the Company announced its decision to discontinue the production and promotion of AZEDRA and it does not expect AZEDRA to contribute to the business after the first quarter of 2024. Precision Diagnostics includes DEFINITY, TechneLite and other diagnostic imaging products. Strategic Partnerships and Other Revenue includes strategic partnerships and other arrangements related to other products of the Company, including our royalty revenue from our license of RELISTOR. On August 2, 2023, the Company sold the RELISTOR royalty asset under its license agreement with Bausch; the Company retained the rights to future sales-based milestone payments. During the fourth quarter of 2023, the Company earned a $15.0 million sales-based milestone payment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the Company entered into a global settlement agreement with Novartis Pharma AG (“Novartis”), Advanced Accelerator Applications USA, Inc., Endocyte, Inc. and their affiliates (the “Novartis Agreement”) to settle certain disputes between the parties. Under the Novartis Agreement, Novartis agreed to make a lump sum payment to the Company, as well as to reimburse the Company for certain fees and expenses in connection with certain German litigation, and the Company agreed to license certain intellectual property to Novartis. In addition, the Company agreed to supply PYLARIFY for clinical purposes at an arms-length value which will be recorded revenue in the future as product is provided. In accordance with the Company's ASC 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, assessment, Novartis is considered to be a customer. The Company determined that the $24.0 million constituted a single element which was satisfied on the date of the execution of the Novartis Agreement. The Company determined that the license of intellectual property carried a fair value of $24.0 million. As such, the Company assigned the value to the fair value of the license, which constitutes the entire transaction price and does not require further allocation. The Company determined that the $24.0 million represented the point at which the licensee was able to use and benefit from the license and recognized revenue when the license was granted to Novartis upon execution of the Novartis Agreement. The Company recognized the $24.0 million fee as revenue on its consolidated statement of operations for the quarter ended March 31, 2022. The Company received the $24.0 million payment in April 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product category on a net basis is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.022%"><tr><td style="width:1.0%"></td><td style="width:33.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PYLARIFY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other radiopharmaceutical oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total radiopharmaceutical oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,507 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEFINITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,768 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,993 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,759 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TechneLite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other precision diagnostics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total precision diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,025 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic Partnerships and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,872 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296,429 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935,061 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Product Revenue, Net</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its products principally to hospitals, independent diagnostic testing facilities, and radiopharmacies. The Company considers customer purchase orders, which in some cases are governed by master sales or group purchasing organization agreements, to be the contracts with a customer.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 60 days from invoicing, the Company has elected to use the significant financing component practical expedient.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each distinct product based on their relative standalone selling price. The product price as specified on the purchase order is considered the standalone selling price as it is an observable input which depicts the price as if sold to a similar customer in similar circumstances.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which typically occurs upon delivery to the customer. Further, in determining whether control has transferred, the Company considers if there is a present right to payment and legal title, along with risks and rewards of ownership having transferred to the customer.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Frequently, the Company receives orders for products to be delivered over multiple dates that may extend across several reporting periods. The Company invoices for each delivery upon shipment and recognizes revenues for each distinct product delivered, assuming transfer of control has occurred.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not separately charge customers for shipping and handling costs, but any shipping and handling costs charged to customers are included in product revenue, net. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Allowances:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying consolidated balance sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. The Company estimates the amount of rebates and allowances that are explicitly stated in the Company’s contracts based on a combination of actual purchases and an estimate of the customer’s buying patterns.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company generally offers customers a limited right of return due to non-conforming product. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. Reserves for product returns are not significant to the Company due to the nature of its products including radiopharmaceutical products with limited half-lives.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the amount of, and change in, reserves is summarized as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.672%"><tr><td style="width:1.0%"></td><td style="width:76.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates and<br/>Allowances</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior period revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or credits made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior period revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or credits made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Royalty Revenues</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into licensing agreements, under which it licenses certain rights to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. The Company also has distribution licenses which are treated as combined performance obligations with the delivery of its products and are classified as product revenue, net.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step approach stated earlier. The Company uses judgment in determining the number of performance obligations in a license agreement by assessing whether the license is distinct or should be combined with another performance obligation, as well as the nature of the license. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are outside the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and royalty revenues and earnings in the period of adjustment. At December 31, 2023, the variable consideration for the milestone payments is constrained and is excluded from contract price until the milestone is achieved by the customer.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Costs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient to expense the costs as they are incurred, within sales and marketing expenses, since the amortization period is less than one year.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized certain revenues as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.595%"><tr><td style="width:1.0%"></td><td style="width:63.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any revenue related to performance obligations satisfied (or partially satisfied) in previous periods during the years ended December 31, 2023 and 2022. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.</span></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by revenue source as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.598%"><tr><td style="width:1.0%"></td><td style="width:32.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Products/Service Lines<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Product revenue, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    License and royalty revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296,429 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935,061 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ______________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The Company’s product revenue includes PYLARIFY and DEFINITY, among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all of its principal products.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product category on a net basis is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.022%"><tr><td style="width:1.0%"></td><td style="width:33.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PYLARIFY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other radiopharmaceutical oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total radiopharmaceutical oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,507 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEFINITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,768 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,993 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,759 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TechneLite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other precision diagnostics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total precision diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,025 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic Partnerships and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,872 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296,429 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935,061 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1263068000 887038000 400356000 33361000 48023000 24852000 1296429000 935061000 425208000 24000000 3 15000000 24000000 24000000 24000000 24000000 24000000 851303000 527405000 43414000 3130000 4102000 5473000 854433000 531507000 48887000 279768000 244993000 232759000 87370000 88864000 91293000 22980000 22825000 26973000 390118000 356682000 351025000 51878000 46872000 25296000 1296429000 935061000 425208000 standard payment terms are 30 to 60 days <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the amount of, and change in, reserves is summarized as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.672%"><tr><td style="width:1.0%"></td><td style="width:76.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates and<br/>Allowances</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior period revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or credits made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior period revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or credits made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10977000 26683000 70000 24331000 13399000 32308000 -453000 29184000 16070000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized certain revenues as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.595%"><tr><td style="width:1.0%"></td><td style="width:63.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 682000 244000 Fair Value of Financial Instruments<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.861%"><tr><td style="width:1.0%"></td><td style="width:35.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.034%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"></td><td style="width:35.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023 and 2022, there were no transfers into or out of Level 3. On December 2, 2022, the Company voluntarily terminated the interest rate swap contracts in connection with the refinancing of debt.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. (“CytoDyn”) related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pertaining to regulatory events and sales targets. During the fourth quarter of 2022, the Company reduced the probability to zero as CytoDyn withdrew their regulatory application. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum cap. Refer to Note 1, “Basis of Presentation” for further details on the CVRs. The Company paid out the maximum amount payable under the CVRs from available cash in May 2023 in full satisfaction of the CVR obligation.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 (also known as 131 I-MIP-1095) and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the 2013 Acquisition each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities will be consistent with any recurring fair value estimate of such contingent consideration liabilities.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of liabilities using Level 3 inputs as of December 31, 2023.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales targets – PYLARIFY (CVRs)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement and sales targets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 – 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1095 commercialization milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales targets – AZEDRA and 1095</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo simulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success and sales targets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0% - 40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20% - 100%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16% - 17%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:38.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-653"><span style="-sec-ix-hidden:f-654">Changes in fair value included in net income (loss)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in a general and administrative expense of $<span style="-sec-ix-hidden:f-667">9.3 million</span> for the year ended December 31, 2023 and was primarily due to changes in revenue forecasts, changes in market conditions, an increase in discount rates (excluding the CVRs) and the passage of time. The Company made the applicable cash payment related to the CVRs in May 2023. <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.861%"><tr><td style="width:1.0%"></td><td style="width:35.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.034%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"></td><td style="width:35.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 574131000 574131000 0 0 574131000 574131000 0 0 2700000 0 0 2700000 2700000 0 0 2700000 342646000 342646000 0 0 342646000 342646000 0 0 111600000 0 0 111600000 111600000 0 0 111600000 5000000 0.05 0.40 100000000 150000000 70000000 5000000 10000000 85000000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of liabilities using Level 3 inputs as of December 31, 2023.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales targets – PYLARIFY (CVRs)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement and sales targets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 – 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1095 commercialization milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales targets – AZEDRA and 1095</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo simulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success and sales targets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0% - 40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20% - 100%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16% - 17%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 99700000 1 1800000 1700000 0.40 0.40 0.40 0.40 0.041 0.038 900000 10200000 0 0.40 0.20 1 0.15 0.16 0.17 2700000 111600000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:38.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-653"><span style="-sec-ix-hidden:f-654">Changes in fair value included in net income (loss)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,600 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 9300000 111600000 86200000 0 9300000 9275000 -25400000 0 0 99625000 0 0 0 2700000 111600000 -9300000 Income Taxes <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income (loss) before provision (benefit) for income taxes consists of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.777%"><tr><td style="width:1.0%"></td><td style="width:47.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,389)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,943 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,719 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,038)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s provision (benefit) for income taxes consists of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.527%"><tr><td style="width:1.0%"></td><td style="width:42.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,914 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,196)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,739)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,315)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,632)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,016)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,282 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,348)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,759)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes at the U.S. federal statutory rate to the income tax expense (benefit) is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.388%"><tr><td style="width:1.0%"></td><td style="width:52.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,758)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of RELISTOR licensed intangible asset associated with net sales royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact on deferred taxes of change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in indemnification deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,282 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,348)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,759)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income tax assets (liabilities) are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.305%"><tr><td style="width:1.0%"></td><td style="width:65.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal benefit of state taxes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves, accruals and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory obsolescence</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,357 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves, accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles other than goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,543)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,978)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recorded in the accompanying consolidated balance sheets as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent deferred tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. Under the Act, research and experimental expenditures incurred for tax years beginning after December 31, 2021, must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on where the research activities are conducted. If the requirement to capitalize Section 174 expenditures is not modified, it may impact our cash tax liability in future years. The increase in worldwide net deferred tax assets is primarily due to the tax capitalization of the Company’s current year research and development expenses that are not currently deductible in 2023 and the decrease in deferred tax liabilities related to the AZEDRA and RELISTOR royalty intangible assets, partially offset by utilization of net operating losses.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence. As of December 31, 2023 and 2022, the Company maintains a valuation allowance of $3.6 million and $3.5 million, respectively, primarily related to net deferred tax assets of certain of its foreign subsidiaries.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of net operating loss carryforwards and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 (“IRC Section 382”) and with Section 383 of the Internal Revenue Code of 1986, as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards and research and development credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change, as defined by IRC Section 382, results from transactions which impact the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the Company had U.S. federal net operating loss carryforwards of approximately $297.6 million, $157.9 million of which will expire between 2027 and 2037, and $139.6 million of which can be carried forward indefinitely. The Company’s state net operating losses are $12.5 million on a tax-effected basis, which will expire between 2024 and 2040. The Company has state research credit carryforwards of $2.1 million, which will expire between 2026 and 2038. The Company has state investment tax credit carryforwards of $0.8 million which have no expiration date.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s U.S. federal income tax returns are subject to examination for three years after the filing date of the return. The state and foreign income tax returns are subject to examination for periods varying from three to four years after filing, depending on the specific jurisdiction’s statutes of limitation, and in the case of Sweden, up to six years after the end of the financial year.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company’s changes in uncertain tax positions for 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.500%"><tr><td style="width:1.0%"></td><td style="width:80.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of uncertain tax positions as of January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Additions related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Reductions related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of uncertain tax positions as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,658 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Additions related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Reductions related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of uncertain tax positions as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Additions related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Reductions related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of uncertain tax positions as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into an indemnification agreement with BMS for any payments made to settle those uncertain tax positions with the taxing authorities. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Company’s accounting policy, the change in the tax liability, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change, adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities. Included in other (income) loss for the years ended December 31, 2023, 2022 and 2021, is tax indemnification expense (income), net of $4.9 million, $9.6 million and $7.1 million, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, total liabilities for uncertain tax positions including interest and penalties were $5.4 million and $8.3 million, respectively, consisting of uncertain tax positions of $4.1 million and $1.5 million, respectively, interest accruals of $1.3 million and $6.4 million, respectively, and no penalty accruals as of December 31, 2023 and $0.4 million of penalty accruals as of December 31, 2022. The increase in uncertain tax positions during the year ended December 31, 2023 was primarily related to certain acquired tax attributes. As of December 31, 2023, $1.3 million, $3.2 million, and $0.9 million of these liabilities were recorded in current liabilities, other long-term liabilities, and as a reduction of deferred tax assets, respectively. As of December 31, 2022 these liabilities were included in other long-term liabilities. Included in the 2023, 2022 and 2021 tax provisions are benefits of $5.0 million, $12.6 million and $9.0 million, respectively, relating to reversals of uncertain tax positions recognized upon settlements, effective settlements, or lapses of relevant statutes of limitation, partially offset by interest accruals.</span></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income (loss) before provision (benefit) for income taxes consists of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.777%"><tr><td style="width:1.0%"></td><td style="width:47.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,389)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,943 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,719 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,038)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 410326000 29012000 -76389000 617000 -2293000 1351000 410943000 26719000 -75038000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s provision (benefit) for income taxes consists of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.527%"><tr><td style="width:1.0%"></td><td style="width:42.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,914 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,196)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,739)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,315)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,632)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,016)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,282 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,348)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,759)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 110108000 42532000 0 29806000 4302000 -8166000 0 -166000 -30000 139914000 46668000 -8196000 -45252000 -39920000 1048000 -10739000 -8315000 3058000 359000 219000 331000 -55632000 -48016000 4437000 84282000 -1348000 -3759000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes at the U.S. federal statutory rate to the income tax expense (benefit) is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.388%"><tr><td style="width:1.0%"></td><td style="width:52.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,758)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of RELISTOR licensed intangible asset associated with net sales royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact on deferred taxes of change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in indemnification deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,282 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,348)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,759)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 86298000 5611000 -15758000 1042000 2309000 1764000 -10817000 0 0 307000 247000 1028000 -5045000 -12629000 -8952000 2118000 4085000 990000 18726000 67000 656000 -330000 4169000 3049000 -1948000 5422000 15015000 128000 68000 23000 -4000 -30000 -400000 -3941000 -4612000 -1164000 -1240000 -2343000 -1786000 744000 -228000 184000 84282000 -1348000 -3759000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income tax assets (liabilities) are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.305%"><tr><td style="width:1.0%"></td><td style="width:65.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal benefit of state taxes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves, accruals and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory obsolescence</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,357 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves, accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles other than goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,543)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,978)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recorded in the accompanying consolidated balance sheets as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent deferred tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 263000 1739000 18923000 31532000 0 919000 17142000 79946000 9266000 0 25214000 0 80184000 88014000 14365000 0 165357000 202150000 0 5354000 11543000 0 0 80770000 0 385000 0 1469000 11543000 87978000 3616000 3525000 150198000 110647000 150198000 110647000 3600000 3500000 297600000 157900000 139600000 12500000 2100000 800000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company’s changes in uncertain tax positions for 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.500%"><tr><td style="width:1.0%"></td><td style="width:80.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of uncertain tax positions as of January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Additions related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Reductions related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of uncertain tax positions as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,658 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Additions related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Reductions related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of uncertain tax positions as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Additions related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Reductions related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of uncertain tax positions as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5292000 0 188000 1446000 0 3658000 0 1180000 306000 692000 1480000 3749000 688000 442000 0 4099000 -4900000 -9600000 -7100000 5400000 8300000 4100000 1500000 1300000 6400000 0 400000 1300000 3200000 900000 -5000000 -12600000 -9000000 Inventory<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.000%"><tr><td style="width:1.0%"></td><td style="width:57.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,987 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,475 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. The Company has no inventory pending regulatory approval as of December 31, 2023.</span></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.000%"><tr><td style="width:1.0%"></td><td style="width:57.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,987 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,475 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 31259000 19987000 13807000 8234000 18963000 7254000 64029000 35475000 Property, Plant and Equipment, Net<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.638%"><tr><td style="width:1.0%"></td><td style="width:64.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,441 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,329 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,864 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,720 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,294 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,697 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,166 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, plant &amp; equipment, net, was $13.2 million, $13.7 million and $13.2 million for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. During the year ended December 31, 2021, the Company reviewed certain facts relating to an asset group that included the right-of-use (“ROU”) asset associated with the lease of office space in the World Trade Center (the “WTC lease”) in New York City and resulted in a change to the asset group due to the negotiation of a sublease. Please refer to Note 16, “Leases” for further details.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, as a result of a decline in expected future cash flows related to a certain asset group, the Company determined certain impairment triggers had occurred. The Company reviewed revised undiscounted cash flows that were estimated to be generated by the asset group as of June 30, 2023. Based on the undiscounted cash flow analysis, the Company determined that the asset group had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on their discounted cash flows. The carrying value exceeded the fair value and as a result, the Company recorded a noncash impairment of $6.0 million for the six months ended June 30, 2023 in cost of goods sold in the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets Held for Sale</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023, the Company committed to a plan to sell a portion of its land and buildings associated with its Billerica, Massachusetts campus. Effective March 16, 2023, the Company entered into a purchase and sale agreement (the “P&amp;S”) with a prospective buyer. The assets were classified as held for sale and comprised entirely of property, plant and equipment, net. The Company determined that the fair value of the net assets being sold exceeded the carrying value as of September 30, 2023. The purchase price for the campus sale is $10.0 million in cash. The transaction is expected to close in the second or third quarter of 2024.</span></div> 9480000 13450000 73441000 76329000 102576000 92604000 27259000 25864000 40964000 14047000 253720000 222294000 107023000 100128000 146697000 122166000 13200000 13700000 13200000 6000000 10000000 Sale of Puerto Rico Subsidiary<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price for the stock sale was $18.0 million in cash, which included a holdback amount of $1.8 million that was remitted to the Company as of December 31, 2021, and paid in the first quarter of 2022; the purchase price also included a working capital adjustment. The SPA contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that this sale of certain net assets did not constitute a strategic shift that had a major effect on the Company’s operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s accompanying consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income (loss) in the consolidated statements of operations for the year ended December 31, 2021.</span></div> 18000000 1800000 15300000 Asset Retirement Obligations<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and Somerset, New Jersey sites. As of December 31, 2023, the liability is measured at the present value of the obligation expected to be incurred, of approximately $25.1 million.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the changes in the Company’s asset retirement obligations:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"></td><td style="width:77.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in useful life estimate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,543 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,916 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts and Somerset, New Jersey production facilities, respectively, upon closure. The Company has provided this financial assurance in the form of a $30.3 million surety bond.</span></div> 25100000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the changes in the Company’s asset retirement obligations:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"></td><td style="width:77.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in useful life estimate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,543 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,916 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 20833000 280000 1430000 22543000 373000 22916000 30300000 Intangibles, Net and Goodwill<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net, consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.583%"><tr><td style="width:1.0%"></td><td style="width:31.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization<br/>Method</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed product</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 – 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 – 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,972)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,968 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,983)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,985 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.861%"><tr><td style="width:1.0%"></td><td style="width:31.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization<br/>Method</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,061)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed product</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 – 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 – 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,761 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,476)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,285 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense for its intangible assets of $46.4 million, $33.2 million and $27.5 million for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&amp;D to currently marketed products and commenced amortization of the asset.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, the Company sold the right to its RELISTOR royalty asset under its license agreement with Bausch; the Company retained the rights to future sales-based milestone payments. The Company received an initial payment of approximately $98.0 million in connection with the sale and has the right to receive an additional payment from the buyer of $5.0 million if worldwide net sales of RELISTOR in 2025 exceed a specified threshold. The additional payment would be recognized upon achievement of the specified threshold. Decreases of $63.6 million of license assets and $17.5 million of associated accumulated amortization, as well as a gain of $51.8 million were recorded as a result of the sale. During the fourth quarter of 2023, the Company earned a $15.0 million sales-based milestone payment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company stopped all development activities in relation to a future indication associated with AZEDRA, which was classified as an IPR&amp;D intangible asset. The asset group, which consisted of the IPR&amp;D asset and a currently marketed product (the “AZEDRA intangible asset group”), was assessed for impairment. The Company considered several factors in estimating the future projections of revenues and cash flows of the AZEDRA intangible asset group as part of the impairment testing. The Company concluded that the carrying amount exceeded the fair value of the AZEDRA intangible asset group, which had no value. The Company recorded a non-cash impairment charge of $<span style="-sec-ix-hidden:f-950">15.6 million</span> in research and development expenses relating to the IPR&amp;D asset and $<span style="-sec-ix-hidden:f-951">116.4 million</span> in cost of goods sold relating to the currently marketed indication of AZEDRA in the consolidated statement of operations for the year ended December 31, 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the Company announced that it had made the decision to discontinue the production and promotion of AZEDRA and would be winding down its Somerset, New Jersey manufacturing site. The Company will continue manufacturing AZEDRA into the first quarter of 2024, to the extent feasible, with the goal of providing doses of AZEDRA to current patients so they can complete their treatment regimen. See Note 7, “Property, Plant and Equipment, Net” for impairment analysis.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company entered into an agreement with the stockholders of Cerveau to purchase all of the outstanding capital stock of Cerveau for approximately $35.3 million. In May 2023, upon successful completion of a technology transfer, the Company paid $10.0 million to the selling stockholders of Cerveau. This additional contingent payment was capitalized as part of the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset cost and increased the Company’s customer relationship intangible assets. See Note 21, “Acquisition of Assets” for further discussion of the Cerveau acquisition.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.166%"><tr><td style="width:1.0%"></td><td style="width:68.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net, consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.583%"><tr><td style="width:1.0%"></td><td style="width:31.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization<br/>Method</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed product</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 – 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 – 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,972)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,968 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,983)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,985 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.861%"><tr><td style="width:1.0%"></td><td style="width:31.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization<br/>Method</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,061)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed product</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 – 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 – 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,761 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,476)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,285 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net, consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.583%"><tr><td style="width:1.0%"></td><td style="width:31.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization<br/>Method</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed product</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 – 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 – 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,972)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,968 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,983)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,985 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.861%"><tr><td style="width:1.0%"></td><td style="width:31.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization<br/>Method</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,061)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 – 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed product</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 – 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 – 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,761 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,476)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,285 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P15Y P25Y 13540000 12216000 1324000 P15Y P25Y 157995000 117574000 40421000 P9Y P15Y 132800000 38277000 94523000 P11Y P16Y 22233000 7972000 14261000 P9Y 2400000 944000 1456000 328968000 176983000 151985000 P15Y P25Y 13540000 12061000 1479000 P15Y P25Y 96681000 95009000 1672000 P9Y P15Y 275700000 47628000 228072000 P11Y P16Y 85800000 19101000 66699000 P9Y 2400000 677000 1723000 15640000 15640000 489761000 174476000 315285000 46400000 33200000 27500000 132800000 -132800000 98000000 5000000 63600000 17500000 51800000 15000000 15600000 116400000 35300000 10000000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.166%"><tr><td style="width:1.0%"></td><td style="width:68.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 39726000 24409000 25206000 19680000 16195000 26769000 151985000 Accrued Expenses and Other Liabilities and Other Long-Term Liabilities <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.388%"><tr><td style="width:1.0%"></td><td style="width:58.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freight, distribution and operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, discounts and chargebacks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,338 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,084 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities (Note 16)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term contingent liability (Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,155 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.388%"><tr><td style="width:1.0%"></td><td style="width:58.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freight, distribution and operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, discounts and chargebacks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,338 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,084 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities (Note 16)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term contingent liability (Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,155 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 36331000 30425000 67529000 49067000 16070000 13399000 10244000 8668000 15164000 25525000 145338000 127084000 54453000 25442000 2700000 11900000 6168000 8813000 63321000 46155000 Long-Term Debt, Net, and Other Borrowings<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.972%"><tr><td style="width:1.0%"></td><td style="width:74.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,955)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net, and other borrowings</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company refinanced its existing credit facility, consisting of (i) a $200.0 million five-year term loan facility (the “2019 Term Facility”) and (ii) a $200.0 million five-year revolving credit facility (the “2019 Revolving Facility” and, together with the 2019 Term Facility, the “2019 Facility”), with a new $100.0 million delayed draw term loan facility (the “2022 Term </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility” and, the loans thereunder, the “Term Loans”) and a new $350.0 million five-year revolving credit facility (the “2022 Revolving Facility” and, together with the 2022 Term Facility, the “2022 Facility”).</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used approximately $7.8 million of cash on hand to primarily repay the principal amount of the loans outstanding related to the 2019 Facility through the nine months ended September 30, 2022. In addition, in December 2022, the Company used approximately $167.6 million of cash on hand to repay in full the aggregate remaining principal amount of the loans outstanding under the 2019 Facility and to pay related interest, transaction fees and expenses.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid off the 2019 Term Facility using available cash and did not utilize another term loan to fund the payoff. While the 2022 Term Facility allowed for a delayed draw term loan, the loan was not drawn upon. The Company recorded a loss on extinguishment of debt of $0.6 million related to the write-off of unamortized debt issuance costs and debt discounts associated with the 2019 Term Facility. In addition, the Company incurred and capitalized $2.7 million of new deferred financing costs related to the refinancing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Revolving Facility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2022 Revolving Facility, the lenders are committed to extending credit to the Company from time to time until December 2, 2027 consisting of revolving loans (the “Revolving Loans”) in an aggregate principal amount not to exceed $350.0 million (the “Revolving Commitment”) at any time, including a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”) and a $10.0 million sub-facility for swingline loans (the “Swingline Loans”). The Letters of Credit, Swingline Loans and the Revolving Loans, if used, are expected to be used for working capital and for other general corporate purposes.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Loans bear interest, with pricing based from time to time at the Company’s election, at (i) the secured overnight financing rate as published by the Federal Reserve Bank of New York on its website plus an applicable margin that ranges from 1.50% to 2.50% based on the Company’s total net leverage ratio or (ii) the alternative base rate plus an applicable margin that ranges from 0.50% to 1.50% based on the Company’s total net leverage ratio. The 2022 Revolving Facility also includes an unused commitment fee at a rate ranging from 0.15% to 0.35% per annum based on the Company’s total net leverage ratio.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans, Letters of Credit and Swingline Loans exceeds the total Revolving Commitment, the Company must prepay the Revolving Loans in an amount equal to such excess. The Company is not required to make mandatory prepayments under the 2022 Revolving Facility. As of December 31, 2023, there were no outstanding borrowings under the 2022 Revolving Facility.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the right to request an increase to the Revolving Commitment in an aggregate principal amount of up to the sum of $335.0 million or consolidated EBITDA for the four consecutive fiscal quarters most recently ended, plus additional amounts in certain circumstances (collectively, the “Incremental Cap”), minus certain incremental term loans made pursuant to specified incremental term loan commitments (“Incremental Term Loans”). The Company has the right to request Incremental Term Loans in an aggregate principal amount of up to the Incremental Cap less any incremental increases to the Revolving Commitment. Proceeds of Incremental Term Loans may be used for working capital and for other general corporate purposes and will bear interest at rates agreed between the Company and the lenders providing the Incremental Term Loans. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Facility Covenants</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Facility contains a number of affirmative, negative and reporting covenants, as well as financial maintenance covenants pursuant to which the Company is required to be in quarterly compliance, measured on a trailing four quarter basis, with two financial covenants. The minimum interest coverage ratio, commencing with the fiscal quarter ended December 31, 2022, must be at least 3.00 to 1.00. The maximum total net leverage ratio permitted by the financial covenant, commencing with the fiscal quarter ending March 31, 2024, is 3.50 to 1.00.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default, the Administrative Agent will have the right to declare the loans and other obligations outstanding under the 2022 Facility immediately due and payable and all commitments immediately terminated.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Facility is guaranteed by Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus MI Real Estate, LLC, and obligations under the 2022 Facility are generally secured by first priority liens over substantially all of the assets of each of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMI, Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus MI Real Estate, LLC (subject to customary exclusions set forth in the transaction documents) owned as of December 2, 2022 or thereafter acquired.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2022, the Company issued $575.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027 (the “Notes”), which includes $75.0 million in aggregate principal amount of Notes sold pursuant to the full exercise of the initial purchasers’ option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among the Company, LMI (the “Guarantor”), a wholly owned subsidiary of the Company, as Guarantor, and U.S. Bank Trust Company, National Association, as Trustee. The net proceeds from the issuance of the Notes were approximately $557.8 million after deducting the initial purchasers’ discounts and offering expenses payable by the Company.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Guarantor. The Notes bear interest at a rate of 2.625% per year, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023, and will mature on December 15, 2027 unless earlier redeemed, repurchased or converted in accordance with their terms. The initial conversion rate for the Notes is 12.5291 shares of the Company’s common stock per $1,000 in principal amount of Notes (which is equivalent to an initial conversion price of approximately $79.81 per share of the Company’s common stock, representing an initial conversion premium of approximately 42.5% above the closing price of $56.01 per share of the Company’s common stock on December 5, 2022). In no event shall the conversation rate per $1,000 in principal amount of notes exceed 17.8539 shares of the Company’s common stock. Prior to the close of business on the business day immediately preceding September 15, 2027, the Notes may be converted at the option of the holders only upon occurrence of specified events and during certain periods, and thereafter until the close of business on the business day immediately preceding the maturity date, the Notes may be converted at any time. The Company will satisfy any conversion by paying cash up to the aggregate principal amount of the Notes to be converted and by paying or delivering, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Company may redeem for cash all or any portion of the Notes, at its option, on or after December 22, 2025 if the closing sale price per share of the Company’s common stock exceeds 130% of the conversion price of the Notes for a specified period of time. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Notes upon completion of the sale and concluded on the following features:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Conversion Feature:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company determined that the conversion feature qualifies for the classification of equity. As a result, the conversion feature should not be bifurcated as a derivative instrument and the Notes were accounted for as a single liability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Redemption Features:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The redemption features were reviewed within the Notes and the Company determined that the redemption features are closely related to the Notes and as such should not be separately accounted for as a bifurcated derivative instrument. </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:4.8pt">Additional Interest Features: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Notes may result in additional interest if the Company fails to timely file any document or report that the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The Company will pay additional interest on the notes at a rate equal to 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day the Company failure to file has occurred or the notes are not otherwise freely tradable. Further, if the notes are assigned a restricted CUSIP number or the notes are not otherwise freely tradable pursuant to Rule 144 under the Securities Act by holders other than our affiliates or holders that were our affiliates at any time during the three months immediately preceding as of the 385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> day after the last date of original issuance of the notes offered hereby, the Company will pay additional interest on the notes at a rate equal to (i) 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day until the restrictive legend has been removed from the notes, the notes are assigned an unrestricted CUSIP and the notes are freely tradable. The Company concluded that the interest feature is unrelated to the credit risk and should be bifurcated from the Notes, however, the Company assessed the probabilities of triggering events occurring under these features and does not expect to trigger the aforementioned events. These events will continue to be monitored to determine whether the interest feature will be bifurcated if it has value.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the carrying value of the Notes was $575.0 million, had an unamortized discount of zero, and the fair value of the liability was $575.0 million. The Company recorded interest expense of approximately $15.1 million related to the Notes for the year ended December 31, 2023.</span></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.972%"><tr><td style="width:1.0%"></td><td style="width:74.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,955)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net, and other borrowings</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 575000000 0 575000000 13955000 1448000 562493000 823000 561670000 200000000 P5Y 200000000 P5Y 100000000 350000000 P5Y 7800000 167600000 -600000 2700000 350000000 20000000 10000000 0.0150 0.0250 0.0050 0.0150 0.0015 0.0035 0 335000000 2 3.00 3.50 575000000 0.02625 75000000 557800000 0.02625 79.81 0.425 56.01 1.30 1 0.0025 0.0050 0.0025 0.0050 575000000 0 575000000 15100000 Derivative Instruments<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps was approximately 0.82%. This agreement involved the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s consolidated balance sheets at fair value, and changes in the fair value of the swap agreements were recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company voluntarily terminated the interest rate swap contracts in connection with the refinancing of debt. Upon termination, the Company received approximately $5.6 million in cash and the remaining balance of approximately $5.5 million in accumulated other comprehensive income (loss) related to the interest rate swap contracts were reclassified into earnings.</span></div> 100000000 0.0082 5600000 5500000 Accumulated Other Comprehensive Loss<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Accumulated Other Comprehensive Loss, net of tax of zero and zero for the year ended December 31, 2023 and 2022, respectively, consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.777%"><tr><td style="width:1.0%"></td><td style="width:34.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:83%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Unrealized loss on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Accumulated other comprehensive loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Balance at January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,037)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,037)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Balance at January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">5,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">5,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(6,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(6,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,259)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,259)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Accumulated Other Comprehensive Loss, net of tax of zero and zero for the year ended December 31, 2023 and 2022, respectively, consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.777%"><tr><td style="width:1.0%"></td><td style="width:34.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:83%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Unrealized loss on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Accumulated other comprehensive loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Balance at January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,037)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,037)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Balance at January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">5,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">5,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(6,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(6,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,259)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">(1,259)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 0 0 -1259000 0 -1259000 222000 0 222000 -1037000 0 -1037000 -754000 269000 -485000 -505000 5838000 5333000 0 6107000 6107000 -1259000 0 -1259000 Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company’s approved equity incentive plans included the 2015 Equity Incentive Plan (“2015 Plan”), the 2013 Equity Incentive Plan (“2013 Plan”), and the 2008 Equity Incentive Plan (“2008 Plan”). These plans are administered by the Board of Directors and permit the granting of stock options, stock appreciation rights, restricted stock, restricted stock units and dividend equivalent rights to employees, officers, directors and consultants of the Company.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain stock option and restricted stock awards outstanding under each of its equity incentive plans but, upon adoption of the 2015 Plan, no longer grants new equity awards under its 2008 and 2013 Plans. The Company adopted its 2015 Plan in June 2015 and subsequently amended the plan in April 2016, 2017, 2019, 2021 and 2022 which increased the common stock reserved for issuance under the plan to an aggregate 10,930,277 shares. The Company assumed Progenics equity plans due to the acquisition as discussed in Note 1, “Description of Business”. The Company no longer grants new equity awards under the Progenics equity plans.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized in the consolidated statements of operations is summarized below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.944%"><tr><td style="width:1.0%"></td><td style="width:55.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,185 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,074 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,507 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,262 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,934 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. All option awards have a ten-year contractual term.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity for 2023 is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.361%"><tr><td style="width:1.0%"></td><td style="width:45.163%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total<br/>Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,058,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled and forfeited</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,283,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,172 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,283,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,462,767 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the key weighted-average assumptions used in valuing stock options granted:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.805%"><tr><td style="width:1.0%"></td><td style="width:36.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, 2022 and 2021, 214,619, 397,822 and 318,662 options were exercised having aggregate intrinsic values of $12.9 million, $13.1 million and $1.6 million, respectively. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there was $13.2 million of unrecognized compensation expense related to outstanding stock options, which is expected to be recognized over a weighted-average period of 2.0 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock awards and restricted stock units activity for 2023 is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.277%"><tr><td style="width:1.0%"></td><td style="width:65.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested balance at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249,992 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612,912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,806)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.71 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock generally vest over 3 years. As of December 31, 2023, there was $48.4 million of unrecognized compensation expense related to outstanding restricted stock, which is expected to be recognized over a weighted-average period of 2.0 years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value for restricted stock granted during the fiscal years ended December 31, 2023, 2022 and 2021 was $74.38, $51.51 and $20.14 per share, respectively. The total fair value of restricted stock vested in fiscal years 2023, 2022 and 2021 was $18.3 million, $11.9 million and $8.8 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Stockholder Return Restricted Stock Awards (“TSR Awards”)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, 2022 and 2021, the Company granted total stockholder return (“TSR”) Awards that include a three-year market condition where the performance measurement period is three years. Vesting of the TSR Awards is based on the Company’s level of attainment of specified TSR targets relative to the percentage appreciation of a specified index of companies for the respective three-year period and is also subject to the continued employment of the grantees. The number of shares that are earned over the performance period ranges from 0% to 200% of the initial award. The fair value of these awards are based on a Monte Carlo simulation valuation model with the following assumptions:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.083%"><tr><td style="width:1.0%"></td><td style="width:36.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of TSR Award activity for 2023 is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.750%"><tr><td style="width:1.0%"></td><td style="width:62.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested balance at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,997)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630,054 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.91 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there was $26.2 million of unrecognized compensation expense related to outstanding performance restricted stock which is expected to be recognized over a weighted-average period of 2.0 years. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value for TSR Awards granted during the fiscal years ended December 31, 2023, 2022 and 2021 was $127.75, $95.31 and $31.25 per share, respectively. The total fair value of TSR Awards vested in fiscal years 2023, 2022 and 2021 was $8.2 million, $8.8 million and $2.0 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company’s Board of Directors authorized the repurchase of up to $150.0 million in aggregate amount of the Company’s common stock under certain circumstances. The Company used approximately $75.0 million of the net proceeds from the Notes to repurchase shares of their common stock from purchasers of the Notes in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate. The purchase price per share of the common stock repurchased in such transactions was equal to the closing sale price per share of the Company’s common stock on the date of the offering memorandum used for the Notes, which was $56.01 per share. Following this initial repurchase, the Company may from time to time repurchase additional shares of their common stock. In the year ended December 31, 2022, the Company purchased approximately 1.3 million shares of their outstanding common stock for $75.0 million as part of the program. The Company did not purchase any shares of its outstanding common stock in the year ended December 31, 2023.</span></div> 10930277 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized in the consolidated statements of operations is summarized below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.944%"><tr><td style="width:1.0%"></td><td style="width:55.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,185 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,074 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,507 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,262 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,934 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 9126000 4422000 2370000 9500000 6185000 2472000 24807000 14876000 9092000 7074000 3779000 2000000 50507000 29262000 15934000 P10Y <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity for 2023 is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.361%"><tr><td style="width:1.0%"></td><td style="width:45.163%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total<br/>Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,058,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled and forfeited</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,283,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,172 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,283,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,462,767 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 874749 30.37 P5Y9M18D 19058224000 332368 76.41 214619 19.02 35326 51.30 957172 48.13 P6Y8M12D 18283464000 957172 48.13 P6Y8M12D 18283464000 466039 26.99 P4Y4M24D 16462767000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the key weighted-average assumptions used in valuing stock options granted:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.805%"><tr><td style="width:1.0%"></td><td style="width:36.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div> 0.561 0.621 0 0.040 0.020 0 P6Y P6Y 0 0 0 214619 397822 318662 12900000 13100000 1600000 13200000 P2Y <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock awards and restricted stock units activity for 2023 is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.277%"><tr><td style="width:1.0%"></td><td style="width:65.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested balance at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249,992 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612,912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,806)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.71 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of TSR Award activity for 2023 is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.750%"><tr><td style="width:1.0%"></td><td style="width:62.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested balance at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,997)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630,054 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.91 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1249992 34.65 710985 74.38 612912 29.78 137806 50.36 1210259 58.71 P3Y 48400000 P2Y 74.38 51.51 20.14 18300000 11900000 8800000 P3Y P3Y P3Y 0 2 The fair value of these awards are based on a Monte Carlo simulation valuation model with the following assumptions:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.083%"><tr><td style="width:1.0%"></td><td style="width:36.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div> 0.528 0.566 0.540 0.046 0.017 0.300 P2Y9M18D P2Y9M18D P2Y9M18D 0 0 0 658875 48.58 365478 127.75 348302 23.43 45997 57.77 630054 78.91 26200000 P2Y 127.75 95.31 31.25 8200000 8800000 2000000 150000000 75000000 56.01 1300000 75000000 0 Leases <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. The Company has operating and finance leases for vehicles, corporate offices and certain equipment. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease agreements with lease and non-lease components are accounted for separately. As the Company’s leases do not provide an implicit rate, the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assumed two operating leases as a result of the Progenics acquisition related to office space at the World Trade Center in New York City, pursuant to a lease agreement expiring in September 2030 (the “WTC Lease”), and a radiopharmaceutical manufacturing facility in Somerset, New Jersey, under a sublease agreement expiring in November 2028, which were recorded as of June 19, 2020, for $18.6 million and $0.6 million, respectively. The Company entered into an operating lease related to office space in Somerset, New Jersey, under a lease agreement expiring in August 2026, which was recorded in October 2021 for $0.7 million. The Company entered into an operating lease agreement in February 2022 to lease office space in Bedford, Massachusetts, under a lease agreement expiring in June 2031, which commenced and was recorded in December 2022 for $11.0 million.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, the Company entered into a modification to the operating lease for office space in Bedford, Massachusetts, (the “Existing Premises”) that was executed in February 2022. The lease commenced and was recorded in December 2022 for $11.0 million and the initial term was set to expire in June 2031. The lease modification includes a lease of additional office and laboratory space at the Bedford location (the “Additional Premises”) for a term of 15 years and 4 months and extends the term of the lease for the Existing Premises to be coterminous with the term of the lease for the Additional Premises. As a result of the extended term for the Existing Premises, the Company recorded an additional right-of-use asset and liability of $6.0 million in May 2023. The modification also contains a provision to convert the rent schedule of the Existing Premises from gross to triple net in 2024, which may result in an additional adjustment to the right-of-use asset and liability. In September 2023, the landlord provided notice to the Company that its renovations of the Additional Premises were completed. As a result of the notice, the Company recorded an additional right-of-use asset and liability of $23.5 million as of September 1, 2023. To determine the value of the additional right-of-use asset and liability, the Company was required to calculate the discount rate of the lease modification. The discount rate was determined based on the expected lease term and by comparing interest rates in the market for similar borrowings with comparable credit quality of the Company. The lease for the Additional Premises allows for the extension of five years to begin immediately upon the expiration of the original term. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet as the Company has elected to apply the short-term lease exemption. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:24.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1211"><span style="-sec-ix-hidden:f-1212">Other long-term assets</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,325 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,033 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1215"><span style="-sec-ix-hidden:f-1216">Property, plant and equipment, net</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,763 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,615 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1221"><span style="-sec-ix-hidden:f-1222">Accrued expenses and other liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1225"><span style="-sec-ix-hidden:f-1226">Current portion of long-term debt and other borrowings</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1229"><span style="-sec-ix-hidden:f-1230">Other long-term liabilities</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,453 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,442 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1233"><span style="-sec-ix-hidden:f-1234">Long-term debt, net and other borrowings</span></span></span></td><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,805 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,204 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021, with respect to the office space in the World Trade Center, the Company negotiated a sublease agreement with an unrelated third party that was signed on October 11, 2021 (the “Sublease”) and has a term of nine years, which represents the remaining term of the WTC Lease. Both the WTC Lease and the Sublease are classified by the Company as operating leases. As a result of the negotiations of the Sublease, the Company determined that an impairment triggering event had occurred. Accordingly, the Company performed an undiscounted cash flow analysis related to the asset group as of September 30, 2021. Based on the undiscounted cash flow analysis, the Company determined that the asset group, including the ROU asset, had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on its discounted cash flows. The carrying value exceeded the fair value and, as a result, the Company recorded a non-cash impairment of $9.5 million for the year ended December 31, 2021 in general and administrative expenses in the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.861%"><tr><td style="width:1.0%"></td><td style="width:41.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Amortization of ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,503 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.416%"><tr><td style="width:1.0%"></td><td style="width:40.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (Years):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">                   </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,440</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating cash flows from finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Financing cash flows from finance leases</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating leases</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,396</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582</span></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December 31, 2023 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"></td><td style="width:55.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,357 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> Leases <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. The Company has operating and finance leases for vehicles, corporate offices and certain equipment. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease agreements with lease and non-lease components are accounted for separately. As the Company’s leases do not provide an implicit rate, the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assumed two operating leases as a result of the Progenics acquisition related to office space at the World Trade Center in New York City, pursuant to a lease agreement expiring in September 2030 (the “WTC Lease”), and a radiopharmaceutical manufacturing facility in Somerset, New Jersey, under a sublease agreement expiring in November 2028, which were recorded as of June 19, 2020, for $18.6 million and $0.6 million, respectively. The Company entered into an operating lease related to office space in Somerset, New Jersey, under a lease agreement expiring in August 2026, which was recorded in October 2021 for $0.7 million. The Company entered into an operating lease agreement in February 2022 to lease office space in Bedford, Massachusetts, under a lease agreement expiring in June 2031, which commenced and was recorded in December 2022 for $11.0 million.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, the Company entered into a modification to the operating lease for office space in Bedford, Massachusetts, (the “Existing Premises”) that was executed in February 2022. The lease commenced and was recorded in December 2022 for $11.0 million and the initial term was set to expire in June 2031. The lease modification includes a lease of additional office and laboratory space at the Bedford location (the “Additional Premises”) for a term of 15 years and 4 months and extends the term of the lease for the Existing Premises to be coterminous with the term of the lease for the Additional Premises. As a result of the extended term for the Existing Premises, the Company recorded an additional right-of-use asset and liability of $6.0 million in May 2023. The modification also contains a provision to convert the rent schedule of the Existing Premises from gross to triple net in 2024, which may result in an additional adjustment to the right-of-use asset and liability. In September 2023, the landlord provided notice to the Company that its renovations of the Additional Premises were completed. As a result of the notice, the Company recorded an additional right-of-use asset and liability of $23.5 million as of September 1, 2023. To determine the value of the additional right-of-use asset and liability, the Company was required to calculate the discount rate of the lease modification. The discount rate was determined based on the expected lease term and by comparing interest rates in the market for similar borrowings with comparable credit quality of the Company. The lease for the Additional Premises allows for the extension of five years to begin immediately upon the expiration of the original term. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet as the Company has elected to apply the short-term lease exemption. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:24.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1211"><span style="-sec-ix-hidden:f-1212">Other long-term assets</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,325 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,033 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1215"><span style="-sec-ix-hidden:f-1216">Property, plant and equipment, net</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,763 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,615 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1221"><span style="-sec-ix-hidden:f-1222">Accrued expenses and other liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1225"><span style="-sec-ix-hidden:f-1226">Current portion of long-term debt and other borrowings</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1229"><span style="-sec-ix-hidden:f-1230">Other long-term liabilities</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,453 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,442 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1233"><span style="-sec-ix-hidden:f-1234">Long-term debt, net and other borrowings</span></span></span></td><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,805 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,204 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021, with respect to the office space in the World Trade Center, the Company negotiated a sublease agreement with an unrelated third party that was signed on October 11, 2021 (the “Sublease”) and has a term of nine years, which represents the remaining term of the WTC Lease. Both the WTC Lease and the Sublease are classified by the Company as operating leases. As a result of the negotiations of the Sublease, the Company determined that an impairment triggering event had occurred. Accordingly, the Company performed an undiscounted cash flow analysis related to the asset group as of September 30, 2021. Based on the undiscounted cash flow analysis, the Company determined that the asset group, including the ROU asset, had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on its discounted cash flows. The carrying value exceeded the fair value and, as a result, the Company recorded a non-cash impairment of $9.5 million for the year ended December 31, 2021 in general and administrative expenses in the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.861%"><tr><td style="width:1.0%"></td><td style="width:41.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Amortization of ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,503 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.416%"><tr><td style="width:1.0%"></td><td style="width:40.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (Years):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">                   </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,440</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating cash flows from finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Financing cash flows from finance leases</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating leases</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,396</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582</span></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December 31, 2023 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"></td><td style="width:55.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,357 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 2 18600000 600000 700000 11000000 11000000 6000000 6000000 23500000 23500000 P5Y <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:24.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1211"><span style="-sec-ix-hidden:f-1212">Other long-term assets</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,325 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,033 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1215"><span style="-sec-ix-hidden:f-1216">Property, plant and equipment, net</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,763 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,615 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1221"><span style="-sec-ix-hidden:f-1222">Accrued expenses and other liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1225"><span style="-sec-ix-hidden:f-1226">Current portion of long-term debt and other borrowings</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1229"><span style="-sec-ix-hidden:f-1230">Other long-term liabilities</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,453 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,442 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1233"><span style="-sec-ix-hidden:f-1234">Long-term debt, net and other borrowings</span></span></span></td><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,805 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,204 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 45325000 19033000 1438000 582000 46763000 19615000 1904000 2177000 823000 354000 54453000 25442000 625000 231000 57805000 28204000 P9Y 9500000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.861%"><tr><td style="width:1.0%"></td><td style="width:41.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Amortization of ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,503 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.416%"><tr><td style="width:1.0%"></td><td style="width:40.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (Years):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">                   </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,440</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating cash flows from finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Financing cash flows from finance leases</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Operating leases</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,396</span></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582</span></td></tr></table></div> 4627000 1797000 795000 426000 81000 28000 5503000 2251000 P13Y6M P7Y10M24D P2Y3M18D P1Y10M24D 0.073 0.048 0.062 0.044 3462000 2440000 81000 28000 504000 384000 29396000 29396000 11019000 11019000 1437000 582000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December 31, 2023 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"></td><td style="width:55.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,357 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December 31, 2023 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"></td><td style="width:55.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,357 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 4624000 846000 5413000 664000 7090000 151000 7312000 0 7453000 0 67642000 0 99534000 1661000 43177000 213000 56357000 1448000 Other Assets<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets are comprised of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.388%"><tr><td style="width:1.0%"></td><td style="width:58.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid Expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,092 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU Asset (Note 16)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Long-Term Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,261 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,355 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets are comprised of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.388%"><tr><td style="width:1.0%"></td><td style="width:58.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid Expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,092 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU Asset (Note 16)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Long-Term Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,261 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,355 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 16437000 12887000 246000 205000 16683000 13092000 45325000 19033000 9936000 15322000 55261000 34355000 Net Income (Loss) Per Common Share<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net income (loss) per common share is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,279)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of convertible debt instrument</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income (loss) per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income (loss) per common share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive securities excluded from diluted net income (loss) per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the Convertible Notes</span></div>The Company considered whether the notes are participating securities through the two-class method. The Company determined that if a cash dividend is paid that is greater than the then stock price, the holder of Notes will receive cash on an if-converted basis. While this feature is considered to be a participating right; basic earnings per share is only impacted if the Company’s earning exceeds the current share price, regardless of whether such dividend is declared. During the year ended December 31, 2023, no such dividend was declared. In addition, the Company is required to settle the principal amount of the Notes in cash upon conversion, and therefore, the Company uses the if-converted method for calculating any potential dilutive effect of the conversion option on diluted net income per share, if applicable, unless the application of the two-class method is dilutive. The conversion option will have a dilutive impact on net income per share of Common Stock when the average price per share of the Company’s Common Stock for a given period exceeds the conversion price of the Notes of $79.81 per share. <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net income (loss) per common share is presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,279)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of convertible debt instrument</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income (loss) per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income (loss) per common share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive securities excluded from diluted net income (loss) per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 326661000 28067000 -71279000 68266000 68487000 67486000 346000 439000 0 1428000 1745000 0 199000 0 0 70239000 70671000 67486000 4.79 0.41 -1.06 4.65 0.40 -1.06 421000 358000 2893000 79.81 Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into purchasing arrangements in which minimum quantities of goods or services have been committed to be purchased on an annual basis.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, future payments required under purchase commitments are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.555%"><tr><td style="width:1.0%"></td><td style="width:72.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,864 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements which contain certain percentage volume purchase requirements. The Company has excluded these future purchase commitments from the table above since there are no minimum purchase commitments or payments under these agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into license agreements in which fixed payments have been committed to be paid on an annual basis.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, no future fixed payments are required under license agreements. The Company may be required to pay additional amounts up to approximately $264.4 million in contingent payments under the Company’s license agreements. These </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingent payments include potential milestone or contractual payment obligations contingent upon the achievement or occurrence of future milestones or events and the amounts and timing of such potential obligations are unknown or uncertain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company did not have any material ongoing litigation to which the Company was a party. On January 26, 2024, the Company was sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the filing of our ANDA and Paragraph IV certification, consistent with the process established by the Hatch-Waxman Act. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved.</span></div> <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, future payments required under purchase commitments are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.555%"><tr><td style="width:1.0%"></td><td style="width:72.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,864 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2716000 2716000 2716000 2716000 0 10864000 264400000 401(k) Plan<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a qualified 401(k) plan (the “401(k) Plan”) for its U.S. employees. The 401(k) Plan covers U.S. employees who meet certain eligibility requirements. Under the terms of the 401(k) Plan, the employees may elect to make tax-deferred contributions through payroll deductions within statutory and plan limits, and the Company may elect to make non-elective discretionary contributions. The Company may also make optional contributions to the 401(k) Plan for any plan year at its discretion.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized by the Company for matching contributions made to the 401(k) Plan was $4.1 million, $3.1 million and $2.6 million for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div> 4100000 3100000 2600000 Acquisition of Assets<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2023, the Company acquired Cerveau. Cerveau holds the rights under a license agreement to develop and commercialize MK-6240, an investigational second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease. The Company determined that upon review of the Cerveau acquisition, the transaction did not meet the definition of a business combination and is therefore treated as an asset acquisition. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company made an upfront payment of approximately $35.3 million to the stockholders of Cerveau (the “Selling Stockholders”) and paid the Selling Stockholders an additional $10.0 million in May 2023 upon the successful completion of a technology transfer. The Company could pay up to an additional $51.0 million in milestone payments upon achievement of specified U.S. regulatory milestones related to MK-6240. The Selling Stockholders are also eligible to receive up to $1.2 billion in sales milestone payments upon the achievement of specified annual commercial sales thresholds of MK-6240 in the event the Company pursues commercialization, as well as up to $13.5 million in research revenue milestones upon achievement of specified annual research revenue thresholds. Additionally, the Company will pay to the Selling Stockholders up to double-digit royalty payments for research revenue and commercial sales. Research revenue is derived from existing partnerships with pharmaceutical companies that use MK-6240 in clinical trials and includes milestone and dose-related payments. The purchase agreement pursuant to which the Company purchased Cerveau specifies, among other things, that certain members of the Selling Stockholders will also provide transition and clinical development services for a prescribed time following the closing of the transaction.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company made upfront payments of $260.0 million to POINT as a part of an asset acquisition with the potential for additional milestone payments of approximately $1.8 billion between the two licensed assets based on U.S. Food and Drug Administration (“FDA”) approval and net sales and commercial milestones. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PNT2002 License Agreement, Lantheus Two paid POINT an upfront cash payment of $250.0 million, and could pay up to an additional $281.0 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2002. POINT is also eligible to receive up to $1.3 billion in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2002.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PNT2003 License Agreement, Lantheus Three paid POINT an upfront cash payment of $10.0 million, and could pay up to an additional $34.5 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2003. POINT is also eligible to receive up to $275.0 million in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2003.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003. Costs of IPR&amp;D projects acquired as part of an asset acquisition that have no alternative future use are expensed when incurred, and therefore, a charge of $260.0 million was recognized in research and development expenses during the year ended December 31, 2022.</span></div> 35300000 10000000 51000000 1200000000 13500000 260000000 1800000000 250000000 281000000 1300000000 10000000 34500000 275000000 0.20 0.15 260000000 Segment Information<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one business segment. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.</span></div> 1 Subsequent Event<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2024, the Company entered into multiple strategic agreements with Perspective Therapeutics, Inc. (“Perspective”), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. Under the agreements: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company obtained an option to exclusively license Perspective’s Pb212-VMT-⍺-NET, a clinical stage alpha therapy in development for the treatment of neuroendocrine tumors, and an option to co-develop certain early stage therapeutic candidates targeting prostate cancer using Perspective’s innovative platform technology, for an aggregate upfront payment of $28 million in cash; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lantheus agreed to purchase up to 19.9% of Perspective’s outstanding shares of common stock for up to approximately $33 million, subject to completion of a qualified third party financing transaction and certain other closing conditions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Perspective agreed to acquire the assets and associated lease of Lantheus’ radiopharmaceutical manufacturing facility in Somerset, New Jersey for an undisclosed price, subject to customary closing conditions including regulatory approval.</span></div> 28000000 0.199 33000000 false false false On November 7, 2023, Sam Leno, a member of our Board, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”), providing for the potential sale of up to 2,045 shares of our common stock obtained from the exercise of vested stock options covered by the 10b5-1 Plan, between March 4, 2024 and May 15, 2024. On November 29, 2023, Mr. Leno amended his 10b5-1 Plan to add the potential sale of up to 20,344 additional shares of our common stock obtained from the exercise of vested stock options covered by the 10b5-1 Plan, between March 4, 2024 and May 15, 2024. November 7, 2023 Sam Leno member of our Board true 2045 November 29, 2023 true 20344

8)/* M6T=/P@W0=+8=1YG7D!M!)S\LQ9>'C[Z_$\\O+YZNJ-:RIP[ #QD]*[QIO=RY M6/89P>_>XSEAD/B+,F\>+"/>WJR?UU]HU MN;9WPO&EA".$-*(Z8GD;K]Q728GX1N,@/]--AIT8B2Y%DE;@=1.DK M" Q2L3"90Y4R+X(^QL@PMM%)";= "I?FEF&:3]TMPY4 ))PP]:_^Q%&+\9-/ M2_ !\&@88=G2VF5T@9KA6^);Z;TT9[RQ]\P_IR@NYFB6V$LX-Z\: +,K@M 3 MZHCN%YDO<$:DT*S85ZV"*Q%,,+W1S7?O#: :@(J552C! 7&>F=)"L:V)VD0N MRIGX&[=>14XJT"'Z7HM\5=4.8]F)NZ/ MV5S#=N'N<1QU#Y*N@I.W1X8H8#E+1UARN-Q>'RP?N9[J^&B<$P@W,#!:X?"3 M89>KXKQ>\7CJIJ19VY;?#F\.W.?Z[;T67*B:^B.:1.%8T=Q%&=%3F2!1B/XR MHU]*BS<="GK7R0@;!=VSGVGU(GHUZ.=3I+)\6WL4"/!V-,=G K+"L_8 _YHM MC*D"X)[.PVY07Y3"Y:1=R!Y!MX;!>]DQ*R>=%)T<[UK3#7&/B,K>G[+4EJDX3-@#&<>'9[")QDQ6I?, MU$042XQ ECK/*Y<22M!E^RI(O Q];!W%(VWF0SO%>UP-/3^>^EO6!G@K"^T.!/=4_B/C5L]L0UV3&ZXTQ#+*0LP#7=7!B.F M$J#]X;%W%:7Z2F78%/B?(+8YF9XDL11W-$&D,*6P#38G-@SOJ"TAM<:--,R0 M1O0/%-S6X[D,?VV%B* W@R'13T[&B2*)@=R1%$Y IA\FA6CW1MH)2]7R&\44 MC(^WK(Y%R/9]C9^UVK@B'P(M&";+&]\=L8N3K/P.KW5SO-;#.[S6'5YKETB- MKA5G8L8,3AG-GR,-]HV68\5E#O]4I>3JYE7$TZI^X6'.$3MJB"WN' G7FTC9 M+?AYP6):B[K7JK$CLZ<\U9\T8AXU1ZQ/V:W=7$QO%>1Q$N1!8),L$QX0Y5WFO#- M&X+QV%\' YG@Z%N>G 0Q6-@SHRZ"?ZXKBG&(BSF97,A"QAU\$X*C3UX"5:VU M56@1=I.R"39#02J0?>!,K\.%$"B2&S&8)\_W33@YX9C]T$W/0Y!V++?<4NG^ MH:1D4'_\G%, /EV.F\AZP A#UNN[K^=+> M+^X+2P.$<,^'?(9+(LE*8WZ#5<[*%NI57/N'!PKO=UEU30?POW+INFK)LY2F M__11\'#A<4P)D%:@_[S(IRJB%$*[?J)7>1-\P8<*^^3N:Z+_11\?+SIO>:P$ MS;#@+X9@N5HGM?A6)YRX[';'K"@V?ER+ MUD%L)-\_TC&-X3G!33] M.)^\%P+J.7)#C$GE:8S_3>06FG_LWXC6H?.<.R2HR<,-JM/F!-GPH+!%.E#( MD?U!Y%F,MPY@DK-7I VCLZ0'V[II^1C?BW<8;,.^OV\-GA&0);E'JC&R [5F MM:N@@WREDYNH"SD8GXEU"J\B:3_,37DM:&C4@R%I8<+;>Z-"0%&TH"3[9?(N M*'ZG@03PHI&NH:I*1X0G2"P1@9E\T97*8L%=M_ %O?9C?NT$V!+G^\6QI7S[ MDE FK-&#Y#@^ERJ<-_[2J*5-WN:)@.,YT M6SJW(5R]H(%=35J-%DH["">H\U,JL[!@57_Y=?K)R[VI)TL0*TG$%DQAN"NJ MX!J0KKC(YZIZT5'EFJS<4@']3P$I0+N M%"_2 Q-^ME7YF'6>[ 6&5;'XTG@/H7S@#9'_MY2F%MYUTY5>[7 M=*R95I]X3K7:9L,JD;90^V^@ 8Y$";?LRE.D6.L0FPFFFR[,\:O\+%L0A2]J M3)H%F#K#GGIV=N]VS7IM.VX;(.6"^8$-@&.@W07#RN1^-HT-.M M4P-'SE?)/@KT/U<_>1)FSKV&/%U-/I0*GS6 H+H2.;V$S>*C3JD^!M$"4;'' MIS.LN#ET( =(8-S%[!K"WR7=KRU_AX-B]W4!=X0MZJJJ0)D1'KE>Y#Y-=!$R M$'"JW%3I?$2W_UJE\V+;3]IMOX%1!J5/+P:)ZAZ_#AZ\N0Q M&8,'#X,M.*2O4_'+":4P_K+5V&X:IOF"1MJW03_D#JPPA'7+@5*@\5F3AK$G M-(XY7SM;4"";6_(3# =.,2,RP&(5U9(DWZ)9Q+ZIL0]K9+GS(8QZ$*7*K,QR M3TXJ+'EP%(NA>;*I,=P,5X[I+;W22/&4?KA&[,^F\YF-Y,/.2J<*7N^/';@6 MS_0P""EP^,X)3ST+*]?$Y$4N;TABPC6%?!_X9 U'*-<&I$P3)=.\^V*F5./$ M&L5NV-5%/>QR1_4EJJE[HZ'KK1"(Q;R2+@L:0KB.-/E;LIE64[\,^K8BF^S&%R)BPH2T M(K8JQN$WZ=?H/\(:%]W\//_XJ_Y>,\.>4F]>$SDDD7S=:._5O*4B]$VME2/F M:A_<=$LOQ,_93H4/+\JE, @,O@#'.V9B8T/ZX$-">I2[(80.;;T'/R_RC+4= M[E&QU,0D[?;$D4WMV7AZ\<_\O!S9$[ )*QY@*FDA+/Q?7<[_T&[4EAJ+6QT\ MRP6S.(V97V5OJ(T0L)##S)PBK^(,W7;+<9"6VN :C0!&1HG41Z:9EICTZ//B:Q3R1;HF+,KMG6BW]V5?'IP2Y5%9^! MT/P4)9E)B*;."M"VB+C_T)"0OJXC=\L?H,A(#.YN#,C@ > CH'O00+E-[)) MK6S22$I0M$N5VZ7>G% Z9@[QX6Z&D23S\.]VDB_YC/:7E\Q$+FCD.=^WK*3+ M05#CG,"+)#\).HA^$MB3;RRUK7:7387@.0*EK?QOMGJT>,H20,% MW6TQ\N94\-GZ4^.6V"-[)^I>\!84P)*IM"4F(3V]/Z6O8DB'\?[2J[FHKP:O MHN&E+!3A;<<)*+8U6&PQ'5UG/C1!H@XB34)K[33(Z1##'=:UC)SEY?"C<=NQ M/DYJ*"#&VQ\&76%$W#W!C-]>UJ,@L@=^>>6 N 4!N1+*BNO$)I-I/F+Z-\T- M>[LTB4'=6!-WOB9_A[$V&,+@]VD4CR^G(5*/!CFY,6+_?,0#J790?%>T9$H==%QD>2 [L<\==B*15O, M+XMD:-=G6@^7!Y2,W@G86\BE.PWBZ_EOCB84XNF?!*]W^-UW3ZZALCEQN_&N MF%Q40"DSC]KSH#[KA?"P'>L$%/G= ,&-DMN8V.W>+D#A[LD M)SHF2T7RX5>(H7 Y:S0O"C,?)6.VG8^_/3M^.C(F61OE$^&OX^JN@FA\\)H*: M;]E+QB_XD<3\5BILGOA35_Z3]NJ-]8BI M@:@;D,LA )5=8FA$/1LE19\YD?2[)<6WIPD+U.B189+.4ZF\D87/'SD;@ MEAS-C5F6177!G%]1AKS%P';*(">G"+D: ]3_);W%-).@3C&!P^>:LA%!JF7\ MZ+9EXZ>QN:_O_O2]3](9?1#@1UQ0VABV^:GW_!%Q%Y!#Q(W XG(53 ^A_=1U M)TI"B!N:X789]&\CD(HH2B_+U "I&TX+ID$3MF1JFY@)15KRD.BG5IE-SZ@L M*E$O6WU.3CQNXJ1X>3$S26*\]>E( PVOYA4S&8N62[U"CQF/Y6;!&J19F5@' MW4DS,1 8Z_E*^VZ,*T*[I"D9"+- E@6S['P@[BB^]K,W5:'ZG>!%E+KJLR12 M=#0/;N5TS9D D"D6-.@7BSS&M(.CB7]DV!@CX]/CR(CH1!LU/5[ MI[]3=NL#SDJ(K"\8OIAJ%JO*ULT>)DR4*W/DM6AN\XXNBN'X$16C^ A,\T%9 M%I=%S73QY-TEJR %ZIN!X1+-J%M)=#A;K:C3(L&,7^N&(MF(I9F)U[K)W2-8 M()_E8V&79I90!,WT4OVWRY:YD2FK<9$W&OE')&-ZWU3+QOE+=,X)/D5^,26L M4UJJ:T+]4>*JHG-P9-? A8.@MT(,RV.L!K,A[^356&=3<'';P=>9KK9>KO:< M.E3+FL\+9TNW/\ S)!6,9 ?2%^Q):XSY-'"9>$E6Y[ <[_0^]#:& L'5.?' M]L&8,KVB3'$XKC)%W.2")RU7J6"'9^P/01[MY= 'LE^96:<8TB42A! M>V 4*VV3*K82#CBE>V\'=Q8M6GP37) LN1SR M*:\%P]NL[&:F$:\AA5Z2J?,]4$;FI&55FMX-KT.+@LES) M@!#H$S%WIZ"#00:RC0:8PW=09+9DT'P4.ZN'[8:W4^-U6E'A6= #RW13F/Z%BY*VDEJ>]?;7.O)-;;C$I9CZL+ X,AX<^ HZ#>C6Z@ M64;:R)B]U_V\UC]_..HU\UMV<] \1RR7%D/=O-AMQW6W'7#+MN!Q*9N6T!]WU(#,?]!]:?LEHO&3-&'1I& M#W=I \S]J6:*DEGY@5H/KFCTK_R#,V*40"UF78ND$9%QH5>8?X8T-Z?%8V,2 MM],U@+&SLYP@XQ9U58/-,!G[:L.+&.DF"^9TH-#D<98P7\L_!@3 M3KQ>=['L>=U8P[/?5";R3GO #.DWU%QL=8$!;#^QG6DE1HHP9>41:1%R,US0 M9V)':@(2I]60#+Z3F!-!B 9R8TLSS#C!VKL5STK.5U+=D$T;IMU7RHG/X0?8 M* KVTJCJ^N?)>4YE59-@G+XH0)!G@,I/V53>0IOAAJ1%[!CA?9C0^,F>1(4+ M240&R]AI-U@(^ @##R+%FGGQ8C44BZ!1$+IB0@S40640ERG!.MM]EJ_/UMA/ M=DEC$^#VK4/XOY"=>8=90CNGL3]*H<"X&'G&J*$%_H+SE3:T#\27_82\IVMQ M5H*&)I0T+?8=)=7DM,19&;K5QW73=$M,8-%;I+WWIWV^5>O&9D1LC(XE?5U" M"4GS![F+B9*E7FD3)J2;C<[ZYM+2V M+1W8@)'_8SB^LUFV(+=[Y$ASJ4&.N[WM;T8 &=FKI*D;&H\*N;04/*W^PV2]L.SH"@\M6RQPH#=*A ME-0UK<>9M&U#@Z$'V32 >5/QPRQ-L V+HEA)0YK+U4Z+&44.VG)^S3YS7/'" MTHF6S1/\@DX?1#'V%S+:'^#@KUFXZ5\H2]V&K*0-*- MU'$K_>9CV6G&;KR)>#5JG24/F/0F5+[54(.VG4]C+$%TS$&G4BT_(6V8L+&4 MLF\+LKQI<=X4$00\/,A \@_]=6^LF'1QD,K9O%3MS%1+/-9Q(X?^K$!O!F/? M@BYD*\0 /KN3=G^.O(,Q-XX[VUP#%DR-\H[P0Y14M1)*)ZU0"I0 MG!P5((+"C(2D>L)N$F$;T60=WF%)HRH-)T-WBX!!P&9(#A2\% ]!&8(N]4M= M$UK#XJ8_8#]$^W%C].W[\T MU9Y]<2?RN&RT8<@#7%,Z5?,)")CU6%;IRER84GQS>!?&T-QFRSV$*U3YG$Y( M9$3@$VKW5]I"J> ;-!TP?2H!>BV!L2S#'SJF;+K,_YZW2WH]A SQ'(\?2++@ M?AZZYX7H$+S,9B_)67Y\LFUTXSXBH,85TQ6L(7:@C;\JC-@ MD^<3MJ1F7 J?;0!^>/(/-0 W;O?G]579-NI(O"86O_;>[O9/9HD":JBB+!!,A?2LW09GJ5"0B-X;:RG&EQ*;F)"RB(U)W:>,QE0WFT3 M% P[]$6R?MAZQB1S-#P8:1)@$>K&J8MK>Z>C0]MS%J=H=PI.B,Y#_#U6PVTO MBF7*Z:'^3E*M@ES\KX.^@R;USZ.HBF FF7?2WD$37Y(&$[0UY5/&HW,'K^* MO]B'O_C^@+\XX"_^F?$7I\:6<9O=H#XABG-CQ85)Z6F6\6&X*8&>08(]_,*1P\4/J1U,!?Q$8X /*Z:GO?%!1BVV MQ$M0]QOKCYP#F+*E&,Y["8AY:!D+'_4SB^ MEEPF8">#BA)H,T"RWYW)V6WO]:N7_%(M,QX[*4+(_82??="V$.>Y\)-;X+MV MO & &JOES,4E]%:BF&&37-U%L5=Y"QXT"<@RJNG?8PQ7*QU*RW M=RIYWL. 1MQ6+V@2:P.N@2PU!]PLQQ:A[IEB(S@<1:U2+30O;T!)\+2D[IS@ MC&3!M>^Z?''9DQHY-2ZN-WV7&4,=C_ M$Z5S;+/(Z,F=M50H3UZ*'WB^<\1HNK#E+9A+P%K+3D/HW=37[&63J)Y_$^E< MTE]:?4?[1Q6 'P$ X=?2&KL,9JWFWA(JF:49)?0QIE!<) %*U*YL' JW.<+? MM'[Q[/^& 0[_&Z%O19R,64?)4=&0)4%&LKA;(/C1@FN#E QL@DW@2D3B4#KM\U'7"1<[_]]\MWQXUDP M%!4 /#<]"9Z94'!^.MUAOAI=^LGQCWII_)C^\IW^)=,81/KBM8G8Z;N0PT ) MWJUT _BS8'"01*I,8LF1_S2K]*GC#7X9.V3B$X M8=DC:*MP28/XV25F#1%T<*\NA"^7%G+8Q8BL>=WSGPAOAHB4P95M4=27#>WV M"U*=%)/"DQ"+>DC>6S4\I1]0?\V'Z^)S\0530O+H5MD7^FT N%ODV'&'$Z"K/N2DWDL*1 M.0LN8FGYO&41/+:.1NL2W9-0M/I;#HZ#-^>VK1:7M )'"Q<+5^LXP'35?#R+%;C<$4"SDXM^6@=M='GQB/ MYO2CTS,^**_"#?G)P[$))U7.EN!M1I3'"O45"NEY HA<5_6?2=B][PDD I*%.5=B!#W:$7 MJRF-V\;X6Y.: BGO@2(QBYW'"%-T1!68.>_+BK*.]_$(>GZ'@%]ZOJKB8Z;] M7BNT5W+PI_,_)S>UX,"*G/3Z K8UPE^';IMPM O<=II$1+,:K M0_ #JE\IXL4\QVGG>0?FJN?<1HJ@-OU*A'C!!AEWOQO42$+CSFE>+J4QMZSH M2 18$*"GI:(%=.WH%#;U1<-MZ\FSVUK)Y)HLYE!)ZIT)ZA30E+.^BEN:CF<$ M].V#BW="&8&^T^C*&'2P":X!\[1(KH3**]S@(CZX93TB*A^1RWAZ#>/.50C[ MH:1UII<*4'\[9#\VA.]=3?;6.)RD,7_XYML(Q,H0QB C]<.C'SA_..#.L9+JD^^'GSN$>K4[ M#LY,76C\[C"92+=%81(P[T:"LF FVPO%JY&_Q'5>>%H3-4)/:!P#[7BWDJF# M[KROOQH0T+.2SCXXQ"]K$^AE_2!$EX=^*9X M<2#+MKAL2CH'D=;"%[Q712N'4 LL[>IH>B8[J>"JD0<%1&;1BF\\#['""J*' M/4*\Q8?+I@)+H6RHBJ!Q(9Z[AV?/KY8W6Q5KTM\XO2R+U>SYQV+18S.SADG+ M>B%\G-.?67>7+=&W&?L:@$I8>>CT,B];17P\;<()E;$#K:J1-)I_I4[",T>: M 018^)K7,L*P%W79)(F5;4$Z=X;]@.P>/#Z>)SD_GR/0"D8JOM'[\$/+*9,M MNPYS7?-4I_G"[Q[]V[3UPR\XW^=",0H4KI1$@](R^.52S8#L I7*89C##*GS MXJ);/:NZ,+SAOGX<]OTF\[2\,_?_;F+_$0TFQ:I( @-(WQ$' M39K1.DFIT&U4>2\VYI##?&$L_H 88TYW2<=@"D3>M.$,*"%F$>YL?)?>C>*: M4;SI\>RY:E@,#B/.96T+:9\AA\9Z183U4:K2OA_EWZ7AVAI>0)1(SAAX\M#: MP AJ;@?EK!/UKC"+;<[EM5CZ2MK\A8<3M+3V,$8*G8B%3PG>X)Q2GX1BW&K: M9T9)F^9>7% IQ=!K**64>'0X":4P/[D8G"J=GI'R .<]*%)'*\5.9:UL+9LX MW]QY6=:0=3L"6B<3]XK_Y;K:])QV;!_X,$10M1 E)+J. F(=(8!"#'9%O?^Y M9-*694=F8FE_5=ILU#T($)WIX/(C MT,IRH6T($!_6VDLN3N> MO6_8ARB(4#38Z+!%Z$ FT=RP2@H&QU#]JRZ8V4= 1< P;@IMBR)Z?ST8%D-2 ML/\ P.!_^[S= I:Z#:<2!?<5& =H>UM1E*R(L2WN!!F@L 2M<:"V7Z2WZU*R M3*8^"]MF>QEN6!?777!^MJ9VAFSB@DMY5=[7"^8PI[Q$,&P$.=+*/MV?$DD? MN6.6]J60)(-W/QQ^W;8JYH24(H65;872/X[\.8!G2L,/@HM:JH=4[-JR?'J3 M.FJ274@O'$G&ZJ;>K5D 2,MPY#.4JUEG#++$ZZ_>B>=HUR8=O1?Z["Z$VH&% M0DPD%L $?/IW%4?"%^+2@YBSDDD1H;NN0BJTD+_474;/BM9-0T/&OHO(]6:!0Q15H17^H=IKSH, WGD/G3." ) M156['*@[HBWORX@%,EH6G0&BX0I1 .F%-5C8\#+S'L\5H9M4"=*= MDX)Y)7.#,F;3+CD]:& KKI$!I\]H:2, $YHZ0N]8)OOAZRV3G5H@ M^W-)T*7[MZA?-*PP'F;X\8_??4_A)UTY. L$Y)J]$:"MOB@.,(!1I?DOV"7 ML9=E?E$W(.N*85Q.##=M."4[#K">'[\\GBW[V5E#"=8BW&D=KA7C4JI)&W:Y MIV]9FAG/]\-C\+2$D:YFKW>T=\Z#ASB?1\*6U^?V"X+G1US*0L#MG%"V9QV^ MAA/ P0954+2CV4,]$0\W.TOT2[&3GSQZ]!@(1Z69#'_X(9N=7(6GSJV@>B9[ M/YN].CX[WOOQ[,';U:J[;-KB(7\3(W5R>G9$>5VBQ3IMCEZB>R)\_NJ4.UR6 M,>O[<\-8)#X\_1CL?7&@)<,X$H7_["]]74C-]!'$3[Z3GD=.FE <+O2IE:.M M808K,8(+X.8Y/)"$O_X8>.!T8,_"05O4E&!H^.YAUH6R_X'C4X]?.XF_=SI. MM]SEE +NO(\B4F@<>5DOCNFV+XIYBZG[7D#2_L[ZT\G[OAV\+X0,B.5BJ1H: M;T[.GYW\U^S/53-'71T!8Z3"Z7;K>5C;- M @E2M #M[B$17C2;DK.>M*A/&)GX#MJ V# O" G_^-'1?V:S_[*H8N+S_\IF MIX)E&W[ZP]%_LK$8T/8V:&OA[Z[*BI-GJ[ZMV8<.9KXCQ6'Z\CF7L=AN//[F M0?Z0OOOXNP?+AZ;+\E&@@R?(!';!2R=?NXLL^3O-9V)DF+DW?0IRE I*O@5' MB$Q9^ D_&&4/L_3QJ(>-[GO^_#0CN&(AT1N!X05:I7$)4KYD49MV8NK,]T]^ M0HCF#\5.XT&TZ?C6)$0-E( 6&ZDW$+M,/U\7.3.LBO@93;=AN4)TS%\^.$TD]47B( #U]OPXQJ4 #EP1'01E6?1]$ MB*Q$Q>TH>G B@$Y6Z6"1XNW#F:\W0@FZ "F4(N, ]E\6VKP'>+XQ>',E_7*W M017HPWV$W+Y%R.WWU9&VX'O MW&8^F#;P98VP_OE'J$G0HSQ5-X)_1JLX.",7/>4QU4DK__OINU?FIO'Z.Y[A MK]"KJ-VV#HL2EJ_2B_22'+ $JXB]7_GF.K!L(#AB>2KMH5/[?$,^[U *'Y7" M?]A?"O\$/^3;_W.HGQ_JY[^U?OX/\E0)5"S^S,GQS$.*OT9W=6^.;GJ#_T_3 MAR.>>]MS(JN7OC\I9:/#DK"!4!BCG _3V0I$NB8.'JGMH-:R%,WAI331ZDE. M%VKJ"JASM-JMQ:U0+!7I;=:(R$.WAY)3> ME.ANKW@NI;!W$[4[7KW3EV?4O=[AD\C@<>8+P//2+DJ)U_P-1F29'FSIM4-IKVOB7MF"%/FX@ M"(2:T"%^E0_V)-8@!2:<'G))*\NSL M?UZ=O'OYXG\X$%O$05!BLU*KC$BWU[,')]P6[-KDSUZ_$-RT]N@7\;KT=^K; MU>LM"P(;9;,'3Q\.^1XTQ^]_Z\#4#TY'OQ#V=&N-QC^4')J]YXQI)'+I_%;2 M>(H#]#[ATL]&E[;K^1$"7+M@RW1V_OID=O;\O64106#K,Q8:N#M&9[(B96O< M/>_/WF-G]]V BX)PT5QL?#YZLH4HO$O'89RS\ >V:;B7'T@8-JF\R.*^T^[^ MJG)-[Z=7& N%!).W!F*)AB3,?U6N2O35>?>IE2MU"E*M^42U6O7QZ%XXKH\)X6?'(A<2)Y(SQSRH/!;9Y&XX*]B@R% M\+:\>':B+!FSKMCDJ-:,J30RO@^]$G];O\OJ4P1&]Y<,?DL5SD3*0OC7!/4J M_<)B\WS1-J(12UU#DCYWD'?"'9T+"GCKQI%A M:-\B7GC4Y"RO8!>C8G2[C,VRP+M4E+TBP?>J@H9I1^7_OBK B$B7Y:LH+^.8 MC02#7^4[]AGHPLLVOY:*T>^@CA/;'(=.6G$?VQ;]RNF:*FTOHU[0ID,]"!B. M> *IL>6L #O,3G3"L=MP2;J2=%KDY+ $6ATIS^UA^ ?<'.) J;G[@"PU^-W% MY0JKRLK9 _Z090,O'.W^!*72@N!0YXKW0N6>@ZO4W+*!O6FX2=@).E#1[OC[<>R*>[YW#,)88)_,MY4C->M30Y,V#W4M*R7XSTBV@T(@^T*\$Q>HQY+V G^K])CG-WTAUM!-L3MS,@( MR!]1/SAGB"-4V1Y1T)=H[.=7TD=)&_1 %Q9,A!!!-3H1 QYWY'.C51%:.US"%V MCH<::CFF#&6QV6[PO6QV^OJI&Y!Y9VP7Z1"#R/@!],;! KR!3 T(WJY\ C'^YZ2EID%ZLR+0@8S M#+7V/,^DW?G;8"'@C;LK\;?#FA%=%"D*VCM*6X/=[!JF0DDBHH=DA.7+.[P+ M%FCX(:WL:SW0Y^$)*BDE<-T-/-X35E;/!+YWH48.^1&%QL(>(SV O(O MC;(YJ/MI5V:(P7X_C'(CM,12(O<[# U^S>DV=AKW!DM&3J&6:9(M,(]SMV^4 M!INF7.TS.DSHZFV-GNZV#_19TO=6GK">V4)LW,:Y_?RJEF0 MXFXP$ZAP84_2K$F3T147F*B8VI*#QI-CXVFFDJ>"ST]G<5'95+37 M,P-(=;,'+UZ^>?:0"_72TL(*F/0*C"K4J,K;/47[.ZP5PLQ-"IGR)V-<%XKH M%U,0MF@T26_/SLX]22!MWY7QVB[;GIHBYB50/8O.3$"(,7'/R:= :WV1(^T0 MP3AJ#6E&PJ'4+[0?+A^_LJ*9E88+3TXX VHY\Z2TUWOL1O3FHHR6^J0\M0UK MM#:B96KQGL2:EHH:'!3:)77C-$3R'W'[-,%".640W5#TCP* I6=-" TYK?#" M3$J&OTZ[E"F7S;^F2TF5$S>S%&LPGZP_T+';DY3C%\E_*7# ]2U]?M8/686D M(\J#E*T?CI]@^A*=4H=1^X3D7(Z]P?4"",56!3^WUTTZ C'[\N?\Z/L?CIAU M:M\],3#OBZK\.,)SOI+=#"1L,)+4FS [^;/@5I +VS<:#*,D&<[GX6>7BEYRF@;@;6)[@ MTE!S5YR9/G$-*1/&[N$2#MO K.0SJB.T1Y8;2QK0=(&!L(0?LWN8B:JP:/\F M+_-'Q: H69,+L-2MQVF&JX+<@J0=#C,8/5]Z$;>5MNR2V9&: CH?MZ[$ M$CG'B QV7G0X?R6-XW*G>(5\VV(?.F(5.\=E8ZF5.^CB_76=8<2@U7+ MH59T9Z(5GTCK)JE@:Q/46&T0PO)1J$=@>'GMNN08THG?#8HZ[JM^YD&F:2F! M2OB D.\)GL+1E@#+G,"W@":<:2\@UY%3PT.6,L0521. M:#M$-H>#0QP9"XIM MVGBCX)2$D4'W!K(XFRV_\27%>&6M9!F\/O./>9A;]MX6E\6ZX=?>/13T)VJ; M8PD^FW!4::$,-V0 M_%D9;MSH#@\L+GNL]R2+@0$5,$*$;.?8/*YV*:>^43YE:@%KBTO"$E/:@I?. MJ18OT(=UT9=+YF&VW-YYLT _-KV!)C"0+=".X]=-&#\T2K^,LX^F+I>MH85" MZ7K"0=T:I=LD[UL)&L,72IX&E9M(>^-&>M^X0G'/I8 AELE,OEO6U*_X_,7+-R_?PR7I^GFS(8;I$)@M+IL%I7.DNUW)FG/& M&UI(I]&0,'MHU)G\?'.YTZ6;G'UL&^!2Q,@4AH'7 -TH6+HB%3JEON3B(S-; MTKO&'.E]1.U<%E_/)!_'[^U+J(19:?,.DEE%?4D;,IHE#NT9"_/GY[.?4UZ9 MIRT!2Y)DQVB1T"T(77+376+ID[(D>];9O11^*"*OAI\O:ALV2JP$N*-J,.BP M*[P/R;NF8_(:(X_$#-JEZ8KVCW?O]TA&CVB+7[HOT'%@EU"^_J[\.'L+#,'L M:=-\.*J(^&,Y6Q=A;I='S8I 7/J V4Q(D*7.RS5'?NMOOA/:^JO1-^0+?TI1 M*/'U!UK5,AC&S42NT<03XMKB ]#5;WA7&BY]7\SAU/7L'5WXQOE(3=2(B"TT M:?Q#)F_Y'<%3MH2XUV#1T&)(C\5Z!RT#1B382.R;[7@_@XEJ944LKE,6SKMD M69#-VO^ZII"3ZY4DE2RFZ*\O3UZ]?OG?LW^CD5#D(YT#$W-PT]JRE&TI[?-/ M'E$#_37[B3C8]3R.QP"U=Q;A+I&+A)P3]EG)0Q$U1OK/X]DO5A_[F22/CG[- M/Q)5/.J#"C\DWUD1AR=OGIUP>*$W!N-M4\>8($SLBG1"QL70<)V]BY"KW>K$ MEES%;-J(VN9]1/?7M036"57;VT>HALU)Q$R(-]1Y419@M/13#2=?%UH8&=][ M/D@=S,N&D&PA#K?L"]?,N:16%5=@ZKXD-9PM4:FDQDV^S^#Q?)MG2L+T,!@F M>7@-?85Z 6\Q?OIE4W325[N"* M^N7>,'W0/9Q))W_B=DE9.>+LR[+=S-C&4 MB9I:#[GVA\^^>_3=@_G#!T\>SFB*X&#R]V2J\ HMY3)0J5+ (8^X%V\06HN5 MF0*,F28^N$M:8%;=-MAH\G-4Q-4O#1T;HN&B>$OD\(H+]"9)(L]ZE-E&#I:7 M#-;X%>-7'I1T$68X1?<./U$;&S,FU]3#V8-M&C6A!8@]L3115E$,*ILS51)&PL>R-R.8+A^/:[L#AWHNM+ M !W=F_P$0!&GUS;+TPVN")>F;Z6H2'4JL"4$)X=?OD[AR%M? *3N?+K:>/%; M97T+B/(#*=IG"EI&,_*LW]#UOGG$+&E8*C(HI'-',/=YL;U&FB-Y&@ M6>TH-%_:&_&JT:OC4; ]Z+$NFS9L*/JRY(O9SNE61:(.TS"X<')7:P%?Y5=$ MPQ1-:WI3@W[QQ.V/@B] GGX2S&<^\)J$*[ M4GCPK0O\E_.S]V]MS0*-5#BNFLVFH HL_MYUYJ51H8Y27E,;R_8O[:Y/V5J9 M#,^1&YZ(=*,;[ 15&3T62\1L6324!F\>171O X@1SB,F3 @931R&NM?RO5.? M#7XN;AVB]CZL[F2.AU].025:_ ^;9,M"WFV$H-&)[G8C/T6WSR/AITT:,J?N MN RFLUZJ5;!5(S'Q_H/>K %PS6%TL'8DQY2WTJHEZ^?K3!#=0:,&%@;TD2M: M!7:.W\*AH1$*+WS!W%*='UDZ,?YRN.[BI/*"WI?G3,%([M)A\.62B; 7;+N* M;3-'(G][\!S)C[*X3D@FOKAVAT46=GI>]:J*2YC@^H+S)\ P6'9I:J.P,IE* MCU"2=I.+L'4T9:,#Q\Z951Z<-B@I9#IG:G)@OES9J7RQ'^T!BRLJP8U4BF70)B0A7@\",Z3 MH=?%!0,M/PD))QF2L;#? 6)R9Q/[S:,#Q.0 ,?EGUO,XB825X'CX\$L$/,BY01TY30-;!HT6A2OQ5W75T7>U:7+-KNS;.33 7E M_JX4)\+&D(Z'?WP9$EH9.DP.L7&SCWO[7ID"Y'O\_=0VR,;+5 KIZ5LL\DUN M(@6X#PI\>Q_J'@8W[)%I1287R5Y?XB)3A-?>6\= Y[&Z50Y_2V6EEC6F)8"* M9=9!V3/S'XO7/%%#O:DH>6-9-3,"?5>Y%5EW;N'5B548O>7P?=EE9,5NL&"< MZX3G#4.;+E%KZ[_M))#:@#3U34V0%9T5)YU ,H8U[:D>D#_,\[U'(!""*6K9 M/UBC?H.@K"2U@1QR]09B\Y0?:.DG3:6=="+U<^*#XEB8FL/8M(//05'XF"[I MQP)-*160:BNTM_FU,4 )_=9&YF??8>2= 9[G369Y%E$UR$V MS\GJMRS^_Q*-+ QBIHGEY',*TL,R7D.HMR7;'XZC=,T)L,1(ZP%"K"JWIH(/ M24RSA4'_[R&JY-?"N'_NM J$V4L7V,XO*Z$9Z$2LZUY"*_;2S4!=^3=SX CI MG?O:S/=(A9NNJCZX+>&QOC*&G+-7_V-W^8.Y<=3==6Q$]3(Y6_B3W9#PYC:W M39_^]R6Z2?PZ61N2_W38^3(\BO6>H>,VX>/LJAK'-,3U;7T4P314*F458&]?Z4=OGO_R M[NVKE^^?A\#QY-VSE_AO3AU>Y8N>PS**HY1 @Q_F/'B7?9B]I]K3/#MMCK/9 MJ^WRV(IIYT\CH?(=GL3YUH/N?SK9F8,="P*[<[MSNX^JMDVW/3)N#7'Y"E/Z M,%?C1C>#J_%X1CUT7+\B/XCU-"#9SC$R-;@6(=:NI2< >(E9MR.B=D@_-Q\+ M5:>LNW[-G"*]8Z88Q9$19(TNUS*8VEGX51V9/1F 4;3!PE,A8G:1WW+)))+1 MWEG:.NH]H=F2U">*5T33+=1,3=L]C&;]NE!^!73C-!4'+4SB*<>Z88#JG2.I MX ,?S$!5)=2 \0MC?\_-5&1ZHZK&Q.4L8$"X,?];P4C:'3#\5YS:0;@N3$2Y'@*00-X9'#?-.^?%E0[1N7;'H(=X;)C?L MF'7X:5Y6/1=?0'GIX-SBP:\9+JEP)K4P\FQ;562!#&_=$3NM?+38S>F0D3O. M65#!* ;IX*6K9;5"'&QR%'%4L\" MO"HU_YXU?/I3$#KI-U_KT3U]GL=7 NPE;NB0*I.^2Q MAWGL]YR9?-STW<":'0H@B^YKBGEV:K7F@8->P$U*D.P)6 M8J+D!;&$=T8=?;M9<"\?CC+J2.=VD)K9-;W%35W!/0MLD("+LS*_6X7RL.ZK M-Z39'2N.&JK\JBD1"*VY3"]2(.5:KZPGH:&+:5C5Z-B*XEX!;O9=]?5"GBYA MT!VXR/O??L_>'ITW,BCI7AY]"Z#9R$MFM"P1\5MZ"OE+4=K$"0ID6E)<@/6= ME'QLA,I)H^BE=]5BNC%$]5A4XG.V(P08#DE:.'_L=S#!U0%B.4Q>,#RN* LKCG*(O/Z.45^;]8EWG='/WX M(W+"P>DHA<&#C@SX9@5S$;OB#UD=XXZK>]!V,OC37.W43^,;W%IZ\23-7Z $ M\_M68.Y4<_BJ2C GQO ;7O4B#$TI7!HNM1,6 2:+4:&^CX^S9:M21-YX2J5* M(Q*%[.PBC.7PB#PCEQ*N8Z,;!?* K[Y\]YP^>%I4%V4?0O(W[\_HW^BL'!'5!QF]%]E-^S[_Q3:M,FXMCR(S\C/G<%% K3 MT?(]^:Q/WSU)GO757]\=/?Y.OWOZ]S",A'J&]&$V^_G%._J(=MP;-,*01'%8 MH^O9Q\R;=G)Z\&[WC_0D@0EX?EQ8$SZ@YA4C,XSY)/++==4:T8@U"+ MS,Y,M(N[?JYT/J3\1].>63?F)%'P_1NB4<4I%Z,,0D1V#7GIBI'&*-YAJV1[ M]@KB *:W0U>E50?HZYIRRRO?XE2R3YH\!H(U(FDI&,YBE_$Y0,[!<4H@PM6T M/I!<3\Q'H5&M'1K!Z.-\X0X88>7@O2N7AX%2ZJ#K(K)G<^M5SD#ICL#;+?)> M2;P9WY,["_APDQXW,0+:QTC&A4(=R8U)N[_SRBF2Q.KPS0U,"RGAWXH&GD\W M2F=4UD !:9V;4^ST1!H]I\$XM:]1G!.>D4BQBJ7+K2+"+MHK:Z=P24:VUSP1 M(^,9\Y$+;WC82>% MX6<+A^>VI1JW"N)&*G^6K!OTX=ZCU,5]_5!BO?]9Y,9E8YZ MSX(U@&M5KK@FY1^#@(:RR?FHUN=!?@2=KL9_&M9R)%K)N(<%E"/F:\;L$=\C M4J=Z=RY:#G$-=P,GQV3X1!#/DAI9+$%%/(.N5:%A.*SSO>O\M2.?]T$&IY%T MTO0D>!%\\F#APD5.G[\[/:&Q?=%JDF>5S^D\(ZAC^%LX[F;,&YGRO_1AHX[&'C75!T)9KQE =,H&*LW31,Z,P+ M%%_%]549+U]-$?)OGJN=X;3Q:RUT8-[^6*. M"@OK3=A$<%[#IGL\2T5*3EXRW(\H/T&-"9*NI4@[()CIFM7V&LI3U[FW_ F1 MOO8HU/ :H<0[5E3[S!E0+EZEXIV!Z73$S/,?=YVH#6V,^N*H*E92._!3=_3X MAW_8S &C]_U/^B)__".D8_/X6U[%D3Q(.'F9<]'S2^OLD5^'5 MQ ;LF%%/>==I?*4DIRI Q-F0,/\0C.;T MG+EZ[4@3SC0C4P+91AKRJI&>N,.$?ZD)][5YUNUBY3D$ 0+6 MZTP^RFB[L2I&FWL /90<&&<-H<%^F,8O-(UY[%5I0?P6$9=A2DKPQ3)E!PO& M];5BCBBU8RH!#"I*+]3LT7ND#_\IG$3R3?X6WNZ(GI>$;D:XJPDAK%@DC;QS M @ MG<06@#[_VY>FQ:;7!BZ99 M2HLI(8?2K#2K%G#IV9GUDN,UFO5!6OF6[,G]\XA/.*B,$-3Z[E!#0<)&I*Q+ M:R([1#B^9@TKZ1+!]!!(K\)R4@5B$O:(HS1=*L2HDT<].=60E=RM@]1#4I1; M!@#^*NIXFT?68@HO?2\3W%+;[WB"U#Z"QNX/&GAQ 8P?0V.\+ M&OO^'W84?04M&G01IQ)_Z,?8UX^1T:&+5CM?_Z7AN\DUG)*LM:!Z&G"@!3K? M/2Z>@Q9BI3'\2F >XIY;OQ(X?9.Z*ON&@\IJK J;P&>>>L'SX%!T\<5I#?+6 M!A]QVM[.#=3<\D%G*B=KB+4[_'HWT)W:#KOCM4'2-[E3;G_4&S\;]\;SD6J, MA-M+JS)B*]S8*^\0BR#I7N;#OGF60>>L^IITE#%,UNK/;4YGKU\(@37J$6 H M1@%A#F5Z3)YUNE(C:HH"9+J83^E9'7@S.FS,.V"1@!]-/)&Z4]8C6G3*2*C^ ME'!?YLFR#@\!*2]AQ^QT'(G$D"!_+#YU)#)6B]D2K3B&+Z)*:LRA>])OIE,H MZ(=;C3XGMP4\K=A*H_5D::EMV(H"G#%"Z1 MW1@45E@,0# D).I81%:H6=+"/W*=S:NWXN,5S"A9WIVD3F$]BA^+534\+=U+[!)*T9(?"SES?S($\GU*AQ$%1_ M@*8G9\HV]<5[8EX/-@8J7V%Y$=N(DF2"%N%WH/WYEZG3.^D1Z_>[+/*K$A;# M*0+ELU5XAHK@$6Z>DF(@:V&X!(7BJ@T,1Y%D51QM+L.B"6%B,$,0]J:CO:?S M_.]8!VMEGGIP?O;\]/W#<#*RIIJ6C90XSU:1X!K/6I4*C_+Q9K0)>'(17"$^ M-&+'/?6X,Y]7+/XDJ'6BM;!3T+\PEZ&Y\%V10)Z^\'XE%1S#FS:\0%OR@>QS MX(/AO(%2QVYT[Q(EPP6';1H.U_#^(B>.O-=R7T."/T!V<25F;E1/X=WF539[ M]^H\F_UR=O8R$V'M5PT(%<.4_:6?A^,BK.UW\8(H.1@L'CE+67F_<<6=H)0( MLVYX/7\0%HGR3>8:X M0.$(D#.=SR]NIO&,:,$\@B+E;P6Y77Q!U:KHBJB$"^OLGBT,&R-0ST MI>]RATRK].QU<5TL[6_R;R2C XR\:J*7 T(..@)WJMGPRREDN9+3]M_9#/D M5QOO_0'G32J[.;K*E BG7!8H<<93M8Q/PJ4Y?8"K9X<)_PQXC# 5&"N8RY![ M5)=:/9)Q[6#4&=G/) BJ5IF-'"_A\^PW:A01J?B3(-9JW/VR1+UO=&_!6A-3 M$$=KUFV-?GZ&=$UP:QY6P63Y;]H'E'82V75L^\$)06=]./'0G9=9QL9W8'IG M,=,(CE,'!*)O=T?SW9'\)^=9I-(0IHC0[OH9,)R\""0;@]"?R5PGX/))5A 0 M2\L[E.VB7Y.;NBC@GCAOE@Y3[ -<49:S=Z(D-!>QJT@3V;3NV\OH6*V;92XI M16:4$E*$=TVU\$9I&.MP4$Z?(1!>\+-Q II?T?RJHCT MI5K&C,#*E2#]EE;X6SW!LB+T7LL:%*2('S99'M+!MQ% M8DTXT] $AR;*6_R: ".;O/('6V3\D54]P?S#_8Q"66VB5[Y]RO35HBHHSLM, M.U;HCN%D+)Q_"\IN[LMD/QY\-,IX5 M0G)5F71QN6V$@D)@Y[\P4 +,4"A$E MA4DZ#;6._[AS '] +GTB<78B(_PS$69WLY,_L]OUM J.TO/PM\M,$CEE.,=:9,98H?K.)N$P\9\Q M\9$=]?:)WZ_KK?[^?O>8<]6'Q?%&[_N;]DT>/GF &'C_Z M\;M,_),I#X,U17EE.#O]T\TV':AB6TE*;Q[+QDD#GJMG.07FQ"LAUSM'NXQY M,!VSI*Z\*W.@^OH$U-8W!]36 ;7UNZ.V#A;Y\RWR-_L-\7X[_/+]:W^NLN5] ME^_^7CPMF]D#;KZ-Y$.B%K$0)K!Y.'=;*A]653A[=Y0;/0\?S>?_ST>-OOO_F_*Z+Y;Q9E04)6W0&%2 (_1C[V&129H_YO:UWMB-"F5% M+$@!6!H+"9K5\^E(:RA$V\B ;HFZB,<_1U(P%1>AIY0L(. #:2,CDH;^K1-+ M81+A,A#^0Y"@$5[2:6B@)%LN9DA*HK<#,%')O881*+:40[++5 WC9\M6%:-) M$+K ]0:4T4FU8DC'*3+1VVVQWFQC"<7PJC&K?7-!Q@7IE":OEY5HI^?LR^6 M,:V:*ISKD?\:V DM9A'[CR(:ED5X9)TPP,<4">K8T2=7W.#-Y@ Z+ $S;"C^ MH?1\0TC"X*?6#0-G\U@(DI)=PB-^#W?LB[ZE,77 Z$%^)3QD#R"P%JJ9O9_2 M]B;/R* LP=1VQ!4& GFTZD,ED"Q!O65@*-(P87R'A.58!.@//!)ZO.6N#J^\ ML&XE>Q3=Q:1T[E"@7/_6^THPBU\#.N&?))M5Q06AC;100R8ELK%I-K: VH_\ MDOR!+"&$FFB-2 "O#[/I&KP'0GF"F VALA<$>,ZWRGY(1B@8)ZWGXY\;#^6% MX1'\4=0#7@KF[&B=?Q" \@@OD"(%#)>;R3\A8II>Y5 Q_/2*X2\W:+72_/'R M!0J ![";(+4;*K92L5SSU_>O<&B*#B64@VX0CS4-)B=KQ=)7T(OM-L05R&B# M$%K^*3/%/1.^: LZ3SKVK?+MI9) ,#DHB]AN^FK=U#EZ0=53"2=06(+: )4O M"4Z([27G\$T2O-I3,I3))5AQWZHY>_Q8'HX(//G1KHGY,(I3X;A0!=%9R_<\!OM4KG]^=%2L_<=?@K'=N3TT]$BQM0Z6(-53MP+<:P MX!#LHZB-4=\'-?* @'N H A?>+O8-LP%E$[:__;<%Z*(!YJK08I>Y)4-=]+- MWFZ"WPTV'I]+"-O$Z=\M20>&.EB6L^N<>S;8@/L^I.#:D(7^NXY:6W8L"'_[ M,JM++R8*2/7-DK9"34RAH?R$Z / MF>)/ GCL]"@*0VB,7_!=Y0BD@0GN#+F)] R=9$CD)]E,>G["'1Y__WBV;!9\ M/% ?E>MM(M;=NEB5SO.Y:0\T_18V0)A,:2A%M;>]2*^:3 K.F7.SW(3;H\*_;'Y,54E5UFR^QFE<^+RL&) M_\-^1^[)1UV_R8/\-"OH+*EU4@LL!)8*9>_A)2]+/8=_H6.) X69"#B^AZ.^ M*@2;',ZK\(/%+I$'$LI9RHRP@#?!8"C28;^2U2'U[]0&1H^3TB=;(VBQ%+W( MV0/MCJ\@PLI;QUL1QJ76M3RPPLO)C5(%<[%F851T3![^)%P'"LON^O6:-C;( M1ZR+;$/1GLW2:?[N^?GLP2FV/7;FU- *>>TA MG7YI[5M9V(.Z3A*CQ4\0C->:208JV#% OXN9,V/".#'[4 MTK^O1:T?I+SG6 MNLN>TEU<42FH).F[MTZ'%>^"772IS*8<%MN5)")(-X<;S)MPO>34;'5L LJP, M;&1B7SR/ER$*$XK>P5F%5#H#?).U,UH*M,0GC[NDV8$L;41FE3F/ 9.OQ1&$ MFAJ&+XP K_F.UKP0O8E EKHRA33>^IL*LV<84F;V'$[JITVFF\2.FME),[8" MJ)- E]P*Q^-DUD:DJH//HXJJM [Q)QJ#(AD!1'G(>/!M)7X>WRJ5VEP0V'8# MC:U-6,K+Q-F+"R+Q^#*=I.AZU_P >N_N4M,@X:;66X0.$Z^'QKM+FBCSEE[I M =GMIE:U KL#>8LL"^CP#_B*[$&_:!]F[#121!1E6?HZ=I>$X%GU"6QS,_>S M?)E\Y+:,F3_XO0/).UDH?G'"U.5&S:^)6C/^O'F.9Z^(5X7E:G@0PB %(T&^ MWYS4N>/(HY$+*8?+B!D2<9*VW*'[ O=)^,] ]XA4_ *WQ[P"L<\ J_OS395Y(- MNVE6WR%"?!<=RG=%N9[WP3X9)]D[H[3Z9T@,OG:2HRX5&W'S26_])M^M(]88 M#3]'W/ 3/F&:"CO2?"*;:-J;ENO3(3Y94Q>TI;/#31B+2(D5UUWL8.C<#23= MQYQ[(>(76'?A9G<%MS+M15K0@RAU7)O,9YMOBXFV@0><;6$2"CDS'>^G?N^A MUJ/X!*.@4,ZP8?/%)QY)7VO*].0.G?[&4"T'N71ZAJW$\\:Q7+<=%_>T:1I) MH'0]WGE"N%58IGC)^:JX$L:+-"X\_J]RJ2+'6(&WK&%*0PZ^1^."NTB=L;S* MX2C3GU0S;KQO7*HB:>EAFAJZN+G(0E4J&0,A/0Q+K[<**P>L]/9A&04/'6UD MH"N,/,5PK\.>HMPT]@"N1UF*PCH_?$L[.>GL%9-ZR5 Z:ECE'/"DNII!,Y=X MEK5Z!]MQY9OK)$/.<^YD?"9&+Q=_E?-)56%U:EF,M?]N>+W]RW]ZC??<+^L7.4$$:DG$JFE+ MXP:^&+<2ZB4?9ARH8/[&O7[)DV:#F&%5@/Z$4,?:1D:MN(NVG*<=EUIC%GWK>BKAT[ITU3&$+<4Y[]CB?(B;/AF;3!+>G ME#/=*$RT9CUK:DOD0CTI,B%,QQX.8P1A>_GCV/)RWE+J9,(CK_$-QD]]C8A49/T7ZJ6\5 M54O&IJO3HTQ->_I#>[_([5+_JQ7F;R78,!; B-S2S#EKBC[AW.GIZ_-9\#-P M1K\_>P\AD=YP:<&V;T ^'S:,9<^*K8F/<>R?VC\2%=PIE[B0$(OE52>D585\ MT%U&E%A5Z$B/,7N;EB0RLWBG:_CGLI8[(N_CK>5[DIEC,KJ8;DG.L3C3L&VVV"*Q3FZ7 M$T#"DV\P+ *>41^$!MBN'@QO,.MY.]L5A"ZBE1<>N0F>Z-^EJNFD6!WXHD25Q87Q7%97J+$[[5E3^V19K M$59%\C49K;$%P'0Z_JDBKT.56ED'" MFG*55[V6CQ/C^!YN>7>;;E@<>AZ9'/ +7/"^L9;)\ M(R,P>R6:$^;27S9!^7(X@!*J%[4;&RH:*TJ2MGV713-*;EI)AQ0M/":U*UI M3Z3\P0%2>N9#6GNX5#HK$B9K5Q*59BE%2(D M>-MM055ZUD[6>T#>^L#SNY\EO???MH7?BMMZ)=X6(0,=,I./@GEA^I _L/)9MM$:^)_?3;()^H7&?4&M<#,@4I:+#)>NK=RC?4MWI]O@\T2?#NOH]G7TFH\3 MGVU#K.:!3NNP4IHEP]QHE2T+9C141,J&J YI0LF9K86U"<3OZHJ9037GAI6B MA'_G-ZX.A>CJ^04"\H0(36[[T^=QMQS6T5WLD8!*1L>AU23\IRPAOO>LC';J M=F>O^WPYL^A( MOOS-AUMVIVSWL*(3%8ZC<;5G"'&E:1,=S\YDMKC <>&)R7O&+5D_+SUWDE&^X54LMYQWDBI%R4Y'+*-204=*J7I:GAK) M=/CFR89[#06>?$*(*GY 4()2HKUHXX,=STX,0D9]8AV1,1)8]<=LSS,B3 6 M.%^2,$BQ3!5?=/ETL4-$>AQ=XZ6P CA^;,@*Y\3:R(7%7;CR>O: :VS\09=< M8J@2(3(6F;&S^9 EHVN0CT+LN9*6IB<6#F@JCK5-"*ZEQ(-$#X@G35N,TU 6 M@IN;$R(D0O+R06;MA@]OJ-P34@TMPD8L::PX'SYOZCZUH=YP 2\0D\(Q)=XLR0ECM2!8 MU7"*"'A=22ZT<6..A"K3Z8?#I='. MVZ]TI(6S_4J2S79.?T9N+PUGIQ-Y2.WZ3'G$2H\.4CMKPM"+FJ>K3_'$;L>S4QGK= !' MZ8([I/P%@48(][)>57W!583",N?0:9JZ@MN6-,@\#!-%;FZR3TO/OT;=L!L> MCCW%9#$1:M]5O]U67SL@8N+\TPYTI;MP.8S7W*,&R9.!^=%)IVK_LNTOTDLE M=L<*20]<\N?1S**@_3J9,?,RB3PWZ1#0I#N#&ARMI M;T!$-KJDO'=%)R>AQ'5X@?QQ:^->6D3LG\0LDDKQZ#R0\FRI#1]EHDD@;#VZ ME"I#R]&0 XM!12[C$O7L)/M-E)DG!0_JL^@%>7Z[JKGFJ'"Q*#9;$S\>$K>0 MV-J1"FHT,6,>99>MH,TM)Q"]W,?:'H&OORDI49U(%*.EQ&MCKN.@Q/N-E)5]^BD?W%ZBSMM6)E[%2!8.K5I'E_0 M$X7?H0-2><_<)&CCKX'*1X$K;(TBRS$OPL2@#I$BAQYEZ/V, M>$VH5D);8\E=8U.C,"QP#FNOK]^]#"?Y^RQ5MPNSXD&*9\_?/W2+^D[W,1?@ MO @SN!76\9]_/HS6&840)2UP_DF8KO T&<,:)0 @[U)@P 6/:V$XY?#:H (!T-IT MMW++4[&SLVA+;&IKM3WYY51;;=6^%1"Z+.IEHSCVL&Z.XLO(+Q5J.R,H$CTV M963D6L?.M:_R/-:LS0 &2^>YK)%QDB0>-]<":,'OZU0Y^:6OY0R U1V^ ML;JUX=V.9\^*NN3F1O02:P]#YZ MA"8 #WQ7CLM5K,7Q*%T0DB@,R&?[8ZD.XN]T&$=\X;"G*#B ]^^@C@;(]2F$ MDV(:!$:H(V3;L0&D[ (R/N94BU/U1J6-3O6ZSPI5&\1"5U%@'$7M8 M38TQN63VZ6K,_X-?'\^>&P+Y==Z&+_P)+#7?:$V*"S+EUFI;^MIR/RJS$-8P MO-;"8XI/7-?_%8HV4(4D8+I.S.N3TS@QR?&Z\$-::D5%JA]TN;_U;=DMRT4Z M65PYG%Q7$LF'J[QX=G)D?"3HW\<^3J>^J94>1A: 'Z?1\4))+WMDK.3=M*-5DU%53P4&@7'\+OBHD:H<-FFG+FG89*Z]RTF3,\8UK$W]3=K()V"T%7'9O M1U=94[9)FDF#$;M&KB-$G%VB5 /S+W V'"N\7&[H"2(7*,V8DD+8?D\H"9K' MN5;0!X9+_+N"Q07&[VA87'KL=W;(9N>&NU?'V$70UD![^O/+LS!C*1_1"7L= MX2#\SJ].:3GK9 J'X$!@0]2]O!6:@L8,8LE2J -UZ: ?IB(V+LDG8-B<.)]Q MI\DS3"X[\S7DI"7;'QR!'F2X-<$/K"AF601@41[_>!P?)^'9-18ZCNW=RFWY MMNZAL2QY38\;&_8^- +O&-_K8%!UL&,>HSB_G$O+8L_ [>WW\8B1,X@A#M)6Z0'!H?CN1&P()_7)5Y(X\][M:Z4F%J4 M6RUNN>_CG=A<1]N?\F@^^;/9R>IB/H,%Q[4D/G0F28_F5G'WJ:? MA]@EG*FK'H^&U#'HZ"FI*-A!];-GQ@\R+Y(DJ_A_ VWWV3;_6# %75&,?MP( M#*COX!50-H0CZ?"%MLG)#Y%5XT"G85 HD]^D^Z,M4+Y4-:;MY-+.]K0+QH:P M?]U*F]&[.MY#$ #,UN7'B1ABODN9)X:L!"*S/N7WS-X!W+RA53C?B5C"_FO1 M+@=B+"6C<*2]T?G.I/;#A56%.X17:K6H3U?CJCC%)104,O9Y;%(8GA&>=D W M54AOQXA+A=]H4$7>'\]XX <2,$J7S.8$ E&1"=,@)*)#$YMO!<0;IPU!2YBT M-+BFC.OVFJP0):+VT1A-TB!-Q-L\EF">7)9ACE$(M^1\>@=91R(O?="!OWTS MOD?P4U5[+!.-P2C.Z%Q-EC!157[-HC=N91A-"G_HJ]C'LS>$_.NH@&.U&RGP MVB*<\DAB?SF[(,1&#(1*XR L4D",QL"T5<)3R7:<"<64UYWH$<%S;2W1/QOQ MKT@U502P7)WY?KOQV]]4_ MI*HHW O1\E8+U&&1+=@_HUU;UUS[QYY%3[[.7]RRUX4>]NZIY$+66X!=')R7 ML)PAM%5\#$:Q,V 'EJ 9";+WB4/+W8) +>*]->Y'7DE,3AB7] MCL)NJGS>0$.H%"RN7Q ?P30/EXS/> 76+,IVT:\[8-RP,C:Y^KB&Q D.A$08 MF61OZ &X3.56-XKE93P?F762Z+DJR&P9OQ^JXVV8TUHKCV0KQ0&R'9)IIT[< M,WP, BA,.6OFL=SQ/N3_A(0!,3GQY1@"I.SR+_^^G9NQ.#6W#5?'NIDBNW5F&A$9YY_I/Y2^FQ9(P^4J;H6:?2B*#3Z0/BNIO]##D67; MHN$W QBBX*K=3L'?E%"QY?D)R[1IQTEV8!CYN%9T1R.*#$5J.)F.C&I\ MG)K_=^ 7%]1XSD6]S-:!,IPSD(1&@DVY(W24R!3**_0?;]Z=\G\ [\1I@MEI M7N?+G/_^_+5\\_7/[_0WK\]._/9"H,U>U[S)J:>,ZA!Z>8]G?RV;*O&0#;@K"XOX\RGYOF;_6A/B!,TAQZ"J-,.N;FB8 MRK;?3&22#_[I_G.+08VPE\&T9$+!)^VNUU/+'%MBC\:%DVDL64%S7F$3EIAC M0P.1_;"LQ2AI;PM =AI%GRR2*4H=R5V'-^4G!-HS!)47ZF+T6[#DRQYB4^:B MMD8W# .*?R:SE[:>D@O$,,6X69/M*73[IA;!-D8CFC@A]$@&*S6IUQ.H3?6>%)^92 ME =A^!QRAA,XN!2M 3#&2S-=$?2@*AJ]NS(*7KQ-,:#AR "DKJ_#ZJ3F6&? M2RU/"D?93*6_(%.SN^'"G!>#U])+DM-,3G20O5\;%D-8A?%T499?E%O]\95T M*FU5(#9V',$WW";)$4>V*C!8)'G)W?CSZ[/4FX]8W8C6I')RVMX2.>EHP"$L MNQ2$45D#/-(-GCKZD4Y>!2N]C-W,]#C[GR%CIX_[L0@N17LJ_'\&8LM.PTA< M _ 3.^4&B,AKQ]LK>BK7E^&BX>_73?N!1PGT+4N]05,7T@$M.46T'U9DO7)A MRK4)CF_E]][ !W'VA*XZF':LYZ2RF>J:N(F?'&:L,L#&_#KPWGETLWB);XD; MU+V$2+M-R#VVFIH65)-%X(G+04[Y6R:3F*%^?P7EU &%\"P>,AR727WHI6#DH7CDW& M"C"2'$ZYP7";VBG,6IYQH.R;Q)'L8DW(U?CMI6<\*E'B&(90Z$.Y^ !.28%. MTP2-OKD*[V5P^.DP:?PC.US7LIP\T)>#GU];N17G]U M"P16LZ' UO/($YEZJ7)(J5K]" M<,6W=[CQ\(UOOGWT5$.O4HE]$N2[9?K/J.+TC )>@;#+&V-/B-/J!+ZYE:69 MS"OPB_VFQW==:?IL3X^Y4DDY/_OI,_KI._XI!,&$9X7=2G-.$I>;I>I]DX62 MVJ)'M6>$U<5#;)M^&&5<2FWPRZ MT$PL>[X3FTJ#X>UD\.>OS75Q&C9-/Y ME7C?G;;,:A#=9X>_;Y/?HN4.TQ.NWJVNZ6&D!Y[DQR-Y#Z(@BY0/+,9?;&X&[0E,(KE'G&OVH'0<$_." M9';"]DDX<5+D$AO<.X5C#P^3_*4F^40T/BAK3N2,75EIK:0UPV5VS;<=YOQ+S?FS M$"SO $L0%RZ=*^)"6[;YM56#--ML M$G]*"13]\(&L]U?IH'X& (U?1RN5K-X=O0)"?4FOXJR%SJ[K"XS>I0>*F_.? M#1)9#"'00O?K /_,04/80L"X,L MKOYRB08.0)32E+4R_+E.50$5#DO-+TZYV*V^P@EEY/]3,_+GG)$GPN]J==06 MJZ)M!4(EQ:G3,\&4/"5)R7;'N'Q4'%W5U<2WIXMS["X\G<0HO/%9D;ONZ["Z5@M B'XJ[$0^%N=4GC&/D.XB(VY;)K M8I9C$#"-8NBIR$F3R-,49@[)-FS84 Q#!#!$'%JQW5;6$CQR!(;!X+@M9]&T MFT92&=OBHD6M.F:DW:9/*^>N8.C*Q;R5%8FN2][JXJ28<]B M'47AYW1^AC ;:&-*,W*N1T99,\+ H47'/;SA+];AF]XC IB98R@>1:GGO2M[JB"Q&I[,4 MH^GH9A^G* M0_N<)9:F,DZ([<&K,^_!AK)G@*+O@9Z[G)6#W-*D4.XU0@EN2W@M\W5^43 N M8&C@^;0*?F#8--5:Z"%A,'K%@DT[4AH-+&HXNVN;Y_ <.IZPPHZ[3/BL9- M*'"Z#R6 FW[PG7&9&']&;5*;!C.:+.BO B93_&:5]S6YJ'542X4LTC4=X"NG M4GQ=8-4LO1=8A".RV14&) SG\ZSOXL5]2Y<=$O&2T0Q25)E#&=CY,4?:7,K: MS\+D?8H2)^^\6.0JU7#+,N/#.RX>X(V['F50\"Q[CA9M"MT24R1=2I:,G-[8 MG0+_,^CNIYU@7Z?#](G6ETO-%2TS]'H80RM;M _%+IEH[Y(N?B.EVE=EXNC8 ME1W)^@*>>(M+^:AG;!0&'\65I'5-VG8Z[=4!Y-X<^<5E6:S"GXM%S^$!5"': MS/VI*HB9H+LL-VPJB[ID)&M^(?P#!6')7A-YX$F8C]G/18C_>%).GG7ZPAI=)O93[PO%85W!,_W5R:K WO&.*L/"(8P SA M44$"4+&'3$%%Y'M3<3$CT2T0,UKJ#K)=T[@]]^.(#?#N"WWQ?\]OT_#OM64#(L=PYAY)"[$@KLM51X%"_+6?*R]080 M5J]GX[ALX!!:-BX>W,%.K83SD;-QJLB$N'HW/@_D:.J4>5L=3IQI90&.2:8P M[MN:S/6-5HY?5J\1&5*X"TQ)SLDVJ]T"ADB\0\G=$TV_^IW1&XYN)_V]+JXS MYVEZ*TS=!^&),"BKGI/KN?3C##0U'?\[R4"RO4/644G%X- Q/'E^\ M.[T,H8#6U)^2CY\IRP60%+<>Y)-'?[SZGE\* ]6VE!A,[H:&ZM$3'2,!D=2* MIYS_3_0>LKUI8J1&:3+$^9)&322"!V&%/,?-<<6_KB>?T'=!_UB6K[ MI&PF[-\L\\W6"@15?AKM\@W][ F^GZZ2DFQ -5'B-FN!6_9 M?*=I"*J7VHB(+$A,#D5Y)TK5ZP@JEI=,/[A9 MAO;9BBG2?=YB,/M$Q99<(KTZ;"K]>]C'&Z-^0TI3=(3BHF9V!!"L;U@'/YLR MT(PTH5I#Y(E!:4:92$RUT0O6WDQ/,J/=W'=R)*84#D@CY" %B:0E@];8(KEP MCJ+(4;3I6ARI=D)(X^T7R=)L@W%CP68]LH8"NV370 K0L ("JR)8U&U.2:E(S+^JKHA!Y!Q.TF5E1F MY$QJEYG@@*A4Y%]*,,C$$9)2RA=A]O:+G[EC"<7B9J<=SJ2=).)%9]MSE M8TMX@'=_*?0:'5;Y5=CO>LX \^'4=F\R;P< Z)><%DJ&++E.XD]TX]V_\S0! ML3/7P^: V_VRT\9-M4,72#. W#'6N-SR83O],?,2=1L;@ZJ29EZ[.XS[EQKW MMVD @RPTLUC'VJWQ K)L(@$6_(*% MT*&FH:F3[E7)<=)47&VO%644ORNI.JDXT&^B.BZ7J@=YK8E?M*1\6DAFG%KF M)@2)18!<\S14BFGJM.=:Z ())2%(8>@O#JY 6K-@B>&>_O1#*7V *SFRHR/ M7VV+6AU!<*?'T6V6N9+R;E^__)1D+(GCQ.L:Q]%<[9 M#@#;HKZDQ(H]W3&6R66XP#4$(6Q&FG:0Y2'\>3WQB#L%Y\0Y0K%%B1#F11VF M8DOH#+#(MP2^*F6+.]:[9(%<;W8IPB$7U!ZF21-K5 M@ M80\Q-!IHSM]I'^ H5!]I 7!.B#9=F B@@:;$ 6BN5OD5Y"YM6 #?"*_'+R&? MV?3Z#X'WB\HT=#=@TU@?;:_@=5P:$(IP.N5=LR@+7N81ZV<"#IY72SI94GXP MFOIU_@'CY^M3L@-5\5LDL)6[R5+/EERD.YWT66L[ MA-XP;EMI4O&68"RN*3T*:3VB(0!(T2T@)5HFY5[;#493&5.&@PU1-==AT/JZ MW,:>E"7)K2-O[_[.+"Q(0J/FB/,YM'7G)Q:=M)A@2X(!^2TDCX&_&C M*J?+-0'QE+F&.\JX;+4;N!85B&##:HF*&.F-.?(<=EGX=AY%A2E">4-]9[3T M;2??W*]*W6@E:$Q,7L:H:72Y)^O7^$WN7]'U5P*<%A]@KR>7Q5W6@EDP;4K# M@:](P[!!@\L0V[UL8A6)>#Q[P2O9U[#2Q^B"KO& 1_7641UP#/ND*Q MH]4"EE$:A0'XPK3GC(\_$@2KD$C?3@74@+OZB-I;L(*[42SOH5%56:_:7-DG MN'L[=N!;2D0+(HB_*TIGM$,*?V2X:[TM)SH\\DA;#R"E@H$PA5YD;TA\BU4 MK?LR'0&?@5$Z'W^#JOQ0H%2C*?:MS)\1M%,)B*83'*[4AD)MZ0,:I5O3 UCJ)X2Z:)5EB". ML*J76[K%A+,7>&K(_82AXRH)A[T-,5MM7!:*"B2E0(F7Q;8M1>U7\KBV<)9N MC0UY=;:,IBF2MV 5G7*+BM/>G- I^K7;=..EO5EX;7FM>F4S3^ZK4@01LCT M$M_J3K=X(#65" R2:T((\*(NA?#;V#WBLG3=J\)A%#-6Z9)^*/E"[I-?5;3C M(I"/!BXN3P^A9PXPR"TQ20W]US%(1)3;Z!JIZ69;I)8F4F?O38J-=I9PY;0T M05>RA2N""B(-R_?2%&Q8:Y#0A?&R-H)E+/ 94[/L>D\](*[OH'J>YC&SJTLA#IJ M8H=TKV7AT#:O&1M>MVK5=!X"CNK/W=1MOJJ<]OO+I)8V;F3IE"ZE^"B=BTQM M$FGDN(.CH$$PZ4V=S91F?]ECJ.G@9H]!1).2D0+Q7(: ,@11T;VY2,]);QX MPVB'U6'[$'# %2Z-WO=O/0L&+L-)#LAW/B/J1W18O&=K>B4H%2BT4146_7WA MK")YNF;%IEIR1WP%02GD5?!EQ"% JB(;^QV1*(D^:HM-[S@/FTFDX+#%R[&J MFM8F+45D-Z$Z=]54?9BQMJRD-Q6/GH9B))G+WR"6ZQEHKAW'-1?YK.LL=J#* MJSJ%O753DX^HFU15ITD#^>L\.VXT3?_5&]XE]@'!-F,0%_$@\0X',VN.CUVD M-;Q-P1]$(HI0,[ZN&C[2(T!I[D!\J/%YXFIF,0*7$X(V.V(.:F*#BJK8,'Y$ M-J =.PY4U=VH_D-D(NV$D?%"1:W$)R/O>LLNO.?(Y NKQ"N=3<6XR:_1'G5! M!$EL,1Q'+&,D'ICH,J851CD(?FGK<.=6C%A>S#PZR9PV WC*"EQ(MU+BS&/ZT8-_7>;7)%Y6?N6C;IA6PB-QQX,2YHK\L M08?3KC3[>?39.S6?.8'@B Y(THC&;/>L.FA(.5H%EU MODX]>TTXM=3XG"5=BE>R8)OJBIEPQJ[ T+HK5&CZ91Q6*#%Y-*D*:<.#J(KW M[VN.0WP/TH=%V2[Z=8?G4CUS)[GP+*P3XUSCLS)M4DQH;F\; M)P[J3)$3*XS8B5)E5?9$;/H=Z6[$M^E:LV[(O7OXZR.W_)ICDI<\25#1S:%R M2RQY'EBSCTEUO/E9H@D10G"_^G* M+)0-7R1**24.1NLTWQ,#$V9X/)H@MBQ MO:.;Q2[6/8Q)3NK=OI$-)H/:N8E-*QAML",*Z)K4NP7U&TZ<_QUYP>?% MQ)O-UC0H2C4*_#V'NX,G$8:<02(N(>SA+&@E.;_QX,:K&.2R23FS>9,!3]Z8<-WI6NC5Q_'=% 82 )G [LX2 M,/"^L(*((F//4&:#D;7K\T2 H-F>3,@M7=>_E*OA,[%(H/AWGF ^>G6S* 1/ MK,?2NHZM[T>=Y5C'E+/2IQ&?EOR@,/F=GL3RO;Y3P>R*Y!%*!M?JCQ#<=@PD M[T1\D'MGC9LSWFS$E>!H)F14)@:O:0=H1]EQLL[WVM##2?;I)]FOC#^_S/^> MMTL"^\4L0IF.5$S=>+V]-,TPK1)1SQ!+]]__ =,&K#6?KVT0&C=L"H M_?X8M:_&@WN;RASL,TDQ?O:?7^?=-M$F0"=1 VP1.4^7P?$2@O0,!Y>TH@Q" MO7EIC27I'?GZG+%+=8627.\^1:$]VBJQL:ENZB-2F)G^HDM*IZ2-N/RFZ, MB!!!QP?5CYCO1ZL4^=DVK,94;]Y#PJI'CT$A+0TX37IZ\&R(1U*8W>H>(F\S M1;=/2[M8V"1I4=<,""2:CC)&EH[ B^%0.YTD.G(0V&>1&I]I!&TBLAM&7D]4 M>M$JKCY-Q3D^=UJLR[#LJ1FIZ!8D!<7<0!S]DR&9/H/1@12<7'B8BP4*'T(L MD$?%>HT!G8Q-496B;HR9XLQGCAH/-40UT"YBTFA**(X&DTD3N0F")0/(P2WK M2V[NA..-*\<5HVP'^MIENV3LA:$$BV1)RR!*\3NZZ0-^99HSH@*_GE4$=?)& M@B\QDQ4A62O:<: M"+[I8==L6MZ"Q'Q."!-16 .UM I%:"<6:XOY1Z(4F!(+"TLDDY. M"R?5ZT:W3Y9XB^'5/+59G/-=<40=BP7>659L46/M M9:D5NV4$!RVE$B%S)O9NVUI5%;T=2@<'"XXB*Y&[I:KWA0M-9T7XHZ^<55874F UJS2OJGK_4X\55 MFE?FNF"#EUT3!BWU?,XID[\M^_71CX\T\B*Q,VX4SBO']DE)E4X14A\*:MS# M(:VY8?$YKIOV@VR]H3G,.4*D^J.KV^Q]MA"48[6PN0IW61T1=_-Q,B;D3Z_7 M);J>R2Y1._PFEQK!5;[0JA;GTP"N0.S^K%A &#VS2-P%3\VQT+9))?%NN9: M?]C/_I8LX@QKC-2=KGNCM92"'J6KP,,+ODELJ-A(K%NK;#VH70%,ONXTL2!X=MS?9FM_^\)G4U65<%F(LYA4* MD"#]+%I)3C9U6!E2>5&!ES!,"S9]"VE\WUG13!60610L/&E]U&]B14^!,9DT MU8J6 N\%*C[URT($P2C)A':0Q>5=KWI(!-UNVA+F\WF_O" H&S?JRR&%8AR? M4HM\4^KY)$/#SFT"9S1G?;]PWZ?X!,S\)D5O/D7IKG9+@.!OS1@I3 MK&=A1JTY!26LBISWB2(N!JB";%@"3PIZS#Y 7!SWD'G\+8^8>@=*NHOU+I0* M"O'#\:/B73R6;%)0"%FEC=+Q;0OD^Z@'8Q[[M,!N](2=52[24%:P'43P;=7X;#9O4+$RV6'E-%)% MZ@75B=I2\E$813 QN4+/K,VWPV><#L@85$F%;'S+*@5 M7G%AX>S@O:4XQ./&3'E787\NQV-%N^8K-2RWPF%E94:R=$(]IG5->L]YV3B! M@5CIE,*(H&9)A*.UG!<#;*(*@5]L,-/8M/M%NKP^/XF MQ!6++I482V%JLC=47=E24(51\A>O[+[D%[!K MK)"E*U+%8 GCO!:UB[B:^3YN^>M8V RKK@!9+"U"PBTM"P@?,^)4+0*]QA6I MI8>#L>R6K(Q^/#M!XB9L70+!)OHT]!5[K*X_B*9^"&V9U8&\J'4W6_I=\##QZ7M(HA\K)<%^"M(E#?DHV8 MDLNX2VOO$=RF*)KM;9S,8 T05X4^>+2 ]R\JI3X,%OL)O!P2[L MF+&X59#A2UM7UDW? BI-O?^AF_D>N@Q7%IE,S&T52W0I1TS/Q_:3ME._# M AQTA^5A57PUJ^(M^0<\7S1(HD8*Z \'5AHV 1P<.?V'K8O+GF>_\%2 !]J( M/X2]!<@T:TR LU1[5/@-%EL4W"*,M!!'ET;HXB.R&X2%.*(H6D '*/P230@^[.3K@':+*Z=7+T;!_V&& MO]0,GZGYX"C"E:Q\[KV+1%)1X:-;$%2(Z_S2 V3@(I00?+FH:\;%T4\J"(PJ M:93C";_:26N6JUT<5LL7M@<X/T_9<,WN_;K53"C4Q&PSR%)\M2U7;V\%6%#5AC5.I!#,)6/\QQ4._A0GV/ MTF?8DX)PQ;;N3-V+"+45YC2=( 5[Q.Q!1%S_G&\7ET>_YA_#LQDV-^[ZA]D- MT;Z )>4WACO9'[9+;Q@9CFQ(H4"HI+X-CJ%<)BZQ9(8>.)%;-&><0"AM;853=!Q((YK$PW M57U*0&\A5AST2=LF7F04+.;JD]+01[)9,N+G!LULJ@:82F9=>(F]G7 MR# M';*=C6\$CE+#;?@]FN."!1?0K9ICF=;D>8]GT5D:(IWW%^>I"2XF%YI;/&&%K2!%()E[4 M#/"=N%5DI;MIT7_JSB>7LFAK71WQ3%&>[KUC$.N:W.&7U$I3BLW?\H2VW-#G M 21JWNYE@0EC)<^]#Y!PX_ 1J$0TW%PD+<94/-Y[B?>7I5(M708S M7# :-C%31/M#?(C8*.J2I^"(W.TN'D ,7F_-==NI:;+&F%C85H_-W'CZ,+@* M)#2*+M%N4VX+I1823T[2YXK& O>H$>R@GZ13N5 N!NP9C8-7\:E>A9H_VP> MONMA312,O(7!=2C_IAB?A9Q[0DPG^4_M"'14EJNA\V=/ !'"'=D/H+R9 /O-"N @)>/X^,=:T*^%Q(08ITO%) M+C40OHRQ(/VDC[WZ_M%?K@8#+E0>KKLCAJZ#?G'KYV6M2N2AUZ/QJ=-;5 M"4=$6^F>T'=W?.V]')_8)/;6)4$&U"^HH)*6@:Z:Z+=I.B(;YGQXWJTYR9H> M!OU#[;@9Y'ZV?3D&5B&?<[%RDF!:;W*.9(O) 4H,GB?1#6M]65+EMAN:$Z:W MB-DHG$3$_\%J*(@+PI%-6A9)P[N+X+$!(G98"EN-,'8V4<)$WTYW MI\8=\!+! UN!B'&P:GS6@@GU!DE>;[C"C6GUY1"F4/:0.1W?=M6JP/9F]J,K MU.E3&U87%TCN5#N9&&U3&\S,@#]R$K%-0.LT-*G1X4$JZ\7$&R#UR)E"!?FM M8G]&1A^':_),Q.&:_IDH'VSJW27-'>9'1X_]RAF^9ZW'?]6R>_O'FZC1HGO\XY*7/C MXH ;,?V07!]RS.9C^7JIG$BRD$K(ON,RT\_M47BU7K1-O^D&BAAGYZ]/Z/I: ME8)23;!)PDW;U,VB$I7Z;3EOD,WAN@@Y@%O\/L/_'FV)\0M4.<(FG5_$AO3P M /D&K=O:8U!L+W=5N/*V+3Y24TO,L9'LV(9^4(7U638E[8)M?M%0C4Q%'5;F ML=%09D+KM,=;RJ3LVQ5Q$"0'DY,3$B8/*,YAX5,:XP:-C]$2N,+S;=V3OLX< MJ]5F =8C30QQR2_:?-T)IX;8!2XR=QWEPI8)";NG"_HD6W6#.7$!1W1628G- M/^W7&9E^NO5PZ WP+ZFA8*4X-BUM<.5;4\2*G"0##:\6Z:6VG/=;D2.,,-\] M7QOLXO 0?PE?I2SMD^]!P/5M9DQ1"@@<^__/2M'T.@520 G1[,\@]JK8-H1M M<4(]/)2,.5DLBJI 66!VXI?O+^=AA[^L%\R;MH+,YG;YHK,FU$+;I% M]!Y!T>G80LJDVY#0GE)D2$PBH>K)FVGM;@,+ZA:&9/3WPGE< M*DH$?";T@J.>CZ]8A2VLC)M)@=YQ>S'SV";?<47C@1<@,"*3B.)N&7)"+79!#." M0>J\5HAGE-3Z&L%@W-7\VVI:15,2LP<14Z.(@JN\K-@!KWV)%]3_6:3Z?YAQ M 8+D1*FL!@FF8(BP8,@RUQ= S;?-+J_ 9K$3V3U*)H#-C@L&0I=+8_;OTA"@ M!LB]A6<^PL%R8QGA7ZN$\-EQQ%CFB4P&51!S-E AE*N;-21894 &Q&59RO?/ MQ[&H!X8[[!K)W*&TWU3WSQ$?Y"6#;0/5,%LV[CE084\E4IM)>!/O!PC,N M)/HS.D\ E@K[5N#LPE]WT5 IO&NJY12)GDJ$0A,S%;SU=(Q<>S<#&"^24L\E M*JC85$]BTUXI2B.5T/R"*R>34BTG?7&*A''J:ZXSDV5A MYS4\(K%ZXC-HA9"[* 7*,4W6BIG]R,H2E9U4*)WZ9K?(A4Z=SJX+^EJY*-+: MEBGV,K?P)?$Q[W WME'(4H\9"&V *G0C#69%:.' O@%;>%!:25W-B? (/QX++X$=/!+I,1/D M6;HKVB MR>9P)2'HX@KAJKA&XAFBHE+Q*0H4P55\"!=2&B.@7@6L);'Z4,PF2P<6CPKE M])(0ESQM-F111'@TC722VK$U24ES2S8?$ M@GAIIV,L ,=8%:6'4DUQ:ICK"3U6%K6)7;)L[JB_CJ"J+"G+"X"< @S61 M@ M\",RUL?;R7.+9\%T^@NTZ732WI-'^ 0%)->Q!D,>L+-S-SB ^[R"J@RNUQ*X M[O<)\=TM5C"6?&7]1/+[>0%7APTRI,)_'[T]1'#$39RD#Q*FLG1*>EBR.*TIET(L/4YF<&H[_#B>#'.;'LZ>R MYY,F6/$8.(B2:B+6HV4<(G>="3]G(QD*=HT7K&/- $9^(B]"RE80+- NH M<&XH1-7KS@.QHO9G7/I>$2&B1-WY&^_,O^H8&FLE.YLJ_@2[(W3(T5SA.W&9 MBA%="(7)+L8Y/GF^9R5^4H0T84GV6)U_QKCHK5OJX[>R0C=^$F+!^=Z%32\D,[/C)_;]*?.OB )!>B5)Q0&]9[-_ M%4R[TDP.$'_BETJU<]'$@2WR2S4WOJ*![UB1,MV2YH Y-G2V7=%$F[2PR$J69'D_F6;U^*FIR1",-]4 M6D-9/CUDQ?_^Z:"PAJLU4F;7;, MN&P)2R+SYLV[GJ/=D'S\7V7%D*@'".L(3HHTWZ!&/!D.C(TURK0G:54V,QOD MBM/2Y["\,U\7+KF_AAS0"NBF2,A>OWE[\O[D\I_1^:5/Y1 ^R&:RR0^%_9*C M>37.;28]SP5J3=O1. MKU-VOZ2!J1:P8*>+M'6:*A_XCW9Q4A0CEZ9["I% MK7:$5/4QLB*1B%Z S.)CL;(%9=;/4;"S:KWY/P-W/3^XO(#7?_^\DQJB>"A MQQ-4FB:D+ E:"])_NB@=-[ZQCVW08PY^DPD -!=(%UUG%4Y7;% M<1\6M0H$L)$X0;>P*<2')V^;Y7LRKY/8FJU-,L/X)07S@B18RIW+63KRBG7( M(GHKBW528?Z]__=^] I9>\'\@A]NUO+)+&#*SXY@!V4-EA'> MX")2>H+@5IDOF0J\H8'8E)."PR($%J#YPO5N9M%?NI%]HHXBF4ETK,4SIS- M6OSA&XZJ9K44JZK!?:4.;=U[?G;?%2.A+?_F?\!5]1-&\+"+&P/SOUG$IX1. MS UGU0V5E'51UKKB.)AKR2-(E9EOY7OQ-"HBH3[?,++F$/ND;\+++5E6*V[? M"('N8JW!ER)#A&&AP$AZ'0Q96B]N_Y[*!,/R!9%-VMQB:LL$_/KZ[-RUN6[D M\0^(UL[ 34]'6)5*'-@@ L.BJ5O@UL)H#$*3-\CL:_G%-P1'3[E*Z76:,7&F MUZDTBNNX H=]-L&L*&A%M0D_J M.8&)H8[#)@9;34C;KAMH=#6+8.Z"$,6Z+*FZYEK5A9I]ZNT%0\:&"=O]O5:Z MNPLD7"G3B#5Y/51DKDZGH!8>*I=L:1'T B M2TE7AS!0+'"7W[(&/XMA+L9:\DB_MN&0GGMI6>NFU)\2YA>7IVR_>,F)UOBS M>.75))UA!S7725=A00P5M=MB%J^ZOU5SSWWBJ9 V=P_%[P*AQF,!_54J5CMS MEUBKV8#M^]I@R"!H&_Q >-3X$@V,'E45 A0>:P=(&S)KC&I X0!'=-YB1+Q$ MIFAJ;,$.;(\Z/:J:BL U"R+ZUYS 868DI*KD7-NKSU))!E?/G;X[,C=L*% M9NJF*+/DAO@+X>%;0PF^,Y5Y6Q&LG?*\E$_F*FXOLW#O.5AJ_7A5T]I^ZY'6 MRPX4H EL;DACJO(0D&IJFE' 7-<"C#UG-BA"==!Q9GE]$2*QL(FHP3Q=35W+X:%Y/I).)?E(K^C5%#"HY&XE*?5@4GQ0='NML%7'+47DQS%F*L>/2C#,/ M2#>O8K&M;4.%;%S$-RZFI%0-%_NJ7MBB5OL"CQZ_F6M>4<=#7'+/-7;IH9B[ MUK4_5&-9$#"+X^87&G=JI@?LQ5;#N< #7*>5K_K\W4^=2XD:__H2N-!R1G"@ MP8F4CA^QW+#OFR)?Q,)D!T^EM:X?4RQ3S@L$1H,_]AY]DOF,U!'B:TBT0DL4 MYJX S9[P&^BT!U3=/M]4W6ZJ;M<<.NW.GGVM8$7UCO"62T+<"TJ56JC9<#>2 MJ9E3>M/J33HV/+!/UYZ;A+I^Q'4=0BN T/K",=>3O("C+21L3831P.H/P;)I M#WA1_Q.!4%!;PKE9/L449DF*2OK@%13=CUTOQ:JBL-$RHM-EE[O#R?NQX4] ?YX%+, HOM[,F M+N-D)U@090+H@(!SPP+4$. +QL<;0I#JJ668D9#1XJ95ZR+KI@L-C]^SNG[^ M&9K04V8R=8C]@A<" \2J4.YZGL)?9;-T3V;*CC\/^/I[.5KV2LN>[F( H<=C_&,5XYQH03F,<[F_\8=6\)/ MX-$&8=]@-4$OQY%\:Z#I7 9T2?N!(P8AR[7B[LI EGJL<2TF15K)F!PVH: ! M2\NQN%543HM(+QDC)Y!L*WR'A [IJ47Y*:I [$B+MKR*?G0DQ<8("=(M[*QB M;9NW(I+XHJTS.#2$JQDTI"K",*=[#3M"O$8SK)G7ZE]U?#P*9WCR=9/A/Q53 MP9:*" :7%(R4MA"?U/@X)7B4/(;!<4E\C#$^(OI&) -PDQ"2JQ<-LWCT"9TF ME(,1EA_#^I$QF10WZ)"8#+]HVN0.RU!WN0MB-SDW]:-2N>8#3A[QF, ^RM)K2V30?HM9'KQ?A?B98 MO5$I)D[26/@VF@&2+2[>KFOXWJHG=(FT?]%^JWGP1! B^ &DQ(A][*A2Q@1Y MC8\(8 @.?!G0%W6W)SX!:@M@?\)><4O/V@^;4A"6CUB2)07-5 &B\ S]:][] M!!4?R2+WHU]1X3L0#.)$A/V9JGL>G+JM;8!O\5'$7 .(8+MAW0P(NL9K26TP MX0GS,,;719IH.719VG ?O116IIFY3VZ=%G[<=M;4RA43]KEWG._?Q8%^Y$^U M'#*HBQLL6]S7[JS^V$+EH-D+%(C6V:0587U= MY;)]U4*"&9JFLO$(I()22415*&9H^#SL2TGX^+-H'/A6C]DP*0SO"<%#N6-D MA&>AC%&(U\FL2'AH%2/)7+'EM60D/3=6'UW89XDB)B,]7_ 3Q5)0WR=X,*KT MT40\BJOB;C5Z2?!-%<<[;U^#8:P,1WCN]Z)F5C@7#.E/IG+8N2(:8G]()P6_ MT<+"V(_OXL(B(A72>Y;J1@9XRVQWST(_^H!(K?BE/6^D,R.'5^>G*DL"<\'E MEH1EZ *H7O-[:##9TU)";^$+[#D'LE8*_06?7:Z^Q2:W>LI ZWC5VW9>X?OI M'1XES@^L-KKBJZEO'\+=M*!8.;C+UEG;6*7(:LM:=0P7C+.KQB'X^HCXAF'S MLL@9H,B>V!ZY:X7',OD3=(!JVUE A>A5&GI48HR?QS"L=.4XC1F"%9[#<5B^ M0 +N_MT_]UQ98BZFI?HD,5A?"')*7N&HE%2TUU C'@E[$:@RQ=H0!$NJ?E 1 ME%I).[MDL08L9#'!E/6B167C;$Y>#[\'-8R;+-A0&B@)[':QV4(C&PTC"J84 M7F!%MA28@[FT"K9&)T$>96@+S;&:LAPB8(%# MP-L1Q+I &$,Z/,]S6'BW'**^@ZQ4HQ+T6WSCTBD*4B]QIPI=J&1@X5.@(,); M!JTM),MN"_N6\3B,T+5*Q@D3*UD\()1P2)"T,F2$ERJ:H-<_=F#*#AZ:I30< M1,< U S$A."RZ@D%K_S2N!I"[V%XMV?Y#]3XT9 LGK]($)DOLZIT"Z[D"?-H M:-\LG:;L\[:1[ILZ18Q["Z+8PE>TO\X17-:6[I'S-8K+<@ZB?A-3&K<0&%'& M#F/CB*J/4EM*M'96_5'%(/*,5?6?_S'8WWX9 %9-XH03P&.3$(T#[#8\N^G# M%R<)'O;3SHN#_CZ8^EE&.N&GP=Y!_P4_6G[H3GZR$4%^4ZK%K&^020S>?4"" MO[.]>X#W[[[H[R^Y7Q'<"92#C&8!=6 MJWW>,@H?R;^[E^ Q!&JU]'6= A7,=?? 4QN(0&QU[UZY2,($'APIQO>&55$. MVXO$B8%(\!1>L M;T6.#G?T/#E1M7DN)8S'16+\%HM@',32@6>)N@"6U!ZC0A3")&5&UJ%>)"<$ MG)ZC3Y,BH_-1'X@@ZQ2\-#[]YY1MBM$GF@I_'G"T!+=@GX[P!+6Y G,S*-/X M3I0HD[A1$(Z6$>U4+'#@=AV?[LV"RWH4)BWZA*TN^H3['8P_#-_16V*E1>H M#+'B?V\65V%Q]KEBOT+'RMF]P]9=CMXB@'?=,)+XC"2; IK[%]#L;0IH-@4T M7QVV[AM)\[>G(B(RXQ:#JO+@4LL"%2<*)R^&I6=SQ?B7I)=SX34.3O=I*3LA2M9C4,[ (+46BUU?*GT2UE.2Q,/Z M-&0^HZ7,O$1BP1-2AXVYT0A:^4AX1OB6*6/P%\C+AS$G-1J5R2@/D*N)68C> MAD$<-D_K.C,<#_.F8!W7\34M"C,&,N A%5;#]Y%7W6G1M'DQ^2K055S VY/Y ML7!B$OQZ7+_*@PQ+SX"UE!9*51*P;_O>!'-3C7!N5M,_N'4!3W(/W41JJ0,N M$*'B8;Z/Q% IB93J$+%XBF%:_"7L65H<;5]+@DWCL[ 5Z$OD&B?U./5ZY$23 M%QSS,>7S8E$+C$W\@1WH/5/"YP&3.14AQ++2O>#FN+8UPB3?"!E9CE-,@T4>*3XRF%>4B M_7Q5XSR1-:*?Y.*P/=>TE%'C7!"JQR2)!'>HJY%K%*^QF*::4,L:)4/;NGFQ M5FB1Z'&!GE5/#9)02TENIQ:6ML3C0HD0+'NLSI9VF'3RUG4NC Y+Z"QN9QOV MF.^\Z:+8,5[CT=_UVAR4%.MPVX2*1*1+K'V(@OIB/4GQ%\GU71*F]?Q MF91O"C]T+96=QU/HZ++@'UCM7+FT\B+!_3)G4U,)O,NGLSK@K$;M5Y=8S$@E MS21^0PQZ6@E+.",CTD7VCFP*1U9+%@U?%[C[: 'IS231VD!D]5L_ND KPVT+ M[MZ1:CSYQPS,3/AZS3 )DV\\UZ;Y>CX3!4^4O)16S6(L?]5^'&ZASU(S1@H# ME%A69L2"U**TU.-7T1YE<#!2QWOCIDU&+H&/8]/9XTIKGLZXUFRELT3(0,4B=;]V52K=;3TV@P?X:TX' M0<#+]J9!!1#FHSPL5I(15W#,[#U\\.#,+PRA*K9P<>!2"=YBP@M-(NDETMBM M_RT:>A^"_:JN!YW;Z2A*RN;*5S)EM6 =>]J7A<7[Y"[YM,.UJTW((?;@[=Q7 M7#"A&P)SL]X9UQ(0RL,&:T_-:FT9F7N4R]^5/;DBP>7;(B;G5/UU'EI;:D9= MV'#[F62FI6\^.@-# /9P6M#4'L.SR!!][8']'L-34LR25BMY(CTNQPDVG4UA MUDA$FS'2"T-",XTWUZ-*#?$0MN\X5>AZJD!IQ@7_VX>3]9?1.#OLC MBQ^]?G'U#[GCW=G9IK#V#EE1R%W94&292MS!G)(H4(QZD$Q.*W((A(,@G;)G MI1L)JSG2+!4F,)HRLADLQ19%SBD @ K4VDZ45U-3VK6:BQGUC'Y'EOG?XAE" M83/V]=_!MHY[A&4=^U5-O\&JPR^1<^ T!AU"JWL9ISWFF@7EA=$Y[LR.1TC7RPK/?]IC0Y$LE"\)UP5PLFCM6])L:5VUQS M_9KST9J4R8/&11D(@DT;Q924PH)=1/XO'0VV[0L(BMF8-SNHW>%:>J\-BD.8 MF;DF5T^L,3SKF?Y1RHRX0<[CW/ (?N_^=I:RI3.33@D_0;.;P8IY2\0AXE[' MS'BTBMZX,+XG 0GQL 0/@ B+?1AZFE0T'*05P7S&YQ,-B+Z*0 $L"SE8'87 MTB[?O*)I$H^X]".6).,.<)6GA-%H2K:%Q-=9-E.]KDH9^AJ[?="TSE X@BXI M4.E@R*/6L>E@_EXK-:Y!?I%4N;> I2O:I^<5R'D&I1.(=IS=YZ.35<<$34SE MJ6]?']EM2,S),WS5[C;ZP_4$9N\--G>D8RF);DTN\]X^= ?9@ XU<(PF4D?O MJ43+^R:>M;$Q+XT+>X$OCRBN%_!URY,7>8Y+@\RO$9OAL$8DCTN)B]))(Y.! M.Y+J4I&'Y;7@GV3@PX%W2K>UGXN^-G=I68I3?HL\:0I[#<]'<&&F&'4Q>3(K M4J)\YJNI:$"\!7TX=1Y63/2+[LLT^G!AWTCF23J=QEP,\-%&/UU?54^\XRW8 M$=JLB(4!. I66'7 E@UNWS2M*NOF1N]?'[V,)MJK<<-M E?I=4>C )6H>BU= M]#X)MT@'+1[()/OT.\O=.C0^?2L"&/*I;/>-3@??QC3MJ/ 1JJ>1!)V4ZZM? M[]Y@B[7I:^Q9X.N,'A=U6]]S$=28MT M0-@8&X]4]_@1RI%Z;.$YILQ%N(.&<,1VV:!!5;-W/0%%'YT%NV]3WW'_^H[] M37W'IK[C>P9(>9U6;5(L;G2_OT4<8>2P(P_B47G3F3M#:#'MY17@+CB?,.F" M#!.5G\3L=A[9B177$ QQRO=PM%!P+=']9*=)VXUO'WE))0=I'ON)A.6F/[Z? M7NH<2,_F1D^P'*9B^80$=4/350#*Y.2@7=?1J(3#4+JAV-02AZPG%E,J4"H_?=!;FOOX>(H6#B23Y$L)<6N/=M(&KYNEO$[,%5M H3;817C%?%S&>(D'76F#U9S.E8BVO8LO3TL M=?KWK?V=Y]L8L/ P-]C;JQ"7.=F2TB \5]Z":[X%3I_!Q.79FTMP584RYHK> M1%XR%F7 @"YAE'6<7TF-R%'V;YB$*;8O20 [22ML".SK&+ E1C!MJ'0'G]M4 M7.-.52P4&GZQS9%6STDA9YP!12MT:N%'2]]&G?'QC,JD_# YOT[F"4,K'R=I M1@7_ 9Z"FRXL4L)/#&:@1_4(H?^-T=,,T[ Y!;E*K*V*RB(SW/1?4^]/5=-3 ML(HNTRH6/K1-/1Z;+AIT5);R0KK[2?W, 4E%[DH[OB] M*E%BWEV .XI3>!&T'6FH(BXQN/MM3$?^W@[SL=L>7/C:IS0$OX]W-4U6M'8RX2D53^RU^DIU:OW/JH_'T M,1>XJ,KUY=E"?(2U6FS,UX:,=+_B#+Y[?_G;UF!W?_>"9Q0C6R"4&6M! M+QB9I6"5(76*7V,?F@]T)!0N!JN0:2Y.[X9Y]L]W1^_3]PE0USV M65OQ"8F9 U/XI84G2-Y()8[,F&*4R41$DY 0VF8N'.]D((.4P^B:?G>(4>,Y M#V#I(VKM;."7R9+Y ^23< :ZK,$(K,+Z*M$)8F0,^IKK M?B6&.AD .R_/W6-/XQH!XOI:8G4!'UZ-N2J.0N19MFP47E$=6K85(['.0%3I'Y902_T"6!?$Q=X1D!Z9'V!X/R?H-_ER/#,9Y!?*<;>=<[>5=M$ MHR)Q=':;C,6?<6+EC.=L>CKCS<3WIG%>]98+!35V4W(WA,H((ML"XR?IC[:5 MJX>U)D]M_2VN5D*M*83R)/0A8@G#U23_;5CSM%[T>W#B*,-1:/V=9@"KNDE< MVDBM.5I2BV3#V2)!F@HG5#JB&99H1"P0!2U7A)"&+(1VF23?2??Y?2V$ZP%. MA564E!5D-NT&@!VY2X*["3H_9V9B.P M0?@B@C MY:_8$X_.Q*)[I'EMG@NI&P\H6%!DX.SH$_C&?G0!)RB:/8BI MJ9/HH*:K"1'L3? MU7I0/SKSEO2N3]<@( Z7L,]*QT)(=J\X1H1"C:HE$80E&*Z@TX+1757DG5-! MLZC-S'L=+W\'TP'M9>%N0P0,S(*V1]ENTFC)J5?L$8)&:#*TLW[)MR8TSF4= M&3@M'\+R71;E;D$WH7-)8&E33//>3 SID)2: M=R39':1RO5J/6"=!P):56.*.-[H9X@3U# X4G"/P&G'M)VW!0 .=31%I:.^[ M4E6W)LZ3=R;:&'Y$I1UX)8%^6MQ/P39GY3S&?@2IS+%0JOZB2J2Z'YUWEY4S M9)8M5Y(\J@6"XL?2\>69FVUY]&+#(PR!H&_ORJ@[L5NI<$$JI-52>4WI9:'D MYD(Q.V8XLR>S;\^=G. MSY38I[FU1E4EKX=IQC"JZ.DTS^'Y"$% ,H$O[0Y&^+7P9/]P![#G+6NCPO*2 MI0T^@X_/L )MVFYY]T\0(LW3/:+XFE2 MK'<*\TJ>JJY3U?)P6IO75S@6F_4V4#-R,&F9F13,_(]UXQ\=*W4,S0T:XDP M:@OT+7K,"U;Z2,%@*Y9_,9(@IW M(OO)&YM>"STICVR%XIUH:K@88VN8=%CK6'T/T!\ 3'=<)MHV.YJ8:Z=%2,@=&JA8 K#I.MJ>N7U-4E H^(1*[F'STR2&1ELRFL#Q@ 73/G\W7Z$W[(FX#[G]*@8.22!1>E<^3#1 M2&YYQ9WB0FO5N]7;5BM2%_,AGHLU:''MGWWMV+7\8L$BUD:NEVI @MS82F\N MI#;FT[(T%[L]W,C _AQ;TS8PUIFT)9.3HLD4K%[F4PTY ^X[:THBR6FXY4X7 MQ?Y3UI#LP&H%%ZV!1_ISA\OA>R=]F$L4QB5$FC;_LR#(?J#"PQV!$=DF0TF8 M4+69-?^M[/>C#[=F&\=!@K@(-$M.-6%\3,T]8H4415,QM+U5CHC MYW<$SM!+1WU"XS=)3S4K+EE2QC?8I*X'N*32)AGXJYS>UHM%#$ZY M^8$K$MJIE+6C+*!HC\[Q((,O&)3$W:&UK$(<,2>@$3[D6)4CIK\M3X.%/X(G M9KCT!XQ(A4X]Q;;Y0C\M[(MPY:HZZ^BF5A""^@A$1VX#>63P5",GO]MA< M&$2O-0"J&D(8K"GVG/)L$5,WTW=8,<:'N2$LW\,45N/P,]E$LKCVLSC(3I$K MJB;P&^L[O:<3Q*:>U8H,L( *T#&IMC&O]>Y6I!\!TK5;KT- 2 ;-9P&\@R_9 MW_XSIGE,A=5BKM^I+=0"JSVRQ=%$GH./.#YZ+4&]E(+6F$>?T$XE?*'H:(JP M+?"7BV*D#=KOFU$&NSDZ1D^'N2%S4^DI+OXNY5_BQRV2+5[55D]%A"(['?R)5U<':8 MAF1"="KY+T/Y+1^Q480@(&Z9]%IYYF#&;:1(E973 YX_S>$>VX3+9-RN M0! TLR*FX3-\ J,O82MTLYE7+37">Z HTKDX6E$".-80?RR#G ^N=$M@$,) M@DGDJ&*?2]&"(D6^ND QX*U:\!J2Y+2U2K3G4E>YL?9WL'S!#&%$+9ZE"6,D@]VQU2!TWVJZC_?O//?+ M724%.2H2 6;!5@SA@Q-4.Y+<&5?9,^8;_SC#72GAE7Q^QVZU(JWL;'Z-(QH& M14[:2UY/1\,I0>$B5BW_+54T6+(,O(0P RA*( 0-+CE9%*,.?TL5PIT:M4>1 M48H.W/D10F.R/$ C$;O[3:PMZ:>D@U3?6K;HMKIAIF(%9?TRG;_J1^A'XP%X M:H<#E_GY[,;#%GZ"K;%1$Z?E!VE(?!%R2XNAX3T8?&>4(:TH9" FY2#.M1Y; M7K9^A^P)(4/G$@-WK;62!@@\6PN0Q2:)=0=XWGNW+(Y>4:#/ ):$!*D L#1 ME@Q.KM3I*&T4"O#B>*#'<%PT4P++^.>[8]3K>*,"?89&-P:/6T<8M^+BW5TH M&)HZU*!$@%9W:TN> X@*5*WEINT(&WGA3]^JD4BG^.@Z;LOY/.AXC&AA M)('F:C-5V0:;PST$"V]6O*HQ"792Q51-7BKJ :5"H%2FP7+35M MCZAJ,+<-6-:Q#4&B]?NIXID+0SO$3GPI(*>&UZU.S)0!S::,B M]9P.U1/SJ_^6]8)UXMQ)7$Q1X[K[;K55U7*36X-2:RC]26)X?X[/$+X7]RQ( MY06_CND !6!0,IFNL<1QP <+ A]3<$Y9CC3N+"RZCC?7J">O1T956VBNK7ZN M:SJT -3DXEQ>/E<0%PE5P\&/7(@,-Z=TY()6;H]N[QIK6&NP,9<8 AY+!*71 M98$H@X#S7Y25&]NIR!&A0.'4Q%(HXG6P>EW@UD;EG$7%@J"LY]*2S^=_RQ:Z M#H_G?O1A84VZ&F1LZKZ[ WP!6Y78;;<\:2J"T3?5HA%9/)K;9CEN2 =*^??B@;'U MB),A+>Q=W!36E.O&J@FMY.7^EW)YJ);69CL+>QK6='!U!I=(SZVYKGNG%P#I M2"NSC[C!/UIHS/<@0!^Y]!ZLPR.1/U?*43SMJM3HU.O$D%O."@K]RUQ;@-<% MCIBMK1 <^L8M1D#6(VZ>!.^6MJ#WO/YS6IGWIUO; X[X.(X7#W?%$]+6Z:O$ MP@Z3-N\X?"O%L-4&^45$"RQ]LB>O ^D5XX5)TGS[I.4X"CJDSRLSQ6I'OR&9 MV,LEEH2BV]XR4J"W=).X TP*Y#B4YP,K>*%C6V[#ME)M [&N+[_2GD.RI48@ M$ F%3.C8])M#+'IQCS^,N9'"/=H)%((=38UMD^57'1&*B3>;1/Z(+5SYFN430ZVUBC*K4%M0G2T+I7F,$BT0=W9S?"[:0@PXA!)Z'F"YN_K=XN9 4Y- M0>3BW*<>VYXY;SOU[!9Q$9)+8A0CUNX5.HQ7Y.1]$+$'VGW'\0P?C<0>#24Q MO@?KXY)+;EQW9)&C3% YJ/%W?;33W]_9^S,ZR]=8-8HR>&%R+-]\7]0"CXZT M]^0RU"#$5U@%Q 6%G6!QRVAG1-1]@[W^-JJ] M3*'6KZZPAA^3*. 28+@P\RCC[SOU 9T%_4I+GE7U2",!#.%A(^#W5%CN0RY@ MG%LD /0O' N "(LV?SL:+B6_*68:=];?^04,]![I@*!7,N0W3YN N.%P<8F) M7#&A'1I7W!4:3GDP'2=ZCYL2KO3Z#3Z*BV?>G9ZPRJ4BYU=Q_BFZ)#ZF8RSG M02?XO<)B'%55,1)0D&?R!GN7]X:*GV ,MN-[ .0C1IXLD?_X&<6:_9&<8%ONO[T'A&2X?.;)_9 M43^3^JXE)H6WB;-,3^RYCN\6OZ!PVE+.U;ZN:W=040$/SRN1L-E'S(>A!8F3 M-<1N<"JIY/)Q\, Y!B !'P=PA[=(65SEXG,.%).R]PB;,!UZ.&CV17SC(AT% M&]-H!24"JT//M5K?P;Y2<=AG!0>CJ-6M.L*M$1LJ=LY"NZ?S+,A2F';0 O.6 M=:X)8UU(L<;N7,]%ODA1'MP-@1H4S6:45SQGFHRC&!A$C*LJ'<\)YX@FV*/T MK!F^S%;?N5D(/I_L3XVPP5$V49@;A+S90IO0H<;JW-RT;$+/2H/1-[8Y&2O!.8"YD;;B5^/ CG,BC./.6Y_#*DR MBSJ&(X@?E(+'!1:M*D.HI9[WO&*Y&38Y5L)C'#MC3*NQ->9\XV6YV#U<3-,@ M+V,A\2H?HQ-I2Z A;=)*6HV8J7;,4#:4:?HKD?=9ZV-#C$H,!CW*I MKO4:H\24+/P1WZ)R"",&XW==13IC43S"T&P1=PYX+ MWVTB-1AGG:_ J=F4M]R_O.7%IKQE4][R=98.RQW0& M'[R:">9T\3G]X-7DMS14N4E^%+8TK&%0^B@,DNX./'(-;(UKF2M["_9*0?6L M-N81K N'E#@_I2VW$@U!MX[9$"V1[D^[@=7E/*XQ',5;B#'# =QSKPZH;@865+:7[_<=\UF* 'YU59FQO4O>\];J[@U./QF MBTBQY?V7^B%__!#"N1D\9X$^#TB#$\/,H"W?U(ND49ARC T8I$V]2( R=+K8 MJ?ITD>2'@JA;T9(&:2T;SCELIN%DW+Z5(^7L""L$67JL@PH#;#W]BP]<+K+G MQ2Q>;B3LB23L%(LR$#\5RJ!8$(;1 Z4:KV9 MY#ZU#@M_&M18_?0Z#%8B,0)P=$"H8/ M*U8S$/, ! .LS#0RLYI/(U-..<_+ M>(&]![I>TF,5N8IXER7^X)>5<,Q&!GU-A#)!:E+C0T.O$PS;@>7Y'1O3V[IU M":-"M%2/T9H?F,];K%4639.+;K ?;#5%Y-'DMGY]MX4H\O"AG.>OE%(X%[1Q MD&B) IK.6UN_*-N'<"_X%2I (VK=\3D>Z)F(\]DCL/,]87]+"B M_L$S8_LK.J;!C]YT.^=>_P:-"4FCR!VA@AC7SPDV\549)]I+(#%_Y8*A2"6A M8?OMC4Z]48&((W-1[U3J_0AINE$@'OT.HK5EW.2J,CA R@G*IQ0!=XW52>1=<+ V;*;PMIXF%G8XVQFF<,GHA\=IF/W0PC1!@_$@ MZ>9%XV#I_!FR19B@P6UKKUS'4^,!N119TG.-3X6E_<&%*THJH+G]&DY(N^Y; MJ6IQV6?M;'%E #93+T3=B:;LJ>O)N]>"TW2<@/83%'.W^TRT&+H]BUW5^3@W M:1;BWT7@Z5FZY'#LI0@-0GL'0;[+1F@;L:@'BSU)%U@.*Q277OML=_&6&RVD M0\U#=<2UWTM@R>2#Y(QL.\Y?51K,O[>^O%,+<(6U&V0[^%?XH&$$4F9APF2N MRBY 8X\0*LXW/:P+A]YK88-;C,:+_N0D#(?O2.7Y%<'F,UCAY5#:I*3=V2'! M@YJ[IR&]4H; 1\41+BD) F9H7"IIF6(B M:7C>LF:16[QV/<:F"8\?GXS8+$^\^8#+80^@,BB0)R7?[+$J!)]/&I,^NLU8 MO)#&\;@9> >%G^WXXK%*?>9V&:&T*JI]&_Q(^CT=.D- C2+)0JGK"D?D6QA^ M^K%D9D>9ZP)Y.-#!<(3G@;?OW4CM)\OFB= 4M0[*M2../?:+O#Q3 M]KWM377IIKKTJU>7;A3=HQ6=C8Q9D-RA0;?ZX=INLR1?MB0G7:;X9KJ?+,\' M/C=,)S+:)!3CH2@[FUD^3/M&XI\R9P[>&)>G;V;YR?0*]:1*"\0X<#K63AIRT20MV*M+5Q M]+!1;ASC/UP&=&DV0RI6E,78H>IQ=M_6?@401L1KUN0!%@;FO8>&V'TUY^DG M8YADFI*\3:7L939.>^U_CVN#\D/:J[EV#XQ>$S96F/SEO.!T%B]VX4D!65 [ MH37CDF5FXM"PTH4XO1?+0"B=/,ZP[D+6A!F38$6F\:@L.HJ[',[)T,P+">,^ MI%YKI:+CK[G>1$"[<-Y@.\!4>&RB5=G,%/.I%IKGGI!]Q#GEU:^R8HB)ZV 1 M0XXCZ\U2K975V"Y4O&YN(YGTS]YBB;$F8'$"N(JQC&V&B,ARGW_Y,2E!^ M29-7N42C7L2U:SC?)J:<-D^MK6"R=2/MSK_'+=-WH8@Q4\;N(3>/\YRJ=C1A M66Q8IL%'7 ?,^=U4H^'>S^1>\%P]1R6>G74A2*= D@(W2U=\C%M MWAO&BO[]';_OI^4'_8+^G[:!4R<\#NAO?"J&5TT^&*0M!N&6J>6&\,A5: M<'Y,8(00K1V1*]!B:W;:ZE!KR6PRP$\7N"$9]NP^.=J&91&CQ:#@67C9)L[P M5,MP1#CNI/]SX4HSR<)FP0WXKR8NP2B /;<,\T-J+S>+]9019D7J0S,96T+) M+DQ\G,@8[-1Y5=L:%S#8P7.NV':G"MP\B3<9ER?.,:)=ABLD%&HF8[LYH8!_@%-#(--$\.FB>'K-C&L M5J$-]Z\M)'$Y&V53?D&ZAVH&S%2SWIT\+RZCZ)99,%?8RU@KF<*, MJ,_PV<*1AS_7;PDH9 +FF"$Q/"#F51;?5$U:V^K17(4WPE!2/JM;O6:3\3'6(W80Q3 M,4W&::U%&EP*,&NX$.N[2-[#BGHB0F$IBQ['\79MCYXUQ !,F?:X'$VD:(9B M\/&P:.K6[#(OD(^/SD%]V72MF+WD=K4 )Z 7DH;7#@ ,&1IA/O%CF;C)8G>T M2A,H2"UI6$ET*WD7E1BL7TV GU@6-=*I/Q6<*#5=R%*V_3=YDYT9,_ZB)$1J@)I'G,:E-00LG7%:58QMZ?*G^1] MJ/JQI%!$2<= P!A^G59>5WH(&V,KS93!-$+,TJ FI2TY7"#K"XXK3.E'I_!U M^ DD]8M?[+[W9E+PQ^+8+3!4]90R[^O,!TCYJBNNCQ;URV4XE >3(&:Q4LLU M:(T++MY%UNO*&*[;:J1VC:JR1@2S<862%!QL4Z1K+5%_.*A6B^JU#!.G8F9ETJ'&(E:-NC,[S#L1T<. M+\55%P:2J,;ELOHB-\%Z&E!97)&C10Q_X[NN:'ER)D6V97BR9"M/[/9 +7($ MNF,+R_-))X.UA\>&5QT")@M6AX"0C 39#!?[M7DX^MJO(@N,HIU\NQ30&V/OHB.$L,HF0X?JW8 M@QI''<[1T*>RPJX']!1XQ9]G1O!!5,$>.1&$D9RD%6(E$="NWV8$ BU=&S3U M6B,T*\AO0&>$350DX..:8ED46Y*B@N$\"X5K\<9DNT"\<0Q3.846U0@/EHL40QU.HR7.!ON$J8JL^RTTH2V>;KQET5M=^); Y;)?@[0^ M7%E*S)CL*B]ETPC.4ZQ"):YE2YMJP6EB ?Q#NH6$RKXK*2>-R[1"'1 CVKS.V4J,36SU2]J#=H& M4UQH+UZ!]=$U; #N"D*DPY6G*KU5LQS?0\WBOYRJ9>E=(IIJI',S *&N$CUW M/4G+A( ]YSZW;M/&?B!B,9DCL:2%6'VT C@Z<#J/&1"6D--P M&:I2RY M.[="P;3HA[&+L\"A+CHUEZU ],SRF#I \P*:F"$3=C$%"=: ?\D7@W/H!; M%S58EPAT]GKQRN*F%.?5[AQ/U87R0/NY?1_H[N*:&\3 3!BBO>3.A["!#!_G M3B3!?;_%ML25N$YA^\18QWU=$.5&Q]9-D[_^Z>X ]8N#/]V]WY]\='O?]%FSW^6!G M+9;LN!\=SX=HI5"<:'[/9?I& S]/JT]^<)@LA!I5V=5]1[XZ O:QQ3XV\M>! M83A[2AXA+IT8UM(91 W>_(N(L.MN6L_02D3POLUHDL-W7:7X+WI&/&.?-26& M!/(;B_RJ($X2A#K&5].!+1P%!@[/8FZ,-/UCJ*\T$SF P_>2!4;^/:R-=(26 M!?KXLTE:3:@[=XIYT=+/-G5^/[8/DO:%Z<[1)E:49HU-\"F'S4AXH+E!$C[T MF&SOZP)C'_AT-*MB+)TEPY=3*0YIF-#NY0$,KNH2,7/I00M=7+)M;#.)'>B5XR:0P%V^W@*C2\9CGV<-N]ZGZ,] MN3?#MR+>'I5[Z066Q1H\Y[MY#8]E4HS@C)RR8%Z5-1XCB M*I R@Z*J$76T>.!6\QD^C;R/EL.\Y %@D!)0?&2P(=2^O3VGXG BI4&L!+#P MU4)N+";@IB3E_B4I.YN2E$U)RM3S'B,9[:PY$V;G$*:$K>"XB)EIA%7E48/1?O1?$!,>NY/YY\ATF->L MX\-CH'UZT6F02%.PJKW>P@ I0SHBWS4K*@886GAP3A"^*X2R]Z*Z:&,6T[3B*A\E$J5L./:,H3D M!8,;V.X-;S$(YB/1:3VKE&" !LG0*%B$O+YD5I(?""#$YY M?(48Z&*P8WM0<+NS=,7XH_,/#14FH<&/RDV- !4]IINI*@F4J$T9C'6U/;<3 M,6S&768^VCMVS=2?6T:>@K4%BW;1^GE_QB:GM7*BP2BQ+'FPT#VJ$0MA5%@# M2C6(2A5Y=\0T9/&'79&Z]O9)5W4Y'%33XJ2^)L09P?KGQ8*]$8;9VMTR2/9^)DU92WV,EN(1U5PK2::UA*Y5F=:_@<^9HBHGB7)'A/LY M53-1T:.^GKVC%%.+B;U5A3&080\09?'=DC=LL!Q6\+/T7!'_:_&-2Z,_="V$(ZD+BVLX=R M@ XU>&<->TSSLL0UIP6I+*7A(#H&X&UU=H+EGK9N\-)ZJEZG=\R1 M+<5ZNE\2?K7,IR,K5(GDVVL$\>'J.12WFT >_9*=1Q[KG+F+\Q ?'>G MK(@)%&2'51%J"ON]&MW):;B5,1$U[FR_I.CR6ZYYIQ\-7N+N.X/-'IWT(HR: M1X,CNR1'9.%%YX8C@3D.%2[8WOK[BMMBOU*1$R)WK)W5]$%+"?C )P.*5(;4 M8CI63)4W9M-&-30C?,ZRE4)X)HO_YOQ4UOQGVPL>\J$5E0G\E);JQH B'I[P MFNMX)#*XAOX;3G'+]:6/>\\E'5JBY M44\74C4'6C59:AF487V"=7%VCLUMS)V]K'Q+H9&(Z^.OZ>TKJ,4<=O!:]2=1 M4G'<=$+0?6\J0BNC!(DG8S02#$*ZPF%]9JG7(UBE5?];A+4GQN>KP@V2Y?-4M/0?PFRDXO);03\UZ)P)XS%W%>?IOD0W)/_6\ MG)3K_&7R4ERL8E'HT9JEZI_20QS6[Z;,%5HP?"Z[JOSVSI%8DNBL=G!@'0V4 MT\X*"9S XTEJQF#@NJWY 5-5L,55R1Z??% EVZ."$^R4HDJ7G;UH;F*VJ)U= MPQDSQMX352*%0UDZ1FYLOLKK?4DP]A:3Q(!3\V^R;^27,/4)E?I7;7W4EEK> M@XL:@E5Z=-JQ3?QT$OL03 D+9U0NN(?#@GQ?=>THV^'"0AEJ ICNEUC B9%2>0F]CW\MZN3PL+^]MX<:I2[A_Q-] ML2B;/LS>7SI^OMO?VS_L_-5V?_# G^\=/NQ)RP;U_'G_^>'NB@UJL-W?V=O_ M?@<%K]A_\!W=/]_I[PYV;GW47TA&64YA)^"F^NN?=O_DCE4"//EE9_8Y&G29 M$NWMP#OAC]>M=(2_*]AOL/1IRNJJ-V2 M 8]&!AS.EV(\D TYJR/BB8KT:VZ9(02,6K @SNP5MP3/][Z"Z;IDF2&7;O_W!/:9L;7-L7;4<=$4X?E2LWT<_#XX0WL_;?G M[H$B15^\?=_O?;P$/\$.Z+:PONG*H(F9/)DT?W?3]?XO1U_% ETG-?G*)&.P M"4 I=AXUW\#R7*?9>V-[A/C\J,*#YHL/E?M,Z6V'2L>4KLFA.QE8C4PGT-SJ- M-_=_)_=_7V9)=]G7<9S'2;P*>FAS_XK<_R,$>OZ[,4,S6E'?;>5F:Q/+^5JQ MG-Y@>W\3REDYZW(3RGFH-3Y'6_SY#Q?%^8)SXP>,V[Q.J[I,APUU?!Z3&'^= M$^3'C><,>L]W=S?QG)73B)MXSJ-.D+WO.,6\I"'QQB3F/MVHZQ,GV=R_B3/= MJ1^;?%6UX\K-U<8\>GQKT*80;R6/^XUY].@B[BXO^R\$1',[,A B5,E';Z&* M@S7,\UM,7AT+(31\-PF5WA:C[2P'YWQ M\TOBQX4KD2LQ&NSW%+&61-EBU2+ZF_+P)$C7G=T/?W355X>6YV]QWB 4XPM: MG>?,'IOGL+M&-&LPY6>F)#(U;$FBA4I\&E""SJLJ([2W\-<"";CA(EE$ALR& MQ4J+V20NI["0#6/.A^#?PO]-4(1=E30]G[26\9'A.:899M3>.42*$%7ZMJ4H;!4A)YWE"] MUN3#+Q'(.-FGMY!9$SF.>VD"UWA^J]7DX68^% M:GVQ@6K=0+5^,53K-]@6W4KR[.C\,CHY>?0!<"=I]3;2[S5(Q<1]>TH=;XFY/ M=)#O \SKO*%@5U+ J)%E2=D^@@>AYKF9%-.HFL3*USDQ&=GV(DTY\J4PSP8& M9^ &^05H*V-J_7D>3[_ 8M\9K*ZTG7F,'[^6\6RRBM)&3_PEK>'P'MU#_BZ9 M',Y^UQ5^5U3Q601^Y]!DQ0T*19:1\ Q-E&# ,+&+3S0PQ/BB'%N>A#!3K%PZ M3C.3Z"_)JT65=?'F6 25WWV3+GM5X"?Z#J+CMJ+@XQS\U0P'Y/2B=^X=(0\; M__3-9S@@P0'&GR%]AV%.1*0EE"<4([BO@J%@.(4(P]" =FQFN$^+<2\RGY%> M3WUGGU#WAGC1:8Z([,,1.J5U\!$\>F0O=.]?PXA9"%//2RI1*^0Q01*DN$PK M2W46C9IIPXX?3%^-(88)QB?O[170QQ5UP',_X0K*UX-KNBT_3Q%W:BYCO M9T0RE5N,_8CA]0>'0NI%D=-N 'YFB^;YC,' F])T3N8SY)SBJ.Y/X*R! %V; MBH(\1+38MB8HY))'Q&*ITT9+$@L/<8+ 5_X8_6$,#OL1&BBP6Y%=9L0SC&0V MHU"-I'S4Y 99H93G)B&6HVOR:20DN>3^!\I]RU%)IU=158[^^J97=)S#U#Q_Y1?\5'LHK/P<,(A MS#:S9_! B^M1ELH#S!2KG5>9J>A@I_]BL/\HIJ*OQ;]SL'<[/\V]!_6BOW/8 M_:O-H-9D4+?+U'?%5 0:^(?EIGD7@Q]DFBK"<&E*U,0G^:AO24R],/'//^H< M+<8![/3\YW]\WGOS\OSWRQ]]CI9'0L*I>O_?OU]<;":K,Q+4,56GG5/U!.TZ MW;/T1[ B+6FWV_G+[N O@\-[B,B#^D4>,D6=I?==30M_D#!US]1/7]+0?G>= M_3?]-OBS_\=",,KG?IWFI(VP;81M(VP;8=L(VT;8?E1A>X(>VQ6U55\\RE:] MIA&UGMW^PLQ&VE5F0[UO8 M=OJ[!QMA6YD%^;Z%;?^;:;8?)JZZL[V)J_[(#N'A?G]G$WQ8G?7XGF5M\'R_ M__SY1MA69D&^;V$[[.]OA&UU%N3[%K:]_N[A)JSZM*;J8!-6_:']PP\U'S;"MA&VQPG;H+__C83MQPFK M[FS"JC^R0[B[L]???VCN8A-]V C;X^I-MA_N&&V$;2-LCQ.VY_WG#Z4_V@C; M1M@>)VPO^B\>6F^RB:L^T%;=W<15?V2'I:G07YGH5ML+?=WQUL MA&UE%N3[%K:]_N&F-GIU%N2[%K;]W?[@6Y:K+F6D6@;@U@66]1 0WH/5!>%] M+0![T1D"S\[7#E7KHXF2-"%T3)CV+&98V5D\)^!:"Q^(D%B(7,DD*3=P4T'W M",4/X6G6. UU03<'-]:$W-7F_^E''XUWO_FLA#*E(3X9@>0T<9DS2$PZQC'U M+('1XB.)+8;)89B/"O; 33VA,2?FVF3%3($1$=]KV%0P'Q6CU-.+<>BX*L/: M)/@;AA>-A\Q'M?AM%1+AU&4Z$@A@?*J0T^1745R6".=+I#/]Z,*8Z"PNZ^CD MI,?\- =]A1(^C?.8+[0@^TB[TE05,N[@\([R.)M7*4%L.U*;8^6ZHFO.3=5D M-5WRP3(WT0-W7KY+_]6D"7X%4>W$,P2RQ#M@R".C5[WY#)LV1[8<_C$^RM[9 M18.6.FC[QX-L[VZO[OX^-ZC)HHLXX]GX/2^)$(%8ZQR,\]KM^_=%_@6PZ+NK M3+UU'[J)M5NO+O3#&>H_)+1*;Z'GFOGS$" :@A:?(G-BPLQOJ"_K20E:"BZI M)Q7B/X.,+X-_/O&P#N$G.SU2?J^*N$RBN*DG10E?E]!30:_*(' ,S0R']1/Z M9]L1S%2&HTZ1^O$*MA8BD<=3L%SJ+@H!@5!7RK%16HZ::56COJ_H/&DJI+L+ M. I^.MCS7B3HC;FIE:JLBL9E,64VBZ*&>>*30$'- MRO2:QY";JZ)F,D2D4JGB$;/JF?'8T-E!JT;G&EAM5_#7W#CH7Y!89%;S7@2* M%WG,Q@C+#D]E,.Z=[<&>2OI)CFH+L2G/LCB'4SLI9G)&-813^;=4!7PY]R-S_[A?WW(7-_\I'F M_V@G>H8?*^@ZT78]_G+()(\CA5,DZ(6TH;(1J/(-@1;E8])$.C:<5+@[DGA$3'LD,_T$&&M\%Z$2.\C4 1#&0JR M4_#8X)2&Q9H5E2R,$Z%P_^E='6.^9:0PI+E'1A!0&J2L^^R>M]0'X;#1RBL- MT7;J Q)F>8-_P\U5$^?"'@#?0K;*WG( Z6^/8_IBT-_9VWXPCNE!?W_GH8"7 MRWZ^M_^P.Y8.:K]_L'VX&=3=@]K9[N_O[ZW8H 8O^@=[S[\$QU0VBX@_^NC$ M>QFIB;%>L(-G<%MQ'R[P^U)^?U>S_MT7+!.EI-U\V\+9FW(Q@,^,O1 M&1%UG,7P(>#O\O1MYNQQLH;&'84GX'=G#9@;([!;CRP!^%E97)7QM-I,[Q*1 M=#X'F\*OT<@IHW_$62,_*<;\7YYY)>D!<^PTGO.__HFT9?B75W*+6YW?+7>4 MK,1706>5-2"/_2$+T!7O_W;5!1]&=2%NZ&[T7U^['M;>O_,5Y[,SB[)ZJ8;G MO1>'CVQM?8AHK6)]UIYD,]ZVM6#V5NMM[L;OI M6%V=]?B>BUWV#Q^.=[$ZLO:DY=QK> C_D%/U%<_9N[M45^N<]3/$W]@U7\-S M]GEO>_^A%:[@X?%-G=WUFJIO[L]^TZ^G M_,ZW=&3#?,[N#,MI&JP"T6__WH+C@YW>BX-'LB]\O4^\-EVE++?)Q,9V9O)+J5:SJ7<_R>[_*WE;/MLOMJ6(V MQ8I9_&\^*LI949*$34QITAPKL$LSAK]3CU)!5>6OS9BJO*^INN/S/+H 4:9V M()I6O&1G>^%([UX[74E%#IK]:XSTU@)6Z97T3JE)_Z"3=OIZ,'MHDDX,;$W,5['.DS.*)BT?IC#Z" M$1;8%5WVP=C:*4_'29TBN,,87EJ4"*Q $\\]P/CPRI#? :O1.AFH=GJJO MS_'%X2XA^"YV+'QB9:@Q6,49WD>).F3' M&#/$E13)6 #">&($#&F"Q:V]7(PEU^-C[,#,L&!1ZQ M4I8XR_DL&!2HG@\@(<(4\&M4$ MAI+@/$H)7Z>IX>T"R3#*8MC$8P;'F95%THQJ@05"L(D1*/ZKHH23\)?H?/%S MH@\YSN\5?,=9:48IJ8/7:7R5%Q5<4#$@T46-,;:K=$3'56[*:I+.6+5](./D M',_WQO!A>]MKX.OLL]5.*>,9759%$Y/-X(\XJRJ='Y>-HDCM"3*'NN/.*)%0_T!3Z1C6R[@ >MR=\V FU*AW+ M5K7>B3 :>"C3U_/KELRF'2,)"XYG9L[)*NS33\(3 CF!]!PM,M3"CS)<.YF M'!:,##"!7;+3.)O 44<;L1?ES2C#DZCSEP7++3^'U(']%QS@V"DXF]#,UV8T MR=TOR0XM]=_135&2'88X+-$UG/ZFGA-@!2D$7##8X0C#15MZ"-L>-A0;PKBM MDPYQ%,".*)WBW\B.<_%SNI.53F4E5K1(8FHTFF:73%*[##N,,'2*< M'1%JN)E>Y"F :EZ! ;.&4OK1R$H9^FK:H'6HHEM?_7N>HK=!EGH5H+7\WK_H M.Z"6RF2B'%)X*HPL0>00F;[C Q>CO<\IX\SU=IEM',M&Y]"?,&4P9_[]&'_ W_/G\9 MG<)X2]B7NACLA[YK\/"]N#$P75]@B#]?W62LX-.]=NB&]S)LGW;$#[3*C]]\ MB"Z:T8@M*(7[AC3N-R-(D&>NVK M$@YT_.$G]+P934W#2L>3."T5#XP@UG '@0X<&CS-Z-IC.._&T1N[(3_0CBI9 MB9[BN,#Q-=%O)LV+]M.7W$FO*$T-&I.>(F_#02R.J \JCY2F#=JAU MT5Z'[5SV[6>BS=I,%2:NX'BV&\GB6S"0!?]N3W74P,&?<6&&3C A>\*U.)0E MGXA(<0487Y1I3W->$IXQ?MLI._U_:\#>B4Y'O^&) K,0PRR\P^#GB7>6O::# MI2COK__HJC02,20-?0;K-Q-YO?0GB^6[D[\"27YZ.P"JV7: M9'4Z(R SG:%X^0SU,,3:X5J*(\ZO8&RXJJ&RI.0ZYI?#R<5"" ():R8!9 Q' ML1NX8(P-BP2<-0<*XH9%WU4,,;R,H"Y@\\S8XBXX6%?!2,$F@[>8'/PS;_PV M\'8VW!GL;/WC]'(++#PX$'=>;KU_4X0PDE&V"2 M0/JX-*;E1D<8\[GJ_-@41.":$LO6ZW2^DJ -QSXZ93,;ER!O" 6L7_73SJ&/ M9#F*JPG9J6#O%KPTB0_%*1"8@Q?]%W\FN)V.8:%!6^.789RF&S\01\9/:@%> M[N[J:'I^ J+K-2B;F5';.([^U8#.&*=&K. MMH(=I+&'7LD.FBQ.05$6+"/" MJVP:J2*<4+7S>H$^?U+7'0$$TF,]@ M*%/Q(4@DN\S%8%I&8+1C@&+>,7P_-P++WX" 8'TAS?=UG/6C-33;/4-E1U6A MARR+>)546"FKC&+!2HD#A(M3A&L"\PG^5PI/[47OXAR>TE31$:J'GA7[)-K; M[^T^W^GM[NUY,KU$+)V<8[+-[9T987[AIMON[QX0[A<]BT,7 KF*6WG$!72> MQ#(:9TU 6)BD!(>14P165]FWW&#"+-Q5.]O]A5W>:]>'PL_#SX]L#6KPM$WI MR_U+7PZ7E[YLBE@V12PK6\32+NZJQ MJ=\G,#&\V(I#1A[2Z8C0T<6-A/75@O M''@IV2;KY\F\40LW>B?V+6KVL_>7 M.]O;G+_FO^^NHP/C-=-K#KKEPKCSF8PYK..@1@9U7D:(23@LM)*''9@/)^\O MHU=J446_9L40A.8D'_5M0HNN<1%>..3XV(/7WX"W%%W!&8NG7VS="M_;P.1" MEMQ@>);DM(J><=D #O1O\0SQR3D8^O<"%'@/O?4\CIXYT^NW O[X._R!P>]^O=KE\K^'M1?HJ&AEP]KLQBXPO, MNEQJ:"0O1-52SFG7 J]@*W@[895U7O?BRERNG4;[V.J_HB48":;HR.67A MYG09&NQ$]4/T,^P9MXE]T,Z_YM8DVZ&#U[]]?62=-M^GXS=0Q("R?1K>P.?F M16[_#1L_[KFZ21*B-O^-I49B=/UPP#/D%F+?E.()"2AG\VF)6^D?6L3*<(/Y M+OBOB+I^N9T%^*T4+ :3T5)WZNJHJU%*R9<9R]B,M++9#; M8-!!([%4S>A9MH:Z_,0R_.>< R77W_&I1V9DJI*KE!ZF8YQH+V(KZF+7AX#( %:J3.%XO%*/M:-E=D MBE)4,,(Y*)K*"R=PY"=)2GQ?DT_!A,F1I&4-5\H_=0>'O:X%8W<=*RF*&3[ M%@!3.>7%V;NCB]_D2"2K?C=B]BG>+5CI@*7!X>+Q713!\-?+P"9O=+4,YC_B M$9.!5?%8JCUTOR!W#==%B)$X/3X_.P:CK^#2SQE"4,,"D7:UD2,;Y^7D+@4( MX4*34U?MK"9>N7IR0QQKDW28XD_4Q#PZ/SNQNY),"_D._D*4@Y2*2E(*U9D\ MH!P\0S@JJ0JF3@W10DI.H7KDFA\<*<;8VQZ*QJRNL4->VS\NSMQ<\4 M1<*2)BXW=CF=D>3MG0"_Z.\I/]*X*-TTT=?;+:AZD4MI>0'VL>7\KCMQ&E1+ M8B%[68#B+Z<8>T<+*JTHW DG(BXLUA8@46\^>[Y-+#.,#S[?(MIB A^+0%-.//EQH MB3Y,UVABDI][MHW@MW.2]D%_,*"PNU )3L$CB.0%"X/!$UU(#9^C5*%=6;3* MB.!4FZ8R6>A/H5YX#0H,%+#-TMCY>O_Z:(U/%=WY;C>1.S>.K^%D)BH?5A)8 M\)AFS'B$1TI"9^WA]M[+7:< MN",A47#DR"YQH"[+MVSRS=';RK>;L<5QF5*O ^V/([GUS35GM?2HH$>( XA_M<616(Z:5KAITKR1[2-S2BP8']!]\[P#S-C@Z&,[N/OP# M=/NN_>U^?^?//35L*=GV\SKF"5 %%Z 'M\ Z,YCP:Q*PP^$#BRGU^S\?[+0. MB;.+TZ,MV'ND8&#._4,C\<\,Y Q#/:>)0[(74K*G2S.F&DD0 -(02,9ELO3* MVJ&P]:>%W-CCF/_.+P,[,.G.Q__,T5E&F!F6HZJ<'[ M.TPO?&X_>H,+-L?]-))4I#S??A1\0"I--%Q8Y9>@A3D)4'O^DU!=8OJ/^HQR M5=FO,K0*<7^.\3&Y/J^KO&K51?PU.S+6+L.@ HNGJ1 ")JTF[&I%;X[.>J&5 M!3^I-/N##A^E>@G808[[F).K,5>'UUP-/1,6%4MGA\:U/6_4.@K, ]I:JOS@ M%U3"CZ7S\,P\3,7A:Z_0]XJIEDKBNFE.\"17:C*B"8E^I).N6LTTN6 MEW^@4I\ B'TF33)E5=OZ6=D8,"U!R-7CEN3K_]6 2#$##1Z]ZQIN6;\ X M9=<+M[1=?C@[76CD/A$0\-10[M ^Q_L[(AL]:8J<8>\5/KJQ9S%'2&R9KGO$8JTF@L2DF>0B"[IC9UVDSA+V!B'D2O"W#SJ'")VYC9J3WSQX8+3ZX? M+61C:\#H2+$=GN08Q?5HLO4Q_CS%@WI44XUFQZC;'Z>R&5A>@T.!#8*'4]P4 M_$EN&\ Q:K9'JFYL';Y?;K+O+3H9$U7C1/5URD3JX!@TI:L>LS^&M[XV&>)J M&5SP(ZV=.P*!R#"(BS:)7SWW^\51C]-8U#UZY_5X.;J6Z.C!1H4Y1@KD&CZH MIR.N+<.M@MUYWE< @]-.E!T OR(39CGA/18T4 MW,.S-"CV.'?<[;O;6QS([$-77E!S04F('30= M<>U]>8EA ?I@!BB@:TVRAE[L6_@6"G4&N4@P@1ES8P=,+8VQAVG\(RJU=7 ; MDA>_"[S%XG(PH.$J>W#=14*M:3A&,+*XB2YM@RRV'J+AL'8^W@>;_>Z0A"5P:#% MEF;?$38#S$N.-"+7[!OP1Z;^C%L*+)VS,@>_>'+B(V?4X?_/NY.+RP[F&L+"0 M%(\9TJ T.?BG=B21SGD//\/;*Q@9:CU0-VNW5A)7E M* UVBG+X<-+9HN[)9.)D"*AL0?Q)F53>6@[45*D32GU>-GEN'ZRG!_W:51RS M#8)#6+1":"5>Q4TUFKS$H7-EO$E\&\;A_-&HMQBXK^N4^VCTJ$S8$.T=#W=_O[=NSP [N\ MCSD)1C,U\'JV*.2(GU$F*ID.$5&7"0;LI:PP%#EIY:QV>WZ<#]M2J=$6QNU& M?:N4K=]Q>L>9,MBV9XI3F56/U".NZ*]%D: !\^.=+:_;!2EPS/X_;UZ?'ZV= M"+AC8K#7Z5D2#)3"@06U.$;#65JA1I!?H-:*<$ZDRH$=5*MWP#ZEW%M2W+#8 M=#7TMC)F8-084N5D-MMAA!?)2ZG1?VE^NJ?V/:P#:6-092C='NS45<&1-#;, M>:BB[N05U&3,6!LVK5_18^<4?K)9(?A)ZN?EL=ASVHEPTS2.6&MK)M,6M*&_/TMN?7IKK(KON&.7B M2\[MI:TWX8MZ'6C9BT-C^\)_:'O0%L(QAX7Z:1",.C$91>"3,KZY>UIV=CJG M10:+%00%@8'B?B(C/!@\1LMK^H-9OPZ_9LKJ&3 M_U&@)%N^R(%G[2):2%Q-L!1B0@=KX2'R8<7,7(YET)GI#'N>B"1+;6%>=Q^% MI,64%0AF /N98S6%5+HS>K*+Q>Q*ZVH+%^2F^WL&^P>AN]#^(OX..!XHS\2Q M7>UB+LU4DDGW_T973!%^GDY@/+?30&7N8-CW DR4,7**:?\+.#;KV+?R<8(5 MWMV["O" GQU%=;/'"X+**064_HZIOTFJB+F5B MAK4 ?3@A:$GA#9:,;Q7C,64G<_$)<41XF]/^WT#YBCPA-;5(>)UH:Z YY'M-@)\ M+K^+0N>S5GJ0[!/+&2K7V^"R) J90V5P\-(#PNL"=*'W<,267\G-=#QUDJ[/ M(U[F!E$QV&-F.)GVM =3EDU5&\/#Q, TU3.9I'(1[=0[+>KP8UJ&X-Z>9]KVA+@RX99'&=WR MR?1.>ZQ:1U8=KEAE"PVM.MJ1PSD8H2MPYMYZPO[=S)5P)SIBJ%/X%F(UX,[* MM8L2?&!VT]TE9$L>AZJ4I3B.%Y)*J5OQLYE5RC1-9J$!4-'57293%.L6^RYY#++QVZXI5E*[6:-"JND$4 M6*JB=$7XI,+A[W]KZU3PQ.O-!,X)@B-FD=]3(Y!!*XJLM_D MQM'978 KB4W2.-3W0MIQJJ0=!,-=9#"8#'Y\HFN)*P;VA#8(CK0%&BGQ.!F" M\[JX_@$TJ9,;J69M*EDC;<^K3"9):5HY7"H6(",,"^#S.+:;>;CL\76<9G1$ M.E:%)*7V[!YC)&])/18>] 3-A/( 0^Z$9<6B+(LL=OK6,\'<%PUQ+;P",0HK MCN+$3!'%0(J_UC"V5/\B8(3'_%0HFP%RC45C=GK8SX5+450 MI[20_8HF(>7BXA6FVL13B[K0+:*P'5'ZW($NFX/1+KD>E/KNE8Z%_ @[.%/,"P,JK%4;!-VY#-LI* [>OZ7AS(MT^XL. MQLWIUWBQ-?67X\NH&F%.PF$:,K*&)ZJT)648?7_4_I"DC0K(S G0FJ*'&"@\W09)%'QW,XF*$W<@B7Q=_(B>\5KI+,GL 5-?L55&KJV M;K]ZM%0=8/.5J*1_-;!_4>49DPP)%2,GZC0$:M"QQ!DQNZ'X224ZKXP*1,5- M[^C5>@>!?A<"CB!':P]\OEK26Z 7D):*2)-9:4=8AL:ZBR$FP C'48H8HX>8 MT:31'LL8BY,5&!)2:(V??Z1X8&%H]F-D"1_GH$Z\1: # [-AG",CT*2:=3^7 M9"R41,**6-N"5JZUHE2MV+F:G/.CB>?1X^+:!CDWF_[&\@D=TQQ6+$Y4T[NJ MG-$GF-G$NT\KXVD+V7/=;;7.[)F;8+.$)2XQZ:_;NQ.Z\IC?O.A2SR '"&I M\P:B#VPT[,J=C\'E:J:WMVC-4K"[0=31ZZXIWN!([>@0_5N3 MS:763Y[7ZB1+:U@#EO<3#*KC?9*#"_#\02$<$8;DV- <4A"(9M M@Q5O?O?R]<.2,%N1F0GF\!AG<7&V/0'PC]0O6M.>+>HV=U '=:%O+^M:\MNM M H@5(K@/GB/4-M:J)W 2[?,98P$S\M_01#'KMI!N#RR+NS(B1UOW)M*E6P># MEY8WU]*VKY]>/.F6@#;H-4%9\B%BXV/;?M+J^!_GL/52E\KOCLUZPL?.)_8? M_O3BA5?DH% 2_SB/M %,@)1LVZ#6O+2Y6E"Q%<-,>BTK;X?@\%8@N_' ^*Z5 MZZ.3Z/?*K%U(UV&,#;I:<=_\S\G[DZ G;6^P_>S3SQ%%#TE>PEBNC=*R#2JZ M]_@-J5\),[!&Y;/L[/S#ZJ*@:M3/?"@];*" .$7L=$]S9 MVZJBUL)/;:NA>IB%[Q2B+<;I20A?T9-I?S3*T[53:V\ /I+FG08[] E@=Y"37I17,@;TV^FA\D0>KH;79%#P MN4C6G-DV.N9>UR:=Q6]UL5&RB./K-/%3?1T?I;8\ RY3V#CWD_J)Z\ IC<(" M,JTZI['@_'.$]VOH=GNG(S.++[03IBV;7J(DY''1TYEE81?RE5/#SAP\XA^IR?-8<.C]UR&L@TH6Y9]A)R42 M8[L$E_.":P9?)T6ST1I[N22<_&-LD2H)4/#9V?'QY?'/Z#%BS.;D_,/[TZ/W MX, 1@0"'.MH0(+ 4F&Y7Q89[>9@6Y-F752L6?73"JDX?S'L;F^8YXDFN:_"V M4TW.6S"^UM>PB-E[4(MKPZ\@W>**-A(&"-A:-)=$\T:Q!>H_(U1OL$PH\I?6 MC7!,.+SEJZP8FC64J#9V,0.^^!&(.&_+S]G)A_=OWIR#9+2$Z/5)?)5_4%S7 M2^X_? _>23[!"QCLQ^OP.",H=9"05^E5]%J0]-\TYZ!9?NY%F2M 6:9M?B_Y M;'P&>YQ0QHZ+HH0C%E$9N8?H58S=[D>_XB5,ZA#_8"[=8()S/J]L]?&#Z5 M.2=-><]]M%*B=U21M>E-&*6&4-6"*U(6PV9(:, 8L $'PS#WLT>Z)BFC>Y61 M4FP&CY<++V6$S.8O'WGW2X M!$V5?D9G) >G^%51?-I";&^N.YT4R58QWB**!AXAB'9.2D'*4JB2HF(LG=T] M*;V^7KA"+C@( 6G<]X<%D3H;C$TJ="<=(Z1GBS.&3^]';[T/I#FR22BJ9.IX MAOTNKX")2_@TVDGN5US7IK0#Z_BTO_H/V]C].CMZ=GOQ/=/[VY/]G[UV; MVT:2=.&_@M!XYY4C(#;!.^T91\BW;LVZ;;^2>OO,?CD!$D4)8Q+@X")9\^M/ M7JH*!1"\BI) "1.[;ELB@;ID9F5E/OGD1Q7\>5)%UP)'%[/$9PBU>3&03DD^ MQA9SI%;G9(Q$' 'N[TA M7F4,ETD4NRR69=P;- D9/$GS&%"O$Z0$QJ@4 048XI<-T'"^>/ \$O?*8$)S M)Q/_9Y80O"%0(4+Z;1V)PY_KA:4/4)&&B0S'L*%>;AT)R"V ,2Y>](V=CUI- M[ZFFAAFV3IY4/R^IE"?B>$E>0C6O$E<&9?IHCIYJ^V,^;F.XYF+TF-JI7/LR M1(3TK@C;$+,Y,O>B>D@R)[Q"Q/)^*6\9YKD'7K(O\:PR+CF*0KS/9U=2B6F$ M:\.O<+!RT(IO+?1]%W&NL#"Q!EVH6Y(Y!5]BE_#H/8E37]6JT*$7RTK.'WZB M^@-3G[+,M6685V].K M-DDJKDX-9(*4\O7(JJ% \%9(79C2@*]N!$9320B!;N*)(F?$Q#SSA>=<>3D. MNV00MBY25.51!KEZ5HI K0.8EY/!_N3%<],Y+).R59N 23A.9>D6DF6 K*%M M*L'FFM LQN-G4%X-&W2 MP61$AFZ,_,(ZCRMLJ:5+@<*E7[>Q;S%LCW6!, K&=]+U#JG"8;?TCXORXL?F MGFM\_3Q2#(,SE:[E"Y(#RI7Z02YW\*-L ( MSX3;/1(%<0"+R6?5)6*Y.&LIM?&,I[ GPW;'F&N2C[D2JMVR3/B30X &#S_) M=EV]"NO8C._RO5[\=-'$9'=Z#?0M E/+&\])$' !Y"I!81H:W+ N8/1@9"6; M?^XE2Q]*7=>F:83Q",_]CUFXAX_^]9/U6Q99_@(O >L5K['"P<6K&U5U$XE M[(KCR[@,D&$<'1/ZV/N\.3?]W^\2XD#?*)S]=%=)0%]/TKG9 ")4'2G-"/=L+ M2FYS2MOHE5*C'C='/;9JU&.->MP_C];"0?5$\LT.P(GJ3ZNNB_ZR]W+5'-S%9&!'9) /&*TU&5VRW 5B_= "5>3YC8)0RY+- ?9(/(B MT^)'JIQ0>*;M7J2R4+P;$I4A5T"U:M?MV[&F/>=7E=4]Q49R>B2X-3&',8ILJXB^*!TKNP,GZ@5-QOZJ\2^.LRJE8B*0:D']+ MHV*)BJ)"6NQ'Y>%:J@XXLIE'!G;)KJY9CZ0EZX$4*QI7A42OB8Q-BX6>2N@J MQH+"&8Y_9X2DI%!'Z-QWXDMS0!=3CX%G7[Y> M_G;BM'OM"\Y8PZ$KIM;$'X%;,24D0!8^ARU)8+[821#<"TO5?"$89SX7T4FO M8RTGY=$SL M5M$+Y*N$/7#0*8<(&>-3=5O(9D*ZXGD1)>7 :SP3!X#"2BFTJ M&+1Q9]W Z0P*HMPC5=/)[#B8-5%+\$O+E:N P"!%/<_]0#:K *^2L2M6\^%. MEKF&)!#L+^$%C.EZ"!)76H$G[W=9$M9$@LL8QP($ GN$8S$=M6?[X2>L'?1 M,F[\4"WM!="Y+$;- E5&:%DELLFVY,UV<1#$R)092L7[0YU-;@1<0!DRA#1% M-]3"KVB+ZB31HR6)B@&O2MS,\ Q9#,45=8!A3T*;.@YAJ,-7^ACS%&XJ6:HT MH\V&^X>O.%A 6[@F@:H@8C_.UXJ'LM+5Z("1/^P+O;:9J:I\$DIQ=74;I7#> M7YQ9QV[,!&)XO%/R1"),-)0#%P#+[0@1+S'WLL(.HQGJD6;'*WU6$OLGO&%) M]9R]2VD*EUK'^1(5S-458'P3]G8RA@KVN\BXA:H&U2*R##I'\*+?R90\J7Z'V)[MCGC$8 -;M M('4+?CJ=(YZ6J .,4@2PUR,1P.+K8A>>$R8YL\T,1!K1?PCL*X,%:A-S4J+L MM,08<<@M4E=U6+Q_,66-3AU^_(9]9-"Q(N*L<"X"Q0T(:@>SXO(06Y[\;7GL MHSL/\'?P8K*-#9^0$[5;.0'ADN%#D@Z.VF!UWA\[N)_7TN4)PY)GIFS M#^??/U"B*8O9+*H@R-QO'[ZS(YA=%V*AV?27=>PL5B;,TVB.+75LQ?(7AS/< M7OJ1PKZSP&4ORA4$J.SWS*6U-[-OFAYAB5)F.82#2['^.@U'2$04G@R'U@5< MHZ:'UT/F3Y%##8-R\'1BFDY6X2 E\TR6>;"/=8X)0C&5'U#&Y>S\4T8Y&*5! M8))Y+1 EJ5XK8(1.D"[MEE.?-S[; >TU(C.73Y@>[H\7A(G/U?X8Y)??E/<\ MZAUY^9W'Y\B7QYIORD_@-)QPDA)9'J_=*;4]0/ !Z*?B @ME M&8]CQ5O>)O MT2N_%](HJ]G!KD>TO3+'6:1*!/>*- MIS7%7^F]X6:;"2:6)RY:&WRL3P3>6)IY17 7QK\HQBH9/\D- W[M(W,?UE;2 MB:8>DW')4:,3/)H+UZ,(X66P[[GG:7(6F0V7CR.;/L6L#OW2!X,]UK1Y\O$Y M_D"$YBOZM2EU::,R5[K=**HL#I-\+'3J9J+)V:$\ WY;"-=$5_\ M1"T95EBX !>.H(((W M0LY/=;,C^J',6_#A(HCOI<^>2*>;>O1(:G!F&:-)(]W"%?L5DC5/,B-FR4R# M4MM!+E=H."T \OG>9OC>L?Z1P=\-&!K^% M4T*21Q<)&A9U3/SCMPOMJ.=<7!@ ^,L$N,5[G#)()B:1]!6& RX6^EEI-#9[ M-/*'OW[ZX_S;E[-+N&U].#W_>$9_YWCTC3N6=<,(FXWY)IC71,H(%CP%MMDP M[ESG _SW[Q>G>BYPWL5+#[N^5 /B6E:.)'6(]/C&,TNQ2M5XIZ(694 @7PWD M*R424>"=(M?Q@;8%/Y3UU07EQ(BH*YD+R6B$"7$$T#/8TPDR9"H6@#RE^@(&6NJ M;FSV)8TKXHX*A0MX.+M$E#VU,'$'0\$KFAO\0#,[OM-G4O;^'"LHKC.\7?+2 M\ %X\?X+78 M$Y^SKUV,$8PUC0VO;/<7NYS?2;<6)R1@+#O!?<#\XP6W!VI><"-JF M9\A8QRR%I"*2',(B.G.J!!ID_,8+E M]!XYSN,8S'**J/YX\9'+O6I\Q?\1<&>N82Z;PUS:-VL+;U6K6LOLXU%2VW"B$/$<*;]3D2"8#H:3[C+ ,'@> MB(?AA,G,]80,.Y8UCC"OB6;G"'@XNC8*TU.$'4_]B1C?88:9@SJ:+R$KB-!7 M!>VXOZF1P/<>0FEZ^7.N'8%TAND:+@)9,LN$M%&< :G(C\RC=A@NP+T;@HE=-J?+$E>J\QQ]%&L;K"+>3BQ%TH\\;Z5U=3F=71 !5R M%B;N#1A.@CG@R8JY4:S\(8CL0A+2N.->A[=(2XV9'O"P@RN)ON%G:T"&QDUD MTJL+IYA*Z>=\*B%EN7*A H^X7AHYL\+(:H#% \H[(^'(&O'?F0F+^DCU:.>_5:@QC268HEAA^DFOS!>Y7)/R%595I^X(+JJU=#^<=)N0Q77@1VWL M-T5!/@XXD=G-'QN<6(O6.M%RFL,N@PGS70UPQ[&2J^WHMI/Q#)-B,VY;*!8! MWB1^.1>#X+2&AT$T?>?GW_Z4V]Z2>^ZMXPQO6-\-F:!@&G]3,:)QCQ99WX^I M,0I&SKY?,0<\G.R4Z54\@>.*K5M?P 51O7>KGA,"B MN25I-S.Q>-4:.'FO ?X*=RR45WW.Z_R'.[[&T+%Z79:NT:Q7XN<)_3T25QA MQQBC?B!&S*=,R1-F=0(\*<6+(:;^E2^3WS)@+L?]RFFTN=,:CS/&7H6[C=8- M LQ^\1,PJ1TC[UZ<*U_(M6ACI[-2-_*M2T;)W]6AE*%^J2Y1$18^).*#W,;)CO@5E'I=S)?[2K. M9'?SU5YMOA U O_^\F%3*^9L:\3:G4;WR6Q8>PL;UNIW\[;B(:U8NV#%MM;V MB0]V3P1K[$_[ )-WWR@LF0LF,NC+I(32]-T9?^C2R&(^"$,.F:;-H99'#%OB MAGT4$9:LX(Q02Z-RC%,>SJ1;[&*.D M1AUD&&T\KY'9(?KP0,^F M682R$,WZ_O'DBX,[+\OXZ?+'B23LH8 (9>S%H%L246T1,4_J"(\1RLGJW1&B MDY^17 R"9A;+C&&E\S,G*Z9!GRI-9"2%C$ K#T?1O-QD191&JPEN1OFW,#]FA)I&ZQ8I\:*U5BQO5,B/9$T+]0O7X1!^&$:IAZZ M(LR@+A+$BH-%PCH66B!II_P@Y_,H.Y,EC)!&7LB2%NL*[@9T,L.HR4Z!H3H+ M8AR,&%M?$B\SN_K'F=TU&IHK,KRB$=N@#7GNP62$P?8&\1C^0 ?H*O4]RD[Q M%6O1,I=.T9R8B:3AFQ06M8>>4/QS-R(K!HMQ&6Y>6Z?3J;BZ%L&=)'_4[:YT M+>EO7[=^ CIQG'RHJ!3:K#\JZD75I2%)"3B M2W-1?@KTR\.9#WN-Q_DQS!-EB\ZEW2;!;KZ=JO1 M/8LXO<$A6L79K'/^+L0\T1VP6X7FC9H%:.&66LZ/JM4D]]NL$P7=#ZX5S$,S M/!20>ZJTCZ*NLOT[)J8PD,+<%K;)W&I;URZUOJ'R\7%X H9RAG8RRXG#$S%9 M)+CUK=5K_E<6!B=UXD8!(D ?Z4;5JL@ ^AC_S40.BGL##C<84H0W;_ H[C1U MAW963W7[#2Z0F_ATX\?RBVLF8J&>7:)5=VGY20S9X4D_G8[+6:)CR8+R&P8US>&D. MSMJYX&V9Z"R4B(6$'0-EC/:T#8)Z=O%WZ, J@1O)+IL82Y-J?<\'NX MZTUDF;X9=?&S+GHV'V":[X"I#E:3/_M)HS \C3[++" 3%B5D8C10$7&*VJ_Y M+$&+QJ ;V"0TG7$9N\X,JD(^:6-!]?PY1M5<)(JT ME6=;[>>T$%C^CI0.80J>W@F%@65VEZJI ]E"$I>B08KXG"8_\[T3>6*5S%QF MKM,D1FBUT5'S\$S[KXH@A9,*NO*V[))6GHV02 8&OR*A%'PMY306G'[)'9_# MLA@8LWE4D:PS6 @L@E,%/3(SHYV8W5G'%%MFHCNXP\0$.N GVH8:$G:W@#^P MS?Q?Z?B4U6=6=35#CIV!'X53Y.Q [N!)-9!E@T-1HI.[F49&8ON M3% ^3&JP@*X$%[''=!AR T-*KL %7H\ RZS@%YA#(#>F--&ON @GF"V])4J= M"/^53_@78K5ZW[!H2H*=\1PQ:0M8D,Q5F127;Q$!P"G;,49,;SB^[$8!].!_?^_O1^@";T^T?U:'2.E1:W;+:=46T"@'U32.@#B[Z6/6KYSSO#3CVH1QW4H-%J M=NLQ'>J8ULC3+V04V#" [4$S]O>C]E'FJ= %\TW3#4CGWED)O^)%X-/6.F]E55_BJ$JDKF__L7I-=^VG4+0 MY)?$VVE?AYML*T]\Z<8^Q7)0XY(;N&)BAD4OQW"!NJ^K8J_!23 M/.9F.BD\PXM?;[#5TLTB=WJ>6.3L66JMKMVL^?40EP+\>$*<:?5 MM5O-02W$M1 ?KA"W>X[=[CU3(=;?;ZW__OT$NH(;.VCTJK:K3[,2FT0@:MM8 MV\:%B7>;0WO0;5=-BVK;>.];M#-L5.X&707CN'7\;$+_.YSXV0>)!:86/M28 M>^GAL$HO2J9](*+?'?3LP6!;SZ!\FQ_,;!5>M[79.MSM:7?;=KN[K3M>;\\C M;4^KW;>[SK8>0;T]C[8];;O;JK6GHMO3ZS6V#?GN8V^JX%C5PK'>)^_:@TZW MUMUJ;D]GT'@*NUH%W=T3J( FWNHV^MTJ7Y!^-:CA=[H:/=.00;\YM+N=.A;T M[#:V.W#L?K/>V&>WL&VSH4]<96?V-;?? 4F_7&/K>-;;4:E=O5*CB@ MM5C=+Z8Z[-C-YXK3>$=H$O@=!R[W]X1^'A@[MPA;D^S M:;=VC:+6V_/0V],;V)U6J]Z=:NX.F+;.L-:=RNY.H_,$>U.%ZV8M'&M#4(X] M:.U8[EBK[H.K;J^Q8YKHX%5W3Y&BP[@>2?YNNB"YWLP/?.*P]F_$"P.!.ZVN MW:E1QI7='H2Q#K;U)NKM>:SMZ3;M]M; @GI['FE[C@>VT^HM< ;6&_/D&]-K M.(^[+57PL&JY6"L73L\>.(\L&K7&;K0S3J/U\E3V1>6,SD4LW&A\76P?]\(2 M1_V^W6_VZPA--7>G[3AV;U 'T"JZ/9V./>S52=>*[LXQEL4.^YW-#_)Z:QYK M:_K=;>Y$SR7J7 O&6FAKKV?WG:?(2M1ZNTG1V+"]=2G[?::,*E\.>QDF M[E1UB=L$;KQ!(."YP?#;Z/XU=V1VJ$1]Q9XB/,]M8[N=KMW=NG"FWMC*;VRK MU[;[@QUIC.J-K>[&'K>:3;O7[&\=LZTWM<*;VNXU!A7:T2HXH;5(W>\ 0-*+ MUHX0AMI65'=CG69O5YZFYVTP]IK3&U;YROJKZP=6"*^E8K!P8KEQ+)+=;JR' M&Z'YZU\&+:?UM@Z@U=M3;\\.$$<;[HCU[E1S=YZ-\MRO,V/U-N;K+Z=UGFM+ MA!E9FH-.33]W*7Y1"1\VJJO_S-AG_& MQKVH-6MT)AYGI/[ZVKK8'=Z6P+:JXWMO(;.VSV MMR:;>!%1WEJN[B=7?;O9VI:"M[87E=]7N&4/&U4ZVZM@*_:4$:KN5?8L2$0D MXD2!%E]8!JC5M)O.CO3 50HO/<_=Z=O.H(:W5W9S^MV:!K"BF^.T[$'[*:CF MZMW99'?Z@\935$)6P:.JI6.M(][M;8'-K97VL;:EWWCD%&05U'7-!(EH1APK!3/[Y&\A.$37IBM!L) M2LE*'(@=W U8M"+=7^$8WP%N3W=04W96=&N.!X-A36!6O6T!E:FWI7K; O]I M-%\>L5PM&6O#)W:GOR-@H5;;AU?;WHND<'WVF<)OR;6(K&-&L[ZV$,UJ6X%X M:1R0Q[V>W6YM<2[5 ;I'.Q;ZS;H;\_ V;6 W6X==8/-, M=Z9M#X>=EYAXJ&5C?=S"[G7J3&$%-Z:_%1?/<]'8%U4">&86]5DC,0DCH2K] M$O=G3?YH+E;':=K#K3OZUICQRF]L"PF(MX7/UOM:^7T][G?M9KM*?'+UGMZ[ MT&_0L5NMRE6$U1N[AW1(>]"H7$56%5S26K+N213HV/UN71O\[#;VV&EW&]NW MOWS>QN+99_#.]/545?M9QR,1B(F?[,9+(Q?@N6D'.DJ#'4N;*F'U]A1Z>V[[ M>NS8[<[V@;EZ2RN\I6UP4+8 5;ZD+3W$_1QT[5Y[QSSQ9@M1[^ACYY;M=K?5 MV+ZQX -M9Q4\S5J>[A%RMCO.CEW5:@-1Q0T][G5V:&_YC*W#B\JC?A7):H+4 M#6,2O']OVC!O+TQ'4Z'=N?NYO&6K]:2R\NH)%ZC:6M1N]>Q>[WXM!O>P2D\4 MSJSUI-:33?LZV_8+ZM9K4:O+2X[]BM_O8%N[6*U"KR0E2D-1S8W>'] M("6'JR<[)) ?2F>J)QH.^!CMQOV@@4\A&E4( -0VO+;ACT?G/;3;G6W)")]> M3VL3_O .L-,>;I.W>7JAJ(+QINCM+XD+,X;_>O[-N[_!'VI,,S>Z\@.U.(46 ML6.!9-QR%N_^-HJ08DT^NO@@.8)V#QXQ#V,_\4-8&S%U$_]&O+WUO>1:#L_\ MEGQO,_N*.X+U3Y/E7\F/&+;SK?P)[E][Q00><1M:..A>+[]8YI\X']_[^Y'? M[DTF?3'L]9U1O],?-@=C3XR[W9$S%J.F-YG\7S"#1^I;UY&:P]R]$B>C2+@_ M3MP)3/&-.[UU[V*T(N92P:J8^[+KDBY?P,ED+PO8+UE WD=8C1#;EH%D@&:+ M"#\%PW$K,Q;K.A*3OQ_]9?U.]H_>7:(6(DW?!W@AR&;\MU_D]Y#+@D]\8V?@!4: M;[!(Y^)&!*E1HK=ZW&^7"L9CF[@_A36>NG'L3^ZL,(VL2$[$\H,DA-V.A+#F M4>BEX\0:NXFX"B-?Q&^L<]?SP_FU&\W=_TD-.__?3Q_/3AG46D!S:UJV GP?@58Q!6'&*GAH;3-#S8WA2 MXL,+2;3E5/&W^##XYRRD?\%K^,GTOP)*8;16YP)9"NE+\_-Q^87+N)-0G':8SLIA-W[$]!B1(>C)K=3'C^&-8$ MY2M,KZYI3=*8[.K(!Z&.?L#S;)C1%6J@1?X$?)'?%Z%ON<#U=9$>R1BZ(ON7&L,[3:7@;O]ED MVGB"E#I6Y%=FWAPYTC#]J3N/Q1OUE[>*I]N7MEK&3#CSG=A<^5A#W8LCW1?7[!/:2K MVC^%&Q7<90L\Y0U"M"O78WB@RT$7A!OP2G(7A.6+\#!4\EO$C"H2B"Y?S6,? M7-GK,(5G>"NZ@6^MBKLN4$4%;I-\R"8S?E&KMHEVUJM67#6G5L*2A?EPC?=& M:R%O5B].MCB;9&TK[^KM"6%/*U=9E+D*.NV["F?G-=PH)7C 6?2MYU_M%-^@ MZ]CM7G(?> MG.-AOU7W0JW>MK3:C2TZO>QC7VJ_QIK\J2RUT[$Y[ MWZF%9Q,).,0M[;8=N]O MTEZSL>^@>NU#5\:'/MC8JZH$JV1GFD/4\U9_:/=[VZKZ5BMQ &&,Y[6EG8X] M'.Z[0V2]I4^YI>T6]F:HM_3Y;&F[8_?[VP+(ZAVM\(XZG<:.B;+:9:Z^R[RB MLWBU7>:,,N$IX\P'J,^#OMWN[]@_Y\!"%X>X.P-[T-L1(5;OSD/OSM"Q6UM? M0>K=>:P4N&-WAMMWD:HWYN$W9AMHPCZVI?81'R>LVJFRB\B(UHRF*B/4BFLH MZW:!FI8]'-18UNKNSJ"U8\REWIT'WYV>/:S1K%7=':=;*TY%MZ;9V+$#5>TY M5L5S/-SH(J%;]^T;7?:-:SU&>WH<.^D K4371DGNOQ64UW?>45K FYL('M2U M?143.?:@7V-=G]&.=GJPH]5"7=4[>K\H<-=N#>_70['>T4KM:-=N-NL-?48; MZNP<<*Z]Z.I[T:M"T<,JN].2:*'8D.YQZ:GK+M"/L$#5M@L(?>S9G=:VY3I[ M7ZVLR@^>B)SLD]1Y*9RHH&H/&_1*Y3R$7=5QC35SC%VK'O&G_YRKTO;Z\%MA? M/!)NC'_)VLY/0NZ0?H<=4\5"QU39T]V-86UF"7\LNZ_/(AZ_2U^8PIM"S M+3\VNIE[*35D5R_U\EWC%:&.%;M3&,5-.$UGW%O]_-.7LXO+;^<6K(*($UAV MRQU?^S!>[(".'0?#"" IU-/3@'32:/DNM#IO=VP\O/'+O:3 M6"0V?@W;J=O8 -S%3O5ZA39NX"XGBF^7JPK_'8=7 346GT3AC'[W-;R!Y\"K MC<[N5Y'@6^=M]9(3,-;&C6^ %<;/X1_UPL=A7?N-+G3HW=C6)J-6KNC MC#^<0-,3WV!#>G^\@8B?BQ%L&._0*?9I=X.Q$8\[E [UG^($5"B1JAD9DW+U MI.#'\TC$I \IJ*W\BF>%([#C) JQE)*[H#ONR)_Z(*RWU_[X&I\. M6CU-Y8!HX/!7\7,.*H8S KV/Q?)5Q,&PBL(48+UG^(N3$=DK,!&@]# 2-Z&9 M9Z9-_A[>ER2N'^!LC&6&#\1S,?8G/GS(-&_\?CCL;Y-KV_I=>'#R^IX<'#P^ MO(K<&6\[[BK\ ! M,1HD_P9LG!!HP/!)Z=R:I]'XVB5[$D97+JRS MW']\V1C.=QBAY>&W_5&:D$CQ#H%!G_DQHJ=YG2SP \;I5!L2W (I">J46+Z4 ML!'9J@1:(M5S2,Y.4,[NT# Y_;Q3>NKP1 MW L5\7(K:UM8I?5$)>DO![ASZOTKC1.^#9,(XX4#9)BC,/N0X)?+*/14!'8O MR/RZ=RRZ(*OC2'@^_'7F>AB/C$B0KU5SAV@F M^RU@AY3D,X%(M^WV\'X P < O;\@HUS[Q ^626_9[:VQ2-4RS0<@P+5/_(". M1:?;?G3RTQ=D>VN'^*$#Y\P>T M.CV[N6L$YVGQK!O!\^38"J>9SG+S?#%;MS0Y+E>KC1C[B)EXP_[2C9#I M:UY*\UORO,8''1BST^OG%,O_$^?C>WX_\ M=F\RZ8MAK^^,^IW^L#D8>V+<[8Z71):))Q8'^"%Z)G][1=WN4HMQ=Z4J6(%08EE M*WGT[MQ1._$1-H1IP2>O@D)%%#/,5K>VG*I $7X"Q_1 )@1X3-[CR4=$(MFLOPQK/ M^7:TB#2V$5D&'_Z/!OY]0#29FRX\.[8U0&^**X]@XV488@,4;6*.ET&+-ST= MAD<'I/L7)!*X9+_3=L$V')S.97.8J3EH="U"+6,_3@QE@6V&[8:_BSR?F$*< MQ@FC%$'3XC (Q!3E<>*+J43*VL9K".68@M[,X!&(< 19MB9I0'CAN"%1^/Q, M>$J\:J02)$PRZ(&(3L,Y:0-^/$W\J2']KD?.9:R& /9E%N(OW:F%D-8(5-8F MJR,(/ L_EH/3HR=$IAN-K^D!/+"9H"'%!PA&72D#F5U\U7$:75V6L3][C.!D M,&6W;LXJ1^!H!V@Q$2KM!S>"HY9+)6$" Y*"DL[G\'?:ZP G DLC]QZ?IC5P_&#]-CX1#PPKD2K-RY,8_$"0*P130&>5+B MY\)3;WS$XM/Z*?2V1();8_BF[R&H<'<3VF\=D@G]500BPLH%K.G(H> /SI*: M4RD ^A<,ZDYF5/P4XQ2?9X-%#3BP-!57:*W\@&H;N- "^S+"G*_NZ-'7*F#E1XD:CZTU:>*.N7P$G^+#,R-<)YZD+6>)3_7\ M2(RQ6()6?S*!-T1&\8G^Y@%:\TWD4-7!@5$?-)RM;/J][;D+!TG'>&E YZDJ M$U)#F("';-VX4RP7,E)6\IU8 P+;2"<\>IPT6;5]J%3'<(V%0>"TKXF?0(#+1U%L JI?0265EGTUA4<9XG0+ZF,9:_&"\G?8:[,XN[ M,0!3UC[\SWG\FKG8?,T_R M\.Q ;B:F3ZRM N,H:12N\P/@Y*@M*A:-?R(ZY'N4PD;N$.3$-28G7DZ2@Q@ M!'YD1F5P8(XFJ-+H0LL?F <%?CL25UB<%D9WQB'U')?=,+ZM=L>H=-[(_.[! MH\;OO&KUFL:KT_DD"A'"DD41$+>EAY390#=@8D!D[M M.']5,M?C6%KDL^_G?W5G\[K0^&>% \)%!@T%1\_R8 M;7.:JW&4LJOD3-_W\/"]UG'@'))U M/,,$!)PJUB<6YH-STO4$I#:NTKE\LM:\"#NMQD +XR8*:8;+_#A.R0&0XHD. M"OD56M<'#)K<_0XXZ!R24'TA'0] IM"M2HUZ\(_@XQ^H/-O)""1=S(\BTD6O!C5WA7#X-RNA+.:93D/O#/$&YK*-ATZ./5 MD:-XG)[PF3?A5=&6))5^= KPFNPOSL'E(PLQ2;%VZ/]7Y;1V_%P%8 MC^3UX4DU6KG)!'W &Y KF!/2^9#T"A?<@/8WE0)I7SY= 4XQ.(9L0N#L:#]7B&K;&0+)G%%FK&=TI M)Z> FP*_PY^,W1C%+YE@"+R03XR%N=$-2R8T&="-X_V 29_@3ID+S%[&<#C2 MHB.&!./N#*_P"7NV*$ YRVH X=AFP0!,.=3@3A)XV*"$6*!!GXRW@CV:(MP$ M%C50BALQD[1!2/ZJVVCIQ)#2L!4JM6#SD4+=!!9V;2O+JFQH]@[O^&P]Q/&I M$XW&J>.:PK/*.JH3RWS>5J>Q69)E:+:>7V;@#20J#&HI^%,6!=!3&$&=,%NZ M[!L!#\BADJ02:;9T#^4*U9ME4&V$J7ZMIU&_&]C,,(WWH7Y# ^.PF_KMGJKM M/6FJ=C4"QO]WZGL*MO[!G6-*%RP-8_9+$ >;SGE=.5VO0MGI#W@D?<;SZ.!\ MQTMJ3(/I9#K7Z62>(U.81XY)AG/%/BX1@<)11^@0GN22T(\;X!XZC6ZKOVV MNS-L]-N=/1'P=[N#_42E.S"5M5'I>E \J#7;MY^0\LJ/.=TZ-E_W?'AV(?0Z M\?!0B8=ZU8JKYCQ$AQ$B9&IU&_UNE=,M7U4(0WI9!&/-XJE9F77=?J1N/[(3 M&6VS:[=Z]V-(JVQ#WUJ(7X80MP:.W1\XM1#70GRX0MQMVT/G?BVVGZ01U//Q MJXY3+L9Y+2D%MO:P5JCO\U'$0U(I>]A>W4/B8>Q[+0?5FL)QJ]^SNYW^,N+O M6@I>@A2TU[:BJPC/^X$=H=FQ:1ZF6:7VTP4IGH^:;3;%:NO?L=.VF[W6HS<. MJ07MA0E:VW'LWG#'<$ M;;6T;6?6VD.[W7Y\LW:@*/;/R$5)#%9I;++53G/0 MH+&$!BDZSP6V-0TI*5+-$J$51,P]8^9B,FS&_@3N]B/\Z3*WX( T:^TV?."1)&'_DVE_ Y1;JHINT& M :/'F,DWL&!]9I;3//GO+6;30J+4J8(#$CCYTP=ZF!A%U*0>$:U+Z&P>&R"V M%"U5+B_H9A)BZKOA7'[3&;#31>?R4,!4&^?VB.JEW>PVVAI3Z&W$O=0N,.,A M1#3RT5LGML,,+TV(;OBQ$CG\G4)6PR?#X(0&ZH-ZQ%:<(LE=7&#WGX;!U;8]\0\$@A4A1$7R/DE]VTDZ%^:G+-(E[.JED/C2,UR#"[Q($#LR8@P MHSE8K'P1$43)=;FS;L/H!P'LIP V$4KWYR&A.Q*KJE7:1XB>)L#-MD6Z\M M@_E=3>2M^B#:Y21"\$L&/^>'E:W'R$W&),?(A'B0Z/#ME+$U,(F7-E/&UB[* M.+Y&Z:(JBU0*^P(CI#N&DQ-_IPDF-6I\(SW>7DTWQ(VS'5B@+"9KUFGT,X!T MU3B,']2*F*JE%;X(Z<]S]V]M51[01"S7[9HTIFA4^LV:-*8FC:&Y'7I3L"V< M\^,_5#SX3*=1GYN;7I8@7N,'%#@E"YS57*84&.\:"^'Q83GL&\Z&+MQ:[R,; MI5^O.N;M <]*NGPRV23Z#VQ[S:99> 2^ZO2,0B8Z8_C,H2,0KKII=-C>GDQ= MW'L_B\Z=47:VAH ^4,C*U:LN:EU>FO3*>4CWMT(\L$YGLJ(GCS MN3_&;C\C\(M\<"T..#J0&1W3%'W62:CG8("4L):EUK8S/KF^@&Z21/XHY8HL M16^K+KAH*K"URBR=65D5+%8JHKMX'4[):S8NAD15>XVUY?EZ2P%&!@W3K1M) ML^9T&IT<>:VZZL+K4+:MK)34I6_\(PV$U6[2')I\CVLQ$]L7/6,[JSW%8[6!L)A+F^WVU]I=4I9X.W\,_IFN[7E6Z2Z&A@O-TXG M_49L71DDLM&'B$!Z7=E@DLDIJ(0[OG7G=#F,W#'WC2E>JTL(QY$U7/6N@7MR M2ATB\,)EB)Y2'"(W#ZY.< 1,-Y[UOQJ%440EE%(1^MWL@+ Q%JRH).@^/9MA M1(Q7!!?+^#"OR"/HJK''.Y-(@W =$HGT)]6^ZR*[R>OZY8,[1,Z,M@N:E=_4 M%) ZU_?(.6@UG2&X+4W3;9F 5I^0[2"!GH9NUH.L82&GC.3\D73_\ZD[%ORX MPI,B :^](8H7U<-,ZQO9GW/]@<_Z!1C_P!?'RHPL^:0EA1EU 9XIN5(^1 (& MEQ&SV);G2G)L:KZ@UD4E4T:Z8FB3A M!D$?8"G^(X+8>N\&/VSK:^.T02TB"VW*W"O5NI,JGA-N9T8_/,97RC 8S;4X M!]5$IF']*:QK]X:#2Y0SQ(%%H,/$Q&.$@J3Y-I8.)JU7+HSTE_!3\%^P^49# M!NSZBP8FQ*8*()3T6/PEC'E!)C1Q#OS?U156@W/_)3"ER9JI.K]^0:/H5,^9YHD^=3J?< MV%F+*T@WR 018FV\!LQ?MCA]M 7B<8JBZ<97FQ0IX8$$(< Q]4R\XF296%U'5P)A8? ]?P$WTB*E-G M>L]3\-%PB5",>27,0^)+]EL^*K(#8M,Q.>8QO3"<&!U6W&RY&)EM%3ZO;W^&8VQJTO*C'K5D+(W.2+ AP,$6__MM3^^SJS.JQV>QGWDP#OT4'71/B;* MYZ!37,4+U)M5.$G=JJ-8@KI4@ $/9G7C-AQ$>@^;,'XE2PFO@SRB HOW+(W$ MDDN%7,.%7<&M=!&"PZA(A'=\KX)>7$8(% MY,&#]WD='UD=@9&)XKS/1+&H!$![?B=FGQF.,+R>[3I4L*H?0P2&7YB)M?HEQJ_H$@1;-3W*(23 MRA_'S)YY2YW!TAG+5Y'Z-OOP:9;+D9?F,,F4YQ;OJC XS%6\:C<;PRSHE--+ M9-J;DVM,E[],]5XULTC=(>X>YKPD,2 H_20-.$(Q25$9M;,0D/XHDE&7\#,2 M$)1_@.(NQ;\K*D2)3$7E"S7HD[1A!L[_ZN>YXS%S"V9C@;7\06 ZL _B3OT3 M;\A\$ADP$YP.B)!M-I"7CX)36UU"E$=.\\YBQ5&$%3'9OXIR' M7K?--(6T1K<^74;D:1=E:8_$_2&4P4K$/.;0"[@4QN=R M#_%GF-/BWX[<*;DO\;406?I%LMO.7'V'-8XL;>%T8-(PF3Q ^;%HL:EL_C#& M5)5_PPY2(*["A&%S1LPFS@V=C]WLR*2YT1DN[3^_WK,MGSC/;3A%4G!E1[C. M,%QUT;A5/P6YI-R>Y- &RRG(S9*@3#G1]Z$;>?Q%/+<\@5@!="[XQ,"CRE/, M]KI^0AGDW,W& $EN[J%5)FOSF0]!ZUP0*';&:GMH=[!%GR0RYK.XQ<$=!M[A MBF!B69FDF&01@3^A?]=X_I%U0=T*/J.-U\B,,KD(*2(>S M&8:G7-WR1EH%I;KU[CS4[N"IRCA/[EVB["%'N\?P$*RSA7,5#'LXGV6I^9(= MTX86/V%^8XRN(P8"MIK-EBW_TK8MISGLTI=__^^37JO3K+?]8952 MJB+72I&KC\)P DZE (<7HR9R%^GOX2B1J=](7,%A3$ J"I;>@(1,5"C6% WZ M'N(BLK-\E,*3J2 .WY:(\74 ZW!5J#C"(WP>XOW2)S^/L\.P.""H$G.A4-WJ M=F/#_>E*D-AJZ(R>(L7$:89SK"E. X8 TJ&"*3-,:.(9A><(E:$%<3K#JX=7 MR^"CR&"&-?>YA8B)F4$W/[,]6F;PDCN)7"Q[&Y/_MKQW=[U7^]HKV@%=XZH! M4=)ZN#/!5TT818JW+\;8DEN7SN>(G36"JES-J>T%?T160YK'/WT_-T,H%;IZPJF0G!SY#22%F- M6GH>Q<1KIW*9MR]^2DC2DIL_E201_EC>WW0>*',<5."!?T7^1Q:#\!!EBL!] M%=Z[O98.@Y#>C34-T=W%UP:$O *1%].Y H1C<*YR,L1)UKB='LUV_2/,_",O60,A;>8PLQ% M1PE?S"9HY+@:@3Y9A)9._*F.UD?6Z5>)#9:7JUH\']K&L1P@?<0B3N84:0.(W1I! :>3*5)Q1?2O19=A6& MGH1;49I(EZ-W"&"K-)KS*6Z/?+J"P&A6UK%(4NV&RX>(*\%CP'^!9*I",':&)A8XJ0-#TNV3P893^.&E89\6U,8M% M=+--'DG1"9;&@3*CDLB&L#GL08&LRKHTU7,T,AJ-J_$CC=+4I:414Y\J_J2S ME65*<<3Q7)YHZ#4CMC,-QJH0YUI;&L8\@D0P&G$&#I7M2 MC@NV3K/S4LTR*LS.S@9MOMPF?<$P'J+);EQ_RC@5HA,2J1QG<30L6)@"CX7X0820?*%A:U ^ P*I- M8-]QK66--<$PV6>FB.JJ=VH(QQ7B=Q'R054=N"%&8DZJCH8;;KJAAV=E3I,E M? 0,20D##$=SN5YB;V ME*.)LA1/Q%@-'F.175;$N57Q#9H@5S++%4&QL[G))F9:#/.V5S(MM!1)Y#/0 M/%F=Z%>@/<+V=E28^9VJR8H$, MJ+5"5-C%R.1/<]764-DMH+*M,@AD#96MH;+/!2K[GO(!ZOXL#[+LQC"?N@%[ MQ2.XI(@"NG75L:/<*2KF$ LGUJI#"1QDI"%A]"98*D.WAG#!N*H^M'5)T (N!X?G]/TIV",@G*.K2?'"D@V-BZU>F7QO-G_FE=-M.'JVJ@I.C2#WXH.3RR]XR3X\D+6B39.PIA5],$G8B!Y'LZ&,4"!E\,;YC9!\5O=J_L>IC& D1&-$,YJE00_,X>Z:Z@(Q<&,QZ^56#*)T@"6V^M)>DMF4XC.;I M=^!G#^$W119Y/%QQI;LY\P*%UE3.R]7S0I^';P%LOK0[LD+*B-!M!P'37A,% MV^AU:D#ZM4MEJ,"/Z(44JM8U>AKIFD.XFNYZF2DV:/S3N20D<(M205?* MTD4B4"%"\M[T2T@]90(J"PTN+K.-*0\7$5?P"N:8,3L:R.H>-;D\0I!BP=D$ MS?'C<]+@1Q#>$KM9&LACBX*0)>DO)(I:Y"J3;&D%UH96K]/H+'!H&*/6>[9J MX@=X6IT2?;5!>7!XRO^1'47-LI(S D3M0-S0BV;.SNP!A3I!M0K,TK)32:]( M-,70=1:%'#QCAD6ZAM!E"JJ>*&M;5WV$)'VDCK;/'T\SV#R^EAA'-4C-P,-F MBMJPEO"'R2**Q<60=DM2(&8**/5(*DTN^T0=7'+7S[*IX#HQ/Z'3:%NC[,,\ MA9*OE!NG"2:>Q_[$)^PH66)^@AF*7SGK]M:S+LRWW3$X=M=.MU6\G#_$A,\" MOC O@P 8>U>@]E,D-6I'"O"P!5K[%2<>YT++C"41Y%"Q1)YC3+G\!L6[-N?$ M2H:]_@K]D3*\0]:X;C-OJU+6ZIO14:YGK* F8M2MB,PF F2\Q_Y3>V M;38ID&M[(4LD+Y &25'J"Y;ZJ7DYBS[:%$/&CE MBX*I_FD<(EKFRI?4WI*[.S-YK?V:/+/ZH6 ,\/-RU H>1+Y:3K@(MBKB151R M#K6C1M_.VSMXDR#BIDC7Y^JE6[WFND-CX0&F*+LQRS M%Z:P$R<>[$BR4/)%L8Z%,10.4=DLZF"-7:6\2Z9(S!@4OV0-PP[/<*<*2)1Q MTILMV:3.Y5+N.=J5?)9%-WR+"QW?EK98RP5,-_BX8A4DR45 M1G<& 1IE!D#Y5]RK2GV*03='49[S)Y:-^$$TK>Q.O0?U6WZ[JY$*"TB%=HU4 MJ)$*SQFIL+_S( W ;0RO GBY1ZU&1B(0$U\5LA:XSAE,+L!/PM<4[6<1N2"C MDU]6DM9+,M?:V-141Q+[RZFP+\$:QAK (-#]]./J823!L-!/-4)A\,E M%L+&0_PA,;O[]%LL[\:#19GCDL;!!$0%4?&]5/;V7M:$)J;6QKFA'9POQ9&Z M=52&PP[O7O(%IPETBQHTX,HHWUE>I2\9T![K\)$,1K M'4S&A_9P1 M:CT,C!*ZK]0MY3VH$:S)V+4+L\"17A"MD" 2<3U>6>-"8S*RXZ!SZ-N _X#7 M(;I>C:]9"+*W".R,+.AL3#/3,N4)&QG^;:V>@=8 M\'#ALQV34/QL*4EK@RNX07C<@>1. 11!E/*.E@EX,7%'F@I&(UEL#EHQ+SMV MM"#B<<8HX'T]8N=$.T7JM_=0RD%UE?(3%2>0V3]3Q90'IXIP6,K\N8(,$[ D M*]:]=F/RD=U<-:HJ\&4DLNKDPV0 1(RA06 YV36O(?0RRZI=L30L'G.QEQVP$&:4?ZI>?B)F< M.^Z1 BE/AD4CY2CS="HXP (K!-"O%DRX PQF3+#VL%E<7AH+(7/M3VAG94&=Z MEU]?5:.')6WRQB2[9,9842K="R'7:<([?\)C4@*!??B\?Z6Q=FF51-*'>;RZ M0-B L:-D2ASZF!Q2-+ :0IX&$_?+?9"7\@'@,I$V[0Y8[U97E#Y&D/2C9V8,39LP&(QU"2G)7[TW0?S4(S6%,9^"$- M4 ;#F+6Q>3$+>K(HS7GMR\2WRK'>9><_8Q-(?#^$JL,Z:?0'14]^<,93S $)Y6O6A@Q"(B)1/6A)O0O-HGF M0!^\8R2NW>E$^@*1QQHG^"ZG\R4:*')[#;867'*S(M,D.C*QRJ,,W13I4LIP MRO6:FJ R5^T0RI)7N;O%'BAZ%/FA3::">Q6(POK!\_350]Y+.;1)(8NI\$RX M$I,=L#F2;5/!8BZ49,"80@7R8?=I'$:ZUG J,SS$E)E7<.Q\;E'7FC?6L?,: MW!H1.0P,,^<[V]JUUW"I\=MEZ9\DV>A1\L_T:FV\BO4S YL;L$$SW%/A0 MYS72@)!_6/X9=8'=^+TH:\?=U\O$YQA);^/7IA@M>?1AVG<0/_]&Y$,FBIHH M5W;&M=2ZT\(DC(JAD@R.I@G&^7R5J*Y/:X(PHQ*:57/,6*OKY@J5+JKR M2=4-1SB(F%^2\Z,N"Y48Q>+CY&Z.GO[4Z#\G@>W(.XDQ.0 M"1@?[C;FR4\8(*^&.!$B?FMV%\G1[2XKH-'YX;?&D4-)H, HOR$6(WI-UGV* M3B(*"<#1C_DBQ%S*OF+R&BWY[EW)SJNNSNP@D/>4T3O=B!-TFV#ZGIAJ'S%O M\+,M/SR7X9L1D,X" 1'[N)'1LB];=?;+CA=6.8)LAR::X?/'DD02%2".2TD?;_!L.@ M2B_4FN+(X58!/Z/[?\:%:AN<=GE.&FKB1;JQQ?6BLG^;+%ZE' T\ MSF-?D"EA8?5J?665FHN9L@J1[LSK<;2MZH!=1K+V]G M'..E;+%>6FG)LNO=DLN;3UNNKVSZMKQ0XJ;613#:ZX![J+!<&4?,/>130$ MU3V X5+\49\,":@MDQS'UXKN$I1I1"S&?"<..!1:_OIBLVKB']:GI7P5X;?P M8-:RET77LBO_PM+(DS,7(R5[ID+">MVP^B9WX:9(Y0E29XE"DS[*OR+SXI+Y MR"O_0O!' ;FP2Y\Y(+.!;4FOUDCXLU$:Q;PG$2D@73C!MB)65'8*L'--R*CI M"*9E6.FU+9-T%883(8O=#B_*^%[FG;#0:B3YG@\OJOBG%F7:5)5,DQHD]3.- M-1FN4?\R X4,&3VHE:$0_-.UL'%6F%E(8; HLJR6OUT:;#I]I?KY4:X$2'HY MGH0SY.IN_Q32B!0*A^B#^:&9X";L=!%P82)_REXZ<%X=E_Q505S1$5.=>I1=^VB"04=^P]#]EU"SV/C;G!L3Z;D!Q37$N8394!D'+%YB+F+X[GF M!QM$X K#E-(1%-P1JR[(L@Z5\9&@B0SS\JU<_VQ8P>(H#=6$]5 !71(<#&$C MA :DRK@O9*W)B"PW55QC\N<%;CJW5*OYBL#I2EI/!48^0'?ILJ!56-EQ%4CX MUH8KO\RV+"2X\XEC0R5S)H8&?*,\IEEDW'N& K\A,PI3)A^EA>'2QEMP<'-/05WZ&YIBCRP5DRNK:#*A( =X2ER%=*?2!X8+#\YG/@IQ! MI-+V+Z1/5)]UD.XSYKURY@#E"R?&AD**'T=NF"I>>GX8L40LKHJK( E9!@8= M^]$XG>$M$(-@<7IUA>_1P.%%65=>5)8$RSQ-+1F9"=$F#[L:FI$4$:W2EZZS73B,G_XHXQ9R-Q9AL3(U;W(#NT[J7D#8-J][?8)TQ1),H=]$Q7:D1>] MC*A=MPW2"\_.7,[!T8V_9!ES3L0.<',^J)H(XV:WPM7. GG:9)I.1T:Q_.V%,D_Z_F+]ODA0Q/Q3Y#24=7-WL_Y5N>ME?@H*B"7WGZY\\#%CIV.! ME%%3?Z+MD12OAO4!;:P>C\EM4G(K7ER[2(.EC.&I'N+:?BL+)IF'_K]XB9NC M.PVLX>6I(1<+D(MN#;FH(1?/G1=DE2E2B8I54:Q@6=!)^STJU*#IS(Q#ERP4 MU8WS_7"4)EG)[)U E\T=7YM',Z5;)^!'^T9/8C?RR W*1_U4/]R-*Q%>12XU (4G4@A>%5%F??7*WC6F0X5WUPP[1W[\ M0U*#:KH PA$FBJ./PTWR\,S[XXNGFUX+O!-118$*/>22"NMR"I+ Y6XSGV.Y M2&X82K8PO3*5H8-L@Y%B U:&:]4--TY%8)?*MYB 8.%UXH]YQF1FQL V?T;6 M##&?P#3=$6ZFLGX)+@G^'"3 MISLS\TL2:;@,O*H26<\G3+5K<.H:]U>)G\VR;&[NM@E7MECWQMPHSK0'E[_L MT-FF J]?W0H\*GGLGS:L_Y\[+K#5QDV 'TS5OS_ZL228B9&U LZ,W]EPGH/Y M.L2PEKSBA#*'*(\!-,9L,(U0E>9SB'1<'U% 8,/EE7=\EQ5(R&R<)$=DVPM# MIXLK_A@PE!5 M!8MD/4""5(JX8JWJDM<1 1A[G@P,O%%%? ,ZR*QO&?G:&D.64B-UJ,Y0619 M+6$T6]U&CH%C<<960L_"^8Y 8*C0V#K+O4=I0H'@((]0PY>6-/*BO'4:Z\ZK MTSM=W9SUMH;C-Z"FJ(7B_37D=0EA%(E)RFQ+2Y1U79.$6@(LEG:II6BFFI:\ MX^>7>K-NK;*46\VU4,==G&R^ ;9V5].$D%&$Q]RB7>P!AK5D/CDQ(,Z7=,=!BM$.),$\W_5S"@);?Q7QL.([S5_D*=_;%B?BTYF MUNB&Y7-A,,:#VP0U@'O!N+YPB'82N;TF,:%M. M83782OHBR,3+$K^TQ;%U?3='&\7<"T[SOPQ^BEQ(BBA%Y$A4+D/Y.L61,CB( MKB'H^RRP>\F3MO164J=5MDBK]):G5;:(8K2:1W4RID[&5+[^=7F';UXMO7\X^GEY^^FA] M/OMZ^O7#V>D7Z^(2?O#[IZ^7%VHJ"6F(/AT0U7^"_#!P-15OU%_>>GX\G[IW M;_R WDE?>INW8J M;^%"02>G7 I:%?ZU-(7#8:/3Z: U3"+X?T^]6!K*!LSA ME\6?#X8-N!24_@KC]E%V$'CH3;UI M6@[H^"_K/M::_\0/+IZ1Q;7B97I\L:&SZ3N<;EJV$V_M(HS<\8\K8OH^D4,< MCP7XT&]73'LJ)HL"$L[Y8"R?MFBWA/,P#@,?R0NGVL.^<>%4"\*M#K16JX<$ M4LS2B'3$&8/+N;CR8V[Y*2FR#:;!SWXTPX//.O[^X?3;>^OLH_4UA.NL_Q-' M\!4\S0B^@)<(&-\Y#F9\XAQ9@3N#I?&$_^8TA4M-&.%SSKPC.ADF)VT83+OS MMU]R3WGWNG!*HC1M*432"M%!.D>:UZGO64H)=I6P'2SUGOR;367O8=^X%]GK M]Q?]I]WLQ83^MV=[4>]9<<^&"*LTY[@(ESO!6ZGK//:PU<@^[VQ_N2R,? MY 2O]ZRP9^U602,O-.O3\J#VK+M2-Q$/'XEK MY%*Y$>!\8^V>=?PEC./7]4%Z\!L_<.J#]*#V;+!:63-LXJ]46\4Z?$>]4'ZD'O\^#=GVD'M2>=8[>87\B@D#E ME+0LCU@?G@>_V8/N*@7]A;)\RQ/=,N\W7($ 69/MK2$L"Q"6_GX@++T:PE)# M6':&L&R@V8\-;#C_]/W;^:7U[;.%$(?OG^"/KY?6^:=?SRXN/YU_^FA]_^/] ME[,/UNF'#]_^^'IY]O57Z_/9^>\+Z[32+CT1N)%1@^8U53,AO@\1WHG5(7XD MF"<:_O'%#>"7:6S]!A]'9*/-B)^S8%QU^/VWN1\8Q2KECL7A@?&Y)@:SY+*M M]?+VC+FNS$NV$Z.+#:;V-L#XW)W^2/)R'+TF8K&29O0*P=V2[6%ED=Q&1:0V M51%G84Y?ACD1R?W:-LL%XY*PBJ"PBEVH<+(SKF.)GDW "I$NFIC1K1K!7RZ M94!S54M9.9N '-5CV=: MJ[$Z1*JV7=9=4M-\4\=3N?P2A*,VW0#C(%%^C.^1QOTXMV:O)4;GM5W@X*$Z M+,D_F751R\2-6S)247RY@-D9 RDV%T3AS75W@)FI37ILEL&E9%T\XP]RQB=4 M_7/%5'*?(WP<4H2A&MV^)*NXZ--4M@(XAZ-[#2 GQ MF# ^S)^R.TA1U?V(]YI617H4!^,^(@4RRJ4A^1P/$2-^0YZDNII$6=(GAI3JP*D>JJ(][8S<\UFK=U2;R= MV6]5(PRJN;P%5V/J\EK)YA:\#?@JZM\TXHY9PHW#P)64*VE$KV;6#9-A?:F* M3"(VL=H5PTU2'['U,V2K8? ,D6\".8IA(*PP>O+$5Z1'*ZF1%$,V>9.Z]P 3 M&2U[K6[/M:1I]8HAV>:"%8? W4:(SI@U ]>?AM*P+K!SD/%A/1WQTV6^*9N; MRQ+MC6Q_)+ #$RYXO@> ZIA#+$$&&8KT[TH["YM+2=Y2-@#).*[;3I1YDVDL MZ9Q-NJB,7YQ8%ZE#I#)V.8[TPBM";D.DO/8<86;YX',-F=W$5 K9IXJ8QK6H M9H1>QOVAZL=EUG^>=/!W:MMTB$>FT1B;9C*CF5#_NC3PN>4!;">R6'(;"_HU M7)^INX>F)Y<=@% MF.^S;&18/8@7Q]0]75>O+8Y\<+EEQ.:[V#(X0/(,:>7I3-4],.#*'%R169"L M*W!]MC/6N9]9)WOFLLLF);6I=!-BRPM%3'6N1(S'I')PD73O3%51WD>YA<1V M:TRG!L8RQ&Z&DB<+YP^/MB5AM1J/(JTNE0H2!%NJ,;7DSS)BL@_7, WN7W7Z MOY\^GI]:Q>];OQ)QN7K(.89E<*4PN6@YS57B6^&U6\):7&99X?8=@T111XR# ML[)G 9*>@4AK_B'MA,[@YRI"($F'QV2)>28;EB+= M2@.-+-,R^@9-\0DY.'&\G,CP&.6MU7RK.?WHW\[;UR4<@-Q7GF252/;5RR4; MN/#489 1!!KLS2LHP#E&*TJ49G,U<&.9BJ):96-CE2M?X&.WXL MR-/1[2-]S2&M&Z?RPDNF3'7/R1J,YF*T:KXKAVR2;A?8^&7;\$9QN-(17&QX M(#FUF(A?!LT7F?A7#D=M&M(K!2%_D=BT7-5B!IXBVVKBZK+O:,IS1I-/371I M.8Q)C=G2K6*8U>T\6.AQZ<,5@K/Z+<2N#V-&^O\8Z]Z\A<>62)ZA61AP52LF M64:7,7<;T639^9 [N"R)#A_F5=?HH9A='W3_L5PGTI7:4E06U9(M3Y6ZI?CJ MI\B6.,2VLUP^R"=:YN=(9EY^ZZ;W*%16/\X\6->ZAN6#25W)B[7+99]9>TL2 MXD"SR'F*U@T^RS2R3&ACW&%YG/G+M.X8QS$N=;,*),_RO79J@5VO!I]L#CX9 MU+3T-8SDD)A0MO35?PMO^?@O]=G_! M[ZGDRHR(/4/K$P;GP.B!G6EZ#+'=# M$[O,5]SNX%+NQ>K#T,]<1?P*-HZG" 7XB=B:!\.F\9M--T*B2D\00LKVQ]R: M$V?P9#M#7G_O[=-E*_-KXW182B4GNEQ^9L.#8U =R3);&'.ZL$1Z0%)\&)WJ M3'1OQVJ/DK61YUH+S6Y"HZ^MC^#*;6A(1G>[F8E^\?+RM#L^[#=;5=KQ3@\7 MXX-N%0@W![@:T"FJ<$KYC*W>\3C!@.N5/Z:LX&;AT7IW=MF=W]T?W/0<+W2^ M**@@JQ.2;8]"V8PT^Z3.^*[>/6J_<0^S6F_C!MMX+ES5O%Z!=8S\2YQWX%9 MA>N3[P%//A7$\')8A7N>;O)DNQ6J$VJ<:%R,3MCK5D_8'(;>[.+)J[O@H-^_ MAJE0[JRQL6LJ=782F$>F%NPT!CUG6VK!X: Q;);_:DM"P+T5)3Z4-%/LY9?X ME^UYW[["#S3K6__HW4;GJ.*3\1IO ,#]&\ M/[$."\$9G(#6Y3"/ZX,/NHU!N[VM#]YK-09.=R_TWDZOT6WWMWK4\I_WFJN9 MPK<:U,.1C@\/E'1\H0G++O[I&AIV*?%2AA?9I'>EFJ[@"*U=D]8SK M5356M?5TS/A/,6-& &\B2??B;U\G8NO6<=?O;S>X1V61>XK=YC:(B>QYO=.N M%Z:\]<8\U/?WI*D6_;?5:'6KL8_E81 "Z>N(,B+ZP _, >KEEFXS^Z:UH?P^ MDHDNG_JK>TW1G%J$3ZW4W&1P\'/$?16M-/ Y-)C&WE$A5M@YLN ^ZL_<:?SW MHY.VBARF\D0&>J=M][H]%6Q40WW';MU]]D8IW\9[M)_3I-:0 MYZHAWC]Q:<'XM.VFY6YRKPH!U2R MUER+*1-HQ+ YM2^Z\Q6?5O/;Y*,?ST-82F+S.:/Z3%@4^"D^S0]2X>EVE3LJ M3?_H7=]VNK7C^ARE;-WU?T]2-O%_"N_D/R(*2P1LP"4D#E;Y5$+$]NGBMKJ- M?D7,]?I]N^?<.WG\&$+WC(!?Y6+Q/4).,&S?@96^"6\!0DH0 M33)G\K1=4V'OW A'?$%:K7-\_;?)'[$@]3K% M\H_3\3B=I43@\E',(R1SQ>' -T]GR-C_'UD2MIT&.F#X.SV[=_^T2>V!5U > MUQCOZLEC"^2QU;*=7E7@1,\(_[DL=:=(5.(:&''/#)Y:27:*OHKDTT]YF_TU M#+U;?SK=5A_:H ]=QQX.[IVAJ8/2%92HM:F]_4L4IOR[=:[53M M-^]J67>5]2[<+QW;&=3AY>] M5"MZ1KU;+]V?VGW85AGZZ'\V;6$Z[O';O=K1&[3P9G*+>D.Z%RVGG MP5$:57#4:Y6J56I+(,JV*H7Y1KO=L>1')2Q*LKS.<#L"H#;L@A>FR)"7VZ$*0D\D-W..V!!N5)G%)CPQXC8&S&8_PA85V/RIYBYZ,=V$HM[L]5W-H_N)4 ^YB.UNKRKT!"_J^G)Q#?<6OJQP5>J5>3.M:8]V-J_OT]C' M9J$?PMG(#[C(5R\P]F?P/5G[JX)#=UL7 ??Z52L"KO.NCVA^]R5BZTWTX.C= M<&CWF\V*B-E+=B-TOZ/R M8 UZIVNWVS74\#E*UW8^\KZEJ]_$PL*^W1S<.U[R..[S <9+5AQ:!T94YVMN_'T+Q7"_JMVQ-=\8N]]N@ M."U[N#>VG]K!KY) ;8+/V[- =4B@NIUG%A*OKJW]DH/L4)7F1KB=.EBY"]"% M6A'-?;B9$ N/H3+;*DKWZ%VWY]B]?E4BDW4 _(G0)/N3J1[6LH$;[#RSOE;5 MM;[%DLXZK+VOND[C4KB[-](_>M=K8S%!1;R1VKU][.+.O8C1X.A=IV<[]Z_P MK)936[4DXJHX#W>8CN:MS\2#%M4]=0?M49;(SW_.F M@@WB4['W*QX]*INVCE^M4J;O(KJX=B.Q\A ]^_IYD3)K=S+QM-YJ/%TCMXU&R4IW(4?6',WLF[P:;:U= 8QOB6^ MW^!II/%IFER'$>R[MZV7TEVQPN7CVVZS[SL^+&#HVLT2=.SBFO-X+5>_[.UC MK/U9'*?%>:T"E@_Z6R_Y+L/ZEB9Q KX,F*,MQC9X%''8>LF&CS*LG99L"'Y^ M$*Z7SLWEUZ?5X119-J)UCF<=;%O;1\7<<;+T6^RRL[=JD#I06T'96=OSY#ZR MTZJ:[#S2->7IW5N\S87!O7S;=6U!20GT MXH*CSW4?P7ZP2=S3 7[0G0=3"TL\L ?=34Q(P[B;2 MT4)5KXIT/'OPUBF,$]?7G8+KY7LG?F"-&8A78[=V+E+0:_H=EO0LD,A&0_BW M/O_ F^\CJK%5E485=7#@,8L4]B]0<"/K.UU[T']F>*Z-X0%/(Q27D7#C-+JS M:-(QF?=AAOR?^V$\6UKUV #>UJVJ!/\GUS76YI\7=6C^0UZC=MKO- MJE2IUC>*A[6S,8P?_O;PHN4@J=&P;3LEO4LVM[V'>*UX(GXY;6BYWGD[1(],=:9BJH^F*O,G4B_P%)_% ];P#8UQ \M8-13JM5=O"X?JC]\2*5[.[2,VL"'>3P+;;=0#N\TL6O34AC#V(7N?H7:?3MYV]]26O5F7? MX5-R3G=N";AA#2:O;K'='D[M?IIW^*V7]KA S\S!0W3WV_-W[ MOE:T+5JMV;5F/R1]P'XTN[?'UL.5T&SR3GY)D+Y=9787V0'DV(9YE1H+V(E( M"LF[OXTB?)R9(G[:!SVBV!*'P>6UL-PQAA?=X ZVQ K"!/V?"'X<6#Z,["HB M'%F48)X]N1:Q0&FF_:0 Y<0/W&#LTX48?D!%\(VE*R%?WN[!Z.9A3!"8-Y&8 MNHC5?7OK>\FU4BCC6W+AFME7W!&,($V6?R6_Y""@;PW2B':%=F#0+$ 4C#]Q M/JC$?KLWF?3%L-=W1OU.?]@9_-]6F_@%Z%O7D9K#W+T2 M)Z-(N#].W E,\8T[O77O8E0A0.V M2D3X*1B.6YFQ6-<1VOZ_K-_)/B@E&C94-V220'WZVR_NFC 8("L2Y@CQ8L&EKF'XOV8_[S:O!T8[]ZOF=2OW M\W6/:G6N.VVCT*/6?]YM#\]\4-V-C]IB5RKHHCVIQ)\O.$>3 GUZAUEQJC_1 MO/*M8?]BIJ=]@?-D2N>'#*WDTVVW]-2,+V<_$Q:$ JI-Q?<:0V7+FO&V.DIG MM6J&6K4]5JU5A'?4/X[GGCTS)\Q6=MW1N'+I1L.+L@FVMD6+$I2^>NX"E4)\ MXC^M8/XI]&%ZS/OR[-6B"K"B0T6'1Z##_NGI<-@8=8RN;C1+=IM5)&:G;CE)GS"O MUIUI3ZX[]7'QIBK]:%^!$M?R;O977$ET,C/OV9HP_P'6M"B5&,W&J#OHZ8.! MZK9XCD#:(@^5"*168]3NMO7VX5$*"D@5!-*6 [U$(&'?Y'9?[[:JD@A9:F>C M897/Z+]ZKN]K2\^=68'J:'24HYN6^ >M<&'*P*)#S6$9C6QKHEDJS)5RRA^" MN0[*ARV]?WA:NL+<66%NBT!P".8PF'W0UWO#@VMA*=+8SR5S M_ W=#LMM\U2R$']9@[L!:0J 6F+)%DB MD 94M;YC'%Q H(J%-RI]1O^5.0QSD?"4-J<+R['\P*.\(>4%VMN4Q-<4".,F MM:+[4@=6H#.Z>D=9\,\23=N,1.6BJ=T4]0P''86F,T33-O-/R6C":FS=IMX^ MW"2DG$*% Z%]9GJ3.9W=4_;,;'>):7)*Q]X_'IBO*%#'YW@]]R4-HS'J]_5^ M\^#21$HYJB"4M@:TE@FE=F/4;K7TWJ"LT%6%I2IA:6M09IE8HI)I^K!7%>-? MF;IVNU_E YM71'-W]]JH\H+[G.:V$\S?1[XQ02;^1P9TPOYJ6@X6A[UST#EQ M-\,XYJ!P1Y5V%_@Q$E%.I]8*EAU4%2]/+16\ 21[C5&WT]6[AT?5*TB>%237 M"!=O ,E^8V3TVGI_4%; :+7"16IK.,#MU; 7._GGW9EFTOXJN\'>!O\5>J&R M]'E$,[-^LNG5?YCGYM'+ ,ME#(R6\:$BHKG2\M[2SE\.B(8*1.<,HFWF_5U! MM/WX[J"CJ*O#"5X1(%V.H8"O[^9_X^!/BUJ>:.^P@=%!K>/6BE?G3E1;CO=H MJ>/F,H6)";/P>AV]USEZCXRSTG-5EF%P)1J5B7P;#G/#P5/MS'JZZU!6:EW"CM5PLX6M?Y0[/00._UN M3<+K99%S&"A;#[6Z7'7V::@H&FKOGDS+^06]"C!,&'9H^7.,4D'WPI2-]PM* MO(R(W1V<"SZN,?/OG"^IQ;V;?8:EY3Z[?WI6P.YF,_QLQCP/NY*/@UO?#TUG MPK ,3 $K$-<#1NC MP>"0[MW5RD2H[L%/SB7M'?<__**A_T'7''9I"0B%"&.;JP&7]+OKN&GKVYYR M?[?9&/5Z>MMHGKZ7O=(73W& EXPGS/8JL>24PE25,+6S9Z!<3&&:E-[N9EE4 M)6T39Q1E<)N,&]#&)'')8(+ _*GR$H[F19 .-5EFW7)"6(ZXLR&7?OEUC[@3 M(")[)JRHY9C>ZVW %C[0'[[4$57%34^%EA>*LS MHSH81J]:3^\?[E53$*X\A(\2ZE E,*.7KZLWVUF[6'DA$RIJ8G?I" 0A&3>A MO1LSA\VL8+\@2U6:=C?!".A+J!(?^7(7IJ%>8S3HZ,:@+'=G)0X$51GY\ -A M5ZM)64"DWG_MSB&\7$'PO"!83"8Y'(*#QJBM][N'N$-J5*N[!E:7[RS8G+%Q M7)&^QEW["L^_VFRC1,$),+5_E'9W""P"%.C>X7TQ:Z) *PI3%%;0WG40A?6: MC9$QT)N]@RO!*0)3!%:AB1]%\CV,U%J-4;^E&_T2XG^J)?#6S7Z6D7.U)?-@ MJHL%5AZ9FQY[OU>WFJPVTH;EG[KAV&:'=X391<6]M-&56@S?N#:Z58;M1].W M)H=$"I[ID56C4VG3H?2#>0_(>S8J6,;JD?3%]!R8O"_O)I!$IT\S/GV,QJAS MG7/VU#:F62'_W)'?*P?Y[<:H>=TIRX*@D*^07YXFL@[Z_17HKU%(=J:!3F/4 MNFYFZRK7-?.@'A+;9\L. S8]P)VQ00@^1^HNO@#5IOWCRWL"8GDTWT6)KW>$ M?KA;]N1$?EY%58JJRI(E-U!5CZ3)LE("%%4IJJK(S-]23MU 7_V#)=4W(:VS M+YWQ3_J#3:],&)+YQ%+V<5]SP\ /3(?F4E)K]S+-T;O$J%_:Z"Y*]+,?/N9L2__;N8_(7-H: SE+=5-BK3ZDGE MZY:,KBU1*\=%UY W[1ZH_H9GBJXM15R.BJX^EJ[H [JJPKLNR@N^QJ:Z$WFD MY2:^@'FBTX%*;>VI:S_)0.Q,AL@*TQ<&2C5UHUURUFP9^UV?O%J%[G(ED]+0 M;1"Z>_V20]H5NA6Z]Y>,2D-WNRS9J!KH)M'JU\"$9\+/J?4\^@O\(T>],+TG MRYVFL-V&8:"] ,_K+V,/'BV8<7:QK,)8$E[A(+UXQO,<

'DT@2,6X'1 >[)J0VTHDG. 0S= M18V2C,$*5X6^Z4OCKIC < 'PUS_14U =F>M]S5OK/'P,<\>*ZO#;X@$L.<$2=2,%Z [Q3 MIK,L#;F)+]F%7.E>X8[]H:SDD_8G:F+*O*G7_^3S5XL,KV6G6L?_[[RR@UFJ MF=Z;@$]TL:>F,-:7*K]45^:+SU7H-#9?J'4"$7\QT;K@3"O[M;HP3:4'HCK@ M0NF4M(CGT>;JTL1B=H+CR7[Q"D\*M)"M$\3-0?>J24A._HS9@ MTEQ1\A8,J-P,8L;;C0!"^RAG\E!B^V7E<(KM[K58Q9@!A[&'+XQ#!*!*5YG! MWW' +4J;FB'?F/>VT,0I8DC@5)#0MM/G%H^BD@3,54$O5BYLZGQ/4&(+=<4' MSRHKT4R2A%LH#7A&1=DTFG.50 !=UYP?.CCX#K\;952PSI9C.#+5_9M_(3Y*4&7@%SIT[T(H(F,-!PI+L^4,/_%&\EBWX+$W MF1E#JD8IEU8.QB";L+OQO%<@*'#\HPJ0@-8E&3BHIT@E9#59*!4J%;1@4IUD MI"/@J&"40(EJ/HX8JL>Z/LCW6W#;*)?$[!?U.P@KQL[AT8=@R,0A MW,)1#71?8EOC^# UCH]3&_RC 369>?GBD8Y^>)^[T3L!\(A,V*O F!'%%3Q( MGA>]< @\<26ZX>X=N W>%/\ @> XN=:[][/:]T 9$P3',8"^(4$ZV/\\EL/0 MT\.P^--O."S^X?W;XU?_BL[.#\^/WAV=G)^-7,2'Y_6L!LW'H;!ICYEG\]PV MC]11JO%$H."Q*(NPQ'$8%^IP5+<-!'4A>%[)(]9GJNDTRSDT[2#'&)88)XH. M3*.-PKA%5><\?87[5SVORF8V[V:[VD-\@)4C)A EN&M#CIIG^< 5%!3DBZ@T MO:%J685Q/'08Q&C;[4J0C6E-UZUTS./!FE-K&DH ++'!D%I=:!D]B)A*5^!Z MXN4#$8LX:N"^N46-.PF$^,K;$[DH M9RG>JMZ8YNL2[.^PU#B0G &CM@:5J.NN#1RW%C/7 (BIW)F77=(-Z*"X6CB: MJ61M)/F/R<3H,Q1K7#^_\H(F"*<-++U"8[6ZJFAO\A@SBA9PAB?52TU&5+OC M."IDVK RSB08?V0L5@IQ$^ .ZBNZ@RK C]"PO@5(M/Z$-\OJIM*,V=ZJ]"'; M07\"UZL&/5$N NP_!6JZN6);&PMJOYP5\!B!*.-2-40I=52;,P M-::..9X78X95M&EF7V'88')!Q BM2JSU*&XT3W4@^YQ)X&H4E"= MGB$PAUG0F':&$::JXO';M+;+,9J[;<$^E,9^0@2IZ] U#[=/[TK4""K;4 A& MLJ8X4S9X$49J8(:"Y++1-=6X8V) MQ\*[+ZYQ4F43_ID%,:"21JN\)Z$\KEDC2,AH1^_/]F/T-BN8#4IHV??!++=# MT#I:#ZR"=XAG#7Q[\/RY/5+\\%]"GL7!M\^> M80G!(4S-L.&;X7D"H\0HB@MZBX5UW1QB).K*U1B8B[NYV6,_A&[AM'5 L*'/ M-M+76A]6M<+!IBNA>),!;E@7?X_#'(C*KTQM'%!CZD"$N-7(5"3K4,T4!D!M M--5E$*6@"NUOL/%.W5Z+WKQV2"1)"IZ%J9>C3\E<@8%#RY$9@S_:&2TKY=G1 MJQ$D8G;=O'LT&T'EVM1&V3C3BJU6.8Z)N^.D$HP[CU._XOT46P>O+!&RN985@6D7(!4 M2SF$][ECE]ME[],FE[I!_<[[<@%,8(V@Z@2#D)T@EWF.7 N"EYC:Y@3KQ,';L?79AI5IF::506!+_096-R#\YGE\<%1'EI'FM& M_'V1"T1@KK+*X@&\(IA8:A!4"DYJZP.\=E 6_C$"GMN*%P$\\Y.9J!CFVQQR 27;W9,-;A("W0A4"/"\#ULML4[#(]'R!G6K]1?$>?[=(OS MO>N4#56'8=13H#>L&^ D5A=K-3U;D@C'91H@#S1ED3SB986 'K+7T.V MT"SOR$&^HT'PEBKJ;$]2NWCW56;:\M5A;!<.,P'/&#_(*8S5JDL;;9GH4"FN M9Q8-";3L64/Y6@2%4/:S39-Z%M*O98/U5YGA7"^QH>HT4_B07(-BZ3!%><&U MW%SF3Y6BDJ)#W@0H@2P&J1*M;J*.F$85%9PCX@F@P7 MK7J;%1O"?O@24"8X)G-XN ,:72<%K4$C^'P8-+"'N7-Z>&C8N&QQYXA[!3=>K> M/G0F[LL!_!,E6I^.+M'Z[O#\Z/3X\.WQ^;^BPY/7T8>//[X]?A6]/CX[.WIW M?')X?OS^Y%%:CS^6HD\&<<&HA4,/M#%:@C$+#V4&Y\\H=:EUP,!O&8.F) /9 M$3C*[%&*!_$_0PF,4<[JYE&4^S*C(]]RP]KMG8T*>%CFD;_(K;#8HXPR_1EP MV(+_503(-I(YOPZ(+4'NH/" \Z@""E4Z*KZ%3L$VEQ6&5(HV'@X MAW782UY1T4BA9^1;QQ[HS+X,/*/-MD9GH-1L^(I.C=X0R5%1%;H"E_9>%=R_ M2KENVX74V _1["SU<:U,!7P/9=K;FNQU-=G@J/S*4C1M, V,HM 4:!)75&2? MU UEF%>Z:#!%B6@%;C4%CJ9A1O-$F7DT!9=!F#,,>F_P>9ZI28;'=I0CN.#> M"#.VJ[EN-5%A+\="+<3HP^Z0>4=&!YD/E:FJ+ MYA:\4&&P.MV(00(U,-%ZNI)XK+:3 >S#MSNR*?=T5@=Q#T2%+D&(#T;.P^6-)>+PDG'^-( MNU:^WR[CPR^C/_>"CA4(4EE1&5A5K@A>45*S'G87.$G?;TIHB[MX^0S7N;K[ M;Y?SH9?SZ%-=*?'RK@2,8&E0AA#%6T7YX$OR2LQ^V HM8*]=F>T"//0"G'GG M%,;=FXRSI%3[B@G-.M?;O?"Y+78NDI]EB=^@!#/9&0P5(=82\VCS?F@^6 ZG MK7?UX&MU3O4U%FQ05C;DA,!*VCZEX0+PFYD[987;.I6VGKMM'$@UX&U+W=3R M06X7^2$/)TF:$^ :+#9BZM_.^\-'=]W&0EK_&OD%3$/PSNTA]-!S_V-954(. MAOC@@?9918V,#@28%'PYA@BY.,/[8"=$3M5$\B6F-Q<8[FZWTF>P*23H@+XF M+"?,4RJ%H;$$%Y)<56VK<$F\&3A_.!Z('T^YO J_;]NAM#F_[3I^5C.]DE)L M-!RN@EY8VX7X+(:?XS)M0W)8D2C6&1CQLTHM+(*R0\2Z/<$^I\I#_(! )).2 M*D+9CMOF$1]\&=ZI7TLL=Z\N-!<-#S+6L!(6%R[+36++<9O<]SRA!C=]8:9A-5W$SS+2FC+@L=V^*. MRP*MA++:KN #KN#Q@C@JL!9=%1=5LZR9- U71W\B!$4B)>780S/*,W!U4W1V MP7Z8Y'JQ;2@1+/.S;:'9^BE;1T6J"Q_HB\SR I0]L47!CP/,?#,&F,ZS+J7M M4*DM D@=9ZT/%451]/HZNRN0MM6TP_",F6+)-2AQAKH&QZ M4I4JY9IU7%,V+Y>Y EWJ*K.0@B2"+8VU[0&Q,97\HB&C.8J.P8VSHU<1LH#P"I/=T46 M NKYQ?,K.UMIAPR>EKY#">!7V5WBF88=P)%D#9N %T6)_";L,2/!]+NRP!' M7)3$[OTMP::?/8G4_F*?A/9?975!4\XBXTV'1]%U7:^'8!JNN3\.Z+S1!L;# M(MT=,+W-0N@!W-#YOL_IOD^>1,N-C/L7G18R\L>IQ%F!R:9J,K MF?QP^O[GXQ^/SX]>1^>GAR=GAZ^P2'+L#+4WLP+9,\!(G8[4^!.9"F'10)MB MO;X?>FQIIJB'F&7$9-8L4# +*N)9@O)AYR$(*-^LJYA3"/>H1HX5RSW9P[Q) M<^MA\DEK#70(.QD^U_:'[H2Z[Z?(YJ_<"_%.=NB:Q 3)T3G*D= F;[0X,XH. M^_+5BFTK]*XCU3!&TSN,6WX 0F(P_41*'S=%VA"Y4-(XJKC>G=IG4^&(1(F(4?.FL%@$([OT&+SB7P.MBMNP#<<5S#:-9SX^]BU %V)##Z'C&A MF:N*"%3YDM1Q$ N; W&!B,Y7KC?;8PL)1&@D6MG0Y@X>TA5Y)\S24TK8:JMM-DX.T>:"9:=4=M3- RE8>^L'\[NCT'1?RV;N&9;NG2/3T% MA@1UN>UQ2QMO*E Y@#/:)-I[FIN1K,!H(9D3)5LJ:ZAS]EK7R"163IBAD-_Z".(&F%;4R24 MLDMC/")6XGFW%*U$5DQFH.0XO.7?JN7-J^4/UO%&8P]VP/MET-YF8S:?SR:- M"-REN"^$78LT\0S$F$33KK&QI_ 6H)TLEF,]&4%7_2;$<6RZ43Y6P#9+9R(F M<*)Q44 B#*">=[PM.W+:+JACV;A4-4$B^2#Q5;5G18K>)W9TL[;ZJ#4F QLR M(&KKNH!^6P;7^ '\T&S%+J-O#Q9\\GFU;G[[A;*:J8)([OBXBF_4V#L]^]!: MI2@,K#8ZG76]1WKJ#$G"BC:T:>0X2!0]8*S=JG^6 M]_$E9P0J7NC7=K=*>N-*>FP2 KOXE>Q*5%;!KD2,$.RUVE)4^KL4"R$XI?-O M795[A."BZG-+TEA6E\BE247GME("&Q*@JSD< ,M1D2.O#=Y8-"0;USBF-MS+ M&A\Y;I@VI)S61)/5:C;B9LZI]L,WZMNB$+R@63(U\G*)7,/*'D^D;? )KFEF MJ)S6CQ_?,D-Z!NP8 MA.W?#\Z%G M( ZI]SNUC]OJH(?00>]HHJ.WI9*.$G",I[.-._/K8\\V'A3$N3AZU/:K'.K^ MX/.\4L:37CQW+VX?L*0)N,6]8>N0EJLI'S6E:C+EM]PJP0:?J;M+^E\A&?5\ M=,FHP]>OCS']=/@V.CTZ.S\]YF14]/X$P0Z'>,A_SMRX,73[[K_W?D4[TF)8B)/(,EP(CHS#.?C]KK48RD9EA' MFG ?+FFO0TT;AOKKA "."DOO*FVYG\!Z>-T2Y=LF@)9UW_8 '&I0@=_W?QIC ML5A%%B$Y;=R>F[4CCN:PB:\?R^!.G45(V16UV$:U3YBN;FES6U=&%3?SN%=]Z[:-^_U@E-XE8$[SQ_7%$@ M96"#8'R!S$6OU56T@SVPD4$#,U*82]GU?I.BPX8=G'JMLVUMA"$41]OQ$7RW M)J^-M.X&'T[.!#:&[MAQ;FN)W@_+M6M/A_9HO_-<%X..,-[AAG?;XL @Z+R3A,\J1O2WHWYX8[VEV*7 M=RD>BKG=4C\+E9:::U>7U)_"W%!$Z4H5W;M)RQ)J[HCO=9D9FQ-?P>#H8FSU M+"7HLM("J?3Q-H<2_-6FEO[#WD/DA=L@,RT,H>,KU]5E*-QZZ^JJ1[MWC)KB ME,G93E97R]1P?00:,:6F6=@@-!R[EAS@IE+:MI)9ZF[8MD2L@J=+0_2]1HO4 M=>D-19R3\;?8"IR65VAVXY78@EX7TI;'ALY11MM+/ B;%1K:AK5+9EC@W!VJ MCV@8"RFJ'&K.Z25 I"/I.8H=PO)THAJO%,*KE,CRG&&^5(](4\"L3AKW9HQ# MSPI$_QG"RT5Y=B%]M+N[-UZW?2<6F.':(5UCNX"<^A7AT41!. M)U"+]&!4U5=@-JSO"7Y<" *5/"*6F"K_G#6%,^%@-C[RI II^ HC=A6-KN^ M\XA+PF44=:08.<^O(7-F+ J*9^ZQ-C\_@B4AS"W=E.8F+6DRII@N116$:]$5 MR]B3.*LO<')O./"I8R.UXPD$R5N"M>M_&SUZ$P,#2[$KNR;#H(X0F5M3JX-N M- ,6]4@-;3I4O6!;(A5E0P<7:+LEEK6BBI9,,\_HM*P&\MLM&(Q[#%E8=>6) MT_EM#]Z@S737G%Q+OZ VG0\>EDN]5+E4!(W^7X:5$MTOP[=", MCR/&]E,(TI%<#%2+NDU\6W]@I$FV"<%5Q[7_-SA5&&C7LO!HCA!Z^+&>ZX=# M@"408DV=4-'(=Z*OKA5VVB?$NC@\<6Z*MI7P1I)5 MXYP46,CMK/1F!=-9FX9OB"W)#5<\Q#8O%;*;:&=2^H'RJ-Y ]9W=1:1N0]QO85D[#,K14(?L88LZBV91;VHNL=MXC&) M,?\U/L663/:JS<\] 7!'NDA41]SPIIT@6[M/D^M";3DQ.+DL'9[#"0D+W.(2 MK\)P\EI$"+W?75$A8]8*OW"D%,.(.P>[(4$ILC=B#%#7]AP8"E\/.%^.$)C" MEV[EM,1?^QL8^;&RH+"OI8>Q A00PD@8I%QEG,6ZDXNGX+66]'II"5:1+FH7 MYIUFE:0"RTYA\$WR"6-?9,98748[3FZHG(QZ6\,756I-0L*ZE=5KU.AI Q)W M\&3RU=Z!"S-_R%5;7S^VM[DC N<]Z,55IB_'^CK7*A)_<6!C+IJ.:[S$_C5-@9TTIKS@S)B+ MN]F*1J2J"M4 9^CA&V*XW/%ZK.ZNRUY8"].CBS2"7V!S4E;D$D[*\I*UQ<1Z M=!89XU_?'N@D>$^_HUP_X\1J(F;G?7$[8!B185W"V^Q1PAC46>H:DBUPP9A8 M2HC["CUCE<O#^^G&4.##3 \DGRR=*CC MP?Q$;"&^+;L>Z(&(1YFUB7HVK0)XS]X0,(M([?".+H+!S*JA>%@PA0=M45UI MV8\.,FW#:=-Q=CSP(<1RC FDY_:H&:JXQZ&9*=M M 8I7_8;..LH+@;Q@(U \Q4M-;''I,*:O'@4N?7-[U(_Z=++MT$=6KP62>B+H% MV\B&AQ1CV!D]=J)I(Z.=BNF9$/VX M3_AW>TJ3UT!1E;JV 64;ND;.,CYZ!:E<5,'WMB"RP.,IIH!L.IQ=K+B$2B_83-1I>6R#@,\[*U,JO*"P:U(DM?4 M1-!-VFD/7YX$QL?^7TA=8'('OK-/VE9$/'6DGJ=%5245#\-'!T]Z,<1N&-5.V M*[) U)K>"6V">BWOK79_QP(_DS&U]=77K2!^[]^R2R-/1=Y4(H6ZUK. R+B4 M\EYO[\78"%B9;8GX#G,-:<1$YIJUR.(*$W=733KY(>5GS M@Z=[Q)4B A/[#O"BY*(;3KU0+8O>8],X?%UA8$8+#)1NR),%RBFILJ6=JSDX MM5UA*:N+V_,4;NXD^."IV/6KU38N&,A#=3LX"'9/K2JP6AY;M@+CGB1A6\N^G]8Y&O/%F1;\K!!SNX090?TP;?OWT M+R<3=Z8J,50ZSUE]M4"#NG.Z<;/DMD,7:I$R%X0KA8/1!6GI$CH5NVM^[LS^ M/MO-[6Y UO56,AY0,MACU9Y6QU.HR15I_'Q6PJ=S:BF)Z?#&54ZKA> B6UQE M*URQ%1G,K-/2NU2$W^^1'*?MZC[@ZK;AJ-">8-)]#D]8S\(T$X. R((J1O.& M*0M6V!.@O!2>"UAQ#SW+&2LO1B66\_J^7L2NTJ(W@@,!G#G;*WAK('Q> ^%\ MGE4CL ]Z'AC9"!P Z^*)>R&JCH3;6JTP09R4%9\,U?TW;%8?BUZ>/Q!CB $C$@0 MA,@J&T.VD8H6M6.#%!ZW$D^E!.5HNW Q$%XL)GVJCDI&WB$;:2<>E9PB>Q,5-I01")K S^&".OL!$=#P8.Q2%% M)$J<20!.<".#N/6A",\@<)V: M"]N'X*\-K*(1=\DG(>L@VM;I3LR5H69=@R&'5;*97&RXR%F-(!<9$WC=(](A M58E.?,N20><= NE;K#EAE& CN]WE\C&N?=- "IDT.;RWQHH<57&-1;K*#"+T MO&231]W13Q+=C/R3A!AF>QRN=S].8+JK)(_^@0+CZV$P^^O#^7] M%<&D+QX%F'2[U>YOJRF8TJK05TY+OB5,:HK@TQKMN#O%N[A9(6X MS%''T3%JB@)6Z[ !*SR.SM4G_'#%I %4'04WJY9(PT"GX*(IQ, RWD(; M6Y[J'ZN(2:6'GC5+:]CCT+B0X*@&ZU'"YJI-YVVE9)-2TH*#//)_I%1!J_D> MFP!\YN:?HRE?/>\Z)&ET"/LB=85>CZ)F]_J0;/B*Z)FM?T.+3;:D1$@4C2"X MQF#0.V#D0<9.2M!DR!?.Z%XR\_WG>0\;].HYUALTQZ5\,-&K$WI,NE(RAEHL MPV&7^CT5*(5/< 7]=E18S\_@18Q[,-='!IL.YD+#8A&KJ*OS#,JL0F>?W5;_ MYS)SERJK6ZI3"QP49(Y#^:Z[,=&"Q)8:0DA\:4[:1PV3VP^@<(/0$N/N)J@^ M)N6*L:&H8SBDWO)?WQJ9ZJ.1^[Y^[\6">+Z-Y'ARV<8!K*'?#@5O5H L\-?^ MNS#="BR^0 Z+LK:\X)V='8[&*UB4@]@"U-?4=D^I;3NFBZIHVM1-I8< RJH; M;#X,%DY$!.'T5"HIDR[-2KF *!$M+A*#'%NIS3I8&1Z"4'OLLT0.+],P1(C[ M[,D>%C=-5,4[$#973=MOKA>K2")[Q%B@*P0.QN&+X=K>$>L0I23(W5B>$"/TZPN8%!HL&7S' M'FB#JWFRA5?LL(Y@W(?Z$373=4.X#EX2#^)+N%$Q'6'W-,U_QT9 *KV-'BI3B:<"_,&DPDD!-6[CSB?9(0==^:OD"W8%*H_$J:C!D5_6-]G0?Q.)>WN.I8Y1Y5 M210T%6IA^7&DZV0_]OI\+$OJM0.GD0#L*A]V%^9Q0M2^'%>V%M'X;H&M[B)< M#2U]#,8+=0JK8-9,5\JD&,^63JKB@AXA-91T(M.MX"\I?6 /A.X2#UMN^Z1@ M06>C+SO,C=&K(=\;+!X/JG6\HWF8-*-'1W2+/A/XNYX1YPJ5_34...OL:$C3L:$H[+GH0^4$$"< 7&[@C M;6-!1C*0"B,3*.CD;BHP@Z]('Y %,R]S(@X2JPPLZ$R1">?O(><:K?&\@XI+ M7WU9EW=E^[BT!;->N-Q7!,W]3P?#[#DJQO9"!>ROO6C6;H93! XN&6FL/%==008QW;OLT MAEPS?][=!;1G?]]6F-RT%0(J"('WVUO&_/AIEFN/V#3XC>&0BE07E 1N/"P* M/+E/J8(=O2=BS,'*]3_-<2=(2C8WG+(;Z]O=>.B%&+SVY5@R+5O3L\[J!Y'E M!4;/I$,<'#U5;5E*8)<, .S1*&SA= D82L@SP&C9(5C0L$TU;#?_/GMYB(YE MK MZ1W$]"3B//W 8.6O;NHSM]6Z45^G'&-I?SCUEWIHPZT/V"^=B"(%I8^R# M3&1(/FG8BU&"+YT25!.^WS.7(LKI=0+R5P0R??UH@$PCWJMOG4F%)^=;*X!; MF.M=1WV"Y">ABH_78M\MI7GG*. 3QY%%LSDD4>*KCG:@=O*PNRD3STEQLI7) MHYHVAM+BO5!Y2T(60M_]ZJ.3LD9]YI7EEET@63@K)'?NW"TI_.U^_NH;5H/+]HM&?C@E^B@ MZ10TFP23NO4U1_[VZP]OCP:K$VP;B%QB^&#;36E(*7MFNI25=/LFQ5(FE MLYW.H>D,N@O5=Q33;='"!I"8PWP#GN[PCT(*NK/G2$4,I83@=*YE8?T@)<+C MU*>]WQI8$"+ LT<>.*N%GF9""-EU(+>@[9$(PY\\/K1"^='IN^.3P_/C]R?1^>GAR=GA*_S[V9BHA%"'80*L_]_' M&3O5X\'.@5_&]\C$USN99DU\^[_S2&#"7EPH$U MRHI[%Q%8':PT.]S]K4;O5E6/3J/["CSZ>/+ZZ#1Z]?[=A\.3?T5'__AX?/ZO MZ/CDU=')^?$_CZ(/;P];+3_2O38\[^)6C'SLZT&:.]FNYXP,NI+C#*!AAG.S MG:#]Q +2UFYY../:L2V9BX66K+G3==@69*P1@VD>N2C=K;)#N\9,#I<=8 MV)%VRDT,2;RJ;R'R04^T4D2\=I44^&\N)VA%G:>)X'KRW!ULP[04FKF@[FR7 M2AH,M_1!+AYRQ;$HWV1!,Q-BT92W*.0>\J(CW)24E+'@(EZ52BO#W;1&OEV' M;9U3V9.P@F_CCT7V:"$N6XOH_BRBMKABG'.%N@96=M-64=7N']%! M5?^S!O>4]P_VZW76*QNJ=S0U[4YZ<$OS^MS27[%>YIM'4R]S=TC5!C-_7X\N\_?3\9OS ML^CPY'7T_OSGHU.&O?CX\.XK> MGT9GAV^/'N59]5,VK=?E?%!-@0)K:4GJH!5TJSG?T,BB=Y9K'.ETB;0F1TKQ MHF8>KQA!D9>H&E7+7D-/075&_9J(P82 AZJJP;TW\VP)U@BQCUS9*I/A=$+( M41.2>\%ONWC[(;A]'S''=>W^111L2!O6ZJXB\7FGVG8TI+!CR?!_,[I]_N'T M_:NCUQ]/C\ZB-^\IN__NX\GQJT-.^?]R?/YS!/L?-OF/;X]?C7QK7YO=Q[U( M;"7J,6>N6B?%)^ 6?'?+F/#FM0U_3G5*;^_ILUQ=,BI[56:IL SF3+;KL33< MC"P:;-\BT"&A>D.>T=C>-.@3+0J)"OR$@#)((_L4)$,,+G'T:]D@J7DFJI*L M8Z)S@?OE&D; 2^!:/Z"FFU89@L)BV^!FSAVJ>@AACS";&H[8IE>MVKNF=XV MI_"M&V,"SU)::4T:DS&O,;)X$HTV#WTGSRYT]#8K+G1Z7,1PHB1Z4I9DT)]? MHDJO=H7"%ZUI715@1DNCM 2#TE59+FR?M, RME?O<7_:]IE[$R+T@(5I%F!1 MM_."M>7BL5;X,N!-3)J:L7UZE96-R:]:"BO[ADE &[][3R"O36XT1+3YO9.\ MHV]*?A;2 ^.TN-WBBSD5:\!X"I[6FJD[J4Z!^>J2>08>'A*1*5?* ;-M=$CW MTH'990M:O%J#@%.$ <6*AZ(?)Z+ ZRMVMBPOL"9M'T( M4CU^ 5I53AE:"L-CPI-NQTQK^8K>&1>P&\'"J+(*&.E2U*K1\)/HP[:M/6Z_/0_6++LD@07[ZRF60 MVZK:A08=E7+I[)T.MFU]UQ^O[R)&KF_V_J=UP=,R:4B\D>TK)?W&* M+O4DH3X40MI(GUNCM5SJKM[$5B2P/#K:4?D$5#)U.87%1@H4:QV@?Z:+/6SW M8L]"<#@RJ]R1%;(U_(QG^$EO5^QX@C[&LD)K=Y?Y(=K6*_.6(Y<($\$CIB86 MZ8J\.:S_%:=.BHT76A62A0N.OFW5[F8$\4-)&2P2&>(R*_L;U5WB&^IRXB+35-Y64T\2OW@ M#JF& U0$)<:62[B4 D[=?C*A:4H=HFO;LHSH,5QK&5)F6:G#UCT$E@ #CH-WW M\A#JL-:V('7-8?#+#W!VTIOZU_:ZL?&7 RW^&+IVJRY_MD&XG^[PK76AQ,*? M84^C2'^BJ;O>:$,([W)FAS@5A'[OU;7RTS M/,.NL&-6:O,I1#]1:\L^@8.V;D!?5#4S!J@*-8.7".H.?<8^&#'V,&[O7BO<].+/*K)^7NO09L>'C! F]S+XH@IH8=,.6Z^T!3<%);KU 9. U4D_79>GZL061A U'$(:UY;I9'4,8 MH1LZ>$1U1.M:B.2>6 [J81LT]R((Q'L49D.O/7&N;QP1<+>Y9$-G=U*X-6X[ M<05L\EXH+=63VOO88_-MHQP[F@CUK ;"\G=8#WP25G9@8)AT;RN'P=;DX[,)Y:N=C0EX6V91W*E\W)IJ\N9 M\)V;.(;K&7LT_[8G3!#/9L9W6"\#1P6C:C=QP#I"R>$CEM!'-7780UUK\V=" M002K)#__0X?P^*%_PU'8XX+Z4=4\]S:E^.<*Y;,0]\.EPGZ@+A6'$*?4K,XT MLYG ULA_N2%BBB<_D;:2 ^/9X,1H%$1P?? 'M999$VJ-R=GF#C6X07N*R4HL MAV>LDN6QYJ9$PK5R6,''3>_FP?].?> M0F6Y;4FMZ\AE+>,@*\EMA'9W:4]*QCJ]P:SZ9[#PFZ/=\#97A:BW-ATXT ^6[BJ#O.J M,.; .>*^L_J3PB8N<32#9QOJA(6::RF<+EPHA-;PT^<1""\J2X+GA6^@D-E> MY^(O9=Y&7O=>C"-HY6E-\@'.ZVF3>>[G,?SGQT[S@R[5BVD8E^EO#CPGQ#AD* M+&,'Y2"];+,E\%9G&$)!5PDW3NOZ?16)M;*?&J;/ U"??W3?$=9'>A_^_[[(KS;C>UF3:*WS)1>L];YP M*<) -ERE+M@))C&1J&] MF^ R(/QN2W!__JUG/ ],,];9?.@-W1X;WDZPG+YH VIT "@QCQ=S3XA^Q&-R M%8>EM#>8]D.C&VEA&;SI1BO+VDI:S)9I2OAZ;3;N0W:V5L'&K0)68V,Z^P]M M+BEV84Y6QGLFJ;(E 4,X 6QLC6PWP6(\]=WF*4#!H,>[)HWWA]70[]4^66$3 MS!ABF/:23-&AAI=@%\DDRIU,P GI=LS%8 M2(&K',5AVDT^HO@18&(HT"]1(2YS$-973OJCFJ< %V&!*C=>F^E LZL;8BCMN%VJZ=&_CYKZ+;7 M[J:E"\-[@,?APA J^"#WBGJ'8J MH2)E@?;'1 @#9?*.*P;.V7$1!_NHNS+@>1[8[H=JEK2N(0SM/E4ZG^I\>R? MX,$[*5?.&S923YHHHJ6"KT>)%%A7LC(&I #-Y]C5Q? KO!O:+MZ1,'$)",J& M99ATR*F%H7.TJ9J-C$..^L!AA&>HX&ELZG^'3A!EVM_YIB8>N")V;1C&3F\8 MC6DC,*V'C[5OT3FF;BZR@LX+^U@O&(.9I:32!$8LHJ; XYVMQAJC7]3!E5K- ML& AM*B' ,$(AM0:,FL=[J +C5"_>M' ),#06%_Y:<<@V2C=<@*0MM5/$RKB MI!UX[-G(1]UTSBW7NJPOI2O)Y!)\I##=&/I?U8C0:+ M@UUC%<"N5SPPYS9\2%RF<"\E&ISL%#&+Z'HR\(2"\-22VO8IQ((#[3:=W\!Z MN\,Z.^Q@?#L,MM2K]R=G1__X>'3RZN@L>O\F^N?Q^[?<>^Q1;K-C#OLZGD3L MPAGAO4HPY,%3IF#>"0:-,3.;EII,\E0MT%O@@Y=) \@?0BL#]P!"GK&.#ME) M*"=L"&9+X%PCZ6?''N!N08$M(1XP;?E-6\,0,P.!X7 UI<8YL-8"$./HTI9P M>P58^$]L^ED0A?NA?;I3 )5>-A(CGY9,73*KJ/ J[K "S,U\=\@"B M%L2Y2;CNX_[9?O3:X7;Q)?\;!2G1,1F!6%A?,(W8#'MG.8N"\M03&DC-Y2MA MVWED.[1@3Q?W7RT6;(5 M7&GFJS62]RVQ _L,K%E.>^_7M&CSX&J29F965=(C%VD3:%]OY_VSJ"MEQ]L#EV<-@)*+TJI0CL*8N MEZ2JG&O *"8^AC(A)NSZ#>C9T2V,]5K6^!&\PAY,<;O(#[;(UH\D4C>M+PBG MI2IV2ET >%HV#'FADD!NW)QRPC/T\RB\#8.CY((B#[ELJ1:L7]\-Y 6D@Y*] MMQ$!.H\K>VYLH%SY5B4[KEH6B]JW-E,3>&SY S4 MA>]^IFS1FK,I^N!,8;2LN#O?>B8#/%HHZ5]QY7R!L*="H[O3(@;H(MUK987I M^Q49SXS7M*B#V"_I7Z@+"_<("OE!W&'4F**@[J1>8H$F?)2HQT0UFVVI[/CM MAVD"0]HXI^(?)Q;R/" Q;5BO.L *71<0T_$1UN%C M,/DGV'G!"HV2%ASK:[$1#V$)QH/2Y<8=U_CB00.?EF(CSY0'.KI-MH^[/"#" MJO"-Y+XI9+J +<9\MHE6(=WS:/8PD)H5C+DJF/BF$"WK&,F[8_2B$Y,K1RGO MYB,C+"XN&4NW^ P+K0QU7A#V6,^%\)P'CG4$;_3ZVI3V\,;!1$R7S$=YB]!A MX>F_(PQNGDVR?F?E]3?I@&<"6JQTE3&CWN_=JUQM1* <8OXCI^O:F1Q:%SM9 ME)Y';;+(3!/6)PQS&JUE=_-+_=R'0Z[;HR&[&U9"\LI[QPO&+9ZI(GGU=1;3R!.0 !8?F68@0(=^2T#@X"C&3 MX7%(MT?U7F@.(A:E1O90,X^DDJ"+=L']F545XD@41E,$V,.43/=5_74/H+11 MW:E"F7RX/7!'0^-4K_:C)P>DZI\^>?K\=[[41L$O_W<=R)__>]/76R!1@)M< M#R3Z^Z1,K^"/>;W(?_C_4$L#!!0 ( #D^5E@J1R)OZ , /0F ; M97@R,3%S=6)S:61I87)I97-Q-#(P,C,N:'1M[5I;<]HX%'[?7Z&EL]N7&&P@ MEQK"3 I,ZUU".X%,^K8C6\>V)K+$2#*$_OJ5;QNZD&RG*=WU C,)9B2=R\=W M/EGF]&.=L$$_!DP&/_5_MBPT$D&: -FWBL_]5NZD[PNR'O0)72)*+AOT3;?K^)T M=T(X[7;/.Q<=^TV +^RNTR:G9_C\#Z=AEIKIQ1JEUPPN&PGE5@R9?[=SMM"] M%24Z=AW;_J61SQOT0\&U<2;-XN*RL+%E2<.#MC"C$7?S?!K%TFHX$$Q(]Y6= MOWK9B!7BA+*U^WI.$U!H"BMT(Q+,7Y\HS)6E0-*PF*CH9S QF?#RCZLBWG-C MAU$.5?Q..PMZ_!!3GQHTG:;S9<2[8PT,LB#_I6 G5]/Y^_'M#+W_,!EYTW>S M$^1-A\W_?-RSV[02+"-#=2T6[JFQ MMPM(C7T&U7Q?2 +2,M$SO%#@5A<]0M6"X;5+>1Y#OJA76O>%UB+)'2Q!:AI@ M5CK)_17#98EU.Q=-VZ26.3:UI4GEN:S 9C'6TF1[L.UTJ[4[QY]=_+SEMOWU MEEMYX+*:47T=IT52!!G,U +SRT:G4NP.S'TSP7 MP%GJ*THHENN_>%6"4O_4M-F2BIH1LGC_H&,H+W]+)56$!IH*7DX*RTDRPIQ^ MQMG(%Z!\ QE\'-Q'4J2<6&7:00 0AKVR^+)B-4@B)1@EJ,+D&9P9A%N5]X-0 MWA*E'.4)Y@;45*%K(%E,R$NP$8K(R#P/FE]!JO\_1"-@>(4E?'\RA?FK5F \ M\L5#0\PQP2]@2@WS+W+>FZ[4"8I-*MR D8ZQRB3[!$TFPY<(1YTP.&K#$X2X M_1U-:$+-H?)0E&',(X8Y0=G?'6:@CB*QR8GQ[8L(461!+.-XH'*P:?)0B DX#A3[&6"8X@#2/31W66>*H#1M@ M7 L&0;W)C./QD[:\PT-59GJ7^\A3A0F1A_\J8> M&E$<<:%TMH5GFG7L";&#P$P184TA\H0T"R@P -COCQS'=JS MA[T=-6M8)4_>7!H'RY<]KZXA&D7.1\W(B#&[OD(C6 (3B[SK92@2D^?Z>"]Q MH$HQ!+D$G*(Y!#$W/B-S=?(5LO,CBZKC0Z6S2ZMA5 T^P7> MS78F39>PU;?UV,>2MZ38CTNPKP1+]?:2?VCU*O\776>MO-OM3U!+ P04 M" Y/E98N&3"O/8" F"0 %@ &5X,C,Q8V]N]73!-L\F(YNL:R[ 9H'2%S0ULHA*I$%23MVOW]'% MV_22;8O>=OU ##UG+N=@2&J. ^>*5R5*"UPCLYA"981< MPUV*Y@TX3H>:J,U.BW5NP7?]$.Z4?B.VK/5;80L\V^<9G[3[\4E39+Q2Z>YL MG(HMB/39@8AC+_*C.,,H"D*7XRKP.?)3[@6G<18UT]"OS^(-G9T+U*;)Y[K_G'P(93I-:&MVB1#@EE\:QTA4^HL\?T^11(\ M4])29YHJM69;\-.RG\G%"K&62:/%X\GW";@JE$X.W>8WJCU.QDI1[)+CI2C1 MP!SO8:%*)H][ADGC&-0B:X%&O$/B1W6;[7U+?T!Y"B%Q+X?GUP),W^9B)>S1 MH7?JCOR@[WU([,?(\R#+ R4XA:+^3;PGU_/;Z7P)UQ+Z3GJ;B7V%')V*7OP+IB#\6 VO5N,. M@2MIZL-L%=@<04BN]$9I9H62L-J!Q@PU2EZ[8(%K86SGO+5T^IN+8*Y,'X(@ M.AV]E1'$9A9P?#<.AUMA<&X1[O1KZW_]]WW7#XWHY<8#+M MPOVA-P2J?Z%T";=.#"H#56GJE/JV!M+F4KK E:Z8WH'O]YHKJ$> @CJGJZKC MF@G))!>L(-D[*J9.=L4DN2L#+U61$M[T8"9YOVFACL,L0V[%%B6:?PLX-J09 M382D"B2SU:H M47]H'#;<]T3VVR0Z=HBG6TN##R7LB+(HH'\0]ASG3\A4[KI M9$41VYUNRNTW&5[O93!R0O M38Q)@@N DM5?OP< 94N6G,A)'"N>YH,C$L!]X!Z<>P'B.#%9>G*<$(]._G+\ MUWJ=O9=AF5%N6*B(&XI8J45^Q7Z+2%^S>KWJ=2J+F1)7B6'M9KO+?I/J6DRX M;S?"I'0REW.\ZY^/=YV2XT!&LY/C2$R8B-[MB$[8Z4:]N!/L'\;=P_TN)]X[ MZ+3"_2 X[!#?^V]K!T/1W8_19I;2NYU,Y/6$K/Y^M]W8[Q7F:"HBD_1;S>;? M=ES7D^-8Y@;Z%,;[GU[,BC!#-Z;.4W&5]YU+.W[HO#F4J53]5TWW[\BVU&.> MB736_VDL,M+L@J;L4F8\_ZFF>:[KFI2(?4P">:YQZDW>1]R4I'3W(56 MVQH]O$E$(,SK5ZV]YE&GU6@MF_UY@]?XNCAE7%UAUHPLH \&+0@)$292S^3V MZ?!R/#H;G0[&HP\7[,,9.ST?#<_8\/?AZ4[LG$0N:RPD940\8R;A@&?OX&ACD!4\BL >]91BT^_LS6$G\@C1Z=?M MFV?RL]68._']M2]/2_N@T;/3,&()GQ!3-!$T!>^:1&@;AI*G[)(*J0R3.3N3 M*F.M9OUG)F/V"\]-0J5FYS*U G7-L\K2,W38#J%02,?HEF,X M+(E(L6DBPH3ITOZY&S\E1940ZT F=(J\;4N J3 )'-0%A :3*"FQ,, MBU@P6YR&EP+!SH\#06*QR!%DBY>[H-: /W1'LUIH%WD,,N%&0([(P[2,(!/ M68A@#: 3*IVQ G&WD+503M,[3%9PT/=4 _:1L()KMD>9H@. *($6ITX[>T*N M$Q:G(JLH#2Q$RC@4>7=A&C"MR $' 19"2#20CH#)(A4YL=]LM SU:BK3/D=!A M*G6)<98XE4P]4@HE0XKP6K,W $9$0)J/_O F3'A^16P 3KHL4_1PE5;O#;UU M0UN]R#_Y1V&+PMPCU,IGEK@6@.N!9&WYK"*?:BMM\9*V&-JLL_[/)!;2:@'D8?=VM0N:3N6E)I@$/;B;E#!@?*P3+DE=[CE MC+C+YQCAJX/%H@:_ K(=P;\83]%7\.U6X3C8'AQ7?+L,XXU):P7-F]/=QJ#& M0IB(R&*5:YESR^M< ^>VLK0 YBJ:@PGP%CP0J3 SF^'7J;5+R^'.0]IMB[K2IM'2:_;-ODC@&C M.9QK=WQBZ2V3VD"F/=U>H!9+3(^H$E;*S5O3.$I.(Y6^3"=CGA+P!F,&5VG(Q_K>%[WRUT!^E@/G6C;C,0W3\Q.<1P&NVDOX MXX UO,8C#-1T2VL/@K.J)3$$"$/)5_.I6B-/ZS(#/C!+SIF*^M>>=;VD-+Q] M.YRZ04>5]$ :(S.G8&)3!4J(2HG3YYNKS]Z'[4:OV[%?O@W,-M%<O]OI[,P'5"NBWRYN6&L9&':1K,11%M^?-]P%B?=8B\O)MO+\ M1W;JC )5VB]C[7;-74MYT+F]+W7.+[K%"R;?V\G7K[H@./>7_?HDY'^PD1V# MR_\\4^IQZMG@&7V_N!@^J^_GS^C[<'1Q[_K-8XBQ:1?9SD9TLT'7*JVZ.JW M1-@#;4S'+\;I>]>,EEQ_%CC]2),WMGX-^^&\ #+M#0/#WF$A4M__67:77>)]T]02P,$% @ .3Y6 M6,V0RM37$P 2%T !X !E>#0R9&5S8W)I<'1I;VYO9G)E9VES=')A;BYH M=&WM7%MSW#:6?M]?@74V&:>*ZDBRI3B2QU4:6;%5XY$\DK+>MRV0!+L1DP0' M(+O5^^OW7 !>NMFR)HFM5LJI)'9W$\#!P;E\YP*^G-5%_NKE3,GTU7^\_,^= M'?':)$VAREHD5LE:I:)QNIR*#ZER'\7.CG_JU%1+JZ>S6NSO[C\7'XS]J.>2 M?Z]UG:M789Z7/_#GES_0(B]CDRY?O4SU7.CTKT]TFJ3JV=XS=; GU?.]_<,X M/?AI-SM\\6Q_7ZJ]9X?_N_<$AL+C/,;5RUS]]4FARYV9PO6/GN]/?CRHZN.% M3NO9T=[N[K=/Z-%7+S-3UK">A?'\5YYF;;):W=8[,M?3\HBV](2'AI\3DQM[ M],TN_7.,O^QDLM#Y\N@O-[I03ERHA;@RA2S_$CE9NAVGK,[X0:?_3P%-0!Y] M7##)/\(\N2Y5V,+>/A)]=CO3L:Z_^V;ONSZ].K\_?Y*/4W,R4RD^=F@=8*C%5B=55K M4PJG:@<_V7HF$F5KJ4M1@&&S6N8"_BB-34U2R7-*GO>,H?-VXU6\6JOW&V/"E::S_ M]GN@-&FLKC5PI9[)6DBKA%53[8!,-,1EJJRX5@EM"P0+"$4ZKKMA9[?)3)93 M)4Z2&G_&@XN$A"V"*4Y5.KGO*1YOBU2NV(O3D_?G-R?OQ/7-Y>G?US;S,*+' M%GM+B!GJ@6L*.-CE)GUPIE!!BJ:J5/8.E1XFU240 QJ)M)'8%W(I8OB^J(!(4$11 M&[$TS43\#&HC16% +5(%T^2@%/V=^0DKJS)E46-P%XDI"MPUDASA/,+-3).G M@I["N7E,?Z^@E$%C: ZK7$U8" V(SG0"'_ Y72;& I5,/#Z)(^-E+A>NKW:# M22*A9#+#X8N9AK\@XTJAV/L'>D[*L@%&7RGD@8#)8>^%V-O=^3L^P0.)[?W] M#V:ZGZJ_^ (&>URQW["\W8?*PP?S*IF,VTT/#1B;== M]$Z9-=>TB^T60,0?RK9&:7"HR'_@/497:; ;G>FGT PR,&+XWOM\?.>!\UX MA,JCDWN+9TY2S( ]EZP3"S.M:ORH@N"8(Q$_'[.Y2 M]$4SLU!S92-VO3C;WXRT*<[U6EN@R\#$Z)&U0&M#3Z-?M!KQJA4JUQ#:HW>=LP2P%*\QRC6!YPY@ M<:USF&[)WX;5P"L2R$>OZ,!!NTP#%V ->JI'2,_UY[)R8/4N5S4-&>?(GPM, MAN1@]W(PDW@*"&3XQ!P0F$M:VRNCRCU69_=?&## '_R5_#%]3)@ M/2\#7EF0?'"(CNF! 3#T%H:Q8!=*$2-P4ZMJ(0A\=F++A$X>G^5\K?$@88>/ MPG:^W6"YV)R"!$E$)ZA!'= 1L708;Y2D\VG8;ZI )[V\C>M4U#=*.)8!#8H" MZ*6W-%ZN>B85G^RCIA48] AEY)T&U4Q9;Q^%F)RS: /NOL;'% )[W1 9DWU='_*)^AO_?V;#S)6?+ZRWW;D(MZWY_@8TA&7X\$*)AZ[+!DI*L43I)Z4XP6!E* M8Y*+GK.D MR)(RNU[$*3PT(M.W/7=%"@?:!S&K#Y&"Q%)BK-:)KB@"BX2IO$G P(2,* :/ M'=#CG!L"3 YIT(5$ L//FC]P#,.A*?L7F$29+,+ )V_(GB!E+0 %) !D)*:$ M0B=9IGBJEL*0KDD*4SI>9_\@-$(8 F:"5^G@P/#DH@U>? 4OIS8GELX ML^ZL*$X=(,:2#T2F*'H*X2;3@D_Z+5%Q@B;:Z&K6X-+#HZ4[3><)\'*GEA^5 M@6V+]UT:9_MMZ&\K+OGD2JBA]1)7A/-)[+S,"8XR$CA3<*RB!EUUTALR"I;F M+!0H5@U;R0J, H?"H[+9D)YT/Z&T "]@=E3HB?@ &G#+JNXSB:Z?6XL\0F'L M@U5"\A6QRLT"?M, V'KT)D;9!&%>>[R51?(1;U&X)U-,#M2]!V*=LL8.EJ7U M9 Z&*U5.3TMV3V!:_4*<+7*@_^JCS]S)A!)7*WLG(VPAF"G5%#1*ANSMIE1# MB\=@AQKTGBVFLY7&^B8FMH(Y1&7DVFO >FC#B!B&6C@LDW-C@ZX.[?7; M+I&KEKSE*7*0LG)$(-E?=)T^N!L5#CH\J@L/LW% /2T^<']#J?)['HZC'K$N MT0C\44B51&M8Z*8($$';UE[;$8K6TX,K$Z<0&;3>T$\8@V;!)^R><&C.3Q+0 M**0\7T9K @KGC4'^J T%>,\.X$\049ZBR].4#&>Y_3-:2X\_>\+#*J#QF$'O M0&)(84G'.E#5)>:E"QD1@%[P;&9-08D4 C+X9TSJW"*3#-,MN9(@<<,L]8;\ M/H@5:;3),IWTJB$#6ADB(:PC^ 31+R,6!,%L?V'0'(XYESV-$*T[7 M/R?X.9*@=3<3;+)@CTA:'2 M'WMM4 < =)5QX,@>@87RR"R$O>Q$?;SIE:]%W&M^-<;&JCRG4ACX'0J!*"<$ M_$0/AK9ES:2PK *3QQZG7JV9U!8V=X<-\C6[TYE6F3B[54E#J;5+,DGW+7X] MG"+W&(].(0A$))KRY;T>E(Q$,1?8D <$4G/L'%6S*WFK-()-)\W'Y\V^QL%N#P2ID6D+S[3$,TV7KE8R]7XN&*B^>?*Y+Z_3&/*7["M1T\J\&TS M9JAZ[8SW)JTI<]1R5I90P;QKFK'E*=Z7'SUUU,O;I?A6)YA)1/CP15/*4A>F M<;CYT!F#^01OHWTJU_N,GZ7.L<4)O1VU0"VYFR%K <, KPU]0N =XV&?7/(Y M3%]S!_5!ISAR5H]0R#_U/OCU MF]-W[96.[38(']1J+7*,";"?X%6]ZT)'UB6FN$Z)*:.67SW[P7T!_G9!-%@ MQ)=:U4,T2W,H:D_CE"&XM09@70+"/E,@A&/SLYM3Y51.R=MBKY _B=8? Z*) M/1P+B(@6!-OQM49ZSQKIPTFI/\V0R L>A>U-.$^V7P#MM$E9/'&#%6":@W96M'5P^^@-JL[ZGKQQ76JLKI3JZR^NC9 M8;ALI<&*E/71SA>IJ-S!Z<-V(U^>A"%O]IY/#I 7>"!QB")Z -0'NOTJ27") M-&1$_86/*GRH]CN/'Q/#IKU#U!>L36NOK4O]V%\EYS-)#B5'$$1AQ:E_1ZQ_ M\J$+O@]#J$29U\Y$_SBX-NPH"_#^BZ]=_95K<7,D(-/AVWE&$QRWGF#%L%#?DI?[N>K MIQ#AY6:I/-X350YD^9]8==H'VF8,A);]MO0V9* :E,+LLBXIF,ZP&0 #6$P] MS!2W;# 1Y/M7X@YKG*53E6'55/M0B!+;Y38_;9MU5RW2FW.V-^#H K3JC$;RL+7 M<__RYZY["1F4@0UHV 4PW/5 VE92@ML9@-@LF%ULW&_SOE^/^>'4>QCB;C+" M=.@S+JGU2E[@2RU@E#""JJ26^JIKU5UY[L[Z'GCD*PC_ LD2ZK*KZKM/HDU5 M@"7(='NO+C>24J]<4("_31N)-[X5==Z3<^AJ?P*P&3R&$-A/,[RR3-D6*D6O MBMR6X])-*>L6C9;B7FE)K ^4(2#'>!Q''<==VEOM-3EFW!JU=DIQ9^XU_3T^]0Q5#L4\6X02 ;^>9> MU[4O^P*Z[UA<[6YERZT&5RA&7PN1]3IK:5YJ<9#VHZKOZ&)]^%K=)]Z,""&= MP^#Y9V-A8]LMJ5XJFJG"H<7D1\^KNVHXDLN)"YJ#M)2<<,N19 M-*QGGH((D,4_G>$T=HG>/,^C]C4R39YC+QFX6ER[0EM2U[V7.<0LBQ#AL;:H M]HAH.2K'/-7?\Q5]X..<:?% A#4I48JB M^K%%Z&$2L@)8M@N!\O0Z^50P;R M[9E]>>-IUY /!D6W[T\+ M,ZVU+G\_?%D'[F0^V AE44" P)" *.*M;>"7PM>T<0C0Y6TILXU= +W.Q-_Y M[A ZKZ?S3W!VBL9M%6SB=3]_GU^D)JDMD.@OLK4O!:&;Q4L\D63&R';8QT3- M3YSP7[9.$S5NY>[PX$U@I#S<;J8*[C7SEY]K;W+]/3Z^=,8:W;VTZ8]X^1R_ M!R[&,3'P!OO(L-E]9CP!K):=X*&0T&W'8=='!T+HE0/4WAS;/N#$2$ M]J_$ &G C,HXIY$L?CL#8@!;>R2 W7GAXI)V/3YIK'!XV:<]\?6C]DT&$[$% MG2Z?>-L'OQ!I^[WFX/8H,#[7SK\@"+7DXN3Z]3@((W_(#N@D9E9,I.EO4^2MZZZN5=LM/[294)Y%\V9)O6_(S MK^VK1XN]H V^"HJ2"#<67Q/B^T,C<3$YV0Q)MZ8OYP=^D_D/] ;U_P=02P,$ M% @ .3Y66.U"W!Q+%P MJ@ !X !E>#DW,6QA;G1H975S+65X96-U M=&EV96-O;2YH=&WM75MSVSB6?M]?@4W7SMA;M-KR+8Z3294[<<]F=R;3E62J M'[<@$K+0)@DU0$K1_/H]%X W48KM;%JT*EU=26R2( B#4KLO3UJYF2 MR>M_>_7O1T?BK8G+3.6%B*V2A4I$Z71^*WY-E+L31T?^KC=FOK+Z=E:(D^.3 M,_&KL7=Z(?EZH8M4O0[CO/J1?W[U([WDU<0DJ]>O$KT0.OG+,WV17*IS=:Q. MQQ-UEIQ?7!ZK\[,D/IF\2"[&YV>G_SM^!H_"[?R,*U:I^LNS3.=',X7OOSH[ M&3T_GQ-:^5=I;N'MBBL)D5Y?S BY/35[ 3"R,S/_D%ZR_ MIOOLRT)]+HYDJF_S*_I\/UAX(#:IL5<_'--_+_'*T51F.EU=_?F3SI03[]52 M?#"9S/\<.9F[(Z>LGO*-3O]+P?SA)?3CDC_O.8R3ZER%SQV?G,,'WGR>Z8DN MQ(OGHW'[&^X[^QBV1MD=3?]O,B]FJG3BOTR: '6Y2+S+X]$]OV1\,J!/N08: M3X!+9)Z(#\H5Q#)(6C>?55P6>J& 5[*YRITLM,G%FU0N)S*^$[^85,>K!WSR M-__ LX?LE3B WXH__7!YIN==+GHDU'2J8EI-Z829 MBG_$A9DH*TXB5%>G Z;=FVKF;X$NAK":(R'>*%M(G8M8SNE#_@4$"Q(WA$B:FQ F63A4]9*+M"X:6L-;DR MI4M!CRRE38C7T.@!,7$TD0Y^CIM* Q@1QU +M.*+F2SH1Z\5\I ^UE=:%ANT'BNLU;9W#B\HFYE"HLP 0[ MHOS@]B]#,D-ZL&[!MT9CZ$"R+ M2'PH4X7K?#1NR(+6"B,-O9A=() I# JDY,C10\5K&L-7,T@4*+RD>;N_KQH9K.Q/U7/P M#;(L9L:RI6UJBB/:B8'H"HM:N?&U> 'NS.0=?#"\-5%HH8,"9AK-%;S52;N* M<+VLF8,:+^![8"EELM".Z#]8'[(EM%D(5F\:B6M0[:WA@Y@,B]K^M(JUZ\DN M-:\+? DPE2-'#>9?*?:\94_0I^&T:DY=4_,'#AR5C^7D-Q#>E4!O<#D^SR_G M+7W(_',%NY"; F=-!P4J:^_?ADONI@/6R)S;'Z1.R.=Z"?%+5AI+I M$=_E9IFJY):MS389[]84N08"G:\Z4ZKEA7<'D*,C^A99?PL*J&B3L;L?='?V ME.@.T0]-0G9WDP:2VBFV(7X&H3DO+?MI;:IF>3LU:6J6*-P9.)K)A6*74LD< M465P 0M40"!6&2EYO Q]?K(36NY?FP-YN$-4K$W,9Z,78UR(0=J8US7Z\*%& M'P9@;Q*).@(TAH.0-/T1'*B"=#9,D4PB:Q6Y5 0I6;1EP:9<:(:6O+M2SZAZ MV#&(!!Q=?9W_VOL]'K%)!4,L39FB&>S*M,#7RWI$]"^JV6I>+I[F$FSF,'F& MF?$:K(;%6^?PN"&C#6D<%NP+=SY>10Y+K$R&)%9.SP8K5LBF'XX4:;@94_%6 M(Z4:ZSKR86]T7SPD(AVP[JM\S6$1ZB>9!ARW'96N7..FX[PW5)L,B6H'+%IO M&H&I:Q^8>E<%IGZBP%23;H9%W#)#.PDI^ ,'VPA8VC9_O%'!I82-&?4Y5BIY M]& TAD'L>*F=\J81N443I1KOFDFP9 K^94"M$ 2@$3U29D,:"<^#XF?-23UT MIT16NH(!NFQ>XL!HL9JR0$@'_ &FL->AH6 ME-3#@2AGY0;X]5?C(D ME*IO6\X,NDZ(>CM\.8$Z1YF\PZ\*+^% 0O4LW.],WG[4:=AY:3<,X*K@0V4# MWW1WJVLF5[N+"0QY<> H,N3*":RBEI9";;8*OJQM?G0IZN^/)T MK].T[QVTH7JJZ\!2>-V\M*Z4[)N_ \=7G!V/P:UC)1("C^+CT?^LQ9'@@4E/ M#,3MBQ">#D<(7XR.ARN$?Z[$U(<*/?J[DJZT W(DD-0SGE2%(S7L&'0N4/!A M#C=!-B@S;=*.W#7DJ!=^&*(O'3_!*4R$+?<(AWY$BH(J]H- MYL81[']E%;+J0FVL0/!<=UP_(B?.I&!7W;]H80?Y[OV;VRDW:/XYLV$RYK./I%WX[6,H''T,0'/8EY;1Z2E;804VN\_@D$ M.O+Y+T#_L?+1_@*)&@P#!<\C3FQ545I0^,N9(C4/&BT6RN1 S P;W/\&TA] 5YYY:FO\W@Y]]Z[+#"[/N0HR*U\=] . M^Q3PJ3X%& - Q>IP7_AF-CR^V8J8D%5#UOD@V2O 24-@)9UO,-1<##3O WI) M218=)]OA[=NX M.PV,?R8V_=*DJBIR0[8CSBVH7*0]1Q+E?,BY:Y.KB)6\<(/RBKRN"_XN!X.:UZ,SI\/5J4UH.!=36Q#OLZPUNF)J/XT MO6=T .L]/03VIQ_.+U\^FNW'QY??^7XKW]?R-L5$$I2X!^-#<$I@73&M3,#+ M%N0PH>VV#IF1(W5PEX='S*>ZI3U0*Y9[BW(DZE([B]F<6F MR3M">TQPUC9B!?5U%2ID,++0>P>,:< @K+86F7EOMGH8RI7""[/MOB_.\3"@ MJ @5-6;;R*"?&;?],Q&]79_71!5+S")A<\D5(I&KC2%5G]G;')9\VE",-=6V M'D$76&&V;-U,BX#3LQJ+ F25J3L58)EQPO12I:#N,]CDF5N+/=)- ]H5>!UBM M]\]N5XY-305PAX(R\BVWT-* E9\%5):RZ0B*5^"QF96G8 ,$H;-):5T;%.PE M8)] _%#RW!=W<("E6W.5)>,7=6/ M$+AK+4(C]&-5&+U.A93T2!%^=(MHY#KZTP[=]"5,>\R&.P:AQ9PP-N(KF1$* MTG-.P('7;PWTD:QMT'-$S?.J3_)IWCURF-*V)R $?2YXW5-G/VRSBR=DF]7 MGC6Q2OZPE.D'&V;?TXZI_>$^IAT/1_L,T9Z>_C\8T,T^;'U61U6(T#&2'V6) M-#JX\1L)G$FTBZT*NJ;SPKH5F\<4X=W>S,?O>7#=9JLJ%+-,=5QBT=54(F1 MS>.TC$,5&@';3-T:^"FBHE=0D]+5/:H& MW_?Y0<9\CAQ"?C'DA\T!UY#6!WYAW2)%LB8?2 >P)_LM-/:Y()+UNDE3A MGF8KW;5V??MB8@_0"<.^6?=C:->H_D#X>4/Q!T82E.V*LX?3#^/0KFZHF$D8 M$O[0,34K@C_C4*+(B&0 (?#-.J<$G4"*V\#F[U&-;QS5:"HD[@Y::T(E8"\T M]F *DH9/3@@_;8!LO'ZY)TERH4.=R+V5\):@64(BY?XE]0R(1!JQB#:%@'^- M9STD_OBFJD$JQOA[NJ92IL,Z.7%9)S>UIX!7>SP0*-S!=U]TRP#AFW?].A]L M09TZ!N?F N(0'4S\$?*-R3=]+ MY]20+VF6LA&\+*9*N<-NEP2@A(9#]*B/W0-T[01V_?G.T+63QZ-K>/@2X;\W M!!D/J,+CA!LQM2(W^:65T!P\U3J @F:OH1U/XFO+#N M^;M#@7]R'X'OQ!FH-OC_:)>IV4BSXB!(U^9Q O7Q SZ);WLA!*>QA3;\:U$2 M%MZ;J.LP I.>6X %'[-B"K8E*Y3+]]4@8MA,K?V=U+Y W=^T==JC43RT?S)5 MS#C1M?*2/9 65HL"09[KX=7-3D"$NPR:%<3S79)_5-LG?8@I)]?1,D>/1D,W M)%#MR:D.ET\H2G=3N0?#B,[MPMK_U+ 6JK8KP61X##+<[L??9@%=15U\XNL! M=ZP@Z35QRC( <=!\X6#?VC_6-]OT8B,_ 4T *C#+,'XMIS> M#')=840JI#WS*[ -2[&!/IKN,KFGCP?&*Y425@)U!GUIGVV/7537,5>PJU4V M+[[:B8\J4(V?7W\%MD2LWQ*U4#E:L@VHW-=5R@Z+H088]>F(LX4V6+T.5)XA M40-IPJ54+JM0#FP4_8BI2WB0-)J,5A/D+M[#2!F=;7Q)AQN?/ '>X0_V3FSW MJWM8R$P(DL9TLKG.^Y[#OYU*(Q]6#1,/I\3U*9'Z% JOS*I9,9_0FUL0=GAY MFTV^IE9B6)PR0 R[LV>IOL-2R%B6C@"6V@CWTN9IKW'N"72%\O MGI#?\1;<_=3LNI$J8Q'M4 KFRO,!C]44W=IIA,U#Y3:T5.U2[53!Q[?[*W3/ M&6([,+RU!CVQWTU]-&/C0%/N[KBE+?'WW$8Z9G'?&#E[< JZ'2!>["5NO4SC.5.G.^/RY*N59HN\J0 M:SAY(1O"XO+TY,X"OC O.(9'B!,JT>"F0YH6W Y@\8N^7B$ M.A\,%T)I=8[>IJ1"C.?3 C2#LST9 'A:(\A^76:NBMDVNMV/Q,^E1?MC8_(B M%CN0I?29/-G[ETQX1=%SKC"G$(&3HQ>J=P=HN;ONR&.2=+L'KKH2XU0*P:>P M#JT"%9J2K=LJMRI1V)\"BO)G(&PH23GL'MBGVZQ=OW%/K+WQ^ F)70Y15T'K M#\38[-V]@9W6%*6LK@]&#/>S1CEG2*@96VT9A)1J@PL40)_ZX XOTM9BW.%T M#Q9\B" Y]-$X>10-HBVZ15ON ,YC41,9W8;C&.9<$4G>G\]\R M+R40SI@AF)$0UYOE7&(49]=B_R&*MMYKI5F$\C$D]8;Y_&X4Q:R@[I_GW59T M+4._G>17UP#"AW7*,MJ5R=SKJ%_[/T[+6U*C_J0&C/:5A6/TLG/ L,>E:MU? MU0#&Q,$8X?4DV@PS+^MS6=;GW'=P?=O1>EP^TK:#ZD.0]>SXQ77=>1AV)*>\ MBX7*2US]A)#G\8O+"ZYH1'I'M*\!T=4F4IV<,J%BCJFB]>@D\6TPEI#%JQ28 M[7DR$VJ)@H*G*0U\8+T!UM"J^[CD@E66BC_A9\4@"3;]K(X\ &<8 M/"4Z:F A/0-ZLZCY@3B.!X*V%JK6M:F'^Q+_'9\\((C^ @T.0KCH$:%IV>/B$Z_5C:A5[(E*V7]P9$=:K0PP.Y\BO[#R"F MWI"ON5LJ?@_"?^9]E(V*?E/!&-@M("'AP[RG3 U\-_;O92:17%+2JV+O5X 6 MVJ,%=PV7VL=D6E]@&UT6?>/GD;C9D$^)_I:W=',C;H$%$?[$<\1U1NK1UCOH M/<"N.IHV 0136<_!)FH_3NYA*]EN_0X_ZD;OMV=M*$&#GFNL8+"0OVS1',*O ML/*08U[MS/PBI+M&(;[<71#U&04/VCV4B^BZI@,L6 ZF"4O&ZEYOCZ\GTH*9 M@U9[8VFVPBQ[(N;.GI*84W2@ 77\V:T8>\?,1WZBVX FK>--#')5S^ 9(,EO MX/3$LJ@,9)V#'$=,4:>L7@WR35.Q4RQZ%?P 'U[VC\'"5$]2,E3K86Z5U #2 M6#8V3L[<\#U1U7CUR].KQ^@_.-(["X'1T;3(RBPP?*YB8%,RKI$//=?)HCFU M];4-AGAC'OO"GP/J./=%_OPK.K]T\,'?Y'* UO(MS<_'##'_%K1583H+3SDT<0J7$FA;<'N5@ Z;+*UQ9P &2;;HO$I.Q645:V&JLX;Y]QU@SG"X=LIT:BTP:#M@') M4#Z6+5-_A&3(3FF"A1_PZOCX[=&X,M'0\O26^#5IM\0G3/'-YQ?'EP_AR,V1 MZ>V,/)3X_G\*^(__^)X)L76ESC9G0OR(S6_AKUF1I:__#U!+ P04 " Y M/E98^D&1_-#! P G#R4 $0 &QN=&@M,C R,S$R,S$N:'1M[+UG<]O(EC#\ M?7\%2C>L7472#**"/>.G: 6/9I16E._<>9]Z:JL)-$E<@P '01+GU[_GG X M&"1*8FC(V+H[%LD&.IS3)X>?_L_#R+/N>!BY@?_S?S=J]?^VN&\'CNL/?O[O M3O?H[.R__\_G__II&,,P&.I''Q]ZH>?^O#.,X_''#Q_N[^]K^$TM" L.OU4%,;ZJ3Z+>O0,? G/-5MJ MD.?'P]R[/0;?\"2JV<&(1C;@?W+TO$4T#@\//SS@YM0KW8=X_MY!SJD31=Q.W: M(+C[@+_DAL+BJO!C;H%J\&/K:[2K]8.J/@EXSR+X-5J9%^GA4;#;;.P_!G,Q M8B>#(HZ;WY0?1CQF%CY:Y7\F[MW/.T>!'W,_ MKMY.QK!F6WSZ>2?F#_$'0K,/G__KO_[KI]B-/?X9T;>JL/2G#^++GSZ(5_<" M9_+Y)\>]LZ)XXO&?=QPW&GML\M$/? X+BC]=Q^$^_0F_7R8C'KJV MF/\AON']GW?L*H#?9R-\$W<_=D;<=^#_XU./#78L%TZK7VTU=S[WF1?QGS[D M7O2,]QX'=D*O=2.;>7]P%I["-Y&>H;7S&7>\J@FN87C@Y*?8W?E\^L?+)SCQ M 1"3(Y@B9-Z9[_"'W_A$O[R]\[D.E*O=;-1;>R^;1!*!CZ?,#?_%O(3?<#L) M0Z"X7UCD1M_\H!?Q\([U/'[FCQ-X'EYDNYY+U_G<93WX.YY\9:Y_'D11-V8Q MQQ.YZI\!Y1[QDP= NLB%Q\_=*%8KWVO#T3]&C_[VE?LLGC8WC@CEY-&]&@RY]!-W8][Q?N.=_\ MD#//_8L[S]WRWOXFMWQP,+WIL]$8MJT6"HQ\@$ND3>,-ZL.,,:SXCCLG#[:7 MH'3Q-0B<>]CXS!:OPJ-@- [Y$#=ZQZ?W?>+CH@@[U/8/V_4GMG_#(Z!$]A#V M?\SON!>,<<:7;?[0M,TWGMC\41#!^W'*"/;?A=OFVCSJ!IZS8.>G(;-Q"BN! ME=.^8=H>#W>FSJ+9 $1PN.V.@&?\O+,_?3#'O -M3RU'J>O[[#E:^O*=:W?]!N'2Y:WWS,:4]/ M?S4F4/J#KZ(!F[P.R"R,5YYA.!1K/Q%"9<@7 < MTNNC2Z"R0(-@@F>A_^[Z-]'<_";$XOC*MM!^8@O780#'%D^N45^!.WD"PB-1 M)/C[D;5T^C'LW ;Y)_%@54#*@%+8DE,"91\%@+Y_T<=GG<<,9J[Z//:*=1Y/ M(+EFXT<"]UYR),VGKBIL*TC\.+IF$Y2-8#L"[VT[3+BCEN#RZ.@%%^ )4K22 M#3YUC=>ZP4=O^$JV]]05/P_\P2T/1\AC5@*BE>_@J4OYVATL>XM2(OZB;1PN MPRXRZ/1"GK'LE7G=;EI/";+KVLU<['KE7I[2-[,(!M?_B(W=F'FTA*N>YPZ( M<$=KN/>OW-=3ZN4:]M7]=$&A1+ICB5L@#_O2+OA1R<) M)Z 'I7LY!'QKM&NMY]ECF@=:Z^6V\_$V=#IA>)PHO63.K [3%I1&ZP 08[_Y MS!E;KYIQ=^Z,'_*&LY#W.2 %Z$9S['UH!_P8D:T:UF217?!C/!G#BB)W-/;0 M0DG?#4-<Y;UHZ6A?4]YRL4NJ3Z^#G MOLM#B];$YYJ$C\Y^RUNKIA_^K+[*OWU,1C7U*8I9&!_#/2'#7;7>@/^IY]+? M]#*==&BC66TUTBG$+^JSFN1#;M_SCZ%IP#$(!T4L#V&OVJKK%\E?EML9ZJRT MK0200GTY@MN;A/RSM*-__-8]5H^KG]1G?'[^*;7,.J5=\HFT7WE*T9#!'9DY M*(E^]./S3VK7K).:NBG/.ZG\SMIF[:SYFIUE;\HU#[L(;+T]Q[V#966'7@K3 M6!"^\%+-/(]?'G,_&(%D,.>URZ)@[A4?\JM_$E/W#(!GC@$TEV< S=4Q@'W3 MCJ&Q_#$T5G<,!^L^!KD;/D"96'QT8+*'L>?:;GS!TX(!>/ 3X51+4>C MY0;4TF T#GSX&'4>7"#>:AA\/PK\;AS8W\6[?OHP=PI]&GHESR,[]=41U,." M'_EM2"1I0HN?:SY_&]XS%R? M.RV=C6H\/?; )FOL7:5 M[BT2 Q, MW;=KJ^RPD(C14*"*7RN[6S;Y;*[W;/ MOU1^MW3PI?)K#BP,4WY7N;52^7V6U+<=OT^S5'X+"KA2^34<0*7R6R!@%5WY MW8@B9@*@BJXQ;\I*\:K H*FPMZ)KRINV4JSR[(NN)6_#2K'*\R^ZLKQ1*\4J M#W[MFO%;5$S6!(M2E7^6:+2=&/Y6J/:[1=?.MZ$AKO+\BZZA;U1#7.7!%UTUW[:&N$I8F.#'S@D? M5#"TJ5.('Q,^IH:^1OC8-593_I)$<,FCJ&,#3HKZ"P(;,9'^XW48#+COVNO6 MC#<%%9W9*NN6J>_SJ:5C^%.]X!FYS<;JV5B7 B@XIU)K$;Q1E&_X,L%BJ1EH M'[%H>,TF^/8(+45/ -U\',NE;^30YE5$S5B]?#4'O6Z\:A4&T,;J]_D"BMFC M3FLI=@'607@9Q#QJ[C7;USRT8>QQPN&0]E>% EAR)Y8E=U*H:X$G74)A)!;C MS 11&./5=1([O@IE$='LK?[CO'-S=OK'"B\UXHFXRC=N]/W+Y OW[>&(A=^G MH,L\'MWP.^Y3S=TU+F 6L^2!S(Q]DZ:K7>/,*"5.FH.3VPFX:1MG7BIQTAR< MW$ZJ6MLXD]L3.'DL:I1/2IQ\L[R[;9PULL1) %RY"@9K0H+%O;/F8<-7Q+7PQYD17&%M(USA:SSV%^$3>QA M"6PR!Z#&^1%>!-!SYCMGHW$8W%$PU:O=V2\F$\8 =L\X8[RQ@"W6C=TSSJ+] M(L!>,'OH^CR<9 >6UW;/.-NPV= MV-TUSLKZ(NB>)J'OQDG(J27D _Y5F&"> M/>.,BB_CB]AB;!AXSV&.YL# .!/:BV#0#?KQ/:-;H/[,-+3&3L^E'%K=,\XP M5218%XR]%;LU4+VU(K/7GK%6DL=CU[R@S\)CUD^\:9 M'DR!QY8:MAEG,3 %'MOQBNP;I^,_X:L[AX]^Q)GOW 03YL43Z3M[F\5Q]HU3 MT@T%SY:HF7$*O*'@V1)Q,Z'K[,4Z^7N06?F'E XQA<6<>?"A;_BP.%5/&O0VZ[./S890,_B.+UE_;=$ODJFFZ_ M+?!LB9H53;/?%GBV1-R*IM??!C'S?ASB5C2M?EO@V1)Q*YJ:ORWP;(FX%4WO M[V+E$#YP[6LX'Y^'T= =1QU?- =YFP2N:,: ;8)H.T2N42^:@6";,-H.I6O4 MC3,:Z.PC%@WA[/$?3,6[8QZ?Z8-T$?A\2O]6@,W^/8:QII*?FRP&&LY.8*%+M,' M_I+'5/[CEH4#'D>G0=CYBSLA*_RM79.-IF&NC69)B'<:]?^ M1<-*>"^ M['&H=6<]!K0:[>^.XM>JK!080#?--8B]-:N6+.TNZSR J;C:"DW M[F"XACI>:])SFL;:7RY$83A\BJ [=>K3/\,U[+&>Z\$6KOK=Q+;APJX*$Q"N M!'O*YW+_3*84K]G?C]W(#A(X:3+;G7K!_:K64EZ1C5\18TUC9DB@YAN&5LH\ MC370E=BP!=I@G)G00/9I!F+^:$SC^8!7&EE+ETP!7M[OT0 M-^1%%*A8W9L;+6,]>^7=*_F>>7QOI3*GL7[4\N[]R#?$5+ZWTKMGK-?:3(0W MP\+[IJ^=04*AL=[J\G*4\J!1UVZE/,E8_W=Y[7[0R_%#B(+&NM7/?#L8\5OV MT$GB81#"TO(0/89?L4#W$>)TN(:&4.N2+XQUU#YUXMT8*$?'=\X#FWF_)J$; M.:Z]Q*4VY^QWC7.#(LV@<\7Q7WDP"-EXB"T9)4F)Q^''B\[KZ25 ]2CDCAL# M/0XG_2"\9Z&3!^^9?P<7"M9_#J3LIKXDB MD(I!2"[.V1MKN;X. ]A)/+D&$,3 J+%M,N: MWKZQOE=MU=,I7E&JLFVLRGKL1N,@8M[7,$C&1QZ+(GCA/$-9;J#X MP)VK_I<).C0O ^%11*=G E^/I;]SW02CWEH9JAJKX&X70DLO4QCQM/LB:_H# M*M=Q'*J5QSQ@,SKZ,LDM.8)7> FJB?-7FJVSEP )#6[@&/P;YKC!>,C" M$;,GHA0RO*&;]"+7<=F:?8'4QK)YN!H,-%;5_W% :T*/TK:QIH=3UW=C?N[> MH$'W@]CPN;/9?)A?L/T%(Y"E/E6Y#YO 1"[]O+]S?(+'46&.&@; M6 +1 MGK'FD?7"UB (&&L->1$$CI(H!KX;WG 1+D?]N4LBVM@SUL)B-IB+1D^-->%L M#,P& N[:^!Y_T!F$G"Q1!>*?;\NH\WQ0_!!D]6U9=XI\W_;?EC%& M1D-PAU+K B\83*AO1H$ \K9L,X6W:J_2S;__M@PRA;=JKQ2V;\L*LR&K]DHA M\#9,+V_1JKU2,+\-T\M;M&JO%,QOP_2R/:OV2H%AG.FE&.;.HI'6MV%\>8M6 M[96"^6V87[9GU5XE, Z,,\"45NW5 _EM&77>CE5[I4!^6]:=0M^WMV6,V8Y5 M>Z4 >1NVF0V+'--1]NVEH^QAZ(JB[ ^,-;><^0[O/QMZ9]"N+JOJP%CCP%(0PQH(5WVJ'?PVX7-HG+U '3W1 ML8[]9^)&[E0!NR,>WG&6:/'5Y9CHN'X -9=/86]6FP>K 9"QNKZ! %I63FJM M4$XZ-%9/%R5D3YE-C7&R_8>;]<;A+0]'YP'SU>^KLL:=!_X@AG[\LU5,DUCS0^/X\,-OPN\.Q#]WQ)" MK.O.&VNH^ %A;,2E-S:"Y#&$:#:1";PE7%C7?3?6RC,/O*E%0=[V_* 2SHOA M;*P)Z0>%LQ&TW5@KU0\OX"]M%8.AARNJ&]BL&VL5>PM$XLD9BY^3")?35 S: M'!B7P=ES'L-B-B)%K!2\QAK]S +OE]!U!AQ95'% :ZRQ[U\L=%G/X]@\%K&- M->7/PIIL>9<\QF;H(1O@+VY0RN6E7+X8NXUU8&P(N]\2#I:T>QJ["^6)*1JZ M;='*EOBN ')?Z.3,^U\[N./P=ZPA/N(,NY@(LC$[3KU9#5.?\=4+T*EAK",' M87E&7<;PP>F@#85!1W+KKTZ(E8V_>[%ZXS5!*S/O_S1@XMVW254:!?7&' 4^ M,,X8TWIPP*KHR2.XM]=L9R;MQOH>-XL?Z]7BC,&]-#MV&<09\ M8Y!I*4VR1*8L,AEK-"\YU[I ;JPYN02Y$SEPK?)&O5IOK4K>:!IKK%P+/JSF MUBY5%6IJZ.MNK;'V15W2YN3/A%P(HW'@X]W)@ZECV\DH@;OD<99\\6L6%@HDQMKOC+T<)F@R36,M9>;? M)"/@9ZQQRMAKMR:;4=-8FY'Y-VE=(#'63%.$R]%8)22,-8@4ZG*L$B0M8VT0 MQEZ.E]QX68O<=T?L!_CYYP\7 FRUC[0MF@VM;U,]8:+ L!L2[1QUUC[AO&-8[9T MRW:--6T8#[%MW3%CC1F=>Q8ZLP%N)Z.Q%TPX@#*POU^-$8AO4\K8-=:,80QD MMD7EC#5@& .9;5$S8VT5"R #'"<.73OF#L'FC5(R8TT2VX+*FKSEN\8:$XQ M_VVQ"V/-!49 95NLPEB#P!14*,WB-HB91] 8!I[#PQL>)Z$_!2AZ\&VVO&RV MC;4%K!=<3R[CQ>GF144$8TT,!B+"6RXZUBZ*Y<(P KXE*:A=%'.&8>#:DGC4 M+HJ-8_O@6E,Z3KLHM@RC(+!*=;J]=KO%\VGW9CJMZ;J/'F<1GU_JD7Y2SS^C MNF/;.",%BDK:,_25!X.0C8>NS;Q\OW.D'H7/! MHHC9PP1._LE"L>8()7O&:=^&'GF]66VNIB;JGG%ZKI%'WJK6VRO#N;SZ73^4:T[YN;\9I>Q!.EB9S)98\%TN,,RFL5V(J$>2Y"&*< 61I"+5^$ @99R\I%*'_ M4;#$V) "TPG]CX(@QMG)S%.U-A.[I?W_\^..[V %+LH^S1*AM'DHD@,LDZ$( MPDJB1X^"!*N CP&I)I=LE*5\USR,QMS&E//;(9#',4]BUU["_/1:C-\EC#]< M!N.GAKZ.%!EK']PT@B)B7-W[ ']=JW_C&)%Q$DP!^55.@GUC37L_(I"-N/9K MMRD^W^K=J&\AN/[ .-,=MYV/9[[CWKE.DH]?8J-S[C_5H'X%WH=M)#D<&&<< MVSHJ_=0$']M6SW M![U+QMF!WC# 7W]I/[@/'T,>!4EH\TA\''+FT'I@)Y]_@O\0:-W67K^_SP_W M]AN]_=W]P_J![7"[W>XU;-ZK._W^_R(S2Y^)XHD'(!ZY?G7(W<$P_KA;:X_C M3_>N R?2J-?_L9,?R,(!C.T%<1R,/K9@I/PF#L;X$49'8^:KX7;@!>''OP&F MU/O]3WW83K7/1JXW^?C?MP"1R+KD]]9-,&+^?U?OU^B?/];E:;J-9_\6]3QN!7T+[:)H7/CI P/ X>'.@1]-ZOIX_3XVFPA!"8C//_7"#U// MS7^:>>[ _VASM#[ PS'-+P?T@A V4843]-@XXA_5'Y\<-QI[; )X3.= #WW* MXPAB$S4FM)DG)Z'YQ,\2T0X/:\V]0\2U&% Z=M3$$@UK@(8?YGQ_4&OMSO^I M7FO,?V3QJW8/]E?U*@-7U:S7#G;W'GW5!SK[4/THD5I<:G@&@(Y8]/-.:V<* M+R2D&^/8B@+/=2RZ9' YY.](&V9_'#,'B?W'N@6_R765=FY/NH_32P-6VSTY^G9S M=GMVTK4ZE\?6R;^/?NEGOW<'O+WEMJU?_[NO];N#U#;\7IU(EM2>'R!F42 MN]K8L7R&TK[#W8_'@9V,I,USA^3*/@SX#)K*;R1[IF]Y0B3Y40"]ZKT=++6W M=UB>W;KR^7NUS(U+;0?MUG.EMMW:?OMQ0639-QVV:O7=W65DFD4,4_&\YO@! MN=[L?9T^A)'K.!Y?'MR_P]MQAFA9G6)W+J2??W4[O@_:[0T?!V&\8_6#<,1B M4 \?XH]]]X$[U3A,]-5N[GS^Y]\.]W?;GQ;>[MAYP1%ZO#^#1<\]P!7=%U)D M.Y>7WSKGULW)]=7-K77][:;[K7-Y:]U>6<"';X'96HV6=75C-=KOG/?6U:EU M^\N)E6'1FCUWCF[QY\9A:S=W0DM+3*U-\(;#Y5A#$%KQD%M]-P(H61/.0HL, M+B_@%]=DOC@1AJD\UCGP374$KQCB8U6'3:HX597["@MWGX/F1TF(S:U.:=%_ MP(N6G32=K[7S^9C;PCR$%ID\YEHK;UEU%;ZIQ' M44F+*6Z?>9$FN6U)E<=L^(MFZ9["XT6:Z?$"\GS2E"'&M^@C:U1;>^V]PU)O-L77T-ZO-?:>+4T= M'M0.ZX];]5\N \WCVF+-<[UOF[,N+51[?&[DXH B\]^*%L0 MX=Z=/# [)B"B/S+4P+-89&%D(CK\'.+'O(0CBR]\\0T-X6Q=NP:KA7 M.VP^VW&Z>UC;;3[/K[CX^W;[<=5PZ47MU_8:AQO5,H$>;-SH\B**B9VSPK$4 M^JAH#.4)A).CP,G;/&!!-D81Q7P%ZW+H#:' MZ3XKG..9-_RYPU8K'PM ;%*,6 ]5Z3A.R*-(_G,.[VMHEVM]YW.SWK"^)*CB M#V* \DW G(K5#9)X"%^['I[8K.GZA6O PKI7X6UPKSE&H['S6=8@6]DL1!:N MPFM@3T "4O]R<^?S16<)4;_D3H^=[G4 S-_[_]RQD SDV;9V/M<;^UA*KV1+ M\J"0!8U#P$!WS#R+/W [P10K^!I(*H]*!C1S<(!4%F+5!SRV?I+H*RB=>@K"Q0%YF %B'?S33\OON&7Y3I!2P MG1QUV-WY?+A_,$T;WC^#P&,K7^\:CR\O$S?:.Y_W]AO5@WI]QL.Z3&B-03C3 M!0(1NK$++Q0F$!YRQQHG892@+20.K"X7LFVC^:[W'LD+>G,Z=OQQ:U[C]E[C MN::!UD&M45]9R/'N07LEKZ)5';S&-B"/&R7)EP;&OLX^N"F'JQN+O($39@^M M(X]%T1*<[(G3S80VQS9@&Y M^WWHPC$FD@=-<>W7/-9O>$%Q.@03U^*M;? MZS50',TOVSK^MT2?5G6+ M%!$33LAI&SJ'7_/F\\8!4,%.][CS/]97+^B!UHCQUSQ^6JE>1CUJ%E34'>&+'<3B]!8_E1(S'FJ5DRA13]_AN_Q;193,RVT6W0FUCVD-O?K1'F.+@" MPS*^9S>RF'7//:_ZW0_N89F<10!,!WZ($E3?660YO._ZPC5]DX!4O%MO*US- MH#B@;6UA;-,SC7"_PX)^P_5TY7+.:#6:@ASN?/Z#1],$XQ61;4_E%RQWZO_\ M6[.]NYF@ND4+F'_^ET'^.QDQ^U8QV@]B^.;/Q$5Z"V2VC^%H(4441_/HKSB6 M1@N]9_FO*)0VIG.\0J",BEV,QS],8ED6]'I<#X,5SL"V'8!EBJA5#0#K\&6.U M+0=^!:4;AXY#;G-2P1M-BS(S(NL=O ^D+RM*0(^,A@'&#ZG0YWC(XNE=W+-H M]I;0PW(C[X'Z^X[UKIG9;0\$.1C4^P_L!1^B\? D+D6^C&HXTDIHI2R*K<.Z MY;!)M#+^(--61)( *@DQBY/T7C1*]E"RA\JM]0[/=/^3U6PU:UINN^U&+!^IKRZ/W*+F'FP/"\Y)W4E[!97L+R$CYV"4GU\& ?W&*VS3VL5 Y( MBUB*>H<_]UN0[?SJG!_@BC K&@$;AHE"Q1< B4=P#),:\%8N]!C*""*O-?HL MF["-!2N@GQN?U+ G!RR<7 ]$9BH' Y-$^ VL01C:K!0> 5$8!.%DCO&3!A&YL.6@U [:;.U\/I]/?+82 M5KP*6*RH3L.4"FGZKE>)@9U97-A:2/DVSV%: #(R%-?D86^'*%_.$_E^2.(@ M+X7U0VZ^*P1LH1]I*5M\E/+S#THKGRNUT$E^22)X410]66.CN;M M.IN\EP*0C)/Y:G9))I8B$^KTOM+A'8FS>YI<+%F3Y_D![]NW;_71++7 =H.1 M[DNZ*-'\#-*,C<(,^BKCP$HB3J-@GZ)JV)SR-4%(A:EA6LN'K05H M=KIS(Q*.?.;;+O-0J\3D5AR,U=$=%CJ1A=FLKK,H#*7UCKV?:VY:>]&8)S&X M.4\I* ;6/-LU(5V*TI2(P:%H.F1QS#$C&2$%0,,J ; T-B"'FT[ 8%$$3!V_ M4H#D_;YH>^3+=!U\TD7BY .6(!4( \\*@%!ED">U8E*"A$:1W?IN)BJ_R\(> M@]=6KQX\/B%GY;M&V_I6ZV(%V_WF'H;PO\>-I[N405 ]#TA0!D7[;C@2'HTQ MS,UP$& U1:$XM&*6.&XLUU5[;@+):GP'RQ/0,[L?=G#!0=A)P7;JL<&3123W MGJXB60RT[UM1ZM &@#XWWV,A0G!1C*5E?^)Z#V: 02D(2,4SB,>FQ[GOD MR(:O[" ,N!#2F2*)3.H!U1+^U\1?)M!^1: M!BKM32(WDNGZ:!6^X]4>0WZ-')W[D2#KZ "&GRA:1,^>161-YJ<3+<,HZTD. M0;JX0[S72Y R1/;>"<]T<[=>:]2/JPVX?%M%X1^ MY/',QIRSU-"H_4N$U\) M[YCU^@$A?+^:J+.\@]EP!BH-%7A62RL>!ZGCH,A4Z1:@S@8#P!M$K!'%QLOT MD\7TP!9I*Q&FK5AP:H1-Y"OO(Z^#-\UCB_#$KXG/!4:TZJ)8+\60L#%H"@\N MG#<'MO=W";A3BO> I[ ?,H$MB9R=*3@V=P"C;7C4BW[>J;9GH7I-PM^I%["I M J]^,JHZ :7GXN.@98/B#(_N:1 ?[GQN5_;VF[6V@K%:TF<+(.'AV@1=#02C M]S#\3 B-\&4$K\-L=7OIHY2OF9>OH$[/T@<'[_S[0:MVV$SSA&K%PKT.8C:UK-X09N/IE&CE46-L\O3.9%]=/B4?=6E5UPE,6FO M0'N60Y:Z+DQ=W_F\=U!I-]N5=GMO%E_$$G&_68C/Y'Q5K"!=PF)PRF-$_^8X M$(K[1V###'GTPC9@,O:BGC[">E'@)?'L(T_UH1+_'8:I96H (D;(V7<@ 2!T M?V3>/9M$:,HJ&Y:5##ZZLO?$+3']4%?Z\3B*WPG!S(QQI-#G7NK]1*6ZRMP?'7T[>+D\K:+)3RO M;JZO;CK8F.G+'];-R>G)SQ1O0@5]$:$H)A*$5,H4HS:)MA.L;6Z MSHQO^E7->FW_B8C.LE]D.DVJ\=-E>3K;%_6&LV5U,M#H3#=O/YB1][+RSLN9!]&A)D]30>$H^Y M!B[U=.VN])!ZS/X^" ,@KE6Y1-OF'.CZ2PLY;YQO"=:Z2>Y4G\.=0$U_#F/" M6E_7'2!R9[/LZ+$J4HN@]0(9[Y%Z;C.S].G_C,6)!0&':\2)>3.^&B<.=SZ? MQ7QD-6JO1(H27!L"EXIBWRZ\7B +E9"<@N3N A ^FU0:SC[?!L0.=Q6I[+R6 M5I;PVA"\;MSHNW7*[#@(7TLO7PFSDEZ^'IK-PU41S%)8V03(]A7!_%(*EP6! MUS<_Y*#(84!N-V;]/KD$YULP2VFS6*!M-TMQLT @:^UB7RM!/X]*@;,P$#N: M]'@HTX FIIJNCFZ7@LA&8[4FZN5L*FD6! MUP6\U.JR/H\GUK$;81)#$I92YQN [/.H9QF,MNU@M/JABD9;43A:&7%6C,NJ MS=KMDFT6!5ZR_ ,F1\Y)IY0-9$_^3-QX4H$1'N4R9C(CK0LLY1:*=$/1VF.W]T@!4))CM'DB"N5]*LD6!U\5L_6"T R6BZ@6*IYU,Z:O3"Y)8E9[$5(Y2QBT\\/=79A0H9:9-P*RIHND.2AFW*/!* MI=9N6JH="6TW&8\]^LS"";7\+F76PD-[?Z^460L$LU9+R:R'IGC-E[$Y!=(?TL9:%- *VM8K<. M7UW2H038I@!V18VYSGS12@;>4DJ>A8=IHU'6PBD6T-J*R5A7C>V'<#IL%&:*$;.:YLC4F=,*]#?H=M-\[\:"Q[9I92:K&QX/FT]K'4 M$L.O[MM(+6FU#W1JR6MS2Z8 ]O+2R7'QA );2 M5&PKSOUH%3:@4B_9/F!72#Y+86'CGVJ^.PBL% MV.T#^IGDM/1O;MN_N:\;N?ZK=&_^4+=5=VM]=>V\$F"; MC)P]#MN3(#_;ULG/[[>:D6\HNA0=FH]EZ[ 9^ MB%G/X^K[)0[]\T^]\,/4ZS*/R>6W]F!_XR"BXGH?0S+OW_%/]ZX3#]5I9I[J M!7$,1OP:B_D['N5 M]6'O'YEWSR81*M&958]Y MX-[R$$=MV';R^%J6Q_;]G<^WB,ODR(<)Y_CSK?;LZO+SLT?UN75[8EU<_*UVR&XP(L/&0P]2Z_)$-#S(8 M[& -CWCH1E;']Q/0PV_X. ACK-F12I4LY%CK_IZ%3M4+@N^8]I-Y%Q;\H+=P M:\29C[_"A%V1\?//OS7VZI^:^QVUB+2FO=6Q8_RV<=AJ52P666R$3DG'>H?C ML!YIL_XI/YR^;'QZ7Y%&=YK":C9.YKS]Y,&F,B69:7873I,=K":I6;=#'CVV M]0JLJ%$^I-K/L@="*8WA[BTQ_0/#W1ZTU\/@_'L M6!>)FS/SM,5FOB>P3G\9("5UF3?S0\@Q3V[F@8CS M[[-?#N>=4@SDAL?3W]Z[WLQD]_BX^@[A';E 95AHP;F%G,K\ HH%(<):?H6? MW-'80PQP=#'@R IUSI_>FC6B:I14UV<,6';'/'K-M@ MB), &@,V.*Z#X,31XE&83?X<68 %=NCVEB)/M/IY:^LG,:8J4A)B C/UPV D M,'G.,O!HU/0UH!T,#D#TXGB$\HG;G[MS]T $V7><%24W& XW%F\^4 !\ 38:"("%%2N$!B,3/1%6 5ON2TN&(C]8R7(C$2*$^5%%7$()6EBU5&P=; MXTJ$D'N?U$8VOX3\V31V!8=&Z<<%7'$D7B.D8 I%*L= )F,A:!%&(UR!+H'L MY$9#CJK=:,1#,F *0U^L_SCLW9Z=_B'BPU4B M(LW].S<,?+*'PX_W0Q>P-J#"!4 %!W3?!H1O0P;#>YS[Z2W"=R//Z'$A'A8D$<\,0IR!O^CQ M$L3K C'(:M; "WI *M@= X8LX07\YB+P)CTXMV14/3RTWDD^?A' )R69"C 3 M.0C9O85R4>@R61+J.Y\0+0E\)!"?2FZQSFN:E>2EO*$%^HH2*E!R![H\"(/[ M>)C1&91H(H0%&"%E!=@4((14Z:WITHK75V>7M]87-Q@/&0CRUE>!1F>^7=/8 M0F-292F=<8HV!#V*(CT][FCYC3C;]>5MLUYOBA)C]'?+:%K0+"0>M6H'<\@] M)J1%H+21U BBQ4 *BF3:$3+'@QN1;*D8-\C+=]P+QB0O((^0J1GP4(3C+GZK M[C5WZZ3\ K)%G(4@3\1!X$D]$M^,\KGGVMP'=J!Q#KX-@V0PE"((2+?$C4+< M4H2KE:\6N Z?^TE(=$FN:$J@@).RW)C6X<^(_49C6.$I51;#$ML&/:^?H(#' M*1^2HTI%Q&&:V@ F*=,!,*V0C7D"\BP0MSS!28?-(SM]UT?@DSXT#\TB2QJ0 M1,$80#-8%F!,),2;8"RKR@26 \L/!+;)BZ)>BJ5IA, K6].D:F?$/&T$0X-8 M&('R;%W^ND#LH;!/";T(J+221BJE";F3Q3YYZ)U(YH:X*:1 M^)XY'+'RJ=.BMCN+X*,N$H7,>$#SJT*C\% F1'A,I.'(!^I-8!K#PM'&8\7< M'OJ =H-2D%NK(,?[<-Q2^(Y!=T=4 LR;1YTK:*D 93 .PDG*<@F;-=!S]%+( M !+E%M@MT-JB)X.7>MKN0BOB8>C"?*@W**TU54\!/3D#RFZSB%=$V2:X?7*8 MDFYLS53@QDP$OXC9=TX6I1*U-D.UM367"(X-9"8D0,$1:WKJ",H':! R1TF( M-E%L^"Y.Z3>]Q''9P \B_*@P*QBC?2WQA0D=M43?)@J243E2K& A9T254;05 MB"4MI(BQVIQ6/*_)Z6*;'UE6X+(XBF,J/I"SZA&,HB@922?O M3*ADO QV6NS==D,[&<'+8*RL\8:O0QL1FKCHA=*Z7;,(?8&U(C+*_G!(/(1! M2>NLP.'(+AL/@XAV#.L<"\[;FXB-+-SQ')<'+L?GKL13_35@XQ!D9B""> ^0 MXUL^7)U!PK!S,Y=F:(!7*+:&9E^IS?&0_"7P-4V'"Z?6S2&';81":9/"RR.P M>9:_#8_)#TATH*4&-N!8S?H=SH2:QAAF^)\RH@?>F@O+CHQ '^#D?L3Z)EL 4D2?8=NRR@^3928J[# MA$PO]#;0N=R(WEM3)XL83]*VO,CDC;,$D0EFKRZ*WNKF@M( \LF RYL+!T-$ M!_X5XJV8#3%X'$21BZ$%*'@D488^@"SKR;6."+6U4 $/9O1>>B2!CS9L+QG3 MMMACIU>!+7.Z_TK;1<($,PF?E'9^:GM-1CJC0R$2?.^B.,0?;#XF=14WW4-# M#;%=HDT>NU\:\[84XM#]=G&!\0U7I]9%Y_;DYJQS;MV<=7_K6IUN]^KH#+X[ MMGX_N_W%NOIV8WWYUCV[/.DN%>0P+;YM]39=95@J8M[CQ"IC?B,>1]B/\&7. M'6J&>(T T>UXBE6':9/30# M;E)#* +U&HA=/_#<0(0F:>_:M90L7Z1ZM'=+U>.9JHN\ M)\:3\6103&((-)R/7-%0. Y&P0!TD.$DM1R=:$/U?',,BA1Z\,5II$=/^;;T MFO![SF.MTS@&\.YDYAN4#4_0Y MD4HBK"C/LC^58L)JQ004!TA4()D #=WCD"!%^F4_%XD"\CIZ>$:(;O8PL-%2 MAF+"*'H\,DH(S<+TPFQA<]2(2S&M<"_TPV@3R6N$&, J7Y.QRH/2YX'0?X>; M2K$_$O*#OIAZ_5,7$UX=L@AS>6"I0TQN3F\:83D0DA4&]$BSTRCQ]!W5*R/% M1FJL9*\*@2Z$)%^C*0P6M6084'F!UGF!TEI<9+;3&E^JN*:H,H&[@OX=-$ B M$Z&HH(HR\B!VVQC]CD9.F LM+8C@2+C1%:.QDSD4'VK=6LB6@&5 MCRR,R1,UP@0P[ ^E\RG&040I(?Z4,34E>PN>R)#1/!ZH$(9L^,U,SD<:WX R M*75+1 MD6X36A$FHW'X!UY+[IB,JE%U;DQ$]#1TA?EO+G2CI6I\E WPOE2HON&4DYD;%'(2=E%O$S5$2!;GL@/!6A% MF)SF3:4Y1;8KJ84F'YE- =AUAJ&M[BP;>1S<:EGKDY"/:]A(1S M88K&7@LB!(3;+GK=JB/V7=J,46P0#&@VST2%>$YELF,XA3)*J2!0(?!%(/*G MT1TD%*7!4L3!9)%RS$B*&=+] &/;?%64'!_C(M,V*^_EC5 BN5<9YV3LX822 M?L7*U#9UD(84^3Q2M&E@AH5KB?9Z^YD8Q>3QWU)+DI'R2QG2DD:>V=1,N80,42TB39&+A(=B*O/[$[GUJ":*2"47 M_K_8%2H#QI4)%P/:";.O6ARX/?E$/C)RGF$&&-+\2CY]5.K0?5>X<:7B*FA_ MRMC%ZT#/AQ>>SAPKAI)BZ$9IMF#CLIEB-0N=G;.^3@4*\H!\?6_I_,2E M4E](=+29R'B98@\@:HC'T6Q!+Z (=N&3$9!*4;N4239/>AXA-:TE2(WTT8&0 M@^ 6)B#;8^X(C>@=YPZQT<&2_-Q#U1&0K9--@/G6[:Q= M\I]>3-I:>>\!MQH']:H#\@J(86Y WG5EQDK+M&2]FU*S(Z.>NN+"FRG7V7?# M*%891;XJC$1%E' U+E912I-'?V&Q/:S^SAX P[".TJ=Y41-KHRXM25V.MT5= M6B5UV2QUT:G'>2(RS;N+FTX]AS"\(KTZ5P: Z(LH03 _'7$@?U_955U\.\H8 MR^EKV"QC+,L8RPW$6)9\YR5\Y_\V#D[_G]7WDG#LAJ[#_M)R7>:[M J")O4@ MV:I,73*M?#VQ?DD=J.]*_>K#IX$X:E9;^QG:?G,P&FIAYCB0H$R936K M%O#_WB(WQU6@P3BA.M:0%FXHYE+5&,4>?[CH> M70]^(_?ZG&!BI1Z)@(2,@C1M7&C6]IKM?Z#40ET'4(CI42"S:%!61(RS9H%VZNT2C ]0;V=P-(T*.9RY?YBNQ'5Q?7 MGYCLM"'C'63)]R'J:#LH-"W^]O0\6_P:*)I\#JNLP M& MMF=/1ZY%Q/^C\$'%7<0!Y1X#/DE"5!J>G0, M9OQ6D3I!-)L+ 01V M9+=5ZYY##9?L@=+:*0H)O;WI')]<=&Y^*Q[I_)V8&09RR,RIK,7T#LA'@+D1 M(<-$[Q!+/$2B&S.IK]+EB;]:/AOQ?-,&!AQQ(.BOU"KZ@"[!/?SX42<5KH7= M[^&!+L'O9PRB")YJBYZ>ZO^$9:F$5/[/OS7V=[5Q/O\X9XMU/5Y0RNH&'M:!H2J.J/#XK@BVR,:OI 1'V#]R-&>) MNDVJVP,2G=N+BM6]D"P=3\N*)J->X%$1&1$IKAFAJ@PCFIFH/5&O#2Y:"?@3 MZYY-TFJ.V!>$'D'K21A7TA)QGH=&$0IKC]%M/'+C6/MTI=\7-3V/W8MP]I3N MXJ?'CJ!FG2"?UT,J&1HLDB/2P]S!I'O!]:F0'!Q%[O6E/VKY^]-:2;^XO;)?7.G$>I43*RWB9T#_N.O.S:UU M]F+-X? )S6%O:XH#5F(4;=L:-9V:\])]-IO&[O/J#ED0OR^B/L1D[0=5=F). MU&BU']A))-H2D1G(,_M\RI5=J44-YOD&TIQ\^EJBU 8EPDW#PJB ME1E)%.O9<2:"X>2KK1['ZJ@ZT%4&\T6B>*D'\H)V\*E*=];)I\WJ6. MFA75DS,%N(?<&^>2G<.@+_JJ81JK\N;^P*CG, &,W.*6JPD+.*IEMPKF(\5GA#M!&! MQFH]E!J$I:!5S!/E?HOJ+STW(-IYF BG3<2$JH^<0 8V2C@'F&HNC[&\7 2B2M9L?S$!@0(Y_\H2W:+]Q!A MT)^BP!?U]X2Y0QL%(]6M)@G59^S\^%T*WXRL+%SDZ^LHN0CN.AI0*[184DZ<#MC'DL0X)15GH1Q?K%\KT@@D M?BM=+D,+HDD48WG;XF'L[RJ'7F6541Q(CG!/;?N;3^$K6.P+"S9FG("Y7Y3= M5L8"J"&U;BV-F(FX)VF)"Q/#YB@E-8C(J4QW0U6DB+,8%',1QIG6C91&Y R5 M=R4OPBGRVT&G*>*FCHA69(NR.WJNKX/7I??"P=07MR<*K,\* M;C%-%]8\5-\4E"R*]C,8*!%@$7EIW_ "FUR9<$)?N .$ ?CE!3 SN+<)DAW- ML=*4'O4X/'(9A/#;%]?SZ&2F'OV4#3J!C?R*?T^L=U-)@L(QSFP%]6<&M#P6 MOD(Y/YF^.FD[W;2>&47>#YG75T7RWG^R+C"QD6/(5@;7SA,4)KKW'."YK(=] M6QVW3ZZLKHBFP4.]]MC2=7O,P5G?^I7Y"7J0FJV*+%]XCS#T@X1R2Y!Y5; @ MB(3N!46'-]38+R%P:?SRNQMA%?)L\-+1D+FAPJ0O 4@$5-"-Z U6T%'2)/V4 MB3!$^Y[(F1/A-\#<^M:)OEE7=#5"00TO<.D='V2&7[CK!],+6/ D31'R&.L" MX%OD;.2 GEET#6@743]9WB; MD;)Z@0,:V3>=89(NB_8EPGRI![ ,TQ1E:T3.%[HT5+#GO*#'ZUZST:S^Z^*V M"G+98?V@^:EZ>7*+VTME_IC"?"E@0 4\PFW))LPHKIANCIHO@* #MR.P0U() MDU$02O$LMU0[J*H02U4]@&-)D:J8>($.+MJA9^OBRO.3"3OS-OMXB";M I-H M!@.LA85U2\?],*!\H(G:U-^;!Q;@K"<%0.P$0,(E"*F!@(PCVE< *4$[23+& MCXW#VN$_*/Q@SJJRH7L1H!-7I8!TY):H!4AOHC#M!Q=;Z0!D_]YJJ=54LA4/ MYDU#M86X$FU8IJ0+B:Y5(;KV1?D=51Q+RD*D>4G82(_*C&A4 W*HA;-*7MC1 MYZ)Z6!$>"\%(MHY1@F9=D^-J\*[8@8AA6-D_&JTF[!QWNE'@W/V89E>F4 MPS05!:'>:#J4I#(=2:, [ECMO4IKMUEIM=L9:"X 2 IA;*N48@T6**-#^'N] MUMI'+YUXEU#,X=<[JB+FP:F(%+,45J)C41S$1(U\U&\R[JU_=V%:)_?OFYBHUM.<.PTXM*M N5+?@C9=6Y:SJQ%+\?03W$ADO\655$J0*]\]%=A;/\&6E MR8R.;JZ/=("X7CVM, )\BNDQRES"%*0@?;+;O;U)6X'(I1*L?9C99F'HHE3O M8(0$>N%C-QE5&_O[F6K)(B%*5S 101VP*67VD[B#,U6%5_^.SY=DBFA\R5ZU M?;IJH$&=>"Z0%55P_TA%8N1O7TYXH$P8Y.1"J2,*C]@I>$_V%]D33-0KEG$K MHK(H&5%$XP!)^>?D).7#VR,^!\6551%-U[)ZHRQ))3B5C67G!,O/5&&<,Y=* ME,A7ADHIR3-9Q#P_=QEP\@AR[I8)T&7LR,H3H)>[C6;FX.U\EMR[<#+=[T@U M909 IMI515!2Y JBSCTRG>FB@OU$J,+4K3A;P\RFZEFB5'6FA.CI<2>3V)R* M8;*2/KW*RQ0JH^[9@9\6_F Q0ZL$\R:1&V4Z\N8:1^+7]WQN%<1QB,6>7=D! M7 1%\N\+"FU0RLP]>J)8I!B5VJW>N>?-:52YH(A;/U5OL>NOFJOEFN/V*,)E&B "W#Q5-E7%="R8TC*5E5!Q0-"OI*&%.HF/:=Z($IP MH&9SU:W"A=VC7S1,!E$J1.,98&)&QF$FB@[UG5*$CNSU,DE@KU9_^DD\!D7V9-%98 HC-)B3UAK%LGD9 A;=^*@)-P__ M(:)+5-R ,&1%% 2_Z"!0L7%@YJ'U;LC^0G<4T=0TO"Q5A>NU_<8G:_QSO5:O M'QP >#J"5E";9JE=*08GPXS[>V36 M@]7& 5P_U9$.SY&L"]955S6:#C'UCSOO*[K:_2\W9'ELU!H-,IT+Y5#TQY43 MS"R-2H12(93F+N)8$"J??1KC TQ+]1PE(]&CY?@RU?@*2(H4'4CO%MFS^NP. M&"^R>$DR5%U00MT!Y6+ K@_J[4^ME!Q416=O)/2B&[("G6[H=](Y22,9\2H> M"=OM+6:/2.?)4>@B6C&Z.QWYHI,[X:92?('>)#"!_M0AC=1J/)+-Y&34C8T> M:J(9L04DC(>B'XRZ/]H"ADZ<(=/WBFXH?OFN5:\U_E&Q&OOT#T[:0#<,+@W6 MTMJ##T#%6_K7O5KS'_G$U?=%C.-"VAP @:R"',;1?9$:$N7!_BP9;N)DF0F A8XW6_>$NR0M@S9(88U8HYO+="7NN0,M<0(5 M& 6Q2C@F1T;S8T,O3 "=2-P3].M@MR;)C][$," J$E)(<[IBY,0J8'F69I,[ M!S0)> 70:SL,Q!;O1*H7LD1\7@M1DMTAZ4+Q)B%[%J/'9H/ATN@N%>VEJ)\< M]AN<,^R[9IT@Y*A^IRWMJG(BO3NTJ J^)Z.8\+D,+LFY"$BEHU+N"A M(N-?/!0$\9;V\36^>M]RH41FX?JQT%VT*(960(&G'-@Q2 S14&A7ULD#+,^1 M=6 !9)@('C)@W(K*G72NT_":G/@,OT3*A(P*(/EZL^F%3'A7F0@!EPTOQV(" M>%*%P+(,LU*"5D[2H,NH:"7\0!'[&"F/!7&G M%4754FMB,<6ZY_AP&1 U6= MFUH9D?$^-=S+F$=BD?GJW5EN3&D!6%$_$YJF(F/E58)CR;FA' &+=/R?">"> MZ!^"?-N ^B,O,K\4SZ4VW_S2RIA?ILT!P&I34\DR%A'0XA#O4-3OY]LUY(O, MR>JYU"95LVYA,='!M9F'17%E$:_[:EN+(H'*,**C;59NA$D+ J_!'M/:D#V& M,G)>9)%I/6*1*: E0D@:S061Y!1^6_0(PA^Y]+="'^ P+EO'0<@!R K> >? MSI.J/*CW)%'U\.!%@45IQ)1%Q2EKF6P\-2L;=;J7607Q\"A)H7U,T>: '4>P MHM17J[_&<%+NL7N\3QLOH"[YVTP]]ZG"ZIFJ1MK%+Y0O@0\H@,IP%H:)5>G:\&:3Q8!N:EI1 MFL0'T>U&RL+35=]<$]\@&%'%P5)6 M<98MQ4FT)LO",+3"DUF:]A#PC_NR^Q,\[#H(*6RRA+S:YJKL'U5;2,N>(_IS M1RT2^0^5B8A2.[-HRYF6$K><@$>R"(6XQXM?B.6_Z*:@L5EQB@RJJX2@W#$2 MSU?7ZY&+,<>GKXKQJX.S90@A0D^6^)D&NA+*A:TO*YDO[JB0O0N*RHH;I\-^ M XD_&G=DDN7B_: M%9! ,@"@V(,!M=O*"C3*7J]#F90CP,WXPD1&+IO(9:'X MGQ6$2\D+6]OKDM9 M)2O)S E';;6FZWSB%8JR%1)E*:]YK6B"1[K(9/K0S!@2(XZFQZJ*J<$R7" + M" \#K.GZY-9R1055F$U+K<(9&%FWL$I0E@:>\-YTO+_@$&!FK:I)(WTVRPEX MURA2]R"-]5=;H5,:,]>1@:2!_5V0DBB##CE315=FF'D+.O!W)2L08( 8/I)NG2#/0=:HJW#@]C6O,WY/Z?PXK-=;- MP4TZ"U416.N,(S*CZ8?GPI3.FH"J? 9IZJPXS'GMJF19/:W*A-H>2 ZT3 1( M/H]"1/2GF4,OKO?4-KLI0 M#H+9'>T)H)N,],)4K)9-)4@P^$^=SG57AT3!UH"](/^; 1N!2+493(W45.(5 MSO0(3S6M8@!2"\<^O3&;R_YQ4MDR1W[B9G M:&U):C=#:E6Q=4DT71]=Q&1'2CP0ZR)0(!V+^T.9SR^(I2!2/(1K'0/!J&:L MOYX[!G5JY&)($U:+PR@F($CT12_I86&VBBYL0407W=#V,!!E["2MY0]L)/SW M09^J9M\'2-=&B:R"1>Y(N7),M2=#A$HPE[U10MX'59:+L$:0LJG/W+M>* )X MU-/O160"O$&&YB#&158O0-(H'Z(( = >A/:#:DN )1]&8WQY(I-PM2L@4P$S MK]?!)C$A'^GS@*)Q0@LD#N58H7(WF3WBN?3" ,O?S%;.F]V'=7,K(ZHE'U+Q M^[23W-EEV9.8DU2>F7#P*.EA?8T1S)L#T$B4\1YCA3%A?T>,LM#/%+HV3(-A M>HS<_60N"E39/ID3@(BI(Q[F/DY9LC@=3-T+0@=5V-]G/*RR]I"GUB""0-/, M:PD1LKDM1N;< 4PC8MEY:EUTA_K*\'-,!J%L$O&9G-TZ8MBN'AZ.M#0AS4;D M,F,9UQM95Z-(.MYT@4M&@<2>+I,Y5T?'J^.AT&,H M Q*)H%+T%*@;HUDDJ09B3UY;#-KI>4'@6'VLPCL$Q*$H(/C._BX\ J+^J$-= M]="1'(?!=[Y<_%2)22_ I']SK!K1:+4TE.F;M.]NM*#(UX!%6@YR@25YTON2 M1"H<.$)O_3CQ1B ]8%1CXJ=UE$@O)LZ* @KHB+R'&4PIJ=#CG4>19DU(HP8>$.J'RTBPX6E@5\X*Y3<.\6EU1'HW>NGWI)] M8-DB]09O^44F@V7WG:GL4EH3MD&G;D[.S[JW5S?6NQ&/AQ,/U-XXY ^H7H,N M.P(A1W+$-)6$ BW&;N Z>*XDNV#%N1C+&F=S+:_.CE+1"?DF7)&0FA"HE"SY M# ;-H_HGBKB279;>"L12S(,>7]EE0&K$(C RPNS1\=#UE<^+.K4R:PO#.C[T/J%JMCK8$9=>9A^S;C*11Y@,L"PV&8F M:"$*/"=?HP\_Z!,%'5%X@*7S&%4Y94#&%,^9:(6T^!_/O)A/1/C"FZ-0MW@3P6 MHS')ZB;5TJ,3$3_NR)#(H!]3XA(,38W&I.Y@R5A?ZR1P1Q3]M@)*EH._=+#- M\=5-1P0!543M:94=SYU*)C6^@BP2#JPED^:QP WH1S%[X)XJ&Y!^08D(:9<0 MD03"'*PYV6RVK'#B%@R)3>5*B+X% RA83U M)&@K28NDIIR8=D&I463/4H%K"IY")@BLTV^_GIV>G5]8M\#[1\PZ&O(1K?0H MJ%GG,8!;X;<:J7%\RLG\Y>KRY++SKS/1-+4T7*R+$K'KFZN+L^Y)IGAJ>@-S MD:-T%W4\1>'4%E9?=F5: PE MY$(10TCU\@.5Q&M1(76T@."J_L3(/2QI11&19-M0D9T8R$'A(DZ#H+8S/*QEYE'<#SC.V99E_"UID&:[V5 M *WK;B<-N%)'@V)2A 2FI[)* MI=1=3OB[GK:SJ)-6MD^9XT23I*PCX3702H MM!;52#JLR\)=HDH;]7E+1;GIL[&!5,^N28?: >W,>\)T^S@I&&'T!LF/V=Y^ MM#;\-J0&02(G0??W$UW LN)K 7.-.S;0(P4TRBB2%7:P*A >K)38*C,G+B^$ M2+<0>>ZR3X(:D);K(3RKDA",\0]D<\G]IM*]Y152[L^9.7UI%,-R,S&= ]EX ML!!2JZ8;C.3?31W;W#LW8ZG*O30.'#;)I.UC-LE(W"&,\,^V'(F []@4]3-@ MH4Z@ M:+CE6!P'.6C(O(R1GWV8:4.L1$M3%,\WN):DCVGW>CY.-K7H+$^WMZ64% MQ/0L)<\Y*E&H ,2C,G 5$3BJNR(&(:DD($9*=9 H]\4IG";W(U']!/#_#K3* MU SHN:*P'3U8LSJ4?RSJO8^PKAU-:$]L+XA#_!O[J< [9\"!\:)E32*5"4J6TQW6* M_?FB%4\\T<7)L*NEU)^R^A0E1N:"88 \()<257'DO85CQB1 'BGE+HWXQ207 MK1.+%'%I88:;RFV&H514R ,.;JH:37;-#MIGG4RQ$M&JE?IR4%T?/O4PL&,N M2X10O0,QR)ND6F^V\$E'Q BJ4JNM1L;$C-53*-B&&&=[=\Y*<;(T8A5^EDA6 MP?XO1'Q:^YEWB.%L[IQ- MQ4BQD:K])S!ER7[D2[J!,/L5-07(7-5)T YXH M \?C#VXO;0TI.E2(#E@"\C)B)*#NF#+Y*;/VFG4E*F+*0T!]1K2S=42DH>7K MDE_9WJ,9(5%B>Q+%U"4)#VAW'P>TZU2D@LM""=FR,4>!E\!=$97FKA.X*8%U MX]I! 0E5IC<5A4#"06>(3\:!*>C0O08(. M@8>NJ1L%L!ES9$G1HG2,V1O$&(%L)P M*0.RQ0?7L;HJLU%G\%RD:U<5T&^O;ZGJ9EI?3O6-1E*L+)PR_CJ'@Y6TAWV, M%U:24+V6.,W#I%MIAX0E5+YQHEW@4A4B$2[3>T:H29IM2BU(+J.6775V2<@@ ML]URX&_LEQ?X,\QI^7J*YN J8,>OB3>1_!R F2DS%$2B&AY<27\@9"F7JI\. M=/B[C:*SR M.CS]C()@7W2OKZ\AH$JAAXO$1^ZYN :Y8U-.6JX3C MXF@]M2:U:'WK MCHFJIVHM0,]XZ#/AQ:&;(_0G=1\U:$+NCGH):!G91F5HJ@6B!Z?4DTU44<&S M)U0?A,I]. !GJOLE0!>I@E>X2MV/&XD!'AI12$_TJQ+Z*=I=0/:F)67+1F5R3O)0G5?W2D)V=P%DV_,A6T"Z(8+, ME 5T,&,!%:8.T18 L0G%NTR(CTK"D2W.4FD/M3H7TY3(-A"G&IM0%(3\H(-P M5/5!H=?+!)D1*(^D0.I'6=ZH.=_6( I@XRWEL3 BBM=23\]4-DJ[94K2HI\0 MP<'"D.=B(LU]8'V%':'[<>] ,\RO##XIEBDC96A%>FK6Q"*U?2H?B M='7AS[1N@WY>VJ@!Q)SQXY: M.G%9*&F1:%#3VL<$'EUD/^>@P)6(FY3/@J4#(3T[(P!J-%+GA!8-BCP A04@ MQ'1E9?('RACDG$&J>&C2Y9PR!:RSBG6&=HM&IZ8J>-U@QZ13P*) 5^Z2'MDT MDB%U(BG#/O99BK(=YO.*.9DV:4(UX[Z>\(+Y;*#+F9,<=NQ&<',C%>[=447R M =*GH"_X9$,\4FT::,R-[*$$0Z[&7+6HKHIZU["Z-)OZFDK.1M:)R ^?MH#3 MVZ@$>U6E3>3.H9^$\729?C)WQJ)#5IZF"CN;/@>A U,RJZI#O/T@B4T7XS ^ MY$/7#"AV6D56/7JD5L4,U<]6ZBE([8-+9<91QI),"Q>T>ZM4&'JC\@-B MBVT9:38[%9HC1(%N$<,Q3D9CHG=R\=DD/>%X)"DB/7]5$4LGKC/E;$3!+OU& MI))H__9T'0]1O#RG2[,[!FP)A2'7_T2!"60I>;RNARKBH0I=BEA2F2L(["Q3 M)D.,P9*M/:J^1T&FLT4]"LCV$R3T0*BNP''BOAR$7<)3";U01 M-24EO&39$6;]ZZQS?G'V;PS+5G_>G)X=5Z:"+2-+>87SOFV\5FEYEA['4K&X MI"'FQ',_0)D8[M"?"6 AG,/W"8I 6 DBK3Y#44^^*F.[;*T9Y=+/[$=*>B$@ MA)_+M*JD2"'NL\NCIV^TO,[1*^XS%<1Q050-*33'8Q-YX82E3^8Q^2JQ+7\C M\Y<8/>XD5]ZY49+K)#,[5I6VR41OD^7I.Q>A78+A8^D R?L7/S0= 10*%NEY#ND-0_QZ%IID=9I'I$Z<'+%=OQ,[QO*L)"N ]DE M(.WIT$] ,44SJ^Q9&:54$1MS IZ,M E9]>"!K1*&MD1TWLR29%A=AK,)]D!] MC,AYKU>KZPUYV(Z1R*%P"\OS$Q/GSV0/C^1PX8FHOB&HPI%HLY:% M1V5!_$DKMQH9DG< 2!(-47_,:)=6Q ?: ?)8Q:1Y);NR96[T?+E8_S$Y]DF\ M0CE F(%.CSO5M!+@XCESW;9F)E&S]2DR9>8\"SBAP4(ARKKQ$&UB"ZX8IFDH"WE(7K!U0F M!E8;Z2IC3BJ]"I*MS5'80UBV I3=7(%_@E+K4_%YH=4*UZD,EU!^BIJUK!)= M_?;(YE',$B%AN9QLL57AC/-<]%E-F=TBA+0Z^9K43XM'('[G.M.TJ8Z=Y MQ(R50\",(/M2LU8JF2E!.7(?YEFU,+<\<*I!OTJM*)7I*E=N+V^U:LNJ,'/,_N?BO51QBKB,[(1[)P5TKO)/:V,9HLV2^>E]BO"G)>SXR&I>M26 M-V^;;:$S+9Y!%Z9@NGV2GZ5>6:G;>A=Q$DJ"^_>5^<;"3RDHM4,_<[BYM\GY MLJT,18C8?[!.(_D/%["]!C62 "*3,W$1T][XY 0%"DFI5RHDC8I,TWC M)N2=]U%"1!L#7GE4S4@6@#\%]9;$^HRRY8"B)*)<.4B;0&3)&-GX!"2>$%*9 M G-"@CI#K450[3O!6@>S^G"VAJA_"*9FS:MT6:,!NK:($W+7B%QN3,Z)L60 MD'B TCQ9Y440MB<8:^[^S5D#A;E4^Q34@@$FLAB<*N.9R8]1'GE\4UH.)1 A M[QC'(J-$A2])+S!C]!.+%RMA@TQ>)NOWW0?A:,.EW9$S"].;*[FL&WVP-$#& M;*,<- Y=&8^MCUO(>O!0[@ RZQ*'7D!TN\W'Z.M#662J(GO#T$5SDS"6I,R( M2L>0>OIK @(0]HGX!3 ':4C8C;%GD +ZK[^D<8M4L@W-+80F&)J(.0VNK)1* MU7!"V5U<91]0 !9&! 2(=GF&"W_)R'(ABHD>X5] $1%=PFTV&LL@0Y!=QBH% MH SK6!IC#LJPCC*LX\V$=:3)"#-UJ[,.)N")E:PR6I'*L[)$WV6KO5&WXK0Y M4E-%>=]SU9'(H3RA;$-*I%5$^51,M0_[HP:I&?E6$]#H\EAW)ZA@V9,AD.._ MI+<^[3PYU4#[\1W&,@WD7M/07*UJF5V!C;!&TLLNRA;+Y#40ZJAMG0.H!ZHS MG)"T,#LS"3^JM*L=1$)19#D]GTQ(P(1MGHL(Y/Z=&P;^:-EZPF;QV4UY\G,Z M]MOVY"_PX6OYL' N[K2H=N'\V=-5T#$E27FXT$8NLFZP88 N?HZA953%M:+R M.%7=<)$GIIH%HTUGB*0)M,9^%;.R*X_50I?9GSJ$7I4QS\?EU>3!,^H&0.6M3I^D6+JBF (/T:C((QL$\&]V1Q:$E_ $R>&F-/X!(XI -AU@(E>:C3 M##/**&7RN2-ITT K]M =CV5"'AQ#%H,G:7)>FH&LNNL-L6:5Q"U9RTL6W8<5 MJHLTI3!A4X!-&A<][)R4)U^7<3.I$-*6LSFG.%X3@IHC=/G4FO M?YH^SRP[SQRJ^HNI MU(X(F&7[(K1-UP&?&'=;A*>FY\N F_2@SO?>99^B%,G/I%/G5"FRW5&W'RK+V=GWWKH? M0!*4$), &R DLW_]66.^UEP@*,M.'(N)3M7N$XLDL+ PUWR..68L>_/6HNYC M/58)W\QQ""FF^8BZF$%M*?0XO'?LNO!?1MDJ_XKMH0+0(M!T-.&T1*:M!)$#R]_C-MR_/LGL_G1W=)SKK[%[8A$OXP6'!?W_N.N/OQPS\2Y>,#3OX4]AV M=+OI0RA3O?W@I],X,H%2!-1X(KO2]RG,[R#707R+33*"312(/\7$^L3 M2?GT,GR% ,4,F\;ZO.CXP$0XA*SQ:C_[>XE:+.V:NR'FF(3X[TIIBJ@I.RQL MM9FB8<<2B(26RZG]^X&<<^%,ZH";E<#[C 0G>8_YHNZ8WI.ZL&./U@PO"/_D M6E>QRFF^A*NM+K6V.K1TXTA*R"V2T]H.M.+TT1T:GX=74( N>8+5@F$3>L-H MJ%!YKG E5SITS,=4R0:?&+<1R3P][1_:A*5D$/3[D2J^(M)7^)3;/XBX;II8\+%P"G2\?FZ%C M=RY&_QE7R4+J6BFEF[T3#NK8XPS1PKQCO: ;(&MGCQ+&>\)(N:J^9#9KC0/& M94V.7Y.U>I&1S<1Y]<^])P\>'8PL!Q'?%=V-B3O37>'A+Z6\ 6/@$K(S7O:S M\IS\I>O7/06C;;VTR0*.,1Q_>WQX<._]_6'N__ N^ X)THVP,@"ILM +4#\7 MBM T,OJ>]GUSH?%01)MJ#5&@L@]F57C/N9X46_2W[ M[@[J<0?U^.W'X-P:U^((".[$NQ \>W#EI>(1#=K2N54CIE/M&RQ*)&^:1U&I MGS>M[V%_Q_:^^X//YMBJUS\^K>,Q"].I$F0SP?C7FR7RE_]C\&1R8\TY_(BW MX;P%=LS4!4GI]OI,X)\Y'OEI/PK]JB+VW9-'#V[-^)?'^X^>8"]Z5(V4^\ON M$1*?/7P_IN5:3V]9SN9=<+IHRH!0<5?9\PXI%R1@J[JK)L746/4,,<8I3;JL MX+TXK"4HZ\9%1_U!0<%W.X;W-HJE-+XI>/C#&GGL=R^K"<\H\N\+S*,B MJI1L2OKFY/4[26=10C9\9^16]'L">M;7L4*I"5@>]8M.]8OOVLDX]:&N(X4E-:4CH_? M'3N\* [U H!\.G["(VWW-#R2IUAE?10!^$/FQW[)U?:RXGZPF6;[C;?+Q=W" M/X0%9EP9PL_.Z>50*^6685GZ:$=N>G>(U&CL%;UPOJ1U'M>2.5#^$M+1-E?U M,CS3U*KM51T^#3'N'K>+3&->X3,GP]\N'^Z[IP=?W,#^*A].3.YBT57U7C]L M_RI.W!Z5)Q/SMU6@:6[/QO1>$O/7>56_RL><;^;8X"6:AL-%59[E*^EAI2ZD M^3HL:D["..@WKGV*KR_DD.H@?UI *H>S@%P0D\.\--HH0D&%31FQM:.K9J]? M[8$?()?30MG) EJ'\!]GI\^/^QROK S]JH@*$8/HLM-G>R\/E?9?JC/IV*63 M05V9[OW(=AA>D[7KSPMN'V(_XD%/NP+/^,^P2G,6CM'N=EYD+^O@@0AR:,M/ MK]"]5"5^"P;@S8N]L*WR'2 ]ZVJO75#_/!J&YQU@W+++AC5XYUB,BFJZK$N( MC=#G]N;U#>R6_G35+>JF/\I*1W^-U_S>Q(DJA-@)!XUZNFR6R[X4#=SP4*8/ M*1?,,L33!'DT*K'2[,6>[3U: P%]PK] E%,(C]/&PG5!*2M""^HWOOCCO^L)*"B//1H%UEW3)L#3$GZ)2%&A-PVCO- M__MI_M.\NBUJG[3.AKOR%O^- ZMA1)N]?'D<$37XV-P2#\%Y'<*V//DA>XKW MK4SCHL>7K]_]N'?X\,G#LZAF)_5R&0[8DT>9(OXVN+2#EJ9 AU"3Y;BIQT3/ MZ9I5=6!>/@_J?[/)9V/&H!6EA.A".,DP:"?2Q2JX,;;Y"!]=4B4BQYS@[[-Y MOE@PYD-XF<+I?2MJ>\2N\?#&CSAIU]?KAQF/*88)BUO7HZ$O-.=2OR]AKO " M@D%-Q@11BU(.O#9U]M9MD*D5022"#QE4BN 7U]EE'33YJE#XDI+7RPB:(J[L MFP>Y+,['EFDO(*1&7C;HP$\HL0IT^"U.Q>7;F?Z-@H,A,_XJI$ M#H([%MQC6ZRAQ43TS:4%Q?WL#*-XI/[L?]PK/.+8FS\39V-0#;=H_Y;=*^]G MQ\'X7N(8)[%HQ '*Q]%M#,+%86?OYFV:OAB(0/VUR!^JF?_-40/)A&)'"CF> MU^#]PE!B'/D)CQ<)-GA%L,7+HJR,[*%8%]^'A\)3Y0WIPNSLZ,QC&NF/\5D4 M!B;M$!M/-#1Z_*RNZN-YW4UE0F@$.BUP3IF;3YZCK!*O5&\7IX #?EKHS('S M>'1.:\Z)KZFFA <1EX;@[L0V7][,C^,T718A$ M!*;Z6F:*6;#^XVLSBS?:B-Y+E=_3 \>'V@O.,1.5P,^^+.%Y8IDV+="#M_3) M>QN:Q]$[R9Y\*)#B"!YA>-6P"_?"8T*T2$)[A]#^[M]V_8F/R/D?]W#\+D?Q MV4;R<)*I-$W$P$-9^R[VZ 2%K*0TAP_B]+88S-JG5=L/<6(]=H/?K;:$# M59_57=CUO>/PM9@^\G\TT4SHEL)+HBN-LA\QC>B?M>3U7^63O-M/KWK!Q/Y3 MYJN0/H-Q@:XM&(J"SLRL;,3OZ6?YX!P0=)%$C[DV)R,,EA7.SO?EM"HBN9O0 M_S+,Q1_8L!0.-WO.#CLA%$N_#EJ;\$S6FNY+#\5&;_K) F"1[!DZTE]J=L-U MIINF>JVC%\52Z0SU-CM*@?:6\7AU>I1LO5/U_BULY35.1BEL,.$)>_&8Z46% MD&8+X_$097'R@DM0H;3+6@"T6"UST#/:M/A7QU[RE'CP:$"7DOK:**>!FM"& ML$FN)*=.T#E3^5 99W,]ZE$+-)>F+D"A 8WY;ZV2^-PN!<4<4O-(YDWYBG(E MF6>=+A$'0'9)LVU0%A\3$'ZS-<4$J=@ZTIU/]86'T >[X$ S%&WG7&99-XE= M)0T"Y;D>>!.R%N!ZJD+N#46I7HW'T-(XE^,$]'=Y9[&J3B&#I:-D9O!&$-T& MT:2L5XZLF[F8X<# X8RE-]$:0.E7&4U'"'(KM#D?WF*+*O),T18IR0'7]W()RH&TX=[-Y6'9- M$3P _6WDA.".!5(AK!V=6@KOC+ AEN,6O\F^4HG-'2HH&](W;%-0Y+5T<:'C M7+V[LW;K0N_C7GZP\=?'5H1EC (K7A394?=>=>N ML@=N GTP4MSWUQ 3K9!:Z-YCJ#C:ZL$@6*_S.2$CV;5UT*E^E?2'O&LG%]\S M79;0DU#G/VXA;1_4\$!7EB[-*,,FLMFIH[#XZ/TL U\$DTG>/?J3&7R%B&J/ M9^/2PVS>3*=/T!1Z31Y()WU8'8&?XF9P@MY#3FZ*#;V9WSMD^F4:A?H;"&[V M*!&Y;(N_Z7]\'_32?]/?#_8#I M_K=/GUY[J6_H(?E!PU;BK?SOOSS\2T_3_.W!\D-VF'IF.&$;NUDOV9OYW5O, M2/V0K+X.LGI&LOH2WCJ3,53K[(RJV]FQ3M#]?X*5ZIGMU?1C^W" 79#]O+W; M]>V-=NM4POI[?[T_L \?$0PYAF0[ERLHTW*:Z9(_<;<^\K4;W>K6".C-;3V] MA'LG3(X=KCIM/^<]Y)/WX&JHIGOR$)-)403W^]9MS+6.0]B%XH,F@/YZ^-C& MNMSXA'YT(SXF9;_I1GZ-/3Q\/ HWL W[+.&9T?_;:>%Y'9R M(Q\<)!+TYU9"#W\3.?J:2NBK;>3#WTR.=O(8I7+T]#3CM5FT3$8 MT3":W4L"@\/B=TD 'R&MOFWU#W8Q[?MH_UML '80#:&!-:!72Z8%,,W^Z6J_P]VIU;W\%0 M TA3@2A,>QE LG).;:BQ10QE8?K_"'5- ML9>W>_E>.H^*V2 3"DH#!##W^.YI%T>'*X' M/X))B%59,/LD=D$]S;C]2"NAVK<*EE.@FIA+R/R4CYY]T^?$ O3,>$,]LS[HH!,W1=N2@K/)W9)D8H/"^!XJ0O>:2F11HW MI"]-46>P1M:B8NWY9D-$S?N'H:S!0>)K_>P?"G]^? M4&3X[0^$/ZG#>F3 $65U^IKMJ2?H'SQ\.MPI,:,N1 R0+3X$*TR,W,<;/ 4* MU#Y*$3'I4ZNWKPURD9"GWY!!%,K$H.P1[J;YG52B*RO\LVY FW/XK:0?@!)^ M=7JBTRN\$\49ADXO;XHC.M<&B'?%PP7(&IE(D*F?=?,0S MB'+W4[8^&^T#MKEDW&6:B #T79\AN-,K'K/>?VF;5].>QCS[A4@(6O2XZG!! MS.0N(NV_3'[MP[28"W6%4,JV>?0*+&W M!3O6+?&OOSXY<-^G28EQV2"KWP(L"UY;22=[RGT?Q 7KT'3A8K27]'O.,"[* MZ1ZS4&0#W^8;U=VJ):9S-SVAGPGHMP4-J :*MYQ#HHJA1[6 ^0V+0L>&[?59 M+BB7BB1],67'\"'T#TEN"^)Z8EB4/9-)-?@WOA233.%8S,'6+_YHC]PSO$_AUB_S= [&^XF%])H-L+9M4FAA>90Q2473TI"^:E M>2U#16B>CDR9J"LB>9\$%TIZ[*AM3:D9I3TSZ6PB#>D\@#1?@T%4*7&-,182 M')]2'YK#'6AX5+B6PJNTTBGAX$[L90VB2FAU&?EG*WDZQ#)6@LHPEH:PA!W8C\[:MMNL<5>BZ$)6U(N MN8&R[Y*,>^.+LG$1=KR2\-U9(.JUY7CXYLP:MZE(R+13@4WQ3N953',1JTG#^.PA#6$3Y0YZ'5U M7B<9N\3);M KO? )VQ&F!R%F0+*R':7,)-M[%6YCL>,V)A>TV/'ZW8.#@P=? ME>)JN)4WY,Q-8U%(T)>\^7-%24YH@EK&UGIR^/ MSGYD\=/0 M4%Y1"P .KD-U,T@;&_-1V-+6RD:&1L;[*$^2X'%GQPF$^]\"$ M5QO'AEGB"SE0LYPLG_3,4>V7;.42$\3"UR^"*QPN>%&.2PQ%_0-PQ]W> _3P M%AZ@L[-W;^V,D'H&?TL0LP:TNSS;&L$B$68>/GV:5)T2&2=QQ>'J^8.XPYX= M'^J')_H*RJ@1 6-+)_ ?>44PA4.>G/5H@^M#1@ >O1:O33:5N2TG$.F"8_#@ M[!%@P^HKR?4?/''7)Z[(MF,ODQ(,/%3R;$6PD6=$W#()5AO )=,A]F>:V3C/ MJ:0;;G?$S+W3["@L9RYC^H[\,)R?SHZ$C(-<3.RBQ@H.MJ+3VAW5Z[U3VU[E]N);UI,[X3]RPA[9,>\ MA?)^+67IB#E+,W5-1S/#=XZ]Z>.Y1<,]\1L%1.WQXF)WLO3HYWN&GYHU8=:X13TO M)MU\&$XG"!\4F6N&?XZ+5>[ETDU:[R.!BQX$SP66+I+Q$@LR_ M5*Y4SGV('XR@#Q#\C,H>PM@X*YNPF!@%$Y0H_-A2O+'8Q;.IF\L2E4JN_=$, MFZ"A<[J4K)<@@PO_O7F[SA;CY6#[<[<'!OB.>ZBOC?0])I;(8AV__ M]>G3_:=:1!UE?WUX>!C_3;_YZZ/'_3*K$.GP[.N8]3*R[O_*%\OOGT7.3CCY MS'D/C1XGPSL&'DK1#:72/(7/4%IOZ#=H#EKR0#E92[8J\H46'82C!Q\KH^+1 M;)8'<6,:2OG;B4L"ST)H)_1Z'%46TPZ5"P=2M/,&="C%)T&+X+%;C6:VI2 C M.20YA4;EMX,"^762[.9KD[+;M_6N;KU1MWZPO6Z-YRFG__LO'Z^1/OCV M+W?%[KMB]Z^AI_N*!;)G+F 84;M186U71.BS<^6Q=PDKOM!8(;<1%'%0KJIZ MWQ=K&9&8Z&CH;,KT#9BUM*)A5DY@]_2K.)<]*.^Z66^O?7U]SJUO#_OQM_O?/GGRA9BR>%/[N[ HI]-Y\5M+YD>IGTBC"[%U MPA7S!WBL(W7N6'FTR?/]3IP!7^_YK[.";P?JH!M3Y7\+)H'?B>'C]]GE#:U^ MX'LG/VO?/OZX7_-8#3_P?_W'X9.#[ZT+]ZOGEY\N[YGT8Y.&'YH9B?E]W"2TV4E6=%A93%B*H/TKSV MLOM0+,9UUYSW).QLF:,L_@4$;??4TO\4E2-V^Z-KI#^U3CD^>OOLY$^K5%27 MJ&LJ2B+Q4+^T';K-ZN%3H\TS*\Z=]HMS/ ;]+4]A^2UTR^<'H#MU2HECRN: MW#M#B5'S\2?5+\+8<_@@6YQ_<[#_)%N\S"[+?/YYT>G.'N?$0_BAFY_GC3_? M9U?EZM]!2.E 'Z\QJ[X-__'OX'[C:W\OFK"*M?,CGJ-YG#YJB@(.A;@'+\J* M+Z*.QG%3AU. H99==4[4.B,K)Q/]#_9 7I;A=JNB:AF %[S^BRZGFWBG MY&6^NL3?7N7S50Y5A'.#ZX0%OZZ;JSQEZ%_6Z*#X#_C9LZK*RXG[T!SIU0!JOL\-%! M.$E_&@/V$=G8/4KH_V65STU>MV-4JTB#RA QP@$>=TW0(#N(?/L9L#0!.BHX M,>74;&\ZD>QCR/'#;_\G2F$HXGT9TX>662W#?=I*[&?QAN%%7I3S HN@ MAA"PW K-'.ZOM#%Z@!4DQQ=(Y"=9B=X=U[#;\X^"&$VHK?:B;I=@NO30Z)8; M43 N@:!^W'&!SA?@;6NHH2&* AY.KPRW2V[A4FZ,B.MOL>/7/%9"9!PK7\'7 MUKK&**/,,[.OQ9SAASJ5E'@5Z6U< MR==IYFK"M/=K9JZ.[+J_9MBJ>\M!E?#:!X[TS1#8#P__\G$]\)7PM6=%WJ() M)QC:G4/2_FP"%'0)'(DV2$I\'FYN"C(2^SW:2#JPR'%4BO=$^@T%WQ&_H'%9 M6;]DD%Y!M%_7V406#\J(NJNT<>T<#7'T%L.J M#@_^$R9$1IJWYD<.-80Q)B?M"AM96]A=5\PG=,4\3#?K\[IB'CZ]ZXJYZXK9 MU:Z8'_+)^WE]OG.*%71W8UZ[,L=P@R9:25B!F&93]#=[#WKN/E%AB]A,P<"(L[:1_'R+/@N19HMU2Z MGZI>E1Q%\#(1YM#ER=6>UOB"43\8\9$^H:R:"/0PWZKA!R@QABH'T^2L0V?V M)"?^AQ5MX$5X(74C<[%H-\L%9I00*9E:G4CJ5]'8;?*2S0@2]6=+2ZL*T !Q M5**=M9=T4,4'3RPG%GL>/J\RHC8;8DNYF6I_='"+?:)ZL2Q69))W[O#^7&P* M&[K4K*E9R!AP@"0GW3+N>\RGH"A M9T)[5E03BG7UHOA8QP$AEJZZ6;@Y^^%"0(6OT]<<#U5"0")SU>1;'R!W!9V\ MH#[FRF%.\WR4MY7<>"Q,W4.,IBDIAQC^-,HX#XC\ KAJ9]QOS=LUY2DS75@' M3CT1 DH''XE$?4-VD]N5-$(W([#-G?N=L6L+E]/6=G[,&=C*#.JHF<0F<#YCE)W/Z['<,;SL M0EX9UD\D45.8HI:L"KO^X)QK"B$0R%<2AW9CY*J);F<&MF(L;Y3*YDBS:R"V MUV[64;;!B\,A9S!)X:$G-^2QO4LF?T8R&79:DY^P,MR5F1G-+R0 M!YMD^0Q\F^"Q"?_>:=4.3ON--"$)PGZJK6^ MJQ]WQ^Y)F51BL:4CFP7>/KS.OBSR> M*F<]O[_>TG[/)2HYA-8/7@ [MWJ*]:"$$>^@Q-[F/P:/[IQ.J',D M[\3FRXO-P^W2LEU83MZ]\HJ3Q>-MOOYW\4-99_>X;&BE0B0R@C[))__JRD8J M?0A>Z_D\*-+1>*TDSP.>?DX6^[W7&4G 7]7FI',% MWHBXB2$S%O07]317P(PF$4$#2V3VQ%"(/%X#;DE9217/JZ6#>$Y5+C,1L=+Z MBH9V)U,SJ[!9_JQS-L=FD&\FF"9AC7O%;,9$G?B)9)1XS(>.<"=L&R6@_![Y M._$4[17_1:H3A&4).T Y+#P9$[V*GQV>NU@AO6"7F==,:5[:X "BJZ;K)3R@ M+F^%MY+Z[JVP4>>K5;%8DK%M+\K9"H7QO:Z5V?3QU<7W(YT=%H8UV3A8[GDA M[YQK?3FAN&;U/!AV3$6WK\LL@VD1%J;O@Q@K9;JB?973C9N"UEO_&$(!QP%5 M(E31"ZKR9%U5"/0T%X0;SWJ1&91M\3ECJ&[/07W1-1!:AL\.A.-OX:E MHR%E;=-U6R8&KU&J,])0!&$RUU7)]87KCLM502T HV/3V@ 1ZTD>8VV6R_EZ M;UHLZ*ROJ[ 1DS8.DY>EZ+F=%Q^LX!6^PU VO:\ )>C7!"CR*\'\VG- W<9= M&W:*2POGP/-4)&*2I L/>X\&W6G);21%,V@F%LN8#*8UT,:6;1W>?]'>3Z[9 M%.5BW#4MNZK+(.AI >3=Z3MJ5NAD3"KQ[F)$[R18$T(N-4TNPSX8G">*%]/T M,)7DBMBPF:X:"BLHLD)8>.F?2YXTPI9.QFX)E%O;2Z?":K2WR-^[R2%.5?O" M)Q-%@W]^F,G]AN6]A[>WO/2;V4G_>,1#1[2V(0Q N-N+M8^0MRO,;[ M-V;@\*2+Y$GES;;"DQY4:)&8@_WL66>39D@9BU-3DG:RTN Q_W"!+UM<'&OZ14.Z'.&44W\]3? M'P%Z$4@5F@;@1+W"P$+]#M*XH1/4"%;=BC'I%-46?L\U@JP(&NJ MKVP&J.0].^=ZJI.R[X9-X;W)C M1[K)^?DYN*0!>TCA67M=9S#O '$;@+A' M=^.-[[!MNX1MHRO^#6T1Y>0&5O55/5^/PS-UB[WOOMLYXXD@PP/!8D,%*UCM MNG"6;SXW>_NJ#L_LG'!1PW&\GIA:REZ.Z\58&/R[X/N5W4)F]07OO(%OZP=( M!%5 Z)3@&N([>?;D"9I/&AHYO#4%34*4F&:2*R2(TB_[=)'P- M_3Z5P!:2E?+5[:KD8)C_?X5!].G"3$.*Z2X-?(10C!.F3O,1/"/0H/#8,>L&7"S7R"8L&!C=C+D M^]DC'-04 \G"[A$+ ^&65D&%%1IG$701S4RZE]0$6:YB[]15WN,^#DWI5CD3M"$YG$'B M:(WT^1Z?&A[?+2"MP;7^\/9!LM:7__UV[_"Q?I?H%()OO^R""SD993^^>(N/ M4-Y,6 S.CEZ@W7KH(=^<'KU,GW'WY 8:+A95Z+SC'=_#%D5'-3O2KYB#B1P! M6L=X>%+05B'DA"N%3"=F?BT0=U!QAMU>FE96E9RK(\ 8MCJY-I> Y5>4_\'(W!"W#*]A M7E])/PB"E(J][&XI 70]X7,V(?'410$,FW;GR2V@VGL/@B,G#SF%2NXXSR76 MPB"[\/L3Q6]X%?S%?"<(X;$%Q15\''*)"<3ZLI&4U')8./Q6Q MW?@7Z>M?4C)4<-'(L];5'ET$/TS7_<:MH6 QF:H&)F3 M<++8)(_Q)8X+;G +CTOZW-<=EQT4WZ/YZH+ZH36WD@NL%@V2!* M1+^*3)BE M^(@W,-KB#E 6)SA?P5V>!9?0TBL,!*[/"8>.JET0_7E1G;-#0I/'_#*H?1DM MXD5%L_#L,A$1CB.!H\"]UMP;S K,>>EZ/?&0"G&28]('[=-(9K&G*W,"V3V1 MRU.:5D'VX4Y6$9IC&$R%P\BEA0T&X5_/9EP:,':;@7'W8Y MI/"?,-I6.EZD074I,WF14EYEG&C3M\G-)F&/M/@%WBWIX^?9@/(LDHY7Q+;K MC9&F:JH5Q51BBMVG=MCL"&N&:%'D+2\ MO+1V*G*TG_W$P"%7^8AV MFE)_U%RVPGS#..91B$984J'FQMW\?3"9VITR59H%CN6OBB06Y;#+]3VX;C3\ MX35-B_H!W'>L(U_E;1NL5XA15]3>[@]5^"_JMH$5RE>9VOZLZ:K6:"SZ-NBQ M^!7PVW- N=>!1K!NVZF" M!XJJWL6N,KE(C<%4_'LQ^C=.EQ(R^'?*!LK7(KD2P$"' MC>KQ.8J3[-@5'R;E4OX[V,KWG%])2R9L8M._H?H8M#W]KA*U+P#CAOHVYT%? M7Q9L(SU$/'[)B9/$+6S>[*3ZD?)LK>G:[ @&)7!>UU,FKB+S"^]S.0_/2<<$ MIZKNN#W3?$]GY018HF9E!UW!WW,2Z98Z6BISGU]M?G)[J\VOO([?.66!>,BU M7?2 $<8G96%;QW@A(N (QY9:-(6_1_HXR3UTA>735R^DC.NSN,[CFZPG\YHR MXQR>;29[@^392H*M>Y$=?CMRF+T\.SS$>.8*95J7-^=%<5'"'"; U+E@!3H5^SI9/O=YX7"&["ZN47':% M+1X3"Q)MA!ZGX/8O^AH7#RO;AXA-9Z335PE'TZXK1!_ARN/Z Q?Z_5O3C>*] MM+2QWS]:D?+ZD1=2SX,#0<.PJ=X?3FP[*YJ&,_YYDO,/BPA;7PL/EH0L) M BAC]MDSG!?FN;_'+15\Z Z6D;2OXO?.@=9/ M(JA/2S8P#QTC-!)Z.#IBMK]-,6O*<^'N IL!@F;B#G8-5".-S6$V@D6^](U? M^]F;*GM1C)L.J$C0]#!93W3II_3R[B *-X2E2' EC% MT]3-T&<"%.DP+$NO ,%A]? M;K578,(VEN06Z6)E=1E,[T( WIRV3Q** ,-7T[P"9T>Y$#+IV;SX4#KR#D+, MPT^H6_8A\J15E>#MC*WW'9E%=5D&SV5WNQBHSNC='\\!Q 4MKG7%MA\8+ER+ M.3 'TSV!7'K$-#7-UXZ/BA/0E%2.Q1_FOZ=, M>*E7MQI$VSM[\C)]:GF2$TVL.Y-6K(AR9/GS08DB_(OD0[S*"1)2(!=BR0OR MVSB,\(R4LDG,A8.I#71.K09"W4A T:]Q4>/!PJNISAFP?@[WK&[6::%0*X$7 MX>IST8'*3=O+YEC.G/6(='++A<,&.*TQTE#0]_#P2VX1XI >3'K T5E'519: M4;>+>177 :%9HBT>=TH0G)8Q>O3'"5U/8G4HTBF;J90V+6W<,VF.($EDJ(S5 MG;+"?2=2.M/$;9"'!;T&G[A-+ANB2(3 +52K9X.74&VS,VO[RFD+\".@N--T MD0;YP7+[\X_KSS 0J[Z@ MGN<-=@1L]FPE)SCYR>:[I W@5AAZ)+#$83D2=?&OAR)SJ^Q3[(Z"ZT6YY&=2 M'CA5I9$!FK3&JFP-=L_9A+1/#A<-3A1Z'44:M4FG%T43GW[K*Y>%TU4M,B#G MX9;%)-(G]9]DTLV9]3E8@/ 6&>>7F(GTGCR60/2TO-A/Z>.Z-26%5ZDIB!TI M1RX[NG.YPP2I2!+'"0( 22A=$/L<-*4DC%O]W=! 2!D%Z@!(:@/LU%R#9F(M2P^LB!-_ M>^Y2CW 8^RS<9QQ6#[0("LG"<_WP@&MII(<-T[=96?X\=H.[H_4Y1RN2F&WK M2[@%A^[$IS,T%YND)J\W3-(Q8(81MO-NCI=L61OV=] M?JO/E;3;?G:!_O&#VUN@/PDJ*@2+$SJ4IY@OU>S@F)53X@"!HFMR8#O))3'L M3>F?<2G/*.-V1MDX?&EC E>0HW!]9).Z<(XX01$4,&77(GER'P63:=+5<@A8 M3HAF)PVEMU(Y>U_55WL7]=7(L:YPO;NJ+S55P<.#2"RC#R9<@;-RRCELRG/' MCZGH+8.;*-7!>?&$]X"035+%HW4WQ6497H:/^SWSBNY6]-*8=T5B7N9@R0$C MGEB6Q?6V4]]U3@3;8>^P0@FSY8]"*C/\I@32"%?OLBYA3F>4T%/JE(^NF;9I MMG:;65.,C=X )7-9U!41MPD[S< R0#Y!:1N2*O6,I2_")O@0R?U2DS*%'T M+\F-Z/&)Q.12O%5XRFX5GNS?2:B:D *U8:E$V5_+K^6-\J0"&["%*X6].O8\ MQ5R70%C<,,$X$TZ/%=+A1X')(+*R:>3E^+3A1GZP;GQ@K2@V$1CMP+SN1>QG M)S.X;C*ZH![3.V@[HW&//$/F+0U>CQR+1$?^DD'31M8(B M]YR%TSZM.<%%*>EBU#_?4$F1( A@_I*R;))DIP\8[(\?GC?UU8J+&>GH ]V1 M8B[1D"WZ(TNE'@V@(133&;0O2L>BN2-&N'#R+- M>>(/ORCI?\*M^9^418NY7-_M@G(6!5U<+_.+]7X]N_\-6O>Z1='4G'0F M'^"78*Y;T!%='_C?06HV(#5/[B U=Y":78+4?*)JE[!C%Q5WKBZ(#IA43U4J ME^9$^SH%/#&RUA7\T&9[).3C!,/Q4EH$VI_R3;KBOM+1LB4@YC>9C M4J.=1ZZH]7+0I]YTN94=1"6HI[#Y?EV79Z0&')S;\Y%Y/;37J_52B /H7 V* M$Q?I=+A SJ@"C[*A%R_%Q@?8F1!-I;BJ0V MZ*;Y%(SCN< EP_%"\9HS$M1=9- ;@>Y03\-GU5&^M"A]4M'B=M3^LKW,:_5E MU[1=83D:2B-4E<@@Y3VCISV8 $OTR7Q-"M.^,$L&$BEX#P=M_Y'D%\-M;Z^_"HC+ZF6GBR[ M%W>-6"=AH_WC[;O/%?-8;[-9\.6'(2EG?V6OGJ$A*HIRTMRI%3,6X\=2ZKG< M^(;*>1*RNN?OC1)4Z=7,'!)7 RND:^,'=HJV/2SME]&/4MA]LW.]NJJO/]M# MC_EX^W$>/L1^*[:][U]SIE'RV_Z\QJB?ZY6D-BFR( Z$-[GQ,8&BZ\Q;I9V+F1PAW[I5AD5*O7QEULJ%4PU-L MKGY:%SS[5\M(],NMY_U>>U^'%ES['6Y6 59T/SMC38,FOJ%7EV=GHG@>'SR^ M-[Y_[\']#*^(( 3\/7E5TC=(C,OAZPKUXQWWM6Y)L,],)=">:0\0X[^$YJ-= M=40#SZH)EW*BH7N#O*Y.>,B)67[.^7JBA2X(*#8IA)C^[MZK/B061[ZP4TWIA M8P&D>=CG!-%7\I![N1&>T1_LNQMW$T(S1)E4U^"< [&'#AXOH@_9$%"['@&. MGG[?WD!D\]6GR>V[9-T064)44\HC6-Y@F,[!A>/'A,S$DL(FE 5 MB\(;Q"?6MQ1G"2XQF GZ]I8-&:./(U^'M=\3YE446N?XRWWNEECB>@\/=-KZ MO461MX2TM_YJNAH\11G@S@O#%FC7['U\)F,\1/.C?1M]/8H63%^N4L#'W:"K MM1@FP67<8&T$YO3P8(_61@\B-2_?AR9>45L'I[%1Y4V_1WS.>"CIS:GJM I^ MD4\5&S5-WKT9H>EV,7 R($5+?OR&2ZPX'U< RJ.'8*YC5V1;@K*#5]*V8C5A MLG!^A5+W-&_R\R9?7F0G_]T[ 1 O&4?"O*R4@Y(N>Z[VE3%C$RN!.^C6'-G MCZG,TL183;52&+?$Q))O"R3ZJ#4RZ/;L\&#OGZ.$W,R:NY%W$>E5JV$2J 5; MHN@/1P*&7(F>\#N"R:GHLSQSQ7?$]G3,^MF$P\O99VN!((Y>#80;A3N%E2"A M.^L@_>*E\W+"@4].RX@U4>^.6MM>ACO!)9>C[G4*/TK/14I:7).V%SJ"UNQ! MRTY/+1.N#G3KKQP=:,)J=U%?#:D3IR;"&:KGB'2#SW254PM-\2%'GPE/.@&K M'9&(4.?(FH!#\V)Z7J0T/YS[8,A!%)2M8H)WK][Q@T>FR#;WG@6)7X]TZ7S. MFQ D)WGE85OG!1(\9\5RQ%U]QZ,EDNSR@!8 M%,*H&%U:SGK%S60",U*'\7;JTD],7SFP\MY736$E+3_PH%V>*LDZ*6)BLTQ4 M>]R7HK)="2[-X3SX;J2-VI2O'\B/7%O0XA\C5[!W53)E#P>"@_>&-B3]$@QZ M1>-N6/I\,N?106\&%IQF&X<5XKL[F M$'2=C*CC+!W@S8R,N\$/ZIAW&WW=@"NU)=4VDF+84(5Q:.G6('F'&[DY;N3I M'6[D#C?RV^)&;KL1LUK4T=K(OW09G0-.Q"D$Q\9_&?DK7&98%@/_Q"^&M/'ZMRW M4X%7?.7"XVO)(+L.JRJXW;'#JFPY;RF!-U4EB%EET+MR^6B2($E@-D5K-,Y< MG\FVHU*\DT91J"LAO9FL:HZ8'CYFHMHJ4A_)O!)I !!.8JV'FX.XO136[S'X M(PA=_L/927C-7U/*!"JM <&PBD".SR8BCU$YGH"6A+!P(5BFH8.42-3+4!Z9 M^*W3 *%(Y(>KC@^$C6*CT"JAQ+?[F+5YORY:CMMLQ[2?E9[5A4Y&&5L MJD>\&9'=!1>3E;GT6JWXZ. /I15G\ZY!7#?-__WU0U@OIUMZNQ*L8P*/C_4= M5TT=H30^2L@Q-Y@N/(H@D9T;E&5C//P$/$+^/H-?>_@ 7QL";/2O]^UHI=_%"I!!Z.DF!_L$=.*WHZG-0'UZAZ)$")AW\(83]]_>[!P<&#KP\V M,IKUN78&%KK[7O&EKE^B$?V1<$B=Z]S$LM=/,JB1I^&=3R05F&*C%0J]0